

<!DOCTYPE html>
<html lang="es">
<head>
    <meta charset="UTF-8">  
    <link rel="icon" href="dc3.png" type="image/png">  
    <script src="https://cdnjs.cloudflare.com/ajax/libs/html2pdf.js/0.9.2/html2pdf.bundle.min.js"></script>
    <script src="https://cdn.jsdelivr.net/npm/sweetalert2@10"></script>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>White Book</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0-beta3/css/all.min.css">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@700&display=swap">
    <!-- Estilos para dispositivos móviles -->
    <link rel="stylesheet" href="estilo_informeM.css?v=1.9&_=${new Date().getTime()}" media="only screen and (max-width: 768px)">
    <!-- Estilos para pantallas de PC -->
    <link rel="stylesheet" href="estilo_informeM.css?v=1.9&_=${new Date().getTime()}" media="only screen and (min-width: 769px)">
    <script src="https://cdnjs.cloudflare.com/ajax/libs/pdf.js/2.10.377/pdf.min.js"></script>
    <script type="text/javascript" src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script>
     <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    

    <!-- Metadatos Open Graph -->
    <meta property="og:title" content="YOU TOMORROW">
    <meta property="og:description" content="Ofrecemos un estudio en profundidad de las propiedades genéticas de nuestros participantes.">
    <meta property="og:image" content="https://drive.google.com/file/d/1ZZI3G6Fit_kovvVZolrvchtXQQDrnWYI/view?usp=sharing">
    <meta property="og:url" content="https://ytomorrow.com/">
    <meta property="og:type" content="website">

    <!-- Otros metadatos -->
    <meta name="description" content="Ofrecemos un estudio en profundidad de las propiedades genéticas de nuestros participantes.">
    <meta name="keywords" content="you, YOU TOMORROW, TOMORROW, TOMORR, TOM, web">

    <style>

   body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    font-size: 17px;
    line-height: 1.4;
    margin: 20px;
    font-weight: 500; /* Grosor medio de la negrita */
    color: #4a4a4a; /* Gris oscuro elegante */
}

h1, h2, h3 {
    color: #4a4a4a; /* Gris oscuro elegante */
}

h1 {
    font-size: 24px;
}

h2 {
    font-size: 20px;
}

h3 {
    font-size: 18px;
}

p {
    margin-bottom: 12px;
    font-size: 18px;
    color: #4a4a4a; /* Gris oscuro elegante */
}

.section {
    margin-bottom: 30px;
    color: #4a4a4a; /* Gris oscuro elegante */
}

.chart-container {
    display: flex;
    flex-direction: column;
    align-items: center;
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    color: white;
    width: 100%;
}

.chart-row {
    display: flex;
    justify-content: center;
    margin: 10px 0;
    width: 50%; /* Ajusta el ancho para que se adapte al contenido */
}

.chart-box {
    background: linear-gradient(135deg, #42a5f5, #1e88e5);
    padding: 10px 20px;
    margin: 0 5px;
    border-radius: 12px;
    text-align: center;
    font-size: 18px;
    box-shadow: 0px 4px 6px rgba(0, 0, 0, 0.1);
    display: flex;
    align-items: center;
    justify-content: center;
    transition: transform 0.3s ease;
    position: relative;
    overflow: hidden;
    min-width: 150px; /* Asegura que las tarjetas tengan un ancho mínimo */
    max-width: 300px; /* Limita el ancho máximo para tarjetas largas */
    word-wrap: break-word; /* Permite que el texto se ajuste dentro de la tarjeta */
    flex: 1; /* Permite que las tarjetas se expandan uniformemente */
}

.chart-box:hover {
    transform: scale(1.05);
}

.chart-box.ceo {
    background: linear-gradient(135deg, #ff6f61, #e53935);
    font-weight: bold;
    font-size: 22px;
}

.chart-box::before {
    content: '';
    position: absolute;
    top: -50%;
    left: -50%;
    width: 200%;
    height: 200%;
    background: rgba(255, 255, 255, 0.1);
    opacity: 0;
    transition: opacity 0.3s ease;
    transform: rotate(45deg);
}

.chart-box:hover::before {
    opacity: 1;
}

.chart-box.ceo::before {
    background: rgba(255, 255, 255, 0.2);
}

.connector {
    width: 2px;
    height: 20px;
    background-color: #1b3a7a;
    margin: 0 auto;
}

.horizontal-connector {
    height: 2px;
    width: 100%;
    background-color: #1b3a7a;
}

.horizontal-connector.long {
    width: 50%;
}

.chart-box i {
    margin-right: 8px;
    font-size: 20px;
    color: rgba(255, 255, 255, 0.8);
}


table {
    width: 100%;
    border-collapse: collapse;
    margin-bottom: 20px;
  }
  
  table, th, td {
    border: 1px solid #ddd;
  }

  th, td {
    padding: 12px;
    text-align: center;
  }

  th {
    background-color: #1b5e20;
    color: #1b5e20;
    font-weight: bold;
  }

  tr:nth-child(even) {
    background-color: #f2f2f2;
  }

  tr:hover {
    background-color: #ddd;
  }

  caption {
    caption-side: top;
    font-size: 18px;
    font-weight: bold;
    margin-bottom: 10px;
  }

    </style>

</head>
<body>
<div class="container">
REFERENCES
<ol>
  <li>Aﬀuso, F., Mercurio, V., Ruvolo, A., Pirozzi, C., Micillo, F., Carlomagno, G., et al. (2012). A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World Journal of Cardiology, 4, 77–83.</li>
  <li>Arruzazabala, M. L., Carbajal, D., Mas, R., Molina, V., Valdes, S., & Laguna, A. (1994). Cholesterol-lowering eﬀects of policosanol in rabbits. Biological Research, 27, 205–208.</li>
  <li>Arruzazabala, M. L., Molina, V., Mas, R., Fernandez, L., Carbajal, D., Valdes, S., et al. (2002). Antiplatelet eﬀects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. Clinical and Experimental Pharmacology & Physiology, 29, 891–897.</li>
  <li>Banerjee, S., Ghoshal, S., & Porter, T. D. (2011). Activation of AMP-kinase by policosanol requires peroxisomal metabolism. Lipids, 46, 311–321.</li>
  <li>Carbajal, D., Molina, V., Valdés, S., Arruzazabala, L., & Más, R. (1995). Anti-ulcer activity of higher primary alcohols of beeswax. The Journal of Pharmacy and Pharmacology, 47, 731–733.</li>
  <li>Castaño, G., Fernández, L., Mas, R., Illnait, J., Mesa, M., & Fernández, J. C. (2003). Comparison of the eﬀects of policosanol and atorvastatin on lipid proﬁle and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clinical Drug Investigation, 23, 639–650.</li>
  <li>Castano, G., Mas, R., Fernandez, L., Illnait, J., Gamez, R., & Alvarez, E. (2001). Eﬀects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: A 6-month double-blind study. International Journal of Clinical Pharmacology Research, 21, 43–57.</li>
  <li>Castaño, G., Menéndez, R., Más, R., Amor, A., Fernández, J. L., González, R. L., et al. (2002). Eﬀects of policosanol and lovastatinon lipid proﬁle and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. International Journal of Clinical Pharmacology Research, 22, 89–99.</li>
  <li>Cho, K. H., Kim, S. J., Yadav, D., Kim, J. Y., & Kim, J. R. (2018). Consumption of Cuban policosanol improves blood pressure and lipid proﬁle via enhancement of HDL functionality in healthy women subjects: Randomized, double-blinded, and placebo-controlled study. Oxidative Medicine and Cellular Longevity, 2018, 4809525.</li>
  <li>Cho, K. H., Yadav, D., Kim, S. J., & Kim, J. R. (2018). Blood pressure lowering eﬀect of Cuban Policosanol is accompanied by improvement of hepatic inﬂammation, lipoprotein proﬁle, and HDL quality in spontaneously hypertensive rats. Molecules, 3, 1080.</li>
  <li>Chu, B., Qu, Y., Huang, Y., Zhang, L., Chen, X., Long, C., et al. (2016). PEG-derivatized policosanol as micellar carrier for paclitaxel delivery. International Journal of Pharmaceutics, 500, 345–359.</li>
  <li>Cicero, A. F., Brancaleoni, M., Laghi, L., Donati, F., & Mino, M. (2005). Antihyperlipidaemic eﬀect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: A pilot study. Complementary Therapies in Medicine, 13, 273–278.</li>
  <li>de Oliveira, A. M., Conserva, L. M., de Souza Ferro, J. N., de Almeida Brito, F., Lyra Lemos, R. P., & Barreto, E. (2012). Antinociceptive and anti-inﬂammatory eﬀects of policosanol from the leaves of Sabicea grisea var. grisea in mice. International Journal of Molecular Sciences, 13, 1598–1611.</li>
  <li>Elseweidy, M. M., Amin, R. S., Atteia, H. H., El-Zeiky, R. R., & Al-Gabri, N. A. (2018). New insight on a combination of policosanol and 10-dehydrogingerdione phytochemicals as inhibitors for platelet activation biomarkers and atherogenicity risk in dyslipidemic rabbits: Role of CETP and PCSK9 inhibition. Applied Biochemistry and Biotechnology. <a href="https://doi.org/10.1007/s12010-018-2776-5" target="_blank">https://doi.org/10.1007/s12010-018-2776-5</a>.</li>
  <li>Fernandez-Arche, A., Marquez-Martin, A., Vazquez, R., Perona, J., Terencio, C., Perez-Camino, C., et al. (2009). Long-chain fatty alcohols from pomace olive oil modulate the release of proinﬂammatory mediators. The Journal of Nutrition Biochemistry, 20, 155–162.</li>
  <li>Fraga, V., Menendez, R., Amor, A. M., Gonzalez, R. M., Jimenez, S., & Mas, R. (1997). Eﬀect of policosanol on in vitro and in vivo rat liver microsomal lipid peroxidation. Archives Medical Research, 28, 355–360.</li>
  <li>Gong, J., Qin, X., Yuan, F., Hu, M., Chen, G., Fang, K., et al. (2018). Eﬃcacy and safety of sugarcane policosanol on dyslipidemia: A meta-analysis of randomized controlled trials. Molecular Nutrition & Food Research, 62, 1700280–1700292.</li>
  <li>Gouni-Berthold, I., & Berthold, H. K. (2002). Policosanol: Clinical pharmacology and therapeutic signiﬁcance of a new lipid-lowering agent. American Heart Journal, 143, 356–365.</li>
  <li>Guardamagna, O., Abello, F., Baracco, V., Stasiowska, B., & Martino, F. (2011). The treatment of hypercholesterolemic children: Eﬃcacy and safety of a combination of red yeast rice extract and policosanols. Nutrition, Metabolism, Cardiovascular Diseases, 21, 424–429.</li>
  <li>Guo, T., Lin, Q., Li, X., Nie, Y., Wang, L., Shi, L., et al. (2017). Policosanol attenuates inﬂammation in both RAW264.7 macrophages and a mouse model of colitis. Journal of Agricultural and Food Chemistry, 5, 3647–3658.</li>
  <li>Gupta, S. S., & Ghosh, M. (2017). Policosanol reduces physico-chemical attributes, release and bioavailability as modiﬁed nanocrystals. European Journal of Pharmaceutics and Biopharmaceutics, 119, 201–214.</li>
  <li>Harrington, A. W., Leiner, B., Blechschmitt, C., Arevalo, J. C., Lee, R., Morl, K., et al. (2004). Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proceedings of the National Academy of Sciences of the United States of America, 101, 6226–6230.</li>
  <li>Hernandez, F., Illnait, J., Mas, R., Castano, G., Fernandez, L., Gonzalez, M., et al. (1992). Eﬀect of policosanol on serum lipids and lipoproteins in healthy volunteers. Current Therapeutical Research, 51, 568–575.</li>
  <li>Therapeutical Research, 51,  568–575.</li>
  <li>Hsu, C. Y., Shih, H. Y., Chang, Y. C., Huang, Z. L., Tsai, M. J., Chia, Y., et al. (2015). The beneﬁcial eﬀects of tetracosanol on insulin-resistance by insulin receptor kinase sensibilization. Journal of Functional Foods, 14, 174–182.</li>
  <li>Hunter, P. M., & Hegele, R. A. (2017). Functional foods and dietary supplements for the management of dyslipidaemia. Nature Reviews Endocrinology, 13, 278–288.</li>
  <li>Kaushik, M. K., Aritake, K., Takeuchi, A., Yanagisawa, M., & Urade, Y. (2017). Policosanol restores stress-aﬀected sleep in mice by alleviating stress. Scientiﬁc Reports, 7, 8892–8899.</li>
  <li>Kim, H., Park, S., Han, D. S., & Park, T. (2003). Policosanol supplementation increases running endurance time and improves biochemical parameters after exhaustion in trained rats. Journal of Medicinal Food, 6, 345–351.</li>
  <li>Kim, S. J., Yadav, D., Park, H. J., Kim, J. R., & Cho, K. H. (2018). Long-term consumption of Cuban policosanol lowers central and brachial blood pressure and improves lipid proﬁle with enhancement of lipoprotein properties in healthy Korean participants. Frontiers in Physiology, 9, 412.</li>
  <li>Lee, J. H., Jia, Y., Thach, T. T., Han, Y., Kim, B., Wu, C., et al. (2017). Hexacosanol reduces plasma and hepatic cholesterol by activation of AMP-activated protein kinase and suppression of sterol regulatory element-binding protein-2 in HepG2 and C57BL/6J mice. Nutrition Research, 43, 89–99.</li>
  <li>Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001). Regulation of cell survival by secreted proneurotrophins. Science, 294, 1945–1948.</li>
  <li>Lee, E. Y., Yoo, J. A., Lim, S. M., & Cho, K. H. (2016). Anti-aging and tissue regeneration ability of policosanol along with lipid-lowering eﬀect in hyperlipidemic zebraﬁsh via enhancement of high-density lipoprotein functionality. Rejuvenation Research, 19, 149–158.</li>
  <li>Lim, S. M., Yoo, J. A., Lee, E. Y., & Cho, K. H. (2016). Enhancement of high-density lipoprotein cholesterol functions by encapsulation of policosanol exerts anti-senescence and tissue regeneration eﬀects via improvement of anti-glycation, anti-apoptosis, and cholesteryl ester transfer inhibition. Rejuvenation Research, 19, 59–70.</li>
  <li>Lin, S. R., Fu, Y. S., Tsai, M. J., Cheng, H., & Weng, C. F. (2017). Natural compounds from herbs that can potentially execute as autophagy inducers for cancer therapy. International Journal of Molecular Science, 18, 1412.</li>
  <li>Liu, Y. W., Zuo, P. Y., Zha, X. N., Chen, X. L., Zhang, R., He, X. X., et al. (2015). Policosanol enhances the proliferation and migration of human umbilical vein endothelial cells via activation of the PI3K/Akt and MAPK/Erk pathways. Lipids, 50, 241–251.</li>
  <li>Long, L., Wu, S. G., Sun, J., Wang, J., Zhang, H. J., & Qi, G. H. (2015). Eﬀects of octacosanol extracted from rice bran on blood hormone levels and gene expressions of glucose transporter protein-4 and adenosine monophosphate protein kinase in weaning piglets. Animal Nutrition, 4, 293–298.</li>
  <li>Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., & Caminiti, G. (2011). Long-term eﬀects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Advances in Therapy, 28, 1105–1113.</li>
  <li>Marazzi, G., Pelliccia, F., Campolongo, G., Quattrino, S., Cacciotti, L., Volterrani, M., et al. (2015). Usefulness of nutraceuticals (Armolipid Plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease. The American Journal of Cardiology, 116, 1798–1801.</li>
  <li>Marinangeli, C. P., Jones, P. J., Kassis, A. N., & Eskin, M. N. (2010). Policosanols as nutraceuticals: Fact or ﬁction. Critical Review of Food Science and Nutrition, 50, 259–267.</li>
  <li>Mazza, A., Lenti, S., Schiavon, L., Zuin, M., D'Avino, M., & Ramazzina, E. (2015). Nutraceuticals for serum lipid and blood pressure control in hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Advances in Therapy, 32, 680–690.</li>
  <li>Molina, V., Arruzazabala, M. L., Carbajal, D., Valdés, S., & Noa, M. (1999). Eﬀect of policosanol on cerebral ischemia in Mongolian gerbils. Brazilian Journal of Medical Biological Research, 32, 1269–1276.</li>
  <li>Molina, V., Ravelo, Y., Noa, M., Mas, R., & Pérez, Y. (2013). Therapeutic eﬀects of policosanol and atorvastatin against global brain ischaemia-reperfusion injury in Gerbils. Indian Journal of Pharmaceutical Sciences, 75, 635–641.</li>
  <li>Montserrat-de la Paz, S., García-Giménez, M. D., Ángel-Martín, M., Pérez-Camino, M. C., & Fernández, A. A. (2014). Long-chain fatty alcohols from evening primrose oil inhibit the inﬂammatory response in murine peritoneal macrophages. Journal of Ethnopharmacology, 151, 131–136.</li>
  <li>Noa, M., Herrera, M., Magraner, J., Más, R., Fraga, V., & Menéndez, R. (1994). Eﬀect of policosanolon isoprenaline-induced myocardial necrosis in rats. The Journal of Pharmacy and Pharmacology, 46, 282–285.</li>
  <li>Noa, M., Más, R., & Lariot, C. (2007). Protective eﬀect of policosanolon endothelium and intimal thickness induced by forceps in rabbits. Journal of Medicinal Food, 10, 452–459.</li>
  <li>Noa, M., Mendoza, S., Más, R., & Mendoza, N. (2003). Eﬀect of policosanol on carbon tetrachloride-induced acute liver damage in Sprague-Dawley rats. Drugs in R & D, 4, 29–35.</li>
  <li>Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., et al. (2004). Sortilin is essential for proNGF-induced neuronal cell death. Nature, 427, 843–848.</li>
  <li>Ohta, Y., Ohashi, K., Matsura, T., Tokunaga, K., Kitagawa, A., & Yamada, K. (2008). Policosanol attenuates disrupted hepatic reactive oxygen species metabolism associated with acute liver injury progression in rats intoxicated with carbon tetrachloride. Journal of Clinical Biochemistry and Nutrition, 42, 118–125.</li>
  <li>Oliaro-Bosso, S., Calcio Gaudino, E., Mantegna, S., Giraudo, E., Meda, C., Viola, F., et al. (2009). Regulation of HMG-CoA reductase activity by policosanol and octacosa-dienol, a new synthetic analogue of policosanol. Lipids, 44, 907–916.</li>
  <li>Peng, K., Long, L., Wang, Y., & Wang, S. (2015). Eﬀects of policosanol extracted from rice bran on the laying performance, egg quality and blood metabolites of laying hens. Asian-Australasian Journal of Animal Sciences, 4, 293–298.</li>
  <li>Ravelo, Y., Molina, V., Carbajal, D., Fernández, L., Fernández, J. C., & Arruzazabala, M. L. (2011). Evaluation of anti-inﬂammatory and antinociceptive eﬀects of D-002 (beeswax alcohols). Journal of Natural Medicine, 65, 330–335.</li>
  <li>Rodrigues, M. J., Custódio, L., Lopes, A., Oliveira, M., Neng, N. R., Nogueira, J. M., et al. (2017). Unlocking the in vitro anti-inﬂammatory and antidiabetic potential of Polygonum maritimum. Pharmaceutical Biology, 55, 1348–1357.</li>
  <li>Singh, D. K., Li, L., & Porter, T. D. (2006). Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. Journal of Pharmacology and Experimental Therapeutics, 318, 1020–1026.</li>
  <li>Tang, M., Wu, S. Z., & Gong, X. (2013). Eﬀects of policosanol combined with simvastatin on serum lipids and sex hormones in male patients with hyperlipidemia. Chinese Journal of Cardiovascular, 41, 488–492.</li>
  <li>Taylor, J. C., Rapport, L., & Lockwood, G. B. (2003). Policosanol in human health. Nutrition, 19, 192–195.</li>
  <li>Tchakam, P. D., Lunga, P. K., Kowa, T. K., Lonfouo, A. H., & Wabo, H. K. (2012). Antimicrobial and antioxidant activities of the extracts and compounds from the leaves of Psorospermum aurantiacum Engl. and Hypericum lanceolatum Lam. BMC Complementary and Alternative Medicine, 12, 136–143.</li>
  <li>Teng, H. K., Teng, K. K., Lee, R., Wright, S., Tevar, S., Almeida, R. D., et al. (2005). ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. Journal of Neuroscience, 25, 5455–5463.</li>
  <li>Thippeswamy, G., Sheela, M. L., & Salimath, B. P. (2008). Policosanol isolated from Tinospora cordifolia downregulates VEGF gene expression by inhibiting nuclear translocation of NF-kappaB and its DNA binding activity. European Journal of Pharmacology, 588, 141–150.</li>
  <li>Torres, O., Agramonte, A. J., Illnait, J., Mas Ferreiro, R., Fernandez, L., & Fernandez, J. C. (1995). Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care, 18, 393–397.</li>
  <li>Varady, K. A., Wang, Y., & Jones, P. J. (2003). Role of policosanols in the prevention and treatment of cardiovascular disease. Nutrition Reviews, 61, 376–383.</li>
  <li>Wang, M. F., Lian, H. Z., Mao, L., Zhou, J. P., Gong, H. J., Qian, B. Y., et al. (2007). Comparison of various extraction methods for policosanol from rice bran wax and establishment of chromatographic fingerprint of policosanol. Journal of Agricultural and Food Chemistry, 55, 5552–5558.</li>
  <li>Wang, T., Liu, Y. Y., Wang, X., Yang, N., Zhu, H. B., & Zuo, P. P. (2010). Protective eﬀects of policosanol on 6-hydroxydopamine-induced Parkinsonism in rats via regulation of ProNGF and NGF signaling. Acta Pharmacologica Sinica, 31, 765–774.</li>
  <li>Wang, T., Liu, Y., Yang, N., Ji, C., Chan, P., & Zuo, P. (2012). Anti-parkinsonian eﬀects of policosanol in 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-treated mice. Neural Regeneration Research, 14, 1080–1087.</li>

</ol>

<!-- Línea de Adyuvantes -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #ef6c00; padding-bottom: 10px;">
    <i class="fas fa-capsules" style="margin-right: 10px; color: #ef6c00;"></i>Línea de Adyuvantes
</h2>
<p style="margin-bottom: 20px; text-align: justify;">
    Los efectos secundarios y las reacciones tóxicas de los medicamentos son la causa del 15% de las muertes prematuras en episodios agudos. Sin embargo, nadie percibe que el uso continuado durante años de medicamentos utilizados en el control y tratamiento de la hipertensión, diabetes, artritis, artrosis, obesidad, enfermedades cardiovasculares, cerebrovasculares, demencias, Alzheimer y cientos de otras enfermedades, alteraciones y síndromes a corto y medio plazo causan más daño que beneficio a los pacientes.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    El uso constante de medicamentos para el control y tratamiento de enfermedades, síndromes y alteraciones desarrolla otras alteraciones, síndromes y enfermedades que suelen ser más fatales y reducen la calidad de vida más que la enfermedad misma para la cual el medicamento ha sido indicado por el médico.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    Afortunadamente, los científicos de "PPG NUTRITIONAL" han utilizado métodos empáticos de inteligencia artificial, genómica y proteómica para investigar la manera de contrarrestar los efectos adversos y tóxicos de los medicamentos utilizados para el control y tratamiento de estas condiciones, al tiempo que mejoran sus acciones farmacológicas y terapéuticas.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    La línea de adyuvantes desarrollada por "PPG NUTRITIONAL" está enfocada en reducir y eliminar los efectos secundarios de cada uno de los medicamentos utilizados por los pacientes para controlar o tratar enfermedades crónicas, como mostraremos en cada uno de los casos presentados a continuación:
</p>

<!-- Hipertensión -->
<h3 style="font-size: 22px; color: #1b5e20; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #1b5e20; padding-bottom: 5px;">
    Hipertensión
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    La hipertensión arterial, si no se trata, puede llevar a condiciones de salud graves. Estudios recientes apoyan una presión arterial objetivo para la mayoría de las personas de 120/80 mm Hg, con un nivel óptimo de 115/75 mm Hg para muchas personas. Nuestro enfoque está dirigido a lograr ese control de la presión arterial recomendado por MIS a través de la combinación de intervenciones naturales y estrategias de cambio de estilo de vida, y el uso de medicamentos antihipertensivos prescritos por médicos es complementado con el uso de productos terapéuticos adyuvantes que contribuyen al aumento de la eficacia de los medicamentos utilizados en el control de esta enfermedad y, al mismo tiempo, previenen los efectos adversos y tóxicos que causan el uso prolongado de los medicamentos, utilizados para la prevención y control de la hipertensión, para que no progresen hacia el desarrollo de síndromes, alteraciones y nuevas enfermedades como el cáncer, que suelen ser fatales o limitan las actividades laborales y sociales con una disminución de la calidad de vida.
</p>

<!-- Tratamientos Convencionales -->
<h3 style="font-size: 22px; color: #c62828; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #c62828; padding-bottom: 5px;">
    Tratamientos Convencionales
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    Si los cambios en la dieta y el estilo de vida por sí solos no reducen suficientemente la presión arterial, entonces los medicamentos se convierten en parte de las estrategias que pueden ser apropiadas para tales fines de la siguiente manera:
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    <strong>Recomendación de primera línea:</strong>
</p>

<!-- Línea de Adyuvantes -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #ef6c00; padding-bottom: 10px;">
    <i class="fas fa-capsules" style="margin-right: 10px; color: #ef6c00;"></i>Línea de Adyuvantes
</h2>
<p style="margin-bottom: 20px; text-align: justify;">
    Los efectos secundarios y las reacciones tóxicas de los medicamentos son la causa del 15% de las muertes prematuras en episodios agudos. Sin embargo, nadie percibe que el uso continuado durante años de medicamentos utilizados en el control y tratamiento de la hipertensión, diabetes, artritis, artrosis, obesidad, enfermedades cardiovasculares, cerebrovasculares, demencias, Alzheimer y cientos de otras enfermedades, alteraciones y síndromes a corto y medio plazo causan más daño que beneficio a los pacientes.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    El uso constante de medicamentos para el control y tratamiento de enfermedades, síndromes y alteraciones desarrolla otras alteraciones, síndromes y enfermedades que suelen ser más fatales y reducen la calidad de vida más que la enfermedad misma para la cual el medicamento ha sido indicado por el médico.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    Afortunadamente, los científicos de "PPG NUTRITIONAL" han utilizado métodos empáticos de inteligencia artificial, genómica y proteómica para investigar la manera de contrarrestar los efectos adversos y tóxicos de los medicamentos utilizados para el control y tratamiento de estas condiciones, al tiempo que mejoran sus acciones farmacológicas y terapéuticas.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    La línea de adyuvantes desarrollada por "PPG NUTRITIONAL" está enfocada en reducir y eliminar los efectos secundarios de cada uno de los medicamentos utilizados por los pacientes para controlar o tratar enfermedades crónicas, como mostraremos en cada uno de los casos presentados a continuación:
</p>

<!-- Hipertensión -->
<h3 style="font-size: 22px; color: #1b5e20; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #1b5e20; padding-bottom: 5px;">
    Hipertensión
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    La hipertensión arterial, si no se trata, puede llevar a condiciones de salud graves. Estudios recientes apoyan una presión arterial objetivo para la mayoría de las personas de 120/80 mm Hg, con un nivel óptimo de 115/75 mm Hg para muchas personas. Nuestro enfoque está dirigido a lograr ese control de la presión arterial recomendado por MIS a través de la combinación de intervenciones naturales y estrategias de cambio de estilo de vida, y el uso de medicamentos antihipertensivos prescritos por médicos es complementado con el uso de productos terapéuticos adyuvantes que contribuyen al aumento de la eficacia de los medicamentos utilizados en el control de esta enfermedad y, al mismo tiempo, previenen los efectos adversos y tóxicos que causan el uso prolongado de los medicamentos, utilizados para la prevención y control de la hipertensión, para que no progresen hacia el desarrollo de síndromes, alteraciones y nuevas enfermedades como el cáncer, que suelen ser fatales o limitan las actividades laborales y sociales con una disminución de la calidad de vida.
</p>

<!-- Recomendación de primera línea -->
<h3 style="font-size: 22px; color: #1b5e20; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #1b5e20; padding-bottom: 5px;">
    Recomendación de primera línea
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    En este caso, se incluyen los bloqueadores de los receptores de angiotensina II (particularmente Telmisartán); Inhibidores de la enzima convertidora de angiotensina como Benazepril (Lotensin), Captopril, Enalapril (Vasotec), Fosinopril, Lisinopril (Prinivil, Zestril), Moexipril, Perindopril, Quinapril (Accupril).
</p>

<!-- Recomendación de segunda línea -->
<h3 style="font-size: 22px; color: #c62828; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #c62828; padding-bottom: 5px;">
    Recomendación de segunda línea
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    Diuréticos tiazídicos como Clorotiazida (Diuril), Clortalidona, Hidroclorotiazida (Microzide), Indapamida, Metolazona.
</p>

<!-- Recomendación de tercera línea -->
<h3 style="font-size: 22px; color: #ef6c00; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #ef6c00; padding-bottom: 5px;">
    Recomendación de tercera línea
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    Bloqueadores de los canales de calcio como Amlodipino (Norvasc), Diltiazem (Cardizem, Tiazac, etc.), Felodipino, Isradipino, Nicardipino, Nifedipino (Adalat CC, Procardia), Nisoldipino (Sular), Verapamilo (Calan, Verelan). El uso simultáneo de más de un medicamento para la presión arterial, llamado terapia combinada, puede ser apropiado para personas cuya presión arterial no puede ser controlada con un solo medicamento.
</p>

<!-- Estrategia para el uso de adyuvantes -->
<h3 style="font-size: 22px; color: #1b5e20; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #1b5e20; padding-bottom: 5px;">
    Estrategia para el uso de adyuvantes
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    Para mejorar las acciones farmacológicas de los medicamentos utilizados en la prevención, control y tratamiento de la hipertensión y al mismo tiempo contrarrestar los efectos secundarios y las reacciones adversas causadas por el uso de estos medicamentos a mediano y largo plazo, que suelen contribuir al desarrollo de alteraciones, síndromes y enfermedades mortales, como el cáncer, y también pueden reducir la calidad de vida y la esperanza de vida de las personas bajo tratamiento; los científicos y médicos de "PPG NUTRICIONAL", junto con médicos de familia y especialistas de clínicas y hospitales, asistidos por el "MIS", definieron una estrategia terapéutica personalizada para desarrollar adyuvantes específicos que mejoran las acciones de los medicamentos utilizados en cada una de las etapas del tratamiento de la hipertensión y al mismo tiempo reducen el riesgo de contraer trastornos, síndromes o enfermedades fatales con disminución de la calidad de vida.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    Estos adyuvantes son, en sí mismos, composiciones únicas o combinaciones de medicamentos etiquetados, ingredientes activos naturales, cofactores enzimáticos, vitaminas, oligoelementos, hidrolizados de proteínas, péptidos, probióticos y otros productos autorizados para su uso en humanos por la FDA.
</p>

<!-- Nombre del producto -->
<h3 style="font-size: 22px; color: #c62828; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #c62828; padding-bottom: 5px;">
    Nombre del producto: SYSTOL 115/75
</h3>

<!-- Referencias -->
<h3 style="font-size: 22px; color: #ef6c00; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #ef6c00; padding-bottom: 5px;">
    Referencias
</h3>
<ol style="margin-bottom: 20px; padding-left: 25px; list-style-type: decimal; color: #333;">
    <li>Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. The American journal of medicine. Feb 2006;119(2):133-141.</li>
    <li>Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. Dec 14 2002;360(9349):1903-1913.</li>
    <li>Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. Dec 2003;42(6):1206-1252.</li>
    <li>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. Journal of clinical hypertension (Greenwich, Conn.). Jan 2014;16(1):14-26.</li>
    <li>Sprint Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine. Nov 9 2015;0(0):null.</li>
    <li>Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Archives of internal medicine. Mar 13 2000;160(5):685-693.</li>
    <li>Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney international. Mar 1997;51(3):793-797.</li>
    <li>Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, . . . Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2017.</li>
    <li>Egan BM, Stevens-Fabry S. Prehypertension--prevalence, health risks, and management strategies. Nature reviews cardiology. May 2015;12(5):289-300.</li>
    <li>Garofalo C, Borrelli S, Pacilio M, et al. Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. American journal of kidney diseases: the official journal of the National Kidney Foundation. Oct 13 2015.</li>
    <li>Stocchetti N, Chieregato A, De Marchi M, Croci M, Benti R, Grimoldi N. High cerebral perfusion pressure improves low values of local brain tissue O2 tension (PtiO2) in focal lesions. Acta neurochirurgica. Supplement. 1998;71:162-165.</li>
    <li>The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine. 2010;362(17):1575-1585.</li>
    <li>Barzilay JI, Howard AG, Evans GW, et al. Intensive Blood Pressure Treatment Does Not Improve Cardiovascular Outcomes in Centrally Obese Hypertensive Individuals With Diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes care. July 1, 2012 2012;35(7):1401-1405.</li>
    <li>Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (Clinical research ed.). 2016-02-25 00:06:06 2016;352.</li>
    <li>Odden MC, Shlipak MG, Whitson HE, et al. Risk factors for cardiovascular disease across the spectrum of older age: the Cardiovascular Health Study. Atherosclerosis. Nov 2014;237(1):336-342.</li>
    <li>Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. The New England journal of medicine. May 1 2008;358(18):1887-1898.</li>
    <li>Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. Journal of the American Geriatrics Society. Mar 2007;55(3):383-388.</li>
    <li>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA : the journal of the American Medical Association. Feb 5 2014;311(5):507-520.</li>
    <li>Krakoff LR. Blood Pressure Out of the Office: Its Time Has Finally Come. American journal of hypertension. Nov 6 2015.</li>
    <li>Fuchs SC, Ferreira-da-Silva AL, Moreira LB, et al. Efficacy of isolated home blood pressure monitoring for blood pressure control: randomized controlled trial with ambulatory blood pressure monitoring - MONITOR study. Journal of hypertension. Jan 2012;30(1):75-80.</li>
    <li>Breaux-Shropshire TL, Judd E, Vucovich LA, Shropshire TS, Singh S. Does home blood pressure monitoring improve patient outcomes? A systematic review comparing home and ambulatory blood pressure monitoring on blood pressure control and patient outcomes. Integrated blood pressure control. 2015;8:43-49.</li>
    <li>Agena F, Prado Edos S, Souza PS, et al. Home blood pressure (BP) monitoring in kidney transplant recipients is more adequate to monitor BP than office BP. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. Nov 2011;26(11):3745-3749.</li>
    <li>Imai Y, Obara T, Asamaya K, Ohkubo T. The reason why home blood pressure measurements are preferred over clinic or ambulatory blood pressure in Japan. Hypertension research : official journal of the Japanese Society of Hypertension. Aug 2013;36(8):661-672.</li>
    <li>Fuchs SC, Mello RG, Fuchs FC. Home blood pressure monitoring is better predictor of cardiovascular disease and target organ damage than office blood pressure: a systematic review and meta-analysis. Current cardiology reports. Nov 2013;15(11):413.</li>
    <li>Sacks FM, Appel LJ, Moore TJ, et al. A dietary approach to prevent hypertension: a review of the Dietary Approaches to Stop Hypertension (DASH) Study. Clinical cardiology. Jul 1999;22(7 Suppl):Iii6-10.</li>
    <li>Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Archives of internal medicine. Feb 8 1999;159(3):285-293.</li>
    <li>Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. The New England journal of medicine. Apr 17 1997;336(16):1117-1124.</li>
    <li>Streppel MT, Arends LR, van 't Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Archives of internal medicine. Jan 24 2005;165(2):150-156.</li>
    <li>Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. The New England journal of medicine. Jan 4 2001;344(1):3-10.</li>
    <li>Hinderliter AL, Sherwood A, Craighead LW, et al. The long-term effects of lifestyle change on blood pressure: One-year follow-up of the ENCORE study. American journal of hypertension. May 2014;27(5):734-741.</li>
    <li>Sikand G. Mediterranean, DASH & TLC Dietary Patterns: Mechanisms for CVD Reduction. Paper presented at: 2014 Clinical Lipid Update; March 16th 2014, 2014; Maui.</li>
    <li>Tognon G, Lissner L, Saebye D, Walker KZ, Heitmann BL. The Mediterranean diet in relation to mortality and CVD: a Danish cohort study. The British journal of nutrition. Jan 14 2014;111(1):151-159.</li>
    <li>Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean diet, cognitive function, and dementia: a systematic review. Epidemiology (Cambridge, Mass.). Jul 2013;24(4):479-489.</li>
    <li>Perez-Lopez FR, Chedraui P, Haya J, Cuadros JL. Effects of the Mediterranean diet on longevity and age-related morbid conditions. Maturitas. Oct 20 2009;64(2):67-79.</li>
    <li>Martinez-Gonzalez MA, Salas-Salvado J, Estruch R, Corella D, Fito M, Ros E. Benefits of the Mediterranean Diet: Insights From the PREDIMED Study. Progress in cardiovascular diseases. Jul-Aug 2015;58(1):50-60.</li>
    <li>Palkowska E, Bartnikowska E, Owsiak D. [The use of low-caloric diet with modified fatty acids pool in the therapy of the metabolic syndrome]. Roczniki Panstwowego Zakladu Higieny. 2012;63(2):163-169.</li>
    <li>Trubitsyn AG. The Lag of the Proliferative Aging Clock Underlies the Lifespan-Extending Effect of Calorie Restriction. Current aging science. 2015;8(3):220-226.</li>
    <li>Stein PK, Soare A, Meyer TE, Cangemi R, Holloszy JO, Fontana L. Caloric restriction may reverse age-related autonomic decline in humans. Aging Cell. Aug 2012;11(4):644-650.</li>
    <li>McCarty MF. AMPK activation--protean potential for boosting healthspan. Age (Dordrecht, Netherlands). Apr 2014;36(2):641-663.</li>
    <li>Kishi T, Hirooka Y, Ogawa K, Konno S, Sunagawa K. Calorie restriction inhibits sympathetic nerve activity via anti-oxidant effect in the rostral ventrolateral medulla of obesity-induced hypertensive rats. Clinical and experimental hypertension (New York, N.Y. : 1993). 2011;33(4):240-245.</li>
    <li>Finckenberg P, Eriksson O, Baumann M, et al. Caloric restriction ameliorates angiotensin II-induced mitochondrial remodeling and cardiac hypertrophy. Hypertension. Jan 2012;59(1):76-84.</li>
    <li>de Cavanagh EM, Inserra F, Ferder L. Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition. American journal of physiology. Heart and circulatory physiology. Jul 1 2015;309(1):H15-44.</li>
    <li>Liu Y, Chen H, Liu D. Mechanistic perspectives of calorie restriction on vascular homeostasis. Science China. Life sciences. Aug 2014;57(8):742-754.</li>
    <li>Jefferson ME, Nicklas BJ, Chmelo EA, et al. Effects of Resistance Training With and Without Caloric Restriction on Arterial Stiffness in Overweight and Obese Older Adults. American journal of hypertension. Aug 20 2015.</li>
    <li>Walford RL, Mock D, Verdery R, MacCallum T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. The journals of gerontology. Series A, Biological sciences and medical sciences. Jun 2002;57(6):B211-224.</li>
    <li>Ravussin E, Redman LM, Rochon J, et al. A 2-Year Randomized Controlled Trial of Human Caloric Restriction: Feasibility and Effects on Predictors of Health Span and Longevity. The journals of gerontology. Series A, Biological sciences and medical sciences. Sep 2015;70(9):1097-1104.</li>
    <li>Riegel G, Moreira LB, Fuchs SC, et al. Long-term effectiveness of non-drug recommendations to treat hypertension in a clinical setting. American journal of hypertension. Nov 2012;25(11):1202-1208.</li>
    <li>Elsevier. First Consult: Hypertension.</li>
    <li>Perez V, Chang ET. Sodium-to-potassium ratio and blood pressure, hypertension, and related factors. Advances in nutrition (Bethesda, Md.). Nov 2014;5(6):712-741.</li>
    <li>Penton D, Czogalla J, Loffing J. Dietary potassium and the renal control of salt balance and blood pressure. Pflugers Arch. Mar 2015;467(3):513-530.</li>
    <li>Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. Jan 2 2001;134(1):1-11.</li>
    <li>Kan AW, Hussain T, Carson KA, et al. The Contribution of Age and Weight to Blood Pressure Levels Among Blacks and Whites Receiving Care in Community-Based Primary Care Practices. Preventing chronic disease. 2015;12:E161.</li>
    <li>Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. Apr 2 2002;136(7):493-503.</li>
    <li>Cornelissen VA, Fagard RH. Effect of resistance training on resting blood pressure: a meta-analysis of randomized controlled trials. Journal of hypertension. Feb 2005;23(2):251-259.</li>
    <li>Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure : A meta-analysis of randomized controlled trials. Hypertension. Mar 2000;35(3):838-843.</li>
    <li>Larsen RN, Kingwell BA, Sethi P, Cerin E, Owen N, Dunstan DW. Breaking up prolonged sitting reduces resting blood pressure in overweight/obese adults. Nutrition, metabolism, and cardiovascular diseases : NMCD. Sep 2014;24(9):976-982.</li>
    <li>Bazzano LA, Green T, Harrison TN, Reynolds K. Dietary approaches to prevent hypertension. Current hypertension reports. Dec 2013;15(6):694-702.</li>
    <li>Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. Nov 2001;38(5):1112-1117.</li>
    <li>Aljadhey H, Tu W, Hansen RA, Blalock SJ, Brater DC, Murray MD. Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC cardiovascular disorders. 2012;12:93.</li>
    <li>Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. Sep 2015;66(3):524-533.</li>
    <li>Medicine AAoS. Rising prevalence of sleep apnea in U.S. threatens public health. 2014.</li>
    <li>Mayo Clinic. Diseases and Conditions. Sleep Apnea. http://www.mayoclinic.org/diseases-conditions/sleep-apnea/basics/complications/con-20020286. 8/25/2015. Accessed 11/19/2015.</li>
    <li>Liu L, Cao Q, Guo Z, Dai Q. Continuous Positive Airway Pressure in Patients With Obstructive Sleep Apnea and Resistant Hypertension: A Meta-Analysis of Randomized Controlled Trials. Journal of clinical hypertension (Greenwich, Conn.). Aug 17 2015.</li>
    <li>Hughes JW, Fresco DM, Myerscough R, van Dulmen MH, Carlson LE, Josephson R. Randomized controlled trial of mindfulness-based stress reduction for prehypertension. Psychosomatic medicine. Oct 2013;75(8):721-728.</li>
    <li>Gasperin D, Netuveli G, Dias-da-Costa JS, Pattussi MP. Effect of psychological stress on blood pressure increase: a meta-analysis of cohort studies. Cadernos de saude publica. Apr 2009;25(4):715-726.</li>
    <li>Larson AJ, Symons JD, Jalili T. Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Advances in nutrition (Bethesda, Md.). Jan 2012;3(1):39-46.</li>
    <li>Laskar MAC, M. D. In silico screening of some plant based natural products as angiotensin receptor blockers against cardiovascular diseases. World Journal of Pharmacy and Pharmaceutical Science. 2015;4(1):1248-1257.</li>
    <li>Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. The British journal of nutrition. Oct 2009;102(7):1065-1074.</li>
    <li>Pfeuffer M, Auinger A, Bley U, et al. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutrition, metabolism, and cardiovascular diseases : NMCD. May 2013;23(5):403-409.</li>
    <li>Brull V, Burak C, Stoffel-Wagner B, et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial. The British journal of nutrition. Oct 2015;114(8):1263-1277.</li>
    <li>Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T. Quercetin reduces blood pressure in hypertensive subjects. The Journal of nutrition. Nov 2007;137(11):2405-2411.</li>
    <li>Zahedi M, Ghiasvand R, Feizi A, Asgari G, Darvish L. Does Quercetin Improve Cardiovascular Risk factors and Inflammatory Biomarkers in Women with Type 2 Diabetes: A Double-blind Randomized Controlled Clinical Trial. International journal of preventive medicine. Jul 2013;4(7):777-785.</li>
    <li>Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annual review of nutrition. 2002;22:19-34.</li>
    <li>Basli A, Soulet S, Chaher N, et al. Wine polyphenols: potential agents in neuroprotection. Oxidative medicine and cellular longevity. 2012;2012:805762.</li>
    <li>Godse S, Mohan M, Kasture V, Kasture S. Effect of myricetin on blood pressure and metabolic alterations in fructose hypertensive rats. Pharmaceutical biology. May 2010;48(5):494-498.</li>
    <li>Borde P, Mohan M, Kasture S. Effect of myricetin on deoxycorticosterone acetate (DOCA)-salt-hypertensive rats. Natural product research. Sep 2011;25(16):1549-1559.</li>
    <li>Hobbs CA, Swartz C, Maronpot R, et al. Genotoxicity evaluation of the flavonoid, myricitrin, and its aglycone, myricetin. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. Sep 2015;83:283-292.</li>
    <li>Wang SJ, Tong Y, Lu S, et al. Anti-inflammatory activity of myricetin isolated from Myrica rubra Sieb. et Zucc. leaves. Planta medica. Oct 2010;76(14):1492-1496.</li>
    <li>Domitrovic R, Rashed K, Cvijanovic O, Vladimir-Knezevic S, Skoda M, Visnic A. Myricitrin exhibits antioxidant, anti-inflammatory and antifibrotic activity in carbon tetrachloride-intoxicated mice. Chemico-biological interactions. Mar 25 2015;230:21-29.</li>
    <li>Fernandez SP, Nguyen M, Yow TT, et al. The flavonoid glycosides, myricitrin, gossypin and naringin exert anxiolytic action in mice. Neurochemical research. Oct 2009;34(10):1867-1875.</li>
    <li>Sales DS, Carmona F, de Azevedo BC, et al. Eugenia punicifolia (Kunth) DC. as an adjuvant treatment for type-2 diabetes mellitus: a non-controlled, pilot study. Phytotherapy research : PTR. Dec 2014;28(12):1816-1821.</li>
    <li>Soejarto DD, Kinghorn AD, Farnsworth NR. Potential Sweetening Agents of Plant Origin. III. Organoleptic Evaluation of Stevia Leaf Herbarium Samples For Sweetness. Journal of natural products. 1982/09/01 1982;45(5):590-599.</li>
    <li>Gardana C, Simonetti P, Canzi E, Zanchi R, Pietta P. Metabolism of stevioside and rebaudioside A from Stevia rebaudiana extracts by human microflora. Journal of agricultural and food chemistry. Oct 22 2003;51(22):6618-6622.</li>
    <li>Liu JC, Kao PK, Chan P, et al. Mechanism of the antihypertensive effect of stevioside in anesthetized dogs. Pharmacology. Jan 2003;67(1):14-20.</li>
    <li>Melis MS. Influence of calcium on the blood pressure and renal effects of stevioside. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.]. 1992;25(9):943-949.</li>
    <li>Melis MS. Stevioside effect on renal function of normal and hypertensive rats. Journal of ethnopharmacology. Jun 1992;36(3):213-217.</li>
    <li>Onakpoya IJ, Heneghan CJ. Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: A systematic review and meta-analysis of randomised clinical trials. European journal of preventive cardiology. Dec 2015;22(12):1575-1587.</li>
    <li>Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. International journal of clinical practice. May 2007;61(5):835-845.</li>
    <li>Pechanova O, Paulis L, Simko F. Peripheral and Central Effects of Melatonin on Blood Pressure Regulation. International journal of molecular sciences. 10/08 07/03/received 09/17/revised 09/17/accepted 2014;15(10):17920-17937.</li>
    <li>Rodella LF, Favero G, Foglio E, et al. Vascular endothelial cells and dysfunctions: role of melatonin. Frontiers in bioscience (Elite edition). 2013;5:119-129.</li>
    <li>Li Y, Wang JG. Isolated nocturnal hypertension: a disease masked in the dark. Hypertension. Feb 2013;61(2):278-283.</li>
    <li>Kimura G. [Nocturnal hypertension and cardio-renal association]. Nihon rinsho. Japanese journal of clinical medicine. Aug 2014;72(8):1404-1409.</li>
    <li>Li F, Huang H, Song L, Hao H, Ying M. Effects of Obstructive Sleep Apnea Hypopnea Syndrome on Blood Pressure and C-Reactive Protein in Male Hypertension Patients. J Clin Med Res. Mar 2016;8(3):220-224.</li>
    <li>Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011;7:577-584.</li>
    <li>Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. Journal of hypertension. Aug 2002;20(8):1493-1499.</li>
    <li>Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. American journal of hypertension. Jul 2014;27(7):885-896.</li>
    <li>Endo J, Arita M. Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. Journal of cardiology. Sep 7 2015.</li>
    <li>Jain AP, Aggarwal KK, Zhang PY. Omega-3 fatty acids and cardiovascular disease. European review for medical and pharmacological sciences. 2015;19(3):441-445.</li>
    <li>Li D. Omega-3 polyunsaturated fatty acids and non-communicable diseases: meta-analysis based systematic review. Asia Pacific journal of clinical nutrition. 2015;24(1):10-15.</li>
    <li>Nestel P, Clifton P, Colquhoun D, et al. Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease. Heart, lung & circulation. Aug 2015;24(8):769-779.</li>
    <li>Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. The Cochrane database of systematic reviews. 2009(4):Cd007435.</li>
    <li>Wyman M, Leonard M, Morledge T. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia? Cleveland Clinic journal of medicine. Jul 2010;77(7):435-442.</li>
    <li>Mortensen SA, Rosenfeldt F, Kumar A, et al. The Effect of Coenzyme Q on Morbidity and Mortality in Chronic Heart Failure: Results From Q-SYMBIO: A Randomized Double-Blind Trial. JACC. Heart failure. Sep 25 2014.</li>
    <li>Gao L, Mao Q, Cao J, Wang Y, Zhou X, Fan L. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. Apr 2012;221(2):311-316.</li>
    <li>Hamilton SJ, Chew GT, Watts GF. Coenzyme Q10 Improves Endothelial Dysfunction in Statin-Treated Type 2 Diabetic Patients. Diabetes care. May 1, 2009 2009;32(5):810-812.</li>
    <li>Kedziora-Kornatowska K, Czuczejko J, Motyl J, et al. Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study. Archives of medical science : AMS. Aug 30 2010;6(4):513-518.</li>
    <li>Alehagen U, Johansson P, Björnstedt M, Rosén A, Dahlström U. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. International journal of cardiology. 9/1/ 2013;167(5):1860-1866.</li>
    <li>Jee SH, Miller ER, 3rd, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. American journal of hypertension. Aug 2002;15(8):691-696.</li>
    <li>Shechter M, Shechter A. The Role of Magnesium in the Cardiovascular System. In: Watson RR, Preedy VR, Zibadi S, eds. Magnesium in Human Health and Disease: Humana Press; 2013:191-204.</li>
    <li>Houston M. Magnesium and Hypertension. In: Watson RR, Preedy VR, Zibadi S, eds. Magnesium in Human Health and Disease: Humana Press; 2013:183-189.</li>
    <li>Rosanoff A. Magnesium supplements may enhance the effect of antihypertensive medications in stage 1 hypertensive subjects. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. Mar 2010;23(1):27-40.</li>
    <li>Qu X, Jin F, Hao Y, et al. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PloS one. 2013;8(3):e57720.</li>
    <li>Grober U, Schmidt J, Kisters K. Magnesium in Prevention and Therapy. Nutrients. 2015;7(9):8199-8226.</li>
    <li>Rosanoff A, Plesset MR. Oral magnesium supplements decrease high blood pressure (SBP>155 mmHg) in hypertensive subjects on anti-hypertensive medications: a targeted meta-analysis. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. Jul-Sep 2013;26(3):93-99.</li>
    <li>Tin A, Grams ME, Maruthur NM, et al. Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney international. 04//print 2015;87(4):820-827.</li>
    <li>Witkowski M, Hubert J, Mazur A. Methods of assessment of magnesium status in humans: a systematic review. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. Dec 2011;24(4):163-180.</li>
    <li>Fekete AA, Givens DI, Lovegrove JA. Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. Nutrients. Jan 2015;7(1):659-681.</li>
    <li>Gold Standard. Drug Monograph. Lisinopril. www.clinicalkey.com. Copyright 2015 by Elsevier, Inc. Last updated 8/5/2014. Accessed 11/19/2015.</li>
    <li>Gold Standard. Drug Monograph. Candesartan. www.clinicalkey.com. Copyright 2015 by Elsevier, Inc. Last updated 6/15/2012. Accessed 11/19/2015.</li>
    <li>Pal S, Ellis V. The chronic effects of whey proteins on blood pressure, vascular function, and inflammatory markers in overweight individuals. Obesity (Silver Spring, Md.). Jul 2010;18(7):1354-1359.</li>
    <li>Pal S, Ellis V. Acute effects of whey protein isolate on blood pressure, vascular function and inflammatory markers in overweight postmenopausal women. The British journal of nutrition. May 2011;105(10):1512-1519.</li>
    <li>FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. The Journal of nutrition. Apr 2004;134(4):980s-988s.</li>
    <li>Cicero AFG, Aubin F, Azais-Braesco V, Borghi C. Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials. American journal of hypertension. 2013;26(3):442-449.</li>
    <li>Pins JJ, Keenan JM. Effects of whey peptides on cardiovascular disease risk factors. Journal of clinical hypertension (Greenwich, Conn.). Nov 2006;8(11):775-782.</li>
    <li>Houston M. The role of nutrition and nutraceutical supplements in the treatment of hypertension. World journal of cardiology. 2014;6(2):38-66.</li>
    <li>Maes W, Van Camp J, Vermeirssen V, et al. Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells. Regulatory peptides. Apr 15 2004;118(1-2):105-109.</li>
    <li>Li SH, Tian HB, Zhao HJ, Chen LH, Cui LQ. The acute effects of grape polyphenols supplementation on endothelial function in adults: meta-analyses of controlled trials. PloS one. 2013;8(7):e69818.</li>
    <li>Li SH, Zhao P, Tian HB, Chen LH, Cui LQ. Effect of Grape Polyphenols on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials. PloS one. 2015;10(9):e0137665.</li>
    <li>Edirisinghe I, Burton-Freeman B, Tissa Kappagoda C. Mechanism of the endothelium-dependent relaxation evoked by a grape seed extract. Clinical science (London, England : 1979). Feb 2008;114(4):331-337.</li>
    <li>Park E, Edirisinghe I, Choy YY, Waterhouse A, Burton-Freeman B. Effects of grape seed extract beverage on blood pressure and metabolic indices in individuals with pre-hypertension: a randomised, double-blinded, two-arm, parallel, placebo-controlled trial. The British journal of nutrition. Nov 16 2015:1-13.</li>
    <li>Asgary S, Keshvari M, Sahebkar A, Hashemi M, Rafieian-Kopaei M. Clinical investigation of the acute effects of pomegranate juice on blood pressure and endothelial function in hypertensive individuals. ARYA atherosclerosis. Nov 2013;9(6):326-331.</li>
    <li>Asgary S, Sahebkar A, Afshani MR, Keshvari M, Haghjooyjavanmard S, Rafieian-Kopaei M. Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti-inflammatory effects of pomegranate juice in hypertensive subjects. Phytotherapy research : PTR. Feb 2014;28(2):193-199.</li>
    <li>Tsang C, Smail NF, Almoosawi S, Davidson I, Al-Dujaili EA. Intake of polyphenol-rich pomegranate pure juice influences urinary glucocorticoids, blood pressure and homeostasis model assessment of insulin resistance in human volunteers. Journal of nutritional science. 2012;1:e9.</li>
    <li>Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis. Sep 2001;158(1):195-198.</li>
    <li>Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clinical nutrition (Edinburgh, Scotland). Jun 2004;23(3):423-433.</li>
    <li>de Nigris F, Balestrieri ML, Williams-Ignarro S, et al. The influence of pomegranate fruit extract in comparison to regular pomegranate juice and seed oil on nitric oxide and arterial function in obese Zucker rats. Nitric Oxide. Aug 2007;17(1):50-54.</li>
    <li>Mohan M, Waghulde H, Kasture S. Effect of pomegranate juice on Angiotensin II-induced hypertension in diabetic Wistar rats. Phytotherapy research : PTR. Jun 2010;24 Suppl 2:S196-203.</li>
    <li>Susalit E, Agus N, Effendi I, et al. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril. Phytomedicine : international journal of phytotherapy and phytopharmacology. Feb 15 2011;18(4):251-258.</li>
    <li>Cherif S, Rahal N, Haouala M, et al. [A clinical trial of a titrated Olea extract in the treatment of essential arterial hypertension]. J Pharm Belg. Mar-Apr 1996;51(2):69-71.</li>
    <li>Perrinjaquet-Moccetti T, Busjahn A, Schmidlin C, Schmidt A, Bradl B, Aydogan C. Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins. Phytotherapy research : PTR. Sep 2008;22(9):1239-1242.</li>
    <li>de Bock M, Derraik JG, Brennan CM, et al. Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trial. PloS one. 2013;8(3):e57622.</li>
    <li>Scheffler A, Rauwald HW, Kampa B, Mann U, Mohr FW, Dhein S. Olea europaea leaf extract exerts L-type Ca(2+) channel antagonistic effects. Journal of ethnopharmacology. Nov 20 2008;120(2):233-240.</li>
    <li>Gilani AH, Khan AU, Shah AJ, Connor J, Jabeen Q. Blood pressure lowering effect of olive is mediated through calcium channel blockade. International journal of food sciences and nutrition. Dec 2005;56(8):613-620.</li>
    <li>Hansen K, Adsersen A, Christensen SB, Jensen SR, Nyman U, Smitt UW. Isolation of an angiotensin converting enzyme (ACE) inhibitor from Olea europaea and Olea lancea. Phytomedicine : international journal of phytotherapy and phytopharmacology. Mar 1996;2(4):319-325.</li>
    <li>Parzonko A, Czerwinska ME, Kiss AK, Naruszewicz M. Oleuropein and oleacein may restore biological functions of endothelial progenitor cells impaired by angiotensin II via activation of Nrf2/heme oxygenase-1 pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology. Sep 15 2013;20(12):1088-1094.</li>
    <li>Madhavi D, Kagan D, Rao V. A Pilot Study to Evaluate the Antihypertensive Effect of a Celery Extract in Mild to Moderate Hypertensive Patients. Age. 2013;57:10.13.</li>
    <li>Moghadam MH, Imenshahidi M, Mohajeri SA. Antihypertensive effect of celery seed on rat blood pressure in chronic administration. Journal of medicinal food. Jun 2013;16(6):558-563.</li>
    <li>Ko FN, Huang TF, Teng CM. Vasodilatory action mechanisms of apigenin isolated from Apium graveolens in rat thoracic aorta. Biochimica et biophysica acta. Nov 14 1991;1115(1):69-74.</li>
    <li>Jorge VG, Angel JR, Adrian TS, et al. Vasorelaxant activity of extracts obtained from Apium graveolens: possible source for vasorelaxant molecules isolation with potential antihypertensive effect. Asian Pac J Trop Biomed. Oct 2013;3(10):776-779.</li>
    <li>Hamet P. The evaluation of the scientific evidence for a relationship between calcium and hypertension. The Journal of nutrition. Feb 1995;125(2 Suppl):311s-400s.</li>
    <li>van Mierlo LA, Arends LR, Streppel MT, et al. Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials. Journal of human hypertension. Aug 2006;20(8):571-580.</li>
    <li>Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. The Journal of nutrition. Nov 2004;134(11):3100-3105.</li>
    <li>Chow CK. Dietary intake of menaquinones and risk of cancer incidence and mortality. The American journal of clinical nutrition. December 1, 2010 2010;92(6):1533-1534.</li>
    <li>Shea MK, O'Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. The American journal of clinical nutrition. Jun 2009;89(6):1799-1807.</li>
    <li>DiNicolantonio JJ, Bhutani J, O'Keefe JH. The health benefits of vitamin K. Open Heart. 10/06 06/01/received 08/27/revised 09/18/accepted 2015;2(1):e000300.</li>
    <li>Shea MK, Holden RM. Vitamin K status and vascular calcification: evidence from observational and clinical studies. Advances in nutrition (Bethesda, Md.). Mar 2012;3(2):158-165.</li>
    <li>Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. American heart journal. Dec 2011;162(6):959-965.</li>
    <li>Kozuma K, Tsuchiya S, Kohori J, Hase T, Tokimitsu I. Antihypertensive effect of green coffee bean extract on mildly hypertensive subjects. Hypertension research : official journal of the Japanese Society of Hypertension. Sep 2005;28(9):711-718.</li>
    <li>Yamaguchi T, Chikama A, Mori K, et al. Hydroxyhydroquinone-free coffee: a double-blind, randomized controlled dose-response study of blood pressure. Nutrition, metabolism, and cardiovascular diseases : NMCD. Jul 2008;18(6):408-414.</li>
    <li>Wang J, Xiong X, Feng B. Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evidence-based complementary and alternative medicine : eCAM. 2013;2013:149363.</li>
    <li>Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clinical nutrition (Edinburgh, Scotland). Feb 2015;34(1):27-34.</li>
    <li>Izzo JL, Jr., Weir MR. Angiotensin-converting enzyme inhibitors. Journal of clinical hypertension (Greenwich, Conn.). Sep 2011;13(9):667-675.</li>
    <li>Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy, and safety. Journal of clinical hypertension (Greenwich, Conn.). Sep 2011;13(9):677-686.</li>
    <li>Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. The Cochrane database of systematic reviews. 2014;8:Cd009096.</li>
    <li>Akhrass PR, McFarlane SI. Telmisartan and cardioprotection. Vascular Health and Risk Management. 11/15 2011;7:677-683.</li>
    <li>Lacourciere Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood pressure monitoring. Aug 2004;9(4):203-210.</li>
    <li>Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. The Canadian journal of cardiology. Sep 2000;16(9):1123-1132.</li>
    <li>Lacourciere Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood pressure monitoring. Oct 1998;3(5):295-302.</li>
    <li>Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. May 2004;43(5):993-1002.</li>
    <li>Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. May 4 2004;109(17):2054-2057.</li>
    <li>Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Molecular endocrinology (Baltimore, Md.). Apr 2003;17(4):662-676.</li>
    <li>Takeuchi K, Yamamoto K, Ohishi M, et al. Telmisartan modulates mitochondrial function in vascular smooth muscle cells. Hypertension research : official journal of the Japanese Society of Hypertension. May 2013;36(5):433-439.</li>
    <li>He H, Yang D, Ma L, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. Hypertension. Apr 2010;55(4):869-879.</li>
    <li>Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Tager M, Bode-Boger SM. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension. Mar 2008;51(3):696-703.</li>
    <li>Feng X, Luo Z, Ma L, et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta/AMPK pathway. Journal of cellular and molecular medicine. Jul 2011;15(7):1572-1581.</li>
    <li>Sanchis-Gomar F, Lippi G. Telmisartan as metabolic modulator: a new perspective in sports doping? Journal of strength and conditioning research / National Strength & Conditioning Association. Mar 2012;26(3):608-610.</li>
    <li>Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension. May 2006;47(5):1003-1009.</li>
    <li>Goyal SN, Bharti S, Bhatia J, Nag TC, Ray R, Arya DS. Telmisartan, a dual ARB/partial PPAR-gamma agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes, obesity & metabolism. Jun 2011;13(6):533-541.</li>
    <li>Iwai M, Inaba S, Tomono Y, et al. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertension research : official journal of the Japanese Society of Hypertension. Jan 2008;31(1):161-168.</li>
    <li>Iwanami J, Mogi M, Tsukuda K, et al. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. Journal of hypertension. Aug 2010;28(8):1730-1737.</li>
    <li>Yuen CY, Wong WT, Tian XY, et al. Telmisartan inhibits vasoconstriction via PPARgamma-dependent expression and activation of endothelial nitric oxide synthase. Cardiovascular research. Apr 1 2011;90(1):122-129.</li>
    <li>Myojo M, Nagata D, Fujita D, et al. Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells. PloS one. 2014;9(5):e96948.</li>
    <li>de Araujo Junior RF, Leitao Oliveira AL, de Melo Silveira RF, de Oliveira Rocha HA, de Franca Cavalcanti P, de Araujo AA. Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells. Experimental biology and medicine (Maywood, N.J.). Jan 2015;240(1):34-44.</li>
    <li>Koyama N, Nishida Y, Ishii T, Yoshida T, Furukawa Y, Narahara H. Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PloS one. 2014;9(3):e93050.</li>
    <li>Lee LD, Mafura B, Lauscher JC, Seeliger H, Kreis ME, Grone J. Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells. Oncology letters. Dec 2014;8(6):2681-2686.</li>
    <li>Pu Z, Zhu M, Kong F. Telmisartan prevents proliferation and promotes apoptosis of human ovarian cancer cells through upregulating PPARgamma and downregulating MMP9 expression. Molecular medicine reports. Nov 6 2015.</li>
    <li>Ferri FF. Ferri's Clinical Advisor. Disease Overview: Hypertension. Copyright 2016 by Elsevier, Inc. www.clinicalkey.com. 11/19/2015.</li>
    <li>Moser M, Feig PU. FIfty years of thiazide diuretic therapy for hypertension. Archives of internal medicine. 2009;169(20):1851-1856.</li>
    <li>ePocrates. Drugs. hydrochlorothiazide. Adverse Reactions. https://online.epocrates.com/drugs/22205/hydrochlorothiazide/Adverse-Reactions. Accessed 11/19/2015.</li>
    <li>Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis.</li>
    <li>Spindler SR, Mote PL, Li R, et al. beta1-Adrenergic receptor blockade extends the life span of Drosophila and long-lived mice. Age (Dordrecht, Netherlands). Dec 2013;35(6):2099-2109.</li>
    <li>Gomez A, Sanchez-Roman I, Gomez J, et al. Lifelong treatment with atenolol decreases membrane fatty acid unsaturation and oxidative stress in heart and skeletal muscle mitochondria and improves immunity and behavior, without changing mice longevity. Aging Cell. Jun 2014;13(3):551-560.</li>
    <li>NPS MEDICINEWISE. Medical tests. ACE and ARB - reductions in GFR. http://www.nps.org.au/medical-tests/tests-by-conditions/for-individuals/kidney-problems-and-disorders-tests/for-health-professionals/medicines-to-be-aware-of/ace-arb-reductions-in-gfr#References. 6/30/2012. Accessed 11/20/2015.</li>
    <li>Schoolwerth A. Cautions with Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) Therapy. CKD Update: Attacking Chronic Kidney Disease. Vol. 1; Issue 3. Copyright 2004 by The National Kidney Foundation. http://www.imakenews.com/ckdupdate/e_article000327587.cfm?x=b11,0,w. Accessed 11/20/2015.</li>
    <li>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. Journal of hypertension. Jan 2014;32(1):3-15.</li>
    <li>Hermida RC, Ayala DE, Mojon A, Fernandez JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. Journal of the American Society of Nephrology : JASN. Dec 2011;22(12):2313-2321.</li>
    <li>Hermida RC, Ayala DE. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension. Jul 2009;54(1):40-46.</li>
    <li>Hermida RC, Ayala DE, Fontao MJ, Mojon A, Fernandez JR. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Chronobiology international. Jul 2010;27(6):1287-1303.</li>
    <li>Hermida RC, Ayala DE, Mojon A, Fernandez JR. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. American journal of hypertension. Aug 2008;21(8):948-954.</li>
    <li>Hermida RC, Ayala DE, Mojon A, Fontao MJ, Fernandez JR. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiology international. Aug 2011;28(7):601-610.</li>
    <li>Zeng J, Jia M, Ran H, et al. Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study. Hypertension research : official journal of the Japanese Society of Hypertension. Jun 2011;34(6):767-772.</li>
    <li>Cruickshank JM. The role of coronary perfusion pressure. European heart journal. Sep 1992;13 Suppl D:39-43.</li>
    <li>Owens P, O'Brien E. Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events? Heart (British Cardiac Society). Oct 1999;82(4):477-481.</li>
    <li>Voudris V, Avramides D, Gatzov P, Malakos J, Skoularigis J, Manolis A, . . . Cokkinos DV. The effect of rapid decreases of blood pressure by different mechanisms on coronary flow and flow reserve in normal coronary arteries. American journal of hypertension. Dec 2003;16(12):1000-1005.</li>
    <li>Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. European heart journal. Dec 2010;31(23):2897-2908.</li>
    <li>Lanza CM. CITRUS FRUITS | Processed and Derived Products of Oranges. In: Caballero B, ed. Encyclopedia of Food Sciences and Nutrition (Second Edition). Oxford: Academic Press; 2003:1346-1354.</li>
    <li>Benavente-Garcia O, Castillo J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem. Aug 13 2008;56(15):6185-6205.</li>

</ol>

<!-- Rheumatoid Arthritis -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #ef6c00; padding-bottom: 10px;">
    <i class="fas fa-hand-holding-medical" style="margin-right: 10px; color: #ef6c00;"></i>Rheumatoid Arthritis
</h2>
<p style="margin-bottom: 20px; text-align: justify;">
    Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by an autoimmune response that causes pain and disfigurement in peripheral joints. A dangerously underappreciated fact about RA is that it also significantly increases the risk of cardiovascular disease. Too often, conventional treatment strategies produce only marginal relief, failing to mitigate the intrinsic systemic risks that decrease the longevity of RA patients. Treatments should be focused on the application of intensive protocols for cardiovascular risk reduction, which should be as high a priority as relieving joint pain. Strategies must be conveniently focused through the use of adjuvants that improve therapeutic actions, reduce toxicity and contribute to retraining the immune system to prevent joints, as well as reduce the risk for the development of cardiovascular diseases and even malignant diseases such as cancer.
</p>

<!-- Conventional treatments -->
<h3 style="font-size: 22px; color: #1b5e20; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #1b5e20; padding-bottom: 5px;">
    Conventional treatments
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    Disease-modifying antirheumatic drugs (DMARDs) (e.g., methotrexate and sulfasalazine); Glucocorticoids (e.g., prednisone); non-steroidal anti-inflammatory drugs (NSAIDs); Statins to prevent cardiovascular disease; Modified-release prednisone to improve on the action of conventional prednisone; Stem cell treatment; Bioidentical hormone replacement therapy.
</p>

<!-- Strategy for use of adjuvants -->
<h3 style="font-size: 22px; color: #c62828; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #c62828; padding-bottom: 5px;">
    Strategy for use of adjuvants
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    To improve the pharmacological actions of the drugs used in the prevention, control and treatment of Rheumatoid arthritis and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term that usually contribute to the development of alterations, syndromes, and deadly diseases, such as cancer, and can also reduce the quality life expectancy of people under treatment; the scientists and doctors of "PPG NUTRICIONAL" together with family doctors and specialists from clinics and hospitals, assisted by the "MIS", defined a personalized therapeutic strategy to develop specific adjuvants that improve the actions of the drugs used in each of the stages treatment of Rheumatoid arthritis and at the same time reduce the risk of contracting disorders, syndromes or fatal diseases with decreased quality of life. These adjuvants are, in themselves, unique compositions or combinations of labeled drugs, natural active ingredients, enzyme cofactors, vitamins, trace elements, protein hydrolysates, peptides, probiotics, and other products authorized for use in humans by the FDA.
</p>

<!-- References -->
<h4 style="font-size: 20px; color: #333; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #ef6c00; padding-bottom: 5px;">
    References
</h4>
<ol style="margin-bottom: 20px; padding-left: 25px; list-style-type: decimal; color: #333;">
    <li>Duijnisveld BJ, et al. Regenerative potential of human muscle stem cells in chronic inflammation. Arthritis Res Ther, 2011. 13(6):R207.</li>
    <li>Ebina K, Shi K, Hirao M, et al. Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis. Mod Rheumatol. 2013;23(5):1001-7.</li>
    <li>Edwards JC, et al. Efficacy of β-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med, 2004. 350(25):2572-81.</li>
    <li>Endres S, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med, 1989. 320(5):265-71.</li>
    <li>Faloon W. "ARTHRITIS UPDATE: Drugs That Inhibit COX-2 May Cause Tissue Damage" Life Extension magazine, 1/2001.</li>
    <li>Feng Z, Xu J, He G, Cao M, Duan L, Chen L, Wu Z. The Efficacy and Safety of the Combination of Total Glucosides of Peony and Leflunomide for the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis. Evidence-based complementary and alternative medicine: eCAM. 2016;2016:9852793.</li>
    <li>Feng Z-T, Xu J, He G-C, Cai S-J, Li J, Mei Z-G. A systemic review and meta-analysis of the clinical efficacy and safety of total glucosides of peony combined with methotrexate in rheumatoid arthritis. Clinical rheumatology. 2018;37(1):35-42. doi:10.1007/s10067-017-3770-y.</li>
    <li>FDA Import Refusal Report. Available at http://www.accessdata.fda.gov/scripts/importrefusals/ir_detail.cfm?EntryId=UPS-2301487-7&DocId=1&LineId=1&SfxId= Accessed 2/8/2012.</li>
    <li>Flint-Wagner HG, et al. Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients. J Clin Rheumatol, 2009. 15(4):165-71.</li>
    <li>Fouda AM and Berika MY. Evaluation of the effect of hydroalcoholic extract of Zingiber officinale rhizomes in rat collagen-induced arthritis. Basic Clin Pharmacol Toxicol, 2009. 104(3):262-71.</li>
    <li>Funk JL, et al. Comparative effects of two gingerol-containing Zingiber officinale extracts on experimental rheumatoid arthritis. J Nat Prod, 2009. 72(3):403-7.</li>
    <li>Gheita TA and Kenawy SA. Effectiveness of Nigella sativa Oil in the Management of Rheumatoid Arthritis Patients: A Placebo Controlled Study. Phytother Res, 2011.</li>
    <li>Gold Standard. Drug Monograph. Methotrexate. www.clinicalkey.com. Last updated 2016. Accessed 10/7/2016.</li>
    <li>Goldberg RJ and Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain, 2007. 129(1-2):210-23.</li>
    <li>Gopinath K and Danda D. Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial. Int J Rheum Dis, 2011. 14(4):332-9.</li>
    <li>Grober U, Reichrath J, Holick M, et al. Vitamin K: an old vitamin in a new perspective. Dermatoendocrinol. 2014;6(1):e968490.</li>
    <li>Grzanna R, Lindmark L, Frondoza CG. Ginger--an herbal medicinal product with broad anti-inflammatory actions. J Med Food, 2005. 8(2):125-32.</li>
    <li>Haqqi TM, et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci U S A, 1999. 96(8):4524-9.</li>
    <li>He DY, Dai SM. Anti-inflammatory and immunomodulatory effects of paeonia lactiflora pall., a traditional chinese herbal medicine. Frontiers in pharmacology.2011;2:10.</li>
    <li>Henrotin Y, et al. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage, 2010. 18(2):141-9.</li>
    <li>Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002. 166(5):608-15.</li>
    <li>Hua J, et al. Evaluation of the suppressive actions of glucosamine on the interleukin-1beta-mediated activation of synoviocytes. Inflamm Res, 2007. 56(10):432-8.</li>
    <li>Huang SC, et al. Vitamin B(6) supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis. Eur J Clin Nutr, 2010. 64(9):1007-13.</li>
    <li>Ierna M, et al. Supplementation of diet with krill oil protects against experimental rheumatoid arthritis. BMC musculoskeletal disorders, 2010. 11:136.</li>
    <li>Jackson JK, et al. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res, 2006. 55(4):168-75.</li>
    <li>James M, Proudman S, Cleland L. Fish oil and rheumatoid arthritis: past, present and future. Proc Nutr Soc, 2010. 69(3):316-23.</li>
    <li>James MJ and Cleland LG, Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Semin Arthritis Rheum, 1997. 27(2):85-97.</li>
    <li>Jia XY, Chang Y, Sun XJ, et al. Total glucosides of paeony inhibit the proliferation of fibroblast-like synoviocytes through the regulation of G proteins in rats with collagen-induced arthritis. International immunopharmacology.Jan 2014;18(1):1-6.</li>
    <li>Juanola-Falgarona M, Salas-Salvado J, Estruch R, et al. Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk. Cardiovasc Diabetol. 2013;12(7).</li>
    <li>Ju YH, et al. beta-Sitosterol, beta-Sitosterol Glucoside, and a Mixture of beta-Sitosterol and beta-Sitosterol Glucoside Modulate the Growth of Estrogen-Responsive Breast Cancer Cells In Vitro and in Ovariectomized Athymic Mice. J Nutr. 2004 May;134(5):1145-51.</li>
    <li>Jurgens MS, Jacobs JW, and Bijlsma JW. The use of conventional disease-modifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol, 2011. 25(4):523-33.</li>
    <li>Kahlenberg JM and Fox DA. Advances in the medical treatment of rheumatoid arthritis. Hand Clin, 2011. 27(1):11-20.</li>
    <li>Karlson EW, et al. A prospective study of androgen levels, hormone-related genes and risk of rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R97. Epub 2009 Jun 25.</li>
    <li>Keystone E, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis, 2009. 68(2):216-21.</li>
    <li>Khan F, et al. The role of endothelial function and its assessment in rheumatoid arthritis. Nat Rev Rheumatol. 2010 May;6(5):253-61. Epub 2010 Mar 30.</li>
    <li>Kim HR, et al. Green tea protects rats against autoimmune arthritis by modulating disease-related immune events. J Nutr, 2008. 138(11):2111-6.</li>
    <li>Klippel, JH. The pocket primer on the rheumatic diseases. 2nd ed2010, Atlanta, GA: Arthritis Foundation. p.242.</li>
    <li>Kremer JM, et al. Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet, 1985. 1(8422):184-7.</li>
    <li>Lee JH and Kim GH. Evaluation of antioxidant and inhibitory activities for different subclasses flavonoids on enzymes for rheumatoid arthritis. J Food Sci, 2010. 75(7):H212-7.</li>
    <li>Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med, 1993. 119(9):867-73.</li>
    <li>Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with blackcurrant seed oil. Br J Rheumatol, 1994. 33(9):847-52.</li>
    <li>Life Extension. Available at: http://www.lifeextension.com/HealthWellness/ClinicalResearch/StudyDetails.aspx?study=CL025 Accessed 2/10/2012.</li>
    <li>Lin J, Xiao L, Ouyang G, et al. Total glucosides of paeony inhibits Th1/Th17 cells via decreasing dendritic cells activation in rheumatoid arthritis. Cell Immunol.Dec 2012;280(2):156-163.</li>
    <li>Lindler BN, Long KE, Taylor NA, Lei W. Use of Herbal Medications for Treatment of Osteoarthritis and Rheumatoid Arthritis. Medicines (Basel, Switzerland). Oct 28 2020;7(11)doi:10.3390/medicines7110067.</li>
    <li>Liu B, Meng X, Ma Y, et al. Clinical safety of total glucosides of paeony adjuvant therapy for rheumatoid arthritis treatment: a systematic review and meta-analysis. BMC Complement Med Ther. Mar 26 2021;21(1):102. doi:10.1186/s12906-021-03252-y.</li>
    <li>Liu GL, Li YC, Shen YJ. [Inhibitory effect of total glucosides of paeonia on the NF-kappaB/p65 protein expression in paws of RA rats]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.Nov 2010;26(11):1082-1084.</li>
    <li>Liu J, Wang ZT, Ge BX. Andrograpanin, isolated from Andrographis paniculata, exhibits anti-inflammatory property in lipopolysaccharide-induced macrophage cells through down-regulating the p38 MAPKs signaling pathways. Int Immunopharmacol. 2008 Jul;8(7):951-8.</li>
    <li>Liu J, Wang ZT, Ji LL, Ge BX. Inhibitory effects of neoandrographolide on nitric oxide and prostaglandin E2 production in LPS-stimulated murine macrophage. Mol Cell Biochem. 2007 Apr;298(1-2):49-57.</li>
    <li>Liu J, Wang ZT, Ji LL. In vivo and in vitro anti-inflammatory activities of neoandrographolide. Am J Chin Med. 2007;35(2):317-28.</li>
    <li>Louw I, et al. A pilot study of the clinical effects of a mixture of beta-sitosterol and beta-sitosterol glucoside in active rheumatoid arthritis (RA). Am J Clin Nutr 2002 75: 2 339S-439S [abstract 40].</li>
    <li>Ma MH, Kingsley GH, and Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford), 2010. 49(1):91-8.</li>
    <li>Macfarlane GJ, et al. Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review. Rheumatology (Oxford), 2011. 50(9):1672-83.</li>
    <li>Manganelli P and Rioda WT. [Weekly low-dose methotrexate in rheumatoid arthritis. Review of the literature]. Minerva medica, 1993. 84(10):541-52.</li>
    <li>Martinez-Calatrava MJ, Largo R, Herrero-Beaumont G. Improvement of experimental accelerated atherosclerosis by chondroitin sulphate. Osteoarthritis Cartilage, 2010. 18 Suppl 1:S12-6.</li>
    <li>Masi AT, et al. Sex hormones and risks of rheumatoid arthritis and developmental or environmental influences. Ann N Y Acad Sci. 2006 Jun;1069:223-35.</li>
    <li>McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs, 2011. 71(18): 2457-89.</li>
    <li>Mikuls TR, et al. The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol, 2007. 34(7):1480-4.</li>
    <li>Moreland LW and O'Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum, 2002. 46(10):2553-63.</li>
    <li>Naik SR, Hule A. Evaluation of immunomodulatory activity of an extract of andrographolides from Andographis paniculata. Planta Med. 2009 Jun;75(8):785-91.</li>
    <li>Nakamura H, Shidara K, Hoshi D, et al. Anti-arthritis effects of vitamin K(2) (menaquinone-4)--a new potential therapeutic strategy for rheumatoid arthritis. The FEBS J. 2007;274(17):4588-94.</li>
    <li>Olendzki BC, et al. Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. Evid Based Complement Alternat Med, 2011. 2011: Article ID 827286. doi: 10.1155/2011/827286.</li>
    <li>Peters MJ, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum, 2009. 61(11): 1571-9.</li>
    <li>Pietschmann P. Principles of osteoimmunology: molecular mechanisms and clinical applications 2011, New York: Springer.</li>
    <li>Plasqui G. The role of physical activity in rheumatoid arthritis. Physiol Behav, 2008. 94(2):270-5.</li>
    <li>Radovits BJ, et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken), 2010. 62(3):362-70.</li>
    <li>Ramadan G, Al-Kahtani MA, El-Sayed WM. Anti-inflammatory and anti-oxidant properties of Curcuma longa (turmeric) versus Zingiber officinale (ginger) rhizomes in rat adjuvant-induced arthritis. Inflammation, 2011. 34(4):291-301.</li>
    <li>Rheaume-Bleue K. Choosing the Right Vitamin K2: Menaquinone-4 vs Menaquinone-7: Clinical considerations of different forms of vitamin K2. Natural Medicine Journal. 2015;7(10).</li>
    <li>Ridker PM and Solomon DH. Should patients with rheumatoid arthritis receive statin therapy? Arthritis Rheum, 2009. 60(5):1205-9.</li>
    <li>Ruffing V and Bingham III CO. Rheumatoid Arthritis Clinical Presentation. Accessed 3/20/12. Available from: <a href="http://www.hopkins-arthritis.org/arthritis-info/rheumatoid-arthritis/rheum_clin_pres.html" target="_blank">http://www.hopkins-arthritis.org/arthritis-info/rheumatoid-arthritis/rheum_clin_pres.html</a>.</li>
    <li>Rutjes AW, et al. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst Rev, 2009(4):CD007321.</li>
    <li>Sengupta K, et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem, 2011. 354(1-2):189-97.</li>
    <li>Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative efficacy and tolerability of 5-Loxin and Aflapin Against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. 2010;7(6):366–377.</li>
    <li>Shabanova SS, et al. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2008 May-Jun;26(3):436-41.</li>
    <li>Sheng X, et al. Effectiveness of Statins on Total Cholesterol and Cardiovascular Disease and All-cause Mortality in Osteoarthritis and Rheumatoid Arthritis. J Rheumatol, 2011.</li>
    <li>Shukla M, et al. Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. Nutrition, 2008. 24(7-8):733-43.</li>
    <li>Simopoulos AP. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol Neurobiol. 2011 Oct;44(2):203-15. Epub 2011 Jan 29.</li>
    <li>Soeken KL, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract, 2002. 51(5):425-30.</li>
    <li>Spector TD, et al. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ, 1993. 306(6877):558.</li>
    <li>St. Clair EW, Pisetsky DS, and Haynes BJ. Rheumatoid arthritis 2004, Philadelphia: Lippincott Williams & Wilkins. xiv, p.555.</li>
    <li>Stoll D, et al. High prevalence of hypovitaminosis D in a Swiss rheumatology outpatient population. Swiss Med Wkly. 2011 May 27;141:w13196. doi: 10.4414/smw.2011.13196.</li>
    <li>Straub RH, et al. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007 Feb;56(2):399-408.</li>
    <li>Tak PP and Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther, 2011. 13 Suppl 1:S5.</li>
    <li>Talbott SM and Hughes K. The health professional's guide to dietary supplements 2007, Philadelphia: Lippincott Williams & Wilkins. xx, p.444.</li>
    <li>Tanasescu C, et al. Endothelial dysfunction in inflammatory rheumatic diseases. Rom J Intern Med. 2009;47(2):103-8.</li>
    <li>Tekeoglu I, et al. Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models. Phytother Res. 2007 Sep;21(9):895-7.</li>
    <li>Trelle S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ, 2011. 342:c7086.</li>
    <li>Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Program, 2011. 2011:280-4.</li>
    <li>Valensa. FlexPro MD Clinical Trial Overview and Results. (Data on File.) 2011</li>
    <li>van Aken J, et al. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis, 2004. 63(3):274-9.</li>
    <li>Van den Ende CH, et al. Dynamic exercise therapy in rheumatoid arthritis: a systematic review. Br J Rheumatol, 1998. 37(6):677-87.</li>
    <li>van Gestel AM, et al. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br J Rheumatol, 1995. 34(4):347-51.</li>
    <li>van Halm VP, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis, 2007. 66(2): 184-8.</li>
    <li>Wang Y, Xing HY. [Clinical observation on effect of total glucosides of paeony combined with methotrexate on rheumatoid arthritis]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban.Sep 2007;27(9):839-840.</li>
    <li>Wang YN, Zhang Y, Wang Y, Zhu DX, Xu LQ, Fang H, Wu W. The beneficial effect of total glucosides of paeony on psoriatic arthritis links to circulating Tregs and Th1 cell function. Phytotherapy research: PTR.Mar 2014;28(3):372-381.</li>
    <li>Wei CC, You FT, Mei LY, Jian S, Qiang CY. Total glucosides of paeony prevents juxta-articular bone loss in experimental arthritis. BMC complementary and alternative medicine. 2013;13:186.</li>
    <li>Weiss EP, et al. droepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011 May;3(5):533-42.</li>
    <li>Weitoft T, et al. Serum levels of sex steroid hormones and matrix metalloproteinases after intra-articular glucocorticoid treatment in female patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Mar;67(3):422-4. Epub 2007 Sep 18.</li>
    <li>Whittle SL and Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford), 2004. 43(3):267-71.</li>
    <li>Youssef PP, et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum, 1997. 40(8):1400-8.</li>


</ol>


<!-- DIABETES -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #1b5e20; padding-bottom: 10px;">
    <i class="fas fa-diagnoses" style="margin-right: 10px; color: #1b5e20;"></i>DIABETES
</h2>
<p style="margin-bottom: 20px; text-align: justify;">
    When diabetes is diagnosed in middle age, life expectancy is reduced by about 10 years. Every seven seconds (7) a person dies from diabetes-related causes. There is a difference between type 1 diabetes and type 2 diabetes. Diabetes mellitus is characterized by high levels of glucose in the blood. Type 2 diabetes is much more common than type 1 diabetes and is primarily caused by resistance to the effects of the hormone insulin, which facilitates the removal of glucose from the blood. Type 1 diabetes is primarily caused by destruction of the insulin-producing pancreatic beta cells. However, in both cases, the effect is the same because, to the same extent, elevated blood sugar, even within the conventional normal range, can damage tissues throughout the body, among other reasons because of the dangers posed by resistance to excess insulin, even associated with the use of some of the drugs used in conventional medicine to treat diabetes that increase insulin levels without taking into account ambient glucose levels, which can contribute to long-term problems.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    Blood sugar control through a self-management program that includes an understanding of home glucose control and lifestyle changes are considered the most rational ways to control blood sugar that we know of, together causing harm to the heart, small and large blood vessels, and other tissues. Chronically elevated fasting blood glucose levels (or recurrent excessive spikes in glucose levels after meals) can have devastating long-term consequences, including heart disease, blindness, kidney failure, liver disease, and cancer. Medications related to lowering blood glucose, such as metformin, should be controlled with the use of specific adjuvants to increase efficacy and to reduce side effects related to the consumption of this medication and reduce the risk of developing malignant diseases such as cancer.
</p>

<!-- Conventional treatments -->
<h3 style="font-size: 22px; color: #1b5e20; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #1b5e20; padding-bottom: 5px;">
    Conventional treatments
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    Metformin is considered the first-line drug for type 2 diabetes. Metformin has also been shown to promote weight loss and protect against some cancers, cardiovascular disease, and Alzheimer disease. Acarbose is a drug that lowers glucose by blocking the breakdown of starches and slowing the absorption of sugar and carbohydrates. Other oral glucose-lowering agents or injectable drugs such as insulin may be necessary depending on individual glycemic control and diabetes severity. Stem cell therapy is aimed at replacing damaged or destroyed insulin-producing pancreatic beta cells in diabetics with new beta cells derived from human stem cells. Glucokinase activators have been shown to lower glucose levels and stimulate the proliferation of pancreatic beta cells. Other treatments, such as lorcaserin and the combination of phentermine and topiramate, have been shown to improve glycemic control in obese individuals with type 2 diabetes.
</p>

<!-- Strategy for use of adjuvants -->
<h3 style="font-size: 22px; color: #c62828; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #c62828; padding-bottom: 5px;">
    Strategy for use of adjuvants
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    To improve the pharmacological actions of the drugs used in the prevention, control, and treatment of diabetes and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term that usually contribute to the development of alterations, syndromes, and deadly diseases, such as cancer, and can also reduce the quality life expectancy of people under treatment; the scientists and doctors of "PPG NUTRICIONAL," together with family doctors and specialists from clinics and hospitals, assisted by the "MIS," defined a personalized therapeutic strategy to develop specific adjuvants that improve the actions of the drugs used in each of the stages of treatment of diabetes and at the same time reduce the risk of contracting disorders, syndromes, or fatal diseases with decreased quality of life. These adjuvants are, in themselves, unique compositions or combinations of labeled drugs, natural active ingredients, enzyme cofactors, vitamins, trace elements, protein hydrolysates, peptides, probiotics, and other products authorized for use in humans by the FDA.
</p>


<!-- REFERENCES -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #1b5e20; padding-bottom: 10px;">
    <i class="fas fa-book" style="margin-right: 10px; color: #1b5e20;"></i>REFERENCES
</h2>
<ul style="margin-bottom: 20px; padding-left: 25px; list-style-type: disc; color: #1b5e20;">
    <li>Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes, obesity & metabolism. Apr 2020;22(4):699-704. doi:10.1111/dom.13924</li>
    <li>Abdul-Ghani M, Puckett C, Adams J, et al. Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Diabetes Care. Feb 2021;44(2):433-439. doi:10.2337/dc20-0978</li>
    <li>ACCORD Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 2008;358(24):2545-2559.</li>
    <li>ADA. American Diabetes Association. A1C and eAG. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/a1c/?loc=keymatch. Last updated 9/29/2014a. Accessed 8/19/2015.</li>
    <li>ADA. American Diabetes Association. Glycemic Index and Diabetes. http://www.diabetes.org/food-and-fitness/food/what-can-i-eat/understanding-carbohydrates/glycemic-index-and-diabetes.html?referrer=https://www.google.com/. Last updated 5/14/2014b. Accessed 8/24/2015.</li>
    <li>ADA. Standards of medical care in diabetes--2014. Diabetes care. Jan 2014c;37 Suppl 1:S14-80.</li>
    <li>ADA. American Diabetes Association. Foundations of Care: Education, Nutrition, Physical Activity, Smoking Cessation, Psychosocial Care, and Immunization. Diabetes Care. 2015a;38(Suppl. 1): S20-S30. http://care.diabetesjournals.org/content/38/Supplement_1/S20.full.pdf</li>
    <li>ADA. American Diabetes Association. Checking Your Blood Glucose. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/checking-your-blood-glucose.html. Last updated 6/17/2015b. Accessed 9/1/2015.</li>
    <li>ADA. American Diabetes Association. Insulin Basics. Available at: http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/insulin/insulin-basics.html. Last updated: 3/9/2015c. Accessed 4/10/2015.</li>
    <li>ADA. American Diabetes Association. What Are My Options? Available at: http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/oral-medications/what-are-my-options.html. Last updated: 3/3/2015d. Accessed 4/12/2015.</li>
    <li>ADA. American Diabetes Association. Glycemic Targets. Diabetes Care. 2015f;38(Suppl. 1): S33-S40. http://care.diabetesjournals.org/content/38/Supplement_1/S33.full</li>
    <li>ADA. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. Jan 2019;42(Suppl 1):S90-S102. doi:10.2337/dc19-S009</li>
    <li>ADA. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. Jan 2021a;44(Suppl 1):S73-S84. doi:10.2337/dc21-S006</li>
    <li>ADA. American Diabetes Association Professional Practice C. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2021b;45(Supplement_1):S60-S82. doi:10.2337/dc22-S005</li>
    <li>ADA. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. Jan 2021c;44(Suppl 1):S111-S124. doi:10.2337/dc21-S009</li>
    <li>ADA. American Diabetes Association. Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. Clinical Diabetes. 2022;40(1):10-38. doi:10.2337/cd22-as01</li>
    <li>Adams RJ, Appleton SL, Hill CL, et al. Independent association of HbA1C and incident cardiovascular disease in people without diabetes. Obesity. 2009;17:559-563.</li>
    <li>Adams TD, Davidson LE, Litwin SE, et al. Weight and Metabolic Outcomes 12 Years after Gastric Bypass. The New England journal of medicine. Sep 21 2017;377(12):1143-1155. doi:10.1056/NEJMoa1700459</li>
    <li>Afaghi A, Ziaee A, Afaghi M. Effect of low-glycemic load diet on changes in cardiovascular risk factors in poorly controlled diabetic patients. Indian journal of endocrinology and metabolism. Nov 2012;16(6):991-995.</li>
    <li>AFAR. TAME: Targeting Aging with Metformin http://www.afar.org/natgeo/. 4/14/2016.</li>
    <li>AHA. American Heart Association. Glycemic Index and Diabetes. http://www.heart.org/HEARTORG/GettingHealthy/NutritionCenter/HealthyEating/Glycemic-Index-and-Diabetes_UCM_457070_Article.jsp, Copyright 2014. Accessed 8/24/2015.</li>
    <li>Aleem E, Nehrbass D, Klimek F, et al. Upregulation of the insulin receptor and type 1 insulin-like growth factor receptor are early events in hepatocarcinogenesis. Toxicol Pathol. 2011;39(3):524-43.</li>
    <li>Al-Tabakha MM. Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus Exubera. Journal of controlled release: official journal of the Controlled Release Society. Jul 26 2015;215:25-38.</li>
    <li>Anisimov VN. Metformin: do we finally have an anti-aging drug? Cell Cycle. 2013;12(22):3483-3489.</li>
    <li>Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, . . . Crandall JP. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of clinical endocrinology and metabolism. Feb 22 2016:jc20153754.</li>
    <li>Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and Risks of Bariatric Surgery in Adults: A Review. Jama. Sep 1 2020;324(9):879-887. doi:10.1001/jama.2020.12567</li>
    <li>Assefa ST, Yang EY, Chae SY, et al. Alpha Glucosidase Inhibitory Activities of Plants with Focus on Common Vegetables. Plants (Basel). Dec 18 2019;9(1)doi:10.3390/plants9010002</li>
    <li>Atkinson FS, Foster-Powell K, Brand-Miller JC. International Tables of Glycemic Index and Glycemic Load Values: 2008. Diabetes care. 2008;31(12):2281-2283.</li>
    <li>Azoulay L. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains. Diabetes care. Jun 2015;38(6):951-953.</li>
    <li>Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, . . . Ernst P. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ (Clinical research ed.). 2016;352:i581.</li>
    <li>Bahr C, Groner B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth factors (Chur, Switzerland). Mar 2005;23(1):1-14.</li>
    <li>Bailey CJ. Tirzepatide: a new low for bodyweight and blood glucose. The lancet Diabetes & endocrinology. Oct 2021;9(10):646-648. doi:10.1016/S2213-8587(21)00217-5</li>
    <li>Bales CW, Kraus WE. Caloric restriction: implications for human cardiometabolic health. J Cardiopulm Rehabil Prev. Jul-Aug 2013;33(4):201-208.</li>
    <li>Barbarawi M, Al-Abdouh A, Barbarawi O, Lakshman H, Al Kasasbeh M, Chen K. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart failure reviews. Feb 23 2021;doi:10.1007/s10741-021-10083-z</li>
    <li>Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P, Brand-Miller JC. Glycemic index, glycemic load, and chronic disease risk--a meta-analysis of observational studies. The American journal of clinical nutrition. Mar 2008;87(3):627-637.</li>
    <li>Bazzano LA, Li TY, Joshipura KJ, Hu FB. Intake of fruit, vegetables, and fruit juices and risk of diabetes in women. Diabetes care. Jul 2008;31(7):1311-1317.</li>
    <li>Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocrine-Related Cancer. 2011;18:R125-R147.</li>
    <li>Benjamin EM. Self-Monitoring of Blood Glucose: The Basics. Clinical Diabetes. 2002;20(1):45-47.</li>
    <li>Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY). 2012;4(5):320-329.</li>
    <li>Bhupathiraju SN, Tobias DK, Malik VS, Pan A, Hruby A, Manson JE, . . . Hu FB. Glycemic index, glycemic load, and risk of type 2 diabetes: results from 3 large US cohorts and an updated meta-analysis. The American journal of clinical nutrition. Jul 2014;100(1):218-232.</li>
    <li>Bjornholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Diabetes Care. 1999;22:45-49.</li>
    <li>Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging (Albany NY). 2009;1(3):281-288.</li>
    <li>Boers I, Muskiet FA, Berkelaar E, Schut E, Penders R, Hoenderdos K, . . . Jong MC. Favourable effects of consuming a Palaeolithic-type diet on characteristics of the metabolic syndrome: a randomized controlled pilot-study. Lipids in health and disease. 2014;13:160.</li>
<li>Bolla AM, Caretto A, Laurenzi A, Scavini M, Piemonti L. Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes. Nutrients. Apr 26 2019;11(5)doi:10.3390/nu11050962</li>
<li>Boniol M, Franchi M, Bota M, et al. Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies. Diabetes Care. Feb 2018;41(2):286-292. doi:10.2337/dc17-0280</li>
<li>Boyle JG, Salt IP, McKay GA. Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new target. Diabet Med. 2010;27(10):1097-106.</li>
<li>Boyle CN, Lutz TA, Le Foll C. Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Molecular metabolism. Feb 2018;8:203-210. doi:10.1016/j.molmet.2017.11.009</li>
<li>Bozkaya G, Ozgu E, Karaca B. The association between estimated average glucose levels and fasting plasma glucose levels. Clinics (Sao Paulo, Brazil). 2010;65(11):1077-1080.</li>
<li>Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, . . . Fineman M. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes care. Feb 2016;39(2):198-205.</li>
<li>Campbell LK, White JR, Campbell RK. Acarbose: its role in the treatment of diabetes mellitus. The Annals of pharmacotherapy. Nov 1996;30(11):1255-1262.</li>
<li>Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine. Nov 2019;66(2):157-165. doi:10.1007/s12020-019-02055-z</li>
<li>Carter P, Gray LJ, Talbot D, Morris DH, Khunti K, Davies MJ. Fruit and vegetable intake and the association with glucose parameters: a cross-sectional analysis of the Let's Prevent Diabetes Study. European journal of clinical nutrition. Jan 2013;67(1):12-17.</li>
<li>Chan J, Cheng-Lai A. Inhaled Insulin: A Clinical and Historical Review. Cardiology in review. May/Jun 2017;25(3):140-146. doi:10.1097/CRD.0000000000000143</li>
<li>Chen X, Zhang J, Zhou Z. Targeting Islets: Metabolic Surgery Is More than a Bariatric Surgery. Obesity surgery. Sep 2019;29(9):3001-3009. doi:10.1007/s11695-019-03979-1</li>
<li>Chen TH, Li YR, Chen SW, et al. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study. Cardiovasc Diabetol. Nov 9 2020;19(1):189. doi:10.1186/s12933-020-01169-3</li>
<li>Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359(9323):2072-7.</li>
<li>Chokrungvaranon N, Deer J, Reaven PD. Intensive glycemic control and cardiovascular disease: are there patients who may benefit? Postgraduate medicine. Nov 2011;123(6):114-123.</li>
<li>Chou HC, Chen WW, Hsiao FY. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study. Drug safety: an international journal of medical toxicology and drug experience. Jul 2014;37(7):521-528.</li>
<li>Cohen O, Gillam M. First Consult. Diabetes mellitus type 1 in adults. Available at: www.clinicalkey.com. Copyright by Elsevier BV, Inc. Last updated 10/17/2013. Accessed 3/19/2015.</li>
<li>Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, . . . Braun B. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes care. Dec 2010;33(12):e147-167.</li>
<li>Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, . . . Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science (New York, N.Y.). Jul 10 2009;325(5937):201-204.</li>
<li>Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes care. Jun 1995;18(6):817-824.</li>
<li>Coughlan KA, Valentine RJ, Ruderman NB, et al. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes. 2014;7:241-253.</li>
<li>Courcoulas AP, Belle SH, Neiberg RH, et al. Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial. JAMA surgery. Oct 2015;150(10):931-40. doi:10.1001/jamasurg.2015.1534</li>
<li>Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes care. Feb 1999;22(2):233-240.</li>
<li>Cummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia. Feb 2018;61(2):257-264. doi:10.1007/s00125-017-4513-y</li>
<li>Dahl D, Onishi Y, Norwood P, Huh R, Patel H, RodrÍGuez Á. 80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5). Diabetes. 2021;70(Supplement_1)doi:10.2337/db21-80-LB</li>
<li>Davani-Davari D, Negahdaripour M, Karimzadeh I, et al. Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. Foods. Mar 9 2019;8(3)doi:10.3390/foods8030092</li>
<li>Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. The American journal of medicine. Jan 1997;102(1):99-110.</li>
<li>de Heer J, Goke B. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas? Expert opinion on drug safety. Nov 2014;13(11):1469-1481.</li>
<li>de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B12 deficiency: randmised placebo controlled trial. BMJ. 2010;340:c2181.</li>
<li>Delamater AM. Clinical Use of Hemoglobin A1C to Improve Diabetes Management. Clinical Diabetes. January 1, 2006 2006;24(1):6-8.</li>
<li>Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. Nov 13 2021;398(10313):1811-1824. doi:10.1016/S0140-6736(21)02188-7</li>
<li>Derdemezis CS, Lovegrove JA. Glycemic index, glycemic control and beyond. Current pharmaceutical design. 2014;20(22):3620-3630.</li>
<li>Derosa G, Maffioli P. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin Ther. 2012;34(6):1221-1236.</li>
<li>Diabetes.co.uk. Treatment: Medication. Metformin Side Effects http://www.diabetes.co.uk/diabetes-medication/metformin-side-effects.html. Copyright 2016. Accessed 8/8/2016.</li>
<li>Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes care. Dec 2002;25(12):2165-2171.</li>
<li>Dicembrini I, Montereggi C, Nreu B, Mannucci E, Monami M. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. Jan 2020;159:107981. doi:10.1016/j.diabres.2019.107981</li>
<li>Donnan K, Segar L. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. European journal of pharmacology. Mar 5 2019;846:23-29. doi:10.1016/j.ejphar.2019.01.002</li>
<li>Dowling RJO, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine. 2011;9:33.</li>
<li>Draznin B. Mechanism of the mitogenic influence of hyperinsulinemia. Diabetology & Metabolic Syndrome. 2011;3:10.</li>
<li>Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet. 2006;368(9548):1696-1705.</li>
<li>Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, . . . Huang GD. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine. 2009;360(2):129-139.</li>
<li>Dworatzek PD, Arcudi K, Gougeon R, Husein N, Sievenpiper JL, Williams SL. Nutrition therapy. Canadian journal of diabetes. Apr 2013;37 Suppl 1:S45-55.</li>
<li>Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C. Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment. New England Journal of Medicine. 2014;370(9):794-797.</li>
<li>Engelhardt K, Ferguson M, Rosselli JL. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors. Ann Pharmacother. Apr 2021;55(4):543-548. doi:10.1177/1060028020951928</li>
<li>Esposito K, Giugliano D. Mediterranean diet and type 2 diabetes. Diabetes/metabolism research and reviews. Mar 2014;30 Suppl 1:34-40.</li>
<li>FDA. U.S. Food and Drug Administration. Safety. Exubera (insulin human [rDNA origin] Inhalation Powder September 2008. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm122978.htm. Last updated: 6/19/2009. Accessed 6/21/2015.</li>
<li>FDA. U.S. Food and Drug Administration. News and Events. FDA News Release. FDA approves Afrezza to treat diabetes. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122.htm. Updated: 6/30/2014. Accessed 4/19/2015.</li>
<li>Feingold KR. Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes. In: Feingold KR, Anawalt B, Boyce A, et al, eds. Endotext. MDText.com, Inc. Copyright ©2000-2021; 2000.</li>
<li>Fleming LW, Fleming JW, Davis CS. Afrezza: an inhaled approach to insulin delivery. J Am Assoc Nurse Pract. 2015;Mar 12. doi: 10.1002/2327-6924.12247.</li>
<li>Fonseca V, Levinson P, Toth DW, Gillam M. First Consult. Diabetes mellitus type 2 in adults. Available at: www.clinicalkey.com. Copyright by Elsevier BV, Inc. Last updated 8/26/2013. Accessed 3/19/2015.</li>
<li>Forouzandeh F, Salazar G, Patrushev N, et al. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014;3(6):e001202.</li>
<li>Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, . . . Pedersen O. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. Dec 10 2015;528(7581):262-266.</li>
<li>Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8(8):e71583.</li>
<li>Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes, obesity & metabolism. Jun 2020;22(6):938-946. doi:10.1111/dom.13979</li>
<li>Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England journal of medicine. Aug 5 2021;385(6):503-515. doi:10.1056/NEJMoa2107519</li>
<li>Fung TT, van Dam RM, Hankinson SE, Stampfer M, Willett WC, Hu FB. Low-Carbohydrate Diets and All-Cause and Cause-Specific MortalityTwo Cohort Studies. Annals of Internal Medicine. 2010;153(5):289-298.</li>
<li>GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med. 2008;121:519-524.</li>
<li>Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl2):S279-S284.</li>
<li>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2020 Executive Summary. Endocr Pract. Jan 2020;26(1):107-139. doi:10.4158/CS-2019-0472</li>
<li>Gerstein HC, Pais P, Pogue J, et al. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. J Am Coll Cardiol. 1999;33:612-619.</li>
<li>Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC, Jr., . . . Friedewald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. The New England journal of medicine. Mar 3 2011;364(9):818-828.</li>
<li>Gerstein HC, Coleman RL, Scott CAB, et al. Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. Diabetes Care. Sep 2020;43(9):2242-2247. doi:10.2337/dc19-2046</li>
<li>Glossmann HH, Lutz OMD. Metformin and Aging: A Review. Gerontology. 2019;65(6):581-590. doi:10.1159/000502257</li>
<li>Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond). 2009;118(Pt 5):315-332.</li>
<li>Gold Standard. Drug Monograph. Metformin. Copyright 2015 Elsevier, Inc. www.clinicalkey.com. Accessed 7/16/2015.</li>
<li>Gotsis E, Anagnostis P, Mariolis A, Vlachou A, Katsiki N, Karagiannis A. Health benefits of the Mediterranean Diet: an update of research over the last 5 years. Angiology. Apr 2015;66(4):304-318.</li>
<li>Gower BA, Goss AM. A lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes. The Journal of nutrition. Jan 2015;145(1):177s-183s.</li>
<li>Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci. 2005;94:1187-1195.</li>
<li>Greer EL, Dowlatshahi D, Banko MR, et al. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr Biol. 2007;17(19):1646-56.</li>
<li>Gu S, Shi J, Tang Z, et al. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. PLoS One. 2015;10(5):e0126704.</li>
<li>Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology. 2011;60(6):910-20.</li>
<li>Halabi A, Sen J, Huynh Q, Marwick TH. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. Aug 5 2020;19(1):124. doi:10.1186/s12933-020-01100-w</li>
<li>Handa K, Inukai K, Onuma H, Kudo A, Nakagawa F, Tsugawa K, . . . Ishida H. Long-term low carbohydrate diet leads to deleterious metabolic manifestations in diabetic mice. PloS one. 2014;9(8):e104948.</li>
<li>Hanefeld M. The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. Journal of diabetes and its complications. Jul-Aug 1998;12(4):228-237.</li>
<li>Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: a meta-analysis of seven long-term studies. Eur Heart J. 2004;25(1):10-6.</li>
<li>Hansawasdi C, Kawabata J. Alpha-glucosidase inhibitory effect of mulberry (Morus alba) leaves on Caco-2. Fitoterapia. Dec 2006;77(7-8):568-573.</li>
<li>Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine. Oct 8 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816</li>
<li>Heinemann L. The failure of exubera: are we beating a dead horse? Journal of diabetes science and technology. May 2008;2(3):518-529.</li>
<li>Henry RR, Mudaliar SR, Howland WC 3rd, et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care. 2003;26(3):754-9.</li>
<li>Higdon J, Drake V, Liu S. Linus Pauling Institute. Micronutrient Information Center. Glycemic Index and Glycemic Load. http://lpi.oregonstate.edu/mic/food-beverages/glycemic-index-glycemic-load. Last updated 2/2009. Accessed 7/22/2015.</li>
<li>Hiraga T, Myoui A, Hashimoto N, Sasaki A, Hata K, Morita Y, . . . Yoneda T. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer research. Aug 15 2012;72(16):4238-4249.</li>
<li>Hodish I. Insulin therapy, weight gain and prognosis. Diabetes, Obesity and Metabolism. 2018;20(9):2085-2092. doi:https://doi.org/10.1111/dom.13367</li>
<li>Horii T, Oikawa Y, Kunisada N, Shimada A, Atsuda K. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study. BMJ Open Diabetes Res Care. Nov 2020;8(2):e001856. doi:10.1136/bmjdrc-2020-001856</li>
<li>Hou G, Zhang S, Zhang X, et al. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res Treat. 2013;137:807-816.</li>
<li>Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, obesity & metabolism. Apr 2017;19(4):524-536. doi:10.1111/dom.12849</li>
<li>Humpert PM, Djuric Z, Zeuge U, Oikonomou D, Seregin Y, Laine K, . . . Bierhaus A. Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor-dependent signaling. Molecular medicine (Cambridge, Mass.). May-Jun 2008;14(5-6):301-308.</li>
<li>Hung CT. Effects of high-fructose (90%) corn syrup on plasma glucose, insulin, and C-peptide in non-insulin-dependent diabetes mellitus and normal subjects. Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association. Sep 1989;88(9):883-885.</li>
<li>Hur KY, Lee MS. Gut Microbiota and Metabolic Disorders. Diabetes Metab J. Jun 2015;39(3):198-203.</li>
<li>Ikramuddin S, Korner J, Lee WJ, et al. Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study. Jama. Jan 16 2018;319(3):266-278. doi:10.1001/jama.2017.20813</li>
<li>Ilyas S, Al-Refai R, Maharjan R, Diaz Bustamante L, Ghattas KN, Khan S. Bariatric Surgery and Type 2 Diabetes Mellitus: Assessing Factors Leading to Remission. A Systematic Review. Cureus. Aug 23 2020;12(8):e9973. doi:10.7759/cureus.9973</li>
<li>Inzucchi SE, Sherman RS, Goldman L (ed.), SchaferAI (ed.). Goldman's Cecil Medicine, Twenty-Fourth Edition. Chapter 236: Type 1 Diabetes Mellitus; 1475-1488. Copyright 2012a Saunders, an imprint of Elsevier, Inc. Available at: www.clinicalkey.com Accessed: 3/19/2015.</li>
<li>Inzucchi SE, Sherman RS, Goldman L (ed.), SchaferAI (ed.). Goldman's Cecil Medicine, Twenty-Fourth Edition. Chapter 237: Type 2 Diabetes Mellitus; 1489-1499. Copyright 2012b Saunders, an imprint of Elsevier, Inc. Available at: www.clinicalkey.com Accessed: 3/19/2015.</li>
<li>Inzucchi SE. Diagnosis of Diabetes. New England Journal of Medicine. 2012c;367(6):542-550.</li>
<li>Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, . . . Matthews DR. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 2012d;35(6):1364-1379.</li>
<li>Inzucchi SE, Docherty KF, Kober L, et al. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care. Feb 2021;44(2):586-594. doi:10.2337/dc20-1675</li>
<li>Jayaram S, Hariharan RS, Madhavan R, Periyandavar I, Samra SS. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes. The Journal of the Association of Physicians of India. Nov 2010;58:679-682, 687.</li>
<li>JDC. Joslin Diabetes Center. Healthy Eating: Why Does Fat Increase Blood Glucose? http://blog.joslin.org/2011/09/why-does-fat-increase-blood-glucose/. 9/27/2011. Accessed 6/7/2016</li>
<li>Jiang M, Liu Q, Jiang T, Nizigiyimana P, Lei M. Adding Sodium-Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in endocrinology. 2021;12:713192. doi:10.3389/fendo.2021.713192</li>
<li>Johnson AB, Webster JM, Sum CF, Heseltine L, Argyraki M, Cooper BG, Taylor R. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism: clinical and experimental. Sep 1993;42(9):1217-1222.</li>
<li>Jonsson T, Granfeldt Y, Ahren B, Branell UC, Palsson G, Hansson A, . . . Lindeberg S. Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. Cardiovascular diabetology. 2009;8:35.</li>
<li>Jorgensen L, Jenssen T, Joakimsen O, et al. Glycated hemoglobin level is strongly related to the prevalence of carotid artery plaques with high echogenicity in nondiabetic individuals: the Tromso study. Circulation. 2004;110:466-470.</li>
<li>Josse RG, McGuire AJ, Saal GB. A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance. Int J Clin Pract 2006;60(7):847-855.</li>
<li>Juanola-Falgarona M, Salas-Salvado J, Ibarrola-Jurado N, Rabassa-Soler A, Diaz-Lopez A, Guasch-Ferre M, . . . Bullo M. Effect of the glycemic index of the diet on weight loss, modulation of satiety, inflammation, and other metabolic risk factors: a randomized controlled trial. The American journal of clinical nutrition. Jul 2014;100(1):27-35.</li>
<li>Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Foundation symposium. 2004;262:247-260; discussion 260-268.</li>
<li>Kajbaf F, De Broe ME, Lalau JD. Therapeutic Concentrations of Metformin: A Systematic Review. Clinical pharmacokinetics. Apr 2016;55(4):439-459.</li>
<li>Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane database of systematic reviews. Oct 25 2021;10:CD013650. doi:10.1002/14651858.CD013650.pub2</li>
<li>Karlstad O, Starup Linde J, Vestergaard P, et al. Use of insulin and insulin analogs and risk of cancer—systematic review and meta-analysis of observational studies. Current drug safety. 2013;8(5):333-348.</li>
<li>Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Annals of translational medicine. Jun 2014;2(6):57. doi:10.3978/j.issn.2305-5839.2014.06.01</li>
<li>Kato M, Noda M, Suga H, et al. Fasting plasma glucose and incidence of diabetes – implication for the threshold for impaired fasting glucose: results from the population-based Omiya MA Cohort study. J Atheroscler Thromb. 2009;16:857-861.</li>
<li>Kishore P. Merck Manual. Professional Version. Diabetes Mellitus (DM). Available at: http://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-disorders-of-carbohydrate-metabolism/diabetes-mellitus-dm. Last update: 6/2014. Accessed 4/2/2015.</li>
<li>Klonoff DC. The Beneficial Effects of a Paleolithic Diet on Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease. Journal of Diabetes Science and Technology. 2009;3(6):1229-1232.</li>
<li>Knapen LM, van Dalem J, Keulemans YC, van Erp NP, Bazelier MT, De Bruin ML, . . . Driessen JH. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Diabetes, obesity & metabolism. Mar 2016;18(3):258-265.</li>
<li>Kocsis T, Molnár B, Németh D, et al. Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. Scientific reports. 2020;10(1):11787.</li>
<li>Koh ES, Han K, Nam YS, et al. Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea). Diabetes, obesity & metabolism. Feb 2021;23(2):455-466. doi:10.1111/dom.14239</li>

<li>Koloverou E, Esposito K, Giugliano D, et al. The effect of Mediterranean diet on the development of type 2 diabetes mellitus: a meta-analysis of 10 prospective studies and 136,846 participants. Metabolism Clinical and Experimental. 2014;63:903-911.</li>
<li>Lai YJ, Hu HY, Chen HH, Chou P. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study. Medicine. Oct 2015;94(43):e1906.</li>
<li>LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. Jan 28 2021;42(1):77-96. doi:10.1210/endrev/bnaa023</li>
<li>La Sala L, Pontiroli AE. Prevention of Diabetes and Cardiovascular Disease in Obesity. International journal of molecular sciences. Oct 31 2020;21(21)doi:10.3390/ijms21218178</li>
<li>Lau E, Belda E, Picq P, et al. Gut microbiota changes after metabolic surgery in adult diabetic patients with mild obesity: a randomised controlled trial. Diabetol Metab Syndr. May 21 2021;13(1):56. doi:10.1186/s13098-021-00672-1</li>
<li>Lee SH, Min KJ. Caloric restriction and its mimetics. BMB reports. Apr 2013;46(4):181-187.</li>
<li>Lee WJ, Kim M, Park HS, Kim HS, Jeon MJ, Oh KS, . . . Park JY. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochemical and biophysical research communications. Feb 3 2006;340(1):291-295.</li>
<li>Lee M, Sun J, Han M, et al. Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors. Diabetes Care. Nov 2019;42(11):2057-2064. doi:10.2337/dc18-2195</li>
<li>Lefevre M, Redman LM, Heilbronn LK, Smith JV, Martin CK, Rood JC, . . . Ravussin E. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis. Mar 2009;203(1):206-213.</li>
<li>Lexicomp. Drug information monographs. UpToDate: https://www.uptodate.com/contents/table-of-contents/drug-information/general-drug-information. Accessed Jan. 6, 2022.</li>
<li>Li S, Flint A, Pai JK, Forman JP, Hu FB, Willett WC, . . . Rimm EB. Low carbohydrate diet from plant or animal sources and mortality among myocardial infarction survivors. J Am Heart Assoc. Oct 2014;3(5):e001169.</li>
<li>Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, . . . Sun X. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ (Clinical research ed.). 2014;348:g2366.</li>
<li>Lilly. Medicines in Development. Updated 1/31/2022. Accessed 2/7/2022, https://www.lilly.com/discovery/clinical-development-pipeline</li>
<li>Lilly. News Release: Lily Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential. Updated 10/26/2021a. Accessed 2/7/2022. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-robust-third-quarter-2021-financial-results</li>
<li>Lilly. News Release: Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program. Updated 2/17/2021b. Accessed 2/10/2022, https://investor.lilly.com/news-releases/news-release-details/tirzepatide-significantly-reduced-a1c-and-body-weight-people</li>
<li>Liu XY, Zhang N, Chen R, Zhao JG, Yu P. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. Journal of diabetes and its complications. Nov-Dec 2015;29(8):1295-303. doi:10.1016/j.jdiacomp.2015.07.011</li>
<li>Lordan S, Smyth TJ, Soler-Vila A, Stanton C, Ross RP. The alpha-amylase and alpha-glucosidase inhibitory effects of Irish seaweed extracts. Food chemistry. Dec 1 2013;141(3):2170-2176.</li>
<li>Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. Aug 14 2021;398(10300):583-598. doi:10.1016/s0140-6736(21)01443-4</li>
<li>Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nature reviews Endocrinology. Oct 2020;16(10):545-555. doi:10.1038/s41574-020-0381-5</li>
<li>Mahajan R, Gupta K. Revisiting Metformin: Annual Vitamin B12 Supplementation may become Mandatory with Long-Term Metformin Use. Journal of young pharmacists: JYP. Oct 2010;2(4):428-429.</li>
<li>Maiorino MI, Chiodini P, Bellastella G, et al. Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes, obesity & metabolism. Sep 2018;20(9):2309-2313. doi:10.1111/dom.13343</li>
<li>Malin SK, Kashyap SR. Effects of various gastrointestinal procedures on β-cell function in obesity and type 2 diabetes. Surg Obes Relat Dis. Jul 2016;12(6):1213-9. doi:10.1016/j.soard.2016.02.035</li>
<li>Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.</li>
<li>Masharani U, Sherchan P, Schloetter M, Stratford S, Xiao A, Sebastian A, . . . Frassetto L. Metabolic and physiologic effects from consuming a hunter-gatherer (Paleolithic)-type diet in type 2 diabetes. European journal of clinical nutrition. Aug 2015;69(8):944-948.</li>
<li>Mayo JJ, Kravitz L. Glycemic Index: Weight Loss Sham or Sensation? https://www.unm.edu/~lkravitz/Article%20folder/glycemicUNM.html. Accessed 3/31/2016</li>
<li>Mazza A, Fruci B, Garinis GA, et al. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:716404.</li>
<li>McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. Mar 2016;59(3):426-435.</li>
<li>McGill JB, Peters A, Buse JB, et al. Comprehensive Pulmonary Safety Review of Inhaled Technosphere((R)) Insulin in Patients with Diabetes Mellitus. Clinical drug investigation. Oct 2020;40(10):973-983. doi:10.1007/s40261-020-00958-8</li>
<li>McRae MP. Dietary Fiber Intake and Type 2 Diabetes Mellitus: An Umbrella Review of Meta-analyses. Journal of chiropractic medicine. 2018;17(1):44-53.</li>
<li>Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med. Apr 1 1998;128(7):524-533.</li>
<li>Mendez CE, Walker RJ, Eiler CR, Mishriky BM, Egede LE. Insulin therapy in patients with type 2 diabetes and high insulin resistance is associated with increased risk of complications and mortality. Postgrad Med. Aug 2019;131(6):376-382. doi:10.1080/00325481.2019.1643635</li>
<li>Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLoS Med. Dec 2019;16(12):e1002983. doi:10.1371/journal.pmed.1002983</li>
<li>Milder TY, Stocker SL, Abdel Shaheed C, et al. Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. J Clin Med. Jan 4 2019;8(1)doi:10.3390/jcm8010045</li>
<li>Milenkovic T, Bozhinovska N, Macut D, et al. Mediterranean Diet and Type 2 Diabetes Mellitus: A Perpetual Inspiration for the Scientific World. A Review. Nutrients. Apr 15 2021;13(4)doi:10.3390/nu13041307</li>
<li>Miles JM, Rule AD, Borlaug BA. Use of metformin in diseases of aging. Curr Diab Rep. 2014;14:490.</li>
<li>Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. The New England journal of medicine. Apr 26 2012;366(17):1577-85. doi:10.1056/NEJMoa1200111</li>
<li>Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. The Lancet. 2021;397(10271):293-304. doi:10.1016/S0140-6736(20)32649-0</li>
<li>Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes care. Jul 2004;27(7):1791-1793.</li>
<li>Moghaddam E, Vogt JA, Wolever TM. The effects of fat and protein on glycemic responses in nondiabetic humans vary with waist circumference, fasting plasma insulin, and dietary fiber intake. The Journal of nutrition. Oct 2006;136(10):2506-2511.</li>
<li>Mohanty RR, Das S. Inhaled Insulin - Current Direction of Insulin Research. Journal of clinical and diagnostic research: JCDR. Apr 2017;11(4):OE01-OE02. doi:10.7860/JCDR/2017/23626.9732</li>
<li>Monami M, Candido R, Pintaudi B, Targher G, Mannucci E. Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. Mar 10 2021;31(3):699-704. doi:10.1016/j.numecd.2020.11.031</li>
<li>Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs. Jan 1999;57(1):19-29.</li>
<li>Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66:17-29.</li>
<li>Mudaliar S, Henry RR. Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease. Diabetes technology & therapeutics. Jun 2007;9 Suppl 1:S83-92.</li>
<li>Muti P, Quattrin T, Grant BJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1361-8.</li>
<li>Nagel AK, Ahmed-Sarwar N, Werner PM, Cipriano GC, Van Manen RP, Brown JE. Dipeptidyl Peptidase-4 Inhibitor-Associated Pancreatic Carcinoma: A Review of the FAERS Database. The Annals of pharmacotherapy. Jan 2016;50(1):27-31.</li>
<li>Napolitano A, Miller S, Nicholls AW, Baker D, Van Horn S, Thomas E, . . . Nunez DJ. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PloS one. 2014;9(7):e100778.</li>
<li>Nasri H, Rafieian-Kopaei M. Metformin: current knowledge. J Res Med Sci. 2014;19(7):658-664.</li>
<li>Nauck MA, Friedrich N. Do GLP-1–Based Therapies Increase Cancer Risk? Diabetes care. 2013;36(Supplement 2):S245-S252.</li>
<li>Neuen BL, Arnott C, Perkovic V, et al. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes, obesity & metabolism. Feb 2021;23(2):382-390. doi:10.1111/dom.14226</li>
<li>Neumiller JJ, Campbell RK. Technosphere insulin: an inhaled prandial insulin product. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. Jun 2010;24(3):165-172.</li>
<li>Niafar M, Hai F, Porhomayon J, et al. The role of metformin on vitamin B12 deficiency: a meta-analysis review. Intern Emerg Med. 2015;10(1):93-102.</li>
<li>NIDDK. National Institute of Diabetes and Digestive Kidney Diseases. Am I at Risk for Type 2 Diabetes? Taking Steps to Lower Your Risk of Getting Diabetes. http://www.niddk.nih.gov/health-information/health-topics/Diabetes/type-2-diabetes-taking-steps-lower-your-risk-diabetes/Pages/index.aspx. 6/2012. Accessed 9/1/2015.</li>
<li>NLM. U.S. National Library of Medicine. Meglitinide analogues for type 2 diabetes mellitus. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0012926/. Copyright 2009 by Cochrane Collaboration. Accessed 8/17/2015.</li>
<li>Noto H, Goto A, Tsujimoto T, Noda M. Low-carbohydrate diets and all-cause mortality: a systematic review and meta-analysis of observational studies. PloS one. 2013;8(1):e55030.</li>
<li>NPG. Nature Publishing Group. Role of insulin-like growth factor 1 in bone metastasis. BoneKEy reports. 2012;1:170.</li>
<li>O'Connor PJ, Sperl-Hillen JM. ePocrates online. Type 2 diabetes mellitus in adults. Available at: https://online.epocrates.com/u/291124/Type+2+diabetes+mellitus+in+adults. Last updated 1/12/2015. Accessed 3/19/2015.</li>
<li>Odegaard AO, Koh WP, Yuan JM, Gross MD, Pereira MA. Western-style fast food intake and cardiometabolic risk in an Eastern country. Circulation. Jul 10 2012;126(2):182-188.</li>
<li>Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Human pathology. Aug 2003;34(8):803-808.</li>

<li>Palau-Rodriguez M, Tulipani S, Isabel Queipo-Ortuno M, Urpi-Sarda M, Tinahones FJ, Andres-Lacueva C. Metabolomic insights into the intricate gut microbial-host interaction in the development of obesity and type 2 diabetes. Front Microbiol. 2015;6:1151.</li>
<li>Peng H, Want LL, Aroda VR. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. Current diabetes reports. May 2016;16(5):44.</li>
<li>Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England journal of medicine. Jun 13 2019;380(24):2295-2306. doi:10.1056/NEJMoa1811744</li>
<li>Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nature reviews. Endocrinology. Mar 2014;10(3):143-156.</li>
<li>Perraudeau F, McMurdie P, Bullard J, et al. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care. 2020;8(1).</li>
<li>Pinto LC, Rados DV, Barkan SS, Leitao CB, Gross JL. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis. Sci Rep. Jan 15 2018;8(1):782. doi:10.1038/s41598-017-19055-6</li>
<li>Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. The Biochemical journal. Nov 1 2015;471(3):307-322.</li>
<li>Rana S, Blowers EC, Natarajan A. Small molecule adenosine 5’-monophosphate activated protein kinase (AMPK) modulators and human diseases. J Med Chem. 2015;58:2-29.</li>
<li>Rehman MB, Tudrej BV, Soustre J, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. Feb 2017;43(1):48-58. doi:10.1016/j.diabet.2016.09.005</li>
<li>Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56(9):1898-1906.</li>
<li>Rizza W, Veronese N, Fontana L. What are the roles of calorie restriction and diet quality in promoting healthy longevity? Ageing Res Rev. Jan 2014;13:38-45.</li>
<li>Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. Jul 10 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6</li>
<li>Roshanov PS, Dennis BB. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials. Diabetes research and clinical practice. Dec 2015;110(3):e13-17.</li>
<li>Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, . . . Cummings DE. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes care. Jun 2016;39(6):861-877.</li>
<li>Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. The Journal of clinical investigation. Jul 2013;123(7):2764-2772.</li>
<li>Ryder RE. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabetic medicine: a journal of the British Diabetic Association. Oct 2013;30(10):1148-1155.</li>
<li>Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl). 2011;89(7):667-76.</li>
<li>Sano R, Shinozaki Y, Ohta T. Sodium-glucose cotransporters: Functional properties and pharmaceutical potential. J Diabetes Investig. Jul 2020;11(4):770-782. doi:10.1111/jdi.13255</li>
<li>Sarafidis PA, Ortiz A. The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern? Clin Kidney J. Feb 2020;13(1):24-26. doi:10.1093/ckj/sfz170</li>
<li>Schaafsma D, Gosens R, Ris JM, et al. Insulin induces airway smooth muscle contraction. Br J Phrmacol. 2007;150(2):136-42.</li>
<li>Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. The New England journal of medicine. Feb 16 2017;376(7):641-651. doi:10.1056/NEJMoa1600869</li>
<li>Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab. 2013;39:179-190.</li>

</ul>

<!-- Cholesterol Management -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #1b5e20; padding-bottom: 10px;">
    <i class="fas fa-heartbeat" style="margin-right: 10px; color: #1b5e20;"></i>Cholesterol Management
</h2>
<p style="margin-bottom: 20px; text-align: justify;">
    Emerging research on underestimated aspects of cholesterol biochemistry has revealed that high blood cholesterol levels represent a minimal part of the risk for the development of alterations, syndromes, and diseases. However, the chemical properties of the molecules responsible for transporting cholesterol through the blood, known as lipoproteins, pose greater health risks. These lipoproteins can alter the structures of proteins, glucose, RNA, and DNA, among other macromolecules, leading to disorders such as atherosclerosis. The use of statins and other drugs to control cholesterol and lipid metabolic disorders has shown that, in the medium and long term, they may cause alterations, syndromes, and diseases that can be more harmful, fatal, and reduce life expectancy with quality more than the conditions associated with high levels of lipids and cholesterol in the blood. Favorably, it is possible to develop therapeutic products (adjuvants) that counteract the development of these findings and enhance the efficacy of conventional drugs.
</p>
<h3 style="font-size: 22px; color: #1b5e20; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #1b5e20; padding-bottom: 5px;">
    Conventional Treatments
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    HMG-CoA reductase inhibitors (statins) are commonly used to reduce cellular production of cholesterol. Other medications, such as bile acid sequestrants like colesevelam, lower cholesterol absorption from the intestine. PCSK9 inhibitors allow LDL to bond to its receptors and be removed from the blood. For people who require additional LDL lowering, the new drug bempedoic acid may be recommended in addition to statin therapy.
</p>
<h3 style="font-size: 22px; color: #c62828; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #c62828; padding-bottom: 5px;">
    Strategy for Use of Adjuvants
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    To improve the pharmacological actions of the drugs used in the prevention, control, and treatment of cholesterol and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term—often contributing to the development of alterations, syndromes, and deadly diseases such as cancer, and reducing the quality of life and life expectancy—scientists and doctors of "PPG NUTRICIONAL," together with family doctors and specialists from clinics and hospitals, assisted by the "MIS," have defined a personalized therapeutic strategy. This strategy aims to develop specific adjuvants that enhance the actions of the drugs used in each stage of cholesterol treatment, while also reducing the risk of contracting disorders, syndromes, or fatal diseases that diminish quality of life. These adjuvants are unique compositions or combinations of labeled drugs, natural active ingredients, enzyme cofactors, vitamins, trace elements, protein hydrolysates, peptides, probiotics, and other products authorized for use in humans by the FDA.
</p>

<!-- References -->
<h3 style="font-size: 22px; color: #333; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #333; padding-bottom: 5px;">
    References
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2018:CIR0000000000000625.<br>
    2. Nicholls SJ. The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. Current cardiology reports. 2019;21(4):18.<br>
    3. Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovascular Research. 2019;115(3):e26-e31.<br>
    4. Elhomsy G. Apolipoprotein B. Medscape. Laboratory Medicine Web site. https://emedicine.medscape.com/article/2087335-overview#a4. Published 2014. Accessed 04/22/19.<br>
    5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018:25709.<br>
    6. Di Donna L, De Luca G, Mazzotti F, et al. Statin-like principles of bergamot fruit (Citrus bergamia): isolation of 3-hydroxymethylglutaryl flavonoid glycosides. J Nat Prod. 2009;72(7):1352-1354.<br>
    7. Häggström M RD. Diagram of the pathways of human steroidogenesis. In: pathways S, ed. WikiJournal of Medicine 1 (1)2014.<br>
    8. Alberts B, Johnson A, Lewis J ea. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. The Lipid Bilayer. In:2002: https://www.ncbi.nlm.nih.gov/books/NBK26871/. Accessed 03/12/2019.<br>
    9. Fardella CE, Miller WL. Molecular biology of mineralocorticoid metabolism. Annu Rev Nutr. 1996;16(1):443-470.<br>
    10. Xu K, Morgan KT, Todd Gehris A, Elston TC, Gomez SM. A whole-body model for glycogen regulation reveals a critical role for substrate cycling in maintaining blood glucose homeostasis. PLoS computational biology. 2011;7(12):e1002272-e1002272.<br>
    11. Salter AM, Brindley DN. The biochemistry of lipoproteins. Journal of inherited metabolic disease. 1988;11 Suppl 1:4-17.<br>
    12. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.<br>
    13. Feingold KR, Grunfeld C. Introduction to Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.<br>
    14. Lagor W, Millar J. Overview of the LDL receptor: relevance to cholesterol metabolism and future approaches to the treatment of coronary heart disease. JRLCR. 2009;3:1-14.<br>
    15. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992;93(3):189-199.<br>
    16. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993;94(4):350-356.<br>
    17. Liu ML, Ylitalo K, Salonen R, Salonen JT, Taskinen MR. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arteriosclerosis, thrombosis, and vascular biology. 2004;24(8):1492-1497.<br>
    18. Koba S, Yokota Y, Hirano T, et al. Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. Journal of atherosclerosis and thrombosis. 2008;15(5):250-260.<br>
    19. Rubenfire M, American College of Cardiology. Lipoprotein(a): Diagnosis, Prognosis, Emerging Therapies. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/02/07/14/21/a-test-in-context-lipoproteina-diagnosis. Published 2017. Accessed Jun. 27, 2019.<br>
    20. Schettler VJJ, Neumann CL, Peter C, et al. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Clinical research in cardiology supplements. 2019;14(Suppl 1):33-38.<br>
    21. Thanassoulis G. Screening for High Lipoprotein(a): The Time Is Now. Circulation. 2019;139(12):1493-1496.<br>
    22. Borrelli MJ, Youssef A, Boffa MB, Koschinsky ML. New Frontiers in Lp(a)-Targeted Therapies. Trends Pharmacol Sci. 2019;40(3):212-225.<br>
    23. Reiner Z. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk? Curr Atheroscler Rep. 2019;21(4):14.<br>
    24. Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochemical and biophysical research communications. 2002;296(5):1051-1057.<br>
    25. Herbst KL, Amory JK, Brunzell JD, Chansky HA, Bremner WJ. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Physiol Endocrinol Metab. 2003;284(6):E1112-1118.<br>
    26. Turhan S, Tulunay C, Gulec S, et al. The association between androgen levels and premature coronary artery disease in men. Coronary artery disease. 2007;18(3):159-162.<br>
    27. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. Journal of lipid research. 2004;45(9):1583-1593.<br>
    28. Reaven PD, Witztum JL. Oxidized low density lipoproteins in atherogenesis: role of dietary modification. Annu Rev Nutr. 1996;16:51-71.<br>
    29. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. Journal of lipid research. 2009;50 Suppl:S376-381.<br>
    30. Chouinard JA, Grenier G, Khalil A, Vermette P. Oxidized-LDL induce morphological changes and increase stiffness of endothelial cells. Experimental cell research. 2008;314(16):3007-3016.<br>
    31. Fournet M, Bonte F, Desmouliere A. Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging. Aging Dis. 2018;9(5):880-900.<br>
    32. Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol. 2012;4(4):90-102.<br>
    33. Havranek EP. Primary prevention of CHD: nine ways to reduce risk. American family physician. 1999;59(6):1455-1463, 1466.<br>
    34. Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. The open cardiovascular medicine journal. 2011;5:76-84.<br>
    35. Wanjia X, Chenggang W, Aihong W, et al. A high normal TSH level is associated with an atherogenic lipid profile in euthyroid non-smokers with newly diagnosed asymptomatic coronary heart disease. Lipids in health and disease. 2012;11:44.<br>
    36. van Tienhoven-Wind LJ, Dullaart RP. Low-normal thyroid function and novel cardiometabolic biomarkers. Nutrients. 2015;7(2):1352-1377.<br>
    37. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18(6):499-502.<br>
    38. Bhatt DL. Non-HDL cholesterol explained. Heart Health Publishing online. https://www.health.harvard.edu/heart-health/non-hdl-cholesterol-explained. 1/2018. Accessed 5/31/2019.<br>
    39. Wolska A, Remaley A. Lipoprotein Subfraction Analysis. Clinical Laboratory News online. https://www.aacc.org/publications/cln/articles/2017/january/lipoprotein-subfractionation-analysis. 1/3/2017. Accessed 5/31/2019. 2017.<br>
    40. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. The New England journal of medicine. 2007;356(23):2388-2398.<br>
    41. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J. 2002;23(8):620-626.<br>
    42. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine. 2008;359(21):2195-2207.<br>
    43. Daviglus ML, Stamler J, Pirzada A, et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. Jama. 2004;292(13):1588-1592.<br>
    44. Sobal G, Menzel J, Sinzinger H. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. Prostaglandins Leukot Essent Fatty Acids. 2000;63(4):177-186.<br>
    45. Nivoit P, Wiernsperger N, Moulin P, Lagarde M, Renaudin C. Effect of glycated LDL on microvascular tone in mice: a comparative study with LDL modified in vitro or isolated from diabetic patients. Diabetologia. 2003;46(11):1550-1558.<br>
    46. Toma L, Stancu CS, Botez GM, Sima AV, Simionescu M. Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochemical and biophysical research communications. 2009;390(3):877-882.<br>
    47. Dong Y, Wu Y, Wu M, et al. Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase. Journal of cellular and molecular medicine. 2009;13(9a):2899-2910.<br>
    48. Calvo C. [Non-enzymatic glycosylation of lipoproteins in the pathogenesis of atherosclerosis in diabetics]. Revista medica de Chile. 1997;125(4):460-465.<br>
    49. Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol. 2011;22(4):254-261.<br>
    50. Miceli N, Mondello MR, Monforte MT, et al. Hypolipidemic effects of Citrus bergamia Risso et Poiteau juice in rats fed a hypercholesterolemic diet. J Agric Food Chem. 2007;55(26):10671-10677.<br>
    51. American Heart Association. Healthy Cooking Oils. https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/fats/healthy-cooking-oils. Published 2018. Updated 04/24/2018. Accessed 04/30/2019.<br>
    52. Association AH. The American Heart Association Diet and Lifestyle Recommendations. https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/nutrition-basics/aha-diet-and-lifestyle-recommendations. Published 2015. Updated 08/15/2015. Accessed 04/30/2019.<br>
    53. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation. 2017;136(3):e1-e23.<br>
    54. LANE MA, BLACK A, INGRAM DK, ROTH GS. Calorie Restriction in Nonhuman Primates: Implications for Age-Related Disease Risk. Journal of Anti-Aging Medicine. 1998;1(4):315-326.<br>
    55. Walford RL, Mock D, Verdery R, MacCallum T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. The journals of gerontology Series A, Biological sciences and medical sciences. 2002;57(6):B211-224.<br>
    56. Meyer TE, Kovacs SJ, Ehsani AA, Klein S, Holloszy JO, Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. Journal of the American College of Cardiology. 2006;47(2):398-402.<br>
    57. Fontana L, Klein S, Holloszy JO, Premachandra BN. Effect of long-term calorie restriction with adequate protein and micronutrients on thyroid hormones. J Clin Endocrinol Metab. 2006;91(8):3232-3235.<br>
    58. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A. 2004;101(17):6659-6663.<br>
    59. Stewart TM, Bhapkar M, Das S, et al. Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy Phase 2 (CALERIE Phase 2) screening and recruitment: methods and results. Contemporary clinical trials. 2013;34(1):10-20.<br>
    60. Lefevre M, Redman LM, Heilbronn LK, et al. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis. 2009;203(1):206-213.<br>
    61. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation.0(0):CIR.0000000000000678.<br>
    62. Nassef Y, Lee KJ, Nfor ON, Tantoh DM, Chou MC, Liaw YP. The Impact of Aerobic Exercise and Badminton on HDL Cholesterol Levels in Adult Taiwanese. Nutrients. 2019;11(3).<br>
    63. Cho AR, Moon JY, Kim S, et al. Effects of alternate day fasting and exercise on cholesterol metabolism in overweight or obese adults: A pilot randomized controlled trial. Metabolism: clinical and experimental. 2019;93:52-60.<br>
    64. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of Diet and Exercise in Men and Postmenopausal Women with Low Levels of HDL Cholesterol and High Levels of LDL Cholesterol. New England Journal of Medicine. 1998;339(1):12-20.<br>
    65. Glenney SS, Brockemer DP, Ng AC, Smolewski MA, Smolgovskiy VM, Lepley AS. Effect of Exercise Training on Cardiac Biomarkers in At-Risk Populations: A Systematic Review. J Phys Act Health. 2017;14(12):968-989.<br>
    66. Patel H, Alkhawam H, Madanieh R, Shah N, Kosmas CE, Vittorio TJ. Aerobic vs anaerobic exercise training effects on the cardiovascular system. World journal of cardiology. 2017;9(2):134-138.<br>
    67.Barter PJ, Rye KA. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? Circulation. 2006;113(12):1553-1555.
68.Devaraj S, Siegel D, Jialal I. Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP? Curr Atheroscler Rep. 2011;13(1):31-42.
69.Fung EC, Crook MA. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovascular therapeutics. 2012;30(5):e212-218.
70.Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve. 2010;42(4):469-479.
71.Hammersley D, Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Therapeutic advances in chronic disease. 2017;8(1):4-11.
72.Davidson MH. Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr Atheroscler Rep. 2011;13(1):95-100.
73.Toth PP, Patti AM, Giglio RV, et al. Management of Statin Intolerance in 2018: Still More Questions Than Answers. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2018;18(3):157-173.
74.Brown JE, Rice-Evans CA. Luteolin-rich artichoke extract protects low density lipoprotein from oxidation in vitro. Free Radic Res. 1998;29(3):247-255.
75.Englisch W, Beckers C, Unkauf M, Ruepp M, Zinserling V. Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung. 2000;50(3):260-265.
76.Bundy R, Walker AF, Middleton RW, Wallis C, Simpson HC. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. Phytomedicine. 2008;15(9):668-675.
77.Rondanelli M, Giacosa A, Opizzi A, et al. Beneficial effects of artichoke leaf extract supplementation on increasing HDL-cholesterol in subjects with primary mild hypercholesterolaemia: a double-blind, randomized, placebo-controlled trial. International journal of food sciences and nutrition. 2013;64(1):7-15.
78.Nazni P, Vijayakumar TP, Alagianambi P, Amirthaveni M. Hypoglycemic and hypolipidemic effect of Cynara scolymus among selected type 2 diabetic individuals. Pak J Nutr. 2006;5(2):147-151.
79.Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. Journal of the American College of Cardiology. 2000;35(3):640-646.
80.McCarty MF. Inhibition of acetyl-CoA carboxylase by cystamine may mediate the hypotriglyceridemic activity of pantethine. Med Hypotheses. 2001;56(3):314-317.
81.Bertolini S, Donati C, Elicio N, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. Int J Clin Pharmacol Ther Toxicol. 1986;24(11):630-637.
82.Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis. 1984;50(1):73-83.
83.Donati C, Bertieri RS, Barbi G. [Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients]. Clin Ter. 1989;128(6):411-422.
84.Tonutti L, Taboga C, Noacco C. [Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia]. Minerva Med. 1991;82(10):657-663.
85.Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr Res. 2011;31(8):608-615.
86.Yadav SS, Singh MK, Singh PK, Kumar V. Traditional knowledge to clinical trials: A review on therapeutic actions of Emblica officinalis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2017;93:1292-1302.
87.Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. International journal of food sciences and nutrition. 2011;62(6):609-616.
88.Kim HY, Okubo T, Juneja LR, Yokozawa T. The protective role of amla (Emblica officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. The British journal of nutrition. 2010;103(4):502-512.
89.Gopa B, Bhatt J, Hemavathi KG. A comparative clinical study of hypolipidemic efficacy of Amla (Emblica officinalis) with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor simvastatin. Indian journal of pharmacology. 2012;44(2):238-242.
90.Usharani P, Fatima N, Muralidhar N. Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study. Diabetes, metabolic syndrome and obesity : targets and therapy. 2013;6:275-284.
91.Khanna S, Das A, Spieldenner J, Rink C, Roy S. Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults. Journal of medicinal food. 2015;18(4):415-420.
92.Reinhart KM, Talati R, White CM, Coleman CI. The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Res Rev. 2009;22(1):39-48.
93.Khoo YS, Aziz Z. Garlic supplementation and serum cholesterol: a meta-analysis. J Clin Pharm Ther. 2009;34(2):133-145.
94.Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med. 2000;133(6):420-429.
95.Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. Nutrition reviews. 2013;71(5):282-299.
96.Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC cardiovascular disorders. 2008;8:13.
97.Gauhar R, Hwang SL, Jeong SS, et al. Heat-processed Gynostemma pentaphyllum extract improves obesity in ob/ob mice by activating AMP-activated protein kinase. Biotechnology letters. 2012;34(9):1607-1616.
98.Nguyen PH, Gauhar R, Hwang SL, et al. New dammarane-type glucosides as potential activators of AMP-activated protein kinase (AMPK) from Gynostemma pentaphyllum. Bioorganic & medicinal chemistry. 2011;19(21):6254-6260.
99.Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. The American journal of physiology. 1999;277(1 Pt 1):E1-10.
100.Park SH, Huh TL, Kim SY, et al. Antiobesity effect of Gynostemma pentaphyllum extract (actiponin): a randomized, double-blind, placebo-controlled trial. Obesity (Silver Spring). 2014;22(1):63-71.
101.Dong Y, Zhang M, Wang S, et al. Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes. 2010;59(6):1386-1396.
102.Umeno A, Horie M, Murotomi K, Nakajima Y, Yoshida Y. Antioxidative and Antidiabetic Effects of Natural Polyphenols and Isoflavones. Molecules (Basel, Switzerland). 2016;21(6).
103.Devi KP, Rajavel T, Nabavi SF, et al. Hesperidin: A promising anticancer agent from nature. Industrial crops and products. 2015;76:582-589.
104.Li C, Schluesener H. Health-promoting effects of the citrus flavanone hesperidin. Crit Rev Food Sci Nutr. 2017;57(3):613-631.
105.Roohbakhsh A, Parhiz H, Soltani F, Rezaee R, Iranshahi M. Neuropharmacological properties and pharmacokinetics of the citrus flavonoids hesperidin and hesperetin--a mini-review. Life Sci. 2014;113(1-2):1-6.
106.Jia S, Hu Y, Zhang W, et al. Hypoglycemic and hypolipidemic effects of neohesperidin derived from Citrus aurantium L. in diabetic KK-A(y) mice. Food Funct. 2015;6(3):878-886.
107.Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011;96(5):E782-792.
108.Zhang J, Sun C, Yan Y, et al. Purification of naringin and neohesperidin from Huyou (Citrus changshanensis) fruit and their effects on glucose consumption in human HepG2 cells. Food Chem. 2012;135(3):1471-1478.
109.Homayouni F, Haidari F, Hedayati M, Zakerkish M, Ahmadi K. Hesperidin Supplementation Alleviates Oxidative DNA Damage and Lipid Peroxidation in Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Phytother Res. 2017.
110.Sun Q, Wedick NM, Tworoger SS, et al. Urinary Excretion of Select Dietary Polyphenol Metabolites Is Associated with a Lower Risk of Type 2 Diabetes in Proximate but Not Remote Follow-Up in a Prospective Investigation in 2 Cohorts of US Women. J Nutr. 2015;145(6):1280-1288.
111.Adab Z, Eghtesadi S, Vafa MR, et al. Effect of turmeric on glycemic status, lipid profile, hs-CRP, and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients. Phytother Res. 2019.
112.Salden BN, Troost FJ, de Groot E, et al. Randomized clinical trial on the efficacy of hesperidin 2S on validated cardiovascular biomarkers in healthy overweight individuals. Am J Clin Nutr. 2016;104(6):1523-1533.
113.Haidari F, Heybar H, Jalali MT, Ahmadi Engali K, Helli B, Shirbeigi E. Hesperidin supplementation modulates inflammatory responses following myocardial infarction. J Am Coll Nutr. 2015;34(3):205-211.
114.Amir Shaghaghi M, Abumweis SS, Jones PJ. Cholesterol-lowering efficacy of plant sterols/stanols provided in capsule and tablet formats: results of a systematic review and meta-analysis. Journal of the Academy of Nutrition and Dietetics. 2013;113(11):1494-1503.
115.Salo P, Wester I. Low-fat formulations of plant stanols and sterols. The American journal of cardiology. 2005;96(1a):51d-54d.
116.Weingartner O, Bohm M, Laufs U. Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J. 2009;30(4):404-409.
117.Calpe-Berdiel L, Escola-Gil JC, Blanco-Vaca F. New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism. Atherosclerosis. 2009;203(1):18-31.
118.Shrestha S, Freake HC, McGrane MM, Volek JS, Fernandez ML. A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake. J Nutr. 2007;137(5):1165-1170.
119.Badimon L, Vilahur G, Padro T. Nutraceuticals and atherosclerosis: human trials. Cardiovascular therapeutics. 2010;28(4):202-215.
120.Normen L, Holmes D, Frohlich J. Plant sterols and their role in combined use with statins for lipid lowering. Current opinion in investigational drugs (London, England : 2000). 2005;6(3):307-316.
121.Berger A, Jones PJ, Abumweis SS. Plant sterols: factors affecting their efficacy and safety as functional food ingredients. Lipids in health and disease. 2004;3:5.
122.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001;285(19):2486-2497.
123.Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(10):2186-2191.
124.Banach M, Patti AM, Giglio RV, et al. The Role of Nutraceuticals in Statin Intolerant Patients. Journal of the American College of Cardiology. 2018;72(1):96-118.
125.Ulbricht C, Basch E, Szapary P, et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complementary therapies in medicine. 2005;13(4):279-290.
126.Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther. 1994;8(4):659-664.
127.Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. Jama. 2003;290(6):765-772.
128.Nohr LA, Rasmussen LB, Straand J. Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study. Complementary therapies in medicine. 2009;17(1):16-22.
129.Patti AM, Al-Rasadi K, Katsiki N, et al. Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome. Angiology. 2015;66(9):856-861.
130.Das S, Datta A, Bagchi C, Chakraborty S, Mitra A, Tripathi SK. A Comparative Study of Lipid-Lowering Effects of Guggul and Atorvastatin Monotherapy in Comparison to Their Combination in High Cholesterol Diet-Induced Hyperlipidemia in Rabbits. Journal of dietary supplements. 2016;13(5):495-504.
131.Amato A, Caldara GF, Nuzzo D, et al. NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet. Nutrients. 2017;9(5).
132.Anderson JW, Randles KM, Kendall CW, Jenkins DJ. Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr. 2004;23(1):5-17.
133.Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30-42.
134.AbuMweis SS, Jew S, Ames NP. beta-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. European journal of clinical nutrition. 2010;64(12):1472-1480.
135.Baker WL, Tercius A, Anglade M, White CM, Coleman CI. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann Nutr Metab. 2009;55(4):368-374.
136.Zhu X, Sun X, Wang M, et al. Quantitative assessment of the effects of beta-glucan consumption on serum lipid profile and glucose level in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis. 2015;25(8):714-723.
137.Jarosz PA, Fletcher E, Elserafy E, Artiss JD, Jen KL. The effect of alpha-cyclodextrin on postprandial lipid and glycemic responses to a fat-containing meal. Metabolism: clinical and experimental. 2013;62(10):1443-1447.
138.Artiss JD, Brogan K, Brucal M, Moghaddam M, Jen KL. The effects of a new soluble dietary fiber on weight gain and selected blood parameters in rats. Metabolism: clinical and experimental. 2006;55(2):195-202.
139.Wagner EM, Catherine Jen KL, Artiss JD, Remaley AT. Dietary alpha-cyclodextrin lowers LDL-C and alters plasma fatty acid profile in LDLr-KO mice on a high-fat diet. Metabolism: clinical and experimental. 2008;57(8):1046-1051.
140.Gallaher DD, Gallaher CM, Plank DW. Alpha-cyclodextrin selectively increases fecal excretion of saturated fats. In: Federation of American Societies for Experimental Biology; 2007.
141.Grunberger G, Jen KL, Artiss JD. The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre. Diabetes Metab Res Rev. 2007;23(1):56-62.
142.Comerford KB, Artiss JD, Jen KLC, Karakas SE. The Beneficial Effects α-Cyclodextrin on Blood Lipids and Weight Loss in Healthy Humans. Obesity. 2011;19(6):1200-1204.
143.Amar MJ, Kaler M, Courville AB, Shamburek R, Sampson M, Remaley AT. Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids. Lipids in health and disease. 2016;15(1):115.
144.Sakurai T, Sakurai A, Chen Y, et al. Dietary α-cyclodextrin reduces atherosclerosis and modifies gut flora in apolipoprotein E-deficient mice. Mol Nutr Food Res. 2017;61(8).
145.Sangle GV, Chowdhury SK, Xie X, Stelmack GL, Halayko AJ, Shen GX. Impairment of mitochondrial respiratory chain activity in aortic endothelial cells induced by glycated low-density lipoprotein. Free radical biology & medicine. 2010;48(6):781-790.
146.Roy Chowdhury SK, Sangle GV, Xie X, Stelmack GL, Halayko AJ, Shen GX. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells. Am J Physiol Endocrinol Metab. 2010;298(1):E89-98.
147.Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007;7 Suppl:S168-174.
148.Tóth Š, Šajty M, Pekárová T, et al. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. Journal of basic and clinical physiology and pharmacology. 2017;28(4):327-336.
149.Jorat MV, Tabrizi R, Mirhosseini N, et al. The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Lipids in health and disease. 2018;17(1):230.
150.Sahebkar A, Simental-Mendía LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacol Res. 2016;105:198-209.
151.Karppi J, Nurmi T, Kurl S, Rissanen TH, Nyyssonen K. Lycopene, lutein and beta-carotene as determinants of LDL conjugated dienes in serum. Atherosclerosis. 2010;209(2):565-572.
152.Ried K, Fakler P. Protective effect of lycopene on serum cholesterol and blood pressure: Meta-analyses of intervention trials. Maturitas. 2011;68(4):299-310.
153.Fuhrman B, Elis A, Aviram M. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Biochemical and biophysical research communications. 1997;233(3):658-662.
154.Mao M, Lei H, Liu Q, et al. Lycopene inhibits neointimal hyperplasia through regulating lipid metabolism and suppressing oxidative stress. Molecular medicine reports. 2014;10(1):262-268.
155.Aidoud A, Ammouche A, Garrido M, Rodriguez AB. Effect of lycopene-enriched olive and argan oils upon lipid serum parameters in Wistar rats. Journal of the science of food and agriculture. 2014;94(14):2943-2950.
156.Cheng HM, Koutsidis G, Lodge JK, Ashor A, Siervo M, Lara J. Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis. Atherosclerosis. 2017;257:100-108.
157.Badiou S, Cristol JP, Morena M, et al. Vitamin E supplementation increases LDL resistance to ex vivo oxidation in hemodialysis patients. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition. 2003;73(4):290-296.
158.Tesoriere L, D'Arpa D, Butera D, et al. Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients. Free Radic Res. 2001;34(5):529-540.
159.Li D, Saldeen T, Romeo F, Mehta JL. Relative Effects of alpha- and gamma-Tocopherol on Low-Density Lipoprotein Oxidation and Superoxide Dismutase and Nitric Oxide Synthase Activity and Protein Expression in Rats. J Cardiovasc Pharmacol Ther. 1999;4(4):219-226.
160.McCarty MF. Gamma-tocopherol may promote effective no synthase function by protecting tetrahydrobiopterin from peroxynitrite. Med Hypotheses. 2007;69(6):1367-1370.
161.Saito F, Iwamoto S, Yamauchi R. Reaction products of gamma-tocopherol with (E)-4-oxo-2-nonenal in acidic acetonitrile. Bioscience, biotechnology, and biochemistry. 2010;74(1):168-174.
162.Singh I, Turner AH, Sinclair AJ, Li D, Hawley JA. Effects of gamma-tocopherol supplementation on thrombotic risk factors. Asia Pac J Clin Nutr. 2007;16(3):422-428.
163.Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88(1):38-50.
164.Onakpoya I, Spencer E, Heneghan C, Thompson M. The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(8):823-836.
165.Alves Ferreira M, Oliveira Gomes AP, Guimarães de Moraes AP, et al. Green tea extract outperforms metformin in lipid profile and glycaemic control in overweight women: A double-blind, placebo-controlled, randomized trial. Clinical nutrition ESPEN. 2017;22:1-6.
166.Fujita H, Yamagami T. Antihypercholesterolemic effect of Chinese black tea extract in human subjects with borderline hypercholesterolemia. Nutr Res. 2008;28(7):450-456.
167.Imran A, Butt MS, Arshad MS, et al. Exploring the potential of black tea based flavonoids against hyperlipidemia related disorders. Lipids in health and disease. 2018;17(1):57.
168.Aviram M, Dornfeld L, Kaplan M, et al. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. Drugs under experimental and clinical research. 2002;28(2-3):49-62.
169.Sezer ED, Akcay YD, Ilanbey B, Yildirim HK, Sozmen EY. Pomegranate wine has greater protection capacity than red wine on low-density lipoprotein oxidation. Journal of medicinal food. 2007;10(2):371-374.
170.Esmaillzadeh A, Tahbaz F, Gaieni I, Alavi-Majd H, Azadbakht L. Cholesterol-lowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition. 2006;76(3):147-151.
171.Fuhrman B, Volkova N, Aviram M. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J Nutr Biochem. 2005;16(9):570-576.
172.Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004;23(3):423-433.
173.Kojadinovic MI, Arsic AC, Debeljak-Martacic JD, et al. Consumption of pomegranate juice decreases blood lipid peroxidation and levels of arachidonic acid in women with metabolic syndrome. Journal of the science of food and agriculture. 2017;97(6):1798-1804.
174.Shema-Didi L, Kristal B, Sela S, Geron R, Ore L. Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients? Nutr J. 2014;13:18.
175.Hosseini B, Saedisomeolia A, Wood LG, Yaseri M, Tavasoli S. Effects of pomegranate extract supplementation on inflammation in overweight and obese individuals: A randomized controlled clinical trial. Complementary therapies in clinical practice. 2016;22:44-50.
176.Ramirez-Boscá A, Soler A, Gutierrez MAC, Alvarez JL, Almagro EQ. Antioxidant curcuma extracts decrease the blood lipid peroxide levels of human subjects. Age. 1995;18(4):167-169.
177.Ramirez Bosca A, Carrion Gutierrez MA, Soler A, et al. Effects of the antioxidant turmeric on lipoprotein peroxides: Implications for the prevention of atherosclerosis. Age (Omaha). 1997;20(3):165-168.
178.Ramirez Bosca A, Soler A, Carrion-Gutierrez MA, et al. An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen. Mech Ageing Dev. 2000;114(3):207-210.
179.Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol. 2009;133(2):145-151.
180.Dou X, Fan C, Wo L, Yan J, Qian Y, Wo X. Curcumin up-regulates LDL receptor expression via the sterol regulatory element pathway in HepG2 cells. Planta Med. 2008;74(11):1374-1379.
181.Peschel D, Koerting R, Nass N. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem. 2007;18(2):113-119.
182.Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian journal of physiology and pharmacology. 1992;36(4):273-275.
183.Alwi I, Santoso T, Suyono S, et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta medica Indonesiana. 2008;40(4):201-210.
184.Baum L, Cheung SK, Mok VC, et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacological research : the official journal of the Italian Pharmacological Society. 2007;56(6):509-514.
185.Qin S, Huang L, Gong J, et al. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr J. 2017;16(1):68.
186.Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014;28(12):1770-1777.
187.Pizzini A, Lunger L, Demetz E, et al. The Role of Omega-3 Fatty Acids in Reverse Cholesterol Transport: A Review. Nutrients. 2017;9(10).
188.Simopoulos AP. Evolutionary Aspects of the Dietary Omega-6/Omega-3 Fatty Acid Ratio: Medical Implications. In: Alvergne A, Jenkinson C, Faurie C, eds. Evolutionary Thinking in Medicine: From Research to Policy and Practice. Cham: Springer International Publishing; 2016:119-134.
189.Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. Journal of clinical lipidology. 2012;6(1):5-18.
190.Allaire J, Vors C, Tremblay AJ, et al. High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study. J Clin Endocrinol Metab. 2018;103(8):2909-2917.
191.Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England journal of medicine. 2019;380(1):11-22.
192.Wu Y, Zhang Q, Ren Y, Ruan Z. Effect of probiotic Lactobacillus on lipid profile: A systematic review and meta-analysis of randomized, controlled trials. PLoS One. 2017;12(6):e0178868.
193.DiRienzo DB. Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets. Nutrition reviews. 2014;72(1):18-29.
194.Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. The British journal of nutrition. 2012;107(10):1505-1513.
195.Semekovich CF, Goldman L. Goldman-Cecil Medicine. Twenty-fifth edition. Chapter 206: Disorders of Lipid Metabolism. 1389-1397..e.3. Copyright 2016 by Saunders, an imprint of Elsevier Inc. www.clinicalkey.com. Accessed 7/7/2016.
196.Lu M, Lu Q, Zhang Y, Tian G. ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity(). Journal of biomedical research. 2011;25(4):266-273.
197.Walldius G, Frank S, Kostner G. Biochemistry, Genetics, and Molecular Biology. Chapter 5: The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk. http://www.intechopen.com/books/lipoproteins-role-in-health-and-diseases/the-apob-apoa-i-ratio-is-a-strong-predictor-of-cardiovascular-risk. 10/3/2012. Accessed 7/7/2016.
198.Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. European journal of clinical nutrition. 2012;66(11):1234-1241.
199.Jones ML, Martoni CJ, Ganopolsky JG, Sulemankhil I, Ghali P, Prakash S. Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial. Expert Opin Biol Ther. 2013;13(12):1643-1651.
200.Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial. J Clin Endocrinol Metab. 2013;98(7):2944-2951.
201.Staels B, Fonseca VA. Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009;32(Suppl 2):S237-245.
202.Kumar M, Nagpal R, Kumar R, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Experimental diabetes research. 2012;2012:902917.
203.Cho YA, Kim J. Effect of Probiotics on Blood Lipid Concentrations: A Meta-Analysis of Randomized Controlled Trials. Medicine. 2015;94(43):e1714.
204.Sun J, Buys N. Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2015;47(6):430-440.
205.Zhao H, Song A, Zhang Y, Shu L, Song G, Ma H. Effect of Resveratrol on Blood Lipid Levels in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Obesity (Silver Spring). 2019;27(1):94-102.
206.He J, Zhang F, Han Y. Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: A meta-analysis of RCTs. Medicine. 2017;96(51):e9166.
207.Brighenti F, Casiraghi MC, Canzi E, Ferrari A. Effect of consumption of a ready-to-eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers. European journal of clinical nutrition. 1999;53(9):726-733.
208.Li S, Guerin-Deremaux L, Pochat M, Wils D, Reifer C, Miller LE. NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in overweight men: a double-blind, randomized, placebo-controlled study. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2010;35(6):773-782.
209.Cunningham E. Is red yeast rice safe and effective for lowering serum cholesterol? J Am Diet Assoc. 2011;111(2):324.
210.Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese medicine. 2006;1:4.
211.Moriarty PM, Roth EM, Karns A, et al. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. Journal of clinical lipidology. 2014;8(6):568-575.
212.Shang Q, Liu Z, Chen K, Xu H, Liu J. A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evidence-based complementary and alternative medicine : eCAM. 2012;2012:636547.
213.Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. The American journal of cardiology. 2008;101(12):1689-1693.
214.Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12):830-839, w147-839.
215.Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. The American journal of cardiology. 2010;105(2):198-204.
216.Kasliwal RR, Bansal M, Gupta R, et al. ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. Nutrition (Burbank, Los Angeles County, Calif). 2016;32(7-8):767-776.
217.Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170(19):1722-1727.
218.Toth PP, Patti AM, Nikolic D, et al. Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. Frontiers in pharmacology. 2015;6:299.
219.Cai Y, Xing G, Shen T, Zhang S, Rao J, Shi R. Effects of 12-week supplementation of Citrus bergamia extracts-based formulation CitriCholess on cholesterol and body weight in older adults with dyslipidemia: a randomized, double-blind, placebo-controlled trial. Lipids in health and disease. 2017;16(1):251.
220.Gliozzi M, Walker R, Muscoli S, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol. 2013;170(2):140-145.
221.D'Andrea E, Hey SP, Ramirez CL, Kesselheim AS. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019;2(4):e192224.
222.Kamanna VS, Kashyap ML. Mechanism of Action of Niacin. The American journal of cardiology. 2008;101(8, Supplement):S20-S26.
223.Garg A, Sharma A, Krishnamoorthy P, et al. Role of Niacin in Current Clinical Practice: A Systematic Review. Am J Med. 2017;130(2):173-187.
224.Neelakantan N, Seah JYH, van Dam RM. The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Clinical Trials. Circulation. 2020.
225.Hoppstädter J, Valbuena Perez JV, Linnenberger R, et al. The glucocorticoid-induced leucine zipper mediates statin-induced muscle damage. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2020:10.1096/fj.201902557RRR.
226.tctMD. FDA Approves New Lipid-Lowering Drug, Bempedoic Acid. https://www.tctmd.com/news/fda-approves-new-lipid-lowering-drug-bempedoic-acid. Published 2020. Accessed February 26, 2020.
227.Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780-1788.
228.Lalwani ND, Hanselman JC, MacDougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial. Journal of Clinical Lipidology. 2019;13(4):568-579.
229.Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62(13):1154-1162.
230.Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European journal of preventive cardiology. 2019:2047487319864671-2047487319864671.
231.Khan SU, Michos ED. Bempedoic acid and ezetimibe – better together. European Journal of Preventive Cardiology. 2019:2047487319864672.
232.Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. New England Journal of Medicine. 2019;380(11):1022-1032.
233.Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Current atherosclerosis reports. 2016;18(10):61-61.
234.Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019;30(1):1-9.
235.Reduction of Revascularizations in Patients with Hypertriglyceridemia With Icosapent Ethyl: Insights From REDUCE-IT REVASC [press release]. Society for Cardiovascular Angiography and Interventions.2020.
236.Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is Over. JAMA Cardiol. Nov 13 2021;doi:10.1001/jamacardio.2021.5080
237.Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology. 2021/03/23/ 2021;77(11):1439-1450. doi:https://doi.org/10.1016/j.jacc.2021.01.027
238.StatPearls. Biochemistry, Apolipoprotein B. Accessed 12/29/2021, https://www.statpearls.com/articlelibrary/viewarticle/17778
239.Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2019;41(1):111-188. doi:10.1093/eurheartj/ehz455
240.Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiology. 2021;doi:10.1001/jamacardio.2021.5083

</p>

<!-- Resumen de Alergias -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #1b5e20; padding-bottom: 10px;">
    <i class="fas fa-leaf" style="margin-right: 10px; color: #1b5e20;"></i> Allergies
</h2>
<p style="margin-bottom: 20px; text-align: justify;">
    Allergic states have increased worldwide in recent decades. Allergies include disorders such as atopic dermatitis, allergic rhinitis, asthma, hives, angioedema (swelling under the skin), as well as food, drug, and insect allergies. Medical treatment and other strategies can help alleviate allergic symptoms, syndromes, and reactions significantly as long as we can identify the allergens and components of the diet or environment that enhance these actions. The best benefits are achieved with the use of natural compounds with immunomodulatory properties because these help calm allergen-induced inflammatory responses to relieve symptoms. The medium and long-term use of conventional medications used for the treatment of allergies usually develop alterations, syndromes and diseases that are sometimes more harmful and deadly than allergies themselves. Our scientists together with doctors in offices, clinics and hospitals have developed therapeutic products (adjuvants) that improve the actions of conventional medications used to treat allergies, and at the same time reduce toxic effects and adverse reactions, alterations and fatal diseases.
</p>

<!-- Tratamientos Convencionales -->
<h3 style="font-size: 22px; color: #1b5e20; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #1b5e20; padding-bottom: 5px;">
    Conventional Treatments
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    Conventional treatments are based on antihistamines (bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, mizolastine, and rupatadine); Decongestants (pseudoephedrine and phenylephrine); glucocorticosteroids (prednisone, hydrocortisone, betamethasone, beclomethasone); leukotriene antagonists; cromolyn sodium; beta-agonists (albuterol and epinephrine).
</p>

<!-- Estrategia para el Uso de Adyuvantes -->
<h3 style="font-size: 22px; color: #c62828; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #c62828; padding-bottom: 5px;">
    Strategy for Use of Adjuvants
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    To improve the pharmacological actions of the drugs used in the prevention, control, and treatment of Allergies and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term that usually contribute to the development of alterations, syndromes, and deadly diseases, such as cancer, and can also reduce the quality life expectancy of people under treatment; the scientists and doctors of "PPG NUTRICIONAL" together with family doctors and specialists from clinics and hospitals, assisted by the "MIS", defined a personalized therapeutic strategy to develop specific adjuvants that improve the actions of the drugs used in each of the stages of treatment of Allergies and at the same time reduce the risk of contracting disorders, syndromes, or fatal diseases with decreased quality of life. These adjuvants are, in themselves, unique compositions or combinations of labeled drugs, natural active ingredients, enzyme cofactors, vitamins, trace elements, protein hydrolysates, peptides, probiotics, and other products authorized for use in humans by the FDA.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
1.Pawankar R, Canonica G, Holgate S, Lockey R. (eds). World Health Organization (WAO) White Book on Allergy. 2011.
2.Chang, Christopher, 2011. Asthma in Children and Adolescents: A Comprehensive Approach to Diagnosis and Management. Clinical Reviews in Allergy and Immunology. Doi: 10.1007/s12016-011-8261-3.
3.Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameters. J Allergy ClinImmunol 2008; 122: S1-S84
4.Fishbein AB, FuleihanRL. The hygiene hypothesis revisited: does exposure to infectious agents protect us from allergy? CurrOpinPediatr. 2012 Feb;24(1):98-102.
5.Jedrychowski W et al. Wheezing and asthma may be enhanced by broad spectrum antibiotics used in early childhood. Concept and results of a pharmacoepidemiology study. J PhysiolPharmacol. 2011 Apr;62(2):189-95.
6.Li XM. Complementary and alternative medicine in pediatric allergic disorders. CurrOpin Allergy ClinImmunol. 2009 Apr;9(2):161-7.
7.Metcalfe A, Williams J, McChesney J, et al. Use of complementary and alternative medicine by those with a chronic disease and the general population—results of a national population based survey. BMC Complement Altern Med. 2010;10:58.
8.Lin SY et al. Sublingual immunotherapy. OtolaryngolClin North Am. 2011 Jun;44(3):753-64, x-xi.
9.American Academy of Allergy, Asthma and Immunology. Allergies. Available at http://www.aaaai.org/conditions-and-treatments/allergies.aspx. Accessibility verified December 17, 2011.
10.Kasper DL, Braunwald DE , et al. Harrison 's Principles of Internal Medicine . 16th ed. New York : McGraw-Hill Professional; 2005.
11.Berger A. Th1 and Th2 responses: What are they? BMJ 2000;321:424.1.
12.Bellanti JA. Cytokines and allergic diseases: clinical aspects. Allergy Asthma Proc 1998 Dec;19(6):337-41.
13.Hansen I, Klimek L, Mosges R, Hormann K. Mediators of inflammation in the early and the late phase of allergic rhinitis. CurrOpin Allergy ClinImmunol. 2004 Jun;4(3):159-63.
14.Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. ClinExp Allergy. 2004 Apr;34(4):520-6.
15.Yuksel H, Dinc G, Sakar A, et al. Prevalence and comorbidity of allergic eczema, rhinitis, and asthma in a city in western Turkey. J InvestigAllergolClinImmunol. 2008;18(1):31-5.
16.Asher MI, Montefort S, ISAAC Phase Three Study Group, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006 Aug 26;368(9537):733-43.
17.Björkstén  B, Clayton T, et al. ISAAC Phase III Study Group. Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008 Mar;19(2):110-24.
18.Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011 Apr;3(2):67-73.
19.Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy ClinImmunol. 2004 May;113(5):832-6.
20.Simpson CR, Newton J, Hippisley-Cox J, Sheikh A. Incidence and prevalence of multiple allergic disorders recorded in a national primary care database. J R Soc Med. 2008 Nov;101(11):558-63.
21.Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy ClinImmunol. 2003 Dec;112(6 Suppl):S118-27.
22.Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am. 2010 Aug;30(3):269-80.
23.Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1-191.
24.Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol. 2004 Sep;93(3 Suppl 2):S1-21.
25.Meltzer EO, Blaiss MS, DereberyMJ, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy ClinImmunol. 2009 Sep;124(3 Suppl):S43-70. Epub 2009 Jul 9.
26.Choi SH, Yoo Y, Yu J, et al. Bronchial hyperresponsiveness in young children with allergic rhinitis and its risk factors. Allergy. 2007 Sep;62(9):1051-6.
27.Craig TJ, Sherkat A, Safaee S. Congestion and sleep impairment in allergic rhinitis. Curr Allergy Asthma Rep. 2010 Mar;10(2):113-21.
28.Rondón  C, Doña I, Torres MJ, Campo P, Blanca M. Evolution of patients with nonallergic rhinitis supports conversion to allergic rhinitis. J Allergy ClinImmunol. 2009 May;123(5):1098-102.
29.Bousquet J, Khaltaev N, Cruz AA, Denburg J, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63Suppl 86:8-160.
30.Sabin BR, Saltoun CA, Avila PC. Advances in upper airway diseases and allergen immunotherapy. J Allergy ClinImmunol. 2011 Feb;127(2):342-50.
31.Zhang J, ParéPD, SandfordAJ. Recent advances in asthma genetics. Respir Res. 2008 Jan 15;9:4.
32.Sicherer SH. Food allergy. Mt Sinai J Med. 2011 Sep-Oct;78(5):683-96. doi: 10.1002/msj.20292.
33.Branum AM, Lukacs SL. Food allergy among U.S. children: trends in prevalence and hospitalizations. NCHS Data Brief. 2008 Oct;(10):1-8.
34.Bahna SL. Clinical expressions of food allergy. Ann Allergy Asthma Immunol. 2003 Jun;90(6 Suppl 3):41-4.
35.Troncone  R, Caputo N, Florio G, Finelli E. Increased intestinal sugar permeability after challenge in children with cow's milk allergy or intolerance. Allergy. 1994;49(3):142–146.
36.Pizzuti D, Senzolo M, Buda A, et al. In vitro model for IgE mediated food allergy. Scand J Gastroenterol. 2011 Feb;46(2):177-87. Epub 2010 Oct 28.
37.Moneret-Vautrin DA, Morisset M. Adult food allergy. Curr Allergy Asthma Rep . 2005 Jan;5(1):80–5.
38.Yu LC. Intestinal epithelial barrier dysfunction in food hypersensitivity. J Allergy (Cairo). 2012;2012:596081.
39.Frank DN, Amand ALS, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(34):13780–13785.
40.Kelly D, Conway S. Bacterial modulation of mucosal innate immunity. Molecular Immunology. 2005;42(8):895–901.
41.Kelly D, King T, Aminov R. Importance of microbial colonization of the gut in early life to the development of immunity. Mutation Research. 2007;622(1-2):58–69.
42.Sudo N, Yu XN, Aiba Y, et al. An oral introduction of intestinal bacteria prevents the development of a long-term Th2-skewed immunological memory induced by neonatal antibiotic treatment in mice. Clinical and Experimental Allergy. 2002;32(7):1112–1116
43.Vinderola CG, Medici M, Perdigon G. Relationship between interaction sites in the gut, hydrophobicity, mucosal immunomodulating capacities and cell wall protein profiles in indigenous and exogenous bacteria. J ApplMicrobiol . 2004;96(2):230–43.
44.Gun F, Salman T, et al. Effect of probiotic supplementation on bacterial transaction in thermal injury. Surg Today . 2005;35(9):760–4.
45.Casas IA , DobrogoszWJ. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microbial Ecology in Health and Disease 2000;12:247–85.
46.Pelto L, Ioslauri E, et al. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects . ClinExp Allergy. 1998 Dec;28(12):1474–9.
47.Goldin BR. Health benefits of probiotics. Br J Nutr1998;80:S203–S207 .
48.Cross ML, Gill HS. Can immunoregulatory lactic acid bacteria be used as dietary supplements to limit allergies? Int Arch Allergy Immunol . 2001 Jun;125(2):112–9.
49.Bouhnik Y, Vahedi K, et al. Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr 1999;129:113–6 .
50.O'Keefe SJ et al. Effect of fiber supplementation on the microbiota in critically ill patients. World J GastrointestPathophysiol. 2011 Dec 15;2(6):138-45.
51.Russel L et al. What's Really Making You Sick? Life Extension Magazine September 2010.
52.Mitchell N et al. Randomised controlled trial of food elimination diet based on IgG antibodies for the prevention of migraine like headaches. Nutr J. 2011 Aug 11;10:85.
53.Bentz S et al. Clinical relevance of IgG antibodies against food antigens in Crohn's disease: a double-blind cross-over diet intervention study. Digestion. 10;81(4):252-64. Epub 2010 Jan 30.
54.Anthoni S et al. Milk protein IgG and IgA: the association with milk-induced gastrointestinal symptoms in adults. World J Gastroenterol. 2009 Oct 21;15(39):4915-8.
55.Atkinson W et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004 Oct;53(10):1459-64.
56.Fischbach F. A manual of Laboratory and Diagnostic Tests . 5th ed. Philadelphia , Pa : Lippincott-Raven; 1996.
57.Rolinck-Werninghaus C, Staden U, et al. Specific oral tolerance induction with food in children: transient or persistent effect on food allergy? Allergy . 2005 Oct;60(10):1320–2.
58.Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systemic review and meta-analysis. Clin Exp Allergy. 2011 Sep;41(9):1263-72.
59.Cox L, Wallace D. Specific allergy immunotherapy for allergic rhinitis: subcutaneous and sublingual. Immunol Allergy Clin North Am. 2011 Aug;31(3):561-99.
60.Bahceciler NN, Cobanoglu N. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma. Immunotherapy. 2011 Jun;3(6):747-56.
61.Penders J, Stobberingh EE, van den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. Allergy. 2007 Nov;62(11):1223-36.
62.Pan SJ, Kuo CH, Lam KP, et al.Probiotics and allergy in children--an update review. Pediatr Allergy Immunol. 2010 Jun;21(4 Pt 2):e659-66.
63.Kalliomaki M, Kirjavainen P, Eerola E, et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy ClinImmunol 2001;107:129–34.
64.Food and Agriculture Organization, World Health Organization (FAO/WHO). Report of Joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. FAO/WHO Report no. 10-1-2001.WHOINT; Córdoba,Argentina.
65.Wang MF, Lin HC, Wang YY, Hsu CH. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol 2004: 15: 152–8.
66.Peng GC, Hsu CH. The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr Allergy Immunol. 2005 Aug;16(5):433-8.
67.Giovannini M, Agostoni C, Riva E et al.; Felicita Study Group. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res. 2007 Aug;62(2):215-20.
68.Ciprandi G, Vizzaccaro A, Cirillo I, Tosca MA. Bacillus clausii effects in children with allergic rhinitis. Allergy. 2005 May;60(5):702-3.
69.Morita H, He F, Kawase M, Kubota A, et al.Preliminary human study for possible alteration of serum immunoglobulin E production in perennial allergic rhinitis with fermented milk prepared with Lactobacillus gasseriTMC0356. MicrobiolImmunol. 2006;50(9):701-6.
70.Xiao JZ, Kondo S, Yanagisawa N, et al. Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial. ClinExp Allergy. 2006 Nov;36(11):1425-35.
71.Iwabuchi N et al. Suppressive effects of Bifidobacteriumlongum on the production of Th2-attracting chemokines induced with T cell-antigen-presenting cell interactions. FEMSImmunol Med Microbiol. 2009 Apr;55(3):324-34.
72.Odamaki T et al. Influence of BifidobacteriumlongumBB536 intake on faecalmicrobiota in individuals with Japanese cedar pollinosis during the pollen season. J Med Microbiol. 2007 Oct;56(Pt 10):1301-8.
73.Takahashi N et al. Oral administration of an immunostimulatory DNA sequence from Bifidobacteriumlongum improves Th1/Th2 balance in a murine model. BiosciBiotechnolBiochem. 2006 Aug;70(8):2013-7.
74.Nagata Y, Yoshida M, Kitazawa H, Araki E, Gomyo T. Improvements in seasonal allergic disease with Lactobacillus plantarum No. 14. BiosciBiotechnolBiochem. 2010;74(9):1869-77.
75.Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am J ClinDermatol. 2008;9(2):93-103.
76.Moroi M, Uchi S, Nakamura K, et al. Beneficial effect of a diet containing heat-killed Lactobacillus paracaseiK71 on adult type atopic dermatitis. J Dermatol. 2011 Feb;38(2):131-9. doi: 10.1111/j.1346-8138.2010.00939.
77.GerasimovSV, VasjutaVV, MyhovychOO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. Am J ClinDermatol. 2010;11(5):351-61.
78.Boyle RJ, Ismail IH, Kivivuori S, et al. Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial.Allergy. 2011 Apr;66(4):509-16.
79.Berni Canani R, Nocerino R, Terrin G, et al. Effect of Lactobacillus GG on tolerance acquisition in infants with cow's milk allergy: A randomized trial. J Allergy ClinImmunol. 2011 Nov 10.
80.Ozdemir O. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. ClinExpImmunol. 2010 Jun;160(3):295-304.
81.Jensen GS. Patterson KM. Barnes J. Schauss AG. Beaman R. Reeves SG. Robinson LE. A double-blind placebo-controlled, randomized pilot study: consumption of a high-metabolite immunogen from yeast culture has beneficial effects on erythrocyte health and mucosal immune protection in healthy subjects. Open Nutr J. 2008;2:68–75.
82.Moyad MA, Robinson LE, Kittelsrud JM, Reeves SG, Weaver SE, Guzman AI, Bubak ME. Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2009 Aug;26(8):795-804.
83.Ishida Y, Bandou I, Kanzato H, Yamamoto N. Decrease in ovalbumin specific IgE of mice serum after oral uptake of lactic acid bacteria. Biosci Biotechnol Biochem. 2003 May;67(5):951-7.
84.Ishida Y, Nakamura F, Kanzato H, Sawada D, Yamamoto N, Kagata H, Oh-Ida M, Takeuchi H, Fujiwara S. Effect of milk fermented with Lactobacillus acidophilus strain L-92 on symptoms of Japanese cedar pollen allergy: a randomized placebo-controlled trial. Biosci Biotechnol Biochem. 2005 Sep;69(9):1652-60.
85.Ishida Y, Nakamura F, Kanzato H, Sawada D, Hirata H, Nishimura A, Kajimoto O, Fujiwara S. Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study. J Dairy Sci. 2005 Feb;88(2):527-33.
86.Calpis Co., Ltd., 2012. https://www.calpis.net/
87.Searing DA, Leung DY. Vitamin D in atopic dermatitis, asthma and allergic diseases. Immunol Allergy Clin North Am. 2010 Aug;30(3):397-409.
88.Clifford RL, Knox AJ. Vitamin D-a new treatment for airway remodelling in asthma?. Br J Pharmacol 2009;158:1426–1428.
89.Weiss ST, Litonjua AA. Childhood asthma is a fat-soluble vitamin deficiency disease. ClinExp Allergy 2008;38:385–387.
90.Litonjua AA. Childhood asthma may be a consequence of vitamin D deficiency. CurrOpin Allergy ClinImmunol 2009;9:202–207.
91.Freishtat RJ, Iqbal SF, Pillai DK, et al. High prevalence of vitamin d deficiency among inner-city African American youth with asthma in Washington, DC. J Pediatr 2010;156:948– 952.
92.Sharief S, Jariwala S, Kumar J, Muntner P, Melamed ML. Vitamin D levels and food and environmental allergies in the United States: results from the National Health and Nutrition Examination Survey 2005–2006. J Allergy ClinImmunol 2011;127:1195–1202.
93.Peroni DG, Piacentini GL, Cametti E, Chinellato I, Boner AL. Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children. Br J Dermatol 2011;164:1078–1082.
94.Chinellato I, Piazza M, Sandri M, et al. Vitamin D serum levels and markers of asthma control in Italian children. J Pediatr 2011;158:437–441.
95.Thorp WA, Goldner W, Meza J, Poole JA. Reduced vitamin D levels in adult subjects with chronic urticaria. J Allergy ClinImmunol 2010;126:413.
96.Javanbakht MH, Keshavarz SA, Djalali M, et al. Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis. J Dermatolog Treat. 2011 Jun;22(3):144-50. Epub 2010 Jul 24.
97.Camargo CA, RifasShiman SL, Litonjua AA, et al. Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age. Am J ClinNutr 2007;85:788–795
98.Erkkola M, Kaila M, Nwaru BI, et al. Maternal vitamin D intake during pregnancy is inversely associated with asthma and allergic rhinitis in 5-year-old children. ClinExp Allergy 2009;39:875–882.
99.Hollams EM, Hart PH, Holt BJ, et al. Vitamin D and atopy and asthma phenotypes in children: a longitudinal cohort study. EurRespir J. 2011 Dec;38(6):1320-7. Epub 2011 May 12.
100.Weiss ST. Randomized trial: maternal vitamin D supplementation to prevent childhood asthma (VDAART). ClinicalTrials.gov: NCT00920621. Last updated 3/13/2018.
101.Centanni S, Santus P, Di Marco F, et al. The potential role of tocopherol in asthma and allergies: modification of the leukotriene pathway. Biodrugs . 2001;15(2):81–6.
102.Zingg JM. Vitamin E and mast cells. VitamHorm 2007;76:393-418.
103.Kempna P, Reiter E, Arock M, Azzi A, Zingg JM. Inhibition of HMC-1 mast cell proliferation by vitamin E: involvement of the protein kinase B pathway. J BiolChem 2004;279:50700-9.
104.Miyake Y, Sasaki S, Tanaka K, Hirota Y. Consumption of vegetables, fruit, and antioxidants during pregnancy and wheeze and eczema in infants. Allergy. 2010 Jun 1;65(6):758-65.
105.Devereux G, Turner SW, Craig LCA, et al. Reduced maternal vitamin E intake during pregnancy is associated with asthma in 5-year-old children. Am J RespirCrit Care Med. 2006;174;499-507.
106.Hijazi N, Abalkhail B, et al. Diet and childhood asthma in a society in transition: A study in urban and rural Saudi Arabia . Thorax . 2000 Sep;55(9):775–9.
107.Troisi RJ, Willett WC, Weiss ST, et al. A prospective study of diet and adult-onset asthma. Am J RespirCrit Care Med. 1995;151:1401-1408.
108.Tsoureli-Nikita E, Hercogova J, Lotti T, Menchini G. Evaluation of dietary intake of vitamin E in the treatment of atopic dermatitis: a study of the clinical course and evaluation of the immunoglobulin E serum levels. Int J Dermatol. 2002 Mar;41(3):146-50.
109.Zheng K, Adjei A, Shinjo M, et al. Effect of dietary vitamin E supplementation on murine nasal allergy. Am. J. Med. Sci. 1999. 318, 49–54.
110.Shahar, E., Hassoun, G., and Pollack, S. (2004). Effect of vitamin E supplementation on the regular treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 92, 654–658.
111.Johnston CS, Solomon RE, Corte C. Vitamin C depletion is associated with alterations in blood histamine and plasma free carnitine in adults. J Am CollNutr . 1996 Dec;15(6):586–91.
112.Bucca C, Rolla G, et al. Effect of vitamin C on histamine bronchial responsiveness of patients with allergic rhinitis. Ann Allergy . 1990 Oct; 65(4):311–4.
113.Soutar A, Seaton A, et al. Bronchial reactivity and dietary antioxidants. Thorax . 1997 Feb;52(2):166–70.
114.Chang HH, Chen CS, Lin JY. High dose vitamin C supplementation increases the Th1/Th2 cytokine secretion ratio, but decreases eosinophilic infiltration in bronchoalveolar lavage fluid of ovalbumin-sensitized and challenged mice. J Agric Food Chem. 2009 Nov 11;57(21):10471-6.
115.Laires MJ, Monteiro C. Exercise, magnesium and immune function. Magnes Res. 2008 Jun;21(2):92-6.
116.Ciarallo L, Sauer AH, Shannon MW. Intravenous magnesium therapy for moderate to severe pediatric asthma: results of a randomized, placebo-controlled trial. J Pediatr. 1996;129(6):809–14.
117.Devi PR, Kumar L, Singhi SC, Prasad R, Singh M. Intravenous magnesium sulfate in acute severe asthma not responding to conventional therapy. Indian Pediatr. 1997;34(5):389–97.
118.Gürkan  F, Haspolat K, Bosnak M, et al. Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy. Eur J Emerg Med. 1999;6(3):201–5.
119.Ciarallo L, Brousseau D, Reinert S. Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma. Arch PediatrAdolesc Med. 2000 Oct;154(10):979-83.
120.Scarfone RJ, LoiselleJM, Joffe MD, et al. A randomized trial of magnesium in the emergency department treatment of children with asthma. Ann Emerg Med. 2000;36(6):572–8.
121.Bede O, Surányi A, Pintér K, Szlávik M, Gyurkovits K. Urinary magnesium excretion in asthmatic children receiving magnesium supplementation: a randomized, placebo-controlled, double-blind study. Magnes Res. 2003 Dec;16(4):262-70.
122.Gontijo-Amaral C, Ribeiro MA, GontijoLS, Condino-Neto A, Ribeiro JD. Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial. Eur J ClinNutr. 2007 Jan;61(1):54-60. Epub 2006 Jun 21.
123.Kazaks AG, Uriu-Adams JY, Albertson TE, Shenoy SF, Stern JS. Effect of oral magnesium supplementation on measures of airway resistance and subjective assessment of asthma control and quality of life in men and women with mild to moderate asthma: a randomized placebo controlled trial. J Asthma. 2010 Feb;47(1):83-92.
124.Calder PC. Polyunsaturated fatty acids and inflammation. BiochemSoc Trans . 2005 Apr; (pt 2): 423–7.
125.Leaf A. On the reanalysis of the GISSI-Prevenzione. Circulation . 2002;105:1874 – 1875.
126.Connor WE. N-3 Fatty acids from fish and fish oil: panacea or nostrum? Am J ClinNutr. 2001;74:415 – 6.
127.Calder PC. N-3 polyunsaturated fatty acids, inflammation and immunity: pouring oil on troubled waters or another fishy tale? Nutr Res . 2001;21:309–41.
128.CederholmTE et al. Low levels of essential fatty acids are related to impaired delayed skin hypersensitivity in malnourished chronically ill elderly people. Eur J Clin Invest. 1994 Sep;24(9):615-20.
129.Watanabe T, Kuroda Y. The effect of a newly developed ointment containing eicosapentaenoic and docosahexaenioc acid in the treatment of atopic dermatitis. J Med Invest . 1999 Aug;46(3–4):173–7.
130.Klemens CM, Berman DR, Mozurkewich EL. The effect of perinatal omega-3 fatty acid supplementation on inflammatory markers and allergic diseases: a systematic review. BJOG. 2011 Jul;118(8):916-25.
131.Miyake Y, Sasaki S, Tanaka K, et al; Osaka Maternal and Child Health Study Group. Fish and fat intake and prevalence of allergic rhinitis in Japanese females: the Osaka Maternal and Child Health Study. J Am CollNutr. 2007 Jun;26(3):279-87.
132.Thomet OA, Schapowal A, Heinisch IV, Wiesmann UN, Simon HU. Anti-inflammatory activity of an extract of Petasiteshybridus in allergic rhinitis. IntImmunopharmacol. 2002 Jun;2(7):997-1006.
133.Shimoda H, Tanaka J, Yamada E, et al. Anti type I allergic property of Japanese butterbur extract and its mast cell degranulation inhibitory ingredients. J Agric Food Chem 2006; 54:2915–2920.
134.Lee JS, Yang EJ, Yun CY, Kim DH, Kim IS. Suppressive effect of Petasitesjaponicus extract on ovalbumin-induced airway inflammation in an asthmatic mouse model. J Ethnopharmacol. 2011 Jan 27;133(2):551-7. Epub 2010 Oct 26.
135.Schapowal A. Butterbur Ze339 for the treatment of intermittent allergic rhinitis: dose-dependent efficacy in a prospective, randomized, double-blind, placebo-controlled study. Arch Otolaryngol Head Neck Surg 2004; 130: 1381–1386.
136.Schapowal A. Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. BMJ 2002; 324:144–146.
137.Schapowal A. Treating intermittent allergic rhinitis: a prospective, randomized, placebo and antihistamine-controlled study of butterbur extract Ze 339. Phytother Res 2005; 19:530–537.
138.Lee DK, Gray RD, Robb FM, et al. A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. ClinExp Allergy 2004; 34:646–64.
139.Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of allergic rhinitis: a systematic review. Ann Allergy Asthma Immunol. 2007 Dec;99(6):483-95.
140.Brattström  A, Schapowal A, Maillet I, et al. Petasites extract Ze 339 (PET) inhibits allergen-induced Th2 responses, airway inflammation and airway hyperreactivity in mice. Phytother Res. 2010 May;24(5):680-5.
141.Lee JS, Yang EJ, Yun CY, et al. Suppressive effect of Petasites japonicas extract on ovalbumin-induced airway inflammation in an asthmatic mouse model. J Ethnopharmacol. 2011 Jan;133(2):551-7.
142.Chirumbolo S, Marzotto M, Conforti A, et al.Bimodal action of the flavonoid quercetin on basophil function: an investigation of the putative biochemical targets. ClinMol Allergy. 2010 Sep 17;8:13.
143.Huang RY, Yu YL, Cheng WC, et al. Immunosuppressive effect of quercetin on dendritic cell activation and function. J Immunol. 2010 Jun 15;184(12):6815-21. Epub 2010 May 17.
144.Shishehbor F, Behroo L, GhafouriyanBroujerdnia M, Namjoyan F, Latifi SM. Quercetin effectively quells peanut-induced anaphylactic reactions in the peanut sensitized rats. Iran J Allergy Asthma Immunol. 2010 Mar;9(1):27-34.
145.Joskova M, Franova S, Sadlonova V. Acute bronchodilator effect of quercetin in experimental allergic asthma. BratislLekListy. 2011;112(1):9-12.
146.Rogerio AP, Dora CL, Andrade EL, et al. Anti-inflammatory effect of quercetin-loaded microemulsion in the airways allergic inflammatory model in mice. Pharmacol Res. 2010 Apr;61(4):288-97.
147.Remberg P, Bjork L, Sterner O. Characteristics, clinical effect profile and tolerability of a nasal spray preparation for Artemisia abrotanum L for allergic rhinitis. Phytomedicine . 2004 Jan;11(1):36–42.
148.Kawai M, Hirano T, Arimitsu J, et al.Effect of enzymatically modified isoquercitrin, a flavonoid, on symptoms of Japanese cedar pollinosis: a randomized double-blind placebo-controlled trial. Int Arch Allergy Immunol. 2009;149(4):359-68. Epub 2009 Mar 17.
149.Hirano T, Kawai M, Arimitsu J, et al. Preventative effect of a flavonoid, enzymatically modified isoquercitrin on ocular symptoms of Japanese cedar pollinosis. Allergol Int. 2009 Sep;58(3):373-82. Epub 2009 May 25.
150.Garg A et al. Chemistry and pharmacology of the Citrus bioflavonoid hesperidin. Phytother Res. 2001 Dec;15(8):655-69.
151.Saylor BW. Treatment of allergic and vasomotor rhinitis with hesperidin chalcone sodium. Arch Otolaryngol. 1949 Dec;50(6):813-20.
152.Guex JJ et al. Quality of life improvement in Latin American patients suffering from chronic venous disorder using a combination of Ruscusaculeatus and hesperidin methyl-chalcone and ascorbic acid (quality study). IntAngiol. 2010 Dec;29(6):525-32.
153.Mainardi T, Kapoor S, Bielory L. Complementary and alternative medicine: herbs, phytochemicals and vitamins and their immunologic effects. J Allergy ClinImmunol. 2009 Feb;123(2):283-94; quiz 295-6.
154.Jang AH, Kim TH, Kim GD, et al. Rosmarinic acid attenuates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. IntImmunopharmacol. 2011 Sep;11(9):1271-7. Epub 2011 Apr 17.
155.Osakabe N, Takano H, Sanbongi C, et al. Anti-inflammatory and anti-allergic effect of rosmarinic acid (RA); inhibition of seasonal allergic rhinoconjunctivitis (SAR) and its mechanism. Biofactors. 2004;21(1-4):127-31.
156.Takano H, Osakabe N, Sanbongi C, et al.Extract of Perillafrutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans.ExpBiol Med (Maywood). 2004 Mar;229(3):247-54.
157.Sanbongi C, Takano H, Osakabe N, et al. Rosmarinic acid in perilla extract inhibits allergic inflammation induced by mite allergen, in a mouse model. ClinExp Allergy. 2004 Jun;34(6):971-7.
158.Inoue K, Takano H, Shiga A, et al. Effects of volatile constituents of a rosemary extract on allergic airway inflammation related to house dust mite allergen in mice. Int J Mol Med. 2005 Aug;16(2):315-9.
159.Oh H, Park CS, AhnHJ, Park YS, Kim HM. Effect of Perillafrutescens var. acutaKudo and rosmarinic acid on allergic inflammatory reactions. ExpBiol Med (Maywood). 2011 Jan;236(1):99-106.
160.Lee J, Jung E, Koh J, Kim YS, Park D. Effect of rosmarinic acid on atopic dermatitis.JDermatol. 2008 Dec;35(12):768-71.
161.Anderson BE, Miller CJ, Adams DR. Stinging nettle dermatitis. Am J Contact Dermat. 2003 Mar;14(1):44-6.
162.Mittman P. Randomized, double-blind study of freeze-dried Urticadioica in the treatment of allergic rhinitis. Planta Med. 1990 Feb;56(1):44-7.
163.Konrad A, Mähler M, Arni S, et al. Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis. Int J Colorectal Dis. 2005 Jan;20(1):9-17.
164.Roschek B Jr, Fink RC, McMichael M, Alberte RS. Nettle extract (Urticadioica) affects key receptors and enzymes associated with allergic rhinitis. Phytother Res. 2009 Jul;23(7):920-6.
165.Deng R, Chow TJ. Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae Spirulina. CardiovascTher. 2010 Aug;28(4):e33-45.
166.Marles RJ et al. United States pharmacopeia safety evaluation of spirulina. Crit Rev Food SciNutr. 2011 Aug;51(7):593-604.
167.Mao TK et al. Effects of a Spirulina-based dietary supplement on cytokine production from allergic rhinitis patients. J Med Food. 2005 Spring;8(1):27-30.
168.Cingi C et al. The effects of spirulina on allergic rhinitis. Eur Arch Otorhinolaryngol. 2008 Oct;265(10):1219-23. Epub 2008 Mar 15.
169.Chen LL et al. [Experimental study of spirulinaplatensis in treating allergic rhinitis in rats]. Zhong Nan Da XueXueBao Yi Xue Ban. 2005 Feb;30(1):96-8.
170.Remirez D et al. Role of histamine in the inhibitory effects of phycocyanin in experimental models of allergic inflammatory response. Mediators Inflamm. 2002 Apr;11(2):81-5.
171.Dillon JS. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy. 2005 Jun;4(3):377-85.
172.Kasperska-Zajac AE et al. Dehydroepiandrosterone in therapy of allergic diseases. Recent Pat Inflamm Allergy Drug Discov. 2009 Nov;3(3):211-3.
  </p>

<!-- Resumen de Ansiedad -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #1b5e20; padding-bottom: 10px;">
    <i class="fas fa-head-side-brain" style="margin-right: 10px; color: #1b5e20;"></i> Anxiety
</h2>
<p style="margin-bottom: 20px; text-align: justify;">
    Nearly 15% of adults will experience an anxiety disorder in their lifetime and approximately 18% of the adult population over 18 years of age in developed and emerging countries are affected by this disorder, which is considered multifaceted and must be addressed as such to achieve symptomatic relief. Psychoactive medications do not address the underlying causes of anxiety such as hormonal and metabolic imbalances that arise as our bodies try to adapt to chronic stress. Clinical studies indicate that nutrients, healthy eating habits, and stress management techniques exist to effectively optimize the body's stress response mechanisms and support healthy neurological communication. In addition, compounds such as vitamins and amino acids can provide the raw materials that the body needs to ensure the correct synthesis and signaling of neurotransmitters that control, prevent and cure this disorder. However, it has been shown that the use of adjuvants is essential, together with the medications used for the treatment of anxiety, in order to increase efficacy, reduce toxicity, minimize adverse reactions and, above all, prevent the use of medications continuously in the medium and long term, to control anxiety, develop diseases such as cancer and reduce the quality life expectancy of patients under treatment with these medications.
</p>

<!-- Tratamientos Convencionales -->
<h3 style="font-size: 22px; color: #1b5e20; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #1b5e20;">
    Conventional Treatments
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    Drug or medication therapy such as: Benzodiazepines such as diazepam (Valium), alprazolam (Xanax), and clonazepam (Klonopin); Azapirones such as buspirone (BuSpar); Antidepressants, including selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac) and sertraline (Zoloft); Beta blockers such as propranolol (Inderal) and atenolol (Tenormin); Pregabalin, an anticonvulsant medication that is also effective in treating anxiety.
</p>

<!-- Estrategia para el uso de adyuvantes -->
<h3 style="font-size: 22px; color: #1b5e20; margin-bottom: 15px; text-align: left; border-bottom: 2px solid #1b5e20;">
    Strategy for Use of Adjuvants
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    To improve the pharmacological actions of the drugs used in the prevention, control, and treatment of anxiety, and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term, it is crucial to incorporate natural compounds that support the body's ability to manage stress and maintain neurological health. These adjuvants can help reduce the dependence on conventional medications and mitigate their potential long-term negative effects.
</p>

<p style="margin-bottom: 20px; text-align: justify;">

  1.Strohle A, Gensichen J, Domschke K. The Diagnosis and Treatment of Anxiety Disorders. Deutsches Arzteblatt international. 2018;155(37):611-620.
2.Craske MG, Stein MB. Anxiety. Lancet. 2016;388(10063):3048-3059.
3.Chand SP, Marwaha R. Anxiety. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
4.Remes O, Brayne C, van der Linde R, Lafortune L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain and behavior. 2016;6(7):e00497.
5.Locke AB, Kirst N, Shultz CG. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. American family physician. 2015;91(9):617-624.
6.Thibaut F. Anxiety disorders: a review of current literature. Dialogues in clinical neuroscience. 2017;19(2):87-88.
7.Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC psychiatry. 2014;14 Suppl 1:S1.
8.Aggarwal R, Kunik M, Asghar-Ali A. Anxiety in Later Life. Focus (Am Psychiatr Publ). 2017;15(2):157-161.
9.Lin E, Tsai SJ. Gene-Environment Interactions and Role of Epigenetics in Anxiety Disorders. Adv Exp Med Biol. 2020;1191:93-102.
10.Juruena MF, Eror F, Cleare AJ, Young AH. The Role of Early Life Stress in HPA Axis and Anxiety. Adv Exp Med Biol. 2020;1191:141-153.
11.Stein DJ, Scott KM, de Jonge P, Kessler RC. Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues in clinical neuroscience. 2017;19(2):127-136.
12.Moller HJ, Bandelow B, Volz HP, Barnikol UB, Seifritz E, Kasper S. The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice. European archives of psychiatry and clinical neuroscience. 2016;266(8):725-736.
13.Niles AN, O'Donovan A. Comparing anxiety and depression to obesity and smoking as predictors of major medical illnesses and somatic symptoms. Health Psychol. 2019;38(2):172-181.
14.Meuret AE, Tunnell N, Roque A. Anxiety Disorders and Medical Comorbidity: Treatment Implications. Adv Exp Med Biol. 2020;1191:237-261.
15.Zimmermann M, Chong AK, Vechiu C, Papa A. Modifiable risk and protective factors for anxiety disorders among adults: A systematic review. Psychiatry research. 2020;285:112705.
16.Masana MF, Tyrovolas S, Kolia N, et al. Dietary Patterns and Their Association with Anxiety Symptoms among Older Adults: The ATTICA Study. Nutrients. 2019;11(6).
17.Maness DL, Khan M. Nonpharmacologic Management of Chronic Insomnia. American family physician. 2015;92(12):1058-1064.
18.Kim HS, Kim EJ. Effects of Relaxation Therapy on Anxiety Disorders: A Systematic Review and Meta-analysis. Archives of psychiatric nursing. 2018;32(2):278-284.
19.Zamorski MA, Albucher RC. What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder. American family physician. 2002;66(8):1477-1484.
20.Uppsala University. Patients' expectations influence the effectiveness of SSRI antidepressants. https://www.sciencedaily.com/releases/2017/10/171003111125.htm. Published 2017. Updated October 3. Accessed July 14, 2020.
21.de Vries YA, Roest AM, Burgerhof JGM, de Jonge P. Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis. Depression and anxiety. 2018;35(6):515-522.
22.Fernández-Rodríguez M, Rodríguez-Legorburu I, López-Ibor Alcocer MI. Nutritional supplements in Anxiety Disorder. Actas espanolas de psiquiatria. 2017;45(Supplement):1-7.
23.Yeung KS, Hernandez M, Mao JJ, Haviland I, Gubili J. Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance. Phytother Res. 2018;32(5):865-891.
24.Crocq MA. The history of generalized anxiety disorder as a diagnostic category. Dialogues in clinical neuroscience. 2017;19(2):107-116.
25.Koyuncu A, Ince E, Ertekin E, Tukel R. Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges. Drugs in context. 2019;8:212573.
26.Rose GM, Tadi P. Social Anxiety Disorder. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC.; 2020.
27.Thng CEW, Lim-Ashworth NSJ, Poh BZQ, Lim CG. Recent developments in the intervention of specific phobia among adults: a rapid review. F1000Research. 2020;9.
28.NIMH. National Institute of Mental Health: Anxiety Disorders. Available at https://www.nimh.nih.gov/health/topics/anxiety-disorders/index.shtml. Last updated 07/2018. Accessed 07/15/2020. 2018.
29.NIMH. National Institute of Mental Health: Generalized Anxiety Disorder. Available at https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder.shtml. Last updated 11/2017. Accessed 05/14/2020. 2017.
30.ADAA. Anxiety and Depression Association of America. Facts & Statistics. https://adaa.org/about-adaa/press-room/facts-statistics. Accessed June 19, 2020.
31.DeMartini J, Patel G, Fancher TL. Generalized Anxiety Disorder. Ann Intern Med. 2019;170(7):Itc49-itc64.
32.NIH. National Institutes of Health. Panic Disorder: When Fear Overwhelms. Available at https://www.nimh.nih.gov/health/publications/panic-disorder-when-fear-overwhelms/index.shtml. Updated 2016. Accessed 06/25/2020. 2016.
33.Baldwin DS, Gordon R, Abelli M, Pini S. The separation of adult separation anxiety disorder. CNS spectrums. 2016;21(4):289-294.
34.Holka-Pokorska J, Pirog-Balcerzak A, Jarema M. The controversy around the diagnosis of selective mutism - a critical analysis of three cases in the light of modern research and diagnostic criteria. Psychiatria polska. 2018;52(2):323-343.
35.French JH, Hameed S. Illness Anxiety Disorder. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC.; 2020.
36.Hellwig S, Domschke K. Anxiety in Late Life: An Update on Pathomechanisms. Gerontology. 2019;65(5):465-473.
37.Subramanyam AA, Kedare J, Singh OP, Pinto C. Clinical practice guidelines for Geriatric Anxiety Disorders. Indian journal of psychiatry. 2018;60(Suppl 3):S371-S382.
38.Peeters G, Feeney J, Carey D, Kennelly S, Kenny RA. Fear of falling: A manifestation of executive dysfunction? International journal of geriatric psychiatry. 2019;34(8):1275-1282.
39.Wetherell JL, Johnson K, Chang D, et al. Activity, balance, learning, and exposure (ABLE): a new intervention for fear of falling. International journal of geriatric psychiatry. 2016;31(7):791-798.
40.Tannenbaum C. Inappropriate benzodiazepine use in elderly patients and its reduction. Journal of psychiatry & neuroscience : JPN. 2015;40(3):E27-E28.
41.Sharma S, Powers A, Bradley B, Ressler KJ. Gene x Environment Determinants of Stress- and Anxiety-Related Disorders. Annual review of psychology. 2016;67:239-261.
42.Dabkowska M, Dabkowska-Mika A. Risk Factors of Anxiety Disorders in Children. IntechOpen. https://www.intechopen.com/books/a-fresh-look-at-anxiety-disorders/risk-factors-of-anxiety-disorders-in-children. Published 2015. Accessed August 17, 2020.
43.Widiger TA, Oltmanns JR. Neuroticism is a fundamental domain of personality with enormous public health implications. World psychiatry : official journal of the World Psychiatric Association (WPA). 2017;16(2):144-145.
44.Lijster JM, Dierckx B, Utens EM, et al. The Age of Onset of Anxiety Disorders. Can J Psychiatry. 2017;62(4):237-246.
45.Russell AL, Tasker JG, Lucion AB, et al. Factors promoting vulnerability to dysregulated stress reactivity and stress-related disease. J Neuroendocrinol. 2018;30(10):e12641.
46.Andolina D, Borreca A. The Key Role of the Amygdala in Stress. IntechOpen. https://www.intechopen.com/books/the-amygdala-where-emotions-shape-perception-learning-and-memories/the-key-role-of-the-amygdala-in-stress. Published 2017. Accessed August 17, 2020.
47.Schmidt CK, Khalid S, Loukas M, Tubbs RS. Neuroanatomy of Anxiety: A Brief Review. Cureus. 2018;10(1):e2055.
48.Agoglia AE, Herman MA. The center of the emotional universe: Alcohol, stress, and CRF1 amygdala circuitry. Alcohol (Fayetteville, NY). 2018;72:61-73.
49.Daviu N, Bruchas MR, Moghaddam B, Sandi C, Beyeler A. Neurobiological links between stress and anxiety. Neurobiology of stress. 2019;11:100191.
50.Dedic N, Chen A, Deussing JM. The CRF Family of Neuropeptides and their Receptors - Mediators of the Central Stress Response. Current molecular pharmacology. 2018;11(1):4-31.
51.Hupalo S, Bryce CA, Bangasser DA, Berridge CW, Valentino RJ, Floresco SB. Corticotropin-Releasing Factor (CRF) circuit modulation of cognition and motivation. Neuroscience and biobehavioral reviews. 2019;103:50-59.
52.Michopoulos V, Powers A, Gillespie CF, Ressler KJ, Jovanovic T. Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond. Neuropsychopharmacology. 2017;42(1):254-270.
53.Felger JC. Imaging the Role of Inflammation in Mood and Anxiety-related Disorders. Curr Neuropharmacol. 2018;16(5):533-558.
54.Costello H, Gould RL, Abrol E, Howard R. Systematic review and meta-analysis of the association between peripheral inflammatory cytokines and generalised anxiety disorder. BMJ open. 2019;9(7):e027925.
55.Mehta ND, Haroon E, Xu X, Woolwine BJ, Li Z, Felger JC. Inflammation negatively correlates with amygdala-ventromedial prefrontal functional connectivity in association with anxiety in patients with depression: Preliminary results. Brain Behav Immun. 2018;73:725-730.
56.Cowan CSM, Hoban AE, Ventura-Silva AP, Dinan TG, Clarke G, Cryan JF. Gutsy Moves: The Amygdala as a Critical Node in Microbiota to Brain Signaling. BioEssays : news and reviews in molecular, cellular and developmental biology. 2018;40(1).
57.Sun LJ, Li JN, Nie YZ. Gut hormones in microbiota-gut-brain cross-talk. Chin Med J (Engl). 2020;133(7):826-833.
58.Zhu S, Jiang Y, Xu K, et al. The progress of gut microbiome research related to brain disorders. Journal of neuroinflammation. 2020;17(1):25.
59.Frankiensztajn LM, Elliott E, Koren O. The microbiota and the hypothalamus-pituitary-adrenocortical (HPA) axis, implications for anxiety and stress disorders. Current opinion in neurobiology. 2020;62:76-82.
60.Simpson CA, Mu A, Haslam N, Schwartz OS, Simmons JG. Feeling down? A systematic review of the gut microbiota in anxiety/depression and irritable bowel syndrome. J Affect Disord. 2020;266:429-446.
61.Peirce JM, Alvina K. The role of inflammation and the gut microbiome in depression and anxiety. Journal of neuroscience research. 2019;97(10):1223-1241.
62.Butler MI, Morkl S, Sandhu KV, Cryan JF, Dinan TG. The Gut Microbiome and Mental Health: What Should We Tell Our Patients?: Le microbiote Intestinal et la Sante Mentale : que Devrions-Nous dire a nos Patients? Can J Psychiatry. 2019;64(11):747-760.
63.Maeng LY, Milad MR. Sex differences in anxiety disorders: Interactions between fear, stress, and gonadal hormones. Hormones and behavior. 2015;76:106-117.
64.Hantsoo L, Epperson CN. Anxiety Disorders Among Women: A Female Lifespan Approach. Focus (Am Psychiatr Publ). 2017;15(2):162-172.
65.Rocca WA, Grossardt BR, Geda YE, et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause (New York, NY). 2018;25(11):1275-1285.
66.Slowik A, Lammerding L, Hoffmann S, Beyer C. Brain inflammasomes in stroke and depressive disorders: Regulation by oestrogen. J Neuroendocrinol. 2018;30(2).
67.Ðoković DD, Jović JJ, Ðoković JD, Knežević M, Djukić-Dejanović S, Ristić-Ignjatović DI. Effects of hormone replacement therapy on depressive and anxiety symptoms after oophorectomy. Med Glas (Zenica). 2015;12(1):79-85.
68.Yazici K, Pata O, Yazici A, Aktaş A, Tot S, Kanik A. [The effects of hormone replacement therapy in menopause on symptoms of anxiety and depression]. Turk Psikiyatri Derg. 2003;14(2):101-105.
69.De Leo V, La Marca A, Lanzetta D, et al. [Assessment of the association of Kava-Kava extract and hormone replacement therapy in the treatment of postmenopause anxiety]. Minerva ginecologica. 2000;52(6):263-267.
70.De Leo V, la Marca A, Morgante G, Lanzetta D, Florio P, Petraglia F. Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety. Maturitas. 2001;39(2):185-188.
71.Latas M, Vucinic Latas D, Spasic Stojakovic M. Anxiety disorders and medical illness comorbidity and treatment implications. Current opinion in psychiatry. 2019;32(5):429-434.
72.Nel C, Augustyn L, Bartman N, et al. Anxiety disorders: Psychiatric comorbidities and psychosocial stressors among adult outpatients. S Afr J Psychiatr. 2018;24:1138-1138.
73.Too LS, Spittal MJ, Bugeja L, Reifels L, Butterworth P, Pirkis J. The association between mental disorders and suicide: A systematic review and meta-analysis of record linkage studies. J Affect Disord. 2019;259:302-313.
74.De Hert M, Detraux J, Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues in clinical neuroscience. 2018;20(1):31-40.
75.Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015;170(6):1105-1115.
76.Davidson KW, Alcantara C, Miller GE. Selected psychological comorbidities in coronary heart disease: Challenges and grand opportunities. Am Psychol. 2018;73(8):1019-1030.
77.Pelgrim CE, Peterson JD, Gosker HR, et al. Psychological co-morbidities in COPD: Targeting systemic inflammation, a benefit for both? European journal of pharmacology. 2019;842:99-110.
78.Becker E, Orellana Rios CL, Lahmann C, Rucker G, Bauer J, Boeker M. Anxiety as a risk factor of Alzheimer's disease and vascular dementia. Br J Psychiatry. 2018;213(5):654-660.
79.Sturgeon JA, Finan PH, Zautra AJ. Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways. Nature reviews Rheumatology. 2016;12(9):532-542.
80.Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis and rheumatism. 2009;61(6):822-829.
81.Holtmann G, Shah A, Morrison M. Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview. Digestive diseases (Basel, Switzerland). 2017;35 Suppl 1:5-13.
82.Mohammad S, Chandio B, Soomro AA, et al. Depression and Anxiety in Patients with Gastroesophageal Reflux Disorder With and Without Chest Pain. Cureus. 2019;11(11):e6103.
83.Pohl D, Van Oudenhove L, Tornblom H, Le Neve B, Tack J, Simren M. Functional Dyspepsia and Severity of Psychologic Symptoms Associate With Postprandial Symptoms in Patients With Irritable Bowel Syndrome. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2018;16(11):1745-1753.e1741.
84.Koloski NA, Jones M, Talley NJ. Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study. Alimentary pharmacology & therapeutics. 2016;44(6):592-600.
85.Ochoa-Repáraz J, Kasper LH. The Second Brain: Is the Gut Microbiota a Link Between Obesity and Central Nervous System Disorders? Current obesity reports. 2016;5(1):51-64.
86.ATS. American Thoracic Society. What is Acute Respiratory Distress Syndrome? ATS Patient Education Series Web site. https://www.thoracic.org/patients/patient-resources/resources/acute-respiratory-distress-syndrome.pdf. Published 2017. Accessed August 13, 2020.
87.Oliveira RP, Teixeira C, Rosa RG. Acute respiratory distress syndrome: how do patients fare after the intensive care unit? Rev Bras Ter Intensiva. 2019;31(4):555-560.
88.Hopkins RO, Weaver LK, Chan KJ, Orme JF, Jr. Quality of life, emotional, and cognitive function following acute respiratory distress syndrome. Journal of the International Neuropsychological Society : JINS. 2004;10(7):1005-1017.
89.Bienvenu OJ, Friedman LA, Colantuoni E, et al. Psychiatric symptoms after acute respiratory distress syndrome: a 5-year longitudinal study. Intensive care medicine. 2018;44(1):38-47.
90.Huang M, Parker AM, Bienvenu OJ, et al. Psychiatric Symptoms in Acute Respiratory Distress Syndrome Survivors: A 1-Year National Multicenter Study. Critical care medicine. 2016;44(5):954-965.
91.Davydow DS, Desai SV, Needham DM, Bienvenu OJ. Psychiatric morbidity in survivors of the acute respiratory distress syndrome: a systematic review. Psychosomatic medicine. 2008;70(4):512-519.
92.McDonald MD, Lane-Fall M, Miano TA, et al. The Effect of Sedation on Long-Term Psychological Impairment After Extracorporeal Life Support. Journal of cardiothoracic and vascular anesthesia. 2020;34(3):663-667.
93.Spencer-Segal JL, Hyzy RC, Iwashyna TJ, Standiford TJ. Psychiatric Symptoms in Survivors of Acute Respiratory Distress Syndrome. Effects of Age, Sex, and Immune Modulation. Annals of the American Thoracic Society. 2017;14(6):960-967.
94.Lee AM, Wong JG, McAlonan GM, et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. Can J Psychiatry. 2007;52(4):233-240.
95.Nalleballe K, Reddy Onteddu S, Sharma R, et al. Spectrum of neuropsychiatric manifestations in COVID-19. Brain Behav Immun. 2020.
96.Shuja KH, Aqeel M, Jaffar A, Ahmed A. COVID-19 Pandemic and Impending Global Mental Health Implications. Psychiatr Danub. 2020;32(1):32-35.
97.Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34-39.
98.Sajadi-Ernazarova KR, Anderson J, Hamilton RJ. Caffeine Withdrawal. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
99.Becker HC. Influence of stress associated with chronic alcohol exposure on drinking. Neuropharmacology. 2017;122:115-126.
101.Sawyer DR, Conner CS, Rumack BH. Managing acute toxicity from nonprescription stimulants. Clin Pharm. 1982;1(6):529-533.
102.Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and Rebound Phenomena. Deutsches Arzteblatt international. 2019;116(20):355-361.
103.Huffman JC, Stern TA. Neuropsychiatric consequences of cardiovascular medications. Dialogues in clinical neuroscience. 2007;9(1):29-45.
104.de Ronde W, Smit DL. Anabolic androgenic steroid abuse in young males. Endocr Connect. 2020;9(4):R102-111.
105.Cazzola M, Rogliani P, Calzetta L, Matera MG. Bronchodilators in subjects with asthma-related comorbidities. Respiratory medicine. 2019;151:43-48.
106.Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging. 2013;30(8):587-592.
107.Wiersinga WM. Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. Nature reviews Endocrinology. 2014;10(3):164-174.
108.Welsh JW, Tretyak V, McHugh RK, Weiss RD, Bogunovic O. Review: Adjunctive pharmacologic approaches for benzodiazepine tapers. Drug and alcohol dependence. 2018;189:96-107.
109.Evans CJ, Cahill CM. Neurobiology of opioid dependence in creating addiction vulnerability. F1000Research. 2016;5.
110.Baker A, Simon N, Keshaviah A, et al. Anxiety Symptoms Questionnaire (ASQ): development and validation. Gen Psychiatr. 2019;32(6):e100144.
111.Creswell C, Waite P, Cooper PJ. Assessment and management of anxiety disorders in children and adolescents. Archives of disease in childhood. 2014;99(7):674-678.
112.Bighelli I, Castellazzi M, Cipriani A, et al. Antidepressants versus placebo for panic disorder in adults. The Cochrane database of systematic reviews. 2018;4:Cd010676.
113.Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768-777.
114.Jakubovski E, Johnson JA, Nasir M, Müller-Vahl K, Bloch MH. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. Depression and anxiety. 2019;36(3):198-212.
115.Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depression and anxiety. 2018;35(6):502-514.
116.Bandelow B, Sagebiel A, Belz M, Görlich Y, Michaelis S, Wedekind D. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry. 2018;212(6):333-338.
117.Hengartner MP, Davies J, Read J. Antidepressant withdrawal - the tide is finally turning. Epidemiol Psychiatr Sci. 2019;29:e52.
118.Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychotherapy and psychosomatics. 2020:1-24.
119.Whiteside SPH, Sim LA, Morrow AS, et al. A Meta-analysis to Guide the Enhancement of CBT for Childhood Anxiety: Exposure Over Anxiety Management. Clin Child Fam Psychol Rev. 2020;23(1):102-121.
120.Schwartz C, Barican JL, Yung D, Zheng Y, Waddell C. Six decades of preventing and treating childhood anxiety disorders: a systematic review and meta-analysis to inform policy and practice. Evid Based Ment Health. 2019;22(3):103-110.
121.Rith-Najarian LR, Mesri B, Park AL, Sun M, Chavira DA, Chorpita BF. Durability of Cognitive Behavioral Therapy Effects for Youth and Adolescents With Anxiety, Depression, or Traumatic Stress:A Meta-Analysis on Long-Term Follow-Ups. Behav Ther. 2019;50(1):225-240.
122.Kreuze LJ, Pijnenborg GHM, de Jonge YB, Nauta MH. Cognitive-behavior therapy for children and adolescents with anxiety disorders: A meta-analysis of secondary outcomes. J Anxiety Disord. 2018;60:43-57.
123.Springer KS, Levy HC, Tolin DF. Remission in CBT for adult anxiety disorders: A meta-analysis. Clin Psychol Rev. 2018;61:1-8.
124.Sanada K, Montero-Marin J, Barcelo-Soler A, et al. Effects of Mindfulness-Based Interventions on Biomarkers and Low-Grade Inflammation in Patients with Psychiatric Disorders: A Meta-Analytic Review. International journal of molecular sciences. 2020;21(7).
125.Apolinario-Hagen J, Druge M, Fritsche L. Cognitive Behavioral Therapy, Mindfulness-Based Cognitive Therapy and Acceptance Commitment Therapy for Anxiety Disorders: Integrating Traditional with Digital Treatment Approaches. Adv Exp Med Biol. 2020;1191:291-329.
126.Marker I, Norton PJ. The efficacy of incorporating motivational interviewing to cognitive behavior therapy for anxiety disorders: A review and meta-analysis. Clin Psychol Rev. 2018;62:1-10.
127.Tolin DF. Can Cognitive Behavioral Therapy for Anxiety and Depression Be Improved with Pharmacotherapy? A Meta-analysis. The Psychiatric clinics of North America. 2017;40(4):715-738.
128.Kirsch I. Placebo Effect in the Treatment of Depression and Anxiety. Frontiers in psychiatry. 2019;10(407).
129.Sugarman MA, Loree AM, Baltes BB, Grekin ER, Kirsch I. The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales. PloS one. 2014;9(8):e106337-e106337.
130.Bandelow B. Current and Novel Psychopharmacological Drugs for Anxiety Disorders. Adv Exp Med Biol. 2020;1191:347-365.
131.Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert opinion on pharmacotherapy. 2018;19(10):1057-1070.
132.Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs in context. 2015;4:212290.
133.Mayo Clinic. Monoamine Oxidase Inhibitors (MAOIs). Available at https://www.mayoclinic.org/diseases-conditions/depression/in-depth/maois/art-20043992. Last updated 09/12/2019. Accessed 05/21/2020. 2019.
134.Quagliato LA, Freire RC, Nardi AE. Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines. Expert opinion on drug safety. 2018;17(3):315-324.
135.Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert opinion on pharmacotherapy. 2018;19(8):883-894.
136.Shinfuku M, Kishimoto T, Uchida H, Suzuki T, Mimura M, Kikuchi T. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. International clinical psychopharmacology. 2019;34(5):211-221.
137.Rissardo JP, Caprara ALF. Buspirone-associated Movement Disorder: A Literature Review. Prague medical report. 2020;121(1):5-24.
138.Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. The Cochrane database of systematic reviews. 2010(12):Cd006815.
139.Murrough JW, Yaqubi S, Sayed S, Charney DS. Emerging drugs for the treatment of anxiety. Expert opinion on emerging drugs. 2015;20(3):393-406.
140.Greenblatt HK, Greenblatt DJ. Gabapentin and Pregabalin for the Treatment of Anxiety Disorders. Clinical pharmacology in drug development. 2018;7(3):228-232.
141.Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues in clinical neuroscience. 2017;19(2):93-107.
142.Gautam CS, Mahajan SS, Sharma J, Singh H, Singh J. Repurposing Potential of Ketamine: Opportunities and Challenges. Indian journal of psychological medicine. 2020;42(1):22-29.
143.Rasmussen KG. Has psychiatry tamed the "ketamine tiger?" Considerations on its use for depression and anxiety. Progress in neuro-psychopharmacology & biological psychiatry. 2016;64:218-224.
144.Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacology & therapeutics. 2019;204:107402.
145.De Berardis D, Fornaro M, Serroni N, et al. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. International journal of molecular sciences. 2015;16(1):1111-1130.
146.Buoli M, Grassi S, Serati M, Altamura AC. Agomelatine for the treatment of generalized anxiety disorder. Expert opinion on pharmacotherapy. 2017;18(13):1373-1379.
147.Santos P, Herrmann AP, Elisabetsky E, Piato A. Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review. Braz J Psychiatry. 2019;41(2):168-178.
148.Yoon S, Kim YK. The Role of the Oxytocin System in Anxiety Disorders. Adv Exp Med Biol. 2020;1191:103-120.
149.Nuss P, Ferreri F, Bourin M. An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action. Neuropsychiatr Dis Treat. 2019;15:1781-1795.
150.Choi YM, Kim KH. Etifoxine for pain patients with anxiety. Korean J Pain. 2015;28(1):4-10.
151.Nutt D. Psychedelic drugs-a new era inpsychiatry?. Dialogues in clinical neuroscience. 2019;21(2):139-147.
152.Chi T, Gold JA. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci. 2020;411:116715.
153.Gasser P. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03153579. LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study. 2020 Mar 13 [cited 2020 June 22]; Available from: https://clinicaltrials.gov/ct2/show/NCT03153579. Accessed.
154.Center for Psychedelic & Consciousness Research. Research. Johns Hopkins. https://hopkinspsychedelic.org/index/#research. Accessed August 17, 2020.
155.Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. J Affect Disord. 2019;258:11-24.
156.Guzmán G, Allen JW, Gartz J. A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion. Annali dei Museo civico, Rovereto. 1998;14:189-280.
157.Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology (Oxford, England). 2016;30(12):1165-1180.
158.Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford, England). 2016;30(12):1181-1197.
159.Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. Journal of psychopharmacology (Oxford, England). 2015;29(1):57-68.
160.Mithoefer MC, Feduccia AA, Jerome L, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology. 2019;236(9):2735-2745.
161.Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK. Long-term effects of psychedelic drugs: A systematic review. Neuroscience and biobehavioral reviews. 2020;113:179-189.
162.Millán-Guerrero RO, Isais-Millán S. Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies. Gaceta medica de Mexico. 2019;155(5):471-474.
163.Hindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. The lancet Psychiatry. 2020;7(4):344-353.
164.Prospéro-García O, Ruiz Contreras AE, Ortega Gómez A, Herrera-Solís A, Méndez-Díaz M. Endocannabinoids as Therapeutic Targets. Arch Med Res. 2019;50(8):518-526.
165.Alger BE. Getting high on the endocannabinoid system. Cerebrum. 2013;2013:14-14.
166.Mackie K. Cannabinoid Receptors: Where They are and What They do. Journal of Neuroendocrinology. 2008;20(s1):10-14.
167.Morena M, Patel S, Bains JS, Hill MN. Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology. 2016;41(1):80-102.
168.Chayasirisobhon S. Cannabis and Neuropsychiatric Disorders: An Updated Review. Acta Neurol Taiwan. 2019;28(2):27-39.
169.Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. The lancet Psychiatry. 2019;6(12):995-1010.
170.Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology. 2019;74:282-298.
171.Skelley JW, Deas CM, Curren Z, Ennis J. Use of cannabidiol in anxiety and anxiety-related disorders. Journal of the American Pharmacists Association : JAPhA. 2020;60(1):253-261.
172.Soares VP, Campos AC. Evidences for the Anti-panic Actions of Cannabidiol. Curr Neuropharmacol. 2017;15(2):291-299.
173.Hser YI, Mooney LJ, Huang D, et al. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017;81:53-58.
174.Gobbi G, Atkin T, Zytynski T, et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(4):426-434.
175.Sideli L, Quigley H, La Cascia C, Murray RM. Cannabis Use and the Risk for Psychosis and Affective Disorders. J Dual Diagn. 2020;16(1):22-42.
176.Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2017;2(1):139-154.
177.Freire RC, Cabrera-Abreu C, Milev R. Neurostimulation in Anxiety Disorders, Post-traumatic Stress Disorder, and Obsessive-Compulsive Disorder. Adv Exp Med Biol. 2020;1191:331-346.
178.Rudebeck PH, Rich EL, Mayberg HS. From bed to bench side: Reverse translation to optimize neuromodulation for mood disorders. Proceedings of the National Academy of Sciences. 2019;116(52):26288-26296.
Mayo Clinic. Transcranial magnetic stimulation. Updated 11/27/2018. Accessed 8/13, 2020.
</p>

<!-- Resumen de Cáncer -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #d32f2f; padding-bottom: 10px;">
    <i class="fa fa-cancer" style="margin-right: 10px; color: #d32f2f;"></i> Cancer
</h2>
<p style="margin-bottom: 20px; text-align: justify;">
    Cancer is the final result of the aggression of normal cells by external and internal factors that cause them to find an internal environment that enables them to survive in a period that takes an average of between 5 and 15 years in which the organism “announces”, at least 4 times, that we are “incubating” a cancer. Understanding these phenomena is essential to prevent the development, progression and consolidation of cancer. After establishing themselves, cancer cells and cancer in general develop "strategies" to perpetuate themselves and invade neighboring organs and tissues until they cause death. Despite these, the conventional medical establishment treats most cancer cases with a one-size-fits-all approach that may deprive many patients of a greater chance of successful treatment. The good news is that we currently have a diagnostic system that allows us to predict, from birth, the predisposition to suffer from different types of cancer, to consequently deploy therapeutic strategies for the control of all critical points related to development of cancer and the strategies developed by cancer cells to evade treatment; considering epigenetic therapies and intelligent nutrition as the most effective to prevent, control, treat and remission cancer (depending on the stage it is in) to make cancer a controllable chronic disease in which the patient can live with an acceptable quality of life.
</p>
<h3 style="font-size: 20px; color: #555; margin-bottom: 15px; border-bottom: 2px solid #d32f2f; padding-bottom: 10px;">
    <i class="fa fa-cogs" style="margin-right: 10px; color: #d32f2f;"></i> Conventional treatments
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    Conventional cancer treatment does not go beyond surgery, chemotherapy and radiotherapy. Currently, a step has been taken in expanding the protocols and so-called immunotherapies are being used which, although they represent an important step, are still far from fully applying integrative medicine as the solution to prevention, control and cancer remission to put true personalized medicine into practice.
</p>
<h3 style="font-size: 20px; color: #555; margin-bottom: 15px; border-bottom: 2px solid #d32f2f; padding-bottom: 10px;">
    <i class="fa fa-stethoscope" style="margin-right: 10px; color: #d32f2f;"></i> Strategy for use of adjuvants
</h3>
<p style="text-align: justify;">
    Implementing adjuvant therapies in the treatment of cancer is possible as long as we analyze the specific needs of each patient and the characteristics of the cancer. Adjuvants can complement conventional treatments by targeting unique aspects of the cancer's biology, reducing side effects, and improving overall outcomes. Through personalized strategies and a holistic approach, the integration of adjuvants aims to enhance the efficacy of standard therapies and support the patient's journey toward remission.
</p>

<p style="margin-bottom: 20px; text-align: justify;">
1.Tan WW et al. Metastatic Cancer With Unknown Primary Site. Medscape web page. Background. Available at: http://emedicine.medscape.com/article/280505-overview. Accessed 10/24/2011.
2.Lancet. [no authors listed] Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 Sep 19;352(9132):930-42.
3.Clarke MJ. WITHDRAWN: Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000487.
4.Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson NO, Sevelda P. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet. 1996 Apr 20;347(9008):1066-71.
5.International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2002; 94(14):1054-65.
6.Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11;357(15):1496-506.
7.Moore, A. Breast-cancer therapy—looking back to the future. N Engl J Med. 2007 Oct 11;357(15):1547-9.
8.Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008 Jan 2;100(1):14-20.
9.Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1;97(11):2869-79.
10.Kuhnl A et al. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res. 2011 Sep 5.
11.Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997 Apr 15;57(8):1597-604.
12.Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8.
13.Wülfing P, Borchard J, Buerger H, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I and III breast cancer patients. Clin Cancer Res. 2006;12(6):1715-20.
14.Cristofanilli M et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007 Feb;7(6):471-9.
15.Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005 Apr;65(4):713-8.
16.Tombal B, Van Cangh PJ, Loric S, Gala JL. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate. 2003 Aug 1;56(3):163-70.
17.Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597
18.Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol. 2003 Feb 1;21(3):490-5.
19.Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007 Dec 1;13(23):7053-8.
20.Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24.
21.Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008 Jul 1;26(19):3213-21.
22.Quintela-Fandino M, López JM, Hitt R, Gamarra S, Jimeno A, Ayala R, Hornedo J, Guzman C, Gilsanz F, Cortés-Funes H. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J Clin Oncol. 2006 Aug 1;24(22):3611-8.
23.Pachmann K, Dengler R, Lobodasch K, Fröhlich F, Kroll T, Rengsberger M, Schubert R, Pachmann U. An increase in cell number at completion of therapy may develop as an indicator of early relapse: Quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer. J Cancer Res Clin Oncol. 2008 Jan;134(1):59-65.
24.Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002 May;8(5):1107-16
25.Ciaparrone M, Quirino M, Schinzari G, et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology. 2006;70(5):366-77.
26.Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer. 2005 Aug 15;104(4):879-90.
27.Hayeshi R, Mutingwende I, Mavengere W, Masiyanise V, Mukanganyama S. The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem Toxicol. 2007 Feb;45(2):286-95.
28.Sears B. A Dietary Road Map.1995.
29.Newmark T. Beyond Aspirin. 2000.
30.Chakraborti AK, Garg SK, Kumar R, Motiwala HF, Jadhavar PS. Progress in COX-2 Inhibitors: A Journey So Far. Curr Med Chem. 2010 Feb 18.
31.Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999 Mar 1;59(5):987-90.
32.Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19(1-2):19-27.
33.Reddy BS, Rao CV. Colon cancer: a role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs. Drugs Aging. 2000 May;16(5):329-34.
34.Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999 Oct 6;282(13):1254-7.
35.Brody JE. Aspirin linked to aid in colon cancer fight. New York Times. 1991;141(48, 812):A12.
36.Knorr J. Aspirin: the multi-purpose compound not just for headaches anymore. Life Extension Magazine 2000 Feb. 2000; Life Extension Magazine 2000 Feb6(2):50.
37.Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology. 1999 Oct;117(4):838-47.
38.Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998 May 29;93(5):705-16.
39.Valsecchi ME, Pomerantz SC, Jaslow R, Tester W. Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors. Clin Breast Cancer. 2009 Nov;9(4):225-30.
40.Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy—Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008 Feb;26(6):848-55.
41.Pruthi RS, Derksen JE, Moore D, e al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res. 2006 Apr;12(7 Pt 1):2172-7.
42.Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000 Nov;18(22):3782-93.
43.Lai V, George J, Richey L, et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck. 2008 Jan;30(1):67-74.
44.Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009 Apr;17(2):55-67.
45.Erovic BM et al. Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer. Eur J Clin Invest. 2008 Jan;38(1):61-6.
46.Khunnarong J et al. Expression of cyclooxygenase-1 in epithelial ovarian cancer: a clinicopathological study. Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):757-62.
47.Wu WK et al. Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):79-84. Epub 2009 Mar 1.
48.Li W et al. Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor. Med Oncol. 2009;26(2):170-7. Epub 2008 Nov 6.
49.McFadden DW et al. Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro. Int J Oncol. 2006 Oct;29(4):1019-23.
50.Wu KK et al. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12.
51.Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010 Nov 20;376(9754):1741-50.
52.Sjodahl R. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects. Am J Med. 2001 Jan 8;110(1A):66S-69S.
53.Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003 Jan;124(1):47-56.
54.Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: a summary review to 2007. Recent Results Cancer Res. 2009;181:231-51.
55.Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer. 2010 Dec 2.
56.Salinas CA, Kwon EM, FitzGerald LM, et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol. 2010 Sep 1;172(5):578-90.
57.Duursma AM, Agami R. Ras interference as cancer therapy. Semin Cancer Biol. 2003 Aug;13(4):267-73.
58.Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review. Cancer Detect Prev. 2000;24(1):1-12.
59.Vachtenheim J. Occurrence of ras mutations in human lung cancer. Minireview. Neoplasma. 1997;44(3):145-9.
60.Bartram CR. Mutations in ras genes in myelocytic leukemias and myelodysplastic syndromes. Blood Cells. 1988;14(2-3):533-8.
61.Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep;49(17):4682-9.
62.Hsieh JS, Lin SR, Chang MY, Chen FM, Lu CY, Huang TJ, Huang YS, Huang CJ, Wang JY. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg. 2005 Apr;71(4):336-43.
63.Däbritz J, Preston R, Hänfler J, Oettle H. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas. 2009 Jul;38(5):534-41.
64.Gibbs JB, Kohl NE, Koblan KS, et al. Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res Treat. 1996;38(1):75-83.
65.Oliff A. Therapies of the Future: New Molecular Targets for Cancer Therapy. 1996.
66.Feramisco JR, Clark R, Wong G, et al. Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein. Nature. 1985 Apr 18;314(6012):639-42.
67.Weden S et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2011 Mar 1;128(5):1120-8. doi: 10.1002/ijc.25449.
68.Lu X, Xu T, Qian J. [An application value of detecting K-ras and p53 gene mutation in the stool and pure pancreatic juice for diagnosis of early pancreatic cancer]. Zhonghua Yi Xue Za Zhi. 2001 Sep 10;81(17):1050-3.
69.Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis. 2006;7(3):170-4.
70.Bland J. Farnesyl transferase inhibitors.2001;October 17-21, 2001.
71.Asamoto M, Ota T, Toriyama-Baba H, et al. Mammary carcinomas induced in human c-Ha-ras proto-oncogene transgenic rats are estrogen-independent, but responsive to d-limonene treatment. Jpn J Cancer Res. 2002 Jan;93(1):32-5.
72.Kim Ms, Kang HJ, Moon A. Inhibition of invasion and induction of apoptosis by curcumin in H-ras-transformed MCF10A human breast epithelial cells. Arch Pharm Res. 2001 Aug;24(4):349-54.
73.Chen X, Hasuma T, Yano Y, et al. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin. Anticancer Res. 1997 Jul-Aug;17(4A):2555-64.
74.Yano T, Uchida M, Yuasa M, et al. The inhibitory effect of vitamin E on K-ras mutation at an early stage of lung carcinogenesis in mice. Eur J Pharmacol. 1997 Mar;323(1):99-102.
75.Prasad KN, Cohrs RJ, Sharma OK. Decreased expressions of c-myc and H-ras oncogenes in vitamin E succinate induced morphologically differentiated murine B-16 melanoma cells in culture. Biochem Cell Biol. 1990 Nov;68(11):1250-5.
76.Singh A, Purohit A, Hejaz HA, et al. Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate. Mol Cell Endocrinol. 2000 Feb 25;160(1-2):61-6.
77.Chung JY, Huang C, Meng X, et al. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res. 1999 Sep 15;59(18):4610-7.
78.Collett ED, Davidson LA, Fan YY, et al. n-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am J Physiol Cell Physiol. 2001 May;280(5):C1066-C1075.
79.Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology. 2000 Sep;59(3):245-54.
80.Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem. 1995 Jul 21;270(29):17508-12.
81.Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001 Apr 6;84(7):886-91.
82.Graf H, Jüngst C, Straub G, Dogan S, Hoffmann RT, Jakobs T, Reiser M, Waggershauser T, Helmberger T, Walter A, Walli A, Seidel D, Goke B, Jüngst D. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion. 2008;78(1):34-8.
83.Samuels AJBHRSSB. Increased alpha 1 antitrypsin, decreased systemic fibrinolysis, hypercoaguable state and increased fibrin split products in patients with lung cancer. Proc Am Soc Clin Oncol. 1975;(16):238.
84.Cafagna D, Ponte E. [Pulmonary embolism of paraneoplastic origin]. Minerva Med. 1997 Dec;88(12):523-30.
85.Ahmad S et al. Therapeutic roles of heparin anticoagulants in cancer and related disorders. Med Chem. 2011 Sep 1;7(5):504-17.
86.Cosgrove RH, Zacharski LR, Racine E, et al. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost. 2002 Feb;28(1):79-87.
87.Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Expert Rev Anticancer Ther. 2002 Apr;2(2):227-33.
88.von Tempelhoff GF, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractioned heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol. 2000;16(4):815-24.
89.Wellness Directory of Minnesota. 2002
90.Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer. 1994 Jul 1;74(1):38-45.
91.Van Doormaal FF, Büller HR, Middeldrop S. Development of anticoagulant therapy. Crit Rev Oncol Hematol. 2008 May;66(2):145-54.
92.Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol. 1994 Apr;21(2 Suppl 3):3-8.
93.Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001 Jun 15;91(12):2214-21.
94.Cazzola M. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin. Med Oncol. 2000 Nov;17 Suppl 1:S11-S16.
95.Reis ST et al. Tgf-β1 expression as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo). 2011;66(7):1143-7.
96.Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 1984 May 15;53(10):2046-52.
97.Zacharski LR, Memoli VA, Rousseau SM, et al. Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung. Cancer. 1987 Dec 1;60(11):2675-81.
98.Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol. 1989 Aug;7(8):993-1002.
99.Saad F, Abrahamsson PA, Miller K. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU Int. 2009 Dec;104(11):1573-9.
100.Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol. 2005;22(2):195-201.
101.Gnant BT, Amenedo C, Freeman K, et al. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Masxillofac Surg. 2008;66:223-230.
102.Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04). http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_226&terms. 12/10/2010.
103.Morgan G, Davies F, Gregory W, et al. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): results of the Medical Research Council (MRC) Myeloma IX study. J Clin Oncol. 2010;28(suppl):578s. (abstr 8021).
104.Hwang SH, Lee SA, Ahn SG, Lee HM, Jeong J, Lee HD. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients. Breast Cancer Res Treat. 2011 Aug 23.
105.Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-9.
106.Weitzman R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Crit Rev Oncol Hematol. 2007 May;62(2):148-52.
107.Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008 Apr 28;168(8):826-31.
108.Miller PD. Curr Osteoporos Rep. 2009 Mar;7(1):18-22. Denosumab: anti-RANKL antibody.
109.Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Lancet. 2011 Mar 5;377(9768):813-22. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
110.Shammas NW, Moss AJ, Sullebarger JT, et al. Acquired coronary angiogenesis after myocardial infarction. Cardiology. 1993;83(3):212-6.
111.Suh DY. Understanding angiogenesis and its clinical applications. Ann Clin Lab Sci. 2000 Jul;30(3):227-38.
112.Cooke R. Dr. Folkman's War: Angiogenesis and the Struggle to Defeat Cancer. Nature Medicine. 2001 May;7(5):525-6.
113.Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 Nov 18;285(21):1182-6
114.Cao Y, Langer R. A review of Judah Folkman's remarkable achievements in biomedicine. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13203-5.
115.Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992b Apr;3(2):65-71.
116.Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol. 1992a;313:355-64.
117.NIH/NCI. Angiogenesis Inhibitors in Cancer Research. NIH/NCI Angiogenesis Inhibitors in Cancer Research 1998 Jul 7 Bethesda, MD: National Cancer Institute (Http://Www Slip Net/~Mcdavis/Database/Angio163 Htm).1998;Jul 7
118.Ghosh J. Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun. 2004 Mar 12;315(3):24-35.
119.Moretti RM, Montagani Marelli M, Sala A, et al. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int J Cancer. 2004 Oct;121(1):87-93.
120.Hassan S, Carraway RE. Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth. Regul Pept. 2006 Jan;133(1-3):105-14.
121.Matsuyama M, Yoshimura R, Mitsuhashi M, et al. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol. 2004a Apr;24(4):821-7.
122.Kelavkar UP, Glasgow W, Olson SJ, Foster BA, Shappell SB. Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia. 2004 Nov;6(6):821-30.
123.Gupta S, Srivastava M, Ahmad N, et al. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer. 2001 Feb 15;91(4):737-43
124.Kelavkar UP, Nixon JB, Cohen C, et al. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis. 2001 Nov;22(11):1765-73.
125.Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun. 1997 Jun;235(2):418-23.
126.Gao X, Grignon DJ, Chbihi T, et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology. 1995;46(2):227-37.
127.Sundaram S, Ghosh J. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochem Biophys Res Commun. 2006 Jan 6;339(1):93-8.
128.Myers CE, Ghosh J. Lipoxygenase inhibition in prostate cancer. Eur Urol. 1999;35(5-6):395-8.
129.Nakao-Hayashi J, Ito H, Kanayasu T, Morita I, Murota S. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis. 1992 Feb;92(2-3):141-9.
130.Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab. 1991 Aug;73(2):401-7.
131.Ghosh J. Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem Biophys Res Commun. 2003 Jul 25;307(2):342-9.
132.Jiang WG, Douglas-Jones AG, Mansel RE. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot Essent Fatty Acids. 2006 Feb;74(2):125-34.
133.Yoshimura R, Matsuyama M, Mitsuhashi M, et al. Relationship between lipoxygenase and human testicular cancer. Int J Mol Med. 2004 Mar;13(3):389-93.
134.Zhang L, Zhang WP, Hu H, et al. Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology. 2006 Apr;26(2):99-106.
135.Soumaoro LT, Iida S, Uetake H, et al. Expression of 5-Lipoxygenase in human colorectal cancer. World J Gastroenterol. 2006 Oct 21;12(39):6355-60.
136.Hayashi T, Nishiyama K, Shirahama T. Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells. Int J Urol. 2006 Aug;13(8):1086-91.
137.Hoque A, Lippman SM, Wu TT, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis. 2005 Apr;26(4):785-91.
138.Hennig R, Ding XZ, Tong WG, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 2002 Aug;161(2):421-8.
139.Ding XZ, Iversen P, Cluck MW, Knezetic JA, Adrian TE. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun. 1999 Jul 22;261(1):218-23.
140.Matsuyama M, Yoshimura R, Mitsuhashi M, et al. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep. 2005 Jul;14(1):73-9.
141.Zhi H, Zhang J, Hu G, et al. The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer. 2003 Sep 1;106(3):327-33.
142.Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol. 2000 Aug 1;165(3):1605-11.
143.Rubinsztajn R, Wronska J, Chazan R. [Urinary leukotriene E4 concentration in patients with bronchial asthma and intolerance of non-steroids anti-inflammatory drugs before and after oral aspirin challenge]. Pol Arch Med Wewn. 2003 Aug;110(2):849-854
144.Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):369-75.
145.Hu Y, Sun H, O’Flaherty JT, et al. 15-Lipoxygenase-1-mediated metabolism of docosahexaenoic acid is required for syndecan-1 signaling and apoptosis in prostate cancer cells. Carcinogenesis. 2013;34(1):176-82.
146.Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology. 2004 Oct 15;203(1-3):179-88.
147.Rajashekhar G, Willuweit A, Patterson CE, et al. Continuous endothelial cell activation increases angiogenesis: evidence for the direct role of endothelium linking angiogenesis and inflammation. J Vasc Res. 2006;43(2):193-204.
148.Hazai E, Bikadi Z, Zsila F, Lockwood SF. Molecular modeling of the non-covalent binding of the dietary tomato carotenoids lycopene and lycophyll, and selected oxidative metabolites with 5-lipoxygenase. Bioorg Med Chem. 2006 Oct 15;14(20):6859-67.
149.Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA. 1998 Oct 27;95(22):13182-7.
150.Yang P, Collin P, Madden T, et al. Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate. 2003 Jun 1;55(4):281-91.
151.Anderson KM, Seed T, Vos M, et al. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate. 1998;37(3):161-73.
152.Steinhilber D et al. 5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Front Pharmacol. 2010;1:143. Epub 2010 Dec 24.
153.Taccone-Gallucci M, Manca-di-Villahermosa S, Battistini L, et al. N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity. Kidney Int. 2006 Apr;69(8):1450-4.
154.Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids. 2003 Apr;38(4):343-52.
155.Jian L, Du CJ, Lee AH, Binns CW. Do dietary lycopene and other carotenoids protect against prostate cancer? Int J Cancer. 2005 Mar 1;113(6):1010-4.
156.Campbell JK, Canene-Adams K, Lindshield BL, et al. Tomato phytochemicals and prostate cancer risk. J Nutr. 2004 Dec;134(12 Suppl):3486S-92S.
157.Wertz K, Siler U, Goralczyk R. Lycopene: modes of action to promote prostate health. Arch Biochem Biophys. 2004 Oct 1;430(1):127-34.
158.Binns CW, LJ LJ, Lee AH. The relationship between dietary carotenoids and prostate cancer risk in Southeast Chinese men. Asia Pac J Clin Nutr. 2004;13(Suppl):S117.
159.Kim L, Rao AV, Rao LG. Effect of lycopene on prostate LNCaP cancer cells in culture. J Med Food. 2002;5(4):181-7.
160.Giovannucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med (Maywood.). 2002 Nov;227(10):852-9.
161.Vogt TM, Mayne ST, Graubard BI, et al. Serum lycopene, other serum carotenoids, and risk of prostate cancer in US blacks and whites. Am J Epidemiol. 2002 Jun 1;155(11):1023-32.
162.Bosetti C, Tzonou A, Lagiou P, et al. Fraction of prostate cancer incidence attributed to diet in Athens, Greece. Eur J Cancer Prev. 2000 Apr;9(2):119-23.
163.Blumenfeld AJ, Fleshner N, Casselman B, Trachtenberg J. Nutritional aspects of prostate cancer: a review. Can J Urol. 2000 Feb;7(1):927-35.
164.Agarwal S, Rao AV. Tomato lycopene and its role in human health and chronic diseases. CMAJ. 2000 Sep 19;163(6):739-44.
165.Gann PH, Ma J, Giovannucci E, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 1999 Mar 15;59(6):1225-30.
166.Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995 Dec;87(23):1767-76.
167.Hill B, Kyprianou N. Effect of permixon on human prostate cell growth: lack of apoptotic action. Prostate. 2004 Sep 15;61(1):73-80.
168.Paubert-Braquet M, Mencia Huerta JM, Cousse H, et al. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-simulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57(3):299-304.
169.Safayhi H, Rall B, Sailer ER, Ammon HP. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther. 1997 Apr;281(1):460-3.
170.Safayhi H, Sailer ER, Ammon HP. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. 1995 Jun;47(6):1212-6.
171.Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee—a randomized double blind placebo controlled trial. Phytomedicine. 2003 Jan;10(1):3-7.
172.Ammon HP. Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory disease. Wien Med Wochenschr. 2002;152(15-16):373-8.
173.Wallace JM. Nutritional and botanical modulation of the inflammatory cascade--eicosanoids, cyclooxygenases, and lipoxygenases—as an adjunct in cancer therapy. Integr Cancer Ther. 2002 Mar;1(1):7-37.
174.Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol. 2001 Jan;39(1):11-7.
175.Gupta I, Gupta V, Parihar A, et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res. 1998 Nov 17;3(11):511-4.
176.Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol. 1991 May;33(1-2):91-5.
177.Park YS, Lee JH, Harwalkar JA, et al. Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2. Adv Exp Med Biol. 2002;507:387-93.
178.Liu JJ, Nilsson A, Oredsson S, Badmaev V, Duan RD. Keto- and acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. Int J Mol Med. 2002 Oct;10(4):501-5.
179.Syrovets T, Büchele B, Gedig E, et al. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. Mol Pharmacol. 2000 Jul;58(1):71-81.
180.Sailer ER, Subramanian LR, Rall B, et al. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol. 1996 Feb;117(4):615-8.
181.Sengupta K, Kolla JN, Krishnaraju AV, et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem. 2011 Aug;354(1-2):189-97.
182.Krishnaraju AV, Sundararaju D, Vamsikrishna U, et al. Safety and toxicological evaluation of Aflapin: a novel Boswellia-derived anti-inflammatory product. Toxicol Mech Methods. 2010;20(9):556-63.
183.Bird NC et al. Biology of colorectal liver metastases: A review. J Surg Oncol. 2006 Jul 1;94(1):68-80.
184.Dowdall JF et al. Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation? J Surg Res. 2002 Sep;107(1):1-6.
185.Raz A et al. Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev. 1987;6(3):433-52.
186.Yu LG et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007 Jan 5;282(1):773-81. Epub 2006 Nov 7.
187.ten Kate M et al. Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelium. Int J Cancer. 2004 Dec 20;112(6):943-50.
188.Nangia-Makker P et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002 Dec 18;94(24):1854-62.
189.Guess BW et al. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301-4.
190.Jackson CL et al. Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure. Glycobiology. 2007;17(8):805-819.
191.Eichbaum C et al. Breast Cancer Cell-derived Cytokines, Macrophages and Cell Adhesion: Implications for Metastasis. Anticancer Res. 2011 Oct;31(10):3219-27.
192.Matsumoto S et al. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer. 2002 Jan 21;86(2):161-7.
193.Adams WJ et al. Short-course cimetidine and survival with colorectal cancer. Lancet. 1994 Dec 24-31;344(8939-8940):1768-9.
194.Shakhar G et al. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003 Oct;10(8):972-92.
195.Koda K et al. Preoperative natural killer cell activity: correlation with distant metastases in curatively research colorectal carcinomas. Int Surg. 1997 Apr-Jun;82(2):190-3.
196.Fisher M et al. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002 May-Jun;22(3):1737-54.
197.Garcia-Lora A et al. Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line. Cancer Immunol Immunother. 2001 Jun;50(4):191-8.
198.Hayakawa K et al. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev. 1997;21(1):71-7.
199.Sakai T et al. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm. 2008 Aug;23(4):461-7.
200.Ohwada S et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer. 2004 Mar 8;90(5):1003-10.
201.Okazaki A et al. [The effects of PS-K on long-term survival of uterine cervical cancer patients treated with radiation]. Gan No Rinsho. 1986 Feb;32(2):181-5.
202.Nakazato H et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994 May 7;343(8906):1122-6.
203.Toi M et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer. 1992 Nov 15;70(10):2475-83.
204.White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. American journal of preventive medicine. 2014;46(3 Suppl 1):S7-S15.
205.Harding C, Pompei F, Wilson R. Peak and decline in cancer incidence, mortality, and prevalence at old ages. Cancer. 2012;118(5):1371-1386.
206.Gomes AP, Ilter D, Low V, et al. Age-induced accumulation of methylmalonic acid promotes tumour progression. Nature. 2020.
207.Vashi P, Edwin P, Popiel B, Lammersfeld C, Gupta D. Methylmalonic Acid and Homocysteine as Indicators of Vitamin B-12 Deficiency in Cancer. PloS one. 2016;11(1):e0147843-e0147843.
208.Ye X, Weinberg RA. Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends in cell biology. 2015;25(11):675-686.

</p>

<!-- Resumen de Trastornos Hematológicos -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #d32f2f; padding-bottom: 10px;">
    <i class="fa fa-blood" style="margin-right: 10px; color: #d32f2f;"></i> Blood Disorders
</h2>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #d32f2f; padding-bottom: 10px;">
    Iron deficiency anemia is one of the most prevalent nutritional conditions in the world, considering that about 30% of the world population suffers from anemia, which makes it clear that nutritional factors play an important role in the health of the hematopoietic (blood) system considering anemia, leukopenia and thrombocytopenia as the main blood disorders. Conventional treatments of these blood disorders are often hampered by significant, and in some cases serious, side effects in which patients must undergo invasive procedures or take medications for the rest of their lives. 
</p>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #d32f2f; padding-bottom: 10px;">
    Using interventions with adjuvants is essential to increase the efficacy of the indicated medications and to decrease their toxicity to avoid the development of fatal diseases and to prolong life with quality in patients receiving conventional treatment for anemia, leukopenia, and thrombocytopenia and support the healthy development and function of blood cells.
</p>

<h3 style="font-size: 20px; color: #555; margin-bottom: 10px; border-bottom: 1px solid #d32f2f; padding-bottom: 5px;">
    <i class="fa fa-medical-kit" style="margin-right: 10px; color: #d32f2f;"></i> Conventional Treatments
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
    The conventional treatments of these alterations are basically based on drugs and vitamins.
    <strong>Anemia:</strong> Supplemental iron, especially the form iron protein succinylate for iron-deficiency anemia; Vitamin C, which facilitates the absorption of iron; Vitamin B12 and/or folate for anemia due to vitamin deficiency; Hydroxycarbamide, a drug that increases a form of hemoglobin that does not participate in sickling in those with sickle cell anemia.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    <strong>Leukopenia:</strong> Antibiotics for leukopenia caused by cancer or fever (ciprofloxacin, amoxicillin/clavulanate, ceftazidime, vancomycin); Granulocyte-macrophage and granulocyte-stimulating colony factors can be used as a preventive measure to stimulate bone marrow to produce more white blood cells.
</p>
<p style="margin-bottom: 20px; text-align: justify;">
    <strong>Thrombocytopenia:</strong> Avoid all drugs that impair clotting; Corticosteroids like prednisolone.
</p>

<h3 style="font-size: 20px; color: #555; margin-bottom: 10px; border-bottom: 1px solid #d32f2f; padding-bottom: 5px;">
    <i class="fa fa-book" style="margin-right: 10px; color: #d32f2f;"></i> References
</h3>

<p style="margin-bottom: 20px; text-align: justify;">
    1.A.D.A.M. Medical Encyclopedia. RBC count. PubMed Health web page. Last updated 2/8/2012. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004110/. Accessed 1/24/2013.
2.Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. Jan 2011;47(1):8-32.
3.Abramson JS, Chatterji M, Rahemtullah A. Case records of the Massachusetts General Hospital. Case 39-2008. A 51-year-old woman with splenomegaly and anemia. N Engl J Med. Dec 18 2008;359(25):2707-2718.
4.Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. Aug 23 2012;367(8):716-724.
5.AHA. Anemia may more than triple your risk of dying after a stroke. 2012; http://newsroom.heart.org/pr/aha/anemia-may-more-than-triple-your-221530.aspx. Accessed 11/20/2012.
6.Ahmed F, Kelsey PR, Shariff N. Lupus syndrome with neutropenia following minocycline therapy - a case report. Int J Lab Hematol. Dec 2008;30(6):543-545.
7.Ahmed F, Khan MR, Akhtaruzzaman M, et al. Long-term intermittent multiple micronutrient supplementation enhances hemoglobin and micronutrient status more than iron + folic acid supplementation in Bangladeshi rural adolescent girls with nutritional anemia. J Nutr. Oct 2010;140(10):1879-1886.
8.Alberts B, Johnson, A, Lewis, J, et al. Molecular Biology of the Cell. Renewal by Multipotent Stem Cells: Blood Cell Formation 2002; 4th:https://www.ncbi.nlm.nih.gov/books/NBK26919/. Accessed 11/19/2012.
9.Allen LH, Peerson JM. Impact of multiple micronutrient versus iron-folic acid supplements on maternal anemia and micronutrient status in pregnancy. Food Nutr Bull. Dec 2009;30(4 Suppl):S527-532.
10.Alon DB, Chaimovitz C, Dvilansky A, et al. Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp Hematol. May 2002;30(5):403-409.
11.AMR. Astragalus membranaceus. Monograph. Alternative medicine review : a journal of clinical therapeutic. Feb 2003;8(1):72-77.
12.Aoki T, Harada Y, Matsubara E, et al. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. J Clin Pharm Ther. May 14 2012.
13.Apr 2011;24(2):237-242.
14.Arnold DM. Immune thrombocytopenia: getting back to basics. Am J Hematol. Sep 2012;87(9):841-842.
15.Arzumanyan ES, Makhro AV, Tyulina OV, Boldyrev AA. Carnosine protects erythrocytes from the oxidative stress caused by homocysteic acid. Dokl Biochem Biophys. Jan-Feb 2008;418:44-46.
16.ASH. Blood Basics. 2011; http://www.hematology.org/Patients/Blood-Basics/5222.aspx. Accessed 11/19/2012.
17.Aspuru K, Villa C, Bermejo F, Herrero P, Lopez SG. Optimal management of iron deficiency anemia due to poor dietary intake. Int J Gen Med. 2011;4:741-750.
18.Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. Aug 9 2007;357(6):580-587.
19.Atanasova BD, Li AC, Bjarnason I, Tzatchev KN, Simpson RJ. Duodenal ascorbate and ferric reductase in human iron deficiency. Am J Clin Nutr. Jan 2005;81(1):130-133.
20.Aydin AF, Kusku-Kiraz Z, Dogru-Abbasoglu S, Uysal M. Effect of carnosine treatment on oxidative stress in serum, apoB-containing lipoproteins fraction and erythrocytes of aged rats. Pharmacol Rep. Jul-Aug 2010;62(4):733-739.
21.Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V, . . . Bhasin S. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. The Journal of clinical endocrinology and metabolism. Oct 2010;95(10):4743-4747.
22.Balduini A, Di Buduo CA, Malara A, et al. Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes. Haematologica. Nov 2012;97(11):1657-1665.
23.Barros F, Neto R, Vaz R, Pestana M. [Anemia in Chronic Kidney Disease: from facts to clinical practice]. Acta Med Port. Dec 2011;24 Suppl 4:869-874.
24.Bender DA. Megaloblastic anaemia in vitamin B12 deficiency. Br J Nutr. 2003;89:439-440.
25.Bercovitz RS, Quinones RR. A Survey of Transfusion Practices in Pediatric Hematopoietic Stem Cell Transplant Patients. J Pediatr Hematol Oncol. Nov 6 2012.
26.Berdoukas V, Farmaki K, Carson S, Wood J, Coates T. Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med. 2012;3:119-129.
27.Berns JS, Mosenkis A. Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis. Hemodial Int. Jan 2005;9(1):7-22.
28.Besarab A, Zeig SN, Martin ER, et al. An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients. BMC Nephrol. Aug 30 2012;13(1):95.
29.Bickford PC, Tan J, Shytle RD, Sanberg CD, El-Badri N, Sanberg PR. Nutraceuticals synergistically promote proliferation of human stem cells. Stem cells and development. Feb 2006;15(1):118-123.
30.Bjorn-Rasmussen E, Hallberg L, Isaksson B, Arvidsson B. Food iron absorption in man. Applications of the two-pool extrinsic tag method to measure heme and nonheme iron absorption from the whole diet. J Clin Invest. Jan 1974;53(1):247-255.
31.Bolaman Z, Kadikoylu G, Yukselen V, Yavasoglu I, Barutca S, Senturk T. Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study. Clin Ther. Dec 2003;25(12):3124-3134.
32.Branda RF, Powden C, Brooks EM, Yildirim Z, Naud SJ, McCormack JJ. Vitamin E but not St. John's wort mitigates leukopenia caused by cancer chemotherapy in rats. Translational research : the journal of laboratory and clinical medicine. Dec 2006;148(6):315-324.
33.Briddon A. Homocysteine in the context of cobalamin metabolism and deficiency states. Amino Acids. 2003;24(1-2):1-12.
34.Brodsky RA, Jones RJ. Aplastic anaemia. Lancet. May 7-13 2005;365(9471):1647-1656.
35.Bruno A, Dovizio M, Tacconelli S, Patrignani P. Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2012;26(4):e1-e13.
36.Bushra M, Elhassan EM, Ali NI, Osman E, Bakheit KH, Adam, II. Anaemia, zinc and copper deficiencies among pregnant women in central Sudan. Biol Trace Elem Res. Dec 2010;137(3):255-261.
37.Carmel R. Mandatory fortification of the food supply with cobalamin: an idea whose time has not yet come. J Inherit Metab Dis. Feb 2011;34(1):67-73.
38.Carrero JJ, Barany P, Yilmaz MI, Qureshi AR, Sonmez A, Heimburger O, . . . Stenvinkel P. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. Feb 2012;27(2):709-715.
39.Centers for Disease Control and Prevention (CDC). MMWR. Recommendations to Prevent and Control Iron Deficiency in the United States. 2001. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00051880.htm. Accessed February 7, 2013.
40.Cervinek L, Cerna O, Caniga M, et al. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. Int J Hematol. Oct 26 2012.
41.Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. May 18 1995;332(20):1317-1322.
42.Chirico EN, Pialoux V. Role of oxidative stress in the pathogenesis of sickle cell disease. IUBMB life. Jan 2012;64(1):72-80.
43.Clark SF. Iron deficiency anemia. Nutr Clin Pract. Apr-May 2008;23(2):128-141.
44.ClinicalTrials.gov. A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura). 2012b; http://www.clinicaltrials.gov/ct2/show/NCT01433978?term=avatrombopag&rank=3. Accessed 11/24/2012.
45.ClinicalTrials.gov. Dose-finding study of empegfilgrastim for neutropenia prophylaxis in cancer patients. 2012a; http://www.clinicaltrials.gov/ct2/show/NCT01569087. Accessed 11/24/2012.
46.Cooper KL, Fitzgerald P, Dillingham K, Helme K, Akehurst R. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison. Int J Technol Assess Health Care. Jul 2012;28(3):249-258.
47.Cremonesi P, Caramazza I. Chemical and biological characterization of iron-protein succinylate (ITF 282). International journal of clinical pharmacology, therapy, and toxicology. Jan 1993;31(1):40-51.
48.Czubkowski P, Socha P, Pawlowska J. Oxidative stress in liver transplant recipients. Ann Transplant. Jan-Mar 2011;16(1):99-108.
49.De la Cruz-Gongora V, Villalpando S, Rebollar R, Shamah-Levy T, Mendez-Gomez Humaran I. Nutritional causes of anemia in Mexican children under 5 years. Results from the 2006 National Health and Nutrition Survey. Salud Publica Mex. Mar-Apr 2012;54(2):108-115.
50.Dean L. Blood Groups and Red Cell Antigens [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2005. Chapter 1, Blood and the cells it contains. Available from: http://www.ncbi.nlm.nih.gov/books/NBK2263/
51.Deniau AL, Mosset P, Pedrono F, Mitre R, Le Bot D, Legrand AB. Multiple beneficial health effects of natural alkylglycerols from shark liver oil. Mar Drugs. 2010;8(7):2175-2184.
52.Deved V, Poyah P, James MT, Tonelli M, Manns BJ, Walsh M, Hemmelgarn BR. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis. Dec 2009;54(6):1089-1097.
53.Dietrich M, Brown CJ, Block G. The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States. J Am Coll Nutr. Aug 2005;24(4):266-274.
54.Egner PA, Munoz A, Kensler TW. Chemoprevention with chlorophyllin in individuals exposed to dietary aflatoxin. Mutation research. Feb-Mar 2003;523-524:209-216.
55.Ekman M, Reizenstein P. Comparative absorption of ferrous and heme-iron with meals in normal and iron deficient subjects. Z Ernahrungswiss. Mar 1993;32(1):67-70.
56.Elghetany MT and Banki K. McPherson: Henry’s Clinical Diagnosis and Management by Laboratory Methods, 22nd ed. Copyright © 2011. Chapter 32 – Erythrocytic Disorders. MD Consult web page. Available at: http://www.mdconsult.com/books/page.do?sid=1404769316&eid=4-u1.0-B978-1-4377-0974-2..00032-4&isbn=978-1-4377-0974-2&uniqId=402021146-2. Accessed February 7, 2013.
57.Elmadfa I, Singer I. Vitamin B-12 and homocysteine status among vegetarians: a global perspective. Am J Clin Nutr. May 2009;89(5):1693S-1698S.
58.Erat M, Ciftci M. Effect of melatonin on enzyme activities of glutathione reductase from human erythrocytes in vitro and from rat erythrocytes in vivo. Eur J Pharmacol. May 10 2006;537(1-3):59-63.
59.Farese AM, Cohen MV, Stead RB, Jackson W, 3rd, Macvittie TJ. Pegfilgrastim administered in an abbreviated schedule, significantly improved neutrophil recovery after high-dose radiation-induced myelosuppression in rhesus macaques. Radiat Res. Nov 2012;178(5):403-413.
60.FDA. FDA News Release. FDA approves Omontys to treat anemia in adult patients on dialysis. 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm297464.htm. Accessed 12/09/2012.
61.Ferri FF. Ferri’s Clinical Advisor 2013, 1st ed. Copyright © 2013a. Sickle Cell Disease. MD Consult web page. Available at: http://www.mdconsult.com/books/page.do?sid=1405141474&eid=4-u1.0-B978-0-323-08373-7..00028-5--sc0110&isbn=978-0-323-08373-7&uniqId=402041952-2. Accessed February 7, 2013.
62.Ferri FF. Ferri’s Clinical Advisor 2013, 1st ed. Copyright © 2013b. Thalassemia.  MD Consult web page. Available at: http://www.mdconsult.com/books/page.do?sid=1405145415&eid=4-u1.0-B978-0-323-08373-7..00029-7--sc0060&isbn=978-0-323-08373-7&uniqId=402041952-2. Accessed February 7, 2013.
63.Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, . . . Longo DL. Low testosterone levels and the risk of anemia in older men and women. Archives of internal medicine. Jul 10 2006;166(13):1380-1388.
64.Fibach E, Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Current molecular medicine. Nov 2008;8(7):609-619.
65.Fishman SM, Christian P, West KP. The role of vitamins in the prevention and control of anaemia. Public Health Nutr. Jun 2000;3(2):125-150.
66.Fossati M, Cappelli B, Biral E, et al. Fatal vancomycin- and linezolid-resistant Enterococcus faecium sepsis in a child undergoing allogeneic haematopoietic stem cell transplantation for beta-thalassaemia major. J Med Microbiol. Jul 2010;59(Pt 7):839-842.
67.Franklin Institute. White Blood Cells: Battling Blood Cells. Available at: http://www.fi.edu/learn/heart/blood/white.html Accessed: 2/4/2013.
68.Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of A. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. Feb 15 2011;52(4):e56-93.
69.Gaitan D, Olivares M, Lonnerdal B, Brito A, Pizarro F. Non-heme Iron as Ferrous Sulfate Does Not Interact with Heme Iron Absorption in Humans. Biol Trace Elem Res. Aug 31 2012.
70.Gammon CS, von Hurst PR, Coad J, Kruger R, Stonehouse W. Vegetarianism, vitamin B12 status, and insulin resistance in a group of predominantly overweight/obese South Asian women. Nutrition. Jan 2012;28(1):20-24.
71.Gao F, Hu XF. Analysis of the therapeutic effect of sodium copper chlorophyllin tablet in treating 60 cases of leukopenia. Chinese journal of integrative medicine. Dec 2005;11(4):279-282.
72.Garcia-de-la-Asuncion J, Gomez-Cambronero LG, Del Olmo ML, Pallardo FV, Sastre J, Vina J. Vitamins C and E prevent AZT-induced leukopenia and loss of cellularity in bone marrow. Studies in mice. Free radical research. Mar 2007;41(3):330-334.
73.Garrido-Martin P, Nassar-Mansur MI, de la Llana-Ducros R, et al. The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial. Interact Cardiovasc Thorac Surg. Aug 31 2012.
74.Gelinas J, Stoddart, L, Snyder, E. Thrombocytopenia and Critical Care Medicine. Journal of Intensive Care Medicine. 2001;16:1-21.
75.Gentili A. Folic Acid Deficiency. Drugs, Diseases & Procedures 2012; http://emedicine.medscape.com/article/200184-overview#showall. Accessed 11/20/2012, 2012.
76.Giugliano RP. Drug-Induced Thrombocytopenia: Is it a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors? J Thromb Thrombolysis. Jul 1998;5(3):191-202.
77.Gomez-Almaguer D, Jaime-Perez JC, Ruiz-Arguelles GJ. Antibodies in the treatment of aplastic anemia. Arch Immunol Ther Exp (Warsz). Apr 2012;60(2):99-106.
78.Grady RW, Galanello R, Randolph RE, Kleinert D, Dessi C, Giardina PJ. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica. Aug 8 2012.
79.Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. Oct 15 2004;104(8):2263-2268.
80.Haider BA, Yakoob MY, Bhutta ZA. Effect of multiple micronutrient supplementation during pregnancy on maternal and birth outcomes. BMC Public Health. 2011;11 Suppl 3:S19.
81.Haliotis FA, Papanastasiou DA. Comparative study of tolerability and efficacy of iron protein succinylate versus iron hydroxide polymaltose complex in the treatment of iron deficiency in children. International journal of clinical pharmacology and therapeutics. Jun 1998;36(6):320-325.
82.He XH, Li WT, Peng WJ, Li GD, Wang SP, Xu LC. Total embolization of the main splenic artery as a supplemental treatment modality for hypersplenism. World J Gastroenterol. Jun 28 2011;17(24):2953-2957.
83.Hegazy AA, Zaher MM, Abd El-Hafez MA, Morsy AA, Saleh RA. Relation between anemia and blood levels of lead, copper, zinc and iron among children. BMC Res Notes. 2010;3:133.
84.Hematol. Jul 2012;91(7):1097-1105.
85.Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. Jul 9 2010;142(1):24-38.
86.Herrera J, Nava M, Romero F, Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis. Apr 2001;37(4):750-757.
87.Higdon J. Iron. Copyright © Linus Pauling Institute. 2006. Available at: http://lpi.oregonstate.edu/infocenter/minerals/iron/. Last updated August 2009. Accessed February 7, 2013.
88.Hoffman HN, 2nd, Phyliky RL, Fleming CR. Zinc-induced copper deficiency. Gastroenterology. Feb 1988;94(2):508-512.
89.Hsu SP, Chiang CK, Yang SY, Chien CT. N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients. Nephron Clin Pract. 2010;116(3):c207-216.
90.Huang GC, Wu LS, Chen LG, Yang LL, Wang CC. Immuno-enhancement effects of Huang Qi Liu Yi Tang in a murine model of cyclophosphamide-induced leucopenia. Journal of ethnopharmacology. Jan 19 2007;109(2):229-235.
91.Hvas AM, Nexo E. Diagnosis and treatment of vitamin B12 deficiency--an update. Haematologica. Nov 2006;91(11):1506-1512.
92.Iannitti T, Palmieri B. An update on the therapeutic role of alkylglycerols. Mar Drugs. 2010;8(8):2267-2300.
93.Ikeda T, Ishibashi H, Fujisaki R, Yamazaki M, Wakame K, Kosuna K, . . . Abe S. [Prophylactic efficacy of a basidiomycetes preparation AHCC against lethal Candida albicans infection in experimental granulocytopenic mice]. Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology. 2003;44(2):127-131.
94.Ishibashi H, Ikeda T, Tansho S, Ono Y, Yamazaki M, Sato A, . . . Abe S. [Prophylactic efficacy of a basidiomycetes preparation AHCC against lethal opportunistic infections in mice]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. Aug 2000;120(8):715-719.
95.Jaing TH, Hung IJ, Yang CP, et al. Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. Bone Marrow Transplant. Jan 2012;47(1):33-39.
96.Jaja SI, Aigbe PE, Gbenebitse S, et al. Changes in erythrocytes following supplementation with alpha tocopherol in children suffering from sickle cell anaemia. Niger Postgrad Med J. 2005  Jun;12(2):110-114.
97.Jaja SI, Aigbe PE, Gbenebitse S, Temiye EO. Changes in erythrocytes following supplementation with alpha-tocopherol in children suffering from sickle cell anaemia. The Nigerian postgraduate medical journal. Jun 2005;12(2):110-114.
98.Jilani T, Iqbal MP. Does vitamin E have a role in treatment and prevention of anemia? Pak J Pharm Sci.
99.Kamhieh-Milz J, Bal G, Sterzer V, Kamhieh-Milz S, Arbach O, Salama A. Reduced antioxidant capacities in platelets from patients with autoimmune thrombocytopenia purpura (ITP). Platelets. 2012;23(3):184-194.
100.KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. Feb 2007;49(2 Suppl 2):S12-154.
101.Kedziora-Kornatowska K, Czuczejko J, Motyl J, et al. Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study. Arch Med Sci. Aug 30 2010;6(4):513-518.
102.Kelly DA, Haber B, Gonzalez-Peralta RP, et al. Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin. J Viral Hepat. Apr 2012;19(4):263-270.
103.Khanduri U, Sharma A. Megaloblastic anaemia: prevalence and causative factors. Natl Med J India. Jul-Aug 2007;20(4):172-175.
104.Kiechl S, Aichner F, Gerstenbrand F, Egger G, Mair A, Rungger G, . . . Willeit J. Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study. Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association. Oct 1994;14(10):1625-1630.
105.Kletzmayr J, Horl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2002;17 Suppl 2:25-29.
106.Koike H, Hama T, Kawagashira Y, et al. The significance of folate deficiency in alcoholic and nutritional neuropathies: analysis of a case. Nutrition. Jul 2012;28(7-8):821-824.
107.Kopcke W, Sauerland MC. Meta-analysis of efficacy and tolerability data on iron proteinsuccinylate in patients with iron deficiency anemia of different severity. Arzneimittel-Forschung. Nov 1995;45(11):1211-1216.
108.Kosenko EA, Aliev G, Tikhonova LA, Li Y, Poghosyan AC, Kaminsky YG. Antioxidant Status and Energy State of Erythrocytes in Alzheimer Dementia: probing for markers. CNS Neurol Disord Drug Targets. Sep 17 2012.
109.Kumar V, Abbas AK, Fausto N, et al. Robbins and Cotran Pathologic Basis of Disease, 8th ed. Copyright © 2009a. Chapter 14 – Red Blood Cell and Bleeding Disorders. MD Consult web page. Available at: http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4377-0792-2..50019-5&isbn=978-1-4377-0792-2&uniqId=402021146-2#4-u1.0-B978-1-4377-0792-2..50019-5. Accessed February 7, 2013.
110.Kumar V, Abbas AK, Fausto N, et al. Robbins and Cotran Pathologic Basis of Disease, 8th ed. Copyright © 2009b. Chapter 14 – Red Blood Cell and Bleeding Disorders. MD Consult web page. Available at: http://www.mdconsult.com/books/page.do?sid=1404713560&eid=4-u1.0-B978-1-4377-0792-2..50019-5&isbn=978-1-4377-0792-2&uniqId=402021146-2. Accessed February 7, 2013.
111.Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. Feb 2 2008;371(9610):395-403.
112.Kutlar A, Ataga K, Reid M, Vichinsky EP, Neumayr L, Blair-Britt L, . . . Perrine SP. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol. Nov 2012;87(11):1017-1021.
113.Labonia W, Rubio D, Arias C. Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients. Nephrology (Carlton). Dec 2005;10(6):583-587.
114.Laboratory Corporation of America® (LabCorp) 2013a. Test Menu page: Complete Blood Count (CBC) With Differential. LabCorp website. Available at: https://www.labcorp.com/wps/portal/!ut/p/c1/04_SB8K8xLLM9MSSzPy8xBz9CP0os_hACzO_ QCM_IwMLXyM3AyNjMycDU2dXQwN3M6B8JG55AwMCuv088nNT9SP1o8zjQ11Ngg09LY0N_ N2DjQw8g439TfyM_MzMLAz0Q_QjnYCKIvEqKsiNKDfUDVQEAOrk-dE!/dl2/d1/L0lJWmltbUEhL3dQRUJGUUFoTlFBaERhQUVBWEtHL1lJNXlsdyEhLzdfVUU0UzFJOTM wT0dTMjBJUzNPNE4yTjY2ODAvdmlld1Rlc3Q!/?testId=407601. Accessed 1/24/2013.
115.Laboratory Corporation of America® (LabCorp) 2013b. Test Menu page: Folate, RBC. LabCorp website. Available at: https://www.labcorp.com/wps/portal/!ut/p/c1/04_SB8K8xLLM9MSSzPy8xBz9CP0os_hACzO_ QCM_IwMLXyM3AyNjMycDU2dXQwN3M6B8JG55AwMCuv088nNT9SP1o8zjQ11Ngg09LY0N_ N2DjQw8g439TfyM_MzMLAz0Q_QjnYCKIvEqKsiNKDfUDVQEAOrk-dE!/dl2/d1/L0lJWmltbUEhL3dQRUJGUUFoTlFBaERhQUVBWEtHL1lJNXlsdyEhLzdfVUU0UzFJOTM wT0dTMjBJUzNPNE4yTjY2ODAvdmlld1Rlc3Q!/?testId=408044. Accessed 1/24/2013.
116.Laidlaw SA, Shultz TD, Cecchino JT, Kopple JD. Plasma and urine taurine levels in vegans. Am J Clin Nutr. Apr 1988;47(4):660-663.
117.Lal A, Porter J, Sweeters N, et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. Nov 11 2012.
118.Landucci G, Frontespezi S. Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. The Journal of international medical research. Nov-Dec 1987;15(6):379-382.
119.Langan RC, Zawistoski KJ. Update on vitamin B12 deficiency. Am Fam Physician. Jun 15 2011;83(12):1425-1430.
120.Lanzkron S, Domm J, and Sweet K. Sickle cell disease. Summary. MD Consult Web page. Available at: http://www.mdconsult.com/das/pdxmd/body/402041952-2/0?type=med&eid=9-u1.0-_1_mt_1014713#Contributors. Last updated May 13, 2010. Accessed February 7, 2013.
121.Latif Z, Malik MA, Jabbar F, Ahmed Y, McDonough C. Clozapine-induced late leukopenia. Ir J Med Sci. Mar 2012;181(1):139-141.
122.Lazarchick J. Update on anemia and neutropenia in copper deficiency. Current opinion in hematology. Jan 2012;19(1):58-60.
123.Lewkowicz P, Banasik M, Glowacka E, Lewkowicz N, Tchorzewski H. [Effect of high doses of shark liver oil supplementation on T cell polarization and peripheral blood polymorphonuclear cell function]. Pol Merkur Lekarski. Jun 2005;18(108):686-692.
124.Liebelt EL, Balk SJ, Faber W, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol. Aug 2007;80(4):259-366.
125.Lissoni P, Mandala M, Rossini F, Fumagalli L, Barni S. Growth Factors: Thrombopoietic Property of the Pineal Hormone Melatonin. Hematology (Amsterdam, Netherlands). 1999;4(4):335-343.
126.Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A, Maestroni G. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. Mar 1997;5(2):126-129.
127.Lledo-Garcia R, Kalicki RM, Uehlinger DE, Karlsson MO. Modeling of red blood cell life-spans in hematologically normal populations. J Pharmacokinet Pharmacodyn. Oct 2012;39(5):453-462.
128.Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation. Blood Rev. Jun 2002;16(2):81-85.
129.Ludvigsson JF, Brandt L, Montgomery SM. Symptoms and signs in individuals with serology positive for celiac disease but normal mucosa. BMC Gastroenterol. 2009;9:57.
130.Macartney G, Zvonar, R., McDiarmid, S., Harris, B, and Laplante, J. Risk stratification and febrile neutropenia. Oncology Exchange. 2007 2007;6(3):43-47.
131.Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis. Mar 2012;59(3):444-451.
132.Maggio M, Snyder PJ, Ceda GP, Milaneschi Y, Luci M, Cattabiani C, . . . Ferrucci L. Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men. Andrology. Jan 2013;1(1):24-28.
133.Magnusson CD, Haraldsson GG. Ether lipids. Chem Phys Lipids. Jul 2011;164(5):315-340.
134.Marcinkiewicz J, Kontny E. Taurine and inflammatory diseases. Amino Acids. Jul 19 2012.
135.Maret W, Sandstead HH. Zinc requirements and the risks and benefits of zinc supplementation. J Trace Elem Med Biol. 2006;20(1):3-18.
136.Mayo Clinic. Anemia. Diseases and Conditions 2011a; http://www.mayoclinic.com/print/anemia/DS00321/DSECTION=all&METHOD=print. Accessed 11/20/2012.
137.Mayo Clinic. Aplastic Anemia. Diseases and Conditions 2011b; http://www.mayoclinic.com/health/aplastic-anemia/DS00322. Accessed 11/20/2012.
138.Mayo Clinic. Iron deficiency anemia. Diseases and Conditions 2011c; http://www.mayoclinic.com/health/iron-deficiency-anemia/DS00323/DSECTION=symptoms. Accessed 11/21/2012.
139.Mayo Clinic. Low white blood cell count. Diseases and Conditions 2010; http://www.mayoclinic.com/health/low-white-blood-cell-count/MY00162. Accessed 11/24/2012.
140.Mayo Clinic. Sickle Cell Anemia. Definition. 2011d. http://www.mayoclinic.com/health/sickle-cell-anemia/DS00324/DSECTION=risk-factors. Accessed 12/10/2012.
141.Mayo Clinic. Sickle Cell Anemia. Risk Factors. 2011e. http://www.mayoclinic.com/health/sickle-cell-anemia/DS00324/DSECTION=risk-factors. Accessed 12/10/2012.
142.Mayo Clinic. Sickle Cell Anemia. Symptoms. 2011f. http://www.mayoclinic.com/health/sickle-cell-anemia/DS00324/DSECTION=symptoms. Accessed 12/10/2012.
143.Mayo Clinic. Thalassemia. Diseases and Conditions 2011g; http://www.mayoclinic.com/health/thalassemia/DS00905/DSECTION=risk-factors. Accessed 11/26/2012.
144.Mayo Clinic. Thrombocytopenia. 2012; http://www.mayoclinic.com/health/thrombocytopenia/DS00691/DSECTION=treatments-and-drugs. Accessed 11/24/2012.
145.Mayo Clinic. Vitamin deficiency anemia. Diseases and Conditions 2011h; http://www.mayoclinic.com/health/vitamin-deficiency-anemia/DS00325/DSECTION=symptoms. Accessed 11/21/2012.Mayo Clinic. Mayo Medical Laboratories. TEST ID: HAEVP. Hemolytic Anemia Evaluation. Clinical and Interpretive page. Available at: http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/84157. Accessed February 7, 2013.
146.McCrae K. Immune thrombocytopenia: no longer 'idiopathic'. Cleveland Clinic journal of medicine. Jun 2011;78(6):358-373.
147.McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. Feb 15 2004;103(4):1364-1369.
148.MD Consult. Tocilizumab. Drugs page. Available at: http://www.mdconsult.com/das/pharm/body/402041952-2/1405136622/full/3599. Last updated October 15, 2012. Accessed February 7, 2013.
149.MedlinePlus. Blood. Health Topics 2012a; http://www.nlm.nih.gov/medlineplus/blood.html. Accessed 11/19/2012.
150.MedlinePlus. Eltrombopag. Drugs & Supplements page. Available at: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a609011.html#side-effects. Last updated August 1, 2010. Accessed February 7, 2013.
151.MedlinePlus. Folate deficiency. 2011a; http://www.nlm.nih.gov/medlineplus/ency/article/000354.htm. Accessed 12/10/2012.
152.MedlinePlus. Hypersplenism. Health Topics 2011b; http://www.nlm.nih.gov/medlineplus/ency/article/001314.htm. Accessed 11/21/2012.
153.MedlinePlus. Idiopathic aplastic anemia. Health Topics 2012b; http://www.nlm.nih.gov/medlineplus/ency/article/000554.htm. Accessed 11/20/2012.
154.MedlinePlus. Neutropenia. Health Topics 2011c; http://www.nlm.nih.gov/medlineplus/ency/article/007230.htm. Accessed 11/19/2012.
155.MedlinePlus. Romiplostim Injection. Drugs & Supplements page. Available at: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a609008.html#side-effects. Last updated February 1, 2009. Accessed February 7, 2013.
156.MedlinePlus. Thalassemia minor. Health Topics 2012c; http://www.nlm.nih.gov/medlineplus/ency/imagepages/1499.htm. Accessed 12/10/2012.
157.MedlinePlus. Thrombocytopenia. Health Topics 2012d; http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm. Accessed 11/24/2012.
158.Mehta PA, Faulkner LB. Hematopoietic Cell Transplantation for Thalassemia: A Global Perspective. Biol Blood Marrow Transplant. Oct 27 2012.
159.Merck. Anemia of Chronic Disease. Blood Disorders 2011; http://www.merckmanuals.com/home/blood_disorders/anemia/anemia_of_chronic_disease.html, 2012.
160.Merck. Components of Blood. Biology of Blood 2006; http://www.merckmanuals.com/home/blood_disorders/biology_of_blood/components_of_blood.html. Accessed 11/19/2012.
161.Merck. Components of the Immune System. Biology of the Immune System 2008a; http://www.merckmanuals.com/professional/immunology_allergic_disorders/ biology_of_the_immune_system/components_of_the_immune_system.html?qt=leukocytes&alt=sh. Accessed 11/19/2012.
162.Merck. Neutropenia and Lymphocytopenia. Hematology and Oncology 2012a; http://www.merckmanuals.com/professional/hematology_and_oncology/neutropenia_and_lymphocytopenia/neutropenia.html. Accessed 10/31/2012.
163.Merck. Overview of Leukemia. Hematology and Oncology [Web page]. 2012b; http://www.merckmanuals.com/professional/hematology_and_oncology/leukemias/overview_of_leukemia.html. Accessed 11/1/2012.
164.Merck. Thalassemia. Blood Disorders 2008b; http://www.merckmanuals.com/home/blood_disorders/anemia/thalassemias.html?qt=&sc=&alt=. Accessed 11/26/2012.
165.Meyers DG. The iron hypothesis--does iron cause atherosclerosis? Clinical cardiology. Dec 1996;19(12):925-929.
166.Mikhail A. Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis. J Blood Med. 2012;3:25-31.
167.Miller JW, Garrod MG, Allen LH, Haan MN, Green R. Metabolic evidence of vitamin B-12 deficiency, including high homocysteine and methylmalonic acid and low holotranscobalamin, is more pronounced in older adults with elevated plasma folate. Am J Clin Nutr. Dec 2009;90(6):1586-1592.
168.Miller JW, Garrod MG, Rockwood AL, et al. Measurement of total vitamin B12 and holotranscobalamin, singly and in combination, in screening for metabolic vitamin B12 deficiency. Clin Chem. Feb 2006;52(2):278-285.
169.Mimura EC, Bregano JW, Dichi JB, Gregorio EP, Dichi I. Comparison of ferrous sulfate and ferrous glycinate chelate for the treatment of iron deficiency anemia in gastrectomized patients. Nutrition. Jul-Aug 2008;24(7-8):663-668.
170.Mindell J, Moody A, Ali A, Hirani V. Using longitudinal data from the Health Survey for England to resolve discrepancies in thresholds for haemoglobin in older adults. Br J Haematol. Nov 15 2012.
171.Mineral Nutrition Information System. apps.who.int/iris/bitstream/10665/75584/1/WHO_NMH_NHD_EPG_12.1_eng.pdf Accessed 12/10/2012.
172.Misselwitz B, Bachli EB, Kaiser P, Fehr J, Goede JS. Diagnosis of hypersplenism with the epinephrine stimulation test - 23 years of experience at a tertiary care hospital. Swiss Med Wkly. 2012;141:w13324.
173.Mocchegiani E, Costarelli L, Giacconi R, Piacenza F, Basso A, Malavolta M. Micronutrient (Zn, Cu, Fe)-gene interactions in ageing and inflammatory age-related diseases: implications for treatments. Ageing Res Rev. Apr 2012;11(2):297-319.
174.Moldovanu R, Dimofte G, Stefan I, Filip V, Vlad N, Curca G, . . . Tarcoveanu E. [Right colon cancer--clinicopathological findings]. Chirurgia (Bucharest, Romania : 1990). May-Jun 2012;107(3):314-324.
175.Montebugnoli L, Gissi DB, Marchetti C, Foschini MP. Multiple squamous cell carcinomas of the oral cavity in a young patient with graft-versus-host disease following allogenic bone marrow transplantation. Int J Oral Maxillofac Surg. May 2011;40(5):556-558.
176.Mousa SA, Al Momen A, Al Sayegh F, Al Jaouni S, Nasrullah Z, Al Saeed H, . . . Qari M. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. Aug 2010;16(4):365-376.
177.MSMR. Iron deficiency anemia, active component, U.S. Armed Forces, 2002-2011. MSMR. Jul 2012;19(7):17-21.
178.Mullin GE. Micronutrients and inflammatory bowel disease. Nutr Clin Pract. Feb 2012;27(1):136-137.
179.Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol. Apr 2011;64(4):281-286.
180.Nakazaki K, Hosoi M, Hangaishi A, Ichikawa M, Nannya Y, Kurokawa M. Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study. Intern Med. 2012;51(8):859-863.
181.National Heart Lung and Blood Institute (NHLBI). Hemolytic Anemia: What Are the Signs and Symptoms of Hemolytic Anemia? 2011; http://www.nhlbi.nih.gov/health//dci/Diseases/ha/ha_signsandsymptoms.html. Accessed 12/10/2012.
182.National Heart Lung and Blood Institute (NHLBI). Thrombocytopenia: What is Thrombocytopenia? 2012; http://www.nhlbi.nih.gov/health/health-topics/topics/thcp/. Accessed 12/12/2012.
183.Nazifi S, Razavi SM, Kianiamin P, Rakhshandehroo E. Evaluation of erythrocyte antioxidant mechanisms: antioxidant enzymes, lipid peroxidation, and serum trace elements associated with progressive anemia in ovine malignant theileriosis. Parasitol Res. Aug 2011;109(2):275-281.
184.NHLBI. Aplastic Anemia. Health Topics 2012; http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/causes.html. Accessed 11/20/2012.
185.Nienhuis AW, Persons DA. Development of gene therapy for thalassemia. Cold Spring Harb Perspect Med. 2012;2(11).
186.NIH. Vitamin B12. MedlinePlus [Web page]. 2011; http://www.nlm.nih.gov/medlineplus/ency/article/002403.htm, 2012.
187.Noe A, Cappelli B, Biffi A, et al. High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome. Ital J Pediatr. 2010;36:14.
188.Nur E, Biemond BJ, Otten HM, et al. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. Am J Hematol. 2011 Jun;86(6):484-9.
189.Nur E, Brandjes DP, Teerlink T, et al. N-acetylcysteine reduces oxidative stress in sickle cell patients. Ann
190.Nur E, Brandjes DP, Teerlink T, Otten HM, Oude Elferink RP, Muskiet F, . . . Schnog JJ. N-acetylcysteine reduces oxidative stress in sickle cell patients. Annals of hematology. Jul 2012;91(7):1097-1105.
191.Office of Dietary Supplements (ODS), National Institutes of Health. Dietary Supplement Fact Sheet: Iron. Available at: http://ods.od.nih.gov/factsheets/Iron-HealthProfessional/ Accessed 12/21/2012.
192.Olivares M, Araya M, Pizarro F, Letelier A. Erythrocyte CuZn superoxide dismutase activity is decreased in iron-deficiency anemia. Biol Trace Elem Res. Sep 2006;112(3):213-220.
193.Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. Jul 5 2012;367(1):11-19.
194.Osunkwo I. Complete resolution of sickle cell chronic pain with high dose vitamin D therapy: a case report and review of the literature. J Pediatr Hematol Oncol. Oct 2011;33(7):549-551.
195.Pacini N, Borziani F. Action of melatonin on bone marrow depression induced by cyclophosphamide in acute toxicity phase. Neuro endocrinology letters. 2009;30(5):582-591.
196.Paez PL, Becerra MC, Albesa I. Chloramphenicol-induced oxidative stress in human neutrophils. Basic Clin Pharmacol Toxicol. Oct 2008;103(4):349-353.
197.Palumbo A, Blade J, Boccadoro M, et al. How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk. Feb 2012;12(1):5-11.
198.Parsh B, Kumar D. Understanding sickle cell disease. Nursing. Aug 2012;42(8):64.
199.Patel KV. Epidemiology of anemia in older adults. Semin Hematol. Oct 2008;45(4):210-217.
200.Payen E, Colomb C, Negre O, Beuzard Y, Hehir K, Leboulch P. Lentivirus vectors in beta-thalassemia. Methods Enzymol. 2012;507:109-124.
201.Penman BS, Gupta S, Buckee CO. The emergence and maintenance of sickle cell hotspots in the Mediterranean. Infect Genet Evol. Oct 2012;12(7):1543-1550.
202.Petrosyan I, Blaison G, Andres E, Federici L. Anaemia in the elderly: an aetiologic profile of a prospective cohort of 95 hospitalised patients. Eur J Intern Med. Sep 2012;23(6):524-528.
203.Pillay J, den Braber I, Vrisekoop N, et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood. Jul 29 2010;116(4):625-627.
204.Porea TJ, Belmont JW, Mahoney DH, Jr. Zinc-induced anemia and neutropenia in an adolescent. The Journal of pediatrics. May 2000;136(5):688-690.
205.Qari MH, Aljaouni SK, Alardawi MS, Fatani H, Alsayes FM, Zografos P, . . . Mousa SA. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and haemostasis. Aug 2007;98(2):392-396.
206.Radtke KK, Coles LD, Mishra U, Orchard PJ, Holmay M, Cloyd JC. Interaction of n-acetylcysteine and cysteine in human plasma. J Pharm Sci. Dec 2012;101(12):4653-4659.
207.Raja JV, Rachchh MA, Gokani RH. Recent advances in gene therapy for thalassemia. J Pharm Bioallied Sci. Jul 2012;4(3):194-201.
208.Raje D, Mukhtar H, Oshowo A, Ingham Clark C. What proportion of patients referred to secondary care with iron deficiency anemia have colon cancer? Diseases of the colon and rectum. Aug 2007;50(8):1211-1214.
209.Rakel RE, Rakel DP. Rakel: Textbook of Family Medicine, 8th ed. Copyright © 2011 Saunders, An Imprint of Elsevier Available at: http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4377-1160-8..C2009-0-50309-1&isbn=978-1-4377-1160-8&uniqId=399886461-3#4-u1.0-B978-1-4377-1160-8..C2009-0-50309-1--TOP Accessed: 2/4/2013.
210.receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative
211.Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev. 2012;10:CD007913.
212.Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, . . . George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. Mar 12 2009;113(11):2386-2393.
213.Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol. Sep 2010;53(3):455-459.
214.Rubin KM, Vona K, Madden K, McGettigan S, Braun IM. Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective. Support Care Cancer. Aug 2012;20(8):1601-1611.
215.Rund D, Rachmilewitz E. Beta-thalassemia. The New England journal of medicine. Sep 15 2005;353(11):1135-1146.
216.Ruz M, Carrasco F, Rojas P, et al. Heme- and nonheme-iron absorption and iron status 12 mo after sleeve gastrectomy and Roux-en-Y gastric bypass in morbidly obese women. Am J Clin Nutr. Oct 2012;96(4):810-817.
217.Sagias FG, Mitry RR, Hughes RD, et al. N-acetylcysteine improves the viability of human hepatocytes isolated from severely steatotic donor liver tissue. Cell Transplant. 2010;19(11):1487-1492.
218.Salzman MB, Smith EM, Koo C. Excessive oral zinc supplementation. J Pediatr Hematol Oncol. Oct 2002;24(7):582-584.
219.Salzman MB, Smith EM, Koo C. Excessive oral zinc supplementation. Journal of pediatric hematology/oncology. Oct 2002;24(7):582-584.
220.Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. Apr 29 2010;115(17):3616-3624.
221.Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. May 2012;142(6):1360-1368 e1361.
222.Scharf RE. Drugs that Affect Platelet Function. Semin Thromb Hemost. Oct 30 2012.
223.Seldrum S, Pierard S, Moniotte S, Vermeylen C, Vancraeynest D, Pasquet A, . . . Gerber BL. Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance. 2011;13:23.
224.Shander A, Berth U, Betta J, Javidroozi M. Iron overload and toxicity: implications for anesthesiologists. Journal of clinical anesthesia. Aug 2012;24(5):419-425.
225.Sharma DC, Mathur R. Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid. Indian J Physiol Pharmacol. Oct 1995;39(4):403-406.
226.Sharma V, Randhawa H, Sharma A, Aggarwal S. Eltrombopag--an oral thrombopoietin agonist. Eur Rev Med Pharmacol Sci. Jun 2012;16(6):743-746.
227.Shaughnessy DT, Gangarosa LM, Schliebe B, Umbach DM, Xu Z, MacIntosh B, . . . Taylor JA. Inhibition of fried meat-induced colorectal DNA damage and altered systemic genotoxicity in humans by crucifera, chlorophyllin, and yogurt. PloS one. 2011;6(4):e18707.
228.Siddique A, Kowdley KV. Review article: the iron overload syndromes. Alimentary pharmacology & therapeutics. Apr 2012;35(8):876-893.
229.Sim JJ, Lac PT, Liu IL, et al. Vitamin D deficiency and anemia: a cross-sectional study. Ann Hematol. May 2010;89(5):447-452.
230.Sirdah MM, El-Agouza IM, Abu Shahla AN. Possible ameliorative effect of taurine in the treatment of iron-deficiency anaemia in female university students of Gaza, Palestine. Eur J Haematol. Oct 2002;69(4):236-242.
231.Smith AD, Refsum H. Do we need to reconsider the desirable blood level of vitamin B12? J Intern Med. Feb 2012;271(2):179-182.
232.Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. Nov 4 2010;116(18):3627-3634.
233.Spierings EL, Fujii H, Sun B, Walshe T. A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. Journal of nutritional science and vitaminology. Dec 2007;53(6):536-539.
234.Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. Apr 2 2003;289(13):1645-1651.
235.Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. Jun 2010;85(6):403-408.
236.stress. Saudi J Kidney Dis Transpl. Sep 2010;21(5):852-858.
237.Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. Apr 2012;87(4):392-400.
238.Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. American journal of hematology. Apr 2012;87(4):392-400.
239.Sutipornpalangkul W, Morales NP, Unchern S, et al .Vitamin E supplement improves erythrocyte membrane fluidity of thalassemia: an ESR spin labeling study. J Med Assoc Thai. 2012 Jan;95(1):29-36.
240.Sutipornpalangkul W, Morales NP, Unchern S, Sanvarinda Y, Chantharaksri U, Fucharoen S. Vitamin E supplement improves erythrocyte membrane fluidity of thalassemia: an ESR spin labeling study. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. Jan 2012;95(1):29-36.
</p>


<!-- Resumen de Leucemia -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #d32f2f; padding-bottom: 10px;">
    <i class="fa fa-leukemia" style="margin-right: 10px; color: #d32f2f;"></i> Leukemia
</h2>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #d32f2f; padding-bottom: 10px;">
    Leukemia is a type of blood cell cancer associated with the bone marrow making too many abnormal blood cells, which then build up in the blood and cause problems. It must be understood that the different types of leukemia are treated differently and not with a tailored suit as was the case a few years ago. New therapies are currently being implemented that, together with adjuvants, developed by us, can improve the effectiveness of treatments against leukemia.
</p>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #d32f2f; padding-bottom: 10px;">
    The indication of the specific treatment protocol for leukemias depends on the type of leukemia and the degree of progress or the aggressiveness of the disease. The first line of treatment is selected depending on the results of clinical trials in patients with the same type and stage of leukemia. There is currently a long list of drugs available and approved by the FDA for use in combinations according to the particularities of each patient. Protocols for patients with acute leukemia typically start chemotherapy immediately after diagnosis. Protocols based on tyrosine kinase inhibitors can also be applied, bone marrow transplantation, monoclonal antibody-based therapy, and interferon therapy are additional types of treatment for specific leukemias. New and emerging strategies based on T cells from patients themselves modified to attack and kill leukemia cells, among others, have recently been applied.
</p>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #d32f2f; padding-bottom: 10px;">
    To improve the pharmacological actions of the drugs used in the prevention, control, and treatment of Leukemia and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term that usually contribute to the development of alterations, syndromes, and deadly diseases, such as cancer, and can also reduce the quality life expectancy of people under treatment; the scientists and doctors of "PPG NUTRICIONAL...
</p>

<!-- Sección de Referencias -->
<h3 style="font-size: 20px; color: #333; margin-top: 30px; border-top: 2px solid #d32f2f; padding-top: 10px;">
    References
</h3>
<p style="margin-bottom: 20px; text-align: justify;">
1.ACS. Ameican Cancer Society. How is acute lymphocytic leukemia classified? Available at: http://www.cancer.org/cancer/leukemia-acutelymphocyticallinadults/detailedguide/leukemia-acute-lymphocytic-classified. Last updated 2/7/2014f. Accessed 7/21/2014.
2.ACS. American Cancer Society online. How is chronic lymphocytic leukemia staged? Available at: http://www.cancer.org/cancer/leukemia-chroniclymphocyticcll/detailedguide/leukemia-chronic-lymphocytic-staging. Last updated 4/18/2014a. Accessed 7/21/2014.
3.ACS. American Cancer Society online. How is chronic lymphocytic leukemia diagnosed? Available at: http://www.cancer.org/cancer/leukemia-chroniclymphocyticcll/detailedguide/leukemia-chronic-lymphocytic-diagnosis. Last updated 4/18/2014c. Accessed 7/21/2014.
4.ACS. American Cancer Society online. How is chronic myeloid leukemia classified? Available at: http://www.cancer.org/cancer/leukemia-chronicmyeloidcml/detailedguide/leukemia-chronic-myeloid-myelogenous-staging. Last updated 2/10/2014d. Accessed 7/21/2014.
5.ACS. American Cancer Society online. Surgery for chronic myeloid leukemia. Available at: http://www.cancer.org/cancer/leukemia-chronicmyeloidcml/detailedguide/leukemia-chronic-myeloid-myelogenous-treating-surgery. Last updated 2/10/2014b. Accessed 7/21/2014.
6.ACS. American Cancer Society online. Types of stem cell transplants for treating cancer. Available at: http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/bonemarrowandperipheralbloodstemcelltransplant/stem-cell-transplant-types-of-transplant. Last updated 10/2/2013c. Accessed 7/21/2014.
7.ACS. American Cancer Society. Benzene. Available at: http://www.cancer.org/cancer/cancercauses/othercarcinogens/intheworkplace/benzene. Last updated 12/9/2013b. Accessed 8/18/2014.
8.ACS. American Cancer Society. Find Support and Treatment page. Staging. Available at: http://www.cancer.org/treatment/understandingyourdiagnosis/staging. Last updated 6/7/2012. Accessed 7/21/2014.
9.ACS. American Cancer Society. How is acute myeloid leukemia classified? Available at: http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-classified. Last updated 2/7/2014e. Accessed 7/21/2014.
10.ACS. American Cancer Society. Leukemia-Acute Lymphocytic Overview. Survival rates for acute lymphocytic leukemia. http://www.cancer.org/cancer/leukemia-acutelymphocyticallinadults/overviewguide/leukemia-all-overview-survival-rates. Last updated 6/25/2013d. Accessed 8/19/2014.
11.ACS. American Cancer Society. Targeted Therapies for Chronic Myeloid Leukemia. Available at http://www.cancer.org/cancer/leukemia-chronicmyeloidcml/detailedguide/leukemia-chronic-myeloid-myelogenous-treating-targeted-therapies. Last updated 9/23/2013e. Accessed 08/09/2014.
12.ACS. American Cancer Society. What Are The Risk Factors For Acute Myelogenous Leukemia (AML): Certain Blood Disorders. Available at: http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-risk-factors. Last updated 7/24/2013a. Accessed 8/19/2014.
13.ACS. American Cancer Society. What are the key statistics about myelodysplastic syndromes? Available at: http://www.cancer.org/cancer/myelodysplasticsyndrome/detailedguide/myelodysplastic-syndromes-key-statistics. Last updated 2/10/2014g. Accessed 9/5/2014.
14.Advani AMS, Coutre S, et al. Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/Cytarabine/Epratuzumab for Relapsed/Refractory Acute Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 2012, 120:2603.
15.Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005 Sep;4(9):1201-15.
16.Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003 Jan-Feb;23(1A):363-98.
17.Agis H, Sperr WR, Herndlhofer S, Semper H, Pirc-Danoewinata H, Haas OA, . . . Valent P. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. Nov 2007;18(11):1834-1841.
18.Ahmad A, Ahmad R. Resveratrol mitigate structural changes and hepatic stellate cell activation in N'-nitrosodimethylamine-induced liver fibrosis via restraining oxidative damage. Chemico-biological interactions. Jul 24 2014;221c:1-12.
19.Ahmed N, Laverick L, et al. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells. Anticancer Res. 2001 Sep-Oct;21(5):3519-23.
20.Alaikov T, Konstantinov SM, et al. Antineoplastic and anticlastogenic properties of curcumin. Ann N Y Acad Sci. 2007 Jan;1095:355-70.
21.Aldoss I, Mark L, Vrona J, Ramezani L, Weitz I, Mohrbacher AM, Douer D. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia. Annals of hematology. Jun 7 2014.
22.Altucci L, Rossin A, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med. 2001 Jun;7(6):680-6.
23.Anand P, Sundaram C, et al. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008 Aug 18;267(1):133-64.
24.Anderson KM, Seed T, et al. Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leuk Res. 1995 Nov;19(11):789-801.
25.Anderson KM, Seed T, Jajeh A, Dudeja P, Byun T, Meng J, . . . Harris JE. An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. Anticancer research. Sep-Oct 1996;16(5a):2589-2599.
26.Angelo LS, Kurzrock R. Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia. Clin Cancer Res. 2009 Feb 15;15(4):1123-5.
27.ARSPI. The Alliance for Radiation Safety in Pediatric Imaging. Campaign Overview. Available at: http://www.imagegently.org/FAQsMore/CampaignOverview.aspx. Accessed 08/08/2014. http://www.imagegently.org/FAQsMore/CampaignOverview.aspx.
28.ASCO. American Society of Clinical Oncology. Navigating Cancer Care page. What is Stem Cell/Bone Marrow Transplantation? Available at: http://www.cancer.net/navigating-cancer-care/how-cancer-treated/bone-marrowstem-cell-transplantation/what-stem-cellbone-marrow-transplantation. Accessed 08/12/2014.
29.ASH. American Society of Hematology. 51st ASH Annual Meeting and Exposition. Online Program and Abstracts. 790 Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia Available at: https://ash.confex.com/ash/2009/webprogram/Paper22999.html. Paper presented at: 51st ASH Annual Meeting and Exposition. 2009; New Orleans, LA. Accessed 08/09/2014.
30.Baccarani M, Castagnetti F, et al. Treatment Recommendations for Chronic Myeloid Leukemia. Mediterr J Hematol Infect Dis. 2014 Jan 2;6(1):e2014005.
31.Baccarani M, Cortes J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10;27(35):6041-51.
32.Bailey HD, Miller M, Langridge A, de Klerk NH, van Bockxmeer FM, Attia J, . . . Milne E. Maternal dietary intake of folate and vitamins B6 and B12 during pregnancy and the risk of childhood acute lymphoblastic leukemia. Nutrition and cancer. 2012;64(7):1122-1130.
33.Balasubramanian S, Eckert RL. Keratinocyte proliferation, differentiation, and apoptosis--differential mechanisms of regulation by curcumin, EGCG and apigenin. Toxicol Appl Pharmacol. 2007 Nov 1;224(3):214-9.
34.Bansal S, Prabhash K, Parikh P. Chronic myeloid leukemia data from India. Indian journal of medical and paediatric oncology: official journal of Indian Society of Medical & Paediatric Oncology. Jul 2013;34(3):154-158.
35.Bartley K, Metayer C, Selvin S, Ducore J, Buffler P. Diagnostic X-rays and risk of childhood leukaemia. International journal of epidemiology. Dec 2010;39(6):1628-1637.
36.Baumann Kreuziger LM, Tarchand G, Morrison VA. The impact of Agent Orange exposure on presentation and prognosis of patients with chronic lymphocytic leukemia. Leukemia & lymphoma. Jan 2014;55(1):63-66.
37.Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. Apr 15 1994;83(8):2038-2044.
38.Begum M, Jahan S, Tawfique M, Mannan MA. Out come of induction of remission in undernourished children with acute lymphoblastic leukaemia. Mymensingh medical journal: MMJ. Oct 2012;21(4):691-695.
39.Beltran B, Salas R, Quinones P, Morales D, Hurtado F, Cotrina E, . . . Castillo J. EBV-positive diffuse large B-cell lymphoma in a human T-lymphotropic virus type 1 carrier. Infectious agents and cancer. 2009;4:10.
40.Benabadji SH, Wen R, Zheng JB, Dong XC, Yuan SG. Anticarcinogenic and antioxidant activity of diindolylmethane derivatives. Acta pharmacologica Sinica. May 2004;25(5):666-671.
41.Bleakley M, Heimfeld S, Loeb KR, et al. Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts. The Journal of Clinical Investigation. 07/01/ 2015;125(7):2677-2689. doi:10.1172/JCI81229
42.Bleakley M, Sehgal A, Seropian S, et al. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. J Clin Oncol. Jan 10 2022:Jco2101755. doi:10.1200/jco.21.01755
43.Borriello A, Bencivenga D, Caldarelli I, et al. Resveratrol: from basic studies to bedside. Cancer Treat Res. 2014;159:167-84.
44.Breccia M, Alimena G. Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs. Mediterr J Hematol Infect Dis. 2014 Jan 2;6(1):e2014003.
45.Breccia M, Cicconi L, Lo-Coco F. ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia? Current opinion in hematology. Mar 2014;21(2):95-101.
46.Brownson RC, Novotny TE, Perry MC. Cigarette smoking and adult leukemia. A meta-analysis. Arch Intern Med. 1993 Feb 22;153(4):469-75.
47.Brugnone F, Perbellini L, Romeo L, Cerpelloni M, Cecco A, Leopard Barra E, . . . Ferracin A. [Environmental exposure and blood levels of benzene in gas station attendants. Comparison with the general population]. La Medicina del lavoro. Mar-Apr 1997;88(2):131-147.
48.Bryan M, Pulte ED, Toomey KC, Pliner L, Pavlick AC, Saunders T, Wieder R. A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer. Investigational new drugs. Dec 2011;29(6):1482-1487.
49.Budhraja A, Gao N, et al. Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther. 2012 Jan;11(1):132-42.
50.Bunce CM, Brown G, et al. Vitamin D and hematopoiesis. Trends Endocrinol Metab. 1997 Aug;8(6):245-51.
51.Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Advanced drug delivery reviews. Oct 30 2010;62(13):1285-1298.
52.Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Current opinion in pharmacology. Oct 2012;12(5):615-622.
53.Calviello G, Serini S, et al. Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer. 2009;61(3):287-301.
54.Can G, Cakir Z, et al. Apoptotic effects of resveratrol, a grape polyphenol, on imatinib-sensitive and resistant K562 chronic myeloid leukemia cells. Anticancer Res. 2012 Jul;32(7):2673-8.
55.Cao LZ, Lin ZB. Regulation on maturation and function of dendritic cells by Ganoderma lucidum polysaccharides. Immunol Lett. 2002 Oct 1;83(3):163-9.
56.Cardeno A, Sanchez-Hidalgo M, Cortes-Delgado A, Alarcon de la Lastra C. Mechanisms involved in the antiproliferative and proapoptotic effects of unsaponifiable fraction of extra virgin olive oil on HT-29 cancer cells. Nutrition and cancer. 2013;65(6):908-918.
57.Casaburi I, Puoci F, Chimento A, Sirianni R, Ruggiero C, Avena P, Pezzi V. Potential of olive oil phenols as chemopreventive and therapeutic agents against cancer: a review of in vitro studies. Molecular nutrition & food research. Jan 2013;57(1):71-83.
58.Cavallo J. Incidence of Chronic Graft-vs-Host Disease: Effect of Depleting Naive T Cells From Peripheral Blood Stem Cell Allografts in Patients with Leukemia. HSP News Service, L.L.C. Updated 1/11/2022. Accessed 1/13/2022, https://ascopost.com/news/january-2022/incidence-of-chronic-graft-vs-host-disease-effect-of-depleting-naive-t-cells-from-peripheral-blood-stem-cell-allografts-in-patients-with-leukemia/
59.CCS. Canadian Cancer Society. Cancer Information page. Side Effects of Chemotherapy. Available at http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/chemotherapy/side-effects-of-chemotherapy/. Copyright © 2014. Accessed 08/08/2014.
60.Chan WK, Lam DT, Law HK, et al. Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy. J Altern Complement Med. 2005 Dec;11(6):1047-57.
61.Chang JS, Selvin S, et al. Parental smoking and the risk of childhood leukemia. Am J Epidemiol. 2006 Jun 15;163(12):1091-100.
62.Checkoway H, Boffetta P, Mundt DJ, Mundt KA. Critical review and synthesis of the epidemiologic evidence on formaldehyde exposure and risk of leukemia and other lymphohematopoietic malignancies. Cancer causes & control: CCC. Nov 2012;23(11):1747-1766.
63.Chen H, Tuck T, Ji X, Zhou X, Kelly G, Cuerrier A, Zhang J. Quality assessment of Japanese knotweed (Fallopia japonica) grown on Prince Edward Island as a source of resveratrol. Journal of agricultural and food chemistry. Jul 3 2013;61(26):6383-6392.
64.Chen L, Wang J, Hu X, Xu X. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Hematology (Amsterdam, Netherlands). Jun 2014;19(4):202-207.
65.Chen Y, Hu Y, Michaels S, et al. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia. 2009 Aug;23(8):1446-54.
66.Chen Y, Hu Y, Zhang H, et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009 Jul;41(7):783-92.
67.Chen Y, Peng C, et al. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anticancer Agents Med Chem. 2010 Feb;10(2):111-5.
68.Cho WC, Leung KN. In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharmacol. 2007a Aug 15;113(1):132-41.
69.Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett. 2007b Jul 8;252(1):43-54.
70.Choi WY, Choi BT, et al. Sulforaphane generates reactive oxygen species leading to mitochondrial perturbation for apoptosis in human leukemia U937 cells. Biomed Pharmacother. 2008 Nov;62(9):637-44.
71.CIRM. California Institute for Regenerative Medicine. Stem cell differentiation and the Cancer Stem Cell Hypothesis. Available at: http://www.cirm.ca.gov/our-progress/advanced-stem-cell-differentiation-and-cancer-stem-cell-hypothesis. Copyright © 2013. Accessed 9/23/2014.
72.Clavel J, Sermage-Faure C, Demoury C, Rudant J, Goujon-Bellec S, Guyot-Goubin A, . . . Hemon D. Reply: comment on 'Childhood leukaemia close to high-voltage power lines--the Geocap study, 2002-2007'--is proximity an appropriate MF exposure surrogate? British journal of cancer. Sep 3 2013;109(5):1383-1384.
73.Cleveland Clinic. Health Information page. Diseases & Conditions. Myelodysplastic Syndrome Overview. Available at: http://my.clevelandclinic.org/disorders/myelodysplastic/bm_overview.aspx. Accessed 5/15/2014.
74.Connell PP, Weichselbaum RR. Small molecule derived from a natural product that mitigates radiation injury. Proceedings of the National Academy of Sciences of the United States of America. Nov 12 2013;110(46):18355-18356.
75.Contractor R, Samudio IJ, Estrov Z, Harris D, McCubrey JA, Safe SH, . . . Konopleva M. A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer research. Apr 1 2005;65(7):2890-2898.
76.Cortes JE, Kim DW, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 7;369(19):1783-96.
77.Cowan AJ, Laszlo GS, Estey EH, et al. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed). 2013;18:1311-1334.
78.Cragg GM, Newman DJ, et al. Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J Nat Prod. 2006 Mar;69(3):488-98.
79.Crews LA, Jamieson CH. Selective elimination of leukemia stem cells: hitting a moving target. Cancer letters. Sep 10 2013;338(1):15-22.
80.Cripe LD. Adult acute leukemia. Current problems in cancer. Jan-Feb 1997;21(1):1-64.
81.Cyopick P, Culliton R, Brockhausen I, Sutherland DR, Mills GB, Baker M. Role of aberrant sialylation of chronic myeloid leukemia granulocytes on binding and signal transduction by chemotactic peptides and colony stimulating factors. Leukemia & lymphoma. Sep 1993;11(1-2):79-90.
82.Dao KH, Tyner JW. Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies. Clin Cancer Res. 2013 Mar 15;19(6):1309-11.
83.Das PP, Shaik AP, Jamil K. Genotoxicity induced by pesticide mixtures: in-vitro studies on human peripheral blood lymphocytes. Toxicology and industrial health. Sep 2007;23(8):449-458.
84.Davila ML, Riviere I, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25.
85.Davila ML, Kloss CC, Gunset G, Sadelain M. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PloS one. 2013;8(4):e61338.
86.Davoli E, Cappellini L, Moggi M, Ferrari S, Fanelli R. On-line monitoring of benzene air concentrations while driving in traffic by means of isotopic dilution gas chromatography/mass spectrometry. International archives of occupational and environmental health. 1996;68(4):262-267.
87.de Lima TM, Amarante-Mendes GP, Curi R. Docosahexaenoic acid enhances the toxic effect of imatinib on Bcr-Abl expressing HL-60 cells. Toxicol In vitro. 2007; 21:1678-85.
88.De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546.
89.Debnam JM, Schellingerhout D, Kumar AJ, Ketonen L, Shah K, Hamberg LM, Hunter GJ. Multidetector CT-Guided Lumbar Puncture in Patients with Cancer. Interventional neuroradiology: journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences. Mar 31 2009;15(1):61-66.
90.Deininger M, Buchdunger E. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005 Apr 1;105(7):2640-53.
91.Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, . . . Pieters R. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. The lancet oncology. Feb 2009;10(2):125-134.
92.Dennis M, Davies M, et al. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer Chemother Pharmacol. 2012 Sep;70(3):461-9.
93.Di Bella G, Mascia F, et al. Melatonin anticancer effects: review. Int J Mol Sci. 2013 Jan 24;14(2):2410-30.
94.Diaz PR, Neira LC, Fischer SG, Teresa Torres MC, Milinarsky AT, Giadrosich VR, . . . Casanova DM. Effect of 1,25(OH)2-vitamin D on bone mass in children with acute lymphoblastic leukemia. Journal of pediatric hematology/oncology. Jan 2008;30(1):15-19.
95.Dierks C, Beigi R, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell. 2008 Sep 9;14(3):238-49.
96.Dirsch VM, Antlsperger DS, et al. Ajoene, an experimental anti-leukemic drug: mechanism of cell death. Leukemia. 2002 Jan;16(1):74-83.
97.Doane L. Overview of tumor lysis syndrome. Semin Oncol Nurs. 2002 Aug;18(3 Suppl 3):2-5.
98.Dong J, Gu HL, et al. [Effects of large dose of Astragalus membranaceus on the dendritic cell induction of peripheral mononuclear cell and antigen presenting ability of dendritic cells in children with acute leukemia]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005 Oct;25(10):872-5.
99.Dorantes-Acosta E, Medina-Sanson A, et al. Clinical features and treatment outcomes of pediatric acute promyelocytic leukemia in a Mexican pediatric hospital. Rev Invest Clin. 2013 Sep-Oct;65(5):392-8.
100.Dörrie J, Gerauer H, et al. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 2001 Jun 15;61(12):4731-9.
101.Dotti G, Garattini E, et al. Leucocyte alkaline phosphatase identifies terminally differentiated normal neutrophils and its lack in chronic myeloid leukaemia is not dependent on p210 tyrosine kinase activity. Br J Haematol. 1999 Apr;105(1):163-72.
102.Doudican NA, Bowling B, Orlow SJ. Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism. Leuk Res. 2010 Feb;34(2):229-34.
103.Druker BJ, Guilhot F,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408-17.
104.Druker BJ, Talpaz M, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 5;344(14):1031-7.
105.Druker BJ, Tamura S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996 May;2(5):561-6.
106.Duvoix A, Blasius R, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005 Jun 8;223(2):181-90.
107.Duvoix A, Morceau F, et al. Curcumin-induced cell death in two leukemia cell lines: K562 and Jurkat. Ann N Y Acad Sci. 2003 Dec;1010:389-92.
108.Elia M, Van Bokhorst-de van der Schueren MA, et al. Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol.2006;28:5-23.
109.El-Sokkary GH, Reiter RJ. et al. Melatonin supplementation restores cellular proliferation and DNA synthesis in the splenic and thymic lymphocytes of old rats. Neuro Endocrinol Lett. 2003 Jun;24(3-4):215-23.
110.Escrich E, Solanas M, Moral R. Olive oil and other dietary lipids in breast cancer. Cancer treatment and research. 2014;159:289-309.
111.Estey E. High cytogenetic or molecular genetic risk acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:474-80.
112.Estrov Z, Shishodia S, et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003 Aug 1;102(3):987-95.
113.Ezzone SA. Tumor lysis syndrome. Semin Oncol Nurs. 1999 Aug;15(3):202-8.
114.Fabiani R, De Bartolomeo A, et al. Cancer chemoprevention by hydroxytyrosol isolated from virgin olive oil through G1 cell cycle arrest and apoptosis. Eur J Cancer Prev. 2002 Aug;11(4):351-8.
115.Fabiani R, De Bartolomeo A, et al. Virgin olive oil phenols inhibit proliferation of human promyelocytic leukemia cells (HL60) by inducing apoptosis and differentiation. J Nutr. 2006 Mar;136(3):614-9.
116.Fabiani R, Rosignoli P, et al. Oxidative DNA damage is prevented by extracts of olive oil, hydroxytyrosol, and other olive phenolic compounds in human blood mononuclear cells and HL60 cells. J Nutr. 2008 Aug;138(8):1411-6.
117.Fahrmann JF, Ballester OF, Ballester G, Witte TR, Salazar AJ, Kordusky B, . . . Hardman WE. Inhibition of nuclear factor kappa B activation in early-stage chronic lymphocytic leukemia by omega-3 fatty acids. Cancer investigation. Jan 2013;31(1):24-38.
118.Fan S, Meng Q, Xu J, Jiao Y, Zhao L, Zhang X, . . . Rosen EM. DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism. Proceedings of the National Academy of Sciences of the United States of America. Nov 12 2013;110(46):18650-18655.
119.Fei F, Lim M, Schmidhuber S, Moll J, Groffen J, Heisterkamp N. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib). Molecular cancer. 2012;11:42.
120.Fellner C. Vismodegib (erivedge) for advanced Basal cell carcinoma. P T. 2012 Dec;37(12):670-82.
121.Ferreira JD, Couto AC, Pombo-de-Oliveira MS, Koifman S. In utero pesticide exposure and leukemia in Brazilian children < 2 years of age. Environmental health perspectives. Feb 2013;121(2):269-275.
122.Ferri FF. Ferri's Clinical Advisor. Leukamia, Acute Myelogenous. Available at: www.clinicalkey.com. Copyright © 2014. Accessed 4/17/2014.
123.Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. Nov 4 2010;116(18):3409-3417.
124.Fimognari C, Lenzi M, et al. Induction of differentiation in human promyelocytic cells by the isothiocyanate sulforaphane. In Vivo. 2008 May-Jun;22(3):317-20.
125.Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol. 2000 Jun;27(3):322-34.
126.Foran J, Ravandi F, et al. Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014;14(3):223-30.
127.Foroni L, Gerrard G, et al. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. Am J Hematol. 2009 Aug;84(8):517-22.
128.Fresco P, Borges F, et al. The anticancer properties of dietary polyphenols and its relation with apoptosis. Curr Pharm Des. 2010 Jan;16(1):114-34.
129.Fukuzawa M, Yamaguchi R, et al. Possible involvement of long chain fatty acids in the spores of Ganoderma lucidum (Reishi Houshi) to its anti-tumor activity. Biol Pharm Bull. 2008 Oct;31(10):1933-7.
130.Gajjar A, Harrison PL, Sandlund JT, Rivera GK, Ribeiro RC, Rubnitz JE, . . . Pui CH. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood. Nov 15 2000;96(10):3381-3384.
131.Gao P, Hirano T, et al. Isolation and identification of C-19 fatty acids with anti-tumor activity from the spores of Ganoderma lucidum (reishi mushroom). Fitoterapia. 2012 Apr;83(3):490-9.
132.Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003 Aug;32(3):201-15.
133.Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014 Jan;89(1):97-108.
134.Gautam SC, Xu YX, et al. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant. 2000;25:639-645.
135.Gentry PR, Rodricks JV, Turnbull D, Bachand A, Van Landingham C, Shipp AM, . . . Irons R. Formaldehyde exposure and leukemia: critical review and reevaluation of the results from a study that is the focus for evidence of biological plausibility. Critical reviews in toxicology. Sep 2013;43(8):661-670.
136.Ghalaut VS, Sangwan L, et al. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. J Oncol Pharm Pract. 2012 Jun;18(2):186-90.
137.Ghosh AK, Kay NE, et al. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res. 2009 Feb 15;15(4):1250-8.
138.Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002 Sep 1;100(5):1532-42.
139.Gobel BH. Management of tumor lysis syndrome: prevention and treatment. Semin Oncol Nurs. 2002 Aug;18(3 Suppl 3):12-6.
140.Gocek E, Baurska H, Marchwicka a, et al. Regulation of Leukemic Cell Differentiation through the Vitamin D Receptor at the Levels of Intracellular Signal Transduction, Gene Transcription, and Protein Trafficking and Stability. Leukemia Research and Treatment. 2012:1-11.
141.Gogos CA, Ginopoulos P, et al. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer. 1998 Jan 15;82(2):395-402.
142.Gokbulut AA, Apohan E, Baran Y. Resveratrol and quercetin-induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology (Amsterdam, Netherlands). May 2013;18(3):144-150.
143.Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Oncogene. 2014 Mar 17.
144.Goldman JM, Melo JV. BCR-ABL in chronic myelogenous leukemia--how does it work? Acta haematologica. 2008;119(4):212-217.
145.Goldman L, Schafer AI. The Acute Leukemias. In: Goldman's Cecil Medicine, Twenty-Fourth Edition. Available at: www.clinicalkey.com. Copyright © 2012a. Accessed 4/21/2014.
146.Goldman L, Schafer AI. The Chronic Leukemias. In: Goldman's Cecil Medicine, Twenty-Fourth Edition. Available at: www.clinicalkey.com. Copyright © 2012b. Accessed 4/21/2014.
147.Gonçalves AC, Alves V, et al. Oxidative stress mediates apoptotic effects of ascorbate and dehydroascorbate in human Myelodysplasia cells in vitro. Toxicol In Vitro. 2013 Aug;27(5):1542-9.
148.Gonzalez-Mejia ME, Voss OH, Murnan EJ, et al. Apigenin-induced apoptosis of leukemia cells is mediated by a biomodal and differentially regulated residue-specific phosphorylation of heat-shock protein-27. Cell Death Dis. 2010;1(8):e64.
149.Gordois A, Scuffham P, et al. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer. 2003 Aug 18;89(4):634-40.
150.Gradishar WJ, Schilsky RL. Effects of cancer treatment on the reproductive system. Critical reviews in oncology/hematology. 1988;8(2):153-171.
151.Granzotto M, Rapozzi V. et al. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal Res. 2001 Oct;31(3):206-13.
152.Grupp SA, Kalos M, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509-18.
153.Gruschkus SK, Lairson D, et al. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma. Cancer. 2010 Nov 15;116(22):5279-89.
154.Gudas LJ, Wagner JA. Retinoids regulate stem cell differentiation. Journal of cellular physiology. Feb 2011;226(2):322-330.
155.Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, Arlinghaus RB. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. American journal of clinical pathology. Oct 1996;106(4):442-448.
156.Gupta SC, Kannappan R, et al. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci. 2011 Jan;1215:150-60.
157.Haimov I, Lavie P. Melatonin - a chronobiotic and soporific hormone. Arch Gerontol Geriatr. 1997 Mar;24(2):167-73.
158.Hall AC, Juckett MB. The role of vitamin d in hematologic disease and stem cell transplantation. Nutrients. 2013 Jun 18;5(6):2206-21.
159.Han DH, Jeong JH, Kim JH. Anti-proliferative and apoptosis induction activity of green tea polyphenols on human promyelocytic leukemia HL-60 cells. Anticancer Res. 2009 Apr;29(4):1417-21.
160.Harakeh S, Diab-Assaf M, Khalife JC, Abu-el-Ardat KA, Baydoun E, Niedzwiecki A, . . . Rath M. Ascorbic acid induces apoptosis in adult T-cell leukemia. Anticancer research. Jan-Feb 2007;27(1a):289-298.
161.Hartsink-Segers SA, Zwaan CM, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia. 2013 Mar;27(3):560-8.
162.Hassan HT. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy. Leuk Res. 2004 Jul;28(7):667-71.
163.Hayes RB, Songnian Y, et al. Benzene and lymphohematopoietic malignancies in humans. Am J Ind Med. 2001 Aug;40(2):117-26.
164.Hayun R, Okun E, et al. Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. Leuk Lymphoma. 2009 Apr;50(4):625-32.
165.Helms S. Cancer prevention and therapeutics: Panax ginseng. Alternative medicine review : a journal of clinical therapeutic. Sep 2004;9(3):259-274.
166.Herlofson BB, Norman-Pedersen K, Redfors M, Fossa SD. Oral mucosal side effects of cytotoxic chemotherapy of testicular cancer. A retrospective study. European journal of oral sciences. Oct 1997;105(5 Pt 2):523-526.
167.Hochhaus A, Kantarjian H. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol. 2013 Dec;139(12):1971-84.
168.Hoelzer DHA, Kaul F. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. Blood (ASH Annual Meeting Abstracts) 2010, 116:170.
169.Hoffmann-La Roche. A PHASE 1B/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS). Available at: http://clinicaltrials.gov/show/NCT01880437. 2014. NLM Identifier: NCT01880437.
170.Hsieh TC, Wu JM. Regulation of cell cycle transition and induction of apoptosis in HL-60 leukemia cells by the combination of Coriolus versicolor and Ganoderma lucidum. International journal of molecular medicine. Jul 2013;32(1):251-257.
171.Hsu JW, Huang HC, Chen ST, Wong CH, Juan HF. Ganoderma lucidum Polysaccharides Induce Macrophage-Like Differentiation in Human Leukemia THP-1 Cells via Caspase and p53 Activation. Evidence-based complementary and alternative medicine: eCAM. 2011;2011:358717.
172.Hsu WL, Preston DL, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res. 2013 Mar;179(3):361-82.
173.Hu J, Liu YF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7.
174.Huang H, Jia Q, Ma J, Qin G, Chen Y, Xi Y, . . . Liu H. Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase inhibitors. European journal of medicinal chemistry. May 2009;44(5):1982-1988.
175.Huang LH, Yan QJ, et al. Astragalus membranaceus lectin (AML) induces caspase-dependent apoptosis in human leukemia cells. Cell Prolif. 2012 Feb;45(1):15-21.
176.Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer. 2010;62(1):1-20.
177.Huang YT, Hwang JJ, Lee PP, Ke FC, Huang JH, Huang CJ, . . . Lee MT. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. British journal of pharmacology. Nov 1999;128(5):999-1010.
178.Hughes PJ, Marcinkowska E, et al. Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy. Leuk Res. 2010 May;34(5):553-65.
179.Huh HJ, Lee SH, et al. Therapy-related myeloid neoplasms in 39 Korean patients: a single institution experience. Ann Lab Med. 2013 Mar;33(2):97-104.
180.Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, . . . Carroll WL. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. May 10 2012;30(14):1663-1669.
181.Iqbal Ahmed CM, Johnson HM. Interferon gene therapy for the treatment of cancer and viral infections. Drugs Today (Barc). 2003 Oct;39(10):763-6.
182.Iseki T. [Vitamin B12 and transcobalamin in chronic myeloproliferative disorders]. Rinsho byori. The Japanese journal of clinical pathology. Dec 1993;41(12):1310-1321.
183.Jaglowski SM, Byrd JC. Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S132-8.
184.Jaglowski SM, Byrd JC. Rituximab in chronic lymphocytic leukemia. Seminars in hematology. Apr 2010;47(2):156-169.
185.Jan RH, Lin TY, Hsu YC, et al. Immuno-modulatory activity of Ganoderma lucidum-derived polysacharide on human monocytoid dendritic cells pulsed with Der p 1 allergen. BMC Immunol. 2011;12:31.
186.Janeway CA Jr, Travers P, Walport M, et al. The components of the immune system. In: Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Sciences; 2001.
187.Jayasooriya RG, Kang SH, et al. Apigenin decreases cell viability and telomerase activity in human leukemia cell lines. Food Chem Toxicol. 2012 Aug;50(8):2605-11.
188.Jensen CD, Block G, Buffler P, Ma X, Selvin S, Month S. Maternal dietary risk factors in childhood acute lymphoblastic leukemia (United States). Cancer causes & control: CCC. Aug 2004;15(6):559-570.
189.Jeurink PV, Noguera CL, Savelkoul HF, Wichers HJ. Immunomodulatory capacity of fungal proteins on the cytokine production of human peripheral blood mononuclear cells. Int Immunopharmacol. 2008 Aug;8(8):1124-33.
190.Jho DH, Cole SM, et al. Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integr Cancer Ther. 2004 Jun;3(2):98-111.
191.Ji Z, Tang Q, Zhang J, Yang Y, Liu Y, Pan YJ. Immunomodulation of bone marrow macrophages by GLIS, a proteoglycan fraction from Lingzhi or Reishi medicinal mushroom Ganoderma lucidium (W.Curt.:Fr.) P. Karst. Int J Med Mushrooms. 2011;13(5):441-8.
192.Jia XH, Yin BH, Li JC. [Effect of astragalus injection on U937 leukemia cells proliferation and apoptosis and relevant molecular mechanisms]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. Dec 2013;15(12):1128-1133.
193.Joe AK, Liu H, et al. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res. 2002 Mar;8(3):893-903.
194.Joh D, Park BJ, Lim YJ. Radiation-induced glioblastoma multiforme in a remitted acute lymphocytic leukemia patient. J Korean Neurosurg Soc. 2011 Sep;50(3):235-9.
195.John EM, Savitz DA, Sandler DP. Prenatal exposure to parents' smoking and childhood cancer. Am J Epidemiol. 1991 Jan 15;133(2):123-32.
196.Johnson-Ansah H, Guilhot J, et al. Cancer. Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia. 2013 Dec 15;119(24):4284-9.
197.Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34-55.
198.Jones RR, Yu CL, Nuckols JR, Cerhan JR, Airola M, Ross JA, . . . Ward MH. Farm residence and lymphohematopoietic cancers in the Iowa Womens Health Study. Environmental research. Jul 16 2014;133c:353-361.
199.Joseph S, Sabulal B, et al. Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum. Acta Pharm. 2011 Sep 1;61(3):335-42.
200.Kadan-Lottick NS, Kawashima T, et al. The risk of cancer in twins: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2006 Apr;46(4):476-81.
201.Kamil N, Kamil S, Ahmed SP, Ashraf R, Khurram M, Ali MO. Toxic effects of multiple anticancer drugs on skin. Pakistan journal of pharmaceutical sciences. Jan 2010;23(1):7-14.
202.Kang JH, Song KH, et al. Ginsenoside Rp1 from Panax ginseng exhibits anti-cancer activity by down-regulating of the IGF-1R/Akt pathway in breast cancer cells. Plant Foods Hum Nutr. 2011;66(3):298-305.
203.Kantarjian HM, Keating MJ, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myeloid leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol. 1992 May;10(5):772-8.
204.Kantarjian HM, Martinelli G, et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013 Jul 15;119(14):2611-9.
205.Kaplan HG, Malmgren JA, Atwood MK. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005. BMC cancer. 2011;11:260.
206.Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. The Journal of experimental medicine. Jul 21 2003;198(2):305-313.
207.Kasim K, Levallois P, Abdous B, Auger P, Johnson KC. Lifestyle factors and the risk of adult leukemia in Canada. Cancer causes & control: CCC. Jun 2005;16(5):489-500.
208.Katagiri S, Tauchi T, et al. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. Clin Cancer Res. 2013 Mar 15;19(6):1422-32.
209.Kawada H, Kaneko M, et al. High concentrations of L-ascorbic acid specifically inhibit the growth of human leukemic cells via downregulation of HIF-1α transcription. PLoS One. 2013 Apr 23;8(4):e62717.
210.Kawahara T, Kawaguchi-Ihara N, et al. Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. Anticancer Res. 2009 Nov;29(11):4629-32.
211.Kawasaki ES, Clark SS, et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5698-702.
212.Kelly KR, Shea TC, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20.
213.Kennel KA, Drake MT. Vitamin D in the cancer patient. Current opinion in supportive and palliative care. Sep 2013;7(3):272-277.
214.Kharfan-Dabaja MA, Moukalled N, Reljic T, El-Asmar J, Kumar A. Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis. Hematol Oncol Stem Cell Ther. Jun 2018;11(2):53-64. doi:10.1016/j.hemonc.2017.11.001
215.Khimani F, Dutta M, Faramand R, et al. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. Jul 2021;27(7):620.e1-620.e9. doi:10.1016/j.jtct.2021.03.026
216.Kilani-Jaziri S, Frachet V, et al. Flavones inhibit the proliferation of human tumor cancer cell lines by inducing apoptosis. Drug Chem Toxicol. 2012 Jan;35(1):1-10.
217.Kim HI, Huang H, Cheepala S, Huang S, Chung J. Curcumin inhibition of integrin (alpha6beta4)-dependent breast cancer cell motility and invasion. Cancer prevention research (Philadelphia, Pa.). Oct 2008;1(5):385-391.
218.Kim M, Mirandola L, et al. Review Application of vitamin D and derivatives in hematological malignancies. Cancer Lett. 2012 Jun 1; 319(1):8-22.
219.Kim SH, Cho SS, et al. Enhancement of 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced HL-60 leukemia cell differentiation by Panax ginseng. Biosci Biotechnol Biochem. 2009 May;73(5):1048-53.
220.Kim YS, Farrar W, et al. Cancer stem cells: potential target for bioactive food components. J Nutr Biochem. 2012 Jul;23(7):691-8.
221.Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med. 1990 Dec 20;323(25):1745-8.
222.Knusli C, Walter M. [Update - health risks induced by ionizing radiation from diagnostic imaging]. Therapeutische Umschau. Revue therapeutique. Dec 2013;70(12):746-751.
223.Korte JE, Hertz-Picciotto I, et al. The contribution of benzene to smoking-induced leukemia. Environ Health Perspect. 2000 Apr;108(4):333-9.
224.Kottaridis PD, Gale RE, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001 Sep 15;98(6):1752-9.
225.Kuo YC, Yu CL, et al. A population-based, case-control study of green tea consumption and leukemia risk in southwestern Taiwan. Cancer Causes Control. 2009 Feb;20(1):57-65.
226.Kwan ML, Jensen CD, Block G, Hudes ML, Chu LW, Buffler PA. Maternal diet and risk of childhood acute lymphoblastic leukemia. Public health reports (Washington, D.C. : 1974). Jul-Aug 2009;124(4):503-514.
227.Kweon SH, Song JH, Kim TS. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun. 2010 Apr 23;395(1):104-10.
228.Lai CY, Hung JT, Lin HH, et al. Immunomodulatory and adjuvant activities of a polysaccharide extract of Ganoderma lucidum in vivo and in vitro. Vaccine. 2010 Jul 12;28(31):4945-54.
229.Lancet JE, Gojo I, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010 Apr;24(4):699-705.
230.Lee HJ, Muindi JR, et al. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer. 2014 Feb 15;120(4):521-9.
231.Lee JM, Hah JO, Kim HS. The effect of red ginseng extract on inflammatory cytokines after chemotherapy in children. J Ginseng Res. 2012 Oct;36(4):383-90.
232.Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, . . . Lee MT. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer research. May-Jun 2002;22(3):1615-1627.
233.Lee MK, Hung TM, Cuong TD, Na M, Kim JC, Kim EJ, . . . Min BS. Ergosta-7,22-diene-2beta,3alpha,9alpha-triol from the fruit bodies of Ganoderma lucidum induces apoptosis in human myelocytic HL-60 cells. Phytotherapy research: PTR. Nov 2011;25(11):1579-1585.
234.Lee R, Kim YJ, et al. The selective effect of genistein on the toxicity of bleomycin in normal lymphocytes and HL-60 cells. Toxicology. 2004 Feb 15;195(2-3):87-95.
235.Lee SJ, Ko WG, et al. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem Pharmacol. 2000 Sep 1;60(5):677-85.
236.Lee SK, Zhang W, Sanderson BJ. Selective growth inhibition of human leukemia and human lymphoblastoid cells by resveratrol via cell cycle arrest and apoptosis induction. J Agric Food Chem. 2008 Aug 27;56(16):7572-7.
237.Lee WJ, Chen YR, Tseng TH. Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol Rep. 2011 Feb;25(2):583-91.
238.Lehtinen M, Koskela P, et al. Maternal herpesvirus infections and risk of acute lymphoblastic leukemia in the offspring. Am J Epidemiol. 2003 158(3):207-213.
239.Leone G, Fianchi L, et al. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact. 2010 Mar 19;184(1-2):39-45.
240.Leone G, Pagano L, et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007 Oct;92(10):1389-98.
241.Li K, Jing Y, Yang C, Liu S, Zhao Y, He X, . . . Li G. Increased leukemia-associated gene expression in benzene-exposed workers. Scientific reports. 2014;4:5369.
242.Li N, Li XM, Xu L, Sun WJ, Cheng XG, Tian W. Comparison of QCT and DXA: Osteoporosis Detection Rates in Postmenopausal Women. International journal of endocrinology. 2013;2013:895474.
243.Liersch R, Muller-Tidow C, Berdel WE, Krug U. Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. British journal of haematology. Apr 2014;165(1):17-38.
244.Lin LC, Yeh CT, et al. Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function. J Agric Food Chem. 2012 Jul 18;60(28):7031-9.
245.Lissoni P, Bolis S, et al. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Anticancer Res. 2000 May Jun;20(3B):2103-5.
246.Liu CY, Hsu YH, Wu MT, Pan PC, Ho CK, Su L, . . . Christiani DC. Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study. BMC cancer. 2009;9:15.
247.Liu LM, Zhang LS. [Effect of astragalus polysaccharide on the function and maturation of plasmacytoid dendritic cells from chronic myelogenous leukemia before and after treatment.]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. Nov 2010;31(11):740-743.
248.Liu Y, Bao EN, Zhong WW, Lu XC, Zhu HL. [Efficacy and safety analysis of interferon combined with imatinib in treating chronic myeloid leukemia]. Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology. Mar 2014;22(2):304-309.
249.LLS. Leukemia & Lymphoma Society. Acute Lymphoblastic Leukemia. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/leukemia/pdf/all.pdf. 2/2014a. Accessed 5/13/2014.
250.LLS. Leukemia & Lymphoma Society. Acute Myeloid Leukemia. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/leukemia/pdf/aml.pdf. 12/2011a. Accessed 5/13/2014.
251.LLS. Leukemia & Lymphoma Society. Chronic Lymphocytic Leukemia. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/leukemia/pdf/cll.pdf. 12/2011b. Accessed 5/13/2014.
252.LLS. Leukemia & Lymphoma Society. Chronic Myeloid Leukemia. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/leukemia/pdf/cml.pdf. 5/2012a. Accessed 5/13/2014.
253.LLS. Leukemia & Lymphoma Society. Disease Information & Support page. Leukemia: What Is Leukemia? Available at: http://www.lls.org/#/diseaseinformation/leukemia/. Accessed 8/18/2014b.
254.LLS. Leukemia & Lymphoma Society. Disease Information and Support. Diagnosis: Lab Tests to Confirm a Diagnosis. Available at: http://www.lls.org/diseaseinformation/leukemia/acutemyeloidleukemia/diagnosis/. 2012c. Accessed 8/7/2014.
255.LLS. Leukemia & Lymphoma Society. Understanding Leukemia. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/leukemia/pdf/understandingleukemia.pdf. 8/2012b. Accessed 5/13/2014.
256.LLS. Leukemia and Lymphoma Society. About Childhood ALL. Available at: http://www.lls.org/#/diseaseinformation/leukemia/acutelymphoblasticleukemia/childhoodall/. 2011c. Accessed 08/11/2014.
257.Lobato-Mendizábal E, Ruiz-Argüelles GJ, Marín-López A. Leukaemia and nutrition. I: Malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk acute lymphoblastic leukaemia. Leuk Res. 1989;13(10):899-906.
258.Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, . . . Platzbecker U. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. The New England journal of medicine. Jul 11 2013;369(2):111-121.
259.Löwenberg B, Muus P, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011 Dec 1;118(23):6030-6.
260.Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. Prevention of development of N,N’-dimethylhydrazine-induced colon tumors by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male ICR mice. Int J Mol Med. 2002 Feb;9(2):113-7.
261.Lu H, Uesaka T, Katoh O, Kyo E, Watanabe H. Prevention of the development of preneoplastic lesions, aberrant crypt foci, by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male F344 rats. Oncol Rep. 2001 Nov- Dec;8(6):1341-5.
262.Lu HF, Tung WL, et al. In vitro suppression of growth of murine WEHI-3 leukemia cells and in vivo promotion of phagocytosis in a leukemia mice model by indole-3-carbinol. J Agric Food Chem. 2012 Aug 8;60(31):7634-43.
263.Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nature reviews. Immunology. Apr 2010;10(4):236-247.
264.Ly BT, Chi HT, et al. Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells. PLoS One. 2013 Jun 20;8(6):e66378.
265.Ma X, Park Y, Mayne ST, Wang R, Sinha R, Hollenbeck AR, . . . Cross AJ. Diet, lifestyle, and acute myeloid leukemia in the NIH-AARP cohort. American journal of epidemiology. Feb 1 2010;171(3):312-322.
266.Machijima Y, Ishikawa C, et al. Anti-adult T-cell leukemia/lymphoma effects of indole-3-carbinol. Retrovirology. 2009 Jan 16;6:7.
267.Magana Torres MT, Gonzalez Garcia JR. Comment on 'Childhood leukaemia close to high-voltage power lines--the Geocap study, 2002-2007'--odds ratio and confidence interval. British journal of cancer. Sep 3 2013;109(5):1384-1385.
268.Maslak P. First Consult. Acute myelogenous leukemia. Available at: www.clinicalkey.com. Last updated 9/6/2012. Accessed 4/22/2014.
269.Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, . . . Darby SC. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ (Clinical research ed.). 2013;346:f2360.
270.Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld JL, Deeg HJ. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. International journal of radiation oncology, biology, physics. Mar 30 1995;31(5):1319-1339.
271.Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. The oncologist. 2001;6(3):233-238.
272.Medeiros BC, Othus M, et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010 Sep 30;116(13):2224-8.
273.Meijerink JP, den Boer ML, Pieters R. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Seminars in hematology. Jan 2009;46(1):16-23.
274.Memorial Sloan Kettering Cancer Center. Allogenic Transplantation. Overview. Accessed 1/13/2022, https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/blood-stem-cell-transplantation/allogeneic
275.Miglioretti DL, Johnson E, Williams A, Greenlee RT, Weinmann S, Solberg LI, . . . Smith-Bindman R. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA pediatrics. Aug 1 2013;167(8):700-707.
276.Miron T, Wilchek M, et al. Allicin inhibits cell growth and induces apoptosis through the mitochondrial pathway in HL60 and U937 cells. J Nutr Biochem. 2008 Aug; 19(8):524-35.
277.Monasterio A, Urdaci MC, et al. Flavonoids induce apoptosis in human leukemia U937 cells through caspase- and caspase-calpain-dependent pathways. Nutr Cancer. 2004;50(1):90-100.
278.Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, . . . Curtis RE. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood. Apr 11 2013;121(15):2996-3004.
279.Mughal TI, Ejaz AA, et al. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev. 2010 Apr;36(2):164-76.
280.Mukherjee Nee Chakraborty S, Ghosh U, et al. Curcumin-induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Mol Cell Biochem. 2007 Mar;297(1-2):31-9.
281.Müller CI, Kumagai T, et al. Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res. 2006 Jul;30(7):841-8.
282.Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer. Aug 15 2011;117(16):3774-3780.
283.Musselman JR, Blair CK, et al. Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol. 2013 Aug;37(4):410-6.
284.Nagao R, Ashihara E, Kimura S, Strovel JW, Yao H, Takeuchi M, . . . Maekawa T. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/beta-catenin signaling inhibitor. Cancer letters. Dec 15 2011;312(1):91-100.
285.Nakazato T, Ito K, et al. Catechin, a green tea component, rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species production in vitroand inhibits tumor growth in vivo. Haematologica. 2005 Mar;90(3):317-25.
286.Nature Education. Library page. Cell Differentiation and Tissue. Available at: http://www.nature.com/scitable/topicpage/cell-differentiation-and-tissue-14046412. Copyright 2014. Accessed 9/23/2014.
287.Naz A, N Qureshi R, et al. Vitamin D levels in patients of acute leukemia before and after remission-induction therapy. Pak J Med Sci. 2013 Jan;29(1):10-4.
288.NCI. National Cancer Institute. Cancer Topics page. Understanding Cancer Prognosis. Available at: http://www.cancer.gov/cancertopics/factsheet/Support/prognosis-stats. 5/11/2012. Accessed 9/25/2014.
289.NCI. National Cancer Institute. NCI Dictionary of Cancer Terms page. Differentiation. Available at: http://www.cancer.gov/dictionary?cdrid=46445. Accessed 9/23/2014c.
290.NCI. National Cancer Institute. Cancer Topics page. FDA Approval for Ponatinib Hydrochloride. Available at: http://www.cancer.gov/cancertopics/druginfo/fda-ponatinibhydrochloride. Last updated 3/12/2014b. Accessed 7/17/2014.
291.NCI. National Cancer Institute. SEER: Surveillance, Epidemiology, and End Results Program. Cancer Statistics page. SEER Stat Facts: Leukemia. Available at: http://seer.cancer.gov/statfacts/html/leuks.html. Accessed 7/21/2014a.
292.Negrin RS. Early complications of hematopoietic cell transplantation. Updated 7/7/2020. Accessed 1/13/2022, https://www.uptodate.com/contents/early-complications-of-hematopoietic-cell-transplantation
293.Neyestani TR, Fereydouni Z, Hejazi S, Salehi-Nasab F, Nateghifard F, Maddah M, Karandish M. Vitamin C status in Iranian children with acute lymphoblastic leukemia: evidence for increased utilization. Journal of pediatric gastroenterology and nutrition. Jul 2007;45(1):141-144.
294.Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, . . . Ong ST. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature medicine. Apr 2012;18(4):521-528.
295.Nguyen HT, Song GY, et al. Dammarane-type saponins from the flower buds of Panax ginseng and their effects on human leukemia cells. Bioorg Med Chem Lett. 2010 Jan 1;20(1):309-14.
296.Nian H, Delage B, et al. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen. 2009 Apr;50(3):213-21.
297.Ntziachristos P, Mullenders J, et al. Mechanisms of epigenetic regulation of leukemia onset and progression. Adv Immunol. 2013;117:1-38.
298.O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, . . . Gregory KM. Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network : JNCCN. Aug 2012;10(8):984-1021.
299.Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer research. Mar 2009;29(3):809-815.
300.Oka S, Tanaka S, Yoshida S, et al. A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci. 2010 Mar;59(1):1-6.
301.O'Mahony D, Bishop MR. Monoclonal antibody therapy. Front Biosci. 2006 May 1;11:1620-35.
302.Omoregie SN, Omoruyi FO, et al. Antiproliferative activities of lesser galangal (Alpinia officinarum Hance Jam1), turmeric (Curcuma longa L.), and ginger (Zingiber officinale Rosc.) against acute monocytic leukemia. J Med Food. 2013 Jul;16(7):647-55.
303.Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem. 2000 Jul;7(7):715-29.
304.Ozer H, George SL, et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993;82:2975-2984.
305.Pae HO, Jeong SO, et al. Curcumin induces pro-apoptotic endoplasmic reticulum stress in human leukemia HL-60 cells. Biochem Biophys Res Commun. 2007 Feb 23;353(4):1040-5.
306.Paneesha S. ePocrates. Chronic lymphocytic leukemia. Available at: https://online.epocrates.com/noFrame/showPage.do?method=diseases&MonographId=275. Last updated 1/30/2014. Accessed 4/17/2014.
307.Panizo C, Patino A, Lecumberri R, Calasanz MJ, Odero MD, Bendandi M, Rocha E. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases. Cancer genetics and cytogenetics. Jun 2003;143(2):178-181.
308.Park S. The effects of high concentrations of vitamin C on cancer cells. Nutrients. Sep 2013;5(9):3496-3505.
309.Passegue E, Ernst P. IFN-alpha wakes up sleeping hematopoietic stem cells. Nature medicine. Jun 2009;15(6):612-613.
310.Paustenbach DJ, Price PS, Ollison W, Blank C, Jernigan JD, Bass RD, Peterson HD. Reevaluation of benzene exposure for the Pliofilm (rubberworker) cohort (1936-1976). Journal of toxicology and environmental health. Jul 1992;36(3):177-231.
311.Pawarode A, Baer MR. Rare Leukemias. Textbook of Uncommon Cancer: John Wiley & Sons, Ltd; 2006:543-554.
312.Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, . . . Berrington de Gonzalez A. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. Aug 4 2012;380(9840):499-505.
313.Pearson RL, Wachtel H, Ebi KL. Distance-weighted traffic density in proximity to a home is a risk factor for leukemia and other childhood cancers. Journal of the Air & Waste Management Association (1995). Feb 2000;50(2):175-180.
314.Pedersen C, Raaschou-Nielsen O, Rod NH, Frei P, Poulsen AH, Johansen C, Schuz J. Distance from residence to power line and risk of childhood leukemia: a population-based case-control study in Denmark. Cancer causes & control: CCC. Feb 2014;25(2):171-177.
315.Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000 Jun 1;95(11):3273-9.
316.Peggs KS. Chimeric antigen receptors: a costimulatory boost promotes immunological memory to B-cell malignancies. Expert Rev Anticancer Ther. 2011 Nov;11(11):1667-70.
317.Perkins SM, Dewees T, et al. Risk of subsequent malignancies in survivors of childhood leukemia. J Cancer Surviv. 2013 Dec;7(4):544-50.
318.Perry AK, Chen G, Zheng D, Tang H, Cheng G. The host type I interferon response to viral and bacterial infections. Cell research. Jun 2005;15(6):407-422.
319.Petridou E, Ntouvelis E, Dessypris N, Terzidis A, Trichopoulos D. Maternal diet and acute lymphoblastic leukemia in young children. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Aug 2005;14(8):1935-1939.
320.Pfeffer LM. Biologic activities of natural and synthetic type I interferons. Seminars in oncology. Jun 1997;24(3 Suppl 9):S9-63-s69-69.
321.Philchenkov AA, Zavelevich MP, et al. Apoptosis and content of mobile lipid domains in human leukemia K-562 cells induced to differentiate by quercetin or dimethyl sulfoxide. Ukr Biokhim Zh. 2010 Mar-Apr;82(2):104-10.
322.Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, . . . Di Carlo V. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. Journal of immunology (Baltimore, Md. : 1950). May 1 2000;164(9):4443-4451.
323.Podhorecka M, Halicka D, et al. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. Ann Hematol. 2011 Feb;90(2):173-83.
324.Ponvilawan B, Kungwankiattichai S, Charoenngam N, Owattanapanich W. Is stem cell transplantation still needed for adult Philadelphia chromosome-positive acute lymphoblastic leukemia receiving tyrosine kinase inhibitors therapy?: A systematic review and meta-analysis. PLoS One. 2021;16(6):e0253896. doi:10.1371/journal.pone.0253896
325.Poole CA, Byers T, et al. Influence of a family history of cancer within and across multiple sites on patterns of cancer mortality risk for women. Am J Epidemiol. 1999 Mar 1;149(5):454-62.
326.Porter DL, Levine BL, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011 Aug 25;365(8):725-33.
327.Pottern LM, Linet M, et al. Familial cancers associated with subtypes of leukemia and non-Hodgkin's lymphoma. Leuk Res. 1991;15(5):305-14.
328.Pray L. Gleevac: the Breakthrough in Cancer Treatment. Nature Education. 2008;1(1):37
329.Preston DL, Kusumi S, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res. 1994 Feb;137(2 Suppl):S68-97.
330.Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. Aug 9 2012;120(6):1165-1174.
331.Quesenberry PJ, Butera JN. An interesting fishing expedition. Cancer Biol Ther. 2009 Feb;8(4):338-9.
332.Quoc Trung L, Espinoza JL, Takami A, Nakao S. Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PloS one. 2013;8(1):e55183.
333.Raj K, Mehta P. ePocrates. Acute myelogenous leukemia. Available at: https://online.epocrates.com/noFrame/showPage.do?method=diseases&MonographId=274. Last updated 8/9/2013. Accessed 4/17/2014.
334.Rao A. ePocrates. Acute lymphocytic leukemia. Available at: https://online.epocrates.com/noFrame/showPage.do?method=diseases&MonographId=273. Last updated 8/30/2013. Accessed 4/17/2014.
335.Rao J, Xu DR, et al. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J Transl Med. 2011 May 19;9:71.
336.Ravandi F, Estey EH, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol. 2012;30(32):3921–3923.
337.Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research. Jan 15 2006;12(2):340-344.
338.Ravindran J, Prasad S, et al. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009 Sep;11(3):495-510.
339.Raynal NJ, Momparler L, et al. Antileukemic activity of genistein, a major isoflavone present in soy products. J Nat Prod. 2008 Jan;71(1):3-7.
340.Reis-Sobreiro M, Gajate C, Mollinedo F. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene. 2009; 28:3221–34.
341.Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011 Oct 15;17(20):6417-27.
342.Robertson MJ, Tantravahi R, Griffin JD, et al. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myeloid leukemia with continuous infusion of low-dose cytarabine. Am J Hematol. 1993 Jun;43(2):95-102.
343.Roomi MW, House D, et al. Growth suppression of malignant leukemia cell line in vitroby ascorbic acid (vitamin C) and its derivatives. Vitamin C: Cancer Lett. 1998 Jan 9;122(1-2):93-9.
344.Roomi MW, Roomi NW, et al. Nutrient mixture inhibits in vitroand in vivogrowth of human acute promyelocytic leukemia HL-60 cells. Exp Oncol. 2011 Dec;33(4):212-5.
345.Roosli M. [Health effects of electromagnetic fields]. Therapeutische Umschau. Revue therapeutique. Dec 2013;70(12):733-738.
346.Ross JA, Spector LG, et al. Epidemiology of leukemia in children with Down syndrome. Pediatr Blood Cancer. 2005 Jan;44(1):8-12.
347.Ruela-de-Sousa RR, Fuhler GM, et al. Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis. 2010;1:e19.
348.Russo M, Spagnuolo C, Volpe S, Mupo A, Tedesco I, Russo GL. Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients. British journal of cancer. Aug 24 2010;103(5):642-648.
349.Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Biochemical pharmacology. Apr 1 2013;85(7):927-936.
350.Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Therapeutics and clinical risk management. Oct 2007;3(5):807-817.
351.Sadrzadeh H, Abtahi SM, Fathi AT. Infectious pathogens and hematologic malignancy. Discov Med. 2012 Dec;14(79):421-33.
352.Sánchez Y, Amrán D, et al. Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK). Int J Cancer. 2008 Sep 1;123(5):1205-14.
353.Sánchez Y, Simón GP, et al. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines. J Pharmacol Exp Ther. 2010 Oct;335(1):114-23.
354.Santoro R, Marani M, et al. Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. Oncogene. 2012 Jun 14;31(24):2931-42.
355.Sanz MA, Montesinos P, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008 Oct 15;112(8):3130-4.
356.Satou Y, Matsuoka M. Virological and immunological mechanisms in the pathogenesis of human T-cell leukemia virus type 1. Rev Med Virol. 2013 Sep;23(5):269-80.
357.Savitz DA, Andrews KW. Review of epidemiologic evidence on benzene and lymphatic and hematopoietic cancers. Am J Ind Med. 1997 Mar;31(3):287-95.
358.Schiffer CA SR. Complications. In: Kufe DW PR, Weichselbaum RR, et al., editors. , ed. Holland-Frei Cancer Medicine, 6th Ed. Hamilton Ontario Canada: BC Decker; 2003.
359.Schlenk RF, Fröhling S, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia. 2004 Nov;18(11):1798-803.
360.Schwilk E, Zhang L, Smith MT, Smith AH, Steinmaus C. Formaldehyde and leukemia: an updated meta-analysis and evaluation of bias. Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine. Sep 2010;52(9):878-886.
361.Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nature reviews. Cancer. Apr 2012;12(4):278-287.
362.Scrimshaw NS. INCAP studies of nutrition and infection. Food and nutrition bulletin. Mar 2010;31(1):54-67.
363.Sekeres M, Sisson S, Kuter DJ, Rao D. First Consult. Myelodysplastic syndromes. Available at: www.clinicalkey.com. Last updated 9/1/2011. Accessed 5/15/2014.
364.Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, . . . Estey E. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. Jan 1 2009;113(1):28-36.
365.Sermage-Faure C, Demoury C, Rudant J, Goujon-Bellec S, Guyot-Goubin A, Deschamps F, . . . Clavel J. Childhood leukaemia close to high-voltage power lines--the Geocap study, 2002-2007. British journal of cancer. May 14 2013;108(9):1899-1906.
366.Shih TY, Wu J, Muo CS, Kao CH. Association between leukaemia and X-ray in children: A nationwide study. Journal of paediatrics and child health. Aug 2014;50(8):615-618.
367.Shanafelt TD, Lee YK, et al. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res. 2006 Jun;30(6):707-12.
368.Shen ZX, Shi ZZ, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35.
369.Shorey LE, Hagman AM, Williams DE, Ho E, Dashwood RH, Benninghoff AD. 3,3'-Diindolylmethane induces G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia cells. PloS one. 2012;7(4):e34975.
370.Sidaway GH. Powerline bioactivity - more than magnetism. SpringerPlus. 2013;2:454.
371.Siddikuzzaman, Guruvayoorappan C, Berlin Grace VM. All trans retinoic acid and cancer. Immunopharmacology and immunotoxicology. Jun 2011;33(2):241-249.
372.Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. Jan-Feb 2014;64(1):9-29.
373.Siegel R, Naishadham D, et al. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29.
374.Siegel R, Naishadham D, et al. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30.
375.Siegel R, Ward E, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36.
376.Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A, . . . Porkka K. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. Sep 22 2011;118(12):3228-3235.
377.Simonsson B, Hjorth-Hansen H, et al. Interferon alpha for treatment of chronic myeloid leukemia. Curr Drug Targets. 2011 Mar 1;12(3):420-8.
378.Sirois P, Borgeat P, Lauziere M, Dube L, Rubin P, Kesterson J. Effect of Zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo. Agents and actions. Sep 1991;34(1-2):117-120.
379.Slapak CA, Desforges JF, et al. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol. 1992 Nov;41(3):178-83.
380.Sliva D. Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther. 2003 Dec;2(4):358-64.
381.Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. 2006:178-84.
382.Smolewski P, et al. New Insights into Biology, Prognostic Factors, and Current Therapeutic Strategies in Chronic Lymphocytic Leukemia. ISRN Oncol. 2013 Aug 22;2013:740615.
383.Snyder R. Leukemia and benzene. International journal of environmental research and public health. Aug 2012;9(8):2875-2893.
384.Sohrabi MR, Tarjoman T, Abadi A, Yavari P. Living near overhead high voltage transmission power lines as a risk factor for childhood acute lymphoblastic leukemia: a case-control study. Asian Pacific journal of cancer prevention: APJCP. 2010;11(2):423-427.
385.Somervaille T. ePocrates. Chronic myelogenous leukemia. Available at: https://online.epocrates.com/noFrame/showPage.do?method=diseases&MonographId=276. Last updated 11/1/2013. Accessed 4/17/2014.
386.Spagnuolo C, Cerella C, Russo M, Chateauvieux S, Diederich M, Russo GL. Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. British journal of cancer. Jul 12 2011;105(2):221-230.
387.Spagnuolo C, Russo M, et al. Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia. Ann N Y Acad Sci. 2012 Jul;1259:95-103.

</p>


<!-- Resumen de Linfoma -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #ff5722; padding-bottom: 10px;">
    <i class="fa fa-lymphoma" style="margin-right: 10px; color: #ff5722;"></i> Lymphoma
</h2>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #ff5722; padding-bottom: 10px;">
    Disruption of the immune system that fights infection, including the white blood cells and the lymphatic system, leads to a type of cancer called lymphoma. There are different types of lymphoma, and treatment can vary depending on the type. The procedure of how it is treated is indicated according to the form of development and the type of lymphoma and how it is treated. Emerging therapies and research and the insertion of adjuvants, developed by us, are an unavoidable part of these protocols to make conventional therapies and emerging treatments more effective.
</p>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #ff5722; padding-bottom: 10px;">
    Lymphomas like leukemias must be treated differently according to their classification and particularities of the cancer and the patient. Hodgkin lymphoma: HL is usually treated with radiation and chemotherapy. Non-Hodgkin lymphoma: Treatment options for patients with NHL range from a "watch and wait" approach to hematopoietic stem cell transplantation; Rituximab is often given together with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). The combination of the 5 agents is called "R-CHOP". Novel and emerging strategies include: Interleukin (IL)-6 inhibitors: Plasma levels of IL-6 are significantly lower in patients whose lymphomas are in complete remission compared to those in partial remission or those who have progressive disease. Regular aspirin use was associated with a significantly reduced risk of HL. The use of acetaminophen was actually linked to an increased risk of the disease. In combination with rituximab, pixantrone has been shown to be superior to other single-agent therapies for the treatment of relapsed/refractory aggressive NHL.
</p>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #ff5722; padding-bottom: 10px;">
    To improve the pharmacological actions of the drugs used in the prevention, control, and treatment of lymphoma and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term, which usually contribute to the development of alterations, syndromes, and deadly diseases, such as cancer, and can also reduce the quality of life expectancy of people under treatment; the scientists and doctors of "PPG NUTRICIONAL" have developed adjuvants that support conventional therapies by reducing toxicity and enhancing therapeutic efficacy.
</p>

<!-- Referencias -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #ff5722; padding-bottom: 10px;">
    <i class="fa fa-references" style="margin-right: 10px; color: #ff5722;"></i> References
</h2>


<p style="margin-bottom: 20px; text-align: justify;">
1.Abe R, Ogawa K, Maruyama Y, Nakamura N, Abe M. Spontaneous regression ofdiffuse large B-cell lymphoma harbouring Epstein-Barr virus: a case report andreview of the literature. J Clin Exp Hematop. 2007 Apr;47(1):23-6. Review. PubMedPMID: 17510535
2.Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. The oncologist. Apr 2006;11(4):384-392
3.ACS. American Cancer Society. Learn About Cancer. Non-Hodgkin Lymphoma. Treating specific types of non-Hodgkin lymphoma. Available at: http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-treating-specific-lymphomas. Last updated 11/14/2013. Accessed 12/13/2013
4.Adhvaryu MR, Reddy N, Parabia MH. Anti-tumor activity of four Ayurvedic herbs in Dalton lymphoma ascites bearing mice and their short-term in vitrocytotoxicity on DLA-cell-line. Afr J Tradit Complement Altern Med. 2008 Jun18;5(4):409-18. PubMed PMID: 20161965; PubMed Central PMCID: PMC2816583
5.Ageberg M, Rydström K, Relander T, Drott K. The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-inducedcell death. Am J Transl Res. 2013;5(2):170-83. Epub 2013 Mar 28. PubMed PMID:23573362; PubMed Central PMCID: PMC3612513
6.Agmon-Levin N, Kivity S, Tzioufas AG, Lopez Hoyos M, Rozman B, Efes I, . . . Shoenfeld Y. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren's syndrome. Journal of autoimmunity. Sep 2012;39(3):234-239
7.Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, Barista I. Rituximab-related viral infections in lymphoma patients. Leukemia & lymphoma. Jul 2007;48(7):1307-1312
8.Aleman BM, van Leeuwen FE. Are we improving the long-term burden of Hodgkin's lymphoma patients with modern treatment? Hematology/oncology clinics of North America. Oct 2007;21(5):961-975
9.Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, Trichopoulos D. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int JCancer. 2007;120 Suppl 12:1-39. Review. PubMed PMID: 17405121
10.Al-Humood SA, Al-Qallaf AS, Alshemmari SH, Francis IM, Junaid TA, Marouf RA, Al-Mulla F. Genotypic and phenotypic differences between nodal and extranodal diffuse large B-Cell lymphomas. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. Oct 2011;59(10):918-931
11.Alshemmari S, Sreedharan PS, Krishnan Y. MALT lymphomas -Treated withchemotherapy or radiotherapy: Clinical Features, Prognostic factors and Survival. Gulf J Oncolog. 2013 Jul;1(14):76-80. PubMed PMID: 23996871
12.Armitage JO, Greer JP, Levine AM, Weisenburger DD, Formenti SC, Bast M, . . . et al. Peripheral T-cell lymphoma. Cancer. Jan 1 1989;63(1):158-163
13.Aschebrook-Kilfoy B, Ward MH, Dave BJ, Smith SM, Weisenburger DD, Chiu BC. Dietary nitrate and nitrite intake and risk of non-Hodgkin lymphoma. Leuk Lymphoma. 2013 May;54(5):945-50. doi: 10.3109/10428194.2012.734613. Epub 2012 Oct 24. PubMed PMID: 23013327
14.Asfour IA, El Shazly S, Fayek MH, Hegab HM, Raouf S, Moussa MA. Effect ofhigh-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis innon-Hodgkin's lymphoma patients. Biol Trace Elem Res. 2006 Apr;110(1):19-32 PubMed PMID: 16679545
15.Baird RD, van Zyl-Smit RN, Dilke T, Scott SE, Rassam SM. Spontaneousremission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal ofmethotrexate in a patient with rheumatoid arthritis: case report and review ofthe literature. Br J Haematol. 2002 Aug;118(2):567-8. Review. PubMed PMID:12139747
16.Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB. Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer causes & control : CCC. Apr 2005;16(3):301-308.
17.Bell JT, Spector TD. A twin approach to unraveling epigenetics. Trends in genetics : TIG. Mar 2011;27(3):116-125
18.Ben-Arye E, Attias S, Tadmor T, et al. Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions. Leuk Lymphoma. 2010;51(8):1414-23
19.Bertolini F, Fusetti L, Rabascio C, Cinieri S, Martinelli G, Pruneri G Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma Leukemia. 2000 Aug;14(8):1477-82. PubMed PMID: 10942245
20.Bokelmann I, Mahlknecht U. Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Molecular medicine (Cambridge, Mass.). Jan-Feb 2008;14(1-2):20-27
21.Braun FK, Al-Yacoub N, Plötz M, Möbs M, Sterry W, Eberle J. Nonsteroidalanti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells andenhance their sensitivity for TNF-related apoptosis-inducing ligand. J InvestDermatol. 2012 Feb;132(2):429-39. doi: 10.1038/jid.2011.316. Epub 2011 Oct 20 PubMed PMID: 22011910
22.Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: asystematic review. Health Technol Assess. 2007 Jul;11(27):iii, ix-x, 1-84 Review. PubMed PMID: 17610809
23.Buglio D, Younes A. Histone deacetylase inhibitors in Hodgkin lymphoma Invest New Drugs. 2010 Dec;28 Suppl 1:S21-7. doi: 10.1007/s10637-010-9588-y. Epub2010 Dec 3. Review. PubMed PMID: 21127943; PubMed Central PMCID: PMC3003791
24.Caligaris-Cappio F. Autoimmune disorders and lymphoma. Ann Oncol. 2008 Jun;19Suppl 4:iv31-4. doi: 10.1093/annonc/mdn190. Review. PubMed PMID: 18519398
25.Campbell BA. The Role of Radiation Therapy in the Treatment of Stage I-IIDiffuse Large B-Cell Lymphoma. Curr Hematol Malig Rep. 2013 Sep;8(3):236-42. doi:10.1007/s11899-013-0170-5. PubMed PMID: 23901002
26.Campbell PT, Campbell KL, Wener MH, Wood BL, Potter JD, McTiernan A, Ulrich CM. A yearlong exercise intervention decreases CRP among obese postmenopausal women. Medicine and science in sports and exercise. Aug 2009;41(8):1533-1539
27.Castillo JJ, Echenique IA. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. American journal of hematology. Mar 2012;87(3):330-333
28.Catassi C, Fabiani E, Corrao G, Barbato M, De Renzo A, Carella AM, . . . Corazza GR. Risk of non-Hodgkin lymphoma in celiac disease. JAMA : the journal of the American Medical Association. Mar 20 2002;287(11):1413-1419
29.Chang ET, Cronin-Fenton DP, Friis S, Hjalgrim H, Sorensen HT, Pedersen L. Aspirin and other nonsteroidal anti-inflammatory drugs in relation to Hodgkin lymphoma risk in northern Denmark. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Jan 2010;19(1):59-64.
30.Chang ET, Froslev T, Sorensen HT, Pedersen L. A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark. British journal of cancer. Nov 22 2011;105(11):1776-1782.
31.Chang ET, Zheng T, Weir EG, Borowitz M, Mann RB, Spiegelman D, Mueller NE. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. Journal of the National Cancer Institute. Feb 18 2004;96(4):305-315.
32.Charbonneau B, O'Connor HM, Wang AH, Liebow M, Thompson CA, Fredericksen ZS, Macon WR, Slager SL, Call TG, Habermann TM, Cerhan JR. Trans fatty acid intake isassociated with increased risk and n3 fatty acid intake with reduced risk ofnon-hodgkin lymphoma. J Nutr. 2013 May;143(5):672-81. doi: 10.3945/jn.112.168658. Epub 2013 Mar 13. PubMed PMID: 23486982; PubMed Central PMCID: PMC3738236
33.Chen GC, Lv DB, Pang Z, Liu QF. Fruits and vegetables consumption and risk ofnon-Hodgkin's lymphoma: a meta-analysis of observational studies. Int J Cancer 2013 Jul;133(1):190-200. doi: 10.1002/ijc.27992. Epub 2013 Jan 18. PubMed PMID:23238796
34.Chua I, Quinti I, Grimbacher B. Lymphoma in common variable immunodeficiency:interplay between immune dysregulation, infection and genetics. Curr OpinHematol. 2008 Jul;15(4):368-74. doi: 10.1097/MOH.0b013e328302c7b6. Review. PubMedPMID: 18536576
35.Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Apr 2006;15(4):630-638
36.CLS. Cell Lines Service. MOLT-4. Copyright © 2013. Available at: http://www.cell-lines-service.de/content/e3969/e4304/e4329/index_eng.html. Accessed 12/17/2013.
37.Cohen JI. Epstein-Barr Virus: An Oncogenic Human Herpesvirus. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Hamilton (ON): BC Decker; 2003. Available at: http://www.ncbi.nlm.nih.gov/books/NBK12886/. Accessed 11/26/2013. 2003
38.Conklin KA. Coenzyme q10 for prevention of anthracycline-inducedcardiotoxicity. Integr Cancer Ther. 2005 Jun;4(2):110-30. Review. PubMed PMID: 15911925
39.Cotto M, Cabanillas F, Tirado M, García MV, Pacheco E. Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clin Transl Oncol. 2010Jun;12(6):401-9. doi: 10.1007/s12094-010-0527-3. Review. PubMed PMID: 20534395
40.CTCA. Cancer Treatment Centers of America. Non-Hodgkin Lymphoma. Learning page. Non-Hodgkin lymphoma symptoms. Available at: http://www.cancercenter.com/non-hodgkin-lymphoma/symptoms/. Accessed 12/13/2013
41.Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leukemia research. Sep 2013;37(9):1107-1115
42.Das L, Vinayak M. Anti-carcinogenic action of curcumin by activation ofantioxidant defence system and inhibition of NF-κB signalling in lymphoma-bearingmice. Biosci Rep. 2012 Apr 1;32(2):161-70. doi: 10.1042/BSR20110043. PubMed PMID:21831045
43.De Falco G, Rogena EA, Leoncini L. Infectious agents and lymphoma. SeminDiagn Pathol. 2011 May;28(2):178-87. Review. PubMed PMID: 21842703
44.Descamps O, Riondel J, Ducros V, Roussel AM. Mitochondrial production ofreactive oxygen species and incidence of age-associated lymphoma in OF1 mice:effect of alternate-day fasting. Mech Ageing Dev. 2005 Nov;126(11):1185-91 PubMed PMID: 16126250
45.Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN, Kelly JL,Macon WR, Nowakowski GS, Inwards DJ, Johnston PB, Singh RJ, Allmer C, Slager SL, Weiner GJ, Witzig TE, Cerhan JR. Vitamin D insufficiency and prognosis innon-Hodgkin's lymphoma. J Clin Oncol. 2010 Sep 20;28(27):4191-8. doi:10.1200/JCO.2010.28.6674. Epub 2010 Aug 16. PubMed PMID: 20713849; PubMed CentralPMCID: PMC2953973
46.Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J,Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E,Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjosé S, Chiu BC, Dal Maso L, Cocco P, Maynadié M, Foretova L, Staines A, Brennan P, Davis S, Severson R,Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W. Autoimmune disorders andrisk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymphConsortium. Blood. 2008 Apr 15;111(8):4029-38. doi: 10.1182/blood-2007-10-119974 Epub 2008 Feb 8. PubMed PMID: 18263783; PubMed Central PMCID: PMC2288717
47.El-Helw LM, Hancock BW. Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas. Expert opinion on investigational drugs. Oct 2007;16(10):1683-1691
48.Emrich HM, von Zerssen D, Kissling W, Moller HJ. Therapeutic effect of valproate in mania. The American journal of psychiatry. Feb 1981;138(2):256
49.Engels EA. Infectious agents as causes of non-Hodgkin lymphoma. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Mar 2007;16(3):401-404
50.Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the centralnervous system. Int J Biol Sci. 2012;8(9):1254-66. doi: 10.7150/ijbs.4679. Epub2012 Oct 25. Review. PubMed PMID: 23136554; PubMed Central PMCID: PMC3491449
51.Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. European journal of nuclear medicine and molecular imaging. Jun 2003;30 Suppl 1:S65-81
52.Fast Stats [SEER] (2013). Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Available at: http://seer.cancer.gov/faststats. Accessed on 9-24-2013.  
53.FDA. Food and Drug Administration. Oncologic Drugs Advisory Committee Meeting Briefing Document. Pixantrone dimaleate (BBR 2778) Injection for the treatment of patients with relapsed or refractory aggressive Non-Hodgkin's Lymphoma who have received 2 or more prior lines of therapy. NDA No. 22-481. 1/6/2010. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm199560.pdf. Accessed 11/26/2013. 2010
54.Ferreri AJM, Ernberg I, Copie-Bergman C. Infectious agents and lymphoma development: molecular and clinical aspects. Journal Of Internal Medicine. 2009;265(4):421-438
55.Fiebich BL, Lieb K, Hüll M, Berger M, Bauer J. Effects of NSAIDs on IL-1beta-induced IL-6 mRNA and protein synthesis in human astrocytoma cells Neuroreport. 1996 Apr 26;7(6):1209-13. PubMed PMID: 8817534
56.Fiebich BL, Muñoz E, Rose T, Weiss G, McGregor GP. Molecular targets of theantiinflammatory Harpagophytum procumbens (devil's claw): inhibition of TNFα and COX-2 gene expression by preventing activation of AP-1. Phytother Res. 2012Jun;26(6):806-11. doi: 10.1002/ptr.3636. Epub 2011 Nov 10. PubMed PMID: 22072539
57.Fields PA, Taylor GP. "Antivirals" in the treatment of adult T cell leukaemia- lymphoma (ATLL). Current hematologic malignancy reports. Dec 2012;7(4):267-275
58.Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. Jan 2004;53(1):34-37
59.Fischbach W. Gastric mucosal-associated lymphoid tissue lymphoma Gastroenterol Clin North Am. 2013 Jun;42(2):371-80. doi:10.1016/j.gtc.2013.01.008. Epub 2013 Mar 15. PubMed PMID: 23639646
60.Flescher E, Rotem R, Kwon P, Azare J, Jaspers I, Cohen D. Aspirin enhances multidrug resistance gene 1 expression in human Molt-4 T lymphoma cells. Anticancer research. Nov-Dec 2000;20(6b):4441-4444.
61.Frankenfeld CL, Cerhan JR, Cozen W, Davis S, Schenk M, Morton LM, . . . Ward MH. Dietary flavonoid intake and non-Hodgkin lymphoma risk. The American journal of clinical nutrition. May 2008;87(5):1439-1445
62.Frazzi R, Valli R, Tamagnini I, Casali B, Latruffe N, Merli F Resveratrol-mediated apoptosis of hodgkin lymphoma cells involves SIRT1inhibition and FOXO3a hyperacetylation. Int J Cancer. 2013 Mar 1;132(5):1013-21. doi: 10.1002/ijc.27748. Epub 2012 Aug 7. PubMed PMID: 22833338
63.Freeman GJ, Freedman AS, Rabinowe SN, Segil JM, Horowitz J, Rosen K, Whitman JF, Nadler LM. Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989 May;83(5):1512-8. PubMed PMID: 2785119; PubMed Central PMCID:PMC303855
64.Fühler M, Ottmann KW, Tronnier M. [Cutaneous marginal zone lymphoma (SALT)and infection with Borrelia burgdorferi]. Hautarzt. 2010 Feb;61(2):145-7. doi:10.1007/s00105-009-1766-5. German. PubMed PMID: 19399378
65.Gajra A. B-Cell Lymphoma. Medscape web page. Practice Essentials page. Available at: http://emedicine.medscape.com/article/202677-overview. Last updated 11/19/2013. Accessed 11/26/2013
66.Garfin PM. Posttransplant Lymphoproliferative Disease. Medscape web page. Available at: http://emedicine.medscape.com/article/431364-overview. Last updated 7/15/2013. Accessed 11/26/2013.
67.Gavrilina OA, Gabeeva NG, Morozova AK, et al. [Role of high-dose chemotherapy and autologous blood stem cell transplantation in patients with diffuse large B-cell lymphoma]. Terapevticheskii arkhiv. 2013;85(7):90-97.
68.Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006Oct;126(10):2194-201. Epub 2006 Jun 1. PubMed PMID: 16741509
69.Georgiev MI, Ivanovska N, Alipieva K, Dimitrova P, Verpoorte R. Harpagoside: from Kalahari Desert to pharmacy shelf. Phytochemistry. 2013 Aug;92:8-15. doi:10.1016/j.phytochem.2013.04.009. Epub 2013 May 1. PubMed PMID: 23642455
70.Gerhauser C. Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. Topics in current chemistry. 2013;329:73-132
71.Giachelia M, Voso MT, Tisi MC, Martini M, Bozzoli V, Massini G, D'Aló F,Larocca LM, Leone G, Hohaus S. Interleukin-6 plasma levels are modulated by apolymorphism in the NF-κB1 gene and are associated with outcome followingrituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2012 Mar;53(3):411-6. doi: 10.3109/10428194.2011.621566. Epub 2011Oct 24. PubMed PMID: 21902578
72.Gill S, Porter DL. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. Expert opinion on biological therapy. Jan 2014;14(1):37-49.
73.Glass C. Role of the primary care physician in Hodgkin lymphoma. American family physician. Sep 1 2008;78(5):615-622
74.Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is achemosensitizer and radiosensitizer for tumors and chemoprotector andradioprotector for normal organs. Nutr Cancer. 2010;62(7):919-30. doi:10.1080/01635581.2010.509835. Review. PubMed PMID: 20924967
75.Goenaga-Infante H, Kassam S, Stokes E, Hopley C, Joel SP. Capabilities ofHPLC with APEX-Q nebulisation ICP-MS and ESI MS/MS to compare selenium uptake andspeciation of non-malignant with different B cell lymphoma lines. Anal BioanalChem. 2011 Feb;399(5):1789-97. doi: 10.1007/s00216-010-4474-1. Epub 2010 Dec 8 PubMed PMID: 21140135
76.Gopee NV, Johnson VJ, Sharma RP. Sodium selenite-induced apoptosis in murine B-lymphoma cells is associated with inhibition of protein kinase C-delta, nuclear factor kappaB, and inhibitor of apoptosis protein. Toxicological sciences: an official journal of the Society of Toxicology. Apr 2004;78(2):204-214
77.Gottfried E, Lang SA, Renner K, Bosserhoff A, Gronwald W, Rehli M, Einhell S,Gedig I, Singer K, Seilbeck A, Mackensen A, Grauer O, Hau P, Dettmer K, AndreesenR, Oefner PJ, Kreutz M. New aspects of an old drug--diclofenac targets MYC andglucose metabolism in tumor cells. PLoS One. 2013 Jul 9;8(7):e66987. doi:10.1371/journal.pone.0066987. Print 2013. PubMed PMID: 23874405; PubMed CentralPMCID: PMC3706586
78.Grudeva-Popova J, Nenova I, Mateva N, Ananoshtev N, Popov V, Atanasova M Non-Hodgkin lymphomas and carrier state of viral hepatitis B and C. J BUON. 2013 Jan-Mar;18(1):239-44. PubMed PMID: 23613411
79.Gu J, Song ZP, Gui DM, Hu W, Chen YG, Zhang DD. Resveratrol attenuatesdoxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by hemeoxygenase-1 induction. Cardiovasc Toxicol. 2012 Dec;12(4):341-9. doi:10.1007/s12012-012-9178-7. PubMed PMID: 22763982
80.Guo SQ, Zhang YZ. Histone deacetylase inhibition: an important mechanism inthe treatment of lymphoma. Cancer Biol Med. 2012 Jun;9(2):85-9. doi:10.3969/j.issn.2095-3941.2012.02.001. PubMed PMID: 23691460; PubMed CentralPMCID: PMC3643654
81.Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a componentof golden spice, and its miraculous biological activities. Clin Exp PharmacolPhysiol. 2012 Mar;39(3):283-99. doi: 10.1111/j.1440-1681.2011.05648.x. Review PubMed PMID: 22118895; PubMed Central PMCID: PMC3288651
82.Güven M, Oztürk B, Sayal A, Ozet A. Lipid peroxidation and antioxidant system in the blood of patients with Hodgkin's disease. Clin Biochem. 2000 Apr;33(3):209-12
83.Han X, Zheng T, Foss F, Holford TR, Ma S, Zhao P, Dai M, Kim C, Zhang Y, Bai Y, Zhang Y. Vegetable and fruit intake and non-Hodgkin lymphoma survival inConnecticut women. Leuk Lymphoma. 2010 Jun;51(6):1047-54. doi:10.3109/10428191003690364. PubMed PMID: 20350273; PubMed Central PMCID:PMC3110752
84.Hermine O, Allard I, Lévy V, et al. A prospective phase II clinical trial with the use of zidovudeine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3(6):276-82
85.Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008 Jul 1;26(19):3159-65 doi: 10.1200/JCO.2007.14.1242. PubMed PMID: 18591554
86.Hirano T. Interleukin 6 in autoimmune and inflammatory diseases: a personalmemoir. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(7):717-30. Review. PubMedPMID: 20689230; PubMed Central PMCID: PMC3066534
87.Hjalgrim H. On the aetiology of Hodgkin lymphoma. Dan Med J. 2012Jul;59(7):B4485. Review. PubMed PMID: 22759852
88.Hofbauer GF, Kessler B, Kempf W, Nestle FO, Burg G, Dummer R. Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment. Dermatology (Basel, Switzerland). 2001;203(2):168-170
89.Holmberg L, Maloney DG. The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. Journal of National Comprehensive Cancer Network: JNCCN. Sep 1 2011;9(9):1060-1071.
90.Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy inoncology. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003297. doi:10.1002/14651858.CD003297.pub2. Review. PubMed PMID: 18425885
91.Hou S, Yang W. A meta-analysis on Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China. Saudi medical journal. Jul 2011;32(7):675-678
92.Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, BrownK, Steward WP, Gescher AJ. Phase I randomized, double-blind pilot study ofmicronized resveratrol (SRT501) in patients with hepatic metastases--safety,pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila). 2011Sep;4(9):1419-25. doi: 10.1158/1940-6207.CAPR-11-0148. Epub 2011 Jun 16. PubMedPMID: 21680702; PubMed Central PMCID: PMC3173869
93.Howman RA, Prince HM. New drug therapies in peripheral T-cell lymphoma. Expert review of anticancer therapy. Mar 2011;11(3):457-472
94.Hu XZ. [Effects of selenium deficiency and supplementation on tumor immuneresponse in mice]. Zhonghua Zhong Liu Za Zhi. 1990 Sep;12(5):328-31. Chinese PubMed PMID: 2276320
95.Hugo F, Dittmar T, Treutler EK, Zänker KS, Kuehn JJ. The Viscum album extractIscador P does not cause an autocrine interleukin-6 loop in B-Non-Hodgkin'sLymphoma cell lines. Onkologie. 2005 Aug;28(8-9):415-20. Epub 2005 Aug 29. PubMedPMID: 16160404
96.Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, AbubakerJ, Platanias LC, Al-Kuraya KS, Uddin S. Curcumin suppresses constitutiveactivation of nuclear factor-kappa B and requires functional Bax to induceapoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther. 2008Oct;7(10):3318-29. doi: 10.1158/1535-7163.MCT-08-0541. PubMed PMID: 18852135
97.Iarussi D, Auricchio U, Agretto A, Murano A, Giuliano M, Casale F, Indolfi P,Iacono A. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity:control study in children with acute lymphoblastic leukemia and non-Hodgkinlymphoma. Mol Aspects Med. 1994;15 Suppl:s207-12. PubMed PMID: 7752832
98.Ignatova TM, Mukhin NA. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma]. Ter Arkh 2012;84(11):81-8. Review. Russian. PubMed PMID: 23252255
99.Iurescia S, Fioretti D, Fazio VM, Rinaldi M. Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: a biotech's challenge. Biotechnology advances. Jan-Feb 2012;30(1):372-383
100.Jagetia GC, Rao SK. Evaluation of the antineoplastic activity of guduchi(Tinospora cordifolia) in Ehrlich ascites carcinoma bearing mice. Biol PharmBull. 2006 Mar;29(3):460-6. PubMed PMID: 16508146
101.Jiang XR, Macey MG, Lin HX, Newland AC. The anti-leukaemic effects and themechanism of sodium selenite. Leuk Res. 1992;16(4):347-52. PubMed PMID: 1314317
102.Johansson E, Wilson B, Brunton L, Tishelman C, Molassiotis A. Symptomsbefore, during, and 14 months after the beginning of treatment as perceived bypatients with lymphoma. Oncol Nurs Forum. 2010 Mar;37(2):E105-13. doi:10.1188/10.ONF.E105-E113. PubMed PMID: 20189909
103.Jüliger S, Goenaga-Infante H, Lister TA, Fitzgibbon J, Joel SP Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclearfactor-kappaB inhibition and the rapid generation of other selenium species Cancer Res. 2007 Nov 15;67(22):10984-92. PubMed PMID: 18006844
104.Kabat GC, Kim MY, Wactawski-Wende J, Shikany JM, Vitolins MZ, Rohan TE Intake of antioxidant nutrients and risk of non-Hodgkin's Lymphoma in the Women'sHealth Initiative. Nutr Cancer. 2012;64(2):245-54. doi:10.1080/01635581.2012.642454. Epub 2012 Jan 2. PubMed PMID: 22211937
105.Kameda G, Kempf W, Oschlies I, Michael K, Seifert G, Längler A. Nodalanaplastic large-cell lymphoma ALK-1- with CD30+ cutaneous lymphoproliferationtreated with mistletoe: spontaneous remission or treatment response? KlinPadiatr. 2011 Nov;223(6):364-7. doi: 10.1055/s-0031-1285914. Epub 2011 Nov 3. PubMed PMID: 22052633
106.Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M,Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J,Shibata H. A phase I study investigating the safety and pharmacokinetics ofhighly bioavailable curcumin (Theracurmin) in cancer patients. Cancer ChemotherPharmacol. 2013 Jun;71(6):1521-30. doi: 10.1007/s00280-013-2151-8. Epub 2013 Mar 30. PubMed PMID: 23543271
107.Kanakry JA, Ambinder RF. EBV-related lymphomas: new approaches to treatment. Current treatment options in oncology. Jun 2013;14(2):224-236
108.Kapil A, Sharma S. Immunopotentiating compounds from Tinospora cordifolia. J Ethnopharmacol. 1997 Oct;58(2):89-95
109.Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y, Podevin P,Bouscary D, Sogni P, Blanche P, Dreyfus F. Response to antiviral treatment inhepatitis C virus-associated marginal zone lymphomas. Leukemia. 2004Oct;18(10):1711-6. PubMed PMID: 15284859
110.Kennedy AR, Ware JH, Carlton W, Davis JG. Suppression of the later stages ofradiation-induced carcinogenesis by antioxidant dietary formulations. Radiat Res 2011 Jul;176(1):62-70. Epub 2011 Apr 26. PubMed PMID: 21520997
111.Khan G, Norton AJ, Slavin G. Epstein-Barr virus in Reed-Sternberg-like cells in non-Hodgkin's lymphomas. The Journal of pathology. Jan 1993;169(1):9-14
112.Khan MA, Gahlot S, Majumdar S. Oxidative stress induced by curcumin promotesthe death of cutaneous T-cell lymphoma (HuT-78) by disrupting the function ofseveral molecular targets. Mol Cancer Ther. 2012 Sep;11(9):1873-83. doi:10.1158/1535-7163.MCT-12-0141. Epub 2012 May 31. PubMed PMID: 22653966
113.Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D,Levy L, Wall D, McCall J, Kosinski M, Weinstein A. Two controlled trials ofantibiotic treatment in patients with persistent symptoms and a history of Lymedisease. N Engl J Med. 2001 Jul 12;345(2):85-92. PubMed PMID: 11450676
114.Kim SR, Bae MK, Kim JY, Wee HJ, Yoo MA, Bae SK. Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochemical and biophysical research communications. Sep 18 2009;387(2):342-347.
115.Kobrinsky B, Hymes KB (2012). Epocrates Online. Non-Hodgkin Lymphoma. Available at: https://online.epocrates.com/noFrame/showPage.do?method=diseases&MonographId=312&ActiveSectionId=11 Accessed: 9/24/2013.
116.Kochenderfer JN, Dudley ME. American Society of Hematology 55th Annual Meeting and exposition. Oral and Poster Abstracts. Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen ReceptorClinically Relevant Abstract. 12/8/2013. Available at: https://ash.confex.com/ash/2013/webprogram/Paper62867.html
117.Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nature reviews. Clinical oncology. May 2013;10(5):267-276.
118.Kovacs E, Kuehn JJ. Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affectthese parameters? Biomed Pharmacother. 2002 May;56(3):152-8. PubMed PMID:12046687
119.Kovacs E, Link S, Toffol-Schmidt U. Comparison of Viscum album QuFrF extractwith vincristine in an in vitro model of human B cell lymphoma WSU-1 Arzneimittelforschung. 2008;58(11):592-7. doi: 10.1055/s-0031-1296562. PubMedPMID: 19137911
120.Kovacs E, Link S, Toffol-Schmidt U. Cytostatic and cytocidal effects ofmistletoe (Viscum album L.) quercus extract Iscador. Arzneimittelforschung. 2006 Jun;56(6A):467-73. PubMed PMID: 16927528
121.Kuehn JJ. [Favorable long-term outcome with mistletoe therapy in a patientwith centroblastic-centrocytic non-Hodgkin lymphoma]. Dtsch Med Wochenschr. 1999 Nov 26;124(47):1414-8. German. PubMed PMID: 10605421
122.Küppers R, Hansmann ML. The Hodgkin and Reed/Sternberg cell. Int J BiochemCell Biol. 2005 Mar;37(3):511-7. Review. PubMed PMID: 15618006
123.Kurzrock R, Redman J, Cabanillas F, et al. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with B symptoms. Cancer Res. 1993;53(9):2118-22
124.Lakka TA, Lakka HM, Rankinen T, Leon AS, Rao DC, Skinner JS, . . . Bouchard C. Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. European heart journal. Oct 2005;26(19):2018-2025
125.Larsson SC, Wolk A. Obesity and risk of non-Hodgkin's lymphoma: a meta-analysis. International journal of cancer. Journal international du cancer. Oct 1 2007;121(7):1564-1570
126.Larsson SC, Wolk A.. Eur J Cancer. 2011Nov;47(16):2422-30. doi: 10.1016/j.ejca.2011.06.029. Epub 2011 Jul 4. Review PubMed PMID: 21733676
127.Lash BW, Dessain SK, Argiris A, Besa EC. Medscape Reference. Hodgkin Lymphoma. Updated 9/16/2013. Available at: http://emedicine.medscape.com/article/201886-overview#aw2aab6b2b4 Accessed 12/17/2013.
128.Lavabre-Bertrand T, Exbrayat C, Liautard J, Gaillard JP, Baskevitch PP, Poujol N, . . . Brochier J. Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. British journal of haematology. Dec 1995;91(4):871-877
129.Lee BJ, Huang YC, Chen SJ, Lin PT. Effects of coenzyme Q10 supplementationon inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition. 2012Jul;28(7-8):767-72. doi: 10.1016/j.nut.2011.11.008. Epub 2012 Feb 17. PubMedPMID: 22342390
130.Leechawengwongs E, Shearer WT. Lymphoma complicating primaryimmunodeficiency syndromes. Curr Opin Hematol. 2012 Jul;19(4):305-12. doi:10.1097/MOH.0b013e328353fa13. Review. PubMed PMID: 22525579
131.Leukemia & Lymphoma Society (2011a). Non-Hodgkin Lymphoma. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/nhl.pdf. Accessed 9/25/2013.
132.Leukemia & Lymphoma Society (2011b). Hodgkin Lymphoma. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/hodgkinlymphoma.pdf. Accessed 9/24/2013.
133.Leukemia & Lymphoma Society. 2013a. Disease Information & support page. Non-Hodgkin Lymphoma. Available at: http://www.lls.org/diseaseinformation/getinformationsupport/factsstatistics/nonhodgkinlymphoma/. Accessed 12/13/2013
134.Leukemia & Lymphoma Society. 2013b. Hodgkin Lymphoma. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/hodgkinlymphoma.pdf. Accessed 12/9/2013
135.Li Y, Liu L, Tollefsbol TO. Glucose restriction can extend normal cell lifespan and impair precancerous cell growth through epigenetic control of hTERT and p16 expression. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. May 2010;24(5):1442-1453
136.Li ZX, Ouyang KQ, Jiang X, Wang D, Hu Y. Curcumin induces apoptosis andinhibits growth of human Burkitt's lymphoma in xenograft mouse model. Mol Cells. 2009 Mar 31;27(3):283-9. doi: 10.1007/s10059-009-0036-9. Epub 2009 Mar 19. PubMedPMID: 19326074
137.Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, . . . Tao M. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. European journal of haematology. Aug 2007;79(2):132-137
138.Lim ST, Levine AM. Recent advances in acquired immunodeficiency syndrome(AIDS)-related lymphoma. CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 Review. PubMed PMID: 16020424
139.Lin WC, Tsai HF, Kuo SH, Wu MS, Lin CW, Hsu PI, Cheng AL, Hsu PN Translocation of Helicobacter pylori CagA into Human B lymphocytes, the origin ofmucosa-associated lymphoid tissue lymphoma. Cancer Res. 2010 Jul15;70(14):5740-8. doi: 10.1158/0008-5472.CAN-09-4690. Epub 2010 Jun 29. PubMedPMID: 20587516
140.Lin YT, Wu YH, Tseng CK, Lin CK, Chen WC, Hsu YC, Lee JC. Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 andattenuate virus-induced inflammation. PLoS One. 2013;8(1):e54466. doi:10.1371/journal.pone.0054466. Epub 2013 Jan 24. PubMed PMID: 23365670; PubMedCentral PMCID: PMC3554764
141.Linos A, Blair A, Gibson RW, Everett G, Van Lier S, Cantor KP, Schuman L,Burmeister L. Leukemia and non-Hodgkin's lymphoma and residential proximity toindustrial plants. Arch Environ Health. 1991 Mar-Apr;46(2):70-4. Erratum in: ArchEnviron Health 1991 Sep-Oct;46(5):305. PubMed PMID: 2006896
142.Lissoni P, Bolis S, Brivio F, Fumagalli L. A phase II study ofneuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormonemelatonin in untreatable advanced hematologic malignancies. Anticancer Res. 2000 May-Jun;20(3B):2103-5. PubMed PMID: 10928160
143.LRF. Lymphoma Research Foundation. Copyright © 2012. Common Types of T-cell Lymphoma. Available at: http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6300161#TypesMoreCommon. Accessed 12/13/2013
144.Luminari S, Bellei M, Biasoli I, Federico M. Follicular lymphoma - treatmentand prognostic factors. Rev Bras Hematol Hemoter. 2012;34(1):54-9. doi:10.5581/1516-8484.20120015. PubMed PMID: 23049385; PubMed Central PMCID:PMC3459616
145.Mackenzie GG, Queisser N, Wolfson ML, Fraga CG, Adamo AM, Oteiza PI Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells Int J Cancer. 2008 Jul 1;123(1):56-65. doi: 10.1002/ijc.23477. PubMed PMID:18386790
146.MacKenzie P, Kamili QU, Menter A, Cooper B. Lymphoma and immunosuppression: a report of a case associated with efalizumab therapy. Clin Lymphoma MyelomaLeuk. 2010 Feb;10(1):E14-6. doi: 10.3816/CLML.2010.n.011. PubMed PMID: 20223722
147.Mahdy AM, Galley HF, Abdel-Wahed MA, el-Korny KF, Sheta SA, Webster NR Differential modulation of interleukin-6 and interleukin-10 by diclofenac inpatients undergoing major surgery. Br J Anaesth. 2002 Jun;88(6):797-802. PubMedPMID: 12173196
148.Mahieux R, Gessain A. Adult T-cell leukemia/lymphoma and HTLV-1. Current hematologic malignancy reports. Oct 2007;2(4):257-264
149.Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. Feb 10 2011;117(6):1792-1798
150.Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. European journal of haematology. Supplementum. Jan 2007(67):5-14
151.Mathus-Vliegen EM. Lymphoma in coeliac disease. J R Soc Med. 1995Dec;88(12):672-7. Review. PubMed PMID: 8786586; PubMed Central PMCID: PMC1295407
152.Mellemkjaer L, Pfeiffer RM, Engels EA, Gridley G, Wheeler W, Hemminki K, . . . Landgren O. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis and rheumatism. Mar 2008;58(3):657-666
153.Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacological research: the official journal of the Italian Pharmacological Society. Jul 2010;62(1):18-34
154.Meynet O, Zunino B, Happo L, Pradelli LA, Chiche J, Jacquin MA, Mondragón L,Tanti JF, Taillan B, Garnier G, Reverso-Meinietti J, Mounier N, Michiels JF,Michalak EM, Carles M, Scott CL, Ricci JE. Caloric restriction modulates Mcl-1expression and sensitizes lymphomas to BH3 mimetic in mice. Blood. 2013 Oct3;122(14):2402-2411. Epub 2013 Aug 21. PubMed PMID: 23966420
155.Minauchi K, Koizumi K, Kondo M, Takigami M, Harada H, Fujita H, Mukai M [Remission induced by dose-reduction of immunosuppressants alone in a patientwith post-transplant lymphoproliferative disorder of central nervous systemorigin]. Rinsho Ketsueki. 2011 May;52(5):272-7. Review. Japanese. PubMed PMID:21646772
156.Mncwangi N, Chen W, Vermaak I, Viljoen AM, Gericke N. Devil's Claw-a review of the ethnobotany, phytochemistry and biological activity of Harpagophytumprocumbens. J Ethnopharmacol. 2012 Oct 11;143(3):755-71. doi:10.1016/j.jep.2012.08.013. Epub 2012 Aug 21. Review. PubMed PMID: 22940241
157.Morton LM. Dissecting lymphoma incidence to inform epidemiologic andclinical research. Leuk Lymphoma. 2013 Aug;54(8):1575-6. doi:10.3109/10428194.2013.774000. Epub 2013 Mar 8. PubMed PMID: 23391143
158.Mozaheb Z, Aledavood A, Farzad F. Diet and non-Hodgkin's lymphoma risk. Pan Afr Med J. 2012;12:53. Epub 2012 Jun 28. PubMed PMID: 22937193; PubMed CentralPMCID: PMC3428173
159.MSKCC. Memorial Sloan-Kettering Cancer Center. Diagnosis & Treatment page. Treatment for Non-Hodgkin Lymphoma. Available at: http://www.mskcc.org/cancer-care/adult/treatment-non-hodgkin-lymphoma. 2013. Accessed 11/25/2013.
160.Mukherji D, Pettengell R. Pixantrone maleate for non-Hodgkin's lymphoma Drugs Today (Barc). 2009 Nov;45(11):797-805. doi: 1396674/dot.2009.45.11.1413767 Review. PubMed PMID: 20126672
161.Mukhopadhyay-Sardar S, Rana MP, Chatterjee M. Antioxidant associatedchemoprevention by selenomethionine in murine tumor model. Mol Cell Biochem. 2000Mar;206(1-2):17-25. PubMed PMID: 10839190
162.Nastoupil LJ, Rose AC, Flowers CR. Diffuse large B-cell lymphoma: currenttreatment approaches. Oncology (Williston Park). 2012 May;26(5):488-95. Review PubMed PMID: 22730604
163.NCI. National Cancer Institute. Health Professional Version page. Adult Non-Hodgkin Lymphoma Treatment (PDQ®). Available at: http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/HealthProfessional/page4. Last updated 11/19/2013. Accessed 11/26/2013. 2013
164.Neve J. Selenium as a 'nutraceutical': how to conciliate physiological and supra-nutritional effects for an essential trace element. Current opinion in clinical nutrition and metabolic care. Nov 2002;5(6):659-663
165.Oh EG, Bang SY, Kim SH, Hyun SS, Chu SH, Jeon JY, Im JA, Lee JE, Lee MK Therapeutic lifestyle modification program reduces plasma levels of thechemokines CRP and MCP-1 in subjects with metabolic syndrome. Biol Res Nurs. 2013Jan;15(1):48-55. doi: 10.1177/1099800411416637. Epub 2011 Aug 22. PubMed PMID:21859748
166.Ollberding NJ, Aschebrook-Kilfoy B, Caces DB, Smith SM, Weisenburger DD,Chiu BC. Dietary intake of fruits and vegetables and overall survival innon-Hodgkin lymphoma. Leuk Lymphoma. 2013 Apr 30. [Epub ahead of print] PubMedPMID: 23488609
167.Ollberding NJ, Aschebrook-Kilfoy B, Caces DB, Wright ME, Weisenburger DD,Smith SM, Chiu BC. Phytanic acid and the risk of non-Hodgkin lymphoma. Carcinogenesis. 2013 Jan;34(1):170-5. doi: 10.1093/carcin/bgs315. Epub 2012 Oct5. PubMed PMID: 23042099; PubMed Central PMCID: PMC3534193
168.Olsson H, Brandt L. Risk of non-Hodgkin's lymphoma among men occupationally exposed to organic solvents. Scandinavian journal of work, environment & health. Aug 1988;14(4):246-251
169.Ostermann T, Büssing A. Retrolective studies on the survival of cancerpatients treated with mistletoe extracts: a meta-analysis. Explore (NY). 2012Sep-Oct;8(5):277-81. doi: 10.1016/j.explore.2012.06.005. Review. PubMed PMID:22938746
170.Otte A, van de Wiele C, Dierckx RA. Radiolabeled immunotherapy innon-Hodgkin's lymphoma treatment: the next step. Nucl Med Commun. 2009Jan;30(1):5-15. doi: 10.1097/MNM.0b013e328313e565. Review. PubMed PMID: 19020470
171.Papadatos-Pastos D, Pettengell R. Pixantrone: merging safety with efficacy. Expert Rev Hematol. 2013 Feb;6(1):25-33. doi: 10.1586/ehm.12.61. Review. PubMedPMID: 23373776
172.Parbhakar S, Cin AD. Primary cutaneous B-cell lymphoma: Role of surgery. CanJ Plast Surg. 2011 Summer;19(2):e12-4. PubMed PMID: 22654537; PubMed CentralPMCID: PMC3328108
173.Parent MÉ, El-Zein M, Rousseau MC, Pintos J, Siemiatycki J. Night work andthe risk of cancer among men. Am J Epidemiol. 2012 Nov 1;176(9):751-9. doi:10.1093/aje/kws318. Epub 2012 Oct 3. PubMed PMID: 23035019
174.Péan E, Flores B, Hudson I, et al. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2013;18(5):625-33
175.Persengiev SP, Kyurkchiev S. Selective effect of melatonin on theproliferation of lymphoid cells. Int J Biochem. 1993 Mar;25(3):441-4. PubMedPMID: 8462731
176.Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C,Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeuticagents as a single-agent salvage treatment in patients with relapsed orrefractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label,randomised trial. Lancet Oncol. 2012 Jul;13(7):696-706. doi:10.1016/S1470-2045(12)70212-7. Epub 2012 May 30. Erratum in: Lancet Oncol. 2012Jul;13(7):e285. PubMed PMID: 22652183
177.Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. The Journal of infectious diseases. Feb 1991;163(2):311-318
178.Portlock CS, Hamlin P, Noy A, Chey W, Gaydos CA, Palomba L, Schwartz I,Corcoran S, Rosenzweig L, Walker D, Papanicolaou G, Markowitz A. Infectiousdisease associations in advanced stage, indolent lymphoma (follicular andnonfollicular): developing a lymphoma prevention strategy. Ann Oncol. 2008Feb;19(2):254-8. Epub 2007 Oct 26. PubMed PMID: 17965114
179.Portlock CS. Hodgkin Lymphoma (Hodgkin's Disease). The Merck Manual Home Health Handbook online. Lymphomas page. Available at: http://www.merckmanuals.com/home/blood_disorders/lymphomas/hodgkin_lymphoma.html. Last updated 10/2012. Accessed 11/26/2013.
180.Poullot E, Bouscary D, Guyader D, Ghandour C, Roussel M, Fest T, Houot R,Lamy T. Large granular lymphocyte leukemia associated with hepatitis C virusinfection and B cell lymphoma: improvement after antiviral therapy. LeukLymphoma. 2013 Aug;54(8):1797-9. doi: 10.3109/10428194.2012.752486. Epub 2012 Dec26. PubMed PMID: 23176408
181.Puligheddu M, Conti S, Campagna M, Meloni M, Pau M, Cocco P, Marrosu F [Cancer risk among shift workers: a review]. G Ital Med Lav Ergon. 2012Jul-Sep;34(3 Suppl):624-6. Review. Italian. PubMed PMID: 23405734
182.Qiao Q, Jiang Y, Li G. Curcumin enhances the response of non-Hodgkin's lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation. Oncology reports. Jan 2013b;29(1):380-386
183.Qiao Q, Jiang Y, Li G. Inhibition of the PI3K/AKT-NF-κB pathway withcurcumin enhanced radiation-induced apoptosis in human Burkitt's lymphoma. JPharmacol Sci. 2013a;121(4):247-56. PubMed PMID: 23603894
184.Ramsay AD. 30 years of lymph node pathology: biomarkers and other advances. Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):103-9. doi:10.1097/PAI.0b013e31827ea77c. Review. PubMed PMID: 23417072
185.Rana MP, Sardar S, Chatterjee M. Selenomethionine in the inhibition of atransplantable murine lymphoma: reflection on hepatic drug metabolizing enzymes. Tumour Biol. 1996;17(2):102-9. PubMed PMID: 8658012
186.Rancea M, Monsef I, von Tresckow B, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. The Cochrane database of systematic reviews. 2013;6:Cd009411.
187.Rapozzi V, Zorzet S, Comelli M, Mavelli I, Perissin L, Giraldi T. Melatonin decreases bone marrow and lymphatic toxicity of adriamycin in mice bearing TLX5lymphoma. Life Sci. 1998;63(19):1701-13. PubMed PMID: 9806226
188.Reynolds GM, Billingham LJ, Gray LJ, et al. Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of ‘B’ symptoms and failure to achieve complete remission in patients with advanced Hodgkin’s disease. Br J Haematol. 2002;118(1):195-201
189.Rezvani K, de Lavallade H. Vaccination strategies in lymphomas and leukaemias: recent progress. Drugs. Sep 10 2011;71(13):1659-1674
190.Riddihough G, Zahn LM. Epigenetics. What is epigenetics? Introduction. Science (New York, N.Y.). Oct 29 2010;330(6004):611
191.Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, . . . Davis DM. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood. Jun 6 2013;121(23):4694-4702
192.Sánchez-Hidalgo M, Lee M, de la Lastra CA, Guerrero JM, Packham G. Melatonininhibits cell proliferation and induces caspase activation and apoptosis in humanmalignant lymphoid cell lines. J Pineal Res. 2012 Nov;53(4):366-73. doi:10.1111/j.1600-079X.2012.01006.x. Epub 2012 May 14. PubMed PMID: 22582944
193.Saxton JA Jr, Silberberg M. Skeletal growth and ageing in rats receivingcomplete or restricted diets. Am J Anat. 1947 Nov;81(3):445-75. PubMed PMID:18895349
194.Schernhammer ES, Bertrand KA, Birmann BM, Sampson L, Willett WC, FeskanichD. Consumption of artificial sweetener- and sugar-containing soda and risk oflymphoma and leukemia in men and women. Am J Clin Nutr. 2012 Dec;96(6):1419-28. doi: 10.3945/ajcn.111.030833. Epub 2012 Oct 24. Erratum in: Am J Clin Nutr. 2013 Aug;98(2):512. PubMed PMID: 23097267; PubMed Central PMCID: PMC3497928
195.Schöllkopf C, Melbye M, Munksgaard L, Smedby KE, Rostgaard K, Glimelius B,Chang ET, Roos G, Hansen M, Adami HO, Hjalgrim H. Borrelia infection and risk of non-Hodgkin lymphoma. Blood. 2008 Jun 15;111(12):5524-9. doi:10.1182/blood-2007-08-109611. Epub 2008 Apr 18. PubMed PMID: 18424667; PubMedCentral PMCID: PMC2972577
196.Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, WinterJN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA,Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW. Vaccination withpatient-specific tumor-derived antigen in first remission improves disease-freesurvival in follicular lymphoma. J Clin Oncol. 2011 Jul 10;29(20):2787-94. doi:10.1200/JCO.2010.33.3005. Epub 2011 May 31. PubMed PMID: 21632504; PubMed CentralPMCID: PMC3139394
197.Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, Kay NE Clinical effects of oral green tea extracts in four patients with low gradeB-cell malignancies. Leuk Res. 2006 Jun;30(6):707-12. Epub 2005 Dec 1. PubMedPMID: 16325256
198.Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. Sep 1 2012;380(9844):848-857
199.Shehzad A, Lee J, Lee YS. Curcumin in various cancers. Biofactors. 2013Jan-Feb;39(1):56-68. doi: 10.1002/biof.1068. Epub 2013 Jan 10. Review. PubMedPMID: 23303705
200.Shields BA, Engelman RW, Fukaura Y, Good RA, Day NK. Calorie restrictionsuppresses subgenomic mink cytopathic focus-forming murine leukemia virustranscription and frequency of genomic expression while impairing lymphomaformation. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11138-42. PubMed PMID:1763029; PubMed Central PMCID: PMC53089
201.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4. PubMed PMID: 22237781
202.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17. PubMed PMID:23335087
203.Singh AT, Ghosh M, Forte TM, Ryan RO, Gordon LI. Curcumin nanodisk-inducedapoptosis in mantle cell lymphoma. Leuk Lymphoma. 2011 Aug;52(8):1537-43. doi:10.3109/10428194.2011.584253. Epub 2011 Jun 24. PubMed PMID: 21699455; PubMedCentral PMCID: PMC3321639
204.Singh N, Singh SM, Shrivastava P. Effect of Tinospora cordifolia on theantitumor activity of tumor-associated macrophages-derived dendritic cells Immunopharmacol Immunotoxicol. 2005;27(1):1-14. PubMed PMID: 15803856
205.Singh SM, Singh N, Shrivastava P. Effect of alcoholic extract of Ayurvedicherb Tinospora cordifolia on the proliferation and myeloid differentiation ofbone marrow precursor cells in a tumor-bearing host. Fitoterapia. 2006Jan;77(1):1-11. Epub 2005 Dec 2. PubMed PMID: 16326030
206.Sisson S, Kuter DJ, Garg S, et al. Non-Hodgkin lymphoma. First Consult. Clinical Key. Summary page. Available at: https://www.clinicalkey.com/#!/ContentPlayerCtrl/doPlayContent/21-s2.0-1014672/{"scope":"all","query":"lymphadenopathy"}. 2013. Accessed 11/26/2013
207.Skibola CF. Obesity, diet and risk of non-Hodgkin lymphoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Mar 2007;16(3):392-395
208.Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, . . . Wolff RR. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Apr 2007;16(4):747-755.
209.Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma andother non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011 Nov;21(5):293-8 doi: 10.1016/j.semcancer.2011.09.010. Epub 2011 Sep 18. Review. PubMed PMID:21945518
210.Smith LT, Otterson GA, Plass C. Unraveling the epigenetic code of cancer fortherapy. Trends Genet. 2007 Sep;23(9):449-56. Epub 2007 Aug 6. Review. PubMedPMID: 17681396
211.Solans-Laqué R, López-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M,Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphomadevelopment in primary Sjögren's syndrome. Semin Arthritis Rheum. 2011Dec;41(3):415-23. doi: 10.1016/j.semarthrit.2011.04.006. Epub 2011 Jun 12. PubMedPMID: 21665245
212.Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-infective propertiesof epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol. 2013 Mar;168(5):1059-73. doi: 10.1111/bph.12009. Review. PubMed PMID: 23072320;PubMed Central PMCID: PMC3594666
213.Stevens J, Waters R, Sieniawska C, Kassam S, Montoto S, Fitzgibbon J,Rohatiner A, Lister A, Joel S. Serum selenium concentration at diagnosis andoutcome in patients with haematological malignancies. Br J Haematol. 2011Aug;154(4):448-56. doi: 10.1111/j.1365-2141.2011.08744.x. Epub 2011 Jul 20. PubMed PMID: 21770918
214.Straus DJ. Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult hodgkin lymphoma patient. Ther Adv Hematol. 2011Apr;2(2):111-9. doi: 10.1177/2040620711402414. PubMed PMID: 23556081; PubMedCentral PMCID: PMC3573398
215.Sumba PO, Kabiru EW, Namuyenga E, Fiore N, Otieno RO, Moormann AM, Orago AS,Rosenbaum PF, Rochford R. Microgeographic variations in Burkitt's lymphomaincidence correlate with differences in malnutrition, malaria and Epstein-Barrvirus. Br J Cancer. 2010 Nov 23;103(11):1736-41. doi: 10.1038/sj.bjc.6605947. PubMed PMID: 21102592; PubMed Central PMCID: PMC2994219
216.Szwajcer D. CancerCare Manitoba/University of Manitoba. HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia. In: ClinicalTrial.gov [Internet]. Manitoba (Canada). National Library of Medicine (US). 2011 [cited 2013 Nov 26]. Available at: http://clinicaltrials.gov/show/NCT00524667%20and%20http://clinicaltrials.gov/show/NCT00810680. NLM Identifier: NCT00524667
217.Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkinlymphoma in response to antiviral therapy for hepatitis C virus infection. InternMed. 2012;51(19):2745-7. Epub 2012 Oct 1. PubMed PMID: 23037466
218.Tantawy AA, Elmasry OA, Shaaban M, Toaima DN, El Shahat AM. Radionuclideventriculography detects early anthracycline cardiotoxicity in children withHodgkin lymphoma. J Pediatr Hematol Oncol. 2011 May;33(4):e132-7. doi:10.1097/MPH.0b013e318212eb6b. PubMed PMID: 21516011
219.Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Critical reviews in oncology/hematology. Oct 2005;56(1):155-167
220.Terbach N, Williams RS. Structure-function studies for the panacea, valproic acid. Biochem Soc Trans. 2009;37(Pt 5):1126-32
221.Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells. The lancet oncology. Jan 2004;5(1):11-18
222.Thomas SK, Kwak LW. Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial. Seminars in oncology. Jun 2012;39(3):253-262
223.Thompson CA, Habermann TM, Wang AH, Vierkant RA, Folsom AR, Ross JA, Cerhan JR. Antioxidant intake from fruits, vegetables and other sources and risk ofnon-Hodgkin's lymphoma: the Iowa Women's Health Study. Int J Cancer. 2010 Feb15;126(4):992-1003. doi: 10.1002/ijc.24830. PubMed PMID: 19685491; PubMed CentralPMCID: PMC2798902
224.Thompson CA, Mauck K, Havyer R, et al. Care of the Adult Hodgkin Lymphoma Survivor. Am J Med. 2011;124(12):1106-1112
225.Tian Y, Ye Y, Gao W, Chen H, Song T, Wang D, . . . Ren C. Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. International journal of colorectal disease. Jan 2011;26(1):13-22.
226.Todisco M, Casaccia P, Rossi N. Cyclophosphamide plus somatostatin, bromociptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin’s lymphomas at advanced stage: results of a phase II trial. Cancer Biother Radiopharm. 2001;16(2):171-7
227.Todisco M. Low-grade non-Hodgkin lymphoma at advanced stage: a casesuccessfully treated with cyclophosphamide plus somatostatin, bromocriptine,retinoids, and melatonin. Am J Ther. 2007 Jan-Feb;14(1):113-5. PubMed PMID:17303979
228.Todisco M. Relapse of high-grade non-Hodgkin's lymphoma after autologousstem cell transplantation: a case successfully treated with cyclophosphamide plussomatostatin, bromocriptine, melatonin, retinoids, and ACTH. Am J Ther. 2006Nov-Dec;13(6):556-7. PubMed PMID: 17122540
229.Tomita N, Takasaki H, Fujisawa S, Miyashita K, Ogusa E, Kishimoto K, . . . Ishigatsubo Y. Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma. Journal of clinical and experimental hematopathology: JCEH. 2013;53(2):121-125
230.Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet. Sep 1 2012;380(9844):836-847.
231.Trofe J, Buell JF, First MR, Hanaway MJ, Beebe TM, Woodle ES. The role ofimmunosuppression in lymphoma. Recent Results Cancer Res. 2002;159:55-66. Review. PubMed PMID: 11785845
232.Troxell ML, Bangs CD, Cherry AM, Natkunam Y, Kong CS. Cytologic diagnosis of Burkitt lymphoma. Cancer. 2005 Oct 25;105(5):310-8
233.Trubiani O, Recchioni R, Moroni F, Pizzicannella J, Caputi S, Di Primio R. Melatonin provokes cell death in human B-lymphoma cells bymitochondrial-dependent apoptotic pathway activation. J Pineal Res. 2005Nov;39(4):425-31. PubMed PMID: 16207299
234.Tsubaki K, Horiuchi A, Kitani T, Taniguchi N, Masaoka T, Shibata H, YonezawaT, Tsubakio T, Kawagoe H, Shinohara Y, et al. [Investigation of the preventiveeffect of CoQ10 against the side-effects of anthracycline antineoplastic agents]. Gan To Kagaku Ryoho. 1984 Jul;11(7):1420-7. Japanese. PubMed PMID: 6742867
235.Tsuboi I, Tanaka H, Nakao M, Shichijo S, Itoh K. Nonsteroidalanti-inflammatory drugs differentially regulate cytokine production in humanlymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast todown-regulation of IL-6 production. Cytokine. 1995 May;7(4):372-9. PubMed PMID:8589268
236.Ujjani C, Cheson BD. The optimal management of follicular lymphoma: anevolving field. Drugs. 2013 Sep;73(13):1395-403. doi: 10.1007/s40265-013-0092-5. PubMed PMID: 23884816
237.van Dorp W, van Beek RD, Laven JS, Pieters R, de Muinck Keizer-Schrama SM,van den Heuvel-Eibrink MM. Long-term endocrine side effects of childhoodHodgkin's lymphoma treatment: a review. Hum Reprod Update. 2012Jan-Feb;18(1):12-28. doi: 10.1093/humupd/dmr038. Epub 2011 Sep 6. Review. PubMed PMID: 21896559
238.Vendrame E, Martínez-Maza O. Assessment of pre-diagnosis biomarkers ofimmune activation and inflammation: insights on the etiology of lymphoma. JProteome Res. 2011 Jan 7;10(1):113-9. doi: 10.1021/pr100729z. Epub 2010 Oct 1. Review. PubMed PMID: 20886858; PubMed Central PMCID: PMC3017655
239.Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, . . . Shpilberg O. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. Journal of the National Cancer Institute. Dec 7 2011;103(23):1799-1806
240.Villanueva H, de Cerio AL, Inoges S, Pastor F, Soldevilla MM, Bendandi M. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma. Expert Rev Vaccines. 2011 Dec;10(12):1661-9. doi: 10.1586/erv.11.132. PubMedPMID: 22085168
241.Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, . . . Rodeghiero F. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. Sep 2006;17(9):1434-1440
242.Vishvakarma NK, Kumar A, Singh SM. Role of curcumin-dependent modulation of tumor microenvironment of a murine T cell lymphoma in altered regulation of tumorcell survival. Toxicol Appl Pharmacol. 2011 May 1;252(3):298-306. doi:10.1016/j.taap.2011.03.002. Epub 2011 Mar 11. PubMed PMID: 21397623
243.von der Weid NX. Adult life after surviving lymphoma in childhood. Support Care Cancer. 2008 Apr;16(4):339-45
244.Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A,Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, HallB, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK. A phase 2 multicentrestudy of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013 May;161(3):357-66. doi: 10.1111/bjh.12266. Epub 2013 Feb 25. PubMed PMID: 23432640
245.Wada H, Tsuboi R, Kato Y, Sugaya M, Tobinai K, Hamada T, Shimamoto T,Noguchi K, Iwatsuki K. Phase I and pharmacokinetic study of the oral histonedeacetylase inhibitor vorinostat in Japanese patients with relapsed or refractorycutaneous T-cell lymphoma. J Dermatol. 2012 Oct;39(10):823-8. doi:10.1111/j.1346-8138.2012.01554.x. Epub 2012 Apr 16. PubMed PMID: 22506596
246.Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathologicalassociation and therapeutic implication. Chang Gung Med J. 2009Sep-Oct;32(5):471-82. Review. PubMed PMID: 19840504
247.Wang SQ. [Electrocardiogram analysis of adriamycin cardiotoxicity in 160cases]. Zhonghua Zhong Liu Za Zhi. 1991 Jan;13(1):71-3. Chinese. PubMed PMID:1889343
248.Wang X, Zhao HR, Gu X, Liu P, Bikmituofu H. [Plasma interleukin-6 andinterleukin-10 levels in different subtypes of lymphoma and their clinicalsignificance]. Nan Fang Yi Ke Da Xue Xue Bao. 2011 Aug;31(8):1360-4. Chinese. PubMed PMID: 21868324
249.Ward MH, Mark SD, Cantor KP, Weisenburger DD, Correa-Villasenor A, Zahm SH. Drinking water nitrate and the risk of non-Hodgkin's lymphoma. Epidemiology (Cambridge, Mass.). Sep 1996;7(5):465-471
250.Wilson KS. Regression of follicular lymphoma with Devil's Claw: coincidence or causation? Curr Oncol. 2009 Aug;16(4):67-70. PubMed PMID: 19672427; PubMedCentral PMCID: PMC2722058
251.Wormser GP. Clinical practice. Early Lyme disease. N Engl J Med. 2006 Jun29;354(26):2794-801. Review. PubMed PMID: 16807416
Xu XJ, Zhao HZ, Tang YM. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials. Leukemia & lymphoma. Feb 2013;54(2):255-260.
</p>

<!-- Resumen de Esclerosis Lateral Amiotrófica -->
<h2 style="font-size: 24px; color: #333; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #ff5722; padding-bottom: 10px;">
    <i class="fa fa-amyotrophic-lateral-sclerosis" style="margin-right: 10px; color: #ff5722;"></i> Amyotrophic Lateral Sclerosis
</h2>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #ff5722; padding-bottom: 10px;">
    Amyotrophic lateral sclerosis (ALS) is a degenerative neuromuscular disease that has an average survival, after diagnosis, of three to five years. The protocol is based on the application of diagnostic strategies and conventional treatments and emerging medical therapies. Favorably, conventional treatments for the treatment of ALS try to reduce symptoms by slowing down the progression of the disease through the personalized use of scientifically studied medications and natural therapies that are used as adjuvants, together with conventional therapies, which has increased the hope of delay disease progression and improve quality of life.
</p>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #ff5722; padding-bottom: 10px;">
    The conventional treatment of this disease is based on multitherapy based on:
    <ul>
        <li>Riluzole: buffers the effects of glutamate accumulation and may prolong survival for a few months;</li>
        <li>Edaravone: a free radical scavenger that can reduce oxidative stress;</li>
        <li>Medications to relieve painful muscle cramps;</li>
        <li>Medications to reduce excessive salivation;</li>
        <li>Stem cell therapy;</li>
        <li>Gene replacement therapy;</li>
        <li>Insulin-like growth factor-1 (IGF-1), which modulates neuronal growth and function;</li>
        <li>Injections can help slow the progression of the disease, but the results have been mixed that can be improved with the use of adjuvants that also minimize the occurrence of fatal diseases and increase quality of life.</li>
    </ul>
</p>
<p style="margin-bottom: 20px; text-align: justify; border-bottom: 2px solid #ff5722; padding-bottom: 10px;">
    To improve the pharmacological actions of the drugs used in the prevention, control, and treatment of Amyotrophic lateral sclerosis and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term that usually contribute to the development of alterations, syndromes, and deadly diseases, such as cancer, and can also...
</p>

<!-- Referencias -->
<h2 style="font-size: 24px; color: #333; margin-top: 40px; margin-bottom: 20px; text-align: center; border-bottom: 2px solid #ff5722; padding-bottom: 10px;">
    <i class="fa fa-references" style="margin-right: 10px; color: #ff5722;"></i> References
</h2>
<p style="text-align: justify;">
   1.Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15(7-8):610-7.
2.ALS Association (ALSA). Available at: http://www.alsa.org/about-als/ Accessed 3/14/2012
3.Andersen PM, Borasio GD, Dengler R, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol 2005; 12:921.
4.Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. CurrNeurolNeurosci Rep 2006; 6:37.
5.Andreassen OA, Dedeoglu A, et al. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp Neurol. 2001b;168(2):419–424.
6.Andreassen OA, Dedeoglu A, et al. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport. 2000;11(11):2491–2493.
7.Andreassen OA, Jenkins BG, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem. 2001a; 77(2):383–390.
8.Atassi N, Ratai EM, et al. A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 December;11(6): 508–513.
9.Babu GN, Kumar A, et al. Chronic Pretreatment with Acetyl-l-Carnitine and ±DL-α-Lipoic Acid Protects Against Acute Glutamate-Induced Neurotoxicity in Rat Brain by Altering Mitochondrial Function. Neurotoxicity Research, 2009;19(2).
10.Baillet A, Chantepedrix V, et al. The Role of Oxidative Stress in Amyotrophic Lateral Sclerosis and Parkinson’s Disease. Neurochem Res (2010) 35:1530–1537.
11.Banack SA, Caller TA, et al. The Cyanobacteria Derived Toxin Beta-N-Methylamino-L-Alanine and Amyotrophic Lateral Sclerosis. Toxins (Basel), 2010;2(12).
12.Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58:495.
13.Beal MF. Neuroprotective Effects of Creatine. Amino Acids (2011) 40:1305–1313.
14.Benkler C, Offen D, et al. Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application. EPMA Journal (2010) 1:343–361.
15.Bigini P, Larini S, et al. Acetyl-l-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons. Neuroscience Letters 329 (2002) 334–338.
16.Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. NeurolClin 2001;19:829.
17.Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J ClinPharmacol 2011;51:1177.
18.Brand MD and Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J. 2011 Apr 15;435(2):297-312.
19.Caban-Holt A, Mattingly M, et al. Neurodegenerative memory disorders: a potential role of environmental toxins. NeurolClin. 2005;23(2):485–521.
20.Callaghan B, Feldman D, et al. The Association of Exposure to Lead, Mercury, and Selenium and the Development of Amyotrophic Lateral Sclerosis and the Epigenetic Implications. Neurodegenerative Dis 2011;8:1–8.
21.Cameron A, Rosenfeld J. Nutritional issues and supplements in amyotrophic lateral sclerosis and other neurodegenerative disorders. CurrOpinClinNutrMetab Care. 2002;5(6):631–643.
22.Carlesi C, et al. Strategies for clinical approach to neurodegeneration in Amyotrophic lateral sclerosis. Arch Ital Biol. 2011 Mar;149(1):151-67.
23.Carmeli C, Knyazeva MG, et al. Glutathione Precursor N-Acetyl-Cysteine Modulates EEG Synchronization in Schizophrenia Patients: A Double-Blind, Randomized, Placebo-Controlled Trial. PLos One, 2012;7(2).
24.Carta A, Calvani M, et al. Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere. Ann N Y Acad Sci. 1993;695:324–326.
25.Carvalho-Silva LB, Mourao LF, et al. Effect of nutritional supplementation with milk whey proteins in amyotrophic lateral sclerosis patients. Arquivos de Neuro-Psiquiatria, 2010; 68(2).
26.Cassarino DS, Bennett JP Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Brain Res Rev 1999;29:1.
27.Cheah BC and Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Dec;13(12):911-20.
28.Chio A, Calva A, et al. ALS in Italian professional soccer players: The risk is still present and could be soccer-specific. Amyotrophic Lateral Sclerosis, 2009.
29.Chiò  A, Traynor BJ, Lombardo F, et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology 2008; 70:533.
30.Cleveland DW. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron. 1999;24(3):515–520.
31.ClinicalTrials.gov. Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) (MITOTARGET). Updated 05/2010: http://clinicaltrials.gov/ct2/show/NCT00868166. Accessed 03/06/2012.
32.Colombo ML. An update on vitamin E, tocopherol and tocotrienol-perspectives. Molecules. 2010 Mar 24;15(4):2103-13.
33.Cozzolino M and Carri MT. Mitochondrial Dysfunction in ALS. Progress in Neurobiology, 2011.
34.Crugnola V, Lamperti C, et al. Mitochondrial Respiratory Chain Dysfunction in Muscle From Patients With Amyotrophic Lateral Sclerosis. Arch Neurol. 2010;67(7):849-854.
35.D’Alessandro G, Calcagno E, et al. Glutamate and glutathione interplay in a motor neuronal model of amyotrophic lateral sclerosis reveals altered energy metabolism. Neurobiology of Disease 2011; 43.
36.Dawson MI. The importance of vitamin A in nutrition. Curr Pharm Des. 2000 Feb;6(3):311-25.
37.De Vos KJ, Chapman AL, et al. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Human Molecular Genetics, 2007; 16(22).
38.Dunlop J, Beal McIlvain H, She Y, Howland DS. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 2003; 23:1688.
39.Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18(sup1):11-19.
40.Ermilova IP, Ermilov VB, et al. Protection by dietary zinc in ALS mutant G93A SOD transgenic mice. NeurosciLett. 2005;379(1):42–46.
41.Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002;136(1):42–53.
42.Exner R, Wessner B, et al. Therapeutic potential of glutathione. Wien KlinWochenschr. 2000;112(14):610–616.
43.Faes L and Callewaert G. Mitochondrial Dysfunction in Familial Amyotrophic Lateral Sclerosis. Journal of Bioenergetics and Biomembranes, 2011; 43(6).
44.Fang F, Kwee LC, et al. Association Between Blood Lead and the Risk of Amyotrophic Lateral Sclerosis. American Journal of Epidemiology, 2010; 171(10).
45.FDA. Food and Drug Administration. News & Events page. FDA approves drug to treat ALS. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm557102.htm. 5/5/2017. Accessed 5/2017.
46.Ferrante KL, Shefner J, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology December 13, 2005 vol. 65 no. 11: 1834-1836.
47.Ferrante RJ, Klein AM, et al. Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. J MolNeurosci. 2001;17(1):89–96.
48.Fosslien E. Mitochondrial medicine—molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci. 2001;31(1):25–67.
49.Franz CK, Federici T, Yang J, et al. Intraspinal cord delivery of IGF-1 mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis. 2009 ;33(3):473-81.
50.Ganji V and Kafal MR. Population prevalence, attributable risk, and attributable risk percentage for high methylmalonic acid concentrations in the post-folic acid fortification period in the US. Nutrition & Metabolism 2012, 9:2.
51.Giess  R, Naumann M, Werner E, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J NeurolNeurosurg Psychiatry 2000; 69:121.
52.Grabrucker AM, Rowan M, et al. Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review. Drug DelivLett. 2011 September;1(1): 13–23.
53.Gresham LS, Molgaard CA , et al. Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study. Neuroepidemiology. 1986;5(1):29–38.
54.Hagen TM, Liu J, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. ProcNatlAcadSci USA. 2002;99(4):1870–1875.
55.Henderson JT, Javaheri M, et al. Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. J Neurosci. 1996;16(23):7574–7582.
56.Hensley K, Mhatre M, et al. On the Relation of Oxidative Stress to Neuroinflammation: Lessons Learned from the G93A-SOD1 Mouse Model of Amyotrophic Lateral Sclerosis. Antioxidants & Redox Signaling, 2006; 8(11-12).
57.Hester ME, FouseKD, et al. AAV as a Gene Transfer Vector for the Treatment of Neurological Disorders: Novel Treatment Thoughts for ALS. Current Gene Therapy, Volume 9, Number 5, October 2009, pp. 428-433(6).
58.Hong JT, Ryu SR, et al. Neuroprotective effect of green tea extract in experimental ischemia-reperfusion brain injury. Brain Res Bull. 2000;53(6):743–749.
59.Hu M, SkibstedLH. Kinetics of reduction of ferrylmyoglobin by (-)-epigallocatechingallate and green tea extract. J Agric Food Chem. 2002;50(10):2998–3003.
60.Ilieva EV, Ayala V, et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis Brain (2007), 130.
61.Izumi Y and Kaji R. [Clinical trials of ultra-high-dose methylcobalamin in ALS]. Brain Nerve. 2007 Oct;59(10):1141-7.
62.Jiang F, DeSilva S, et al. Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice. J NeurolSci, 2000;180(1–2):52–54.
63.Jin HW, Flatters SJ, et al. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Experimental Neurology 210 (2008) 229–237.
64.Johnson FO and Atchison WD. The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis. NeuroToxicology 30 (2009) 761–765.
65.Kanekura K, Suzuki H, et al. ER Stress and Unfolded Protein Response in Amyotrophic Lateral Sclerosis. MolNeurobiol (2009) 39:81–89.
66.Karch CM, Prudencio M, Winkler DD, et al. Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. ProcNatlAcadSci USA 2009; 106:7774.
67.Kauffman P, Thompson JL, et al. Phase II Trial of CoQ10 for ALS Finds Insufficient Evidence to Justify Phase III. Ann Neurol. 2009;66:235–244.
68.Kawamata K and Manfredi G. Mitochondrial Dysfunction and Intracellular Calcium Dysregulation in ALS. Mechanisms of Ageing and Development, 2011; 131(7-8).
69.Kim D, Nguyen MD, et al. SIRT1deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. The EMBO Journal (2007) 26, 3169–3179.
70.Kim YH, Park KH, et al. Transcriptional Activation of the Cu,Zn-Superoxide Dismutase gene through the AP2 site by ginsenosideRb2 extracted from a medicinal plant, Panax ginseng. J Biol Chem. 1996 Oct 4;271(40):24539-43.
71.Kira Y, Nishikawa M, et al. L-Carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Research, 2006; 1070.
72.Klopstock T, Elstner M, et al. Creatine in mouse models of neurodegeneration and aging. Amino Acids (2011) 40:1297–1303.
73.Kobayashi MS, Han D, Packer L. Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity. Free Radic Res. 2000;32(2):115–124.
74.Kokkalis ZT, SoucacosPN, et al. Effect of Acetyl-L-Carnitine on Axonal Sprouting Following Donor Nerve Injury Distal to an End-to-Side Neurorrhaphy Model. Journal of reconstructive Microsurgery, 2009; 25(8).
75.Kolacek M, Muchova J, et al. Effect of Natural Polyphenols, Pycnogenol® on Superoxide Dismutase and Nitric Oxide Synthase in Diabetic Rats. Prague Medical Report, 2010; 111 (4).
76.Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998; 18:3241.
77.Kuhnlein P, Gdynia HJ, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nature Clinical Practice, 2008; 4(7).
78.Kwiatkowski TJ, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009 Feb 27;323(5918):1205-8.
79.Lagier-Tourenne C and Cleveland DW. Rethinking ALS: The FUS about TDP-43. Cell 136, March 20, 2009.
80.Leishear K, Lucci F, et al. Vitamin B12 and Homocysteine Levels and 6-Year Change in Peripheral Nerve Function and Neurological Signs. Journal of Gerentology, 2011.
81.Lepore AC, Haenggeli C, et al. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Research, 2007; 1185.
82.Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20:589.
83.Lindberg MJ, Tibell L, Oliveberg M. Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state. ProcNatlAcadSci USA 2002; 99:16607.
84.Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003; 61:1279.
85.Liu J, Lillo C, Jonsson PA, et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 2004; 43:5.
86.Liu J. The Effects and Mechanisms of Mitochondrial Nutrient α-Lipoic Acid on Improving Age-Associated Mitochondrial and Cognitive Dysfunction: An Overview. Biomedical and Life Sciences, 2008; 33(1).
87.Lo Coco D, Marchese S, Pesco MC, et al. Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology 2006; 67:761.
88.Lunn JS, Hefferan MP, et al. Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors, June 2009; 27(3): 133–140.
89.Mackenzie IR, Bigio EH, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Annals of Neurology, 2007; 61(5).
90.Mancuso M, Orsucci D, et al. Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders. Current Drug Targets, 2010 , 11, 111-121.
91.Mandel SA, Amit T, et al. Targeting Multiple Neurodegenerative Diseases Etiologies with Multimodal-Acting Green Tea Catechins. The Journal of Nutrition, 2008.
92.Mandel SA, Amit T, et al. Understanding the Broad-Spectrum Neuroprotective Action Profile of Green Tea Polyphenols in Aging and Neurodegenerative Diseases. Journal of Alzheimer’s Disease, 2011; 25(2).
93.Mandl J, et al.Vitamin C: update on physiology and pharmacology. Br J Pharmacol. 2009 Aug;157(7):1097-110. Epub 2009 Jun 5.
94.Mano Y, Takayanagi T, et al. [Amyotrophic lateral sclerosis and mercury—preliminary report]. RinshoShinkeigaku. 1990;30(11):1275–1277.
95.Martin LJ. Mitochondrial pathobiology in ALS. J Bioenerg Biomembr. 2011;43(6):569-79.
96.Martinez HR, et al. Stem cell transplantation in amyotrophic lateral sclerosis patients. Methodological approach, safety, and feasibility. Cell Transplant. 2012 Feb 13. [Epub ahead of print]
97.Martinez HR, et al. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy. 2009;11(1):26-34.
98.Matsumoto Y, et al. Nizofenone, a neuroprotective drug, suppresses glutamate release and lactate accumulation. Eur J Pharmacol. 1994 Sep 1;262(1-2):157-61.
99.Matthews RT, Yang L, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. ProcNatlAcadSci USA. 1998;95(15):8892–8897.
100.Mazzini L, Balzarini C, et al. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J Neurol Sci. 2001;191(1–2):139–144.
101.Miana-Mena FJ, Gonzalez-Mingot C, et al. Monitoring systemic oxidative stress in an animal model of amyotrophic lateral sclerosis J Neurol (2011) 258:762–769.
102.Miller RG, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001447.
103.Mitchell J. Amyotrophic lateral sclerosis: toxins and environment. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(4):235–250.
104.Moore E, Mander A, et al. Cognitive impairment and vitamin B12: a review. International Psycogeriatrics, 2012.
105.Morozova N, Weisskopf MG, et al. Diet and Amytorophic Lateral Sclerosis. Epidemiology, 2008; 19(2).
106.Morselli LL, et al. Growth hormone secretion is impaired in amyotrophic lateral sclerosis. ClinEndocrinol (Oxf). 2006 Sep;65(3):385-8.
107.Muller U, Krieglstein J. Prolonged pretreatment with alpha-lipoic acid protects cultured neurons against hypoxic, glutamate-, or iron-induced injury. J Cereb Blood Flow Metab. 1995;15(4):624–630.
108.Mustfa N, Walsh E, Bryant V, et al. The effect of noninvasive ventilation on ALS patients and their caregivers. Neurology 2006; 66:1211.
109.Nagano I, Shiote M, et al. Beneficial effects of intrathecalIGF-1 administration in patients with amyotrophic lateral sclerosis. Neurological Research, 2005; 27(7).
110.Packer L, Rimbach G, et al. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinusmaritima) bark, pycnogenol. Free RadicBiol Med. 1999;27(5–6):704–724.
111.Palma A, de Carvalho M, et al. Biochemical characterization of plasma in amyotrophic lateral sclerosis: amino acid and protein composition. Amyotoph Lateral Scler Other Motor Neuron Disord. 2005;6(2):104–110.
112.PastulaDM, Moore DH, et al. Creatine for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Collaboration, 2010.
113.Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev. 2001;53(2):161–176.
114.Phukan J. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010;13(7):482-96.
115.Pott JW, Wassink-Ruiter JS, et al. Methylmalonic acid and homocysteine assessment in the detection of vitamin B12 deficiency in patients with bilateral visual loss. Acta Opthamologica, 2012.
116.Radad K, Moldzio R, et al. Ginsenosides and their CNS Targets. CNS Neuroscience and Therapeutics, 2011; 17.
117.Rooney J. Further Thoughts on Mercury, Epigenetics, Genetics and Amyotrophic Lateral Sclerosis. Neurodegenerative Dis 2011;8:523–524.
118.Ross E, Wilkins H, et al. A non-denatured whey protein supplement (Immunocal®) protects neurons from mitochondrial oxidative stress and delays disease onset in the mutant SOD1 mouse model of ALS. http://www.immunotec.com/IRL/Public/en/CAN/Research_KeystoneConf_ALS_2011.pdf. 2011.
119.Rothstein JD, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005 Jan 6;433(7021):73-7.
120.Rothstein JD, Kuncl RW. Neuroprotective strategies in the model of chronic glutamate-mediated motor neuron toxicity. J Neurochem. 1995b;65(2):643-51.
121.Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28:18.
122.Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38:73.
123.Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009 Jan;65Suppl1:S3-9.
124.Rowland L. Amyotrophic lateral sclerosis: theories and therapies. J Neorol Sci. 1994;31(169):126–127.
125.Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688–1700.
126.Sacca F, et al. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. J Neurol. 2012 Jan;259(1):132-8. Epub 2011 Jun 25.
127.Sakowski SA, Schuyler AD, et al. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, 2009; 10(2).
128.Sanmartin C, et al. Selenium and clinical trials: new therapeutic evidence for multiple diseases. Curr Med Chem. 2011;18(30):4635-50.
129.Schroeder EK, Keley NA, et al. Green Tea Epigallocatechin 3-Gallate Accumulates in Mitochondria and Displays a Selective Antiapoptotic Effect Against Inducers of Mitochondrial Oxidative Stress in Neurons. Antioxidants & Redox Signaling. March 2009, 11(3): 469-480.
130.Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995; 4:209.
131.Shi C, Zhao L, et al. Dosage Effects of EGb761 on Hydrogen Peroxide-Induced Cell Death in SH-SY5Y Cells. ChemBiol Interact, 2009; 180(3):389-97.
132.Shi P, Gal J, et al. Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis. Biochimica et BiophysicaActa 1802 (2010) 45–51.
133.Sohmiya M, Tanaka M, et al. An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci. 2005;228(1):49–53.
134.Sorenson EJ, WindbankAJ, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology, 2008; 71(22).
135.Stone CA, O'Leary N. Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis. J Pain Symptom Manage 2009; 37:246.
136.Suh JH, Moreau R, Heath SH, Hagen TM. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep.2005;10:52–60.
137.Suh JH, Shenvi SV, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. PNAS, 2004a; 101(10).
138.Suh JH, Zhu BZ, DeSzoeke E, et al. Dihydrolipoic acid lowers the redox activity of transition metal ions but does not remove them from the active site of enzymes. Redox Rep.2004b;9:57–61.
139.Sun AY, Wang Q, et al. Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases. MolNeurobiol (2010) 41:375–383.
140.Sung JJ, Kim HJ, et al. Homocysteine induces oxidative cytotoxicity in Cu, Zn-superoxide dismutase mutant motor neuronal cell. Neuroreport. 2002;13(4):377–381.
141.Suzuki M and SvendsenCN. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends in Neurosciences, 2008; 31(4).
142.Trophos.com Therapeutic Pipeline Accessed 3/16/2012 http://www.easybib.com/reference/guide/apa/website
143.Trumbull KA and Beckman JS. A Role for Copper in the Toxicity of Zinc-Deficient Superoxide Dismutase to Motor Neurons in Amyotrophic Lateral Sclerosis. Antioxid Redox Signal. 2009 Jul;11(7):1627-39.
144.Turnbull J. Is edaravone harmful? (A placebo is not a control). Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7-8): 477-482
145.VadakkadathMeethal S and Atwood CS. e dyscrasia: a novel explanation for amyotrophic lateral sclerosis. Neurobiol Aging. 2012 Mar;33(3):569-81.
146.Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009 Feb 27;323(5918):1208-11.
147.Vargas MR, Johnson DA, et al. Nrf2 Activation in Astrocytes Protects against Neurodegeneration in Mouse Models of Familial Amyotrophic Lateral Sclerosis. The Journal of Neuroscience, December 10, 2008; 28(50):13574 –13581.
148.Vielhaber S, Kaufmann J, et al. Effect of creatine supplementation on metabolite levels in ALS motor cortices. Exp Neurol. 2001;172(2):377–382.
149.Virmani A, Gaetani F, et al. The Protective Role of L-Carnitine against Neurotoxicity Evoked by Drug of Abuse, Methamphetamine, Could Be Related to Mitochondrial Dysfunction. Ann. N.Y. Acad. Sci. 965: 225–232 (2002).
150.Wang J, Zhang Y, et al. Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Neuroscience Letters 503 (2011) 250– 255.
151.Wilson AD, Hart A, et al. Acetyl-l-carnitine increases nerve regeneration and target organ reinnervation – a morphological study. The Journal of Plastic, Reconstructive and Aesthetic Surgery, 2010; 63(7).
152.Woodall CJ and Graham DI. Evidence for neuronal localisation of enteroviral sequences in motor neurone disease/amyotrophic lateral sclerosis by in situ hybridization. The European Journal of Histochemistry, 2004; 48(2).
153.Writing Group. Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017; 16(7):505.
154.Wu SN. Large-conductance Ca2+- activated K+ channels: physiological role and pharmacology. Curr Med Chem. 2003;10(8):649–661.
155.Yamada T, Hashida K, et al. α-Lipoic acid (LA) enantiomers protect SH-SY5Y cells against glutathione depletion. Neurochemistry International, 2011; 59(7).
156.Yamashita M, Nonaka T, et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models FEBS Letters, 2009; 583(14).
157.Yanez M, Galan L, et al. CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: Protection by resveratrol but not riluzole. Brain Research, 2011; 1423.
158.Yoon DH, Kwon OY, et al. Protective potential of resveratrol against oxidative stress and apoptosis in Batten disease lymphoblast cells. Biochemical and Biophysical Research Communications 414 (2011) 49–52.
159.Yu J, Jia Y, et al. Epigallocatechin-3-gallate Protects Motor Neurons and Regulates Glutamate Levels. FEBS Letters 584 (2010) 2921–2925.

GOUT
Summary
Gout is one of the oldest and most common forms of arthritis; is a crystal deposition disease in which monosodium urate crystals form in joints and other tissues. A wide variety of drugs for conventional use are known, including NSAIDs, corticosteroids, colchicine, emerging therapies and integrative interventions that, together with the adjuvants developed by us, can significantly improve the results of treatment and prevention of gout while preventing progression. of deadly diseases with the extension of life with quality.
Conventional treatments.
Regardless of the fact that uric acid levels above normal parameters are an indication of gout; The most important thing in the diagnosis of gout is the identification of monosodium urate crystals in joint fluid or tophi aspirates. Conventional medical gout treatments include:
Medications for acute attacks (nonsteroidal anti-inflammatory drugs [NSAIDs], corticosteroids, colchicine); Drugs to reduce hyperuricemia (xanthine oxidase inhibitors such as allopurinol to decrease uric acid production; uricosuric drugs to increase uric acid excretion) and emerging therapeutics that are directed at converting uric acid to allantoin and then excreting the uric acid through the kidneys, for this recently injectable drugs that break down uric acid into allantoin in the blood have become available such as Rasburicase (Elitek) and pegloticase (Krystexxa), which is approved by the Food and Drug Administration to reduce uric acid levels in patients with gout Strategy for use of adjuvants. 
To improve the pharmacological actions of the drugs used in the prevention, control and treatment of Gout and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term that usually contribute to the development of alterations , syndromes and deadly diseases, such as cancer, and can also reduce the quality life expectancy of people under treatment; the scientists and doctors of "PPG NUTRICIONAL" together with family doctors and specialists from clinics and hospitals, assisted by the "MIS", defined a personalized therapeutic strategy to develop specific adjuvants that improve the actions of the drugs used in each of the stages treatment of Gout and at the same time reduce the risk of contracting disorders, syndromes or fatal diseases with decreased quality of life. These adjuvants are, in themselves, unique compositions or combinations of labeled drugs, natural active ingredients, enzyme cofactors, vitamins, trace elements, protein hydrolysates, peptides, probiotics and other products authorized for use in humans by the FDA.


REFERENCES

1.Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136–3141.
2.Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis 2002;40:37–42.
3.Richette P, Bardin T. Gout. Lancet 2010; 375:318–28.
4.Choi HK, Mount DB, Reginato AM, American College of Physicians, American Physiological Society. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499–516.
5.Enomoto, A. et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417, 447–452.
6.Glantzounis GK, Tsimoyiannis EC, Kappas AM, et al. Uric acid and oxidative stress. Curr Pharm Des. 2005;11(32):4145-51.
7.Alvarez-Lario B, Macarrón-Vicente J. Is there anything good in uric acid? QJM. 2011.
8.Hediger, M. A. New view at C. Nature Med. 8, 445–446 (2002).
9.Roch-Ramel, F. & Guisan, B. News Physiol. Sci. 14, 80–84 (1999).
10.Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J NeurolSci 2009; 285:95–9.
11.Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, et al. Serum uric acid and mul- tiple sclerosis. ClinNeurolNeurosurg 2006; 108:527–31.
12.Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington’s disease progression. MovDisord 2010; 25:224–8.
13.Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, et al. Serum uric acid levels in pa- tients with Parkinson’s disease: their relationship to treatment and disease duration. ClinNeurolNeurosurg 2009; 111:724–8.
14.Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, et al. Decreased plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2006; 21:344–8.
15.Zhang W, Doherty M, Pascual E et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006a;65:1301–11.
16.Sun SZ, Flickinger BD, Williamson-Hughes PS, Empie MW. Lack of association between dietary fructose and hyperuricemia risk in adults.NutrMetab. 2010;7(1):16.
17.Schlesinger N, Norquist JM, Watson DJ. Serum Urate During Acute Gout. The Journal of Rheumatology. 2009;36(6):1287–1289.
18.Campion EW, Glynn RJ, DeLabry LO.Asymptomatic hyper- uricemia.Risk and consequences in the Normative Aging Study.Am J Med 1987; 82:421–6.
19.Puig JG, de Miguel E, Castillo MC, Rocha AL, Martinez MA, Torres RJ. Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 2008;27:592–5.
20.Doherty M. New insights into the epidemiology of gout.Rheumatology (Oxford). 2009;48Suppl 2:ii2–ii8.
21.Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237–41.
22.Eggebeen AT. Gout: an update. Am Fam Physician. 2007;76(6):801–808.
23.Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout.Arthritis Rheum 1991; 34:141–5.
24.Chhana A, Callon KE, Pool B, et al. Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Ann. Rheum. Dis. 2011;70(9):1684–1691.
25.Pak CY, Moe OW, Sakhaee K, Peterson RD, Poindexter JR. Physicochemical metabolic characteristics for calcium oxal- ate stone formation in patients with gouty diathesis. J Urol 2005; 173:1606–9.
26.Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyper- uricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33:225–34.
27.Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61:885–92.
28.Ekundayo OJ, Dell’Italia LJ, Sanders PW, et al. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int. J. Cardiol. 2010;142(3):279–287.
29.Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a sys- tematic review and meta-analysis. Arthritis Care Res 2010; 62:170–80.
30.Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, Feig D, et al. Uric acid and hypertension: cause or effect? CurrRheumatol Rep 2010; 12:108–17.
31.Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. 2011;63(1):102–110.
32.Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–932.
33.Dao HH, Harun-Or-Rashid M, Sakamoto J. Body compos- ition and metabolic syndrome in patients with primary gout in Vietnam. Rheumatology 2010; 49:2400–7.
34.Choi HK, Ford ES.Prevalence of the metabolic syndrome in individuals with hyperuricemia.Am J Med 2007a; 120:442–7.
35.Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008a;47(10):1567–1570.
36.Bierer DW, Quebbemann AJ.Effect of L-dopa on renal handling of uric acid.J PharmacolExpTher. 1982;223(1):55–59.
37.Scott JT. Drug-induced gout. Baillieres Clin Rheumatol. 1991 Apr;5(1):39-60.
38.Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. CurrOpinRheumatol.2011:1.
39.Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients.Arthritis Rheum. 2000;43(1):103–108.
40.Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004b;350(11):1093–1103.
41.Choi HK, Curhan G. Beer, liquor, wine, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004a; 51:1023 – 1029.
42.Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004c;363(9417):1277–1281.
43.Puig JG, Fox IH. Ethanol-induced activation of adenine nucleotide turnover.Evidence for a role of acetate. J Clin Invest 1984; 74: 936–41.
44.Vandenberg MK, Moxley G, Breitbach SA, Roberts WN. Gout attacks in chronic alcoholics occur at lower serum urate levels than in nonalcoholics. J Rheumatol 1994; 21: 700–04.
45.Gibson T, Rodgers AV, Simmonds HA, Toseland P. Beer drinking and its effect on uric acid. Br J Rheumatol 1984; 23: 203–09.
46.Choi JWJ, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008b;59(1):109–116.
47.Kasper DL Braunwald DE et al. Harrison’s Principles of Internal Medicine . 16th ed. New York , NY : McGraw-Hill Professional; 2005.
48.De Miguel E, Puig JG, Castillo C, et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann. Rheum. Dis. 2011.
49.Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 2006b;65(10):1312–1324.
50.Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461.
51.Larmon WA (1970) Surgical management of tophaceous gout. ClinOrthopRelat Res 71:56–69.
52.Ford TC (1992) Surgical management of chronic tophaceous gout. A case report. J Am Podiatr Med Assoc 82(10):514–519.
53.FDA. FDA approves new drug for gout. FDA NEWS RELEASE. Sept. 14, 2010. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm225810.htm Accessed 11/11/2011.
54.Sundy JS et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17;306(7):711-20.
55.Ea HK et al. Pegloticase and chronic gout.JAMA. 2011 Nov 9;306(18):1979; author reply 1979-80.
56.Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout.CurrOpinRheumatol. 2010;22(2):165–172.
57.Feigelson P. The inhibition of xanthine oxidase in vitro by trace amounts of I-ascorbic acid. J BiolChem 1952;197:843–50.
58.Juraschek SP, Miller ER III, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: A meta-analysis of randomized controlled trials. Arthritis Care Res. 2011;63(9):1295–1306.
59.Huang H-Y, Appel LJ, Choi MJ, et al. The effects of vitamin C supplementation on serum concentrations of uric acid: Results of a randomized controlled trial. Arthritis Rheum. 2005;52(6):1843–1847.
60.Bates CJ, Walmsley CM, Prentice A, Finch S. Does vitamin C reduce blood pressure?Results of a large study of people aged 65 or older. J. Hypertens. 1998 Jul;16(7):925.
61.Block G, Jensen CD, Norkus EP, Hudes M, Crawford PB. Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young Black and White women. Nutr J 2008;7:35.
62.Jacob RA, Spinozzi GM, Simon VA, et al. Consumption of cherries lowers plasma urate in healthy women. J Nutr. 2003;133(6):1826–1829.
63.Fam AG. Gout: excess calories, purines, and alcohol intake and beyond. Response to a urate-lowering diet. J Rheumatol . 2005 May;32(5):773-7.
64.Blau LW. Cherry diet control for gout and arthritis. Tex Rep BiolMed . 1950;8(3):309-11.
65.Jancin B. Cherry Juice Flowing in Gout Treatment Pipeline.Family Practice News. 2010.
66.Salazar-Martinez E, Willett WC, Ascherio A, Manson JE, Leitz- mann MF, Stampfer MJ, et al. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med 2004;140:1–8.
67.Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum. 2007b;56(6):2049–2055.
68.Kela U, Vijayvargiya R, Trivedi CP. Inhibitory effects of methyl-xanthines on the activity of xanthine oxidase. Life Sci 1980;27:2109–19.
69.Mascitelli L, Goldstein MR. Does inhibition of iron absorption by coffee reduce the risk of gout? Int. J. Clin. Pract. 2011;65(6):713.
70.Romero-Gonzalez RR et al. Salting-out gradients in centrifugal partition chromatography for the isolation of chlorogenic acids from green coffee beans. J Chromatogr A. 2009 May 8;1216(19):4245-51. Epub 2009 Feb 10.
71.Farah A et al. Chlorogenic acids from green coffee extract are highly bioavailable in humans. J Nutr. 2008 Dec;138(12):2309-15.
72.Lyu L-C, Hsu C-Y, Yeh C-Y, et al. A case-control study of the association of diet and obesity with gout in Taiwan.Am J ClinNutr. 2003;78(4):690–701.
73.Koguchi T, Koguchi H, Nakajima H, Takano S, Yamamoto Y, Innami S, Maekawa A, Tadokoro T: Dietary fiber suppresses elevation of uric acid and urea nitrogen concentrations in serum of rats with renal dysfunction induced by dietary adenine. Int J VitamNutr Res 2004, 74(4):253-263.
74.Streppel MT, Arends LR, van t Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med 2005 Jan.;165(2):150–156.
75.Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J. Hypertens. 2005 Mar.;23(3):475–481.
76.Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J ClinNutr 1999 Jan.;69(1):30-42.
77.Kong LD, Cai Y et al. Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout. J Ethnopharmacol . 2000 Nov;73(1-2):199-207.
78.Yan H, Ma Y, Liu M, Zhou L. The Dual Actions of PaederiascandensExtract as a Hypouricemic Agent: Xanthine Oxidase Inhibitory Activity and Uricosuric Effect. Planta Med. 2008;74(11):1345–1350.
79.Chen L, Yin H, Lan Z, et al. Anti-hyperuricemic and nephroprotective effects of Smilax china L. J Ethnopharmacol. 2011;135(2):399–405.
80.Kumar V, Ajeesh R, Vidyasagaran K, Chourasia S. Evaluation of pulp content and physical characters of Thriphala in Western Ghats, India. Environment and Ecology. 2014;33(4):1454-1459.
81.Motamarri S, Karthikeyan M, Kannan M, Rajasekar S. Terminalia belerica Roxb.—A phytopharmacological review. Int J Res Pharma.2012;3:96-99.
82.Usharani P, Nutalapati C, Pokuri VK, Kumar CU, Taduri G. A randomized, double-blind, placebo-, and positive-controlled clinical pilot study to evaluate the efficacy and tolerability of standardized aqueous extracts of Terminalia chebula and Terminalia bellerica in subjects with hyperuricemia. Clinical pharmacology: advances and applications. 2016;8:51-59.
83.Cock IE. The medicinal properties and phytochemistry of plants of the genus Terminalia (Combretaceae). Inflammopharmacol.Oct 2015;23(5):203-229.
84.Pauff JM, Hille R. Inhibition Studies of Bovine Xanthine Oxidase by Luteolin, Silibinin, Quercetin, and Curcumin. J. Nat. Prod. 2009;72(4):725–731.
85.Lin C-M, Chen C-S, Chen C-T, Liang Y-C, Lin J-K.Molecular modeling of flavonoids that inhibits xanthine oxidase.BiochemBiophys Res Commun. 2002;294(1):167–172.
86.Li Y et al. Virtual and In vitro bioassay screening of phytochemical inhibitors from flavonoids and isoflavones against Xanthine oxidase and Cyclooxygenase-2 for gout treatment.ChemBiol Drug Des.2011 Oct 3.doi: 10.1111/j.1747-0285.2011.01248.x. [Epub ahead of print]
87.Flemmig J et al. Oleaeuropaea leaf (Ph.Eur.) extract as well as several of its isolated phenolics inhibit the gout-related enzyme xanthine oxidase. Phytomedicine. 2011 May 15;18(7):561-6. Epub 2010 Dec 8.
88.Mo S-F, Zhou F, Lv Y-Z, et al. Hypouricemic action of selected flavonoids in mice: structure-activity relationships. Biol. Pharm. Bull. 2007;30(8):1551–1556.
89.Hu QH, Wang C, Li JM, Zhang DM, Kong LD. Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement. AJP: Renal Physiology. 2009;297(4):F1080–F1091.
90.Wang Y, Zhu JX et al. Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice. Basic ClinPharmacolToxicol. 2004 May;94(5):232-7.
91.Di Giovine FS, Malawista SE, Nuki G, Duff GW: Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol. 1987;138:3213–3218.
92.Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases.Journal of Internal Medicine. 2010;269(1):16–28.
93.Busso N, So A. Mechanisms of inflammation in gout.Arthritis Res. Ther. 2010;12(2):206.
94.Schumacher HR. The pathogenesis of gout.Cleve Clin J Med. 2008;75Suppl 5:S2–4.
95.Moon D-O, Kim M-O, Choi YH, Park Y-M, Kim G-Y.Curcumin attenuates inflammatory response in IL-1β-induced human synovial fibroblasts and collagen-induced arthritis in mouse model. International Immunopharmacology. 2010;10(5):605–610.
96.Belcaro G, Cesarone MR, Dugall M, et al. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010;15(4):337–344.
97.Wann AK, Mistry J, Blain EJ, Michael-Titus AT, Knight MM. Eicosapentaenoic acid and docosahexaenoic acid reduce interleukin-1β-mediated cartilage degradation. Arthritis Res. Ther. 2010;12(6):R207.
98.Shakibaei M, Csaki C, Nebrichi S, Mobasheri A. Resveratrol suppresses interleukin-1β-induced inflammatory signaling and apoptosis in human articular chondrocytes: Potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem.Pharmacol. 2008;76(11):1426–1439.
99.Tate GA, Mandell BF, Karmali RA, et al. Suppression of monosodium urate crystal-induced acute inflammation by diets enriched with gamma-linolenic acid and eicosapentaenoic acid. Arthritis Rheum. 1988;31(12):1543–1551.

CEREBROVASCULAR DISEASES
INSOMNIA
Summary
It is recommended to sleep between seven to nine hours a night. Global surveys estimate that the majority of adults in the world do not sleep the recommended amount; But beyond that, conventional treatment options are far from ideal because there are many risks associated with pharmaceutical sleep therapies, which can be improved with simple strategies based on lifestyle changes, emerging therapies, and various natural compounds for sleep. improve sleep. Supplementation with hormones such as melatonin have been used to eliminate insomnia. Drug therapies must be accompanied by adjuvants, developed by PPG NUTRITIONAL, that improve the efficacy of drugs used in conventional treatments and prevent the progression of deadly diseases, thus prolonging life with quality.
Conventional treatments.
Conventional treatment for insomnia relies on over-the-counter medications, such as antihistamines for occasional use; benzodiazepines such as alprazolam (Xanax), clonazepam (Klonipin), and diazepam (Valium); benzodiazepine-like medications such as zaleplon (Sonata), zolpidem (Ambien), and eszopiclone (Lunesta); antidepressants with sedating properties such as doxepin (Silenor), trazodone (Desyrel), and amitriptyline (Elavil) and with novel and emerging therapies such as drugs that target melatonin receptors (MT1 and MT2) such as ramelteon (Rozerem); orexin receptor antagonists such as suvorexant (Belsomra) that prevent neuropeptides that promote wakefulness from binding to their receptors; serotonin receptor antagonists among others that are combined with natural adjuvants, developed by us, that improve the effectiveness of conventionally used drugs and reduce the incidence of lethal diseases with an increase in life expectancy with quality. 
Strategy for use of adjuvants. 
To improve the pharmacological actions of the drugs used in the prevention, control and treatment of insomnia  and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term that usually contribute to the development of alterations , syndromes and deadly diseases, such as cancer, and can also reduce the quality life expectancy of people under treatment; the scientists and doctors of "PPG NUTRICIONAL" together with family doctors and specialists from clinics and hospitals, assisted by the "MIS", defined a personalized therapeutic strategy to develop specific adjuvants that improve the actions of the drugs used in each of the stages treatment of insomnia and at the same time reduce the risk of contracting disorders, syndromes or fatal diseases with decreased quality of life. These adjuvants are, in themselves, unique compositions or combinations of labeled drugs, natural active ingredients, enzyme cofactors, vitamins, trace elements, protein hydrolysates, peptides, probiotics and other products authorized for use in humans by the FDA.


REFERENCES

1.NSF. National Sleep Foundation. Insomnia. https://www.sleepfoundation.org/sleep-disorders/insomnia. Copyright 2019. Accessed 5/13/2019.
2.CDC. Centers for Disease Control and Prevention. 1 in 3 adults don’t get enough sleep. https://www.cdc.gov/media/releases/2016/p0215-enough-sleep.html. 2/16/2016. Accessed 5/13/2019.
3.Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Sleep health. 2015;1(1):40-43.
4.University H. Sleep and mental health. Harvard Mental Health Letter. 2010.
5.Insititue NHLaB. Sleep Deprivation and Deficiency. 2018.
6.Terauchi M, Hiramitsu S, Akiyoshi M, et al. Associations between anxiety, depression and insomnia in peri- and post-menopausal women. Maturitas. 2012;72(1):61-65.
7.Ohayon MM, Caulet M, Lemoine P. Comorbidity of mental and insomnia disorders in the general population. Comprehensive psychiatry. 1998;39(4):185-197.
8.Kakizaki M, Inoue K, Kuriyama S, et al. Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study. British journal of cancer. 2008;99(1):176-178.
9.Verkasalo PK, Lillberg K, Stevens RG, et al. Sleep duration and breast cancer: a prospective cohort study. Cancer Res. 2005;65(20):9595-9600.
10.Phillips B, Mannino DM. Do insomnia complaints cause hypertension or cardiovascular disease? Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2007;3(5):489-494.
11.Mayo Clinic. Insomnia. https://www.mayoclinic.org/diseases-conditions/insomnia/symptoms-causes/syc-20355167. 10/15/2016. Accessed 5/13/2019.
12.Kripke DF. I petitioned the FDA to restrict hypnotics: here is why. Sleep Med. 2016;23:119-120.
13.Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research. 2016;5:918.
14.Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ open. 2012;2(1):e000850.
15.Yang CM, Lin SC, Hsu SC, Cheng CP. Maladaptive sleep hygiene practices in good sleepers and patients with insomnia. Journal of health psychology. 2010;15(1):147-155.
16.Lande RG, Gragnani C. Nonpharmacologic approaches to the management of insomnia. J Am Osteopath Assoc. 2010;110(12):695-701.
17.Xu Z, Jiang X, Li W, Gao D, Li X, Liu J. Propofol-induced sleep: efficacy and safety in patients with refractory chronic primary insomnia. Cell Biochem Biophys. 2011;60(3):161-166.
18.Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2017;13(2):307-349.
19.Saddichha S. Diagnosis and treatment of chronic insomnia. Annals of Indian Academy of Neurology. 2010;13(2):94-102.
20.Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clinical cornerstone. 2003;5(3):5-15.
21.NSF. National Sleep Foundation. Menopause and Sleep. https://www.sleepfoundation.org/articles/menopause-and-sleep. Copyright 2019. Accessed 4/2/2019.
22.Silva BH, Martinez D, Wender MC. A randomized, controlled pilot trial of hormone therapy for menopausal insomnia. Archives of women's mental health. 2011;14(6):505-508.
23.Barrett-Connor E, Dam TT, Stone K, Harrison SL, Redline S, Orwoll E. The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. J Clin Endocrinol Metab. 2008;93(7):2602-2609.
24.Kim SD, Cho KS. Obstructive Sleep Apnea and Testosterone Deficiency. The world journal of men's health. 2019;37(1):12-18.
25.Wittert G. The relationship between sleep disorders and testosterone in men. Asian journal of andrology. 2014;16(2):262-265.
26.Burschtin O, Wang J. Testosterone Deficiency and Sleep Apnea. Sleep medicine clinics. 2016;11(4):525-529.
27.Canguven O, Salepci B, Albayrak S, Selimoglu A, Balaban M, Bulbul M. Is there a correlation between testosterone levels and the severity of the disease in male patients with obstructive sleep apnea? Arch Ital Urol Androl. 2010;82(4):143-147.
28.Mayo Clinic. Symptoms & causes. Obstructive sleep apnea. https://www.mayoclinic.org/diseases-conditions/obstructive-sleep-apnea/symptoms-causes/syc-20352090. 3/6/2018. Accessed 4/2/2019.
29.NSF. National Sleep Foundation. Sleep Apnea. https://www.sleepfoundation.org/sleep-apnea. Copyright 2019. Accessed 4/2/2019.
30.Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proceedings of the American Thoracic Society. 2008;5(2):136-143.
31.Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. 2011;140(2):534-542.
32.AHA. American Heart Association. Sleep Apnea and Heart Disease, Stroke. https://www.heart.org/en/health-topics/consumer-healthcare/sleep-apnea-and-heart-disease-stroke. 7/31/2015. Accessed 5/13/2019.
33.Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122(4):352-360.
34.Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811-817.
35.Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. American journal of respiratory and critical care medicine. 2010;181(5):507-513.
36.Nieto FJ, Peppard PE, Young T, Finn L, Hla KM, Farre R. Sleep-disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. American journal of respiratory and critical care medicine. 2012;186(2):190-194.
37.Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. The New England journal of medicine. 2005;353(19):2034-2041.
38.Morin CM, LeBlanc M, Daley M, Gregoire JP, Merette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006;7(2):123-130.
39.Buysse DJ, Germain A. Diagnosis, Epidemiology, and Consequences of Insomnia. Primary Psychiatry. 2005;12(8):37-44.
40.Baroni A, Hernandez M, Grant MC, Faedda GL. Sleep Disturbances in Pediatric Bipolar Disorder: A Comparison between Bipolar I and Bipolar NOS. Frontiers in psychiatry. 2012;3:22.
41.Yokoyama E, Ohida T, Tamaki T, et al. Association between Depression and Insomnia Subtypes: A Longitudinal Study on the Elderly in Japan. Sleep. 2010;33(12):1693-1702.
42.NSF. National Sleep Foundation. Sleep Hygiene, Insomnia and Mental Health. https://www.sleepfoundation.org/articles/sleep-hygiene-insomnia-and-mental-health. Copyright 2019. Accessed 4/2/2019.
43.Roane BM, Taylor DJ. Adolescent Insomnia as a Risk Factor for Early Adult Depression and Substance Abuse. Sleep. 2008;31(10):1351-1356.
44.Singareddy R, Vgontzas AN, Fernandez-Mendoza J, et al. Risk factors for incident chronic insomnia: a general population prospective study. Sleep Med. 2012;13(4):346-353.
45.Franzen PL, Buysse DJ, Dahl RE, Thompson W, Siegle GJ. Sleep deprivation alters pupillary reactivity to emotional stimuli in healthy young adults. Biological Psychology. 2009;80(3):300-305.
46.Medicine. AAoS. Insomnia may cause dysfunction in emotional brain circuitry. Science Daily. 2013.
47.Bastien CH, St-Jean G, Morin CM, Turcotte I, Carrier J. Chronic psychophysiological insomnia: hyperarousal and/or inhibition deficits? An ERPs investigation. Sleep. 2008;31(6):887-898.
48.Espie CA. Insomnia: conceptual issues in the development, persistence, and treatment of sleep disorder in adults. Annual review of psychology. 2002;53:215-243.
49.van de Laar M, Pevernagie D, van Mierlo P, Overeem S. Psychiatric Comorbidity and Aspects of Cognitive Coping Negatively Predict Outcome in Cognitive Behavioral Treatment of Psychophysiological Insomnia. Behavioral sleep medicine. 2015;13(2):140-156.
50.National Heart, Lung, and Blood Institiute. Insomnia. https://www.nhlbi.nih.gov/health-topics/insomnia. 11/9/2011. Accessed 5/13/2019.
51.NSF. National Sleep Foundation. What causes insomnia? https://www.sleepfoundation.org/insomnia/what-causes-insomnia. Copyright 2019. Accessed 4/2/2019.
52.Dhaval Patel MJS, MD; Pragnesh Patel, MD. Insomnia in the Elderly: A Review. Journal of Clinical Sleep Medicine. 2018;14(6).
53.Carroll JE, Irwin MR, Levine M, et al. Epigenetic Aging and Immune Senescence in Women With Insomnia Symptoms: Findings From the Women’s Health Initiative Study. Biological psychiatry. 2017;81(2):136-144.
54.Foral PK, Jon; Dewan, Naresh; Malesker, Mark. Medication-Induced Sleep Disturbances. The Consultant Pharmacist. 2011:414-425(412).
55.NSF. National Sleep Foundation. How Medications May Affect Sleep. https://www.sleepfoundation.org/articles/how-medications-may-affect-sleep. Copyright 2019. Accessed 4/2/2019.
56.Neikrug AB, Ancoli-Israel S. Sleep disorders in the older adult - a mini-review. Gerontology. 2010;56(2):181-189.
57.Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49(3):239-248.
58.Nerbass FB, Pedrosa RP, Genta PR, Drager LF, Lorenzi-Filho G. Calcium channel blockers are independently associated with short sleep duration in hypertensive patients with obstructive sleep apnea. J Hypertens. 2011;29(6):1236-1241.
59.Bercovitch RS, Tsai SC. Respiratory medications and sleep. Current Respiratory Care Reports. 2012;1(2):123-130.
60.Roehrs T, Roth T. Caffeine: sleep and daytime sleepiness. Sleep medicine reviews. 2008;12(2):153-162.
61.Chaudhary NS, Grandner MA, Jackson NJ, Chakravorty S. Caffeine consumption, insomnia, and sleep duration: Results from a nationally representative sample. Nutrition (Burbank, Los Angeles County, Calif). 2016;32(11):1193-1199.
62.Clark I, Landolt HP. Coffee, caffeine, and sleep: A systematic review of epidemiological studies and randomized controlled trials. Sleep medicine reviews. 2017;31:70-78.
63.Youngberg MR, Karpov IO, Begley A, Pollock BG, Buysse DJ. Clinical and physiological correlates of caffeine and caffeine metabolites in primary insomnia. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2011;7(2):196-203.
64.Jaehne A, Loessl B, Barkai Z, Riemann D, Hornyak M. Effects of nicotine on sleep during consumption, withdrawal and replacement therapy. Sleep medicine reviews. 2009;13(5):363-377.
65.Brook JS, Zhang C, Rubenstone E, Brook DW. Insomnia in adults: the impact of earlier cigarette smoking from adolescence to adulthood. Journal of addiction medicine. 2015;9(1):40-45.
66.Sabanayagam C, Shankar A. The association between active smoking, smokeless tobacco, second-hand smoke exposure and insufficient sleep. Sleep medicine. 2011;12(1):7-11.
67.Hendler RA, Ramchandani VA, Gilman J, Hommer DW. Stimulant and sedative effects of alcohol. Curr Top Behav Neurosci. 2013;13:489-509.
68.Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32(8):1429-1438.
69.Stein MD, Friedmann PD. Disturbed Sleep and Its Relationship to Alcohol Use. Substance Abuse. 2006;26(1):1-13.
70.Brooks AT, Wallen GR. Sleep Disturbances in Individuals with Alcohol-Related Disorders: A Review of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and Associated Non-Pharmacological Therapies. Substance Abuse: Research and Treatment. 2014;8:SART.S18446.
71.Zhabenko N, Wojnar M, Brower KJ. Prevalence and Correlates of Insomnia in a Polish Sample of Alcohol-Dependent Patients. 2012;36(9):1600-1607.
72.Brower KJ, Krentzman A, Robinson EAR. Persistent insomnia, abstinence, and moderate drinking in alcohol-dependent individuals. The American journal on addictions. 2011;20(5):435-440.
73.Baglioni C, Spiegelhalder K, Lombardo C, Riemann D. Sleep and emotions: A focus on insomnia. Sleep medicine reviews. 2010;14(4):227-238.
74.Fernández-Mendoza J, Vela-Bueno A, Vgontzas AN, et al. Cognitive-Emotional Hyperarousal as a Premorbid Characteristic of Individuals Vulnerable to Insomnia. 2010;72(4):397-403.
75.Kolla BP, Auger RR. Jet lag and shift work sleep disorders: how to help reset the internal clock. Cleveland Clinic journal of medicine. 2011;78(10):675-684.
76.NSF. National Sleep Foundation. Shift Work Disorder. https://www.sleepfoundation.org/sleep-disorders/shift-work-disorder. Copyright 2019. Accessed 4/2/2019.
77.Bertisch SM, Mittleman MA, Redline S, et al. Insomnia with objective short sleep duration and risk of incident cardiovascular disease and all-cause mortality: Sleep Heart Health Study. Sleep. 2018;41(6).
78.Vatten LJ, Strand LB, Laugsand LE, Platou C, Janszky I. Insomnia and the risk of incident heart failure: a population study. European Heart Journal. 2013;35(21):1382-1393.
79.Domínguez F, Fuster V, Fernández-Alvira JM, et al. Association of Sleep Duration and Quality With Subclinical Atherosclerosis. Journal of the American College of Cardiology. 2019;73(2):134-144.
80.Ibarra-Coronado EG, Pantaleón-Martinez, Velazquéz-Moctezuma J, et al. The Bidirectional Relationship between Sleep and Immunity against Infections %J Journal of Immunology Research. 2015;2015:14.
81.Aldabal L, Bahammam AS. Metabolic, endocrine, and immune consequences of sleep deprivation. The open respiratory medicine journal. 2011;5:31-43.
82.Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep medicine reviews. 2010;14(1):9-15.
83.Zhang J, Ma RC, Kong AP, et al. Relationship of sleep quantity and quality with 24-hour urinary catecholamines and salivary awakening cortisol in healthy middle-aged adults. Sleep. 2011;34(2):225-233.
84.Chiodini I, Scillitani A. [Role of cortisol hypersecretion in the pathogenesis of osteoporosis]. Recenti progressi in medicina. 2008;99(6):309-313.
85.Butcher SK, Killampalli V, Lascelles D, Wang K, Alpar EK, Lord JM. Raised cortisol:DHEAS ratios in the elderly after injury: potential impact upon neutrophil function and immunity. Aging Cell. 2005;4(6):319-324.
86.Duong M, Cohen JI, Convit A. High cortisol levels are associated with low quality food choice in type 2 diabetes. Endocrine. 2012;41(1):76-81.
87.Haack M, Scott-Sutherland J, Santangelo G, Simpson NS, Sethna N, Mullington JM. Pain sensitivity and modulation in primary insomnia. 2012;16(4):522-533.
88.Schuh-Hofer S, Wodarski R, Pfau DB, et al. One night of total sleep deprivation promotes a state of generalized hyperalgesia: A surrogate pain model to study the relationship of insomnia and pain. PAIN®. 2013;154(9):1613-1621.
89.Harsora P, Kessmann J. Nonpharmacologic management of chronic insomnia. American family physician. 2009;79(2):125-130.
90.CDC. Centers for Disease Control and Prevention. Sleep and Sleep Disorders: Tips for Better Sleep. https://www.cdc.gov/sleep/about_sleep/sleep_hygiene.html. Last updated 7/15/2016. Accessed 4/2/2019. 2016.
91.Gellis LA, Park A, Stotsky MT, Taylor DJ. Associations between sleep hygiene and insomnia severity in college students: cross-sectional and prospective analyses. Behav Ther. 2014;45(6):806-816.
92.Holt B, Tran S, Cochran A, Saffle J, Lin H, Faraklas I. Impact of a Nursing-Driven Sleep Hygiene Protocol on Sleep Quality. Journal of Burn Care & Research. 2013;34(2):249-254.
93.McCurry SM, Logsdon RG, Teri L, Vitiello MV. Sleep disturbances in caregivers of persons with dementia: contributing factors and treatment implications. Sleep medicine reviews. 2007;11(2):143-153.
94.Hoch CC, Reynolds CF, 3rd, Buysse DJ, et al. Protecting sleep quality in later life: a pilot study of bed restriction and sleep hygiene. The journals of gerontology Series B, Psychological sciences and social sciences. 2001;56(1):P52-59.
95.Miller CB, Espie CA, Epstein DR, et al. The evidence base of sleep restriction therapy for treating insomnia disorder. Sleep medicine reviews. 2014;18(5):415-424.
96.Mayo Clinic. Insomnia treatment: Cognitive behavioral therapy instead of sleeping pills. https://www.mayoclinic.org/diseases-conditions/insomnia/in-depth/insomnia-treatment/art-20046677. 9/28/2016. Accessed 4/2/2019.
97.Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA. 2001;285(14):1856-1864.
98.Smith MT, Neubauer DN. Cognitive behavior therapy for chronic insomnia. Clinical cornerstone. 2003;5(3):28-40.
99.Smith MT, Huang MI, Manber R. Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. Clin Psychol Rev. 2005;25(5):559-592.
100.Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. J Clin Oncol. 2005;23(25):6083-6096.
101.Lancee J, Eisma MC, van Straten A, Kamphuis JH. Sleep-Related Safety Behaviors and Dysfunctional Beliefs Mediate the Efficacy of Online CBT for Insomnia: A Randomized Controlled Trial. Cognitive behaviour therapy. 2015;44(5):406-422.
102.Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Family Practice. 2012;13(1):40.
103.Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research. 2018;5:918-918.
104.Brasure M, MacDonald R, Fuchs E, et al. AHRQ Comparative Effectiveness Reviews. In: Management of Insomnia Disorder. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015.
105.Ong JC, Ulmer CS, Manber R. Improving sleep with mindfulness and acceptance: A metacognitive model of insomnia. Behaviour Research and Therapy. 2012;50(11):651-660.
106.Gross CR, Kreitzer MJ, Reilly-Spong M, et al. Mindfulness-Based Stress Reduction Versus Pharmacotherapy for Chronic Primary Insomnia: A Randomized Controlled Clinical Trial. EXPLORE. 2011;7(2):76-87.
107.Afonso RF, Hachul H, Kozasa EH, et al. Yoga decreases insomnia in postmenopausal women: a randomized clinical trial. 2012;19(2):186-193.
108.Dhaval Patel MJS, MD; Pragnesh Patel, MD. Insomnia in the Elderly: A Review. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2018;14(6):1017-1024.
109.Mayo Clinic. Sleep aids: Understand over-the-counter options. https://www.mayoclinic.org/healthy-lifestyle/adult-health/in-depth/sleep-aids/art-20047860. 2/17/2018. Accessed 4/2/2019.
110.Randall S, Roehrs TA, Roth T. Over-the-counter sleep aid medications and insomnia. Primary Psychiatry. 2008;15(5):52.
111.Mayo Clinic. Sleep aids: Understand over-the-counter options. https://www.mayoclinic.org/healthy-lifestyle/adult-health/in-depth/sleep-aids/art-20047860. 2/17/2018. Accessed 5/13/2019.
112.Stone JA, Lester CA, Aboneh EA, Phelan CH, Welch LL, Chui MA. A preliminary examination of over-the-counter medication misuse rates in older adults. Research in Social and Administrative Pharmacy. 2017;13(1):187-192.
113.Abraham O, Schleiden L, Albert SMJIJoCP. Over-the-counter medications containing diphenhydramine and doxylamine used by older adults to improve sleep. 2017;39(4):808-817.
114.Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Primary care companion to the Journal of clinical psychiatry. 2007;9(1):25-31.
115.Bourgeois J, Elseviers, M.M., Van Bortel, L. et al. . One-Year Evolution of Sleep Quality in Older Users of Benzodiazepines: A Longitudinal Cohort Study in Belgian Nursing Home Residents. Drugs and Aging. 2014;31(677).
116.Medicine NUSNLo. Zaleplon. 2018.
117.Greenblatt DJ, Roth T. Zolpidem for insomnia. Expert opinion on pharmacotherapy. 2012;13(6):879-893.
118.Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6(6):487-495.
119.Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010;33(2):225-234.
120.FDA. U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. https://www.fda.gov/drugs/drugsafety/ucm397260.htm. 5/15/2014. Accessed 4/2/2019.
121.Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN. Adverse Effects of Hypnotic Medications. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2017;13(6):839-839.
122.FDA. FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines. https://www.fda.gov/news-events/press-announcements/fda-requires-stronger-warnings-about-rare-serious-incidents-related-certain-prescription-insomnia. Published 2019. Updated Apr. 30, 2019. Accessed May 8, 2019.
123.University H. Overcoming insomnia. Harvard Mental Health Letter. 2011.
124.Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30(11):1555-1561.
125.Krystal AD, Durrence HH, Scharf M, et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep. 2010;33(11):1553-1561.
126.Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34(10):1433-1442.
127.Walsh JK, Erman M, Erwin C, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII–R primary insomnia. Human Psychopharmacology: Clinical and Experimental. 1998;13(3):191-198.
128.Park PKNaSH. Antidepressant management of insomnia disorder in the absence of a mood disorder. Mental Health Clinician. 2014;4:41-46.
129.Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. 2011;20(4):552-558.
130.Camargos EF, Louzada LL, Quintas JL, Naves JOS, Louzada FM, Nóbrega OT. Trazodone Improves Sleep Parameters in Alzheimer Disease Patients: A Randomized, Double-Blind, and Placebo-Controlled Study. The American Journal of Geriatric Psychiatry. 2014;22(12):1565-1574.
131.NIH. National Institutes of Health. https://medlineplus.gov/druginfo/meds/a682388.html. Amitriptyline. Last updated 5/7/2019. Accessed 5/13/2019.
132.Karsten J, Hagenauw LA, Kamphuis J, Lancel M. Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. Journal of Psychopharmacology. 2017;31(3):327-337.
133.Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk WJCPR. Effects of Antidepressants on Sleep. 2017;19(9):63.
134.Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR. Mortality associated with sleep duration and insomnia. Archives of general psychiatry. 2002;59(2):131-136.
135.Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annual review of pharmacology and toxicology. 2016;56:361-383.
136.Miyamoto M. [A novel therapeutic drug: ramelteon]. Nihon rinsho Japanese journal of clinical medicine. 2009;67(8):1595-1600.
137.CH B Praveena Devi SS, N Kusuma Kumari and JVC, Sharma AK. A review on insomnia: The sleep disorder. The Pharma Innovation. 2018;7(12):227-230.
138.Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med. 2004;5(6):523-532.
139.Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301-310.
140.Sateia MJ, Kirby-Long P, Taylor JL. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep medicine reviews. 2008;12(4):319-332.
141.Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7(4):312-318.
142.Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2007;3(5):495-504.
143.Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009;373(9662):482-491.
REFERENCES.

1.A.D.A.M. PubMed Health. Celiac disease - sprue. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001280/. 2/21/2014. Accessed 2/24/2015.
2.Abdulkarim AS, Burgart LJ, See J, et al. Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol 2002;97(8):2016-2021.
3.ACDA. American Celiac Disease Alliance. Diagnosis: What are the appropriate screening tests for celiac disease? Available at: http://americanceliac.org/celiac-disease/diagnosis/ Accessed 4/24/2015b.
4.ACDA. American Celiac Disease Alliance. What is Celiac Disease? Available at: http://americanceliac.org/celiac-disease/. Last updated 2/18/2015a. Accessed 3/6/2015.
5.Addolorato G, Stefanini GF, Capristo E, et al. Anxiety and depression in adult untreated celiac subjects and in patients affected by inflammatory bowel disease: a personality “trait” or a reactive illness? Hepatogastroenterology. 1996;Nov-Dec;43(12):1513-7.
6.Adelman D. Alvine Pharmaceuticals, Inc. National Institutes of Health. A phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014- [cited 2014 Dec 2]. Available at: https://clinicaltrials.gov/ct2/show/NCT01917630?term=ALV003&rank=4. NLM Identifier: NCT01917630.
7.AGA. The American Gastroenterological Association. American Gastroenterological medical position statement: celiac sprue. Gastroenterology. 2001;120(6):1522-5.
8.AGA. The American Gastroenterological Association. The American Gastroenterological Association Institute. Digestive Disease Week 2014. The AGA Report. Available at: http://www.gastro.org/journals-publications/gi-hepatology-news/GI_-_Hepatology_News_2014_DDW_Report.pdf. Updated 2014. Accessed 12/10/14.
9.Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41:40-59.
10.Agmon-Levin N, Theodor E, Segal RM, et al. Vitamin D in systemic and organ-specific autoimmune diseases. Clinic Rev Allerg Immunol. 2013;45:256-266.
11.Alhamdani MS, Al-Kassir AH, Abbas FK, Jaleel NA, Al-Taee MF. Antiglycation and antioxidant effect of carnosine against glucose degradation products in peritoneal mesothelial cells. Nephron. Clinical practice. 2007;107(1):c26-34.
12.Allred LK, Ritter BW. Recognition of gliadin and glutenin fractions in four commercial gluten assays. Journal of AOAC International. Jan-Feb 2010;93(1):190-196.
13.Alt Med Rev. Therapeutic applications of whey protein. Alternative Medicine Review. 2008;13(4):341-347.
14.Alwitry A. Vitamin A deficiency in coeliac disease. The British Journal of Ophthalmology. 2000;84(9):1075-1075.
15.Amgen, Inc. National Institutes of Health.  AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014- [cited 2014 Dec 9]. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00443326?term=AMG+714&rank=1. NLM Identifier: NCT00443326
16.Amgen, Inc. National Institutes of Health. Phase 2 AMG 714 in Rheumatoid Arthritis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2007- [cited 2014 Dec 8]. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00433875?term=AMG714&rank=2. NLM Identifier: NCT00433875.
17.Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006;72:1100-1116.
18.Andrews R. All about gluten. Precision Nutrition. Available at: http://www.precisionnutrition.com/all-about-gluten. 2015. Accessed 12/22/2014.
19.Andrews R. All about gluten. Precision Nutrition. Available at: http://www.precisionnutrition.com/all-about-gluten. 2015a. Accessed 12/28/2014. 
20.Antico A, Tampoia M, Tozzoli R, et al. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? a systematic review of the literature. Autoimmunity Reviews 2012;12:127-136.
21.Antony B, Merina B, Iyer VS, et al. Bioavailability of BCM-95 CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci. 2008;Jul-Aug;70(4):445-9.
22.Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut. 2006;55:1512:1520.
23.Aziz I, Evans KE, Papageorgiou V, et al. Are patients with celiac disease seeking alternative therapies to a gluten-free diet? J Gastrointest Liver Dis. 2011;Mar;20(1):27-31.
24.AZO Network. Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment. Available at: http://www.news-medical.net/news/20140211/Alba-Therapeutics-reports-positive-results-from-Phase-IIb-trial-of-larazotide-acetate-for-CeD-treatment.aspx. 2/11/2014. Accessed 3/2/2015.
25.Babar MI, Ahmed I, Rao MS, et al. Celiac disease and celiac crisis in children. J Coll Physicians Surg Pak. 2011;Aug;21(8):487-90.
26.Bai JC, Fried M, Corazza GR, et al. World gastroenterology organization global guidelines on celiac disease. J Clin Gastroenterol 2013; Feb;47(2):121-126.
27.Bakshi A, Stephen S, Borum ML, et al. Emerging therapeutic options for celiac disease. Gastroenterol Hepatol. 2012;8(9):582-588.
28.Barker JM, Liu E. Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions. Advances in pediatrics. 2008;55:349-365.
29.Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therapeutic advances in gastroenterology. Jul 2012;5(4):261-268.
30.Battisti C, Dotti MT, Formichi P, et al. Disappearance of skin lipofuscin storage and marked clinical improvement in adult onset coeliac disease and severe vitamin E deficiency after chronic vitamin E megatherapy. J Submicrosc Cytol Pathol. 1996;Jul;28(3):339-44.
31.Benjamin J, Makharia G, Ahuja V, et al. Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn’s disease: a randomized controlled trial. Dig Dis Sci. 2012;57:1000-1012.
32.Bernardo D, Martinez-Abad B, Vallejo-Diez S, et al. Ascorbate-dependent decrease of the mucosal immune inflammatory response to gliadin in celiac disease patients. Allergol Immunopathol (Madr). 2012;40(1):3-8.
33.Berthoux E, Fabien N, Chayvialle JA, Ninet J, Durieu I. [Adult celiac disease with thrombosis: a case series of seven patients. Role of thrombophilic factors]. La Revue de medecine interne / fondee ... par la Societe nationale francaise de medecine interne. Oct 2011;32(10):600-604.
34.Beutheu S, Ghouzali I, Galas L, et al. Glutamine and arginine improve permeability and tight junction protein expression in methotrexate-treated Caco-2 cells. Clinical Nutrition. 2013;32:863-869.
35.Bianchi ML, Bardella MT. Bone in celiac disease. Osteoporos Int. 2008;19:1705-1716.
36.Biesiekierski JR, Appl B, Newnham ED, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011;106:508-514.
37.Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;Aug;145(2):320-8.
38.Blazina S, Bratanic N, Campa AS, et al. Bone mineral density and importance of strict gluten-free diet in children and adolescents with celiac disease. Bone. 2010;Sep;47(3):598-603.
39.Booth SL. Roles for vitamin K beyond coagulation. Annu Rev Nutr. 2009;29:89-110.
40.Briani C, Zara G, Alaedini A, et al. Neurological complications of celiac disease and autoimmune mechanisms: a prospective study. J Neuroimmunol. 2008;195:171-175.
41.Bright JJ. Curcumin and autoimmune disease. Adv Exp Med Biol. 2007;595:425-451.
42.Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients. Aug 2012;4(8):1095-1119.
43.Brumatti LV, Marcuzzi A, Tricarico PM, et al. Curcumin and inflammatory bowel disease: potential and limits of innovative treatments. Molecules 2014;19:211270-21153.
44.Bucci C, Zingone F, Russo I, et al. Gliadin does not induce mucosal inflammation or basophil activation in patients with nonceliac gluten sensitivity. Clin Gastroenterol Hepatol. 2013;Oct;11(10):1294-1299.
45.Bushara KO. Neurologic presentation of celiac disease. Gastroenterology. 2005;128:S92-S97.
46.Calder PC. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2007;77:327-335.
47.Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochimica et biophysica acta. Apr 2015;1851(4):469-484.
48.Carroccio A, Mansueto P, Iacono G, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol. 2012;107(12):1898-906.
49.Carta MG, Hardoy MC, Boi MF, et al. Association between panic disorder, major depressive disorder and celiac disease: a possible role of thyroid autoimmunity. J Psychosom Res. 2002;Sep;53(3):789-93.
50.CARTA. Center for Academic Research & Training in Anthropogeny. Small/Large Intestine Length Ratio. Available at: http://carta.anthropogeny.org/moca/topics/smalllarge-intestine-length-ratio. Accessed 2/25/2015.
51.Caruso R, Pallone F, Stasi E, et al. Appropriate nutrient supplementation in celiac disease. Ann Med. 2013;Dec;45(8):522-31.
52.Cascella NG, Kryszak D, Bhatti B, et al. Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. Schizophrenia Bulletin. 2011;37(1):94-100.
53.Cascella NG, Santora D, Gregory P, et al. Increased prevalence of transglutaminase 6 antibodies in sera from schizophrenia patients. Schizophrenia Bulletin. 2013;39(4):867-871.
54.Castillo NE, Theethira TG, Leffler DA. The present and the future in the diagnosis and management of celiac disease. Gastroenterol Rep (Oxf). 2014; Oct 17:1-9.
55.Catassi C, Bai JC, Bonaz B, et al. Non-celiac gluten sensitivity: the new frontier of gluten related disorders. Nutrients. 2013;Oct;5(10):3839-3853.
56.Catassi C, Fasano A. Celiac disease diagnosis: simple rules are better than complicated algorithms. Am J Med. 2010 Aug;123(8):691-3.
57.CDF. Celiac Disease Foundation. What Can I Eat? Available at: http://celiac.org/live-gluten-free/glutenfreediet/food-options/. Copyright 2015. Accessed 3/2/2015.
58.Chen CS, Cumbler EU, Triebling AT. Coagulopathy due to celiac disease presenting as intramuscular hemorrhage. Journal of general internal medicine. Nov 2007;22(11):1608-1612.
59.Chen P, Ma QG, Ji C, et al. Dietary lipoic acid influences antioxidant capability and oxidative status of broilers. Int J Mol Sci. 2011;12(12):8476-8488.
60.Choi K, Lee SS, Oh SJ, et al. The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr. 2007;26:57-62.
61.Choi K, Siegel M, Piper JL, et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.  Chem Biol. 2005;Apr;12:469-475.
62.CHP. Children's Hospital of Pittsburgh. Organs: Small and Large Intestines. Available at: http://www.chp.edu/CHP/organs+intestine. Last updated 12/5/2014. Accessed 2/25/2015.
63.Ciacci C, Peluso G, Iannoni E, et al. L-carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study. Dig Liver Dis. 2007;39:922-928.
64.Clemente MG, De Virgiliis S, Kang JS, et al. Early effects of gliadin on enterocyte intracellular signaling involved in intestinal barrier function. Gut. 2003;52:218-223.
65.Compston A, Coles A. Multiple sclerosis. Lancet. 2002;Apr 6;359(9313):1221-31.
66.Corvaglia L, Catamo R, Pepe G, et al. Depression in adult untreated celiac subjects: diagnosis by the pediatrician. Am J Gastroenterol. 1999;Mar;94(3):839-43.
67.Costantino G, della Torre A, Lo Presti MA, et al. Treatment of life-threatening type 1 refractory celiac disease with long-term infliximab. Dig Liver Dis. 2008;40:74-7.
68.Cristofori F, Fontana C, Magista A, Capriati T, Indrio F, Castellaneta S, . . . Francavilla R. Increased prevalence of celiac disease among pediatric patients with irritable bowel syndrome: a 6-year prospective cohort study. JAMA pediatrics. Jun 2014;168(6):555-560.
69.Czaja-Bulsa G. Non coeliac gluten sensitivity – a new disease with gluten intolerance. Clin Nutr. 2014;Aug 29;1-6.
70.Dahele A, Ghosh S. Vitamin B12 deficiency in untreated celiac disease. Am J Gastroenterology. 2001;96(3):745-750.
71.De Angelis M, Rizzello CG, Fasano A, et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue. Biochim Biophys Acta. 2006;Jan;1762(1):80-93.
72.de Vasconcelos MI, Tirapegui J. [Nutritional importance of glutamine]. Arquivos de gastroenterologia. Jul-Sep 1998;35(3):207-215.
73.De Vivo G, Di Lorenzo R, Ricotta M, Gentile V. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases. Current medicinal chemistry. 2009;16(36):4767-4773.
74.Denham JM, Hill ID. Celiac disease and autoimmunity: review and controversies. Curr Allergy Asthma Rep. 2013;13:347-353.
75.Di Sabatino A, Corazza GR. Coeliac disease. Lancet. 2009;373:1480-93.
76.Dickey W, Ward M, Whittle CR, et al. Homocysteine and related B-vitamin status in coeliac disease: effects of gluten exclusion and histological recovery. Scand J Gastroenterol. 2008;43:682-688.
77.Dickey W. Low serum vitamin B12 is common in coeliac disease and is not due to autoimmune gastritis. Eur J Gastroenterol Hepatol. 2002;14(4):425-427.
78.Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3(7):797-801.
79.DiRaimondo TR, Klock C, Khosla C, et al. Interferon gamma activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapy. J Pharmacol Exp Ther. 2012;341(1):104-114.
80.Dirks MH. Practical considerations for the identification and follow-up of children with celiac disease. Paediatrics & child health. Dec 2004;9(10):714-718.
81.Duerksen DR. Dramatic effect of vitamin D supplementation and a gluten-free diet on bone mineral density in a patient with celiac disease. J Clin Densitom. 2012;Jan-Mar;15(1):120-123.
82.Eberman LE, Cleary MA. Celiac disease in an elite female collegiate volleyball athlete: a case report. Journal of athletic training. Oct-Dec 2005;40(4):360-364.
83.Elfström P, Montgomery SM, Kämpe O, et al. Risk of primary adrenal insufficiency in patients with celiac disease. J Clin Endocrinol Metab. 2007;92(9):3595-8.
84.El-Salhy M, Gundersen D. Diet in irritable bowel syndrome. Nutrition journal. Apr 14 2015;14(1):36.
85.Eren E, Ellidag HY, Aydin O, Yilmaz N. Homocysteine, Paraoxonase-1 and Vascular Endothelial Dysfunction: Omnibus viis Romam Pervenitur. Journal of clinical and diagnostic research: JCDR. Sep 2014;8(9):Ce01-04.
86.Esposito C, Caputo I, Troncone R. New therapeutic strategies for coeliac disease: tissue transglutaminase as a target. Curr Med Chem. 2007;14:2572-2580.
87.Eswaran S, Goel A, Chey WD. What role does wheat play in the symptoms of irritable bowel syndrome? Gastroenterology & hepatology. Feb 2013;9(2):85-91.
88.Evans KE, Leeds JS, Morley S, Sanders DS. Pancreatic insufficiency in adult celiac disease: do patients require long-term enzyme supplementation? Digestive diseases and sciences. Oct 2010;55(10):2999-3004.
89.Fahey AJ, Adrian Robins R, Constantinescu CS. Curcumin modulation of IFN-beta and IL-12 signalling and cytokine induction in human T cells. Journal of cellular and molecular medicine. Sep-Oct 2007;11(5):1129-1137.
90.FARE. Food Allergy Research & Education. About Food Allergies. Blood Tests. Available at: http://www.foodallergy.org/diagnosis-and-testing/blood-tests. Copyright 2015c. Accessed 3/6/2015.
91.FARE. Food Allergy Research & Education. About Food Allergies. Skin Prick Test. Available at: http://www.foodallergy.org/diagnosis-and-testing/skin-tests. Copyright 2015b. Accessed 3/6/2015.
92.FARE. Food Allergy Research & Education. About Food Allergies. Wheat Allergy. Available at: http://www.foodallergy.org/allergens/wheat-allergy. Copyright 2015a. Accessed 3/6/2015.
93.Fasano A, Catassi C. Celiac disease. N Engl J Med. 2012;Dec 20;367(25):2419-2426.
94.Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001;Feb;120(3):636-651.
95.Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005;Sep;2(9):416-22.
96.Fasano A. Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. Oct 2012a;10(10):1096-1100.
97.Fasano A. Leaky gut and autoimmune diseases. Clinic Rev Allerg Immunol. 2012b;42:71-78.
98.Fasano A. Physiological, pathological, and therapeutic implications of zonulin-mediated intestinal barrier modulation: living life on the edge of the wall. Am J Pathol. 2008;Nov;173:1243-52.
99.Fasano A. Surprises from celiac disease. Scientific American. 2009;301(2):54-61.
100.Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiological Reviews. 2011;Jan1;91(1):151-175.
101.Ferretti G, Bacchetti T, Masciangelo S, Saturni L. Celiac disease, inflammation and oxidative damage: a nutrigenetic approach. Nutrients. Apr 2012;4(4):243-257.
102.Ferri FF. Ferri's Clinical Advisor. Celiac Disease. Available at: www.clinicalkey.com. Copyright 2015. Accessed 2/3/2015.
103.Finsterer J, Leutmezer F. Celiac disease with cerebral and peripheral nerve involvement mimicking multiple sclerosis. J Med Life. 2014;Sep 15;7(3):440-4.
104.Ford AC, Chey WD, Talley NJ, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of Irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med. 2009;Apr 13;169(7):651-8.
105.Gass J, Bethune MT, Siegel M, et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology. 2007;133:472-480.
106.Gillett HR, Arnott IDR, McIntyre M, et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology. 2002;122:800-805. 
107.Goldman AS, Van Fossan DD, Baird EE. Magnesium deficiency in celiac disease. Pediatrics. Jun 1962;29:948-952.
108.Gopalakrishnan S, Tripathi A, Tamiz AP, et al. Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides. 2012;35:95-101.
109.Goronzy JJ, Weyand CM. The Innate and Adaptive Immune Systems. In: Goldman's Cecil Medicine, 24th edition. Available at: www.clinicalkey.com. Copyright 2012 by Saunders, an imprint of Elsevier Inc.
110.Green PHR, Jabri B. Coeliac disease. Lancet. 2003;Aug 2;362:383-391.
111.Grey V, Mohammed SR, Smountas AA, et al. Improved glutathione status in young adult patients with cystic fibrosis supplemented with whey protein. J Cyst Fibros. 2003;2:195-198.
112.Guandalini S, Assiri A. Celiac disease: a review. JAMA Pediatr 2014;168(3):272-278.
113.Guevara Pacheco G, Chavez Cortes E, Castillo-Duran C. [Micronutrient deficiencies and celiac disease in Pediatrics]. Arch Argent Pediatr. 2014;Oct;112(5):457-63.
114.Gujral N, Freeman HJ, Thomson ABR. Celiac disease: Prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol. 2012;18(42):6036-6059.
115.Guo Y, Lu N, Bai A. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. BioMed research international. 2013;2013:581631.
116.Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;Jan;15(1):195-218.
117.Haapalahti M, Kulmala P, Karttunen TJ, et al. Nutritional status in adolescents and young adults with screen-detected celiac disease. J Pediatr Gastroenterol of Nutr. 2005;May;40:566-570.
Hadithi M, Mulder CJJ, Stam f, et al. Effect of B vitamin supplementation on plasma homocysteine levels in celiac disease. World J Gastroenterol. 2009; Feb 28;15(8):955-960.
1.Aldoori W, Ryan-Harshman M. Preventing diverticular disease. Review of recent evidence on high-fibre diets. Canadian family physician Medecin de famille canadien. Oct 2002;48:1632-1637. 
2.Aldoori WH, Giovannucci EL, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, . . . Willett WC. Prospective study of physical activity and the risk of symptomatic diverticular disease in men. Gut. Feb 1995;36(2):276-282. 
3.Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Trichopoulos DV, Willett WC. A prospective study of alcohol, smoking, caffeine, and the risk of symptomatic diverticular disease in men. Annals of epidemiology. May 1995;5(3):221-228. 
4.Aldoori WH, Giovannucci EL, Rockett HR, Sampson L, Rimm EB, Willett WC. A prospective study of dietary fiber types and symptomatic diverticular disease in men. The Journal of nutrition. Apr 1998;128(4):714-719. 
5.Alok S, Jain SK, Verma A, Kumar M, Mahor A, Sabharwal M. Herbal antioxidant in clinical practice: a review. Asian Pac J Trop Biomed. Jan 2014;4(1):78-84. 
6.Andersen JC, Bundgaard L, Elbrond H, Laurberg S, Walker LR, Stovring J. Danish national guidelines for treatment of diverticular disease. Danish medical journal. May 2012;59(5):C4453. 
7.Andeweg CS, Wegdam JA, Groenewoud J, van der Wilt GJ, van Goor H, Bleichrodt RP. Toward an evidence-based step-up approach in diagnosing diverticulitis. Scandinavian journal of gastroenterology. Jul 2014;49(7):775-784. 
8.Annibale B, Maconi G, Lahner E, De Giorgi F, Cuomo R. Efficacy of Lactobacillus paracasei sub. paracasei F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: a pilot study. Minerva gastroenterologica e dietologica. Mar 2011;57(1):13-22. 
9.Asadollahi K, Hastings IM, Beeching NJ, Gill GV, Asadollahi P. Leukocytosis as an alarming sign for mortality in patients hospitalized in general wards. Iranian journal of medical sciences. Mar 2011;36(1):45-49. 
10.Aydin N, Lauer GM, Pollak RF. First Consult. Diverticular disease. Available at: www.clinicalkey.com. Last updated 5/1/2012. Accessed 2/20/2015. 
11.Baliga MS, Joseph N, Venkataranganna MV, Saxena A, Ponemone V, Fayad R. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations. Food & function. Nov 2012;3(11):1109-1117. 
12.Banasiewicz T, Krokowicz L, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, . . . Drews M. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. Feb 2013;15(2):204-209. 
13.Bianchi M, Festa V, Moretti A, Ciaco A, Mangone M, Tornatore V, . . . Koch M. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Alimentary pharmacology & therapeutics. Apr 2011;33(8):902-910. 
14.Bose KP, Khorshidi I, Southern WN, Brandt LJ. The impact of ethnicity and obesity on the course of colonic diverticulitis. Journal of clinical gastroenterology. Feb 2013;47(2):160-164. 
15.Boynton W, Floch M. New strategies for the management of diverticular disease: insights for the clinician. Therapeutic advances in gastroenterology. May 2013;6(3):205-213. 
16.Bugiantella W, Rondelli F, Longaroni M, Mariani E, Sanguinetti A, Avenia N. Left colon acute diverticulitis: An update on diagnosis, treatment and prevention. International journal of surgery (London, England). Jan 2015;13c:157-164. 
17.Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert review of gastroenterology & hepatology. Feb 2014;8(2):197-210. 
18.Catanzaro D, Rancan S, Orso G, et al. Boswellia serrata Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage. PLoS One. 2015;10(5):e0125375. 
19.CCFA. Crohn’s & Colitis Foundation of America. Aminosalicylates. Available at: http://www.ccfa.org/assets/pdfs/aminosalicylates.pdf. 10/2013. Accessed 5/6/2015. 
20.CDRF. California Dairy Research Foundation. Probiotics Basics. Available at: http://cdrf.org/home/checkoff-investments/usprobiotics/probiotics-basics/. Accessed 6/1/2015. 
21.Celasco G, Moro L, Aiello C, Mangano K, Milasi A, Quattrocchi C, R DIM. Calcium butyrate: Anti-inflammatory effect on experimental colitis in rats and antitumor properties. Biomed Rep. Jul 2014;2(4):559-563. 
22.Cianci R, Frosali S, Pagliari D, Cesaro P, Petruzziello L, Casciano F, . . . Pandolfi F. Uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after rifaximin. J Immunol Res. 2014;2014:696812. 
23.Collins D, Winter DC. Modern concepts in diverticular disease. Journal of clinical gastroenterology. May-Jun 2015;49(5):358-369. 
24.Comstock SS, Lewis MM, Pathak DR, Hortos K, Kovan B, Fenton JI. Cross-sectional analysis of obesity and serum analytes in males identifies sRAGE as a novel biomarker inversely associated with diverticulosis. PloS one. 2014;9(4):e95232. 
25.Crowe FL, Appleby PN, Allen NE, Key TJ. Diet and risk of diverticular disease in Oxford cohort of European Prospective Investigation into Cancer and Nutrition (EPIC): prospective study of British vegetarians and non-vegetarians. BMJ (Clinical research ed.). 2011;343:d4131. 
26.Cuomo R, Barbara G, Pace F, Annese V, Bassotti G, Binda GA, . . . Annibale B. Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterol J. Oct 2014;2(5):413-442. 
27.de Korte N, Unlu C, Boermeester MA, Cuesta MA, Vrouenreats BC, Stockmann HB. Use of antibiotics in uncomplicated diverticulitis. The British journal of surgery. Jun 2011;98(6):761-767. 
28.Dobbins C, Defontgalland D, Duthie G, Wattchow DA. The relationship of obesity to the complications of diverticular disease. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. Jan 2006;8(1):37-40. 
29.Dugani A, Auzzi A, Naas F, Megwez S. Effects of the oil and mucilage from flaxseed (linum usitatissimum) on gastric lesions induced by ethanol in rats. The Libyan journal of medicine. 2008;3(4):166-169. 
30.Erbayrak M, Turkay C, Eraslan E, Cetinkaya H, Kasapoglu B, Bektas M. The role of fecal calprotectin in investigating inflammatory bowel diseases. Clinics (Sao Paulo, Brazil). May 2009;64(5):421-425. 
31.Farrukh A, Mayberry JF. Is there a role for fish oil in inflammatory bowel disease? World journal of clinical cases. Jul 16 2014;2(7):250-252. 
32.Fengming Y, Jianbing W. Biomarkers of inflammatory bowel disease. Disease markers. 2014;2014:710915. 
33.Ferri FF. Ferri's Clinical Advisor. Diverticular Disease (Diverticulosis, Diverticulitis). Available at: www.clinicalkey.com. 2015. Accessed 2/20/2015. 
34.Fleming SE, Zambell KL, Fitch MD. Glucose and glutamine provide similar proportions of energy to mucosal cells of rat small intestine. The American journal of physiology. Oct 1997;273(4 Pt 1):G968-978. 
35.Franklin ME, Jr., Portillo G, Trevino JM, Gonzalez JJ, Glass JL. Long-term experience with the laparoscopic approach to perforated diverticulitis plus generalized peritonitis. World journal of surgery. Jul 2008;32(7):1507-1511. 
36.Gatta L, Vakil N, Vaira D, Pilotto A, Curlo M, Comparato G, . . . Di Mario F. Efficacy of 5-ASA in the treatment of colonic diverticular disease. Journal of clinical gastroenterology. Feb 2010;44(2):113-119. 
37.Gerhardt H, Seifert F, Buvari P, et al. [Therapy of active Crohn disease and Boswellia serrata extract H 15]. Z Gastroenterol. 2001;39(1):11-7. 
38.Gill RE, Hirst EL, Jones JK. Constitution of the mucilage from the bark of Ulmus fulva (slippery elm mucilage); the sugars formed in the hydrolysis of the methylated mucilage. Journal of the Chemical Society. Nov 1946:1025-1029. 
39.Gold Standard. Drug Monograph: Rifaximin. Available at: www.clinicalkey.com. Last updated 4/14/2014. Accessed 5/28/2015. 
40.Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, . . . Kim N. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. Journal of clinical gastroenterology. Jul 2012;46(6):468-481. 
41.Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997;2(1):37-43. 
42.Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med. 2001;67(5):391-5. 
43.Haukioja A. Probiotics and oral health. European journal of dentistry. Jul 2010;4(3):348-355. 
44.Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. May 2014;109(5):637-645. 
45.Hjern F, Josephson T, Altman D, Holmstrom B, Mellgren A, Pollack J, Johansson C. Conservative treatment of acute colonic diverticulitis: are antibiotics always mandatory? Scandinavian journal of gastroenterology. Jan 2007;42(1):41-47. 
46.Hjern F, Mahmood MW, Abraham-Nordling M, Wolk A, Hakansson N. Cohort study of corticosteroid use and risk of hospital admission for diverticular disease. The British journal of surgery. Jan 2015;102(1):119-124. 
47.Hjern F, Wolk A, Hakansson N. Obesity, physical inactivity, and colonic diverticular disease requiring hospitalization in women: a prospective cohort study. Am J Gastroenterol. Feb 2012;107(2):296-302. 
48.Hjern F, Wolk A, Hakansson N. Smoking and the risk of diverticular disease in women. The British journal of surgery. Jul 2011;98(7):997-1002. 
49.Hobson KG, Roberts PL. Etiology and pathophysiology of diverticular disease. Clinics in colon and rectal surgery. Aug 2004;17(3):147-153. 
50.Humes DJ, Spiller RC. Review article: The pathogenesis and management of acute colonic diverticulitis. Alimentary pharmacology & therapeutics. Feb 2014;39(4):359-370. 
51.Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, Okada S. Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacology & toxicology. Jan 2003;92(1):33-38. 
52.Jung HK, Choung RS, Locke GR, 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol. Mar 2010;105(3):652-661. 
53.Köckerling F. Emergency Surgery for Acute Complicated Diverticulitis. Viszeralmedizin. 2015;31(2):107-110. 
54.Krokowicz L, Kaczmarek BF, Krokowicz P, Stojcev Z, Mackiewicz J, Walkowiak J, . . . Banasiewicz T. Sodium butyrate and short chain fatty acids in prevention of travellers' diarrhoea: a randomized prospective study. Travel Med Infect Dis. Mar-Apr 2014;12(2):183-188. 
55.Krokowicz L, Stojcev Z, Kaczmarek BF, Kociemba W, Kaczmarek E, Walkowiak J, . . . Banasiewicz T. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis--a prospective randomized study. International journal of colorectal disease. Mar 2014;29(3):387-393. 
56.Kruse E, Leifeld L. [Prevention and conservative therapy of diverticular disease]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. Apr 2014;85(4):299-303. 
57.Kvasnovsky CL, Papagrigoriadis S, Bjarnason I. Increased diverticular complications with nonsteriodal anti-inflammatory drugs and other medications: a systematic review and meta-analysis. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. Jun 2014;16(6):O189-196. 
58.Lahner E, Esposito G, Zullo A, Hassan C, Cannaviello C, Paolo MC, . . . Annibale B. High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World journal of gastroenterology : WJG. Nov 7 2012;18(41):5918-5924. 
59.Lamiki P, Tsuchiya J, Pathak S, Okura R, Solimene U, Jain S, . . . Marotta F. Probiotics in diverticular disease of the colon: an open label study. Journal of gastrointestinal and liver diseases : JGLD. Mar 2010;19(1):31-36. 
60.Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Alimentary pharmacology & therapeutics. Feb 2002;16(2):197-205. 
61.Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Current opinion in clinical nutrition and metabolic care. Sep 2012;15(5):474-479. 
62.LHMC. Lahey Hospital & Medical Center. Fish Oil. Available at: https://lahey.org/Departments_and_Locations/Departments/Colon_and_Rectal_Surgery/Ebsco_Content/Diverticular_Disease/Diverticulitis.aspx?chunkiid=21684. Copyright 2015 EBSCO Publishing. Accessed 5/8/2015. 
63.Lizardi-Cervera J, Vazquez-Elizondo G, Becerra-Laparra I, Chavez-Tapia N, Noriega-Iriondo MF, Uribe M. [Comparative study of the clinical presentation and complications of acute colonic diverticulitis in patients older and younger than 65 years.]. Revista de gastroenterologia de Mexico. 2008;73(3):153-158. 
64.LPI. Linus Pauling Institute. Glossary. Copyright 2015 Oregon State University. Available at: http://lpi.oregonstate.edu/mic/glossary#P. Accessed 5/7/2015. 
65.Mann NS, Hoda KK. Segmental colitis associated with diverticulosis: systematic evaluation of 486 cases with meta-analysis. Hepato-gastroenterology. Oct 2012;59(119):2119-2121. 
66.Maykel JA, Opelka FG. Colonic diverticulosis and diverticular hemorrhage. Clinics in colon and rectal surgery. Aug 2004;17(3):195-204. 
67.Mayo Clinic. Patient Care & Health Info page. Diseases and Conditions. Diverticulitis. Definition. Available at: http://www.mayoclinic.org/diseases-conditions/diverticulitis/basics/definition/con-20033495. 8/7/2014a. Accessed 5/26/2015. 
68.Mayo Clinic. Patient Care & Health Info page. Nutrition and healthy eating. Diverticulitis diet. Available at: http://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/diverticulitis-diet/art-20048499. 4/13/2014b. Accessed 5/6/2015. 
69.McDermott FD, Collins D, Heeney A, Winter DC. Minimally invasive and surgical management strategies tailored to the severity of acute diverticulitis. The British journal of surgery. Jan 2014;101(1):e90-99. 
70.Medina-Fernandez FJ, Diaz-Jimenez N, Gallardo-Herrera AB, Gomez-Luque I, Garcilazo-Arsimendi DJ, Gomez-Barbadillo J. New trends in the management of diverticulitis and colonic diverticular disease. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. Mar 2015;107(3):162-170. 
71.Mengheri E. Health, probiotics, and inflammation. Journal of clinical gastroenterology. Sep 2008;42 Suppl 3 Pt 2:S177-178. 
72.Morris AM, Regenbogen SE, Hardiman KM, Hendren S. Sigmoid diverticulitis: a systematic review. JAMA : the journal of the American Medical Association. Jan 15 2014;311(3):287-297. 
73.Mosadeghi S, Bhuket T, Stollman N. Diverticular disease: evolving concepts in classification, presentation, and management. Current opinion in gastroenterology. Jan 2015;31(1):50-55. 
74.Nagata N, Niikura R, Shimbo T, Kishida Y, Sekine K, Tanaka S, . . . Uemura N. Alcohol and smoking affect risk of uncomplicated colonic diverticulosis in Japan. PloS one. 2013;8(12):e81137. 
75.Nagata N, Sakamoto K, Arai T, Niikura R, Shimbo T, Shinozaki M, . . . Uemura N. Visceral Abdominal Obesity Measured by Computed Tomography is Associated With Increased Risk of Colonic Diverticulosis. Journal of clinical gastroenterology. Nov 19 2014. 
76.NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases. What I need to know about Diverticular Disease. Available at: http://www.niddk.nih.gov/health-information/health-topics/digestive-diseases/diverticular-disease/Pages/ez.aspx . Last updated 5/10/2012. Accessed 4/8/2015. 
77.Papagrigoriadis S, Macey L, Bourantas N, Rennie JA. Smoking may be associated with complications in diverticular disease. The British journal of surgery. Jul 1999;86(7):923-926. 
78.Peery AF, Sandler RS. Diverticular disease: reconsidering conventional wisdom. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Dec 2013;11(12):1532-1537. 
79.Peng X, Yan H, You Z, Wang P, Wang S. Effects of enteral supplementation with glutamine granules on intestinal mucosal barrier function in severe burned patients. Burns : journal of the International Society for Burn Injuries. Mar 2004;30(2):135-139. 
80.Pengelly A. The Constituents of Medicinal Plants: An Introduction to the Chemistry and Therapeutics of Herbal Medicine, 2nd edition. Sydney, NSW, Australia: Allen and Unwin. 2006. 
81.Peppercorn MA. The overlap of inflammatory bowel disease and diverticular disease. Journal of clinical gastroenterology. May-Jun 2004;38(5 Suppl 1):S8-10. 
82.Pisanu A, Vacca V, Reccia I, Podda M, Uccheddu A. Acute diverticulitis in the young: the same disease in a different patient. Gastroenterology research and practice. 2013;2013:867961. 
83.PSH. Penn State Hershey. Health Information Library. Diverticular disease. Available at: http://pennstatehershey.adam.com/content.aspx?productId=107&pid=33&gid=000051. 3/25/2015. Accessed 5/8/2015. 
84.Razik R, Nguyen GC. Diverticular Disease: Changing Epidemiology and Management. Drugs & aging. Apr 18 2015. 
85.Regenbogen SE, Hardiman KM, Hendren S, Morris AM. Surgery for diverticulitis in the 21st century: a systematic review. JAMA surgery. Mar 2014;149(3):292-303. 
86.Saeedi M, Morteza-Semnani K, Ansoroudi F, Fallah S, Amin G. Evaluation of binding properties of Plantago psyllium seed mucilage. Acta pharmaceutica (Zagreb, Croatia). Sep 2010;60(3):339-348. 
87.Saul N. Ask the Expert topics. page. Copyright 2015 National Women's Health Resource Center. Available at: http://www.healthywomen.org/content/ask-expert/1572/caffeine-and-diverticulitis. Accessed 5/6/2015. 
88.Schaffzin DM, Wong WD. Nonoperative management of complicated diverticular disease. Clinics in colon and rectal surgery. Aug 2004;17(3):169-176. 
89.Sengupta K, Kolla JN, Krishnaraju AV, et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem. 2011;354(1-2):189-97. 
90.Shahedi K, Fuller G, Bolus R, Cohen E, Vu M, Shah R, . . . Spiegel B. Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Dec 2013;11(12):1609-1613. 
91.Sheiman L, Levine MS, Levin AA, Hogan J, Rubesin SE, Furth EE, Laufer I. Chronic diverticulitis: clinical, radiographic, and pathologic findings. AJR. American journal of roentgenology. Aug 2008;191(2):522-528. 
92.Shenefelt PD, Benzie IFF, Wachtel-Galor S (eds.). Chapter 18: Herbal Treatment for Dermatologic Disorders. In: Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Copyright 2011 CRC Press. <http://www.ncbi.nlm.nih.gov/books/NBK92761/>. 
93.Siddiqui MZ. Boswellia Serrata, A Potential Antiinflammatory Agent: An Overview. Indian J Pharm Sci. 2011;73(3):255-261. 
94.Siguel EN, Lerman RH. Prevalence of essential fatty acid deficiency in patients with chronic gastrointestinal disorders. Metabolism: clinical and experimental. Jan 1996;45(1):12-23. 
95.Slavin J. Fiber and Prebiotics: Mechanisms and Health Benefits. Nutrients. 2013;5(4):1417-1435. 
96.Sopena F, Lanas A. Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies. Therapeutic advances in gastroenterology. Nov 2011;4(6):365-374. 
97.Sorser SA, Hazan TB, Piper M, Maas LC. Obesity and complicated diverticular disease: is there an association? Southern medical journal. Apr 2009;102(4):350-353. 
98.Sossai P. Butyric acid: what is the future for this old substance? Swiss medical weekly. 2012;142:w13596. 
99.Spiller R. Editorial: new thoughts on the association between diverticulosis and irritable bowel syndrome. Am J Gastroenterol. Dec 2014;109(12):1906-1908. 
100.Spiller R. Is it diverticular disease or is it irritable bowel syndrome? Digestive diseases (Basel, Switzerland). 2012;30(1):64-69. 
101.Spiller RC. Changing views on diverticular disease: impact of aging, obesity, diet, and microbiota. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. Mar 2015;27(3):305-312. 
102.Stollman N, Magowan S, Shanahan F, Quigley EM. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of clinical gastroenterology. Aug 2013;47(7):621-629. 
103.Strate LL, Liu YL, Aldoori WH, Giovannucci EL. Physical activity decreases diverticular complications. Am J Gastroenterol. May 2009;104(5):1221-1230. 
104.Strate LL, Liu YL, Aldoori WH, Syngal S, Giovannucci EL. Obesity increases the risks of diverticulitis and diverticular bleeding. Gastroenterology. Jan 2009;136(1):115-122.e111. 
105.Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology. May 2011;140(5):1427-1433. 
106.Strate LL, Liu YL, Syngal S, Aldoori WH, Giovannucci EL. Nut, corn, and popcorn consumption and the incidence of diverticular disease. JAMA : the journal of the American Medical Association. Aug 27 2008;300(8):907-914. 
107.Strate LL, Modi R, Cohen E, Spiegel BM. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. Am J Gastroenterol. Oct 2012;107(10):1486-1493. 
108.Strate LL. Lifestyle factors and the course of diverticular disease. Digestive diseases (Basel, Switzerland). 2012;30(1):35-45. 
109.Telem DA, Buch KE, Nguyen SQ, Chin EH, Weber KJ, Divino CM. Current recommendations on diagnosis and management of right-sided diverticulitis. Gastroenterology research and practice. 2009;2009:359485. 
110.Thaha MA, Williams NS. ePocrates. Diverticular disease. Available at: https://online.epocrates.com/noFrame/showPage?method=diseases&MonographId=16. Last updated 1/5/2015. Accessed 2/20/2015. 
111.Turley RS, Mantyh CR, Migaly J. Minimally invasive surgery for diverticulitis. Techniques in coloproctology. Feb 2013;17 Suppl 1:S11-22. 
112.Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticular disease: a case-control study. International journal of colorectal disease. Jan 2009;24(1):49-55. 
113.Tursi A, Brandimarte G, Elisei W, Picchio M, Forti G, Pianese G, . . . Danese S. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study. Alimentary pharmacology & therapeutics. Oct 2013;38(7):741-751. 
114.Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepato-gastroenterology. May-Jun 2008;55(84):916-920. 
115.Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. Journal of clinical gastroenterology. Apr 2006;40(4):312-316. 
116.Tursi A, Elisei W, Brandimarte G, Giorgetti GM, Inchingolo CD, Nenna R, . . . Ierardi E. Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case-control study. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. Sep 2012;24(9):836-e396. 
117.Tursi A, Elisei W, Giorgetti G, Aiello F, Brandimarte G. Role of fecal calprotectin in the diagnosis and treatment of segmental colitis associated with diverticulosis. Minerva gastroenterologica e dietologica. Sep 2011;57(3):247-255. 
118.Tursi A, Elisei W, Giorgetti GM, Inchingolo CD, Nenna R, Picchio M, . . . Brandimarte G. Expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor alpha in resected acute colonic diverticulitis. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. Mar 2014;16(3):O98-103. 
119.Tursi A, Elisei W, Picchio M, Brandimarte G. Increased faecal calprotectin predicts recurrence of colonic diverticulitis. International journal of colorectal disease. Aug 2014;29(8):931-935. 
120.Tursi A, Elisei W, Picchio M, Giorgetti GM, Brandimarte G. Moderate to Severe and Prolonged Left Lower-abdominal Pain is the Best Symptom Characterizing Symptomatic Uncomplicated Diverticular Disease of the Colon: A Comparison With Fecal Calprotectin in Clinical Setting. Journal of clinical gastroenterology. Mar 2015;49(3):218-221. 
121.Tursi A. Advances in the management of colonic diverticulitis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. Sep 18 2012;184(13):1470-1476. 
122.Tursi A. Diverticular disease of the colon and irritable bowel syndrome: it is time to differentiate. Am J Gastroenterol. May 2015;110(5):774-775. 
123.Tursi A. Diverticular disease: A therapeutic overview. World journal of gastrointestinal pharmacology and therapeutics. Feb 6 2010;1(1):27-35. 
124.Tursi A. New physiopathological and therapeutic approaches to diverticular disease: an update. Expert opinion on pharmacotherapy. May 2014;15(7):1005-1017. 
125.Turunen P, Wikstrom H, Carpelan-Holmstrom M, Kairaluoma P, Kruuna O, Scheinin T. Smoking increases the incidence of complicated diverticular disease of the sigmoid colon. Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society. 2010;99(1):14-17. 
126.UMMC. University of Maryland Medical Center. Medical Reference Guide: Complementary and Alternative Medicine Guide: Condition: Diverticular Disease. Available at http://umm.edu/health/medical/altmed/condition/diverticular-disease. Last udated 07/01/2013. Accessed 03/23/2015. 
127.Unlu C, Daniels L, Vrouenraets BC, Boermeester MA. A systematic review of high-fibre dietary therapy in diverticular disease. International journal of colorectal disease. Apr 2012;27(4):419-427. 
128.von Rahden BH, Germer CT. Pathogenesis of colonic diverticular disease. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie. Oct 2012;397(7):1025-1033. 
129.Watts CR. Slippery Elm, its biochemistry and use as a complementary and alternative treatment for laryngeal irritation. Journal of Investigational Biochemistry. 2012;1(1):17-23. 
130.Wick JY. Diverticular disease: eat your fiber! The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. Sep 2012;27(9):613-618. 
131.Wilkins T, Embry K, George R. Diagnosis and management of acute diverticulitis. American family physician. May 1 2013;87(9):612-620. 
132.Williams PT. Incident diverticular disease is inversely related to vigorous physical activity. Medicine and science in sports and exercise. May 2009;41(5):1042-1047. 
133.Xue H, Sufit AJ, Wischmeyer PE. Glutamine therapy improves outcome of in vitro and in vivo experimental colitis models. JPEN. Journal of parenteral and enteral nutrition. Mar 2011;35(2):188-197. 
Yamada E, Inamori M, Uchida E, Tanida E, Izumi M, Takeshita K, . . . Nakajima A. Association between the location of diverticular disease and the irritable bowel syndrome: a multicenter study in Japan. Am J Gastroenterol. Dec 2014;109(12):1900-1905. 
1.Abd-Allah AR et al. Pro-inflammatory and oxidative stress pathways which compromise sperm motility and survival may be altered by L-carnitine. Oxid Med Cell Longev. 2009 Apr-Jun;2(2):73-81.
2.Abitbol V et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther. 2002 May;16(5):919-27.
3.Abraham C and Cho JH. Inflammatory bowel disease. N Engl J Med. 2009 Nov 19;361(21):2066-78.
4.Aghdassi E, Wendland BE, et al. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress: a randomized controlled trial. Am J Gastroenterol. 2003 Feb;98(2):348-53.
5.Agrawal M et al. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep. 2011 Dec;9(4):251-7.
6.Alastair F et al. Nutrition in inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2011 Sep;35(5):571-80. Epub 2011 Aug 8.
7.Almallah YZ et al. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol. 1998 May;93(5):804-9.
8.Almeiner HA, Al Menshawy HH, Maher MM, Al Gamal S. Oxidative stress and inflammatory bowel disease. Front Biosci 2012;E4:1335-44.
9.Andus T, Klebl F, et al. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther. 2003 Feb;17(3):409-14.
10.Aratari A, Papi C, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liv Dis 2008;40:821-6.
11.Aslan A et al. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol. 1992 Apr;87(4):432-7.
12.Assisi RF; GISDI Study Group. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol 2008;54(3):231-8.
13.Axelsson C and Jarnum S. Assessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease. Scand J Gastroenterol. 1977;12(1):89-95.
14.Azcarate-Peril Ma et al. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol. 2011 Sep;301(3):G401-24. Epub 2011 Jun 23.
15.Babickova J, Gardlik R. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease. World journal of gastroenterology: WJG. Oct 28 2015;21(40):11321-11330.
16.Barclay GR, McKenzie H, et al. The effect of dietary yeast on the activity of stable chronic Crohn's disease. Scand J Gastroenterol 1992;27:196-200.
17.Bartel G, Weiss I, et al. Ingested matter affects intestinal lesions in Crohn’s disease. Inflamm Bowel Dis 2008;14:374-82.
18.Bebb JR, Scott BB. How effective are the usual treatments for Crohn's disease? Aliment Pharmacol Ther. 2004 Jul 15;20(2):151-9.
19.Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database System Rev 2008;(1):CD006893.
20.Belizario JE, Napolitano M. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front Microbiol.2015;6:1050.
21.Belli DC et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology. 1988 Mar;94(3):603-10.
22.Belluzzi A, Brignola C, et al. Effect of enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334(24):1557-60.
23.Benjamin J et al. Glutamine and Whey Protein Improve Intestinal Permeability and Morphology in Patients with Crohn's Disease: A Randomized Controlled Trial. Dig Dis Sci. 2011 Oct 26. [Epub ahead of print]
24.Bentz S, Hausmann M, et al. Clinical relevance of igg antibodies against food antigens in Crohn’s disease: a double-blind cross-over diet intervention study. Digestion 2010;81:252-64.
25.Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003;98(8):1797-801.
26.Bernstein CN, Nugent Z, Blanchard JF. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011;106:731-6.
27.Biasco G et al. Folate and prevention of colorectal cancer in ulcerative colitis. Eur J Cancer Prev. 2005 Aug;14(4):395-8.
28.Boznanska P, Wichan P, et al. 24-hour urinary 6-hydroxymelatonin sulfate excretion in patients with ulcerative colitis. Pol Merkur Lekarski 2007;22(131):369-72 [in Polish].
29.Braunwald E. Harrison's Principles of Internal Medicine. 15th ed. New York, NY: McGraw-Hill; 2001.
30.Brown AC, Roy M. Does evidence exist to include dietary therapy in the treatment of Crohn's disease? Expert Rev Gastroenterol Hepatol 2010;4(2):191-215.
31.Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrobial agents and chemotherapy.Jul 2005;49(7):2874-2878.
32.Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002;47(10):2336-48.
33.Buyse J et al. Dietary L-carnitine supplementation enhances the lipopolysaccharide-induced acute phase protein response in broiler chickens. Vet Immunol Immunopathol. 2007 Jul 15;118(1-2):154-9. Epub 2007 May 3.
34.Campos FG, Waitzberg DL, et al. Pharmacological nutrition in inflammatory bowel diseases. Nutr Hosp. 2003 Mar;18(2):57-64.
35.Chambers ES et al. The impact of vitamin D on regulatory T cells. Curr Allergy Asthma Rep. 2011 Feb;11(1):29-36.
36.Chan SSM, Luben R, et al. Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Ther 2011;34:649-55.
37.Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brussow H. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother.Jul 2004;48(7):2558-2569.
38.Chin J. Intestinal microflora: negotiating health outcomes with the warring community within us. Asia Pac J Clin Nutr. 2004;13(suppl):S24-S25.
39.Chojnacki C, Wisniewska-Jarosinska M, et al. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol 2011;62(3):327-34.
40.Clokie MRJ, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage.Jan-Feb 2011;1(1):31-45.
41.Colombel JF, Loftus EV Jr, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126;19-31.
42.Coogan PF, Rosenberg L. The use of folic acid antagonists and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 2007;16(10):1111-9.
43.Connerton PL, Timms AR, Connerton IF. Campylobacter bacteriophages and bacteriophage therapy. J Appl Microbiol.Aug 2011;111(2):255-265.
44.Cosnes J. Can we modulate the clinical course of inflammatory bowel diseases by our current treatment strategies? Dig Dis 2009;27:516-21.
45.Dalmasso M, Hill C, Ross RP. Exploiting gut bacteriophages for human health. Trends in microbiology.Jul 2014;22(7):399-405.
46.Dalmasso M, Strain R, Neve H, Franz CM, Cousin FJ, Ross RP, Hill C. Three New Escherichia coli Phages from the Human Gut Show Promising Potential for Phage Therapy. PloS one.2016;11(6):e0156773.
47.Danelli P, Bartolucci C, et al. Surgical options in the treatment of perianal Crohn's disease [in Italian]. Ann Ital Chir. 2003 Nov;74(6):635-40.
48.de Moreno de Leblanc A et al. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. SRN Gastroenterol. 2011;2011:892971. Epub 2011 Feb 8.
49.Deckelbaum RJ et al. The omega-3 Fatty Acid nutritional landscape: health benefits and sources. J Nutr. 2012 Mar;142(3):587S-91S. Epub 2012 Feb 8.
50.Den Hond E, Hiele M, et al. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr 1999;23(1):7-11.
51.Di Sabatino A, Morera R, et al. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther 2005;22(9):789-94.
52.Dinleyici Ec et al. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther. 2012 Feb 16. [Epub ahead of print]
53.Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol 2004;99(11):2178-85.
54.Elahi B, Nikfar S, et al. On the benefit of probiotics in the management of pouchitis in patients that underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008;53(5):1278-84.
55.Esaki M, Matsumoto T, et al. Preventive effect of nutritional therapy against postoperative recurrence of Crohn disease, with reference to ﬁndings determined by intra-operative enteroscopy. Scand J Gastroenterol 2005;40:1431-7. 
56.Etzel JP et al. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis. 2011 Jan 13. [Epub ahead of print]
57.Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis. 2004 May;10(3):286-99.
58.Feller ER, Ribaudo S, et al. Gynecologic aspects of Crohn's disease. Am Fam Physician. 2001 Nov 15;64(10):1725-8.
59.Fernandez-Miranda C, Martinez Prieto M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C-->T and 1298A-->C mutations in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2005 Jul;97(7):497-504.
60.Fife J et al. Folic acid supplementation and colorectal cancer risk: a meta-analysis. Colorectal Dis. 2011 Feb;13(2):132-7. doi: 10.1111/j.1463-1318.2009.02089.x.
61.Fujimori S, Tatsuguchi A, Gudis K, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol. 2007;22(8):1199-204.
62.Furrie E, Macfarlane S, et al. Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. Gut. 2004 Jan;53(1):91-8.
63.Garcia Vilela E et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol. 2008;43(7):842-8. 
64.Geerling BJ, Badart-Smook A, Stockbrügger RW, Brummer RJ. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 2000a;54(6):514-21.
65.Geerling BJ, Badart-Smook A, van Deursen C, et al. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000b;6(2):77-84.
66.Gerhardt H, Seifert F, et al. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 2001;39:11-7 [in German].
67.Giaffer MH, Cann P, Holdsworth CD. Long-term effects of elemental and exclusion diets for Crohn's disease. Aliment Pharmacol Ther 1991;5(2):115-25.
68.Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2006;25:19-37.
69.Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Feb;17(3):307-20.
70.Golias C et al. Physiology and pathophysiology of selectins, integrins, and IgSF cell adhesion molecules focusing on inflammation. A paradigm model on infectious endocarditis. ll Commun Adhes. 2011 Jun;18(3):19-32. Epub 2011 Sep 5.
71.Gupta I, Parihar A, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997;2:37-43.
72.Gupta I, Parihar A, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001;67:391–5.
73.Haden ST, Glowacki J et al. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. Calcif Tissue Int. 2000 Jun;66(6):414-8.
74.Hanai H, Iida T, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4(12):1502-6.
75.Hanai H, Kanauchi O, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004;13(5):643-7.
76.Harpavat M, Keljo DJ et al. Metabolic bone disease in inflammatory bowel disease. J Clin Gastroenterol. 2004 Mar;38(3):218-24.
77.Hawthorne AB, Daneshmend TK, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992;33(7):922-8.
78.Head KA et al. Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2003 Aug;8(3):247-83.
79.Heaton KW, Thornton JR, Emmett PM. Treatment of Crohn's disease with an unrefined-carbohydrate, fiber-rich diet. Br Med J 1979;ii:764-6.
80.Heckers H, Melcher FW, et al. Chemically prepared fats and Crohn disease: a pilot study of the occurrence of trans-fatty acids in the subcutaneous tissue of Crohn patients in comparison with healthy controls as a parameter of long-term fat intake. Z Gastroenterol. 1988;26(5):259-64.
81.Hengstermann S et al. Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. Clin Nutr. 2008 Aug;27(4):571-8. Epub 2008 Mar 7.
82.Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57(11):1518-23.
83.Hillier K et al. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991;32(10):1151-5.
84.Hinks IJ, Inwards KD, Lloyd B, Clayton B. Reduced concentration of selenium in mild Crohn's disease. J Clin Pathol 1988;41:198-201.
85.Holt PR et al. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005 Nov;50(11):2191-3.
86.Holtmeier W, Zeuzem S, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 2011;17(2):573-82.
87.Homik J, Suarez-Almazor ME, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;(2):CD000952.
88.Hou JK et al. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011 Apr;106(4):563-73. 
89.Hwang JM et al. Surgery for inflammatory bowel disease. World J Gastroenterol. 2008 May 7;14(17):2678-90. 
90.Ibrahim A et al. Dietary α-linolenic acid-rich formula reduces adhesion molecules in rats with experimental colitis. Nutrition. 2012 Jan 18. [Epub ahead of print]
91.Ishikawa H et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion. 2011;84(2):128-33. Epub 2011 Apr 28.
92.Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-G17.
93.Iwami D et al. Immunomodulatory effects of eicosapentaenoic acid through induction of regulatory T cells. Int Immunopharmacol. 2011 Mar;11(3):384-9. Epub 2010 Dec 18. 
94.Jahnsen J, Falch JA, et al. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37(2):192-9.
95.Jaiswal A, Koley H, Ghosh A, Palit A, Sarkar B. Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model. Microbes Infect.Feb 2013;15(2):152-156.
96.Jansen G et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications ofr combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum. 2004 Jul;50(7):2130-9
97.Johe PD, Osterud B. The in vivo effect of melatonin on cellular activation processes in human blood during strenuous physical exercise. J Pineal Res 2005;39:324–330.
98.Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005;21:921–31.
99.Jones VA. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn's disease. Long-term maintenance of remission by personalized food exclusion diets. Dig Dis Sci 1987;32(12 Suppl):100S--7S.
100.Jorgensen SP, Agnholt J, et al. Clinical trial:Vitamin D3 treatment in Crohn's disease---A randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010;32:377-83.
101.Jowett SL, Seal CJ, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 2004;53(10):1479-84.
102.Kaplan GG, Hubbard J, et al. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol 2010;105(11):2412-9.
103.Kappelman MD, Horvath-Puho E, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011;60:937–43.
104.Karimi O, Peña AS, van Bodegraven AA. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: A pilot study. Drugs Today (Barc) 2005;41(7):453-9.
105.Kim DH et al. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control. 2010 Nov;21(11):1919-30. Epub 2010 Sep 5.
106.Koutroubakis IE, Malliaraki N, et al. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci. 2004 Sep;49(9):1433-7. 
107.Koutroubakis IE. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2(6):266-72.
108.Krasinski SD, Russell RM et al. The prevalence of vitamin K deficiency in chronic gastrointestinal disorders. Am J Clin Nutr 1985;41(3):639-43.
109.Kruidenier L, Kuiper I, et al. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003 Sep;201(1):28-36.
110.Kruschewski M, Perez-Canto S et al. [Protective effect of glutamine on microcirculation of the intestine in experimental colitis]. Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):229-31.
111.Kuroki F, Matsumoto T, et al. Selenium is depleted in Crohn's disease on enteral nutrition. Dig Dis. 2003;21(3):266-70.
112.Kuwabara A, Tanaka K, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int 2009;20(6):935-42.
113.Langmead L et al. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 2004b Mar 1;19(5):521-7. 
114.Langmead L et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 2004a Apr 1;19(7):739-47. 
115.Lavasani S et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One. 2010 Feb 2;5(2):e9009.
116.Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2(7):308-15
117.Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage.Mar-Apr 2011;1(2):111-114.
118.Lorenz-Meyer H, Bauer P, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease: a randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol. 1996;31:778-85.
119.Mahmood A, Needham J, et al. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2005;17:739-44.
120.Maldonado MD, Calvo JR. Melatonin usage in ulcerative colitis: a case report. J Pineal Res 2008;45(3):339-40.
121.Malik T, Mannon P. Inflammatory bowel diseases: emerging therapies and promising molecular targets. Front Biosci 2012;S4:1172-89.
122.Malolepszy J, Kuczymska-Sekieta K, Chachaj W. Sodium cromoglycate therapy in ulcerative colitis. Acta Allergol 1977;13:82–86.
123.Matters GL et al. The opioid antagonist naltrexone improves murine inflammatory bowel disease. J Immunotoxicol. 2008 Apr;5(2):179-87. 
124.McCarville JL, Caminero A, Verdu EF. Novel perspectives on therapeutic modulation of the gut microbiota. Therapeutic advances in gastroenterology.Jul 2016;9(4):580-593.
125.McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010 May 14;16(18):2202-22.
126.McNamara DA, Brophy S, Hyland JM. Perianal Crohn’s disease and infliximab therapy. Surgeon. 2004 Oct;2(5):258-63.
127.Meader E, Mayer MJ, Steverding D, Carding SR, Narbad A. Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe.Aug 2013;22:25-30.
128.Meister D, Bode J, et al. Anti-inflammatory effects of enteral diet components on Crohn's disease-affected tissues in vitro. Dig Liver Dis. 2002 Jun;34(6):430-8.
129.Miheller P et al. Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World J Gastroenterol. 2010 Nov 28;16(44):5536-42. 
130.Miheller P, Muzes G, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009;15:1656-1662.
131.Mikhailova TL et al. Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Aliment Pharmacol Ther. 2011 Nov;34(9):1088-97.
132.Mitamura T, Sakamoto S et al. The more an ulcerative colitis is repeated, the more the risk of colorectal carcinogenesis is increased in mice. Anticancer Res. 2002 Nov-Dec;22(6C):3955-61.
133.Mortimore M and Florin TH. A role for B₁₂ in inflammatory bowel disease patients with suppurative dermatoses? An experience with high dose vitamin B₁₂ therapy. J Crohns Colitis. 2010 Oct;4(4):466-70. Epub 2010 Mar 21.
134.Muijsers RB, Goa KL. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs. 2002;62(11):1689-705.
135.Nakajima S, Iijima H, et al. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition 2011;27(10):1023-8.
136.Nale JY, Spencer J, Hargreaves KR, Buckley AM, Trzepinski P, Douce GR, Clokie MR. Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth In Vitro and Proliferation In Vivo. Antimicrob Agents Chemother.Feb 2016;60(2):968-981.
137.Neuman MG. Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroenterol. 2004 Dec;13(4):309-16.
138.Newman WG et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics. 2011 Jun;12(6):815-26. Epub 2011 May 3.
139.Norman JM, Handley SA, Baldridge MT, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell.Jan 29 2015;160(3):447-460.
140.Ockenga J et al. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur J Clin Nutr. 2005 Nov;59(11):1302-9.
141.Ojuawo A and Keith L. The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. Cent Afr J Med. 2002 Sep-Oct;48(9-10):116-9.
142.Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: A double-blind placebo-controlled study. Phytomedicine 2007;14(2-3):87-95.
143.Ooi JH et al. Vitamin D regulation of immune function in the gut: why do T cells have vitamin D receptors? Mol Aspects Med. 2012 Feb;33(1):77-82. Epub 2011 Nov 6.
144.Oussalah A et al. ta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther. 2011 Nov;34(10):1173-84. doi: 10.1111/j.1365-2036.2011.04864.x. Epub 2011 Oct 3.
145.Papa A, Santoliquido A, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005 Nov 1;22(9):839-46.
146.Patel V, Macdonald JK, et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009 Oct 7;(4):CD006884.
147.Phang M, Lazarus S, Wood LG, Garg M Diet and thrombosis risk: nutrients for prevention of thrombotic disease. Semin Thromb Hemost 2011;37(3):199-208.
148.Phelip JM et al. Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Feb;14(2):242-8.
149.Pitcher MCL, Cummings JH. Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut 1996;39:1-4.
150.Preiss JC et al. Use of methotrexate in patients with inflammatory bowel disease. Clin Exp Rheumatol. 2010 Sep-Oct;28 (5 Suppl 61):S151-5
151.Rakhimova OIu . Use of melatonin in combined treatment for inflammatory bowel diseases. Ter Arkh 2010;82(12):64-8 [in Russian].
152.Riordan AM, Hunter JO, et al. Treatment of active Crohn's disease by exclusion diet: East Anglian Multicentre Controlled Trial. Lancet 1993;342:1131-4.
153.Roblin X, Germain E, et al. Factors associated with hyperhomocysteinemia in inflammatory bowel disease: prospective study in 81 patients [in French]. Rev Med Interne. 2006 Feb;27(2):106-10. 
154.Roediger WE. Decreased sulphur aminoacid intake in ulcerative colitis. Lancet 1998;351(9115):1555.
155.Roediger WEW, Moore J, Babidge W. Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci 1997;42:1571-9.
156.Rogler G, Scholmerich J. Extraintestinal manifestations of inflammatory bowel disease [in German]. Med Klin (Munich). 2004 Mar 15;99(3):123-30.
157.Rogler G. Prebiotics and probiotics in ulcerative colitis: where do we stand? Digestion. 2011;84(2):126-7. Epub 2011 Apr 15.
158.Ross E. The role of marine fish oils in the treatment of ulcerative colitis. Nutr Rev. 1993;51(2):47-9.
159.Rowan FE, Docherty NG, Coffey JC, O'Connell PR. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. Br J Surg 2009;96(2):151-8.
160.Ruffolo C et al. Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire. J Gastrointest Surg. 2010 Jan;14(1):24-31. Epub 2009 Nov 10. 
161.Rutgeerts P, Löfberg R, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994;331:842–5.
162.Sakamoto N et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005 Feb;11(2):154-63.
163.Sarker SA, McCallin S, Barretto C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology.Dec 20 2012;434(2):222-232.
164.Sartor RB. Efficacy of probiotics for the management of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011 Sep;7(9):606-8. 
165.Sato S, Sasaki I, et al. Management of urinary complications in Crohn's disease. Surg Today. 1999;29(8):713-7.
166.Scholz D. The role of nutrition in the etiology of inflammatory bowel disease. Curr Probl Pediatr Adolesc Health Care. 2011 Oct;41(9):248-53.
167.Segain JP, Raingeard de la Bletiere D, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000 Sep;47(3):397-403.
168.Sengupta K et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem. 2011 Aug;354(1-2):189-97. Epub 2011 Apr 11.
169.Shakeri A et al. Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int. 2010 Oct;14(4):498-504. 
170.Sido B, Seel C, Hochlehnert A, et al. Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation? Dig Dis Sci 2006;51(12):2170-9.
171.Siffledeen JS, Siminoski K, et al. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol. 2003 Aug;17(8):473-8.
172.Simopoulos AP. Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet. World Rev Nutr Diet. 2011;102:10-21. Epub 2011 Aug 5.
173.Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002 Oct;56(8):365-79.
174.Smith JP, Bingaman SI, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci 201156:2088-97.
175.Smith JP, Stock H, Bingaman S, et al. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol 2007;102:820-8.
176.Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99(1):97-101.
177.Sonoda K, Ikeda S, et al. Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease. J Gastroenterol 2004;39(10):948-54.
178.Srirajaskanthan R, Winter M, et al. Venous thrombosis in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2005 Jul;17(7):697-700.
179.Stefanini GF et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol. 1995 Jun;30(6):535-41.
180.Steinhart AH et al. Nutrition in inflammatory bowel disease. Curr Opinion Gastroenterol. 1997;13(2):140-5.
181.Stenson WF et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med. 1992 Apr 15;116(8):609-14.
182.Straub RH, Scholmerich J, et al. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases: substitutes of adrenal and sex hormones. Z Rheumatol. 2000;59(suppl 2):II/108-18.
183.Tavarela VF. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2004 Oct;20(suppl 4):50-3.
184.Taylor RA et al. Curcumin for inflammatory bowel disease: a review of human studies. Altern Med Rev. 2011 Jun;16(2):152-6.
185.Teahon K, Smethurst P, et al. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology. 1991 Jul;101(1):84-9.
186.Terry PD, Villinger F, Bubenik GA, Sitaraman SV. Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. Inflamm Bowel Dis 2009;15:134-40.
187.Thomas S et al. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2011 Dec;301(6):G1083-92. Epub 2011 Sep 8.
188.Tighe MP, Cummings JR, Afzal NA. Nutrition and inflammatory bowel disease: primary or adjuvant therapy. Curr Opin Clin Nutr Metab Care. 2011 Sep;14(5):491-6.
189.Trebble TM, Arden NK, et al. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr. 2004 Nov;80(5):1137-44.

1.Ambizas EM, Ginzburg R. Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother. Jun 2007;41(6):957-964.
2.Asahina S, Hasegawa K, Tsuboi K. [Depression in patients of irritable bowel syndrome]. Nihon rinsho. Japanese journal of clinical medicine. Aug 2006;64(8):1527-1531.
3.Asif M. Phytochemical study of polyphenols in Perilla Frutescens as an antioxidant. Avicenna journal of phytomedicine. Fall 2012;2(4):169-178.
4.Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology. Jan 2006;130(1):34-43.
5.Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. Oct 2004;53(10):1459-1464.
6.Attar A, Lemann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. Feb 1999;44(2):226-230.
7.Azpiroz F. Gastrointestinal perception: pathophysiological implications. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. Jun 2002;14(3):229-239.
8.Bafutto M, Almeida JR, Leite NV, Oliveira EC, Gabriel-Neto S, Rezende-Filho J. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. Arquivos de gastroenterologia. Jan-Mar 2011;48(1):36-40.
9.Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The Fecal Microbial-Population in the Irritable Bowel Syndrome. Microbiologica. 1982;5(3):185-194.
10.Barbara G, Zecchi L, Barbaro R, et al. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol. Oct 2012;46 Suppl:S52-55.
11.Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. Apr 2010;55(4):1090-1097.
12.Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therap Adv Gastroenterol. Jul 2012;5(4):261-268.
13.Berman SM, Suyenobu BY, Naliboff BD, et al. Evidence for Altered Central Noradrenergic Modulation in Irritable Bowel Syndrome (IBS). Gastroenterology. May 2009;136(5):A170-A170.
14.Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. Mar 2011;106(3):508-514; quiz 515.
15.Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. May 1999;94(5):1327-1331.
16.Bradford K, Shih W, Videlock EJ, et al. Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol. Apr 2012;10(4):385-390 e381-383.
17.Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. Jan 2009;104 Suppl 1:S1-35.
18.Brennan BP, Fogarty KV, Roberts JL, Reynolds KA, Pope HG, Jr., Hudson JI. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol. Jul 2009;24(5):423-428.
19.Buchwald-Werner S, Fujii H, Reule C, Schoen C. Perilla extract improves gastrointestinal discomfort in a randomized placebo controlled double blind human pilot study. BMC complementary and alternative medicine. 2014;14:173.
20.Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med. Dec 2004a;10(6):1015-1018.
21.Bundy R, Walker AF, Middleton RW, Marakis G, Booth JC. Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: a subset analysis. J Altern Complement Med. Aug 2004b;10(4):667-669.
22.Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J, . . . Kopacova M. Small intestinal bacterial overgrowth syndrome. World journal of gastroenterology : WJG. Jun 28 2010;16(24):2978-2990.
23.Camilleri M, Lasch K, Zhou W. Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. American journal of physiology. Gastrointestinal and liver physiology. Oct 2012;303(7):G775-785. 
24.Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. Jun 2007;39(6):530-536.
25.Carroccio A, Mansueto P, Iacono G, et al. Non-Celiac Wheat Sensitivity Diagnosed by Double-Blind Placebo-Controlled Challenge: Exploring a New Clinical Entity. Am J Gastroenterol. Jul 24 2012.
26.Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog. 2010;2(1):19.
27.Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. Jun 2012;24(6):521-e248.
28.Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology. Mar 2011;140(3):761-765. 
29.Chassard C, Dapoigny M, Scott KP, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther. Apr 2012;35(7):828-838.
30.Chen CQ, Fichna J, Bashashati M, Li YY, Storr M. Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol. Sep 14 2011;17(34):3888-3898.
31.Chen CY, Leu YL, Fang Y, et al. Anti-inflammatory effects of Perilla frutescens in activated human neutrophils through two independent pathways: Src family kinases and Calcium. Scientific reports. 2015;5:18204.
32.Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. Journal of clinical gastroenterology. Sep 2011;45(8):679-683. 
33.Ciorba MA. A Gastroenterologist's Guide to Probiotics. Clin Gastroenterol Hepatol. Sep 2012;10(9):960-968.
34.Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, De Giorgio R, . . . Barbara G. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Alimentary pharmacology & therapeutics. Aug 2009;30(3):245-252. 
35.Cremonini F, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo A. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. Sep 2012;36(5):437-448.
36.Cui N, Wu BP, Wu SZ. [Association of peripheral blood estradiol, progesterone and testosterone levels with irritable bowel syndrome]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. Mar 2006;26(3):367-368. 
37.Dang J, Ardila-Hani A, Amichai MM, Chua K, Pimentel M. Systematic review of diagnostic criteria for IBS demonstrates poor validity and utilization of Rome III. Neurogastroenterol Motil. Sep 2012;24(9):853-e397.
38.Davis KD, Pope G, Chen J, Kwan CL, Crawley AP, Diamant NE. Cortical thinning in IBS: implications for homeostatic, attention, and pain processing. Neurology. Jan 8 2008;70(2):153-154. 
39.De Vuyst L, Van Kerrebroeck S, Harth H, Huys G, Daniel HM, Weckx S. Microbial ecology of sourdough fermentations: diverse or uniform? Food microbiology.Feb 2014;37:11-29.
40.Di Palma JA, Herrera JL. The Role of Effective Clinician-Patient Communication in the Management of Irritable Bowel Syndrome and Chronic Constipation. J Clin Gastroenterol. 2012; 46(9):748-51. 
41.Di Sabatino A, Corazza GR. Nonceliac gluten sensitivity: sense or sensibility? Annals of internal medicine. Feb 21 2012;156(4):309-311. 
42.Dorofeyev AE, Kiriyan EA, Vasilenko IV, Rassokhina OA, Elin AF. Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. Clinical and experimental gastroenterology. 2011;4:141-153. 
43.Drisko J, Bischoff B, Hall M, McCallum R. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr. Dec 2006;25(6):514-522.
44.Duboc H, Rainteau D, Rajca S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. Jun 2012;24(6):513-e247.
45.Duigenan S, Gee MS. Imaging of pediatric patients with inflammatory bowel disease. AJR Am J Roentgenol. Oct 2012;199(4):907-915.
46.Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Apr 2005;3(4):349-357. 
47.Edwards D, Heufelder A, Zimmermann A. Therapeutic Effects and Safety of Rhodiola rosea Extract WS(R) 1375 in Subjects with Life-stress Symptoms - Results of an Open-label Study. Phytother Res. Aug 2012;26(8):1220-1225.
48.Etienne-Mesmin L, Livrelli V, Privat M, Denis S, Cardot JM, Alric M, Blanquet-Diot S. Effect of a New Probiotic Saccharomyces cerevisiae Strain on Survival of Escherichia coli O157:H7 in a Dynamic Gastrointestinal Model. Applied and Environmental Microbiology.Feb 2011;77(3):1127-1131.
49.Ferri: In: Ferri’s Clinical Advisor 2013, 1st ed. Copyright © 2012 Mosby, An Imprint of Elsevier. Available at: http://www.mdconsult.com/books/page.do?sid=1379453946&eid=4-u1.0-B978-0-323-08373-7..00018-2--sc29015&isbn=978-0-323-08373-7&uniqId=381015809-97. Accessed November 12, 2012. 
50.Fichna J, Storr MA. Brain-Gut Interactions in IBS. Frontiers in pharmacology. 2012;3:127. 
51.Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. Mar 2009;58(3):367-378. 
52.Gallo-Torres H, Brinker A, Avigan M. Alosetron: ischemic colitis and serious complications of constipation. The American journal of gastroenterology. May 2006;101(5):1080-1083. 
53.Generoso SV, Viana M, Santos R, et al. Saccharomyces cerevisiae strain UFMG 905 protects against bacterial translocation, preserves gut barrier integrity and stimulates the immune system in a murine intestinal obstruction model. Archives of microbiology.Jun 2010;192(6):477-484.
54.Ghoshal UC, Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. Journal of gastroenterology and hepatology. Apr 2011;26 Suppl 3:94-101. 
55.Gordon M, Naidoo K, Akobeng AK, Thomas AG. Osmotic and stimulant laxatives for the management of childhood constipation. Cochrane Database Syst Rev. 2012;7:CD009118.
56.Grassi M, Petraccia L, Mennuni G, Fontana M, Scarno A, Sabetta S, Fraioli A. Changes, functional disorders, and diseases in the gastrointestinal tract of elderly. Nutricion hospitalaria : organo oficial de la Sociedad Espanola de Nutricion Parenteral y Enteral. Jul-Aug 2011;26(4):659-668. 
57.Greenwood-Van Meerveld B, Gibson M, Gunter W, Shepard J, Foreman R, Myers D. Stereotaxic delivery of corticosterone to the amygdala modulates colonic sensitivity in rats. Brain research. Mar 2 2001;893(1-2):135-142. 
58.Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. May 2011;33(10):1123-1132.
59.Hatoum R, Labrie S, Fliss I. Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications. Frontiers in microbiology.2012;3:421.
60.Hauser G, Tkalcic M, Pletikosic S, Grabar N, Stimac D. Erythrocyte sedimentation rate - possible role in determining the existence of the low grade inflammation in Irritable Bowel Syndrome patients. Medical hypotheses. Jun 2012;78(6):818-820. 
61.Hayee B, Forgacs I. Psychological approach to managing irritable bowel syndrome. Bmj. May 26 2007;334(7603):1105-1109. 
62.Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gender medicine. 2009;6 Suppl 2:152-167. 
63.Hellhammer J, Hero T, Franz N, Contreras C, Schubert M. Omega-3 fatty acids administered in phosphatidylserine improved certain aspects of high chronic stress in men. Nutr Res. Apr 2012;32(4):241-250.
64.Holtmann G, Liebregts T, Collet W, Windeck T. Functional dyspepsia and irritable bowel syndrome - Treatment effects of artichoke-leaf-extract: A placebo-controlled, randomised, multicenter trial. Gastroenterology. Apr 2003;124(4):A182-A182.
65.Jane ZY, Chang CC, Lin HK, Liu YC, Chen WL. The association between the exacerbation of irritable bowel syndrome and menstrual symptoms in young Taiwanese women. Gastroenterology nursing: the official journal of the Society of Gastroenterology Nurses and Associates. Jul-Aug 2011;34(4):277-286. 
66.Jarrett ME, Burr RL, Cain KC, Hertig V, Weisman P, Heitkemper MM. Anxiety and depression are related to autonomic nervous system function in women with irritable bowel syndrome. Digestive diseases and sciences. Feb 2003;48(2):386-394. 
67.Ji WW, Li RP, Li M, et al. Antidepressant-like effect of essential oil of Perilla frutescens in a chronic, unpredictable, mild stress-induced depression model mice. Chinese journal of natural medicines. Oct 2014;12(10):753-759.
68.Johannesson E, Simren M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. May 2011;106(5):915-922.
69.Kanazawa M, Hongo M, Fukudo S. Visceral hypersensitivity in irritable bowel syndrome. J Gastroenterol Hepatol. Apr 2011;26 Suppl 3:119-121.
70.Kerckhoffs AP, Akkermans LM, de Smet MB, et al. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci. Mar 2010;55(3):716-723.
71.Keszthelyi D, Dackus GH, Masclee GM, Kruimel JW, Masclee AA. Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study. BMC Gastroenterol. Sep 5 2012;12(1):121.
72.Klotz U. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid). Arzneimittel-Forschung. Feb 2012;62(2):53-58. 
73.Koezuka Y, Honda G, Tabata M. An Intestinal Propulsion Promoting Substance from Perilla frutescens and Its Mechanism of Action. Planta medica. Dec 1985;51(6):480-482.
74.Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357-364.
75.Ladabaum U, Sharabidze A, Levin TR, et al. Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. Jan 2010;8(1):42-48 e41. 
76.Lee HA, Han JS. Anti-inflammatory Effect of Perilla frutescens (L.) Britton var. frutescens Extract in LPS-stimulated RAW 264.7 Macrophages. Preventive nutrition and food science. Jun 2012;17(2):109-115.
77.Lee HR, Pimentel M. Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Current gastroenterology reports. Aug 2006;8(4):305-311. 
78.Lee L, Clarke JO, Pearson RL. Irritable bowel syndrome. First Consult 2012; http://www.mdconsult.com/das/pdxmd/body/379362381-3/0?type=med&eid=9-u1.0-_1_mt_1014787#Contributors. Accessed 11/8/2012. 
79.Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. Aug 11 2011;365(6):527-536. 
80.Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. Dec 1997;32(6):765-768. 
81.Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. Apr 2006;130(5):1480-1491. 
82.Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. Jul 2012;10(7):712-721 e714. 
83.Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther. Nov 15 2005;22(10):927-934. 
84.Lundin KE, Alaedini A. Non-celiac Gluten Sensitivity. Gastrointestinal endoscopy clinics of North America. Oct 2012;22(4):723-734. 
85.Lydiard RB, Falsetti SA. Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. The American journal of medicine. Nov 8 1999;107(5A):65S-73S. 
86.Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? The Journal of clinical psychiatry. 2001;62 Suppl 8:38-45; discussion 46-37. 
87.Mach T. The brain-gut axis in irritable bowel syndrome--clinical aspects. Medical science monitor : international medical journal of experimental and clinical research. Jun 2004;10(6):RA125-131.
88.Macpherson H, Tilbrook H, Bland MJ, Bloor K, Brabyn S, Cox H, . . . Whorwell P. Acupuncture for irritable bowel syndrome: primary care based pragmatic randomised controlled trial. BMC gastroenterology. Oct 24 2012;12(1):150. 
89.Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, Berman BM, Lao L. Acupuncture for treatment of irritable bowel syndrome. Cochrane database of systematic reviews. 2012;5:CD005111. 
90.Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, Patkar AA. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. Jan-Feb 2009;50(1):78-86. 
91.May B, Kuntz HD, Kieser M, Kohler S. Efficacy of a fixed peppermint oil/caraway oil combination in non-ulcer dyspepsia. Arzneimittel-Forschung. Dec 1996;46(12):1149-1153. 
92.Mayer EA, Naliboff BD, Chang L, Coutinho SV. V. Stress and irritable bowel syndrome. American journal of physiology. Gastrointestinal and liver physiology. Apr 2001;280(4):G519-524. 
93.Mayer EA. Clinical practice. Irritable bowel syndrome. The New England journal of medicine. Apr 17 2008;358(16):1692-1699. 
94.Mayo Clinic. Irritable bowel syndrome. Definition. Available at: http://www.mayoclinic.com/health/irritable-bowel-syndrome/DS00106. July 29, 2011. Accessed November 12, 2012.
95.Mearin F, Lacy BE. Diagnostic criteria in IBS: useful or not? Neurogastroenterol Motil. Sep 2012;24(9):791-801.
96.Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci. May 2010;55(5):1385-1390. 
97.Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. Aliment Pharmacol Ther. Jun 2002;16(6):1187-1195. 
98.Moloney RD, Johnson AC, O'Mahony SM, Dinan TG, Greenwood-Van Meerveld B, Cryan JF. Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome. CNS neuroscience & therapeutics. Feb 2016;22(2):102-117.
99.National Digestive Diseases Information Clearinghouse (NDDIC). Irritable Bowel Syndrome. Available at: http://digestive.niddk.nih.gov/ddiseases/pubs/ibs/index.aspx. Last updated July 2, 2012. Accessed November 12, 2012.
100.Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. May 2000;95(5):1231-1238.
101.Noreen EE, Sass MJ, Crowe ML, Pabon VA, Brandauer J, Averill LK. Effects of supplemental fish oil on resting metabolic rate, body composition, and salivary cortisol in healthy adults. J Int Soc Sports Nutr. 2010;7:31. 
102.Oh HA, Park CS, Ahn HJ, Park YS, Kim HM. Effect of Perilla frutescens var. acuta Kudo and rosmarinic acid on allergic inflammatory reactions. Experimental biology and medicine (Maywood, N.J.).Jan 2011;236(1):99-106.
103.O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. Mar 2005;128(3):541-551. 
104.Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. Aug 2010;25(8):1366-1373. 
105.Orr WC, Crowell MD, Lin B, Harnish MJ, Chen JD. Sleep and gastric function in irritable bowel syndrome: derailing the brain-gut axis. Gut. Sep 1997;41(3):390-393. 
106.Ostgaard H, Hausken T, Gundersen D, El-Salhy M. Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. Mol Med Report. Jun 2012;5(6):1382-1390. 
107.Pallotti F, Fogacci E, Frisoni C, Serra M, Bellacosa L, Carini G, . . . Barbara G. [Post-infectious irritable bowel syndrome]. La Clinica terapeutica. 2011;162(2):157-161. 
108.Pietzak M. Celiac disease, wheat allergy, and gluten sensitivity: when gluten free is not a fad. JPEN. Journal of parenteral and enteral nutrition. Jan 2012;36(1 Suppl):68S-75S. 
109.Pillai U, Devasahayam J, Kurup AN, Lacasse A. Invasive Saccharomyces cerevisiae infection: a friend turning foe? Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.Nov 2014;25(6):1266-1269.
110.Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. Feb 2015;47(2):119-124.
111.PubMed Health. Alosetron. AHFS Consumer Medication Information 2010; http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000163/. Accessed 11/6/2012.
112.PubMed Health. Propantheline. AHFS Consumer Medication Information 2011; http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000812/. Accessed 11/7/2012. 
113.Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. May 2012;57(5):1321-1329. 
114.Qin HY, Wu JC, Tong XD, Sung JJ, Xu HX, Bian ZX. Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. Journal of gastroenterology. Feb 2011;46(2):164-174. 
115.Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. Feb 2006;130(2 Suppl 1):S78-90. 
116.Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. Nov 2011;141(5):1792-1801. 
117.Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol. 2010;10:23. 
118.Roerig JL, Steffen KJ, Mitchel JE, Zunker C. Laxative abuse: epidemiology, diagnosis and management. Drugs. 2010;70(12):1487-503. 
119.Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011(8):CD003460. 
120.Sachdeva S, Rawat AK, Reddy RS, Puri AS. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors. Journal of gastroenterology and hepatology. Apr 2011;26 Suppl 3:135-138. 
121.Saha L, Malhotra S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol. Jan 2007;41(1):29-32. 
122.Santino I, Alari A, Bono S, et al. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. International journal of immunopathology and pharmacology.Jan-Mar 2014;27(1):143-146.
123.Schwille-Kiuntke J, Frick JS, Zanger P, Enck P. Post-infectious irritable bowel syndrome--a review of the literature. Zeitschrift fur Gastroenterologie. Aug 2011;49(8):997-1003. 
124.Serghini M, Karoui S, Boubaker J, Filali A. [Post-infectious irritable bowel syndrome]. La Tunisie medicale. Mar 2012;90(3):205-213. 
125.Shanahan F, Whorwell PJ. IgG-mediated food intolerance in irritable bowel syndrome: a real phenomenon or an epiphenomenom? Am J Gastroenterol. Jul 2005;100(7):1558-1559. 
126.Shi ZM, Zhu YS, Wang QX, Lei MN. [Comparative study on irritable bowel syndrome treated with acupuncture and western medicine]. Zhongguo zhen jiu = Chinese acupuncture & moxibustion. Jul 2011;31(7):607-609. 
127.Singh RH and Singh L. Studies on the anti-anxiety effect of the medyha rosayanna drug, Brahmi (Bapopa monniera Wettst) Part 1. J Res Ayur Siddha. 1980;1:133-48.
128.Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut. Oct 2005;54(10):1402-1407.
129.Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. Apr 2010;105(4):848-858. 
130.Spiller R, Lam C. An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. J Neurogastroenterol Motil. Jul 2012;18(3):258-268. 
131.Spiller R. Clinical update: irritable bowel syndrome. Lancet. May 12 2007;369(9573):1586-1588. 
132.Starks MA, Starks SL, Kingsley M, Purpura M, Jager R. The effects of phosphatidylserine on endocrine response to moderate intensity exercise. J Int Soc Sports Nutr. 2008;5:11. 
133.Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. Journal of gastroenterology. Jul 6 2012. 
134.Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. Oct 2011;24(5):487-495. 
135.Stuardi T, Macpherson H. Acupuncture for Irritable Bowel Syndrome: Diagnosis and Treatment of Patients in a Pragmatic Trial. Journal of alternative and complementary medicine (New York, N.Y.). Oct 26 2012. 
136.Suarez-Hitz KA, Otto B, Bidlingmaier M, Schwizer W, Fried M, Ehlert U. Altered psychobiological responsiveness in women with irritable bowel syndrome. Psychosom Med. Feb-Mar 2012;74(2):221-231. 
137.Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. May 2010;22(5):512-519, e114-515. 
138.Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World journal of gastroenterology : WJG. Aug 7 2009;15(29):3591-3596. 
139.Thompson WG. The Road to Rome. Gastroenterology. 2006;130:1552-1556.
140.Torpy JM, Golub RM. JAMA patient page. Irritable bowel syndrome. JAMA : the journal of the American Medical Association. Oct 5 2011;306(13):1501. 
141.Trinkley KE and Nahata MC. Treatment of irritable bowel syndrome. Journal of Clinical Pharmacy and Therapeutics. 2011;36:275-282.
142.Tubaki BR, Chandrashekar CR, Sudhakar D, et al. Clinical efficacy of Manasamitra Vataka (an Ayurveda medication) on generalized anxiety disorder with comorbid generalized social phobia: a randomized controlled study. J Altern Complement Med. 2012;18(6):612-21.
143.Urushima H, Nishimura J, Mizushima T, Hayashi N, Maeda K, Ito T. Perilla frutescens extract ameliorates DSS-induced colitis by suppressing proinflammatory cytokines and inducing anti-inflammatory cytokines. American journal of physiology. Gastrointestinal and liver physiology. Jan 1 2015;308(1):G32-41.
144.Usai P, Manca R, Cuomo R, Lai MA, Boi MF. Effect of gluten-free diet and co-morbidity of irritable bowel syndrome-type symptoms on health-related quality of life in adult coeliac patients. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. Sep 2007;39(9):824-828. 
145.Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivity. The American journal of gastroenterology. Jun 2009;104(6):1587-1594. 
146.Verspohl EJ, Fujii H, Homma K, Buchwald-Werner S. Testing of Perilla frutescens extract and Vicenin 2 for their antispasmodic effect. Phytomedicine : international journal of phytotherapy and phytopharmacology.Mar 15 2013;20(5):427-431.
147.Villarreal AA, Aberger FJ, Benrud R, Gundrum JD. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ. Feb 2012;111(1):17-20.
148.Volta U, De Giorgio R. New understanding of gluten sensitivity. Nat Rev Gastroenterol Hepatol. May 2012;9(5):295-299. 
149.Wahnschaffe U, Schulzke JD, Zeitz M, Ullrich R. Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Jul 2007;5(7):844-850; quiz 769. 
150.Walker AF, Middleton RW, Petrowicz O. Artichoke leaf extract reduces symptoms of irritable bowel syndrome in a post-marketing surveillance study. Phytother Res. Feb 2001;15(1):58-61. 
151.Wittmann T, Paradowski L, Ducrotte P, Bueno L, Delestrain MCA. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome - a randomized, double-blind, placebo-controlled study. Aliment Pharm Ther. Mar 15 2010;31(6):615-624. 
152.Yadav SK, Jain AK, Tripathi SN, et al. Irritable bowel syndrome: therapeutic evaluation of indigenous drugs. Indian J Med Res. 1989;90:496-503.
153.Yakoob J, Abbas Z, Khan R, Hamid S, Awan S, Jafri W. Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. Nov-Dec 2011;17(6):371-375. 
154.Yamini D, Pimentel M. Irritable bowel syndrome and small intestinal bacterial overgrowth. J Clin Gastroenterol. Nov-Dec 2010;44(10):672-675.
155.Yi LT, Li J, Geng D, et al. Essential oil of Perilla frutescens-induced change in hippocampal expression of brain-derived neurotrophic factor in chronic unpredictable mild stress in mice. Journal of ethnopharmacology.May 2 2013;147(1):245-253.
156.Zernicke KA, Campbell TS, Blustein PK, et al. Mindfulness-Based Stress Reduction for the Treatment of Irritable Bowel Syndrome Symptoms: A Randomized Wait-list Controlled Trial. Int J Behav Med. May 23 2012. 
157.Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane database of systematic reviews. 2009(1):CD006442.
1.Lane M, Black A and Ingram D. Calorie restriction in nonhuman primates: implications for age-related disease risk. Journal of Anti-Aging 1998;
2.Morley JE, Chahla E and Alkaade S. Antiaging, longevity and calorie restriction. Current Opinion in Clinical Nutrition and Metabolic Care. 2010;13(1):40-45
3.McCay CM, Crowell MF and Maynard LA. The effect of retarded growth upon the length of life span and upon the ultimate body size. Nutrition. 1935;10(1):63-79
4.Lane MA, Ingram DK. and Roth, GS. 2-Deoxy-D-glucose feeding in rats mimics physiologic effects of calorie restriction. Journal of Anti-Aging Medicine, 1998;1(4):327-337
5.Spindler SR. Caloric restriction: from soup to nuts. Ageing Res Rev. 2010;9(3):324-353
6.Masoro EJ. Dietary restriction-induced life extension: a broadly based biological phenomenon. Biogerontology. 2006;7(3):153-155
7.Bodkin NL, Alexander TM, Ortmeyer HK, Johnson E and Hansen BC. Mortality and morbidity in laboratory-maintained Rhesus monkeys and effects of long-term dietary restriction. J Gerontol A Biol Sci Med Sci. 2003;58(3):212-219
8.Yankner BA, Lu T and Loerch P. The aging brain. Annu Rev Pathol. 2008;3(41-66
9.Colman RJ, Anderson RM, Johnson SC, et al. Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys. Science. 2009;325(5937):201-204
10.Colman RJ, Anderson RM, Johnson SC, et al. Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys. Science. 2009;325(5937):201-204
11.Rodriguez NA, Garcia KD, Fortman JD, Hewett TA, Bunte RM and Bennett BT. Clinical and histopathological evaluation of 13. cases of adenocarcinoma in aged rhesus macaques (Macaca mulatta). J Med Primatol. 2002;31(2):74-83
12.Bodkin NL, Alexander TM, Ortmeyer HK, Johnson E and Hansen BC. Mortality and morbidity in laboratory-maintained Rhesus monkeys and effects of long-term dietary restriction. J Gerontol A Biol Sci Med Sci. 2003;58(3):212-219
13.Bodkin NL, Ortmeyer HK and Hansen BC. A comment on the comment: relevance of nonhuman primate dietary restriction to aging in humans. J Gerontol A Biol Sci Med Sci. 2005;60(8):951-952
14.Oeppen, Vaupel. Demography. Broken limits to life expectancy. Science.2002;296(5570):1029-1031
15.Lane M, Black A and Ingram D. Calorie restriction in nonhuman primates: implications for age-related disease risk. Journal of Anti-Aging 1998;
16.Kalimi M, Regelson W, eds. Dehydroepiandrosterone (DHEA): Biochemical, Physiological and Clinical Aspects. New York , NY : Walter de Gruyter; 1999.
17.Lane MA, Ingram DK, Ball SS and Roth GS. Dehydroepiandrosterone sulfate: a biomarker of primate aging slowed by calorie restriction. J Clin Endocrinol Metab. 1997;82(7):2093-2096
18.N. W. Shock et al., Eds., Normal Human Aging: The Baltimore Longitudinal Study on Aging (U.S. Government Printing Office, Washington, DC, 1984).
19.Roth GS, Lane MA, Ingram DK, et al. Biomarkers of caloric restriction may predict longevity in humans. Science. 2002;297(5582):811
20.Kagawa Y. Impact of Westernization on the nutrition of Japanese: changes in physique, cancer, longevity and centenarians. Prev Med. 1978;7(2):205-217
21.Vallejo EA. Hunger diet on alternate days in the nutrition of the aged. Prensa Med Argent. 1957; 44(2):119-120
22.Walford RL, Mock D, Verdery R and MacCallum T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. J Gerontol A Biol Sci Med Sci. 2002;57(6):B211-224
23.Fontana L, Meyer TE, Klein S and Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA. 2004;101(17):6659-6663
24.Fontana L, Klein S, Holloszy JO and Premachandra BN. Effect of long-term calorie restriction with adequate protein and micronutrients on thyroid hormones. J Clin Endocrinol Metab. 2006;91(8):3232-3235
25.Meyer TE, Kovács SJ, Ehsani AA, Klein S, Holloszy JO and Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol. 2006;47(2):398-402
26.Civitarese AE, Carling S, Heilbronn LK, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med. 2007;4(3):e76
27.Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351(9113):1393-1396
28.Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279(5350):563-566
29.Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst. 2000;92(19):1592-1600
30.Chang S-H, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA. 2004;101(2):591-596
31.Cianchi F, Cortesini C, Fantappiè O, et al. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res. 2004;10(8):2694-2704
32.Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37(5):431-502
33.About CALERIE. http://calerie.dcri.duke.edu/about/index.html
34.Smith DL, Nagy TR and Allison DB. Calorie restriction: what recent results suggest for the future of ageing research. Eur J Clin Invest. 2010;40(5):440-450
35.Larson-Meyer DE, Heilbronn LK, Redman LM, et al. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care. 2006;29(6):1337-1344
36.Redman LM, Heilbronn LK, Martin CK, et al. Effect of calorie restriction with or without exercise on body composition and fat distribution. J Clin Endocrinol Metab. 2007;92(3):865-872
37.Larson-Meyer DE, Newcomer BR, Heilbronn LK, et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring). 2008;16(6):1355-1362
38.Redman LM, Heilbronn LK, Martin CK, et al. Effect of calorie restriction with or without exercise on body composition and fat distribution. J Clin Endocrinol Metab. 2007;92(3):865-872
39.Heilbronn LK, de Jonge L, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA. 2006;295(13):1539-1548
40.Lefevre M, Redman LM, Heilbronn LK, et al. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis. 2009;203(1):206-213
41.Heilbronn LK, de Jonge L, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA. 2006;295(13):1539-1548
42.DeLany JP, Hansen BC, Bodkin NL, et a. Long-term calorie restriction reduces energy expenditure in aging monkeys. J Gerontol A Biol Sci Med Sci. 1999;54(1):B5-11
43.Civitarese AE, Carling S, Heilbronn LK, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med. 2007;4(3):e76
44.López-Lluch G, Irusta PM, Navas P, de Cabo R. Mitochondrial biogenesis and healthy aging. Experimental Gerontology. 2008; 43(9): 813-9.
45.Weiss EP, Racette SB, Villareal DT, et al. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr. 2006;84(5):1033-1042
46.Riordan MM, Weiss EP, Meyer TE, et al. The effects of caloric restriction- and exercise-induced weight loss on left ventricular diastolic function. Am J Physiol Heart Circ Physiol. 2008;294(3):H1174-1182
47.Fontana L, Villareal DT, Weiss EP, et al. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Am J Physiol Endocrinol Metab. 2007;293(1):E197-202
48.Weiss EP, Villareal DT, Racette SB, et al. Caloric restriction but not exercise-induced reductions in fat mass decrease plasma triiodothyronine concentrations: a randomized controlled trial. Rejuvenation Research. 2008;11(3):605-609
49.Weiss EP, Racette SB, Villareal DT, et al. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr. 2006;84(5):1033-1042
50.Weiss EP, Racette SB, Villareal DT, et al. Lower extremity muscle size and strength and aerobic capacity decrease with caloric restriction but not with exercise-induced weight loss. J Appl Physiol. 2007;102(2):634-640
51.Weiss EP, Racette SB, Villareal DT, et al. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr. 2006;84(5):1033-1042
52.Villareal DT, Fontana L, Weiss EP, et al. Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med. 2006;166(22):2502-2510
53.Redman LM, Rood J, Anton SD, et al. Calorie restriction and bone health in young, overweight individuals. Arch Intern Med. 2008;168(17):1859-1866
54.Das SK, Gilhooly CH, Golden JK et al. Long-term effects of 2 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y randomized controlled trial. Am J Clin Nutr. 2007;85(4):1023-30
55.Das SK, Gilhooly CH, Golden JK et al. Long Term Effects of Energy-Restricted Diets Differing in Glycemic Load on Metabolic Adaptation and Body Composition. Open Nutr J. 2007;85(4):1023-1030
56.Pittas AG, Roberst SB, Das SK et al. et al. The effects of the dietary glycemic load on type 2 diabetes risk factors during weight loss. Obesity 2006;14(12):2200-2209
57.International Diabetes Federation. Guideline For Management of Postmeal Glucose. 2007. Available at: http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf . Accessed Feb 15, 2011
58.Masoro EJ. Caloric restriction-induced life extension of rats and mice: A critique of proposed mechanisms. BBA - General Subjects. 2009;1790(10):1040-1048
59.Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11(3):298-300
60.Harman D. Extending functional life span. Experimental Gerontology. 1998;33(1-2):95-112
61.Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science. 1996;273(5271):59-63
62.Heilbronn LK, de Jonge L, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA. 2006;295(13):1539-1548
63.Yu BP. Aging and oxidative stress: modulation by dietary restriction. Free Radic Biol Med. 1996;21(5):651-668
64.Lass A, Sohal BH, Weindruch R, Forster MJ and Sohal RS. Caloric restriction prevents age-associated accrual of oxidative damage to mouse skeletal muscle mitochondria. Free Radic Biol Med. 1998;25(9):1089-1097
65.Armeni T, Pieri C, Marra M, Saccucci F and Principato G. Studies on the life prolonging effect of food restriction: glutathione levels and glyoxalase enzymes in rat liver. Mech Ageing Dev. 1998;101(1-2):101-110
66.Kim JD, McCarter RJ and Yu BP. Influence of age, exercise, and dietary restriction on oxidative stress in rats. Aging (Milano). 1996;8(2):123-129
67.Van Remmen H, Ward WF, et al. Gene expression and protein degradation. In: Masoro EJ, ed. Handbook of Physiology. Oxford , England : Oxford University Press; 1995:171-234.
68.Heydari AR, Unnikrishnan A, Lucente LV and Richardson A. Caloric restriction and genomic stability. Nucleic Acids Res. 2007;35(22):7485-7496
69.Chung HY, Kim HJ, Kim KW, et al. Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microsc Res Tech. 2002;59(4):264-272
70.Jung KJ, Lee EK, Kim JY, et al. Effect of short term calorie restriction on pro-inflammatory NF-kB and AP-1 in aged rat kidney. Inflamm. Res. 2009;58(3):143-150
71.Civitarese AE, Carling S, Heilbronn LK, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med. 2007;4(3):e76
72.Chung, HY, Kim HJ, Shim KH, and Kim KW. Dietary modulation of prostanoid synthesis in the aging process: role of cyclooxygenase-2. Mech Ageing Dev. 1999;111(2-3):97-106
73.Rabinowitz JD and White E. Autophagy and metabolism. Science. 2010;330(6009):1344-1348
74.Weber TA and Reichert AS. Impaired quality control of mitochondria: aging from a new perspective. Experimental Gerontology. 2010;45(7-8):503-511
75.Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 2005;120(2):237-248
76.Wohlgemuth SE, Seo AY, Marzetti E, Lees HA and Leeuwenburgh C. Skeletal muscle autophagy and apoptosis during aging: effects of calorie restriction and life-long exercise. Experimental Gerontology. 2010;45(2):138-148
77.Donati A, Recchia G, Cavallini G and Bergamini E. Effect of aging and anti-aging caloric restriction on the endocrine regulation of rat liver autophagy. J Gerontol A Biol Sci Med Sci. 2008;63(6):550-555
78.López-Lluch G, Hunt N, Jones B, et al. Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency. Proc Natl Acad Sci USA. 2006;103(6):1768-1773
79.Hagopian K, Harper M-E, Ram JJ, Humble SJ, Weindruch R and Ramsey JJ. Long-term calorie restriction reduces proton leak and hydrogen peroxide production in liver mitochondria. Am J Physiol Endocrinol Metab. 2005;288(4):E674-684
80.Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev. 2008 Apr; 88(2): 611-38.
81.Aquilano K, Vigilanza P, Baldelli S, Pagliei B, Rotilio G, Ciriolo MR. Peroxisome Proliferator-activated Receptor Co-activator 1 (PGC-1 ) and Sirtuin 1 (SIRT1) Reside in Mitochondria: POSSIBLE DIRECT FUNCTION IN MITOCHONDRIAL BIOGENESIS. Journal of Biological Chemistry. 2010; 285(28): 21590-9.
82.Ekstrand MI, Falkenberg M, Rantanen A, et al. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet. 2004 May 1; 13(9): 935-44.
83.Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci. 2010 Sep 20; Epub ahead of print
84.Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008 Oct; 8(4): 333-41.
85.Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003 Sep 11; 425(6954): 191-6.
86.Morley JE, Chahla E and Alkaade S. Antiaging, longevity and calorie restriction. Current Opinion in Clinical Nutrition and Metabolic Care. 2010;13(1):40-45
87.Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395
88.Cao SX, Dhahbi JM, Mote PL and Spindler SR. Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice. Proc Natl Acad Sci USA. 2001;98(19):10630-10635
89.Chung HY, Kim HJ, Kim KW, et al. Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microsc Res Tech. 2002;59(4):264-272
90.Chung HY, Kim HJ, Kim JW, and Yu BP. The inflammation hypothesis of aging: molecular modulation by calorie restriction. Ann N Y Acad Sci. 2001;928:327-35
91.Masoro EJ. Caloric restriction-induced life extension of rats and mice: A critique of proposed mechanisms. BBA - General Subjects. 2009;1790(10):1040-1048
92.Calabrese EJ and Baldwin LA. Hormesis as a biological hypothesis. Environ Health Perspect. 1998;106 Suppl 1(357-362
93.Rattan SIS. Aging, anti-aging, and hormesis. Mech Ageing Dev. 2004;125(4):285-289
94.Morley JE, Chahla E and Alkaade S. Antiaging, longevity and calorie restriction. Current Opinion in Clinical Nutrition and Metabolic Care. 2010;13(1):40-45
95.Viljanen APM, Karmi A, Borra R, et al. Effect of caloric restriction on myocardial fatty acid uptake, left ventricular mass, and cardiac work in obese adults. Am J Cardiol. 2009;103(12):1721-1726
96.Viljanen APM, Iozzo P, Borra R, et al. Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metab. 2009;94(1):50-55
97.Keys A, Brozek J, Henschels A, Mickelsen O, Taylor H. The Biology of Human Starvation. Vol 2. Minneapolis: University of Minnesota Press; 1950:1133.
98.Racette SB, Weiss EP, Villareal DT, et al. One year of caloric restriction in humans: feasibility and effects on body composition and abdominal adipose tissue. J Gerontol A Biol Sci Med Sci. 2006;61(9):943-950
99.Cheney KE, Liu RK, Smith GS, Meredith PJ, Mickey MR and Walford RL. The effect of dietary restriction of varying duration on survival, tumor patterns, immune function, and body temperature in B10C3F1 female mice. J Gerontol. 1983;38(4):420-430
100.Nelson W and Halberg F. Meal-timing, circadian rhythms and life span of mice. J Nutr. 1986;116(11):2244-2253
101.Varady KA and Hellerstein MK. Alternate-day fasting and chronic disease prevention: a review of human and animal trials. Am J Clin Nutr. 2007;86(1):7-13
102.Stote KS, Baer DJ, Spears K, et al. A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. Am J Clin Nutr. 2007;85(4):981-988
103.Heilbronn LK, Smith SR, Martin CK, Anton SD and Ravussin E. Alternate-day fasting in nonobese subjects: effects on body weight, body composition, and energy metabolism. Am J Clin Nutr. 2005;81(1):69-73
104.Bloomer RJ, Kabir MM, Canale RE, et al. Effect of a 21 day Daniel Fast on metabolic and cardiovascular disease risk factors in men and women. Lipids Health Dis. 2010;9:94
105.Trepanowski JF and Bloomer RJ. The impact of religious fasting on human health. Nutr J. 2010;9:57
106.Cao SX, Dhahbi JM, Mote PL and Spindler SR. Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice. Proc Natl Acad Sci USA. 2001;98(19):10630-10635
107.Calton JB. Prevalence of micronutrient deficiency in popular diet plans. J Int Soc Sports Nutr. 2010;7:24
108.Gilhooly CH, Das SK, Golden JK et al. Use of cereal fiber to facilitate adherence to a human caloric restriction program. Aging Clin Exp Res. 2008;20(6):513-520
109.Veldhorst MA, Nieuwenhuizen AG, Hochstenbach-Waelen A, et al. Dose-dependent satiating effect of whey relative to casein or soy. Physiol Behav. 2009 Mar 23; 96(4-5): 675-82.
110.Hall WL, Millward DJ, Long SJ, Morgan LM. Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr. 2003 Feb; 89(2): 239-48.
111.Lane MA, Roth GS and Ingram DK. Caloric restriction mimetics: a novel approach for biogerontology. Methods Mol Biol. 2007;371(143-149
112.Racette SB, Weiss EP, Villareal DT, et al. One year of caloric restriction in humans: feasibility and effects on body composition and abdominal adipose tissue. J Gerontol A Biol Sci Med Sci. 2006;61(9):943-950
113.Ingram DK, Zhu M, Mamczarz J, et al. Calorie restriction mimetics: an emerging research field. Aging Cell. 2006;5(2):97-108
114.Kitani K, Osawa T and Yokozawa T. The effects of tetrahydrocurcumin and green tea polyphenol on the survival of male C57BL/6 mice. Biogerontology. 2007;8(5):567-573
115.Winter JC. The effects of an extract of Ginkgo biloba, EGb 761, on cognitive behavior and longevity in the rat. Physiol Behav. 1998;63(3):425-433
116.Nadon NL, Strong R, Miller RA, et al. Design of aging intervention studies: the NIA interventions testing program. Age (Dordr). 2008;30(4):187-199
117.Miller RA, Harrison DE, Astle CM, et al. An Aging Interventions Testing Program: study design and interim report. Aging Cell. 2007;6(4):565-575
118.Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011;66(2):191-201
119.Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395
120.Strong R, Miller RA, Astle CM, et al. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell. 2008;7(5):641-650
121.National Institute on Aging. Compounds in Testing. http://www.nia.nih.gov/ResearchInformation/ScientificResources/CompoundsInTesting.htm
122.Howitz KT and Sinclair DA. Xenohormesis: sensing the chemical cues of other species. Cell. 2008;133(3):387-391
123.Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191-196
124.Westphal CH, Dipp MA and Guarente L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem Sci. 2007;32(12):555-560
125.Lee JH, Song MY, Song, EK et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009;58(2):344-351
126.Kubota S, Kurihara T, Mochimaru H et al. Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor-kappaB activation. Invest Ophthalmol Vis Sci 2009;50(7): 3512-3519
127.Hofseth LJ, Singh UP, Singh NP, Nagarkatti M, Nagarkatti PS. Taming the beast within: resveratrol suppresses colitis and prevents colon cancer. Aging 2010;2(4):183-184
128.Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70(22):9003-11
129.Pan MH, Chiou YS, Chen WJ, Wang JM, Badmaev V, Ho CT. Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. Carcinogenesis 2009;30(7):1234-1242
130.Hougee S, Faber J, Sanders A et al. Selective COX-2 Inhibition by a Pterocarpus marsupiumExtract Characterized by Pterostilbene, and its Activity in Healthy Human Volunteers. Planta Med 2005;71(5):387-392
131.Howitz KT and Sinclair DA. Xenohormesis: sensing the chemical cues of other species. Cell. 2008;133(3):387-391
132.Howitz KT, Bitterman,KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425(6954):191-196
133.Suh Y, Afaq F, Khan N, Johnson JJ, Khusro FH, Mukhtar H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis 2010;31(8): 1424-1433
134.Sung B, Pandey MK, Aggarwal BB. Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol Pharmacol 2007;71(6):1703-1714
135.Hanneken A, Lin FF, Johnson J, Maher P. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci 2006;47(7):3164-77
136.Howitz KT, Bitterman,KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425(6954):191-196
137.Wood JG, Rogina B, Lavu S et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004;430(7000):686-689
138.Wen W, Lu J, Zhang K, Chen S. Grape seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor signaling pathway. Cancer Prev Res. 2008;1(7):554-61.
139.Powolny AA, Wang S, Carlton PS, Hoot DR, Clinton SK. Interrelationships between dietary restriction, the IGF-I axis, and expression of vascular endothelial growth factor by prostate adenocarcinoma in rats. Mol Carcinog 2008;47(6):458-65
140.Gosslau A, En Jao D, Huang M et al. Effects of the black tea polyphenol theaflavin-2 on apoptotic and inflammatory pathways in vitro and in vivo. Mol. Nutr. Food Res. 2011;55:198-208
141.Abbas AK, Lichtman AH. Basic Immunology: Functions and Disorders of the Immune System. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2009.
142.Abe Y, Yuasa M, Kajiwara Y, Hosono M. Defects of immune cells in the senescence-accelerated mouse: a model for learning and memory deficits in the aged. Cell Immunol. Aug 1994;157(1):59-69.
143.Adams WJ, Morris DL, Ross WB, Lubowski DZ, King DW, Peters L. Cimetidine preserves non-specific immune function after colonic resection for cancer. The Australian and New Zealand journal of surgery. Dec 1994;64(12):847-852.
144.Adolfsson O, Huber BT, Meydani SN. Vitamin E-enhanced IL-2 production in old mice: naive but not memory T cells show increased cell division cycling and IL-2-producing capacity. Journal of immunology (Baltimore, Md.: 1950). Oct 1 2001;167(7):3809-3817.
145.Agarwal S, Busse PJ. Innate and adaptive immunosenescence. Ann Allergy Asthma Immunol. Mar 2010;104(3):183-190; quiz 190-182, 210.
146.Ahmed T, Das SK, Golden JK, Saltzman E, Roberts SB, Meydani SN. Calorie restriction enhances T-cell-mediated immune response in adult overweight men and women. J Gerontol A Biol Sci Med Sci. Nov 2009;64(11):1107-1113.
147.Aldabal L, Bahammam AS. Metabolic, endocrine, and immune consequences of sleep deprivation. The Open Respiratory Medicine Journal. 2011;5:31-43.
148.Aleem E. beta-Glucans and their applications in cancer therapy: focus on human studies. Anti-cancer agents in medicinal chemistry. Jun 2013;13(5):709-719.
149.Ambrosia LLC. ClinicalTrials.gov entry: Young Donor Plasma Transfusion and Age-Related Biomarkers. https://clinicaltrials.gov/ct2/show/NCT02803554?term=young+plasma&rank=2. Accessed 8/12/2016.
150.Andresen RH, Hass GM, Madden DA, Monroe CW. Postparabiotic tissue reactions of rabbits to musculofascial cross-transplants. J Exp Med. Jan 1 1957;105(1):85-92.
151.Antoni MH, Lutgendorf SK, Blomberg B, et al. Cognitive-behavioral stress management reverses anxiety-related leukocyte transcriptional dynamics. Biological psychiatry. Feb 15 2012;71(4):366-372.
152.Aranha I, Clement F, Venkatesh YP. Immunostimulatory properties of the major protein from the stem of the Ayurvedic medicinal herb, guduchi (Tinospora cordifolia). Journal of ethnopharmacology. Jan 31 2012;139(2):366-372.
153.Arndt PA, Garratty G, Brasfield FM, Vemuri SL, Asuncion DJ. Immune hemolytic anemia due to cimetidine: the first example of a cimetidine antibody. Transfusion. Feb 2010;50(2):302-307.
154.Arvedson T, O'Kelly J, Yang BB. Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. Jun 2015;29(3):185-198.
155.Avtonomova AV, Krasnopolskaya LM. [Antiviral properties of basidiomycetes metabolites]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] / Ministerstvo meditsinskoi i mikrobiologicheskoi promyshlennosti SSSR. 2014;59(7-8):41-48.
156.Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. Apr 2007;120(4):435-446.
157.Bai D, Yang G, Yuan H, Li Y, Wang K, Shao H. Perioperative cimetidine application modulates natural killer cells in patients with colorectal cancer: a randomized clinical study. Journal of Tongji Medical University = Tong ji yi ke da xue xue bao. 1999;19(4):300-303.
158.Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. Nov 10 2011;479(7372):232-236.
159.Bala M, Pratap K, Verma PK, Singh B, Padwad Y. Validation of ethnomedicinal potential of Tinospora cordifolia for anticancer and immunomodulatory activities and quantification of bioactive molecules by HPTLC. Journal of ethnopharmacology. Dec 4 2015;175:131-137.
160.Bala M, Verma PK, Awasthi S, Kumar N, Lal B, Singh B. Chemical prospection of important ayurvedic plant Tinospora cordifolia by UPLC-DAD-ESI-QTOF-MS/MS and NMR. Natural product communications.Jan 2015;10(1):43-48.
161.Bales CW, Kraus WE. Caloric restriction: implications for human cardiometabolic health. J Cardiopulm Rehabil Prev. Jul-Aug 2013;33(4):201-208.
162.Bao B, Prasad AS, Beck FW, et al. Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. The American journal of clinical nutrition. Jun 2010;91(6):1634-1641.
163.Batra P, Sharma AK, Khajuria R. Probing Lingzhi or Reishi medicinal mushroom Ganoderma lucidum (higher Basidiomycetes): a bitter mushroom with amazing health benefits. International journal of medicinal mushrooms. 2013;15(2):127-143.
164.Bauer ME. Chronic stress and immunosenescence: a review. Neuroimmunomodulation. 2008;15(4-6):241-250.
165.Bauer ME, Wieck A, Petersen LE, Baptista TS. Neuroendocrine and viral correlates of premature immunosenescence. Annals of the New York Academy of Sciences. Sep 2015;1351:11-21.
166.Belcaro G, Cesarone MR, Cornelli U, et al. Prevention of flu episodes with colostrum and Bifivir compared with vaccination: an epidemiological, registry study. Panminerva Med. Dec 2010;52(4):269-275.
167.Beli E, Duriancik DM, Clinthorne JF, Lee T, Kim S, Gardner EM. Natural killer cell development and maturation in aged mice. Mechanisms of ageing and development. Jan 2014;135:33-40.
168.Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nature reviews. Immunology. 2007;7(11):875-888.
169.Bendall LJ, Bradstock KF. G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine and Growth Factor Reviews. 2014;25(4):355-367.
170.Bert P. J Anatomie Physiologie. 1864;1:69–87.
171.Bollinger T, Bollinger A, Skrum L, Dimitrov S, Lange T, Solbach W. Sleep-dependent activity of T cells and regulatory T cells. Clinical and experimental immunology. Feb 2009;155(2):231-238.
172.Bosch JA, Fischer JE, Fischer JC. Psychologically adverse work conditions are associated with CD8+ T cell differentiation indicative of immunesenescence. Brain Behav Immun. May 2009;23(4):527-534.
173.Brender E, Lynm C, Glass RM. GRanulocyte-colony stimulating factor. JAMA. 2006;295(9):1088-1088.
174.Brosnan JT, Brosnan ME. The sulfur-containing amino acids: an overview. The Journal of nutrition. Jun 2006;136(6 Suppl):1636s-1640s.
175.Buford TW, Willoughby DS. Impact of DHEA(S) and cortisol on immune function in aging: a brief review. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. Jun 2008;33(3):429-433.
176.Buoso E, Lanni C, Molteni E, Rousset F, Corsini E, Racchi M. Opposing effects of cortisol and dehydroepiandrosterone on the expression of the receptor for Activated C Kinase 1: implications in immunosenescence. Experimental gerontology. Nov 2011;46(11):877-883.
177.Butcher S, Chahel H, Lord JM. Ageing and the neutrophil: no appetite for killing? Immunology. 2000;100(4):411-416.
178.Butterfield DA, Poon HF. The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Experimental gerontology. Oct 2005;40(10):774-783.
179.Cabrera AJ. Zinc, aging, and immunosenescence: an overview. Pathobiol Aging Age Relat Dis. 2015;5:25592.
180.Caccavo D, Pellegrino NM, Altamura M, Rigon A, Amati L, Amoroso A, Jirillo E. Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. J Endotoxin Res. 2002;8(6):403-417.
181.Candore G, Balistreri CR, Colonna-Romano G, et al. Immunosenescence and anti-immunosenescence therapies: the case of probiotics. Rejuvenation Res. Apr 2008;11(2):425-432.
182.Cannizzo ES, Clement CC, Sahu R, Follo C, Santambrogio L. Oxidative stress, inflamm-aging and immunosenescence. Journal of proteomics. Oct 19 2011;74(11):2313-2323.
183.Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microbial ecology in health and disease. 2015;26:26191.
184.Carlson LE, Speca M, Faris P, Patel KD. One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. Brain Behav Immun. Nov 2007;21(8):1038-1049.
185.Carroll JE, Cole SW, Seeman TE, et al. Partial sleep deprivation activates the DNA damage response (DDR) and the senescence-associated secretory phenotype (SASP) in aged adult humans. Brain Behav Immun. Jan 2016;51:223-229.
186.Casas R, Sacanella E, Estruch R. The immune protective effect of the Mediterranean diet against chronic low-grade inflammatory diseases. Endocrine, metabolic & immune disorders drug targets. 2014;14(4):245-254.
187.Casey, J. L., J. J. Feld and S. A. MacParland. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection." Cells. 2019;8(4).
188.Castelo-Branco C, Soveral I. The immune system and aging: a review. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. Jan 2014;30(1):16-22.
189.CDC. Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and Congenital CMV Infection. Interpretation of Lab Tests. http://www.cdc.gov/cmv/clinical/lab-tests.html. Last updated 6/17/2016b. Accessed 8/16/2016.
190.Chan GC, Chan WK, Sze DM. The effects of beta-glucan on human immune and cancer cells. Journal of hematology & oncology. 2009;2:25.
191.Chaplin DD. Overview of the immune response. The Journal of allergy and clinical immunology. Feb 2010;125(2 Suppl 2):S3-23.
192.Chen J, Seviour R. Medicinal importance of fungal beta-(1-->3), (1-->6)-glucans. Mycological research. Jun 2007;111(Pt 6):635-652.
193.Chen W, Zhang Y, Tan N, Qi Y, Zhu J-S. Synergy of Ganoderma lucidum Extract ReishiMax and Green Tea Polyphenols Tegreen in Anti-Cancer in a S180-inoculation model. The FASEB Journal. 2007;21(6):A1100.
194.Choi JY, Paik DJ, Kwon DY, Park Y. Dietary supplementation with rice bran fermented with Lentinus edodes increases interferon-gamma activity without causing adverse effects: a randomized, double-blind, placebo-controlled, parallel-group study. Nutrition journal. 2014;13:35.
195.Choi S, Youn J, Kim K, Joo da H, Shin S, Lee J, Lee HK, An IS, Kwon S, Youn HJ, Ahn KJ, An S, and Cha HJ. 2016. Apigenin inhibits UVA-induced cytotoxicity in vitro and prevents signs of skin aging in vivo. Int J Mol Med, 38: 627-34.
196.Cholujova D, Jakubikova J, Czako B, et al. MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients. Cancer immunology, immunotherapy: CII. Mar 2013;62(3):437-445.
197.Cholujova D, Jakubikova J, Sedlak J. BioBran-augmented maturation of human monocyte-derived dendritic cells. Neoplasma. 2009;56(2):89-95.
198.Chou JP, Effros RB. T cell replicative senescence in human aging. Current pharmaceutical design. 2013;19(9):1680-1698.
199.Chu SL, Fu H, Yang JX, et al. A randomized double-blind placebo-controlled study of Pu'er tea extract on the regulation of metabolic syndrome. Chin J Integr Med. Jul 2011;17(7):492-498.
200.Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005;433:760–764.
201.Corsini E, Racchi M, Sinforiani E, et al. Age-related decline in RACK-1 expression in human leukocytes is correlated to plasma levels of dehydroepiandrosterone. Journal of leukocyte biology. Feb 2005;77(2):247-256.
202.Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP. CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med. 2009;7:102.
203.Currais A, Farrokhi C, Dargusch R, et al. Fisetin Reduces the Impact of Aging on Behavior and Physiology in the Rapidly Aging SAMP8 Mouse. The journals of gerontology Series A, Biological sciences and medical sciences. Mar 2 2018;73(3):299-307. doi:10.1093/gerona/glx104
204.Dalonso N, Goldman GH, Gern RM. beta-(1-->3),(1-->6)-Glucans: medicinal activities, characterization, biosynthesis and new horizons. Appl Microbiol Biotechnol. Oct 2015;99(19):7893-7906.
205.Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Friedman G. Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine. 1995;13(15):1445-1448.
206.de Araujo AL, Silva LC, Fernandes JR, Benard G. Preventing or reversing immunosenescence: can exercise be an immunotherapy? Immunotherapy. Aug 2013;5(8):879-893.
207.de Brouwer SJ, van Middendorp H, Kraaimaat FW, et al. Immune responses to stress after stress management training in patients with rheumatoid arthritis. Arthritis research & therapy. 2013;15(6):R200.
208.De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. The European respiratory journal. Jul 1997;10(7):1535-1541.
209.De la Fuente M, Hernanz A, Guayerbas N, Victor VM, Arnalich F. Vitamin E ingestion improves several immune functions in elderly men and women. Free radical research. Mar 2008;42(3):272-280.
210.de Moreno de LeBlanc A, Matar C, Perdigon G. The application of probiotics in cancer. The British journal of nutrition. Oct 2007;98 Suppl 1:S105-110.
211.Delves PJ. Components of the Immune System. Merck Manual - Professional Version http://www.merckmanuals.com/professional/immunology-allergic-disorders/biology-of-the-immune-system/components-of-the-immune-system. Last updated 11/2014. Accessed September 24, 2015.
212.Derhovanessian E, Maier AB, Beck R, et al. Hallmark features of immunosenescence are absent in familial longevity. J Immunol. Oct 15 2010;185(8):4618-4624.
213.Dhabhar FS. Effects of stress on immune function: the good, the bad, and the beautiful. Immunol Res. May 2014;58(2-3):193-210.
214.Dimeloe S, Nanzer A, Ryanna K, Hawrylowicz C. Regulatory T cells, inflammation and the allergic response-The role of glucocorticoids and Vitamin D. The Journal of steroid biochemistry and molecular biology.May 31 2010;120(2-3):86-95.
215.Dionysius DA, Grieve PA, Milne JM. Forms of lactoferrin: their antibacterial effect on enterotoxigenic Escherichia coli. J Dairy Sci. Sep 1993;76(9):2597-2600.
216.Dixit D, Sharma V, Ghosh S, Mehta VS, and Sen E. 2012. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. Cell Death Dis, 3: e271.
217.Dock JN, Effros RB. Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence. Aging Dis. Oct 2011;2(5):382-397.
218.Drake VJ. Linus Pauling Institute. Overview of the Immune System. http://lpi.oregonstate.edu/mic/micronutrients-health/immunity. Last updated 8/2010. Accessed September 24, 2015.
219.Drela N, Kozdron E, Szczypiorski P. Moderate exercise may attenuate some aspects of immunosenescence. BMC geriatrics. Sep 29 2004;4:8.
220.Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004;30(3):261-277.
221.Duarte PO, Duarte MG, Pelichek A, Pfrimer K, Ferriolli E, Moriguti JC, Lima NK. Cardiovascular risk factors and inflammatory activity among centenarians with and without dementia. Aging Clin Exp Res. Jul 4 2016.
222.Duggal NA, Pollock RD, Lazarus NR, Harridge S, Lord JM. Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood. Aging Cell. 2018;17(2):e12750. doi:10.1111/acel.12750.
223.Duncan SH, Flint HJ. Probiotics and prebiotics and health in ageing populations. Maturitas. May 2013;75(1):44-50.
224.Ebrahimi M, Mohammad Hassan Z, Mostafaie A, Zare Mehrjardi N, Ghazanfari T. Purif ied Protein Fraction of Garlic Extract Modulates Cellular Immune Response against Breast Transplanted Tumors in BALB/c Mice Model. Cell journal. Spring 2013;15(1):65-75.
225.Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne. Feb 22 2011;183(3):310-319.
226.Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annual review of medicine. 2000;51:245-270.
227.Estruch R. Anti-inflammatory effects of the Mediterranean diet: the experience of the PREDIMED study. Proc Nutr Soc. Aug 2010;69(3):333-340.
228.Fantacone ML, Lowry MB, Uesugi SL, et al. The Effect of a Multivitamin and Mineral Supplement on Immune Function in Healthy Older Adults: A Double-Blind, Randomized, Controlled Trial. Nutrients. 2020;12(8).
229.Fernandes G, Venkatraman JT, Turturro A, Attwood VG, Hart RW. Effect of food restriction on life span and immune functions in long-lived Fischer-344 x Brown Norway F1 rats. Journal of clinical immunology. Jan 1997;17(1):85-95.
230.Fessler J, Ficjan A, Duftner C, Dejaco C. The impact of aging on regulatory T-cells. Frontiers in immunology. 2013;4:231.
231.Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World journal of gastroenterology: WJG. 2014;20(43):16079-16094.
232.Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proceedings of the National Academy of Sciences of the United States of America. Apr 27 2004;101(17):6659-6663.
233.Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. Jun 2014;69 Suppl 1:S4-9.
234.Franceschi C, Olivieri F, Marchegiani F, et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mechanisms of ageing and development. Feb 2005;126(2):351-361.
235.Franco, F., A. Jaccard, P. Romero, Y. R. Yu and P. C. Ho. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab. 2020;2(10): 1001-1012.
236.Freeman SL, Fisher L, German JB, et al. Dairy proteins and the response to pneumovax in senior citizens: a randomized, double-blind, placebo-controlled pilot study. Annals of the New York Academy of Sciences. Mar 2010;1190:97-103.
237.Fu G, Pang H, Wong YH. Naturally occurring phenylethanoid glycosides: potential leads for new therapeutics. Current medicinal chemistry. 2008;15(25):2592-2613.
238.Ganz FD. Sleep and immune function. Critical care nurse. Apr 2012;32(2):e19-25.
239.Garbers C, Kuck F, Aparicio-Siegmund S, et al. Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR). Cell cycle (Georgetown, Tex.). Nov 1 2013;12(21):3421-3432.
240.Ghazanfari T, Hassan ZM, Ebtekar M, Ahmadiani A, Naderi G, Azar A. Garlic induces a shift in cytokine pattern in Leishmania major-infected BALB/c mice. Scandinavian journal of immunology. Nov 2000;52(5):491-495.
241.Ghezzi P. Role of glutathione in immunity and inflammation in the lung. International journal of general medicine. 2011;4:105-113.
242.Ghoneum M, Abedi S. Enhancement of natural killer cell activity of aged mice by modified arabinoxylan rice bran (MGN-3/Biobran). The Journal of pharmacy and pharmacology. Dec 2004;56(12):1581-1588.
243.Ghoneum M, Agrawal S. Mgn-3/biobran enhances generation of cytotoxic CD8+ T cells via upregulation of dec-205 expression on dendritic cells. International journal of immunopathology and pharmacology. Oct-Dec 2014;27(4):523-530.
244.Ghoneum M, Badr El-Din NK, Abdel Fattah SM, Tolentino L. Arabinoxylan rice bran (MGN-3/Biobran) provides protection against whole-body gamma-irradiation in mice via restoration of hematopoietic tissues. Journal of radiation research. May 2013;54(3):419-429.
245.Ghoneum M, Badr El-Din NK, Ali DA, El-Dein MA. Modified arabinoxylan from rice bran, MGN-3/biobran, sensitizes metastatic breast cancer cells to paclitaxel in vitro. Anticancer research. Jan 2014;34(1):81-87.
246.Ghoneum M, Gollapudi S. Synergistic apoptotic effect of arabinoxylan rice bran (MGN-3/Biobran) and curcumin (turmeric) on human multiple myeloma cell line U266 in vitro. Neoplasma. 2011;58(2):118-123.
247.Ghoneum M, Matsuura M. Augmentation of macrophage phagocytosis by modified arabinoxylan rice bran (MGN-3/biobran). International journal of immunopathology and pharmacology. Sep-Dec 2004;17(3):283-292.
248.Ghoneum M, Matsuura M, Gollapudi S. Modified arabinoxylan rice bran (MGN3/Biobran) enhances intracellular killing of microbes by human phagocytic cells in vitro. International journal of immunopathology and pharmacology. Jan-Mar 2008;21(1):87-95.
249.Ghosh T, Auerochs S, Saha S, Ray B, Marschall M. Anti-cytomegalovirus activity of sulfated glucans generated from a commercial preparation of rice bran. Antiviral chemistry & chemotherapy. 2010;21(2):85-95.
250.Gifford RR, Voss BV, Schmidtke JR, Ferguson RM. Histamine type-2 receptor antagonist immune modulation. I. Increased cell-mediated cytotoxicity in normal and in down-regulated systems. Surgery. Feb 1988;103(2):184-192.
251.Gleeson M, Williams C. Intense exercise training and immune function. Nestle Nutrition Institute workshop series. 2013;76:39-50.
252.Gold Standard. Drug Monograph. Filgrastim, G-CSF. www.clinicalkey.com. Last updated 3/7/2016. Accessed 8/16/2016.
253.Gomez CR, Karavitis J, Palmer JL, Faunce DE, Ramirez L, Nomellini V, Kovacs EJ. Interleukin-6 contributes to age-related alteration of cytokine production by macrophages. Mediators Inflamm. 2010;2010:475139.
254.Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14(5):428-436.
255.Graf D, Di Cagno R, Fak F, Flint HJ, Nyman M, Saarela M, Watzl B. Contribution of diet to the composition of the human gut microbiota. Microbial ecology in health and disease. 2015;26:26164.
256.Griffith AV, Venables T, Shi J, et al. Metabolic Damage and Premature Thymus Aging Caused by Stromal Catalase Deficiency. Cell reports. Aug 18 2015;12(7):1071-1079.
257.Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res. Jun 2009;21(3):201-209.
258.Grynkiewicz G, Demchuk OM. New Perspectives for Fisetin. Front Chem. 2019;7:697-697. doi:10.3389/fchem.2019.00697
259.Haase H, Rink L. The immune system and the impact of zinc during aging. Immunity & ageing: I & A. 2009;6:9.
260.Hahm KB, Kim WH, Lee SI, Kang JK, Park IS. Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scandinavian journal of gastroenterology. Mar 1995;30(3):265-271.
261.Hahm KB, Lee SI, Chung JP, Kim WH, Kim JH, Park IS. Comparison of immunomodulative effects of histamine-2 receptor antagonists in gastric cancer patients: focus on the lymphoblastogenesis and cytotoxicity of peripheral blood mononuclear cells. International journal of immunopharmacology. Dec 1994;16(12):985-993.
262.Hakim FT, Gress RE. Immunosenescence: deficits in adaptive immunity in the elderly. Tissue antigens. Sep 2007;70(3):179-189.
263.Han SN, Meydani SN. Impact of vitamin E on immune function and its clinical implications. Expert review of clinical immunology. Jul 2006;2(4):561-567.
264.Han X, Zhang J, Xue X, et al. Theflavin ameliorates ionizing radioan-induced hematopoietic injury via the NRF2 pathway. Free Rad Bio and Med. 2017;113:59-70.
265.Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. The American journal of medicine. May 1999;106(5):506-512.
266.Hast R, Bernell P, Hansson M. Cimetidine as an immune response modifier. Medical oncology and tumor pharmacotherapy. 1989;6(1):111-113.
267.Hazeldine J, Lord JM. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev. Sep 2013;12(4):1069-1078.
268.Heidari B. The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease. Caspian J Intern Med. Spring 2012;3(2):428-435.
269.Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. The Cochrane database of systematic reviews. 2013;1:Cd000980.
270.Hinken AC, Powers JM, Luo G, Holt JA, Billin AN, Russell AJ. Lack of evidence for GDF11 as a rejuvenator of aged skeletal muscle satellite cells. Aging Cell. Jun 2016;15(3):582-584.
271.Hirai N, Hill NO, Motoo Y, Osther K. Cimetidine enhances interferon induced augmentation of NK cell activity and suppresses interferon production. Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology. Aug 1985;93(4):153-159.
272.Hirotsu C, Tufik S, Andersen ML. Interactions between sleep, stress, and metabolism: From physiological to pathological conditions. Sleep Science (Sao Paulo, Brazil). Nov 2015;8(3):143-152.
273.Holmannova D, Kolackova M, Krejsek J. [Vitamin C and its physiological role with respect to the components of the immune system]. Vnitrni lekarstvi. Oct 2012;58(10):743-749.
274.Homayoni Rad A, Vaghef Mehrabany E, Alipoor B, Vaghef Mehrabany L. The Comparison of Food and Supplement as Probiotic Delivery Vehicles. Critical reviews in food science and nutrition. Apr 25 2016;56(6):896-909.
275.Homayouni Rad A, Torab R, Ghalibaf M, Norouzi S, Mehrabany EV. Might patients with immune-related diseases benefit from probiotics? Nutrition (Burbank, Los Angeles County, Calif.). Mar 2013;29(3):583-586.
276.Horrington EM, Pope F, Lunsford W, Mc CC. Age changes in the bones, blood pressure, and diseases of rats in parabiosis. Gerontologia. 1960;4:21-31.
277.Humphreys, D., M. ElGhazaly and T. Frisan. Senescence and Host-Pathogen Interactions. Cells. 2020;9(7).
278.Iannello A, Raulet DH. Immune surveillance of unhealthy cells by natural killer cells. Cold Spring Harbor symposia on quantitative biology. 2013;78:249-257.
279.Ibarra-Coronado EG, Pantaleon-Martinez AM, Velazquez-Moctezuma J, et al. The Bidirectional Relationship between Sleep and Immunity against Infections. J Immunol Res. 2015;2015:678164.
280.Ibrahim F, Ruvio S, Granlund L, Salminen S, Viitanen M, Ouwehand AC. Probiotics and immunosenescence: cheese as a carrier. FEMS immunology and medical microbiology. Jun 1 2010;59(1):53-59.
281.Iwatsuki K, Akihisa T, Tokuda H, et al. Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation. Journal of natural products. Dec 2003;66(12):1582-1585.
282.Jagger A, Shimojima Y, Goronzy JJ, Weyand CM. Regulatory T cells and the immune aging process: a mini-review. Gerontology. 2014;60(2):130-137.
283.Jain S, Gautam V, Naseem S. Acute-phase proteins: As diagnostic tool. Journal of pharmacy & bioallied sciences. Jan 2011;3(1):118-127.
284.Jensen GS, Patel D, Benson KF. A novel extract from bovine colostrum whey supports innate immune functions. II. Rapid changes in cellular immune function in humans. Preventive medicine. May 2012;54 Suppl:S124-129.
285.Ji LL, Wang Z, Dong F, Zhang WB, Wang ZT. Andrograpanin, a compound isolated from anti-inflammatory traditional Chinese medicine Andrographis paniculata, enhances chemokine SDF-1alpha-induced leukocytes chemotaxis. Journal of cellular biochemistry. Aug 1 2005;95(5):970-978.
286.Jia Q, Cao H, Shen D, Yan L, Chen C, Xing S. Fisetin, via CKIP-1/REGγ, limits oxidized LDL-induced lipid accumulation and senescence in RAW264.7 macrophage-derived foam cells. European journal of pharmacology. Dec 15 2019;865:172748. doi:10.1016/j.ejphar.2019.172748
287.Jiang Y, Tu PF. Analysis of chemical constituents in Cistanche species. Journal of chromatography. A. Mar 13 2009;1216(11):1970-1979.
288.Jin JO, Zhang W, Du JY, Wong KW, Oda T, Yu Q. Fucoidan can function as an adjuvant in vivo to enhance dendritic cell maturation and function and promote antigen-specific T cell immune responses. PloS one. 2014;9(6):e99396.
289.Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. The Cochrane database of systematic reviews. 2012;6:CD007731.
290.Jin ZW, Kumar A, Cleveland RP, Murray DL, Kaufman DB. Inhibition of suppressor cell function by cimetidine in a murine model. Clinical immunology and immunopathology. Mar 1986;38(3):350-356.
291.Jolly CA. Dietary restriction and immune function. The Journal of nutrition. Aug 2004;134(8):1853-1856.
292.Karmazin J. Ambrosia LLC. Young Donor Plasma Transfusion and Age-Related Biomarkers. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Last updated 2016 Oct. 31. https://clinicaltrials.gov/ct2/show/NCT02803554. NLM Identifier: NCT02803554.
293.Karumuthil-Melethil S, Gudi R, Johnson BM, Perez N, Vasu C. Fungal beta-glucan, a Dectin-1 ligand, promotes protection from type 1 diabetes by inducing regulatory innate immune response. Journal of immunology (Baltimore, Md.: 1950). Oct 1 2014;193(7):3308-3321.
294.Katoh J, Tsuchiya K, Osawa H, et al. Cimetidine reduces impairment of cellular immunity after cardiac operations with cardiopulmonary bypass. J Thorac Cardiovasc Surg. Aug 1998;116(2):312-318.
295.Kent KD, Harper WJ, Bomser JA. Effect of whey protein isolate on intracellular glutathione and oxidant-induced cell death in human prostate epithelial cells. Toxicol In Vitro. Feb 2003;17(1):27-33.
296.Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol A Biol Sci Med Sci. Jan 1997;52(1):M1-7.
297.Kikuchi Y, Oomori K, Kizawa I, Kato K. Augmented natural killer activity in ovarian cancer patients treated with cimetidine. European journal of cancer & clinical oncology. Sep 1986;22(9):1037-1043.
298.Kim HY, Kim JH, Yang SB, et al. A polysaccharide extracted from rice bran fermented with Lentinus edodes enhances natural killer cell activity and exhibits anticancer effects. Journal of medicinal food. Mar 2007;10(1):25-31.
299.Kirkland JL and Khosla S. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03675724, AFFIRM-LITE: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults. Last updated 2/24/2020. Accessed 11/4/2020. https://clinicaltrials.gov/ct2/show/NCT03675724
300.Kladar NV, Gavaric NS, Bozin BN. Ganoderma: insights into anticancer effects. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP). Aug 27 2015.
301.Kloek J, Mortaz E, Van Ark I, Bloksma N, Garssen J, Nijkamp FP, Folkerts G. A whey-based glutathione-enhancing diet decreases allergen-induced airway contraction in a guinea-pig model of asthma. The British journal of nutrition. May 2011;105(10):1465-1470.
302.Kokhaei P, Barough MS, Hassan ZM. Cimetidine effects on the immunosuppression induced by burn injury. International immunopharmacology. Sep 2014;22(1):273-276.
303.Komlos L, Notmann J, Arieli J, Hart J, Levinsky H, Halbrecht I, Sendovsky U. IN vitro cell-mediated immune reactions in herpes zoster patients treated with cimetidine. Asian Pac J Allergy Immunol. Jun 1994;12(1):51-58.
304.Koonin, E. V., V. V. Dolja and M. Krupovic. The healthy human virome: from virus-host symbiosis to disease. Curr Opin Virol. 2021;47:86-94.
305.Krissansen GW. Emerging health properties of whey proteins and their clinical implications. Journal of the American College of Nutrition. Dec 2007;26(6):713s-723s.
306.Kroll J. Dehydroepiandrosterone, molecular chaperones and the epigenetics of primate longevity. Rejuvenation Res. Feb 23 2015.
307.Kubota T, Fujiwara H, Ueda Y, et al. Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients. British journal of cancer. Apr 22 2002;86(8):1257-1261.
308.Kyo E, Uda N, Kasuga S, Itakura Y. Immunomodulatory effects of aged garlic extract. The Journal of nutrition. Mar 2001;131(3s):1075s-1079s.
309.Kyo E, Uda N, Ushijima M, Kasuga S, Itakura Y. Prevention of psychological stress-induced immune suppression by aged garlic extract. Phytomedicine: international journal of phytotherapy and phytopharmacology. Nov 1999;6(5):325-330.
310.Kyung J, Kim D, Park D, et al. Synergistic anti-inflammatory effects of Laminaria japonica fucoidan and Cistanche tubulosa extract. Laboratory animal research. Jun 2012;28(2):91-97.
311.LabCorp Laboratory Corporation of America. Test Menu. Natural Killer Cell Surface Antigen (CD3-CD56+ Marker Analysis). https://www.labcorp.com/. Accessed November 8, 2015.
312.Lang PO, Govind S, Aspinall R. Reversing T cell immunosenescence: why, who, and how. Age (Dordrecht, Netherlands). Jun 2013;35(3):609-620.
313.Lange T, Perras B, Fehm HL, Born J. Sleep enhances the human antibody response to hepatitis A vaccination. Psychosomatic medicine. Sep-Oct 2003;65(5):831-835.
314.Le Balc'h, P., K. Pinceaux, C. Pronier, P. Seguin, J. M. Tadié and F. Reizine. Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients. Crit Care 2020;24(1): 530.
315.Lee JH, Lee SH, Choi SH, Asahara T, Kwon SM. The sulfated polysaccharide fucoidan rescues senescence of endothelial colony-forming cells for ischemic repair. Stem cells (Dayton, Ohio). Jun 2015;33(6):1939-1951.
316.Lee LK, Foo KY. Recent advances on the beneficial use and health implications of Pu-Erh tea. Food Research International. 2013;53(2):619-628.
317.Lefevre M, Racedo SM, Ripert G, et al. Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Immunity & ageing: I & A. 2015;12:24.
318.Lefevre M, Redman LM, Heilbronn LK, et al. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis. Mar 2009;203(1):206-213.
319.Lefranc F, Yeaton P, Brotchi J, Kiss R. Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review). International journal of oncology. May 2006;28(5):1021-1030.
320.Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin structure and functions. Advances in experimental medicine and biology. 2008;606:163-194.
321.Li B, Cao F, Zhu Q, Li B, Gan M, Wang D. Perioperative cimetidine administration improves systematic immune response and tumor infiltrating lymphocytes in patients with colorectal cancer. Hepato-gastroenterology. Mar-Apr 2013;60(122):244-247.
322.Li L, Tsao R, Yang R, Liu C, Young JC, Zhu H. Isolation and purification of phenylethanoid glycosides from Cistanche deserticola by high-speed counter-current chromatography. Food chemistry. 2008;108(2):702-710.
323.Li YQ, Wang SF. Anti-hepatitis B activities of ganoderic acid from Ganoderma lucidum. Biotechnology letters. Jun 2006;28(11):837-841.
324.Li Z, Liu J, Zhao Y. Possible mechanism underlying the antiherpetic activity of a proteoglycan isolated from the mycelia of Ganoderma lucidum in vitro. Journal of biochemistry and molecular biology. Jan 31 2005;38(1):34-40.
325.Licastro F, Porcellini E. Persistent infections, immune-senescence and Alzheimer's disease. Oncoscience. 2016;3(5-6):135-142.
326.Lim H, Park H, and Kim HP. 2015. Effects of flavonoids on senescence-associated secretory phenotype formation from bleomycin-induced senescence in BJ fibroblasts. Biochem Pharmacol, 96: 337-48.
327.Liu Q, Zhang C, Sun A, Zheng Y, Wang L, Cao X. Tumor-Educated CD11bhighIalow Regulatory Dendritic Cells Suppress T Cell Response through Arginase I. The Journal of Immunology. May 15, 2009 2009;182(10):6207-6216.
328.Loffredo FS, Steinhauser ML, Jay SM, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. May 09 2013;153(4):828-839.
329.Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. Jun 6 2013;153(6):1194-1217.
330.Ludwig FE, R. Mortality in syngenic rat parabioints of different chronological age. Transactions of the New York Academy of Sciences. 1972;34(7):582–587.
331.Luna-Castro S, Aguilar-Romero F, Samaniego-Barron L, Godinez-Vargas D, de la Garza M. Effect of bovine apo-lactoferrin on the growth and virulence of Actinobacillus pleuropneumoniae. Biometals: an international journal on the role of metal ions in biology, biochemistry, and medicine. Oct 2014;27(5):891-903.
332.Lv S, Wu Y, Zhou J, et al. The study of fingerprint characteristics of Dayi Pu-Erh tea using a fully automatic HS-SPME/GC-MS and combined chemometrics method. PloS one. 2014;9(12):e116428.
333.Ma B, Ren W, Zhou Y, Ma J, Ruan Y, Wen CN. Triterpenoids from the spores of Ganoderma lucidum. North American journal of medical sciences. Nov 2011;3(11):495-498.
334.Maeda H, Ichihashi K, Fujii T, Omura K, Zhu X, Anazawa M, Tazawa K. Oral administration of hydrolyzed rice bran prevents the common cold syndrome in the elderly based on its immunomodulatory action. BioFactors (Oxford, England). 2004;21(1-4):185-187.
335.Maharaj D, Inventor; Advanced Neuroregenerative Therapies, Llc, assignee. Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for therapeutic use. 2014.
336.Maijo M, Clements SJ, Ivory K, Nicoletti C, Carding SR. Nutrition, diet and immunosenescence. Mechanisms of ageing and development. Mar-Apr 2014;136-137:116-128.
337.Maranduba CM, De Castro SB, de Souza GT, et al. Intestinal microbiota as modulators of the immune system and neuroimmune system: impact on the host health and homeostasis. J Immunol Res. 2015;2015:931574.
338.MayoClinic. Mayo Medical Laboratories. Cytomegalovirus (CMV) Antibodies, IgM and IgG, Serum. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/62067. Accessed November 8, 2015a.
339.MayoClinic. Mayo Medical Laboratories. Immunoglobulins (IgG, IgA, and IgM), Serum. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/8156. Accessed November 9, 2015b.
340.Maywald M, Rink L. Zinc homeostasis and immunosenescence. J Trace Elem Med Biol. Jan 2015;29:24-30.
341.McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine. Mar 9 2012;30(12):2060-2067.
342.McGregor BA, Antoni MH, Boyers A, Alferi SM, Blomberg BB, Carver CS. Cognitive-behavioral stress management increases benefit finding and immune function among women with early-stage breast cancer. Journal of psychosomatic research. Jan 2004;56(1):1-8.
343.McLaughlin B, O'Malley K, Cotter TG. Age-related differences in granulocyte chemotaxis and degranulation. Clinical science (London, England: 1979). Jan 1986;70(1):59-62.
344.Mekker A, Tchang VS, Haeberli L, Oxenius A, Trkola A, Karrer U. Immune senescence: relative contributions of age and cytomegalovirus infection. PLoS pathogens. 2012;8(8):e1002850.
345.Mena MP, Sacanella E, Vazquez-Agell M, et al. Inhibition of circulating immune cell activation: a molecular antiinflammatory effect of the Mediterranean diet. The American journal of clinical nutrition. Jan 2009;89(1):248-256.
346.Mendelsohn AR, Larrick JW. Overcoming the aging systemic milieu to restore neural stem cell function. Rejuvenation Res. Dec 2011;14(6):681-684.
347.Messaoudi I, Warner J, Fischer M, et al. Delay of T cell senescence by caloric restriction in aged long-lived nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America. Dec 19 2006;103(51):19448-19453.
348.Meydani SN, Barnett JB, Dallal GE, Fine BC, Jacques PF, Leka LS, Hamer DH. Serum zinc and pneumonia in nursing home elderly. The American journal of clinical nutrition. Oct 2007;86(4):1167-1173.
349.Meyer TE, Kovacs SJ, Ehsani AA, Klein S, Holloszy JO, Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol. Jan 17 2006;47(2):398-402.
350.Michan S. Calorie restriction and NAD(+)/sirtuin counteract the hallmarks of aging. Front Biosci (Landmark Ed). 2014;19:1300-1319.
351.Micke P, Beeh KM, Schlaak JF, Buhl R. Oral supplementation with whey proteins increases plasma glutathione levels of HIV-infected patients. European journal of clinical investigation. Feb 2001;31(2):171-178.
352.Millea PJ. N-acetylcysteine: multiple clinical applications. American family physician. Aug 1 2009;80(3):265-269.
353.Miller A, Harel D, Laor A, Lahat N. Cimetidine as an immunomodulator in the treatment of herpes zoster. J Neuroimmunol. Mar 1989;22(1):69-76.
354.Mitchell WA, Lang PO, Aspinall R. Tracing thymic output in older individuals. Clinical and experimental immunology. Sep 2010;161(3):497-503.
355.Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. The Journal of clinical investigation. Oct 2014;124(10):4212-4218.
356.Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. The Journal of clinical investigation. Mar 2013;123(3):958-965.
357.Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
358.Morey JN, Boggero IA, Scott AB, Segerstrom SC. Current Directions in Stress and Human Immune Function. Current opinion in psychology. Oct 1 2015;5:13-17.
359.Moss, P. 'From immunosenescence to immune modulation': a re-appraisal of the role of cytomegalovirus as major regulator of human immune function. Med Microbiol Immunol.2019;208(3-4):271-280.
360.Moss, P. "The ancient and the new": is there an interaction between cytomegalovirus and SARS-CoV-2 infection? Immun Ageing. 2020;17:14.
361.Muller L, Fulop T, Pawelec G. Immunosenescence in vertebrates and invertebrates. Immunity & ageing: I & A. 2013;10(1):12.
362.Nagler A, Rozenbaum H, Enat R, Tatarsky I, Katz R, Pollack S. Immune basis for cimetidine-induced pancytopenia. Am J Gastroenterol. Apr 1987;82(4):359-361.
363.Nair PK, Rodriguez S, Ramachandran R, et al. Immune stimulating properties of a novel polysaccharide from the medicinal plant Tinospora cordifolia. International immunopharmacology. Dec 15 2004;4(13):1645-1659.
364.Naylor K, Li G, Vallejo AN, et al. The influence of age on T cell generation and TCR diversity. J Immunol. Jun 1 2005;174(11):7446-7452.
365.Negishi H, Mori M, Mori H, Yamori Y. Supplementation of elderly Japanese men and women with fucoidan from seaweed increases immune responses to seasonal influenza vaccination. The Journal of nutrition. Nov 2013;143(11):1794-1798.
366.NIH. National Heart, Lung, and Blood Institute. Types of Blood Tests. White Blood Cells. http://www.nhlbi.nih.gov/health/health-topics/topics/bdt/types. Last updated 1/6/2012. Accessed November 8, 2015.
367.NIH. NIH. US National Library of Medicine. Medline Plus: Drug Info: Cimetidine. Available at https://medlineplus.gov/druginfo/meds/a682256.html. Last updated 09/01/2010. Accessed 10/07/2016. 2010.
368.Nikolich-Zugich, J., F. Goodrum, K. Knox and M. J. Smithey. Known unknowns: how might the persistent herpesvirome shape immunity and aging? Curr Opin Immunol. 2017;48:23-30.
369.Nikolich-Žugich, J., L. Čicin-Šain, D. Collins-McMillen, S. Jackson, A. Oxenius, J. Sinclair, C. Snyder, M. Wills and N. Lemmermann. Advances in cytomegalovirus (CMV) biology and its relationship to health, diseases, and aging. Geroscience 2020;42(2):495-504.
370.Nikolich-Zugich J, Messaoudi I. Mice and flies and monkeys too: caloric restriction rejuvenates the aging immune system of non-human primates. Experimental gerontology. Nov 2005;40(11):884-893.
371.Ning Y, Xu D, Zhang X, et al. beta-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses. International journal of cancer. Journal international du cancer. Jun 1 2016;138(11):2713-2723.
372.Nishiguchi S, Tamori A, Shiomi S, et al. Cimetidine reduces impairment of cellular immunity after transcatheter arterial embolization in patients with hepatocellular carcinoma. Hepato-gastroenterology. Mar-Apr 2003;50(50):460-462.
373.Niu X, Yang Y, Wang J. Synergistic and additive effects of cimetidine and levamisole on cellular immune responses to hepatitis B virus DNA vaccine in mice. Scandinavian journal of immunology. Feb 2013;77(2):84-91.
374.Noberini R, Koolpe M, Lamberto I, et al. Inhibition of Eph receptor-ephrin ligand interation by tea polyphenols. Pharm Res. 2012:66:363-373.
375.Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? Trends in microbiology. Dec 2004;12(12):562-568.
376.O'Sullivan M, McLean-Tooke A, Loh RK. Antinuclear antibody test. Australian family physician. Oct 2013;42(10):718-721.
377.Oh B, Kim JS, Kweon M, Kim BS, Huh IS. Six-week Diet Correction for Body Weight Reduction and Its Subsequent Changes of Gut Microbiota: A Case Report. Clin Nutr Res. Apr 2016;5(2):137-140.
378.Oldways. What is the Mediterranean Diet? https://oldwayspt.org/traditional-diets/mediterranean-diet/what-mediterranean-diet. Accessed 8/16/2016.
379.Oliviero F, Spinella P, Fiocco U, Ramonda R, Sfriso P, Punzi L. How the Mediterranean diet and some of its components modulate inflammatory pathways in arthritis. Swiss medical weekly. 2015;145:w14190.
380.Palmer DB. The effect of age on thymic function. Frontiers in immunology. 2013;4:316.
381.Pandey VK, Amin PJ, Shankar BS. G1-4A, a polysaccharide from Tinospora cordifolia induces peroxynitrite dependent killer dendritic cell (KDC) activity against tumor cells. International immunopharmacology. Dec 2014;23(2):480-488.
382.Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent. Ecancermedicalscience. 2014;8:485.
383.Parkin J, Cohen B. An overview of the immune system. Lancet. Jun 2 2001;357(9270):1777-1789.
384.Peng C, Chan H, Li Y, et al. Black tea theaflavins extend the lifespan of fruit flies. Exp Ger. 2009;44:773-783.
385.Pera A, Campos C, Lopez N, Hassouneh F, Alonso C, Tarazona R, Solana R. Immunosenescence: Implications for response to infection and vaccination in older people. Maturitas. Sep 2015;82(1):50-55.
386.Percival SS. Aged Garlic Extract Modifies Human Immunity. The Journal of nutrition. Feb 2016;146(2):433s-436s.
387.Perez-Martinez A, Valentin J, Fernandez L, et al. Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma in vitro and in vivo. Cytotherapy. May 2015;17(5):601-612.
388.Perrott KM, Wiley CD, Desprez P-Y, and Campisi J. 2017. Apigenin suppresses the senescence-associated secretory phenotype and paracrine effects on breast cancer cells. Geroscience, 39: 161-73.
389.Pishel I, Shytikov D, Orlova T, Peregudov A, Artyuhov I, Butenko G. Accelerated aging versus rejuvenation of the immune system in heterochronic parabiosis. Rejuvenation Res. Apr 2012;15(2):239-248.
390.Pohanka M, Pejchal J, Snopkova S, Havlickova K, Karasova JZ, Bostik P, Pikula J. Ascorbic acid: an old player with a broad impact on body physiology including oxidative stress suppression and immunomodulation: a review. Mini reviews in medicinal chemistry. Jan 2012;12(1):35-43.
391.Polak L. The transfer of tolerance to DNCB-contact sensitivity in guinea pigs by parabiosis. J Immunol. Mar 1975;114(3):988-991.
392.Prall SP, Muehlenbein MP. Dehydroepiandrosterone and multiple measures of functional immunity in young adults. American journal of human biology: the official journal of the Human Biology Council. Nov-Dec 2015;27(6):877-880.
393.Prasad AS, Beck FW, Bao B, Fitzgerald JT, Snell DC, Steinberg JD, Cardozo LJ. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. The American journal of clinical nutrition. Mar 2007;85(3):837-844.
394.Prather AA, Janicki-Deverts D, Hall MH, Cohen S. Behaviorally Assessed Sleep and Susceptibility to the Common Cold. Sleep. 2015;38(9):1353-1359.
395.Pregliasco F, Anselmi G, Fonte L, Giussani F, Schieppati S, Soletti L. A new chance of preventing winter diseases by the administration of synbiotic formulations. Journal of clinical gastroenterology. Sep 2008;42 Suppl 3 Pt 2:S224-233.
396.Purev U, Chung MJ, Oh DH. Individual differences on immunostimulatory activity of raw and black garlic extract in human primary immune cells. Immunopharmacology and immunotoxicology. Aug 2012;34(4):651-660.
397.Purwanto B, Prasetyo DH. Effect of oral N-acetylcysteine treatment on immune system in continuous ambulatory peritoneal dialysis patients. Acta medica Indonesiana. Apr 2012;44(2):140-144.
398.Quest. Quest Diagnostics. Test Center. C3 and C4 Complement. http://www.questdiagnostics.com/testcenter/BUOrderInfo.action?tc=65201A &labCode=QER. Accessed November 8, 2015.
399.Ravussin E, Redman LM, Rochon J, et al. A 2-Year Randomized Controlled Trial of Human Caloric Restriction: Feasibility and Effects on Predictors of Health Span and Longevity. J Gerontol A Biol Sci Med Sci. Sep 2015;70(9):1097-1104.
400.Ray B, Hutterer C, Bandyopadhyay SS, et al. Chemically engineered sulfated glucans from rice bran exert strong antiviral activity at the stage of viral entry. Journal of natural products. Dec 27 2013;76(12):2180-2188.
401.Rebo J, Mehdipour M, Gathwala R, Causey K, Liu Y, Conboy MJ, Conboy IM. A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood. Nature communications. Nov 22 2016;7:13363.
402.Rege N, Bapat RD, Koti R, Desai NK, Dahanukar S. Immunotherapy with Tinospora cordifolia: a new lead in the management of obstructive jaundice. Indian journal of gastroenterology: official journal of the Indian Society of Gastroenterology. Jan 1993;12(1):5-8.
403.Rezzani R, Nardo L, Favero G, Peroni M, Rodella LF. Thymus and aging: morphological, radiological, and functional overview. Age (Dordrecht, Netherlands). Feb 2014;36(1):313-351.
404.Ried K. Garlic Lowers Blood Pressure in Hypertensive Individuals, Regulates Serum Cholesterol, and Stimulates Immunity: An Updated Meta-analysis and Review. The Journal of nutrition. Feb 2016;146(2):389s-396s.
405.Rizza W, Veronese N, Fontana L. What are the roles of calorie restriction and diet quality in promoting healthy longevity? Ageing Res Rev. Jan 2014;13:38-45.
406.Rothan, C., A. Yero, T. Shi, O. Farnos, C. Chartrand-Lefebvre, M. El-Far, C. T. Costiniuk, C. Tsoukas, C. Tremblay, M. Durand and M. A. Jenabian. ART-treated HIV-infected adults with coronary artery disease are characterized by a distinctive regulatory T-cell signature. AIDS. 2021 Feb 3. [Online ahead of print].
407.Rusu D, Drouin R, Pouliot Y, Gauthier S, Poubelle PE. A bovine whey protein extract can enhance innate immunity by priming normal human blood neutrophils. The Journal of nutrition. Feb 2009;139(2):386-393.
408.Salehi B, Venditti A, Sharifi-Rad M, Kręgiel D, Sharifi-Rad J, Durazzo A, Lucarini M, Santini A, Souto EB, Novellino E, Antolak H, Azzini E, Setzer WN, and Martins N. 2019. The Therapeutic Potential of Apigenin. Int J Mol Sci, 20: 1305.
409.Sang Y, Zhang F, Wang H, Yao J, Chen R, Zhou Z, Yang K, Xie Y, Wan T, and Ding H. 2017. Apigenin exhibits protective effects in a mouse model of d-galactose-induced aging via activating the Nrf2 pathway. Food Funct, 8: 2331-40.
410.Sannegowda KM, Venkatesha SH, Moudgil KD. Tinospora cordifolia inhibits autoimmune arthritis by regulating key immune mediators of inflammation and bone damage. International journal of immunopathology and pharmacology. Dec 2015;28(4):521-531.
411.Santus P, Corsico A, Solidoro P, Braido F, Di Marco F, Scichilone N. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine. COPD. Dec 2014;11(6):705-717.
412.Schiaffino S, Pereira MG, Ciciliot S, Rovere-Querini P. Regulatory T cells and skeletal muscle regeneration. The FEBS journal. Aug 1 2016.
413.Schmitt V, Rink L, Uciechowski P. The Th17/Treg balance is disturbed during aging. Experimental gerontology. Dec 2013;48(12):1379-1386.
414.Schröder AK, Rink L. Neutrophil immunity of the elderly. Mechanisms of ageing and development. 2003;124(4):419-425.
415.Schwingshackl L, Hoffmann G. Mediterranean dietary pattern, inflammation and endothelial function: a systematic review and meta-analysis of intervention trials. Nutrition, metabolism, and cardiovascular diseases: NMCD. Sep 2014;24(9):929-939.
416.Sehrawat, S., D. Kumar and B. T. Rouse. Herpesviruses: Harmonious Pathogens but Relevant Cofactors in Other Diseases? Front Cell Infect Microbiol 2018;8:177.
417.Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. bioRxiv. 2016-01-01 00:00:00 2016.
418.Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS pathogens. May 2014;10(5):e1004078.
419.Sha S. Stanford University. The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Mild-To-Moderate Alzheimer's Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Last updated 2016 Nov. 29. https://clinicaltrials.gov/ct2/show/NCT02256306. NLM Identifier: NCT02256306.
420.Sharma U, Bala M, Kumar N, Singh B, Munshi RK, Bhalerao S. Immunomodulatory active compounds from Tinospora cordifolia. Journal of ethnopharmacology. Jun 14 2012;141(3):918-926.
421.Sheeja K, Kuttan G. Andrographis paniculata downregulates proinflammatory cytokine production and augments cell mediated immune response in metastatic tumor-bearing mice. Asian Pacific journal of cancer prevention: APJCP. 2010;11(3):723-729.
422.Shrivastava AK, Singh HV, Raizada A, et al. Inflammatory markers in patients with rheumatoid arthritis. Allergologia et immunopathologia. Jan-Feb 2015;43(1):81-87.
423.Simoes CD, Maukonen J, Scott KP, Virtanen KA, Pietilainen KH, Saarela M. Impact of a very low-energy diet on the fecal microbiota of obese individuals. Eur J Nutr. Sep 2014;53(6):1421-1429.
424.Simpson RJ. Aging, persistent viral infections, and immunosenescence: can exercise "make space"? Exercise and sport sciences reviews. Jan 2011;39(1):23-33.
425.Simpson RJ, Cosgrove C, Chee MM, et al. Senescent phenotypes and telomere lengths of peripheral blood T-cells mobilized by acute exercise in humans. Exercise immunology review. 2010;16:40-55.
426.Simpson RJ, Kunz H, Agha N, Graff R. Exercise and the Regulation of Immune Functions. Progress in molecular biology and translational science. 2015;135:355-380.
427.Singh S, Singh AK, Garg G, Rizvi SI. Fisetin as a caloric restriction mimetic protects rat brain against aging induced oxidative stress, apoptosis and neurodegeneration. Life Sci. Jan 15 2018;193:171-179. doi:10.1016/j.lfs.2017.11.004
428.Siqueiros-Cendon T, Arevalo-Gallegos S, Iglesias-Figueroa BF, Garcia-Montoya IA, Salazar-Martinez J, Rascon-Cruz Q. Immunomodulatory effects of lactoferrin. Acta pharmacologica Sinica. 2014;35(5):557-566.
429.Söderberg-Nauclér, C. Does reactivation of cytomegalovirus contribute to severe COVID-19 disease? Immun Ageing. 2021;18(1):12.
430.Sorice A, Guerriero E, Capone F, Colonna G, Castello G, Costantini S. Ascorbic acid: its role in immune system and chronic inflammation diseases. Mini reviews in medicinal chemistry. May 2014;14(5):444-452.
431.Soto-Gamez A, Demaria, M. Therapeutic interventions for aging: the case of cellular senescence. Drug Disc Today. 2017;22(5):786-795.
432.Spiegel K, Sheridan JF, Van Cauter E. Effect of sleep deprivation on response to immunization. JAMA. Sep 25 2002;288(12):1471-1472.
433.Spielmann G, McFarlin BK, O'Connor DP, Smith PJ, Pircher H, Simpson RJ. Aerobic fitness is associated with lower proportions of senescent blood T-cells in man. Brain Behav Immun. Nov 2011;25(8):1521-1529.
434.Stein PK, Soare A, Meyer TE, Cangemi R, Holloszy JO, Fontana L. Caloric restriction may reverse age-related autonomic decline in humans. Aging Cell. Aug 2012;11(4):644-650.
435.Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. Diabet Med. Sep 2015;32(9):1149-1155.
436.Storey M, Jordan S. An overview of the immune system. Nursing standard (Royal College of Nursing (Great Britain): 1987). Dec 17-2009 Jan 6 2008;23(15-17):47-56; quiz 58, 60.
437.Straub RH, Konecna L, Hrach S, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. The Journal of clinical endocrinology and metabolism. Jun 1998;83(6):2012-2017.
438.Takemoto M, Takemoto H. Synthesis of Theaflavins and Their Functions. Molecules (Basel, Switzerland). Apr 16 2018;23(4).
439.Tayama E, Hayashida N, Fukunaga S, Tayama K, Takaseya T, Hiratsuka R, Aoyagi S. High-dose cimetidine reduces proinflammatory reaction after cardiac surgery with cardiopulmonary bypass. The Annals of thoracic surgery. Dec 2001;72(6):1945-1949.
440.Lu, J., Ho, C., Ghai, G., Chen, K., Differential effects of theaflavin monogallates on cell growth, apoptosis, and Cox-2 gene expression in cancerous versus normal cells. Cancer Res. 2000;60:6465–6471.
441.Cameron AR, Anton S, Melville L et al. Black tea polyphenols mimic insulin/insulin-like growth factor-1 signalling to the longevity factor FOXO1a. Aging Cell 2008;7(1):69-77
442.Dhahbi JM, Mote PL, Fahy GM and Spindler SR. Identification of potential caloric restriction mimetics by microarray profiling. Physiol Genomics. 2005;23(3):343-350
443.Onken B and Driscoll M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS ONE. 2010;5(1):e8758
444.Anisimov VN. Metformin for aging and cancer prevention. Aging. 2010;2(11):760-774
445.Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Experimental Gerontology. 2005;40(8-9):685-693
446.Anisimov VN, Piskunova TS, Popovich IG, et al. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY). 2010 Dec;2(12):945-58.
447.Yu Y-B, Dosanjh L, Lao L, Tan M, Shim BS and Luo Y. Cinnamomum cassia Bark in Two Herbal Formulas Increases Life Span in Caenorhabditis elegans via Insulin Signaling and Stress Response Pathways. PLoS ONE. 2010;5(2):e9339
448.Kim YJ, Kim H, No JK, Chung H, Fernandes G. Anti-inflammatory action of dietary fish oil and calorie restriction. Life Sci 2006:78(21):2523-32
449.Sun X, Zemel MB. Leucine modulation of mitochondrial mass and oxygen consumption in skeletal muscle cells and adipocytes. Nutr Metab (Lond). 2009; 6: 26.
D'Antona G, Ragni M, Cardile A, et al. Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice. Cell Metab. 2010 Oct 6; 12(4): 362-72.




(1)O. Vardeny, M. Madjid, S.D. Solomon, Applying the  Lessons  of Influenza to COVID-19  During a Time  of Uncertainty, Circulation 141  (21) (2020) 1667–1669, https://doi.org/10.1161/CIRCULATIONAHA.120.046837.
(2) L. Setti, M. Kirienko, S.C. Dalto, M. Bonacina, E. Bombardieri,  FDG-PET/CT findings highly suspicious for COVID-19  in an Italian case  series of asymptomatic patients, Eur  J Nucl  Med  Mol Imaging (2020), https://doi.org/10.1007/s00259-
020-04819-6.
(3)J.M.  Sanders, M.L. Monogue, T.Z. Jodlowski, J.B.  Cutrell, Pharmacologic Treatments for  Coronavirus  Disease 2019 (COVID-19): A Review, JAMA (2020), https://doi.org/10.1001/jama.2020.6019.
(4)P. Lapolla, A. Mingoli, R. Lee,  Deaths from  COVID-19  in healthcare workers in Italy—What can  we  learn? Infect Control Hosp  Epidemiol (2020) 1–2,  https:// doi.org/10.1017/ice.2020.241.
[5]  J. Corburn, D. Vlahov, B. Mberu, L. Riley,  W.T.  Caiaffa, S.F. Rashid, A. Ko,
(5)S. Patel, S. Jukur, E. Martínez-Herrera, S. Jayasinghe, S. Agarwal, B. Nguendo- Yongsi,  J. Weru, S. Ouma, K. Edmundo, T. Oni,  H. Ayad,  Slum  Health, Arresting COVID-19  and  Improving Well-Being in Urban Informal Settlements, J Urban Health 97  (2020) 348–357, https://doi.org/10.1007/s11524-020-00438-6.
[6]  R.J.  Pereira, G.N.L.D.  Nascimento, L.H.A. Grata˜o, R.S. Pimenta, The  risk  of
(6)COVID-19  transmission in favelas and  slums in Brazil, Public Health 183  (2020)
42–43, https://doi.org/10.1016/j.puhe.2020.04.042.
(7)M.M.  Cowan, Plant Products as Antimicrobial Agents, Clin  Microbiol Rev  12  (4) (1999) 564–582, https://doi.org/10.1128/CMR.12.4.564.
(8)F. Bakkali, S. Averbeck, D. Averbeck, M. Idaomar, Biological effects of essential oils–a review, Food  Chem Toxicol 46  (2)  (2008) 446–475, https://doi.org/10.1016/j.fct.2007.09.106.
(9) A. Saklani, S.K. Kutty, Plant-derived compounds in clinical trials, Drug  Discov Today 13  (3-4) (2008) 161–171, https://doi.org/10.1016/j.drudis.2007.10.010.
(10) H. Maruta, H. He, PAK1-blockers: Potential Therapeutics  against COVID-19,  Med Drug  Discov  (2020), https://doi.org/10.1016/j.medidd.2020.100039.
(11) J. Serkedjieva, N. Manolova, V. Bankova, Anti-influenza virus effect of some propolis constituents and  their analogues (esters of substituted cinnamic acids), J Nat  Prod 55  (3)  (1992) 294–302, https://doi.org/10.1021/np50081a003.
(12)J. Calixto, Efficacy, safety, quality control, marketing and  regulatory guidelines for  herbal medicines (phytotherapeutic agents), Braz  J Med  Biol Res 33  (2) (2000) 179–189, https://doi.org/10.1590/S0100-879X2000000200004.
(13) J.B. Calixto, Twenty-five years of research on medicinal plants in Latin  America: a personal view, J Ethnopharmacol 100  (1-2) (2005) 131–134, https://doi.org/
10.1016/j.jep.2005.06.004.
(14)  M.F.  Uddin M, T.A. Rizvi,  T. Loney, H.A.  Suwaidi, A.H.H.  Al-Marzouqi,  A. K. Eldin, N. Alsabeeha, T.E. Adrian, C. Stefanini, N. Nowotny, A. Alsheikh-Ali, A. C. Senok, SARS-CoV-2/COVID-19: Viral  Genomics, Epidemiology, Vaccines, and Therapeutic Interventions, Viruses 12  (2020) 526, https://doi.org/10.3390/ v12050526.
(15)S. Vardhan, S.K. Sahoo, Searching inhibitors for  three important proteins of COVID-19  through molecular docking studies, arXiv  (2020), 2004.08095.
(16)Y. Wan,  J. Shang, R. Graham, R.S. Baric,  F. Li, Receptor Recognition by the  Novel Coronavirus from  Wuhan: an Analysis Based  on Decade-Long Structural Studies of SARS Coronavirus, J Virol  94  (7)  (2020) e00127–20, https://doi.org/10.1128/ JVI.00127-20.
(17)M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Kruger, T. Herrler, S. Erichsen, T. S. Schiergens, G. Herrler, N.H.  Wu,  A. Nitsche, M.A. Muller, C. Drosten, S. Pohlmann, SARS-CoV-2  Cell Entry Depends on  ACE2 and  TMPRSS2  and  Is Blocked by a Clinically Proven Protease Inhibitor, Cell  181  (2)  (2020) 271–280, https://doi.org/10.1016/j.cell.2020.02.052, e8.
(18)J.W.  Xu, K. Ikeda, A. Kobayakawa, T. Ikami, Y. Kayano, T. Mitani, Y. Yamori, Downregulation of Rac1  activation by caffeic acid  in aortic smooth muscle cells, Life Sci 76  (24) (2005) 2861–2872, https://doi.org/10.1016/j.lfs.2004.11.015.
(19)[19]  Y. Ding,  L. He,  Q. Zhang, Z. Huang, X. Che,  J. Hou,  H. Wang, H. Shen, L. Qiu, Z. Li, J. Geng,  J. Cai,  H. Han, X. Li, W. Kang,  D. Weng, P. Liang,  S. Jiang, Organ distribution of          severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV)  in SARS patients: implications for  pathogenesis and  virus transmission pathways, J Pathol 203  (2)     (2004) 622–630, https://doi.org/10.1002/path.1560.
(20)J. Stebbing, A. Phelan, I. Griffin, C. Tucker, O. Oechsle, D. Smith, P. Richardson, COVID-19:  combining antiviral and  anti-inflammatory treatments, Lancet Infect Dis 20  (4)  (2020) 400–402, https://doi.org/10.1016/S1473-3099(20)30132-8.
(21)C. Qin,  L. Zhou, Z. Hu,  S. Zhang, S. Yang,  Y. Tao,  C. Xie, K. Ma,  K. Shang, W. Wang, D.S. Tian, Dysregulation of immune response in patients with COVID-19  in Wuhan, China, Clin  Infect Dis 71  (15) (2020) 762–768, https://doi.org/ 10.1093/cid/ciaa248.
(22)J.I.  Hori, D.S. Zamboni, D.B. Carrao, G.H. Goldman, A.A. Berretta, The Inhibition of Inflammasome by  Brazilian Propolis (EPP-AF),  Evid  Based  Complement Alternat Med  2013 (2013) 418508, https://doi.org/10.1155/2013/418508.
(23)A.R. Pineros, M.H.F.  de  Lima,  T. Rodrigues, A.F. Gembre, T.B. Bertolini, M. D. Fonseca, A.A. Berretta, L.N.Z. Ramalho, F.Q.  Cunha, J.I.  Hori, V.L.D. Bonato, Green propolis increases myeloid suppressor cells  and  CD4(+)Foxp3(+) cells  and reduces Th2  inflammation in the  lungs after allergen exposure, J Ethnopharmacol 252  (2020) 112496, https://doi.org/10.1016/j.jep.2019.112496.
(24)J.L.  Machado, A.K. Assuncao, M.C. da  Silva,  A.S. Dos Reis,  G.C. Costa, S. Arruda Dde,  B.A. Rocha, M.M.  Vaz,  A.M. Paes, R.N.  Guerra, A.A. Berretta, F.R. do Nascimento, Brazilian green propolis: anti-inflammatory property by  an immunomodulatory activity, Evid  Based  Complement Alternat Med  2012 (2012) 157652, https://doi.org/10.1155/2012/157652.
(25)O. Sekiou, I. Omar, Z. Bouziane, A. Djemel Bouslama, In-silico identification  of potent inhibitors of COVID-19  main protease (Mpro) and  Angiotensin converting enzyme 2 (ACE2)  from  natural products, ChemRxiv (2020), https://doi.org/ 10.26434/chemrxiv.12181404.
(26)H.I.  Güler, G. Tatar, O. Yildiz,  A.O. Belduz, S. Kolayli, Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19  treatment by Molecular Docking Study, ScienceOpen Preprints (2020), https://doi.org/10.14293/S2199-1006.1.SOR-.PP5BWN4.v1.
(27)F. Asgharpour, A.A. Moghadamnia, M. Motallebnejad, H.R.  Nouri, Propolis attenuates lipopolysaccharide-induced inflammatory responses through intracellular ROS and  NO levels along with downregulation of IL-1beta and  IL-6 expressions in murine RAW 264.7 macrophages, J Food  Biochem 43  (8)  (2019), https://doi.org/10.1111/jfbc.12926  e12926.
(28) T. Shimizu, Y. Takeshita, Y. Takamori, H. Kai, R. Sawamura, H. Yoshida, W. Watanabe, A. Tsutsumi, Y.K. Park, K. Yasukawa, K. Matsuno, K. Shiraki, M. Kurokawa, Efficacy of Brazilian Propolis against Herpes Simplex Virus  Type  1 Infection in Mice  and  Their Modes of Antiherpetic Efficacies, Evid  Based Complement Alternat Med  2011 (2011) 976196, https://doi.org/10.1155/2011/976196.
(29)W.J.  Guan, Z.Y. Ni, Y. Hu, W.H. Liang,  C.Q. Ou, J.X. He, L. Liu, H. Shan, C.L. Lei, D.S.C. Hui,  B. Du,  L.J.  Li, G. Zeng,  K.Y. Yuen,  R.C. Chen, C.L. Tang, T. Wang, P. Y. Chen, J. Xiang,  S.Y. Li, J.L. Wang, Z.J. Liang,  Y.X. Peng, L. Wei, Y. Liu, Y.H. Hu, P. Peng, J.M.  Wang, J.Y. Liu, Z. Chen, G. Li, Z.J.  Zheng, S.Q. Qiu,  J. Luo, C.J.  Ye, S.Y. Zhu,  N.S. Zhong, China Medical Treatment Expert Group for,  Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl  J Med  382  (18) (2020) 1708–1720, https://doi.org/10.1056/NEJMoa2002032.
(30)R.A. Stein, COVID-19:  Risk.  groups, mechanistic insights and  challenges, Int  J Clin  Pract (2020), https://doi.org/10.1111/ijcp.13512  e13512.
(31)H.U.  Fuliang, H.R.  Hepburn, H. Xuan,  M. Chen, S. Daya, S.E. Radloff, Effects  of propolis on  blood glucose, blood lipid and  free  radicals in rats  with diabetes mellitus, Pharmacol Res 51  (2)  (2005) 147–152, https://doi.org/10.1016/j. phrs.2004.06.011. 
(32)M. Al-Hariri, T.G. Eldin, B. Abu-Hozaifa, A. Elnour, Glycemic control and  anti- osteopathic effect of propolis in diabetic rats, Diabetes Metab Syndr Obes  2011 (4)  (2011) 377–384, https://doi.org/10.2147/DMSO.S24159.
(33)S. Mishima, C. Yoshida, S. Akino, T. Sakamoto, Antihypertensive effects of Brazilian propolis: identification of caffeoylquinic acids as constituents involved in the  hypotension in spontaneously hypertensive rats, Biol Pharm Bull  28  (10) (2005) 1909–1914, https://doi.org/10.1248/bpb.28.1909.
(34)H. Maruyama, Y. Sumitou, T. Sakamoto, Y. Araki, H. Hara, Antihypertensive effects of flavonoids isolated from  brazilian green propolis in spontaneously hypertensive rats, Biol Pharm Bull  32  (7)  (2009) 1244–1250, https://doi.org/10.1248/bpb.32.1244.
(35)S. Chopra, K.K. Pillai, S.Z. Husain, D.K. Giri,  Propolis protects against doxorubicin-induced myocardiopathy in rats, Exp Mol  Pathol 62  (3)  (1995) 190–198, https://doi.org/10.1006/exmp.1995.1021.
(36)Y. Fang, H. Sang,  N. Yuan,  H. Sun,  S. Yao,  J. Wang, S. Qin,  Ethanolic extract of propolis inhibits atherosclerosis in ApoE-knockout mice, Lipids  Health Dis 12 (2013) 123, https://doi.org/10.1186/1476-511X-12-123.
(37)R.D. Ansorge, S. Lendeckel, Propolis and  some  of its  constituents down-regulate DNA synthesis and  inflammatory cytokine production but  induce TGF-beta1 production of human immune cells,  Z Naturforsch C J Biosci  58  (7)  (2003), https://doi.org/10.1515/znc-2003-7-823.
(38)G.C.-F. Chan, K.-W. Cheung, D.M.-Y. Sze, The Immunomodulatory and  Anticancer Properties of Propolis, Clin Rev Allerg  Immu 44 (3)  (2013) 262–273, https://doi. org/10.1007/s12016-012-8322-2.
(39)M.F.  Balandrin, J.A.  Klocke, E.S. Wurtele, W.H.  Bollinger, Natural plant chemicals: sources of industrial and  medicinal materials, Science 228  (4704) (1985) 1154–1160, https://doi.org/10.1126/science.3890182.
(40)J.H.  Langenheim, Higher plant terpenoids: A phytocentric overview of their ecological roles, J Chem Ecol  20  (6)  (1994) 1223–1280, https://doi.org/10.1007/BF02059809.
(41)A.-X. Cheng, Y.-G. Lou, Y.-B. Mao, S. Lu, L.-J. Wang, X.-Y. Chen, Plant Terpenoids: Biosynthesis and  Ecological Functions, J Integr Plant Biol 49 (2) (2007) 179–186, https://doi.org/10.1111/j.1744-7909.2007.00395.x.
(42)V.C. Toreti, H.H.  Sato, G.M. Pastore, Y.K. Park, Recent progress of propolis for its biological and  chemical compositions and  its  botanical origin, Evid  Based Complement Alternat Med  2013 (2013) 697390, https://doi.org/10.1155/2013/697390.
(43)J.S.  Mani, J.B.  Johnson, J.C.  Steel, D.A. Broszczak, P.M.  Neilsen, K.B. Walsh, M. Naiker, Natural product-derived phytochemicals as potential agents against coronaviruses: A review, Virus  Res 284  (2020) 197989, https://doi.org/10.1016/ j.virusres.2020.197989.
(44)M. Simone-Finstrom, M. Spivak, Propolis and  bee  health: the  natural history and significance of resin use  by  honey bees, Apidologie 41  (3)  (2010) 295–311, https://doi.org/10.1051/apido/2010016.
(45)J.D.  Evans, M. Spivak, Socialized medicine: individual and  communal disease barriers in honey bees, J Invertebr Pathol 103  (Suppl 1) (2010) S62–S72, https:// doi.org/10.1016/j.jip.2009.06.019.
(46)D. Nicodemo, E.B. Malheiros, D. De Jong, R.H.N.  Couto, Increased brood viability and  longer lifespan of honeybees selected for propolis production, Apidologie 45 (2)  (2014) 269–275, https://doi.org/10.1007/s13592-013-0249-y.
(47)A.P.  Turcatto, A.P.  Lourenço, D. De Jong, Propolis consumption ramps up  the immune response in honey bees  infected with bacteria, Apidologie 49  (3)  (2018) 287–296, https://doi.org/10.1007/s13592-017-0553-z.
(48)V. Bankova, Recent trends and  important developments in propolis research, Evid Based  Complement Alternat Med  2 (1)  (2005) 29–32, https://doi.org/10.1093/ ecam/neh059.
(49)M. Miguel, S. Nunes, S.A. Dandlen, A.M. Cavaco, M.D. Antunes, Phenols, flavonoids and  antioxidant activity of aqueous and  methanolic extracts of propolis (Apis mellifera  L.) from  Algarve, South Portugal, Food  Sci Technol 34 (1) (2014), https://doi.org/10.1590/S0101-20612014000100002.
(50)A.A. Berretta, C. Arruda, F. Miguel, N. Baptista, A. Nascimento, F. Marquele- Oliveira, J. Hori, H. Barud, B. Damaso, C. Ramos, R. Ferreira, J. Bastos, Functional Properties of Brazilian Propolis: From Chemical Composition Until  the Market, in: V. Waisundara (Ed.), Superfood and  Functional Food  - An Overview of Their Processing and  Utilization, Intech Open, London, 2017, pp.  55–98, https:// doi.org/10.5772/65932.
(51)M.A.D. Silveira, F. Teles,  A.A. Berretta, T.R. Sanches, C.E. Rodrigues, A.C. Seguro, L. Andrade, Effects  of Brazilian green propolis on  proteinuria and  renal function in patients with chronic kidney disease: a randomized, double-blind, placebo- controlled trial, BMC Nephrol 20  (1)  (2019) 140, https://doi.org/10.1186/ s12882-019-1337-7.
(52)V. Zaccaria, E.U. Garzarella, C. Di Giovanni, F. Galeotti, L. Gisone, D. Campoccia, N. Volpi,  C.R. Arciola, M. Daglia, Multi Dynamic Extraction: An Innovative Method to  Obtain a Standardized Chemically and  Biologically Reproducible Polyphenol Extract from  Poplar-Type Propolis to  Be Used  for  Its Anti-Infective Properties, Materials 12  (22) (2019) 3746, https://doi.org/10.3390/ ma12223746.
(53)D.A.C. Cusinato, E.Z. Martinez, M.T.C.  Cintra, G.C.O.  Filgueira, A.A. Berretta,  V.L. Lanchote, E.B. Coelho, Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF(R)) using an  in vivo  cocktail approach, J Ethnopharmacol 245  (2019) 112174, https://doi.org/10.1016/j. jep.2019.112174.
(54)A.A. Berretta, A.P.  Nascimento, P.C. Bueno, M.M.  Vaz,  J.M.  Marchetti, Propolis standardized extract (EPP-AF(R)), an  innovative chemically and  biologically reproducible pharmaceutical compound for  treating wounds, Int  J Biol Sci 8 (4) (2012) 512–521, https://doi.org/10.7150/ijbs.3641.
(55)A. Ramos, J. Miranda, Propolis: a review of its  anti-inflammatory and  healing actions, J Venom Anim  Toxins Trop  Dis 13  (4)  (2007) 697–710, https://doi.org/10.1590/S1678-91992007000400002.
(56)O. Barth, A. Freitas, A. Matsuda, L. Almeida-Muradian, Botanical origin and Artepillin-C content of Brazilian propolis samples, Grana 52 (2)  (2013) 129–135, https://doi.org/10.1080/00173134.2012.747561.
(57)V. Pedrazzi, M.F.  Leite,  R.C. Tavares, S. Sato, G.C. do  Nascimento, J.P.M. Issa, Herbal mouthwash containing extracts of Baccharis dracunculifolia as agent for the  control of biofilm: clinical evaluation in humans, ScientificWorldJournal 2015 (2015), https://doi.org/10.1155/2015/712683,  712683-712683.
(58)Y.K. Park, I. Fukuda, H. Ashida, S. Nishiumi, K.-i. Yoshida, A. Daugsch, H.H. Sato, G.M. Pastore, Suppressive Effects  of Ethanolic Extracts from  Propolis and  Its Main Botanical Origin on  Dioxin Toxicity, J Agr Food  Chem 53  (26) (2005)10306–10309, https://doi.org/10.1021/jf058111a.
(59)A.A. da  Silva  Filho, J.P.  de Sousa, S. Soares, N.A. Furtado, M.L. Andrade e Silva, W.R. Cunha, L.E. Grego´rio, N.P.  Nanayakkara, J.K. Bastos, Antimicrobial activity of the  extract and  isolated compounds from  Baccharis  dracunculifolia D. C. (Asteraceae), Z Naturforsch C J Biosci  63  (1–2) (2008) 40–46, https://doi.org/10.1515/znc-2008-1-208.
(60)M.C. Búfalo, A.S. Figueiredo, J.P.  de  Sousa, J.M.  Candeias, J.K.  Bastos, J.M. Sforcin, Anti-poliovirus activity of Baccharis dracunculifolia and  propolis by cell  viability determination and  real-time PCR, J Appl  Microbiol 107  (5)  (2009) 1669–1680, https://doi.org/10.1111/j.1365-2672.2009.04354.x.
(61)S. Castaldo, F. Capasso, Propolis, an  old  remedy used in modern medicine, Fitoterapia 73  (Suppl 1) (2002) S1–S6,  https://doi.org/10.1016/s0367-326x(02)00185-5.
(62)R. Silva-Carvalho, F. Baltazar, C. Almeida-Aguiar, Propolis: A Complex Natural Product with a Plethora of Biological Activities That Can  Be Explored for  Drug Development, Evid  Based  Complement Alternat Med  2015 (2015) 206439, https://doi.org/10.1155/2015/206439.
(63)A.K. Kuropatnicki, E. Szliszka, W. Krol, Historical Aspects of Propolis Research in Modern Times, Evid  Based  Complement Alternat Med  2013 (2013) 964149, https://doi.org/10.1155/2013/964149.
(64)S. Sun,  J. He,  M. Liu, G. Yin, X. Zhang, A Great Concern Regarding the Authenticity Identification and  Quality Control of Chinese Propolis and  Brazilian Green Propolis, J Food  Nutr Res 7 (10) (2019) 725–735, https://doi.org/10.12691/jfnr-7-10-6.
(65)J.L. Sun,  Y.L. Hu,  D.Y. Wang, B.K. Zhang, J.G.  Liu, Immunologic enhancement  of compound Chinese herbal medicinal ingredients and  their efficacy comparison with compound Chinese herbal medicines, Vaccine 24  (13) (2006) 2343–2348, https://doi.org/10.1016/j.vaccine.2005.11.053.
(66)M.H.  Akao  Y, K. Matsumoto, K. Ohguchi, K. Nishizawa, T. Sakamoto, Y. Araki, S. Mishima, Y. Nozawa, Cell growth inhibitory effect of cinnamic acid  derivatives from  propolis on  human tumor cell  lines, Biol Pharm Bull  26  (7)  (2003) 1057, https://doi.org/10.1248/bpb.26.1057.
(67)A.H. Banskota, Y. Tezuka, S. Kadota, Recent progress in pharmacological research of propolis, Phytother Res 15  (7)  (2001) 561–571, https://doi.org/10.1002/ ptr.1029.
(68)J.H.C. Furtado Júnior, L.A.R. Valadas, S. Fonseca, P.L.D. Lobo,  L.H.M. Calixto, A.G.F. Lima,  M.H.R.  de Aguiar, I.S. Arruda, M.A.L. Lotif, E.M. Rodrigues Neto, M.M. F. Fonteles, Clinical and  Microbiological Evaluation of Brazilian Red  Propolis Containing-Dentifrice in Orthodontic Patients: A Randomized Clinical Trial, Evid Based  Complement Alternat Med  2020 (2020) 8532701, https://doi.org/10.1155/2020/8532701.
(69)G. Gajek, B. Marciniak, J. Lewkowski, R. Kontek, Antagonistic Effects  of CAPE (a Component of Propolis) on  the  Cytotoxicity and  Genotoxicity of Irinotecan and SN38  in Human Gastrointestinal Cancer Cells  In Vitro, Molecules 25  (3)  (2020)658, https://doi.org/10.3390/molecules25030658.
(70)L.M. Santos, M.S. Fonseca, A.R. Sokolonski, K.R. Deegan, R.P.  Araújo, M.A. Umsza-Guez, J.D.  Barbosa, R.D. Portela, B.A. Machado, Propolis: types, composition, biological activities, and  veterinary product patent prospecting,J Sci Food  Agric  100  (4) (2020) 1369–1382, https://doi.org/10.1002/jsfa.10024. 
(71)J. He-rim, ‘Health functional foods’ see  boom in wake of virus outbreak, The Investor, The  Korea  Herald, Korea, 2020. http://www.theinvestor.co.kr/view.php?ud=20200305000843.
(72)T. Koe,  New  rules: South Korea  expands propolis oral  formats, removes upper limit for  functional ingredients, 2020. https://www.nutraingredients-asia.com/ Article/2020/03/09/.
(73)[73]  G.d.M.S. Pina, E.N. Lia, A.A. Berretta, A.P.  Nascimento, E.C. Torres, A.F. M. Buszinski, T.A. de Campos, E.B. Coelho, V.d.P.  Martins, Efficacy of Propolis on the  Denture Stomatitis Treatment in Older Adults: A Multicentric Randomized Trial, Evid  Based  Complement Alternat Med  2017 (2017) 8971746, https://doi. org/10.1155/2017/8971746.
(74)A.A. Berretta, Pesquisa pr´e-clínica e clínica de um  gel termorreversível contendo extrato padronizado de  pro´polis (EPP-AF)  para a reduça˜o do  tempo de cicatrizaça˜o de  leso˜es em  pacientes queimados, Ph.D.  thesis, Faculdade de Ciˆencias Farmacˆeuticas de  Ribeirao Preto, Universidade de  Sa˜o Paulo, Ribeirao Preto, 2007, https://doi.org/10.11606/T.60.2007.tde-03122008-164750.
(75)Coronaviridae Study Group of the  International Committee on  Taxonomy of Viruses, The  species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and  naming it SARS-CoV-2,  Nat.  Microbiol. 5 (2020) 536–544, https://doi.org/10.1038/s41564-020-0695-z.
(76)H. Hashem, IN Silico  Approach of Some  Selected Honey Constituents as SARS- CoV-2  Main  Protease  (COVID-19) Inhibitors,  EJMO  4 (3)  (2020) 196–200, https://doi.org/10.26434/chemrxiv.12115359.
(77)V. Kumar, J.K. Dhanjal, S.C. Kaul,  R. Wadhwa, D. Sundar, Withanone and  caffeic acid  phenethyl ester are  predicted to  interact with main protease (M(pro)) of SARS-CoV-2  and  inhibit its  activity, J Biomol Struct Dyn  (2020) 1–13, https:// doi.org/10.1080/07391102.2020.1772108.

(78)P. Zhou, X.L. Yang,  X.G. Wang, B. Hu,  L. Zhang, W. Zhang, H.R. Si, Y. Zhu,  B. Li, C.L. Huang, H.D. Chen, J. Chen, Y. Luo, H. Guo,  R.D. Jiang, M.Q. Liu, Y. Chen, X. R. Shen, X. Wang, X.S. Zheng, K. Zhao, Q.J.  Chen, F. Deng,  L.L. Liu, B. Yan,  F. X. Zhan, Y.Y. Wang, G.F. Xiao,  Z.L. Shi,  A pneumonia outbreak associated with a new  coronavirus of probable bat  origin, Nature 579  (7798) (2020) 270–273, https://doi.org/10.1038/s41586-020-2012-7.
(79)D. Wang, B. Hu,  C. Hu,  F. Zhu,  X. Liu,  J. Zhang, B. Wang, H. Xiang,  Z. Cheng, Y. Xiong,  Y. Zhao, Y. Li, X. Wang, Z. Peng, Clinical Characteristics of 138 Hospitalized Patients With  2019 Novel  Coronavirus-Infected Pneumonia in Wuhan, China, JAMA 323  (11) (2020) 1061–1069, https://doi.org/10.1001/ jama.2020.1585.
(80)M.R.  Mehra, S.S. Desai, S. Kuy,  T.D. Henry, A.N. Patel, Cardiovascular Disease, Drug  Therapy, and  Mortality in Covid-19, N Engl  J Med  382  (2020), https://doi. org/10.1056/NEJMoa2007621 e102.
(81)F. Sanchis-Gomar, C.J.  Lavie,  C. Perez-Quilis, B.M. Henry, G. Lippi,  Angiotensin- Converting Enzyme 2 and  Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019, Mayo Clin  Proc  95  (6)  (2020) 1222–1230, https://doi.org/10.1016/j. mayocp.2020.03.026.
(82)S.M. Oses, P. Marcos, P. Azofra, A. de Pablo, M.A. Fernandez-Muino, M.T. Sancho, Phenolic Profile, Antioxidant Capacities and  Enzymatic Inhibitory Activities of Propolis from  Different Geographical Areas:  Needs for Analytical Harmonization, Antioxidants 9 (1)  (2020) 75,  https://doi.org/10.3390/antiox9010075.
(83)J. Da,  M. Xu, Y. Wang, W. Li, M. Lu, Z. Wang, Kaempferol Promotes Apoptosis While Inhibiting Cell Proliferation via  Androgen-Dependent Pathway and Suppressing Vasculogenic Mimicry and  Invasion in Prostate Cancer, Anal  Cell Pathol 2019 (2019) 1907698, https://doi.org/10.1155/2019/1907698.
(84)M. Debiaggi, F. Tateo, L. Pagani, M. Luini,  E. Romero, Effects  of propolis flavonoids on  virus infectivity and  replication, Microbiologica 13  (3)  (1990) 207–213.
(85)S.M. Messerli, M.-R. Ahn,  K. Kunimasa, M. Yanagihara, T. Tatefuji, K. Hashimoto, V. Mautner, Y. Uto,  H. Hori, S. Kumazawa, K. Kaji, T. Ohta, H. Maruta, Artepillin C (ARC) in Brazilian green propolis selectively blocks oncogenic PAK1 signaling and  suppresses the  growth of NF tumors in mice, Phytother Res 23  (3)  (2009)423–427, https://doi.org/10.1002/ptr.2658.
(86)M.H.V.  Fernandes, L.N. Ferreira, G.D.A. Vargas, G. Fischer, S.O. Hübner, Effect  of Water Extract from  Brown Propolis on  Production of IFN-ϒ After  Immunization Against Canine Parvovirus (Cpv)  and  Canine Coronavirus (Ccov), Ciˆenc Anim Bras  16  (2)  (2015) 235–242, https://doi.org/10.1590/1089-6891v16i223458.
(87)A.M. Mahmoud, S.M. Abd El-Twab, Caffeic  acid  phenethyl ester protects the  brain against hexavalent chromium toxicity by enhancing endogenous antioxidants and modulating the  JAK/STAT signaling pathway, Biomed Pharmacother 91  (2017) 303–311, https://doi.org/10.1016/j.biopha.2017.04.073.
(88)Y. Okamoto, M. Tanaka, T. Fukui, T. Masuzawa, Brazilian propolis inhibits the differentiation of Th17 cells  by inhibition of interleukin-6-induced phosphorylation of signal transducer and  activator of transcription 3, Immunopharm Immunot 34  (5)  (2012) 803–809, https://doi.org/10.3109/08923973.2012.657304.
(89)N. Paulino, S.R. Abreu, Y. Uto,  D. Koyama, H. Nagasawa, H. Hori, V.M. Dirsch, A. M. Vollmar, A. Scremin, W.A. Bretz, Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis, Eur  J Pharmacol 587  (1–3) (2008)296–301, https://doi.org/10.1016/j.ejphar.2008.02.067.
(90)S.H.  Nile,  A. Nile,  J. Qiu,  L. Li, X. Jia, G. Kai, COVID-19:  Pathogenesis, cytokine storm and  therapeutic potential of interferons, Cytokine Growth F R 53  (2020)66–70, https://doi.org/10.1016/j.cytogfr.2020.05.002.
(91)C.C. Li, X.J.  Wang, H.R.  Wang, Repurposing host-based therapeutics to control coronavirus and  influenza virus, Drug  Discov  Today 24  (3)  (2019) 726–736, https://doi.org/10.1016/j.drudis.2019.01.018.
(92)C.L. Orsatti, F. Missima, A.C. Pagliarone, T.F. Bachiega, M.C. Búfalo, J.P. Araújo Jr.,  J.M.  Sforcin, Propolis immunomodulatory action in vivo  on  Toll- like  receptors 2 and  4 expression and  on  pro-inflammatory cytokines production in mice, Phytother Res 24  (8)  (2010) 1141–1146, https://doi.org/10.1002/ ptr.3086.
(93)J. Ito,  F.R. Chang, H.K. Wang, Y.K. Park, M. Ikegaki, N. Kilgore, K.H. Lee,  Anti- AIDS agents. 48.(1) Anti-HIV  activity of moronic acid  derivatives and  the  new melliferone-related triterpenoid isolated from  Brazilian propolis, J Nat  Prod 64 (10) (2001) 1278–1281, https://doi.org/10.1021/np010211x.
(94)T. Shimizu, A. Hino, A. Tsutsumi, Y.K. Park, W. Watanabe, M. Kurokawa, Anti- influenza virus activity of propolis in vitro and  its  efficacy against influenza infection in mice, Antivir Chem Chemother 19  (1)  (2008) 7–13, https://doi.org/10.1177/095632020801900102.
(95)S. Nolkemper, J. Reichling, K.H. Sensch, P. Schnitzler, Mechanism of herpes simplex virus type 2 suppression by propolis extracts, Phytomedicine 17  (2) (2010) 132–138, https://doi.org/10.1016/j.phymed.2009.07.006.
(96)Z. Harish, A. Rubinstein, M. Golodner, M. Elmaliah, Y. Mizrachi, Suppression of HIV-1  replication by propolis and  its  immunoregulatory effect, Drugs  Exp  Clin Res 23  (2)  (1997) 89–96.
(97)M. Amoros, C.M. Simo˜es, L. Girre, F. Sauvager, M. Cormier, Synergistic effect of flavones and  flavonols against herpes simplex virus type 1 in cell  culture. Comparison with the  antiviral activity of propolis, J Nat  Prod 55  (12) (1992)1732–1740, https://doi.org/10.1021/np50090a003.
(98)J.T.  England, A. Abdulla, C.M. Biggs,  A.Y.Y. Lee,  K.A. Hay,  R.L. Hoiland,  C.L. Wellington, M. Sekhon, S. Jamal, K. Shojania, L.Y.C. Chen, Weathering the COVID-19  storm: Lessons  from  hematologic cytokine syndromes, Blood  Rev (2020) 100707, https://doi.org/10.1016/j.blre.2020.100707.
(99)H. Maruta, A. Kittaka, Chemical evolution for  taming the  ‘pathogenic kinase’ PAK1, Drug  Discov  Today 25  (6)  (2020) 959–964, https://doi.org/10.1016/j. drudis.2020.03.008.
(100)J. Tozser, S. Benko, Natural Compounds as Regulators of NLRP3 Inflammasome- Mediated IL-1beta Production, Mediators Inflamm 2016 (2016) 5460302, https:// doi.org/10.1155/2016/5460302.
(101)S.H. Ashry  el, T.A. Ahmad, The  use  of propolis as vaccine’s adjuvant, Vaccine 31 (1)  (2012) 31–39, https://doi.org/10.1016/j.vaccine.2012.10.095.
(102)Y. Fan,  L. Guo,  W. Hou,  C. Guo,  W. Zhang, X. Ma,  L. Ma,  X. Song,  The  Adjuvant Activity of Epimedium Polysaccharide-Propolis Flavone Liposome on  Enhancing Immune Responses to Inactivated Porcine Circovirus Vaccine in Mice,  Evid  Based Complement Alternat Med  2015 (2015) 972083, https://doi.org/10.1155/2015/972083.
(103)L. Yang,  Y. Hu,  J. Xue,  F. Wang, D. Wang, X. Kong,  P. Li, W. Xu, Compound Chinese herbal medicinal ingredients can  enhance immune response and  efficacy of RHD vaccine in rabbit, Vaccine 26  (35) (2008) 4451–4455, https://doi.org/10.1016/j.vaccine.2008.06.075.
(104)Y. Tao,  D. Wang, Y. Hu,  Y. Huang, Y. Yu, D. Wang, The  immunological enhancement activity of propolis flavonoids liposome in vitro and  in vivo,  Evid Based  Complement Alternat Med  2014 (2014) 483513, https://doi.org/10.1155/2014/483513.
(105)G. Fischer, M.B. Cleff,  L.A. Dummer, N. Paulino, A.S. Paulino, C. de  Oliveira Vilela, F.S. Campos, T. Storch, G. D’Avila  Vargas, S. de Oliveira Hübner, T. Vidor, Adjuvant effect of green propolis on  humoral immune response of bovines immunized with bovine herpesvirus type 5, Vet  Immunol Immunopathol 116 (1–2) (2007) 79–84, https://doi.org/10.1016/j.vetimm.2007.01.003.
(106)G. Fischer, F.R. Conceicao, F.P. Leite,  L.A. Dummer, G.D. Vargas, O. Hubner Sde, O.A. Dellagostin, N. Paulino, A.S. Paulino, T. Vidor, Immunomodulation produced by  a green propolis extract on  humoral and  cellular responses of mice immunized with SuHV-1,  Vaccine 25  (7)  (2007) 1250–1256, https://doi.org/ 10.1016/j.vaccine.2006.10.005.
(107)X. Ma,  Z. Guo,  Z. Shen, J. Wang, Y. Hu,  D. Wang, The  immune enhancement of propolis adjuvant on  inactivated porcine parvovirus vaccine in guinea pig,  Cell Immunol 270  (1) (2011) 13–18, https://doi.org/10.1016/j.cellimm.2011.03.020.
(108)Aˆ . Sena-Lopes, F.S.B. Bezerra, R.N.  das  Neves, R.B. de  Pinho, M.T.O.  Silva,L. Savegnago, T. Collares, F. Seixas, K. Begnini, J.A.P. Henriques, M.R.  Ely,  L. C. Rufatto, S. Moura, T. Barcellos, F. Padilha, O. Dellagostin, S. Borsuk, Chemical composition, immunostimulatory, cytotoxic and  antiparasitic activities of the essential oil  from  Brazilian red  propolis, PLoS One  13  (2)  (2018), e0191797, https://doi.org/10.1371/journal.pone.0191797
(109)G. Fischer, N. Paulino, M.C. Marcucci, B.S. Siedler, L.S. Munhoz, P.F.  Finger, G.
(110)D. Vargas, S.O. Hübner, T. Vidor, P.M.  Roehe, Green propolis phenolic compounds act as vaccine adjuvants, improving humoral and  cellular responses in mice  inoculated with inactivated vaccines, Mem  Inst  Oswaldo Cruz  105  (7) (2010) 908–913, https://doi.org/10.1590/S0074-02762010000700012.
(111)S. Mojarab, D. Shahbazzadeh, M. Moghbeli, Y. Eshraghi, K.P. Bagheri, R. Rahimi, M.A. Savoji, M. Mahdavi, Immune responses to HIV-1 polytope vaccine candidate formulated in aqueous and  alcoholic extracts of Propolis: Comparable immune responses to  Alum  and  Freund adjuvants, Microb Pathog 140  (2020) 103932, https://doi.org/10.1016/j.micpath.2019.103932.
(112)E. Raymond, C. Thieblemont, S. Alran, S. Faivre, Impact of the  COVID-19 Outbreak on  the  Management of Patients with Cancer, Targ  Oncol 15  (2020)249–259, https://doi.org/10.1007/s11523-020-00721-1.
(113)S. Patel, Emerging Adjuvant Therapy for  Cancer: Propolis and  its  Constituents, J Diet  Suppl 13  (3)  (2016) 245–268, https://doi.org/10.3109/19390211.2015.1008614. 
(114) Y. Frio´n-Herrera, D. Gabbia, M. Scaffidi, L. Zagni, O. Cuesta-Rubio, S. De Martin, M. Carrara, The  Cuban Propolis Component Nemorosone Inhibits Proliferation and  Metastatic Properties of Human Colorectal Cancer Cells,  Int  J Mol Sci 21  (5) (2020) 1827, https://doi.org/10.3390/ijms21051827.
(115)Y.S. Song,  E.H.  Park, K.J.  Jung, C. Jin, Inhibition of angiogenesis by propolis, Arch  Pharm Res 25  (4)  (2002) 500–504, https://doi.org/10.1007/BF02976609.
(116)N. Orsoli´c, I. Basi´c, Antitumor, hematostimulative and  radioprotective action ofwater-soluble derivative of propolis (WSDP),  Biomed Pharmacother  59  (10) (2005) 561–570, https://doi.org/10.1016/j.biopha.2005.03.013.
(117)M.A. Watanabe, M.K. Amarante, B.J. Conti, J.M.  Sforcin, Cytotoxic constituents of propolis inducing anticancer effects: a review, J Pharm Pharmacol 63 (11) (2011)1378–1386, https://doi.org/10.1111/j.2042-7158.2011.01331.x.
(118)J. Wu,  C. Omene, J. Karkoszka, M. Bosland, J. Eckard, C.B. Klein,  K. Frenkel, Caffeic  acid  phenethyl ester (CAPE),  derived from  a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer, Cancer Lett  308  (1)  (2011) 43–53, https://doi.org/10.1016/j. canlet.2011.04.012.
(119)S. Akyol,  G. Ozturk, Z. Ginis,  F. Armutcu, M.R. Yigitoglu, O. Akyol,  In vivo  and  in vitro antıneoplastic actions of caffeic acid  phenethyl ester (CAPE):  therapeutic perspectives, Nutr Cancer 65  (4)  (2013) 515–526, https://doi.org/10.1080/01635581.2013.776693.
(120)H. Chang, Y. Wang, X. Yin, X. Liu, H. Xuan,  Ethanol extract of propolis and  its constituent caffeic acid  phenethyl ester inhibit breast cancer cells  proliferation in inflammatory microenvironment by inhibiting TLR4 signal pathway and  inducing apoptosis and  autophagy, BMC Complement Altern Med  17  (1)  (2017) 471, https://doi.org/10.1186/s12906-017-1984-9.
(121)N. Orsoli´c, A.H.  Knezevi´c, L. Sver,  S. Terzi´c, I. Basi´c, Immunomodulatory and antimetastatic action of propolis and  related polyphenolic compounds, J Ethnopharmacol 94  (2–3) (2004) 307–315, https://doi.org/10.1016/j. jep.2004.06.006.

(122)D. Sawicka, H. Car,  M.H.  Borawska, J. Niklin´ski, The  anticancer activity of propolis, Folia  Histochem Cytobiol 50  (1)  (2012) 25–37, https://doi.org/10.2478/18693. 
(123)D. Grunberger, R. Banerjee, K. Eisinger, E.M. Oltz,  L. Efros,  M. Caldwell,V. Estevez, K. Nakanishi, Preferential cytotoxicity on  tumor cells  by  caffeic acid phenethyl ester isolated from  propolis, Experientia 44  (3)  (1988) 230–232, https://doi.org/10.1007/BF01941717.
(124)T. Nagaoka, A.H.  Banskota, Y. Tezuka, I. Saiki,  S. Kadota, Selective antiproliferative activity of caffeic acid  phenethyl ester analogues on highly liver- metastatic murine colon 26-L5  carcinoma cell  line,  Bioorg Med  Chem 10  (10) (2002) 3351–3359, https://doi.org/10.1016/s0968-0896(02)00138-4.
(125)E. Szliszka, Z.P.  Czuba, M. Domino, B. Mazur, G. Zydowicz, W. Krol,  Ethanolic extract of propolis (EEP)  enhances the  apoptosis- inducing potential of TRAIL in cancer cells,  Molecules 14  (2)  (2009) 738–754, https://doi.org/10.3390/ molecules14020738.
(126)T.M. Cook,  The  importance of hypertension as a risk  factor for severe illness and mortality in COVID-19,  Anaesthesia 75  (7)  (2020) 976–977, https://doi.org/10.1111/anae.15103.
(127)K. Mahajan, K. Chandra, Cardiovascular comorbidities and  complications associated with coronavirus disease 2019, Med  J Armed Forces India (2020), https://doi.org/10.1016/j.mjafi.2020.05.004.
(128)A. Emami, F. Javanmardi, N. Pirbonyeh, A. Akbari, Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19:  a Systematic Review and  Meta- Analysis, Arch  Acad  Emerg Med  8 (1)  (2020), e35, https://doi.org/10.22037/ aaem.v8i1.600. 
(129)Y. Kubota, K. Umegaki, K. Kobayashi, N. Tanaka, S. Kagota, K. Nakamura, M. Kunitomo, K. Shinozuka, Anti-hypertensive effects of Brazilian propolis in spontaneously hypertensive rats, Clin Exp Pharmacol Physiol 31 (Suppl 2) (2004) S29–S30, https://doi.org/10.1111/j.1440-1681.2004.04113.x.
(130)H. Zhou, H. Wang, N. Shi, F. Wu, Potential Protective Effects  of the  Water-Soluble Chinese Propolis on  Hypertension Induced by High-Salt Intake, Clin  Transl Sci (2020), https://doi.org/10.1111/cts.12770.
(131)S. Zingue, C.B.M. Nde,  T. Michel, D.T. Ndinteh, J. Tchatchou, M. Adamou, X. Fernandez, F.T. Fohouo, C. Clyne, D. Njamen, Ethanol-extracted Cameroonian propolis exerts estrogenic effects and  alleviates hot  flushes in ovariectomized Wistar rats, BMC Complement Altern Med  17  (1)  (2017) 65,  https://doi.org/10.1186/s12906-017-1568-8.
(132)W. Yuan,  H. Chang, X. Liu, S. Wang, H. Liu,  H. Xuan,  Brazilian Green Propolis Inhibits Ox-LDL-Stimulated Oxidative Stress  in Human Umbilical Vein Endothelial Cells Partly through PI3K/Akt/mTOR-Mediated Nrf2/HO-1 Pathway, Evid  Based  Complement Alternat Med  2019 (2019) 5789574, https://doi.org/10.1155/2019/5789574.
(133)V. Mujica, R. Orrego, J. P´erez, P. Romero, P. Ovalle, J. Zún˜iga-Herna´ndez, M. Arredondo, E. Leiva,  The  Role  of Propolis in Oxidative Stress  and  Lipid Metabolism: A Randomized Controlled Trial, Evid  Based  Complement Alternat Med  2017 (2017) 4272940, https://doi.org/10.1155/2017/4272940.
(134)K. Michalakis, I. Ilias,  SARS-CoV-2 infection and  obesity: Common inflammatory and  metabolic aspects, Diabetes Metab Syndr 14 (4) (2020) 469–471, https://doi. org/10.1016/j.dsx.2020.04.033.
(135)S. Koya-Miyata, N. Arai,  A. Mizote, Y. Taniguchi, S. Ushio, K. Iwaki, S. Fukuda, Propolis prevents diet-induced hyperlipidemia and  mitigates weight gain  in diet- induced obesity in mice, Biol Pharm Bull 32 (12) (2009) 2022–2028, https://doi. org/10.1248/bpb.32.2022.
(136)S. Rayalam, D. Mills,  Y. Azhar, E. Miller, X. Wang, Caffeic  Acid  Phenethyl Ester and  Its Fluorinated Derivative as Natural Anti-obesity Agents (P06-089-19), Curr Dev Nutr 3 (Supplement_1) (2019), https://doi.org/10.1093/cdn/nzz031.P06-089-19.
(137)B.J.  Barnes, J.M.  Adrover, A. Baxter-Stoltzfus, A. Borczuk, J. Cools-Lartigue, J. M. Crawford, J. Daßler-Plenker, P. Guerci, C. Huynh, J.S.  Knight, M. Loda,  M. R. Looney, F. McAllister, R. Rayes, S. Renaud, S. Rousseau, S. Salvatore, R.E. Schwartz, J.D.  Spicer, C.C. Yost,  A. Weber, Y. Zuo,  M. Egeblad, Targeting potential drivers of COVID-19:  Neutrophil extracellular traps, J Exp Med  217  (6) (2020), e20200652, https://doi.org/10.1084/jem.20200652.
(138)L. Bertoletti, F. Couturaud, D. Montani, F. Parent, O. Sanchez, Venous thromboembolism and  COVID-19,  Respir Med Res 78 (2020) 100759, https://doi. org/10.1016/j.resmer.2020.100759.
(139)R.J.  Jose, A. Manuel, COVID-19  cytokine storm: the  interplay between inflammation and  coagulation, Lancet Respir Med  (2020), https://doi.org/10.1016/S2213-2600(20)30216-2.
(140)F.A. Klok,  M.J.H.A. Kruip, N.J.M. van  der  Meer, M.S. Arbous, D.A.M.P.J. Gommers, K.M. Kant,  F.H.J. Kaptein, J. van  Paassen, M.A.M.  Stals,  M.V. Huisman, H. Endeman, Incidence of thrombotic complications in critically ill ICU patients with COVID-19,  Thromb Res 191  (2020) 145–147, https://doi.org/10.1016/j.thromres.2020.04.013.
(141)D.E. Vaughan, PAI-1  and  atherothrombosis, J Thromb Haemost 3 (8)  (2005)1879–1883, https://doi.org/10.1111/j.1538-7836.2005.01420.x.
(142)[141]  M. Cesari, M. Pahor, R.A. Incalzi, Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and  age-related subclinical and  clinical conditions, Cardiovasc Ther  28  (5)  (2010) e72–e91, https://doi.org/10.1111/j.1755-5922.2010.00171.x.
(143)N. Ohkura, K. Oishi, F. Kihara-Negishi, G.-I. Atsumi, T. Tatefuji, Effects  of a diet containing Brazilian propolis on  lipopolysaccharide-induced increases in plasma plasminogen activator inhibitor-1 levels in mice, J Intercult Ethnopharmacol 5 (4) (2016) 439–443, https://doi.org/10.5455/jice.20160814112735.
(144)H. Kitamura, Effects  of Propolis Extract and  Propolis-Derived Compounds on Obesity and  Diabetes: Knowledge from  Cellular and  Animal Models, Molecules 24 (23) (2019) 4394, https://doi.org/10.3390/molecules24234394.
(145)J.B.  Daleprane, D.S. Abdalla, Emerging roles of propolis: antioxidant, cardioprotective, and  antiangiogenic actions, Evid  Based  Complement Alternat Med  2013 (2013) 175135, https://doi.org/10.1155/2013/175135.
(146)M. Boji´c, A. Antoli´c, M. Tomiˇci´c, Zˇ. Debeljak, Zˇ. Maleˇs, Propolis ethanolic extracts reduce adenosine diphosphate induced platelet aggregation determined on whole blood, Nutr J 17  (1)  (2018) 52,  https://doi.org/10.1186/s12937-018-0361-y.
(147)Y.-X. Zhang, T.-T. Yang,  L. Xia, W.-F.  Zhang, J.-F.  Wang, Y.-P. Wu,  Inhibitory Effect  of Propolis on  Platelet Aggregation In Vitro, J Healthc Eng  2017 (2017) 3050895, https://doi.org/10.1155/2017/3050895.
(148)G. Hsiao, J.J. Lee,  K.H. Lin, C.H.  Shen, T.H.  Fong,  D.S. Chou, J.R.  Sheu, Characterization of a novel and  potent collagen antagonist, caffeic acid  phenethyl ester, in human platelets: in vitro and  in vivo  studies, Cardiovasc Res 75  (4) (2007) 782–792, https://doi.org/10.1016/j.cardiores.2007.05.005.
(149)E.O. Gubernatorova, E.A. Gorshkova, A.I. Polinova, M.S. Drutskaya,  IL-6: Relevance for immunopathology of SARS-CoV-2,  Cytokine Growth F R 53  (2020)13–24, https://doi.org/10.1016/j.cytogfr.2020.05.009.
(150)J. Kocot,  M. Kiełczykowska, D. Luchowska-Kocot, J. Kurzepa, I. Musik, Antioxidant Potential of Propolis, Bee Pollen, and  Royal  Jelly: Possible Medical Application, Oxid  Med  Cell  Longev 2018 (2018) 7074209, https://doi.org/10.1155/2018/7074209.
(151)S. Havermann, Y. Chovolou, H.U.  Humpf, W. Wa¨tjen, Caffeic  acid  phenethylester increases stress resistance and  enhances lifespan in Caenorhabditis elegans by modulation of the  insulin-like DAF-16 signalling pathway, PLoS One 9 (6) (2014), e100256, https://doi.org/10.1371/journal.pone.0100256.
(152)A. Zhu,  Z. Wu, X. Zhong, J. Ni, Y. Li, J. Meng, C. Du, X. Zhao, H. Nakanishi, S. Wu, Brazilian Green Propolis Prevents Cognitive Decline into  Mild  Cognitive Impairment in Elderly People Living  at  High  Altitude, J Alzheimers Dis 63  (2) (2018) 551–560, https://doi.org/10.3233/JAD-170630.
(153)I. Jasprica, A. Mornar, Z. Debeljak, A. Smolci´c-Bubalo, M. Medi´c-Sari´c, L. Mayer, Z. Romi´c, K. Bu´can, T. Balog,  S. Sobocanec, V. Sverko, In vivo  study of propolis supplementation effects on  antioxidative status and  red  blood cells, J Ethnopharmacol 110  (3)  (2007) 548–554, https://doi.org/10.1016/j. jep.2006.10.023.
(154)H.R.  Sameni, P. Ramhormozi, A.R. Bandegi, A.A. Taherian,M. Mirmohammadkhani, M. Safari, Effects  of ethanol extract of propolis on histopathological changes and  anti-oxidant defense of kidney in a rat  model for type 1 diabetes mellitus, J Diabetes Investig 7 (4)  (2016) 506–513, https://doi. org/10.1111/jdi.12459.
(155)J. Ni, Z. Wu, J. Meng, A. Zhu,  X. Zhong, S. Wu, H. Nakanishi, The Neuroprotective Effects  of Brazilian Green Propolis on  Neurodegenerative Damage in Human Neuronal SH-SY5Y Cells,  Oxid  Med  Cell  Longev 2017 (2017) 7984327, https:// doi.org/10.1155/2017/7984327.
(156)M. Ayaz,  A. Sadiq, M. Junaid, F. Ullah, M. Ovais, I. Ullah, J. Ahmed, M. Shahid, Flavonoids as Prospective Neuroprotectants and  Their Therapeutic Propensity in Aging  Associated Neurological Disorders, Front Aging  Neurosci 11  (2019) 155, https://doi.org/10.3389/fnagi.2019.00155.
(157)Y. Dong,  T. Stewart, L. Bai, X. Li, T. Xu, J. Iliff, M. Shi, D. Zheng, L. Yuan,  T. Wei, X. Yang,  J. Zhang, Coniferaldehyde attenuates Alzheimer’s pathology via activation of Nrf2  and  its  targets, Theranostics 10  (1)  (2020) 179–200, https:// doi.org/10.7150/thno.36722.
(158)C. Sargiacomo, F. Sotgia, M.P.  Lisanti, COVID-19  and  chronological aging: senolytics and  other anti-aging drugs for  the  treatment or  prevention of corona virus infection? Aging  12  (8)  (2020) 6511–6517, https://doi.org/10.18632/ aging.103001.
(159)R. Vinayagam, B. Xu, Antidiabetic properties of dietary flavonoids: a cellular mechanism review, Nutr Metab 12  (1)  (2015) 60,  https://doi.org/10.1186/ s12986-015-0057-7.
(160)A.P. Tiveron, P.L. Rosalen, M. Franchin, R.C. Lacerda, B. Bueno-Silva, B. Benso, C. Denny, M. Ikegaki, S.M. Alencar, Chemical Characterization and  Antioxidant, Antimicrobial, and  Anti-Inflammatory Activities of South Brazilian Organic Propolis, PLoS One  11  (11) (2016), e0165588, https://doi.org/10.1371/journal. pone.0165588.
(161)R. El Adaouia Taleb, N. Djebli, H. Chenini, H. Sahin, S. Kolayli, In vivo  and  in vitro anti-diabetic activity of ethanolic propolis extract, J Food  Biochem 44 (2020), e13267, https://doi.org/10.1111/jfbc.13267.
(162)T. Matsui, S. Ebuchi, T. Fujise, K.J.  Abesundara, S. Doi,  H. Yamada, K. Matsumoto, Strong antihyperglycemic effects of water-soluble fraction of Brazilian propolis and  its  bioactive constituent, 3,4,5-tri-O-caffeoylquinic acid, Biol Pharm Bull  27  (11) (2004) 1797–1803, https://doi.org/10.1248/ bpb.27.1797.
(163)Y. Zamami, S. Takatori, T. Koyama, M. Goda, Y. Iwatani, S. Doi,  H. Kawasaki, [Effect of propolis on  insulin resistance in fructose-drinking rats], Yakugaku Zasshi 127  (12) (2007) 2065–2073, https://doi.org/10.1248/yakushi.127.2065.
(164)Y. Li, M. Chen, H. Xuan,  F. Hu,  Effects  of Encapsulated Propolis on  Blood Glycemic Control, Lipid  Metabolism, and  Insulin Resistance in Type  2 Diabetes Mellitus Rats,  Evid  Based  Complement Alternat Med  2012 (2012) 981896, https://doi.org/10.1155/2012/981896.
(165)W. Aoi, S. Hosogi, N. Niisato, N. Yokoyama, H. Hayata, H. Miyazaki, K. Kusuzaki, T. Fukuda, M. Fukui, N. Nakamura, Y. Marunaka, Improvement of insulin resistance, blood pressure and  interstitial pH  in early developmental stage of insulin resistance in OLETF rats  by intake of propolis extracts, Biochem Biophys Res Commun 432  (4)  (2013) 650–653, https://doi.org/10.1016/j. bbrc.2013.02.029.
(166)O.M.  Abo-Salem, R.H.  El-Edel,  G.E. Harisa, N. El-Halawany, M.M.  Ghonaim, Experimental diabetic nephropathy can  be  prevented by  propolis: Effect  on metabolic disturbances and  renal oxidative parameters, Pak  J Pharm Sci 22  (2) (2009) 205–210.
(167)H. Kitamura, Y. Naoe, S. Kimura, T. Miyamoto, S. Okamoto, C. Toda,Y. Shimamoto, T. Iwanaga, I. Miyoshi, Beneficial effects of Brazilian propolis on type 2 diabetes in ob/ob mice: Possible involvement of immune cells  in mesenteric adipose tissue, Adipocyte 2 (4)  (2013) 227–236, https://doi.org/10.4161/adip.25608.
(168)W. Gao,  L. Pu,  J. Wei,  Z. Yao,  Y. Wang, T. Shi,  L. Zhao, C. Jiao, C. Guo,  Serum Antioxidant Parameters are  Significantly Increased in Patients with Type  2 Diabetes Mellitus after Consumption of Chinese Propolis: A Randomized Controlled Trial  Based  on  Fasting Serum Glucose Level,  Diabetes Ther  9 (1) (2018) 101–111, https://doi.org/10.1007/s13300-017-0341-9.
(169)N. Samadi, H. Mozaffari-Khosravi, M. Rahmanian, M. Askarishahi, Effects  of bee propolis supplementation on glycemic control, lipid profile and  insulin resistance indices in patients with type 2 diabetes: a randomized, double-blind clinical trial, J Integr Med  15  (2)  (2017) 124–134, https://doi.org/10.1016/S2095-4964(17)60315-7.
(170)S. Hesami, S. Hashemipour, M.R.  Shiri-Shahsavar, Y. Koushan, H. Khadem Haghighian, Administration of Iranian Propolis attenuates oxidative stress and blood glucose in type II diabetic patients: a randomized, double-blind, placebo- controlled, clinical trial, Caspian J Intern Med  10  (1)  (2019) 48–54, https://doi. org/10.22088/cjim.10.1.48.
(171)M. Zakerkish, M. Jenabi, N. Zaeemzadeh, A.A. Hemmati, N. Neisi,  The  Effect  of Iranian Propolis on  Glucose Metabolism, Lipid  Profile, Insulin Resistance, Renal Function and  Inflammatory Biomarkers in Patients with Type  2 Diabetes Mellitus: A Randomized Double-Blind Clinical Trial, Sci Rep 9 (1) (2019) 7289, https://doi. org/10.1038/s41598-019-43838-8.
(172)A. Oryan, E. Alemzadeh, A. Moshiri, Potential role  of propolis in wound healing: Biological properties and  therapeutic activities, Biomed Pharmacother 98  (2018)469–483, https://doi.org/10.1016/j.biopha.2017.12.069.
(173)A. Picolotto, D. Pergher, G.P.  Pereira, K.G. Machado, H. da  Silva  Barud, M. Roesch-Ely, M.H.  Gonzalez, L. Tasso, J.G.  Figueiredo, S. Moura, Bacterial cellulose membrane associated with red  propolis as phytomodulator: Improved healing effects in experimental models of diabetes mellitus, Biomed Pharmacother 112  (2019) 108640, https://doi.org/10.1016/j. biopha.2019.108640.
(174)M. Afkhamizadeh, R. Aboutorabi, H. Ravari, M. Fathi Najafi, S. Ataei  Azimi, A. Javadian Langaroodi, M.A. Yaghoubi, A. Sahebkar, Topical propolis improves wound healing in patients with diabetic foot  ulcer: a randomized controlled trial, Nat  Prod Res 32  (17) (2018) 2096–2099, https://doi.org/10.1080/14786419.2017.1363755.
(175)F.R. Henshaw, T. Bolton, V. Nube, A. Hood, D. Veldhoen, L. Pfrunder,  G.L. McKew,  C. Macleod, S.V. McLennan, S.M. Twigg, Topical application of the  bee hive  protectant propolis is well  tolerated and  improves human diabetic foot  ulcer healing in a prospective feasibility study, J Diabetes Complicat 28  (6)  (2014)850–857, https://doi.org/10.1016/j.jdiacomp.2014.07.012.
(176)S.H.  Shin,  S.G. Seo,  S. Min,  H. Yang,  E. Lee,  J.E.  Son,  J.Y.  Kwon,  S. Yue,  M.Y. Chung, K.H. Kim, J.X. Cheng, H.J.  Lee, K.W. Lee, Caffeic  acid  phenethyl ester, a major component of propolis, suppresses high fat  diet-induced obesity through inhibiting adipogenesis at the  mitotic clonal expansion stage, J Agric  Food  Chem 62  (19) (2014) 4306–4312, https://doi.org/10.1021/jf405088f.
(177)J. Nie, Y. Chang, Y. Li, Y. Zhou, J. Qin,  Z. Sun,  H. Li, Caffeic  Acid Phenethyl Ester (Propolis Extract) Ameliorates Insulin Resistance by  Inhibiting JNK and  NF-κB Inflammatory Pathways in Diabetic Mice  and  HepG2 Cell  Models, J Agric  Food Chem 65  (41) (2017) 9041–9053, https://doi.org/10.1021/acs.jafc.7b02880.
(178)J.J. Ramírez-Espinosa, J. Saldan˜a-Ríos, S. García-Jimenez, R. Villalobos-Molina, G. A´ vila-Villarreal, A.N. Rodríguez-Ocampo, G. Bernal-Ferna´ndez, S. Estrada- Soto,  Chrysin Induces Antidiabetic, Antidyslipidemic and  Anti-Inflammatory Effects  in Athymic Nude Diabetic Mice,  Molecules 23  (1)  (2017) 67,  https://doi. org/10.3390/molecules23010067.
(179)L. D’Marco, M.J. Puchades, M. Romero-Parra, J.L. Gorriz, Diabetic Kidney Disease and  COVID-19:  The  Crash of Two  Pandemics, Front Med  7 (2020) 199, https://doi.org/10.3389/fmed.2020.00199.
(180)L. Perico, A. Benigni, G. Remuzzi, Should COVID-19  Concern Nephrologists? Why and  to  What Extent? The  Emerging Impasse of Angiotensin Blockade, Nephron 144  (5)  (2020) 213–221, https://doi.org/10.1159/000507305.
(181)V. Monteil, H. Kwon,  P. Prado, A. Hagelkrüys, R.A. Wimmer, M. Stahl, A. Leopoldi, E. Garreta, C. Hurtado del  Pozo,  F. Prosper, J.P.  Romero, G. Wirnsberger, H. Zhang, A.S. Slutsky, R. Conder, N. Montserrat, A. Mirazimi, J. M. Penninger, Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using  Clinical-Grade Soluble Human ACE2, Cell 181  (4) (2020) 905–913, https:// doi.org/10.1016/j.cell.2020.04.004,  e7.
(182)F. Alberici, E. Delbarba, C. Manenti, L. Econimo, F. Valerio, A. Pola, C. Maffei, S. Possenti, S. Piva, N. Latronico, E. Foca`, F. Castelli, P. Gaggia, E. Movilli,S. Bove,  F. Malberti, M. Farina, M. Bracchi, E.M. Costantino, N. Bossini, M. Gaggiotti, F. Scolari, Management Of Patients On Dialysis And  With  Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic  In Brescia, Italy, Kidney Int  Rep  5 (5)  (2020) 580–585, https://doi.org/10.1016/j.ekir.2020.04.001.
(183)M. Bhadauria, Propolis Prevents Hepatorenal Injury Induced by Chronic Exposure to  Carbon Tetrachloride, Evid  Based  Complement Alternat Med  2012 (2012) 235358, https://doi.org/10.1155/2012/235358.
(184)K. Boutabet, W. Kebsa, M. Alyane, M. Lahouel, Polyphenolic fraction of Algerian propolis protects rat  kidney against acute oxidative stress induced by doxorubicin, Indian J Nephrol 21  (2)  (2011) 101–116, https://doi.org/10.4103/0971-4065.82131.
(185)F. Teles,  T.M. da  Silva,  F.P. da  Cruz  Júnior, V.H. Honorato, H. de Oliveira Costa, A.P.F.  Barbosa, S.G. de  Oliveira, Z. Porfírio, A.B. Libo´rio, R.L. Borges, C. Fanelli, Brazilian Red  Propolis Attenuates Hypertension and  Renal Damage in 5/6 Renal Ablation Model, PLoS ONE 10  (1)  (2015), e0116535, https://doi.org/10.1371/ journal.pone.0116535.
(186)T.P.  Cushnie, A.J.  Lamb, Antimicrobial activity of flavonoids, Int  J Antimicrob Agents 26  (5)  (2005) 343–356, https://doi.org/10.1016/j. ijantimicag.2005.09.002.
(187)J.M.  Grange, R.W. Davey, Antibacterial properties of propolis (bee glue), J R Soc Med  83  (3)  (1990) 159–160.
(188)A. Kujumgiev, I. Tsvetkova, Y. Serkedjieva, V. Bankova, R. Christov, S. Popov, Antibacterial, antifungal and  antiviral activity of propolis of different geographic origin, J Ethnopharmacol 64  (3)  (1999) 235–240, https://doi.org/10.1016/ s0378-8741(98)00131-7.
(189)L. Cornara, M. Biagi,  J. Xiao,  B. Burlando, Therapeutic Properties of Bioactive Compounds from  Different Honeybee Products, Front Pharmacol 8 (2017) 412, https://doi.org/10.3389/fphar.2017.00412.
(190)J.V.d. Campos, O.B.G.  Assis,  R. Bernardes-Filho, Atomic force  microscopy evidences of bacterial cell  damage caused by  propolis extracts on  E. coli and S. aureus,  Food  Sci Technol 40 (2019) 55–61, https://doi.org/10.1590/fst.32018. 
(191)V. Bankova, R. Christov, A. Kujumgiev, M.C. Marcucci, S. Popov, Chemical composition and  antibacterial activity of Brazilian propolis, Z Naturforsch C J Biosci  50  (3-4) (1995) 167–172, https://doi.org/10.1515/znc-1995-3-402.
(192)S. Boisard, A.-M. Le Ray,  A. Landreau, M. Kempf, V. Cassisa, C. Flurin, P. Richomme, Antifungal and  Antibacterial Metabolites from  a French Poplar Type  Propolis, Evid  Based  Complement Alternat Med  2015 (2015) 319240, https://doi.org/10.1155/2015/319240.
(193)I. Al-Ani,  S. Zimmermann, J. Reichling, M. Wink,  Antimicrobial Activities of European Propolis Collected from  Various Geographic Origins Alone  and  in Combination with Antibiotics, Medicines 5 (1)  (2018) 2, https://doi.org/10.3390/medicines5010002.
(194)F. Scazzocchio, F.D. D’Auria, D. Alessandrini, F. Pantanella, Multifactorial aspects of antimicrobial activity of propolis, Microbiol Res 161  (4)  (2006) 327–333, https://doi.org/10.1016/j.micres.2005.12.003.
(195)S.A. Liberio, A.L. Pereira, M.J.  Araújo, R.P. Dutra, F.R. Nascimento, V. Monteiro-Neto, M.N. Ribeiro, A.G. Gonçalves, R.N. Guerra, The  potential use  of propolis as a cariostatic agent and  its  actions on  mutans group streptococci,J Ethnopharmacol 125  (1)  (2009) 1–9,  https://doi.org/10.1016/j. jep.2009.04.047.
(196)O.K. Mirzoeva, R.N. Grishanin, P.C. Calder, Antimicrobial action of propolis and some  of its  components: the  effects on  growth, membrane potential and  motility of bacteria, Microbiol Res 152  (3)  (1997) 239–246, https://doi.org/10.1016/ S0944-5013(97)80034-1.
(197)M. Popova, S. Silici,  O. Kaftanoglu, V. Bankova, Antibacterial activity of Turkish propolis and  its  qualitative and  quantitative chemical composition, Phytomedicine 12  (3)  (2005) 221–228, https://doi.org/10.1016/j. phymed.2003.09.007.
(198)V. Mazzarello, M.G. Donadu, M. Ferrari, G. Piga, D. Usai,  S. Zanetti, M.A. Sotgiu, Treatment of acne with a combination of propolis, tea  tree oil,  and  Aloe  vera compared to  erythromycin cream: two  double-blind investigations, Clin Pharmacol 2018 (10) (2018) 175–181, https://doi.org/10.2147/CPAA.S180474.
(199)A. Meto, B. Colombari, A. Meto, G. Boaretto, D. Pinetti, L. Marchetti, S. Benvenuti, F. Pellati, E. Blasi,  Propolis Affects  Pseudomonas aeruginosa  Growth, Biofilm Formation, eDNA Release and  Phenazine Production: Potential Involvement of Polyphenols, Microorganisms 8 (2)  (2020) 243, https://doi.org/10.3390/ microorganisms8020243.
(200)K.C. Loureiro, T.C. Barbosa, M. Nery, M.V. Chaud, C.F. da Silva,  L.N. Andrade, C.B. Correa, A. Jaguer, F.F. Padilha, J.C.  Cardoso, E. Souto, P. Severino, Antibacterial activity of chitosan/collagen membranes containing red  propolis extract, Pharmazie 75 (2)  (2020) 75–81, https://doi.org/10.1691/ph.2020.9050.
(201)Y.K. Park, M.H.  Koo,  J.A.  Abreu, M. Ikegaki, J.A.  Cury,  P.L. Rosalen, Antimicrobial properties of propolis on  oral  microorganisms, Curr  Microbiol 36 (1998) 24–28, https://doi.org/10.1007/s002849900274.
(202)Y.K. Park, S.M. Alencar, C.L. Aguiar, Botanical origin and  chemical composition of Brazilian propolis, J Agr Food  Chem 50  (9)  (2002) 2502–2506, https://doi. org/10.1021/jf011432b.
(203)J. Sforcin, A.J.  Fernandes, C. Lopes,  V. Bankova, S. Funari, Seasonal effect on Brazilian propolis antibacterial activity, J Ethnopharmacol 73  (1-2) (2000) 243–249, https://doi.org/10.1016/s0378-8741(00)00320-2.
(204)F. Galeotti, F. Maccari, A. Fachini, N. Volpi,  Chemical Composition and Antioxidant Activity of Propolis Prepared in Different Forms and  in Different Solvents Useful  for  Finished Products, Foods  7 (3)  (2018) 41,  https://doi.org/10.3390/foods7030041.
(205)[204]  M.T.  Khayyal, A.S. el-Ghazaly, A.S. el-Khatib, Mechanisms involved in the antiinflammatory effect of propolis extract, Drugs  Exp Clin  Res 19  (5)  (1993)197–203.
(206)P.A. de Castro, M. Savoldi, D. Bonatto, M.H. Barros, M.H. Goldman, A.A. Berretta, G.H.  Goldman, Molecular characterization of propolis-induced cell  death in Saccharomyces cerevisiae,  Eukaryot Cell  10  (3)  (2011) 398–411, https://doi.org/10.1128/EC.00256-10.
(207)G.C. Pietta, PG, A.M. Pietta, Analytical methods for  quality control of propolis, Fitoterapia 73 (2002) S7–S20, https://doi.org/10.1016/s0367-326x(02)00186-7.
(208)F.S. Marquiafa´vel, A.P. Nascimento, H.d.S. Barud, F. Marquele-Oliveira, L.A.P. de-Freitas, J.K.  Bastos, A.A. Berretta, Development and  characterization of a novel  standardized propolis dry  extract obtained by factorial design with high artepillin C content, J Pharm Technol Drug  Res 4 (2015) 1, https://doi.org/10.7243/2050-120X-4-1.
(209)I. Cunha, A. SawayaI, F. Caetano, M.T.  ShimizuI, M.C. MarcucciIII, F.T. DrezzaI, G.S. PoviaI, P.d.O. Carvalho, Factors that influence the  yield and  composition of Brazilian propolis extracts, J Braz  Chem Soc 15  (6)  (2004) 964–970, https://doi. org/10.1590/S0103-50532004000600026.
(210)European Food  Safety Authority Panel on Dietetic Products, Scientific Opinion on the  substantiation of health claims related to  propolis (ID 1242, 1245, 1246,1247, 1248, 3184) and  flavonoids in propolis (ID 1244, 1644, 1645, 3526, 3527,3798, 3799) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, EFSA J 8 (10) (2010) 1810, https://doi.org/10.2903/j.efsa.2010.1810.
(211)P.H.  Nikam, J. Kareparamban, J. Aruna, V. Kadam, Future Trends in Standardization of Herbal Drugs, J Appl  Pharm Sci 2 (6)  (2012) 38–44, https:// doi.org/10.7324/JAPS.2012.2631.
(212)F.G. Waldesch, B. Konigswinter, H. Remagen, Herbal Medicinal Products - Scientific and  regulatory basis  for  development quality assurance and  marketing authorisation, Medpharm CRC Press, Boca  Raton, 2003.
(213)J. Souza, L. Tacon, C. Correia, J. Bastos, L. Freitas, Spray-dried propolis extract, II:prenylated components of green propolis, Pharmazie 62  (7)  (2007) 488–492. [213]  B.A. Rocha, P.C.P.  Bueno, M.M.d.O.L.L. Vaz, A.P. Nascimento, N.U. Ferreira, G.d.P. Moreno, M.R. Rodrigues, A.R.d.M. Costa-Machado, E.A. Barizon, J.C.L. Campos, P.F.  de  Oliveira, N.d.O. Acesio, S.d.P.L.  Martins, D.C. Tavares, A. A. Berretta, Evaluation of a Propolis Water Extract Using  a Reliable RP-HPLC Methodology and  In Vitro  and  In Vivo Efficacy and  Safety Characterisation,  Evid Based  Complement Alternat Med  2013 (2013) 670451, https://doi.org/10.1155/2013/670451.
(214)P. de  Castro, M. Savoldi, D. Bonatto, I. Malavazi, M. Goldman, A. Berretta, G. Goldman, Transcriptional profiling of Saccharomyces cerevisiae  exposed to propolis, BMC Complement Altern Med  12 (2012) 194, https://doi.org/10.1186/1472-6882-12-194.
(215)A.A. Berretta, P.A. de  Castro, A.H.  Cavalheiro, V.S. Fortes, V.P. Bom,  A.P. Nascimento, F. Marquele-Oliveira, V. Pedrazzi, L.N. Ramalho, G.H.  Goldman, Evaluation of Mucoadhesive Gels with Propolis (EPP-AF)  in Preclinical Treatment of Candidiasis Vulvovaginal Infection, Evid  Based  Complement Alternat Med 2013 (2013) 641480, https://doi.org/10.1155/2013/641480.
(216)S. Barud Hda, A.M. de Araujo Junior, S. Saska, L.B. Mestieri, J.A. Campos, R.M. de Freitas, N.U.  Ferreira, A.P. Nascimento, F.G. Miguel, M.M.  Vaz,  E.A. Barizon, F. Marquele-Oliveira, A.M. Gaspar, S.J.  Ribeiro, A.A. Berretta, Antimicrobial Brazilian Propolis (EPP-AF)  Containing Biocellulose Membranes as Promising Biomaterial for Skin  Wound Healing, Evid Based  Complement Alternat Med 2013 (2013) 703024, https://doi.org/10.1155/2013/703024.
(217)F.D. Marquele, A.R. Oliveira, P.S. Bonato, M.G. Lara,  M.J.  Fonseca, Propolis extract release evaluation from  topical formulations by  chemiluminescence and HPLC, J Pharm Biomed Anal  41  (2)  (2006) 461–468, https://doi.org/10.1016/j. jpba.2005.12.022.
(218)S. Mohammadzadeh, M. Shariatpanahi, M. Hamedi, R. Ahmadkhaniha, N. Samadi, S.N. Ostad, Chemical composition, oral  toxicity and  antimicrobial activity of Iranian propolis, Food  Chemistry 103  (4)  (2007) 1097–1103, https:// doi.org/10.1016/j.foodchem.2006.10.006.
(219)J. Dobrowolski, S. Vohora, K. Sharma, S. Shah, S. Naqvi, P. Dandiya, Antibacterial, Antifungal, Antiamoebic, Antiinflammatory and  Antipyretic Studies on  Propolis Bee Products, J Ethnopharmacol 35  (1)  (1991) 77–82, https://doi.org/10.1016/0378-8741(91)90135-Z.
(220)F. Mani, H.C. Damasceno, E.L. Novelli, E.A. Martins, J.M.  Sforcin, Propolis: Effect of different concentrations, extracts and  intake period on  seric  biochemical variables, J Ethnopharmacol 105  (1–2) (2006) 95–98, https://doi.org/10.1016/j. jep.2005.10.011.
(221)J.M.  Senedese, A.R. Rodrigues, M.A. Furtado, V.D. Faustino, A.A. Berretta, J. M. Marchetti, D.C. Tavares, Assessment of the  mutagenic activity of extracts of brazilian propolis in topical pharmaceutical formulations on  Mammalian cells  in vitro and  in vivo,  Evid  Based  Complement Alternat Med  2011 (2011) 315701, https://doi.org/10.1093/ecam/nen049.
(222)D.C. Tavares, G.R. Mazzaron Barcelos, L.F. Silva,  C.C. Chacon Tonin, J.K. Bastos, Propolis-induced genotoxicity and  antigenotoxicity in Chinese hamster ovary cells,  Toxicol In Vitro  20  (7)  (2006) 1154–1158, https://doi.org/10.1016/j. tiv.2006.02.009.
(223)C.M.F.  Reis,  J.C.T.  Carvalho, L.R.G. Caputo, K.C.M. Patricio, M.V.J.  Barbosa, A. L. Chieff,  J.K. Bastos, Atividade antiinflamato´ria, antiúlcera ga´strica e toxicidade subcroˆnica do extrato etano´lico de pro´polis, Rev Bras Farmacogn 9-10  (1)  (2000) 43–52, https://doi.org/10.1590/S0102-695X2000000100005.
(224)H.A. Cohen, I. Varsano, E. Kahan, E.M. Sarrell, Y. Uziel,  Effectiveness of an herbal preparation containing echinacea, propolis, and  vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo- controlled, multicenter study, Arch Pediatr Adolesc Med 158  (3) (2004) 217–221, https://doi.org/10.1001/archpedi.158.3.217.
(225)L. Soroy, S. Bagus, I.P.  Yongkie, W. Djoko, The  effect of a unique propolis compound (PropoelixTM) on  clinical outcomes in patients with dengue hemorrhagic fever, Infect Drug  Resist  7 (2014) 323–329, https://doi.org/10.2147/IDR.S71505.
(226)M. Lotfy,  Biological activity of bee  propolis in health and  disease, Asian  Pac  J Cancer Prev  7 (1)  (2006) 22–31.
(227)C.E. Finch, Evolution in health and  medicine Sackler colloquium: Evolution of the human lifespan and  diseases of aging: roles of infection, inflammation, and nutrition, Proc  Natl  Acad  Sci U S A 107  (Suppl 1) (2010) 1718–1724, https://doi. org/10.1073/pnas.0909606106.
(228)M.R. Ahn,  K. Kunimasa, T. Ohta, S. Kumazawa, M. Kamihira, K. Kaji,  Y. Uto, H. Hori, H. Nagasawa, T. Nakayama, Suppression of tumor-induced angiogenesis by Brazilian propolis: major component artepillin C inhibits in vitro tube formation and  endothelial cell proliferation, Cancer Lett 252  (2) (2007) 235–243, https://doi.org/10.1016/j.canlet.2006.12.039.
(229)E. Szliszka, G. Zydowicz, B. Janoszka, C. Dobosz, G. Kowalczyk-Ziomek, W. Krol, Ethanolic extract of Brazilian green propolis sensitizes prostate cancer cells  to TRAIL-induced apoptosis, Int  J Oncol 38  (4)  (2011) 941–953, https://doi.org/10.3892/ijo.2011.930.
(230)M.-h.  Chuang, C.-y.  Peng, C.-y.  Chi,  H.-y.  Chung, C.-t.  Liu, H.-c.  Kuo,  Device method of making artepillin c in propolis for  anti-cancer, U.-M.B.  Technology, United States, 2016. https://patents.google.com/patent/US20170226042A1/en.
(231)C.K. Ferrari, Functional foods, herbs and  nutraceuticals: towards biochemical mechanisms of healthy aging, Biogerontology 5 (5)  (2004) 275–289, https://doi. org/10.1007/s10522-004-2566-z.
(232)D. Bachevski, K. Damevska, V. Simeonovski, M. Dimova, Back  to  the  basics: Propolis and  COVID-19,  Dermatol Ther  2020 (2020), e13780, https://doi.org/10.1111/dth.13780.
(233)J.M.  Sforcin, Propolis and  the  immune system: a review, J Ethnopharmacol 113 (1)  (2007) 1–14, https://doi.org/10.1016/j.jep.2007.05.012.
(234)A. Salatino, C.C. Fernandes-Silva, A.A. Righi, M.L. Salatino, Propolis research and the  chemistry of plant products, Nat  Prod Rep  28  (5)  (2011) 925–936, https:// doi.org/10.1039/c0np00072h.
(235)I.C.G. de  Mendonça, I.C.C.d.M. Porto, T.G. do  Nascimento, N.S. de  Souza, J.M.d.S. Oliveira, R.E.d.S.  Arruda, K.C. Mousinho, A.F. dos  Santos, I.D. Basílio-Júnior, A. Parolia, F.S. Barreto, Brazilian red  propolis: phytochemical screening, antioxidant activity and  effect against cancer cells,  BMC Complem Altern Med 15 (2015) 357, https://doi.org/10.1186/s12906-015-0888-9.
(236)C. Magro, J.J. Mulvey, D. Berlin, G. Nuovo, S. Salvatore, J. Harp, A. Baxter- Stoltzfus, J. Laurence, Complement associated microvascular injury and thrombosis in the  pathogenesis of severe COVID-19  infection: a report of five cases, Transl Res 220  (2020) 1–13, https://doi.org/10.1016/j.trsl.2020.04.007.
(237)A. Porfidia, R. Pola, Venous thromboembolism  and  heparin use  in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and  the  lack  of guidelines, J Thromb Thrombolysis 50 (2020) 68–71, https://doi. org/10.1007/s11239-020-02125-4.
(238)[238]  S. Schwarz, D. Sauter, K. Wang, R. Zhang, B. Sun,  A. Karioti, A.R. Bilia,  T. Efferth, W. Schwarz, Kaempferol derivatives as antiviral drugs against the  3a  channel protein of coronavirus, Planta Med  80  (2-3) (2014) 177–182, https://doi.org/10.1055/s-0033-1360277.
(239)L. Yang,  Y.-T. Li, J. Miao, L. Wang, H. Fu,  Q. Li, W.-B. Wen,  Z.-Y. Zhang, R.-W. Song,  X.-G. Liu, H.-W. Wang, H.-T. Cui, Network pharmacology studies on the effect of Chai-Ling decoction in coronavirus disease 2019, Traditional Medicine Research 5 (3)  (2020) 145, https://doi.org/10.12032/TMR20200324170.
(240)C.W. Lin,  F.J.  Tsai,  C.H.  Tsai,  C.C. Lai, L. Wan,  T.Y. Ho,  C.C. Hsieh, P.D.  Chao, Anti-SARS  coronavirus 3C-like protease effects of Isatis  indigotica root and  plant- derived phenolic compounds, Antiviral Res 68 (1)  (2005) 36–42, https://doi.org/10.1016/j.antiviral.2005.07.002.
(241)Z. Wu,  Y. Liu, A. Zhu,  S. Wu,  H. Nakanishia, Brazilian green propolis suppresses microglia-mediated neuroinflammation by inhibiting NF-kB activation, J Neurol Sci 381  (2017), https://doi.org/10.1016/j.jns.2017.08.1910.
(242)T. Adachi, H. Tezuka, N.M.  Tsuji,  T. Ohteki, H. Karasuyama, T. Kumazawa, Propolis induces Ca2+ signaling in immune cells,  Biosci  Microbiota Food  Health 38  (4)  (2019) 141, https://doi.org/10.12938/bmfh.19-011.
(243)L.B. Sy, Y.L. Wu,  B.L. Chiang, Y.H. Wang, W.M.  Wu,  Propolis extracts exhibit an immunoregulatory activity in an  OVA-sensitized airway inflammatory animal model, Int Immunopharmacol 6 (7) (2006) 1053–1060, https://doi.org/10.1016/ j.intimp.2006.01.015.
(244)E. Szliszka, A.Z. Kucharska, A. Sokol-Letowska, A. Mertas, Z.P. Czuba, W. Krol, Chemical Composition and  Anti-Inflammatory Effect  of Ethanolic Extract of Brazilian Green Propolis on  Activated J774A.1 Macrophages, Evid  Based Complement Alternat Med  2013 (2013) 976415, https://doi.org/10.1155/2013/976415.
(245)J. Shvarzbeyn, M. Huleihel, Effect  of propolis and  caffeic acid  phenethyl ester (CAPE)  on  NFkappaB activation by  HTLV-1 Tax,  Antiviral Res 90  (3)  (2011) 108–115, https://doi.org/10.1016/j.antiviral.2011.03.177.
(246)Z.H. Shi,  N.G.  Li, Y.P. Tang, L. Wei,  Y. Lian,  J.P.  Yang,  T. Hao,  J.A.  Duan, Metabolism-based synthesis, biologic evaluation and  SARs analysis of O- methylated analogs of quercetin as thrombin inhibitors, Eur  J Med  Chem 54 (2012) 210–222, https://doi.org/10.1016/j.ejmech.2012.04.044.
(247)F.J.  Tsai,  C.W. Lin, C.C. Lai, Y.C. Lan,  C.H. Lai, C.H. Hung, K.C. Hsueh, T.H.  Lin, H.C.  Chang, L. Wan,  J.J. Sheu, Y.J.  Lin,  Kaempferol inhibits enterovirus 71 replication and  internal ribosome entry site  (IRES)  activity through FUBP and HNRP  proteins, Food  Chem 128  (2)  (2011) 312–322, https://doi.org/10.1016/j. foodchem.2011.03.022.
(248)B.S. Min,  M. Tomiyama, C.M. Ma,  N. Nakamura, M. Hattori, Kaempferol acetylrhamnosides from  the  rhizome of Dryopteris  crassirhizoma and  their inhibitory effects on three different activities of human immunodeficiency virus-1 reverse transcriptase, Chem Pharm Bull (Tokyo). 49 (5)  (2001) 546–550, https:// doi.org/10.1248/cpb.49.546.
(249)M. Behbahani, S. Sayedipour, A. Pourazar, M. Shanehsazzadeh, In vitro anti-HIV-1 activities of kaempferol and  kaempferol-7-O-glucoside isolated from  Securigera securidaca, Res Pharm Sci 9 (6)  (2014) 463–469.
(250)S. Ganesan, A.N. Faris, A.T. Comstock, Q. Wang, S. Nanua, M.B. Hershenson, U.S. Sajjan, Quercetin inhibits rhinovirus replication in vitro and  in vivo,  Antiviral Res 94  (3)  (2012) 258–271, https://doi.org/10.1016/j.antiviral.2012.03.005.

(251)A. Rojas, J.A.  Del Campo, S. Clement, M. Lemasson, M. Garcia-Valdecasas, A. Gil- Gomez, I. Ranchal, B. Bartosch, J.D.  Bautista, A.R. Rosenberg, F. Negro, M. Romero-Gomez, Effect  of Quercetin on Hepatitis C Virus  Life Cycle: From Viral to  Host  Targets, Sci Rep  6 (2016) 31777, https://doi.org/10.1038/srep31777. 
(252)Z. Cheng, G. Sun,  W. Guo,  Y. Huang, W. Sun,  F. Zhao, K. Hu,  Inhibition of hepatitis B virus replication by quercetin in human hepatoma cell  lines, Virol  Sin 30  (4)  (2015) 261–268, https://doi.org/10.1007/s12250-015-3584-5.
(253)G.F. Wang, L.P. Shi,  Y.D. Ren,  Q.F.  Liu, H.F.  Liu,  R.J.  Zhang, Z. Li, F.H.  Zhu,  P. L. He, W. Tang, P.Z. Tao, C. Li, W.M. Zhao, J.P.  Zuo, Anti-hepatitis B virus activity of chlorogenic acid, quinic acid  and  caffeic acid  in vivo  and  in vitro, Antiviral Res 83  (2)  (2009) 186–190, https://doi.org/10.1016/j.antiviral.2009.05.002.

(254)H. Utsunomiya, M. Ichinose, K. Ikeda, M. Uozaki, J. Morishita, T. Kuwahara,  A. H. Koyama, H. Yamasaki, Inhibition by  caffeic acid  of the  influenza A virus multiplication in vitro, Int  J Mol Med  34  (4)  (2014) 1020–1024, https://doi.org/ 10.3892/ijmm.2014.1859.
(255)Y. Xie, B. Huang, K. Yu, F. Shi, T. Liu, W. Xu, Caffeic  acid  derivatives: a new  type of influenza neuraminidase inhibitors, Bioorg Med  Chem Lett  23  (12) (2013) 3556–3560, https://doi.org/10.1016/j.bmcl.2013.04.033.
(256)M.R. Fesen, Y. Pommier, F. Leteurtre, S. Hiroguchi, J. Yung,  K.W. Kohn, Inhibition of HIV-1 integrase by flavones, caffeic acid  phenethyl ester (CAPE) and related compounds, Biochem Pharmacol 48 (3)  (1994) 595–608, https://doi.org/10.1016/0006-2952(94)90291-7. 
(257)Marrero-Ponce, Y.; González-Díaz, H.; Romero-Zaldivar, V.; Torrens, F.; Castro, E. A. 3DChiral Quadratic Indices of the “Molecular Pseudograph’s Atom Adjacency Matrix” and their Application to Central Chirality Codification: Classification of ACE Inhibitors and Prediction of Receptor Antagonist Activities. Bioorg. Med. Chem. 2004, 12, 5331-5342. DOI: 10.1016/j.bmc.2004.07.051, ISSN: 0968-0896, IF: 3.205 
(258)Marrero-Ponce, Y. Linear Indices of the “Molecular Pseudograph’s Atom Adjacency Matrix”: Definition, Significance-Interpretation and Application to QSAR Analysis of Flavone Derivatives as HIV-1 Integrase Inhibitors. J. Chem. Inf. Comput. Sci. 2004, 44, 2010-2026. DOI: 10.1021/ci049950k, ISSN: 1549-9596 and IF: 4.068. 
(259)Marrero-Ponce, Y.; Castillo-Garit, J. A.; Torrens, F.; Romero-Zaldivar, V.; Castro, E. Atom, Atom-Type and Total Linear Indices of the “Molecular Pseudograph’s Atom Adjacency Matrix”: Application to QSPR/QSAR Studies of Organic Compounds. Molecules. 2004, 9, 1100-1123. DOI: 10.3390/91201100, ISSN: 1420-3049, IF: 2.638, City: Basel, Country: Switzerland and URL: http://www.mdpi.com/journal/molecules 
(260)Simon-Vidal, L., et al., Perturbation-Theory and Machine Learning (PTML) Model for High-Throughput Screening of Parham Reactions: Experimental and Theoretical Studies. J Chem Inf Model, 2018. 58(7): p. 1384-1396.
(261)Quevedo-Tumailli, V.F., B. Ortega-Tenezaca, and H. Gonzalez-Diaz, Chromosome Gene Orientation Inversion Networks (GOINs) of Plasmodium Proteome. J Proteome Res, 2018. 17(3): p. 1258-1268.
(262)Meneses-Marcel, A., et al., Drug repositioning for novel antitrichomonas from known antiprotozoan drugs using hierarchical screening. Future Med Chem, 2018. 10(8): p. 863-878.
(263)Fiandaca, M.S., R. Gonzalez-Dominguez, and H. Gonzalez-Diaz, New Experimental and Computational Tools for Drug Discovery: From Chemistry to Biology. Metabolomics, Pharmacokinetics, and Medicinal Chemistry. Part - IV. Curr Top Med Chem, 2018. 18(11): p. 881-882.
(264)Marrero-Ponce, Y. Total and Local (Atom and Atom-Type) Molecular Quadratic Indices: Significance-Interpretation, Comparison to Other Molecular Descriptors and QSPR/QSAR Applications. Bioorg. Med. Chem. 2004, 12, 6351-6369. DOI: 10.1016/j.bmc.2004.09.034, ISSN: 0968-0896 and IF: 3.205. 
(265)Marrero-Ponce, Y.; Nodarse, D.; González-Díaz, H.; Ramos de Armas, R.; Romero-Zaldivar, V.; Torrens, F.; Castro, E. Nucleic Acid Quadratic Indices of the “Macromolecular Graph’s Nucleotides Adjacency Matrix”. Modeling of Footprints after the Interaction of Paromomycin with the HIV-1 -RNA Packaging Region. Int. J. Mol. Sci. 2004, 5, 276-293 (see also CPS: physchem/0401004.) DOI: 10.3390/i5110276, ISSN: 1422-0067, IF: 2.721, City: Basel, Country: Switzerland and URL: http://www.mdpi.com/journal/ijms. 
(266)Cabrera-Perez, M.A. and H. Pham-The, Computational modeling of human oral bioavailability: what will be next? Expert Opin Drug Discov, 2018. 13(6): p. 509-521.
(267)Vazquez-Prieto, S., et al., A study of the Immune Epitope Database for some fungi species using network topological indices. Mol Divers, 2017. 21(3): p. 713-718.
(268)Martinez-Santiago, O., et al., Exploring the QSAR's predictive truthfulness of the novel N-tuple discrete derivative indices on benchmark datasets. SAR QSAR Environ Res, 2017. 28(5): p. 367-389.
(269)Martinez-Arzate, S.G., et al., PTML Model for Proteome Mining of B-Cell Epitopes and Theoretical-Experimental Study of Bm86 Protein Sequences from Colima, Mexico. J Proteome Res, 2017. 16(11): p. 4093-4103.
(270)Estrada, E., et al., Effects of reduced glutathione on acrosin activity in frozen-thawed boar spermatozoa. Reprod Fertil Dev, 2017. 29(2): p. 283-293.
(271)Estrada, E., et al., The addition of reduced glutathione to cryopreservation media induces changes in the structure of motile subpopulations of frozen-thawed boar sperm. Cryobiology, 2017. 78: p. 56-64.
(272)Aguilera-Mendoza, L., et al., Overlap and diversity in antimicrobial peptide databases: compiling a non-redundant set of sequences. Bioinformatics, 2015. 31(15): p. 2553-9.
(273)Yeste, M., et al., The increase in phosphorylation levels of serine residues of protein HSP70 during holding time at 17 degrees C is concomitant with a higher cryotolerance of boar spermatozoa. PLoS One, 2014. 9(3): p. e90887.
(274)Yeste, M., et al., The improving effect of reduced glutathione on boar sperm cryotolerance is related with the intrinsic ejaculate freezability. Cryobiology, 2014. 68(2): p. 251-61.
(275)Vergara-Galicia, J., F.J. Prado-Prado, and H. Gonzalez-Diaz, Galvez-Markov network transferability indices: review of classic theory and new model for perturbations in metabolic reactions. Curr Drug Metab, 2014. 15(5): p. 557-64.
(276)Vazquez-Prieto, S., et al., A QSPR-like model for multilocus genotype networks of Fasciola hepatica in Northwest Spain. J Theor Biol, 2014. 343: p. 16-24.
(277)Tenorio-Borroto, E., et al., QSPR and flow cytometry analysis (QSPR-FCA): review and new findings on parallel study of multiple interactions of chemical compounds with immune cellular and molecular targets. Curr Drug Metab, 2014. 15(4): p. 414-28.
(278)Tenorio-Borroto, E., et al., Model for high-throughput screening of drug immunotoxicity--study of the anti-microbial G1 over peritoneal macrophages using flow cytometry. Eur J Med Chem, 2014. 72: p. 206-20.
(279)Romero Duran, F.J., et al., Prediction of multi-target networks of neuroprotective compounds with entropy indices and synthesis, assay, and theoretical study of new asymmetric 1,2-rasagiline carbamates. Int J Mol Sci, 2014. 15(9): p. 17035-64.
(280)Ramirez-Garzon, Y.T., et al., Measurement of radiation exposure in relatives of thyroid cancer patients treated with (131)I. Health Phys, 2014. 107(5): p. 410-6.
(281)Ramio-Lluch, L., et al., Oligomycin A-induced inhibition of mitochondrial ATP-synthase activity suppresses boar sperm motility and in vitro capacitation achievement without modifying overall sperm energy levels. Reprod Fertil Dev, 2014. 26(6): p. 883-97.
(282)Perez-Castillo, Y., et al., Toward the computer-aided discovery of FabH inhibitors. Do predictive QSAR models ensure high quality virtual screening performance? Mol Divers, 2014. 18(3): p. 637-54.
(283)Najem, C., et al., An unusual case of hematuria. Arthritis Care Res (Hoboken), 2014. 66(7): p. 1119-26.
(284)Munteanu, C.R., et al., LECTINPred: web Server that Uses Complex Networks of Protein Structure for Prediction of Lectins with Potential Use as Cancer Biomarkers or in Parasite Vaccine Design. Mol Inform, 2014. 33(4): p. 276-85.
(285)Martins Alho, M.A., et al., Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones. Bioorg Med Chem, 2014. 22(5): p. 1568-85.
(286)Martinez-Santiago, O., et al., Discrete Derivatives for Atom-Pairs as a Novel Graph-Theoretical Invariant for Generating New Molecular Descriptors: Orthogonality, Interpretation and QSARs/QSPRs on Benchmark Databases. Mol Inform, 2014. 33(5): p. 343-68.
(287)Martinez-Santiago, O., et al., Discrete Derivatives for Atom-Pairs as a Novel Graph-Theoretical Invariant for Generating New Molecular Descriptors: Orthogonality, Interpretation and QSARs/QSPRs on Benchmark Databases. Mol Inform, 2014. 33(5): p. 343-68.
(288)Luan, F., et al., Computer-aided nanotoxicology: assessing cytotoxicity of nanoparticles under diverse experimental conditions by using a novel QSTR-perturbation approach. Nanoscale, 2014. 6(18): p. 10623-30.
(289)Le-Thi-Thu, H., et al., A rational workflow for sequential virtual screening of chemical libraries on searching for new tyrosinase inhibitors. Curr Top Med Chem, 2014. 14(12): p. 1473-85.
(290)Kleandrova, V.V., et al., Computational tool for risk assessment of nanomaterials: novel QSTR-perturbation model for simultaneous prediction of ecotoxicity and cytotoxicity of uncoated and coated nanoparticles under multiple experimental conditions. Environ Sci Technol, 2014. 48(24): p. 14686-94.
(291)Kleandrova, V.V., et al., Computational ecotoxicology: simultaneous prediction of ecotoxic effects of nanoparticles under different experimental conditions. Environ Int, 2014. 73: p. 288-94.
(292)Ibanez-Escribano, A., et al., A sequential procedure for rapid and accurate identification of putative trichomonacidal agents. J Microbiol Methods, 2014. 105: p. 162-7.
(293)Haemer, M.A., et al., Addressing prediabetes in childhood obesity treatment programs: support from research and current practice. Child Obes, 2014. 10(4): p. 292-303.
(294)Gonzalez-Diaz, H., A. Speck-Planche, and M.N. Cordeiro, Editorial: Chemoinformatics in metabolomics, modeling chemical reactivity and ADMET processes part 1. Curr Drug Metab, 2014. 15(4): p. 345.
(295)Gonzalez-Diaz, H., A. Speck-Planche, and M.N. Cordeiro, Chemoinformatics in metabolomics, from molecular mechanics, dynamics, and docking to complex metabolic networks, part 2. Curr Drug Metab, 2014. 15(5): p. 489.
(296)Gonzalez-Diaz, H., L.G. Perez-Montoto, and F.M. Ubeira, Model for vaccine design by prediction of B-epitopes of IEDB given perturbations in peptide sequence, in vivo process, experimental techniques, and source or host organisms. J Immunol Res, 2014. 2014: p. 768515.
(297)Garcia-Jacas, C.R., et al., QuBiLS-MIDAS: a parallel free-software for molecular descriptors computation based on multilinear algebraic maps. J Comput Chem, 2014. 35(18): p. 1395-409.
(298)Garcia-Fuentes, M., H. Gonzalez-Diaz, and N. Csaba, Nanocarriers & drug delivery: rational design and applications. Curr Top Med Chem, 2014. 14(9): p. 1095-6.
(299)Fernandez-Lozano, C., et al., Markov mean properties for cell death-related protein classification. J Theor Biol, 2014. 349: p. 12-21.
(300)Estrada Espinosa, J.C., S.A. Martinez Ovalle, and C.K. Pereira Benavides, Dosimetric algorithm to reproduce isodose curves obtained from a LINAC. Comput Math Methods Med, 2014. 2014: p. 849505.
(301)Estrada, E., et al., Supplementing cryopreservation media with reduced glutathione increases fertility and prolificacy of sows inseminated with frozen-thawed boar semen. Andrology, 2014. 2(1): p. 88-99.
(302)Estrada, E. and J. Gomez-Gardenes, Communicability reveals a transition to coordinated behavior in multiplex networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2014. 89(4): p. 042819.
(303)Estrada, E., et al., Children's Hospital Association consensus statements for comorbidities of childhood obesity. Child Obes, 2014. 10(4): p. 304-17.
(304)Estrada, E. and M. Benzi, Walk-based measure of balance in signed networks: detecting lack of balance in social networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2014. 90(4): p. 042802.
(305)Duardo-Sanchez, A., et al., Modeling complex metabolic reactions, ecological systems, and financial and legal networks with MIANN models based on Markov-Wiener node descriptors. J Chem Inf Model, 2014. 54(1): p. 16-29.
(306)Casanola-Martin, G.M., et al., Tyrosinase enzyme: 1. An overview on a pharmacological target. Curr Top Med Chem, 2014. 14(12): p. 1494-501.
(307)Barigye, S.J., et al., Trends in information theory-based chemical structure codification. Mol Divers, 2014. 18(3): p. 673-86.
(308)Yeste, M., et al., Reduced glutathione and procaine hydrochloride protect the nucleoprotein structure of boar spermatozoa during freeze-thawing by stabilising disulfide bonds. Reprod Fertil Dev, 2013. 25(7): p. 1036-50.
(309)Yeste, M., et al., Good and bad freezability boar ejaculates differ in the integrity of nucleoprotein structure after freeze-thawing but not in ROS levels. Theriogenology, 2013. 79(6): p. 929-39.
(310)Yang, Y., et al., Early inhibition of MMP activity in ischemic rat brain promotes expression of tight junction proteins and angiogenesis during recovery. J Cereb Blood Flow Metab, 2013. 33(7): p. 1104-14.
(311)Tenorio-Borroto, E., et al., Entropy model for multiplex drug-target interaction endpoints of drug immunotoxicity. Curr Top Med Chem, 2013. 13(14): p. 1636-49.
(312)Sobarzo-Sanchez, E., et al., Synthetic oxoisoaporphine alkaloids: in vitro, in vivo and in silico assessment of antileishmanial activities. PLoS One, 2013. 8(10): p. e77560.
(313)Ruiz-Blanco, Y.B., et al., Global stability of protein folding from an empirical free energy function. J Theor Biol, 2013. 321: p. 44-53.
(314)Ruiz-Blanco, Y.B., et al., Global stability of protein folding from an empirical free energy function. J Theor Biol, 2013. 321: p. 44-53.
(315)Rivera, N., et al., In vivo genotoxicity and cytotoxicity assessment of a novel quinoxalinone with trichomonacide activity. J Appl Toxicol, 2013. 33(12): p. 1493-9.
(316)Prado-Prado, F., et al., Patents of bio-active compounds based on computer-aided drug discovery techniques. Front Biosci (Elite Ed), 2013. 5: p. 399-407.
(317)Pham-The, H., et al., The Use of Rule-Based and QSPR Approaches in ADME Profiling: A Case Study on Caco-2 Permeability. Mol Inform, 2013. 32(5-6): p. 459-79.
(318)Pham-The, H., et al., Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number. Mol Pharm, 2013. 10(6): p. 2445-61.
(319)Luan, F., et al., TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases. Bioorg Med Chem, 2013. 21(7): p. 1870-9.
(320)Han, P., et al., Reduction of nutrient contaminants into shallow eutrophic waters through vegetated treatment beds. Water Sci Technol, 2013. 68(6): p. 1280-7.
(321)Gonzalez-Diaz, H., et al., The Rucker-Markov invariants of complex Bio-Systems: applications in Parasitology and Neuroinformatics. Biosystems, 2013. 111(3): p. 199-207.
(322)Gonzalez-Diaz, H., et al., MIANN models in medicinal, physical and organic chemistry. Curr Top Med Chem, 2013. 13(5): p. 619-41.
(323)Gonzalez-Diaz, H., et al., General theory for multiple input-output perturbations in complex molecular systems. 1. Linear QSPR electronegativity models in physical, organic, and medicinal chemistry. Curr Top Med Chem, 2013. 13(14): p. 1713-41.
(324)Gonzalez-Diaz, H., Computational prediction of drug-target interactions in medicinal chemistry. Curr Top Med Chem, 2013. 13(14): p. 1619-21.
(325)Estrada, E. and E. Vargas-Estrada, How peer pressure shapes consensus, leadership, and innovations in social groups. Sci Rep, 2013. 3: p. 2905.
(326)Estrada, E., Communicability in temporal networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2013. 88(4): p. 042811.
(327)Duardo-Sanchez, A. and H. Gonzalez-Diaz, Legal issues for chem-bioinformatics models. Front Biosci (Elite Ed), 2013. 5: p. 361-74.
(328)Castillo-Gonzalez, D., et al., FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA. Curr Pharm Des, 2013. 19(12): p. 2164-73.
(329)Brito-Sanchez, Y., et al., Comparative study to predict toxic modes of action of phenols from molecular structures. SAR QSAR Environ Res, 2013. 24(3): p. 235-51.
(330)Barigye, S.J., et al., Shannon's, mutual, conditional and joint entropy information indices: generalization of global indices defined from local vertex invariants. Curr Comput Aided Drug Des, 2013. 9(2): p. 164-83.
(331)Barigye, S.J., et al., Shannon's, mutual, conditional and joint entropy information indices: generalization of global indices defined from local vertex invariants. Curr Comput Aided Drug Des, 2013. 9(2): p. 164-83.
(332)Barigye, S.J., et al., Relations frequency hypermatrices in mutual, conditional and joint entropy-based information indices. J Comput Chem, 2013. 34(4): p. 259-74.
(333)Barigye, S.J., et al., Event-based criteria in GT-STAF information indices: theory, exploratory diversity analysis and QSPR applications. SAR QSAR Environ Res, 2013. 24(1): p. 3-34.
(334)Barigye, S.J., et al., Event-based criteria in GT-STAF information indices: theory, exploratory diversity analysis and QSPR applications. SAR QSAR Environ Res, 2013. 24(1): p. 3-34.
(335)Alvarez-Ginarte, Y.M., et al., Integration of ligand and structure-based virtual screening for identification of leading anabolic steroids. J Steroid Biochem Mol Biol, 2013. 138: p. 348-58.
(336)Alonso, N., et al., Model for high-throughput screening of multitarget drugs in chemical neurosciences: synthesis, assay, and theoretic study of rasagiline carbamates. ACS Chem Neurosci, 2013. 4(10): p. 1393-403.
(337)Vega, M.C., et al., Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug. Eur J Med Chem, 2012. 58: p. 214-27.
(338)Tenorio-Borroto, E., et al., Immunotoxicity, flow cytometry, and chemoinformatics: review, bibliometric analysis, and new QSAR model of drug effects over macrophages. Curr Top Med Chem, 2012. 12(16): p. 1815-33.
(339)Tenorio-Borroto, E., et al., ANN multiplexing model of drugs effect on macrophages; theoretical and flow cytometry study on the cytotoxicity of the anti-microbial drug G1 in spleen. Bioorg Med Chem, 2012. 20(20): p. 6181-94.
(340)Rivera-Borroto, O.M., et al., Dunn's index for cluster tendency assessment of pharmacological data sets. Can J Physiol Pharmacol, 2012. 90(4): p. 425-33.
(341)Riera-Fernandez, P., et al., New Markov-Shannon Entropy models to assess connectivity quality in complex networks: from molecular to cellular pathway, Parasite-Host, Neural, Industry, and Legal-Social networks. J Theor Biol, 2012. 293: p. 174-88.
(342)Riera-Fernandez, P., et al., From QSAR models of drugs to complex networks: state-of-art review and introduction of new Markov-spectral moments indices. Curr Top Med Chem, 2012. 12(8): p. 927-60.
(343)Prado-Prado, F., et al., 3D MI-DRAGON: new model for the reconstruction of US FDA drug- target network and theoretical-experimental studies of inhibitors of rasagiline derivatives for AChE. Curr Top Med Chem, 2012. 12(16): p. 1843-65.
(344)Perez-Castillo, Y., et al., GA(M)E-QSAR: a novel, fully automatic genetic-algorithm-(meta)-ensembles approach for binary classification in ligand-based drug design. J Chem Inf Model, 2012. 52(9): p. 2366-86.
(345)Morera, C., et al., Contralateral hearing aid use in cochlear implanted patients: multicenter study of bimodal benefit. Acta Otolaryngol, 2012. 132(10): p. 1084-94.
(346)Marrero-Ponce, Y., et al., Derivatives in discrete mathematics: a novel graph-theoretical invariant for generating new 2/3D molecular descriptors. I. Theory and QSPR application. J Comput Aided Mol Des, 2012. 26(11): p. 1229-46.
(347)Jacob, J.C., et al., Coronary artery dissection in Prader-Willi syndrome: case report and literature review. Can J Cardiol, 2012. 28(6): p. 759 e9-759 e11.
(348)Gonzalez-Diaz, H. and P. Riera-Fernandez, New Markov-autocorrelation indices for re-evaluation of links in chemical and biological complex networks used in metabolomics, parasitology, neurosciences, and epidemiology. J Chem Inf Model, 2012. 52(12): p. 3331-40.
(349)Gonzalez-Diaz, H., et al., LIBP-Pred: web server for lipid binding proteins using structural network parameters; PDB mining of human cancer biomarkers and drug targets in parasites and bacteria. Mol Biosyst, 2012. 8(3): p. 851-62.
(350)Gonzalez-Diaz, H., Editorial: QSAR/QSPR models as enabling technologies for drug & targets discovery in: medicinal chemistry, microbiology-parasitology, neurosciences, bioinformatics, proteomics and other biomedical sciences. Curr Top Med Chem, 2012. 12(8): p. 799-801.
(351)Estrada, E., Complex networks in the Euclidean space of communicability distances. Phys Rev E Stat Nonlin Soft Matter Phys, 2012. 85(6 Pt 2): p. 066122.
(352)Estrada, E., Complex biomolecular networks: challenges and opportunities. Brief Funct Genomics, 2012. 11(6): p. 417-9.
(353)Diaz-Molina, J.P., et al., Functional and oncological results of non-surgical vs surgical treatment in squamous cell carcinomas of the oropharynx. Acta Otorrinolaringol Esp, 2012. 63(5): p. 348-54.
(354)Castillo-Gonzalez, D., et al., Computational tools in the discovery of new G-quadruplex ligands with potential anticancer activity. Curr Top Med Chem, 2012. 12(24): p. 2843-56.
(355)Castillo-Garit, J.A., et al., Identification in silico and in vitro of novel trypanosomicidal drug-like compounds. Chem Biol Drug Des, 2012. 80(1): p. 38-45.
(356)Castillo-Garit, J.A., et al., A review of QSAR studies to discover new drug-like compounds actives against leishmaniasis and trypanosomiasis. Curr Top Med Chem, 2012. 12(8): p. 852-65.
(357)Cabrera-Perez, M.A., et al., QSPR in oral bioavailability: specificity or integrality? Mini Rev Med Chem, 2012. 12(6): p. 534-50.
(358)Aguiar-Pulido, V., et al., Naive Bayes QSDR classification based on spiral-graph Shannon entropies for protein biomarkers in human colon cancer. Mol Biosyst, 2012. 8(6): p. 1716-22.
(359)Saiz-Urra, L., et al., Combining molecular docking and QSAR studies for modelling the antigyrase activity of cyclothialidine derivatives. Eur J Med Chem, 2011. 46(7): p. 2736-47.
(360)Rivera-Borroto, O.M., et al., Comparison of combinatorial clustering methods on pharmacological data sets represented by machine learning-selected real molecular descriptors. J Chem Inf Model, 2011. 51(12): p. 3036-49.
(361)Rivera-Borroto, O.M., et al., Comparison of combinatorial clustering methods on pharmacological data sets represented by machine learning-selected real molecular descriptors. J Chem Inf Model, 2011. 51(12): p. 3036-49.
(362)Riera-Fernandez, P., et al., From chemical graphs in computer-aided drug design to general Markov-Galvez indices of drug-target, proteome, drug-parasitic disease, technological, and social-legal networks. Curr Comput Aided Drug Des, 2011. 7(4): p. 315-37.
(363)Rescigno, A., et al., Vanilloid derivatives as tyrosinase inhibitors driven by virtual screening-based QSAR models. Drug Test Anal, 2011. 3(3): p. 176-81.
(364)Prado-Prado, F., et al., 2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins. Eur J Med Chem, 2011. 46(12): p. 5838-51.
(365)Prado-Prado, F., et al., Using entropy of drug and protein graphs to predict FDA drug-target network: theoretic-experimental study of MAO inhibitors and hemoglobin peptides from Fasciola hepatica. Eur J Med Chem, 2011. 46(4): p. 1074-94.
(366)Phulwani, P., et al., Hereditary hypophosphatemic rickets with hypercalciuria and nephrolithiasis-identification of a novel SLC34A3/NaPi-IIc mutation. Am J Med Genet A, 2011. 155A(3): p. 626-33.
(367)Pham The, H., et al., In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, 2011. 30(4): p. 376-85.
(368)Perez-Castillo, Y., et al., Molecular dynamics and docking simulations as a proof of high flexibility in E. coli FabH and its relevance for accurate inhibitor modeling. J Comput Aided Mol Des, 2011. 25(4): p. 371-93.
(369)Moran, V.P., et al., Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba. MEDICC Rev, 2011. 13(1): p. 35-40.
(370)Marzaro, G., et al., Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. Eur J Med Chem, 2011. 46(6): p. 2185-92.
(371)Marrero-Ponce, Y., et al., Discovery of novel anti-inflammatory drug-like compounds by aligning in silico and in vivo screening: the nitroindazolinone chemotype. Eur J Med Chem, 2011. 46(12): p. 5736-53.
(372)Le-Thi-Thu, H., et al., A Comparative Study of Nonlinear Machine Learning for the "In Silico" Depiction of Tyrosinase Inhibitory Activity from Molecular Structure. Mol Inform, 2011. 30(6-7): p. 527-37.
(373)Le-Thi-Thu, H., et al., Novel coumarin-based tyrosinase inhibitors discovered by OECD principles-validated QSAR approach from an enlarged, balanced database. Mol Divers, 2011. 15(2): p. 507-20.
(374)Grindrod, P., et al., Communicability across evolving networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2011. 83(4 Pt 2): p. 046120.
(375)Gonzalez-Diaz, H., et al., NL MIND-BEST: a web server for ligands and proteins discovery--theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum. J Theor Biol, 2011. 276(1): p. 229-49.
(376)Gonzalez-Diaz, H., et al., MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae. J Proteome Res, 2011. 10(4): p. 1698-718.
(377)Gonzalez-Diaz, H., et al., MISS-Prot: web server for self/non-self discrimination of protein residue networks in parasites; theory and experiments in Fasciola peptides and Anisakis allergens. Mol Biosyst, 2011. 7(6): p. 1938-55.
(378)Gonzalez-Diaz, H., QSPR models for computer-aided drug design in microbiology, parasitology, and pharmacology. Curr Comput Aided Drug Des, 2011. 7(4): p. 228-30.
(379)Gonzalez, E.E., et al., Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. Invest New Drugs, 2011. 29(6): p. 1459-64.
(380)Garcia, I., et al., First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines. Mol Divers, 2011. 15(2): p. 561-7.
(381)Estrada, E., F. Kalala-Mutombo, and A. Valverde-Colmeiro, Epidemic spreading in networks with nonrandom long-range interactions. Phys Rev E Stat Nonlin Soft Matter Phys, 2011. 84(3 Pt 2): p. 036110.
(382)Estrada, E., Community detection based on network communicability. Chaos, 2011. 21(1): p. 016103.
(383)Estrada, E., Combinatorial study of degree assortativity in networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2011. 84(4 Pt 2): p. 047101.
(384)Concu, R., et al., Review of computer-aided models for predicting collagen stability. Curr Comput Aided Drug Des, 2011. 7(4): p. 287-303.
(385)Cetina, L., et al., F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma. Rev Invest Clin, 2011. 63(3): p. 227-35.
(386)Caumette, G., et al., Arsenic speciation in plankton organisms from contaminated lakes: transformations at the base of the freshwater food chain. Environ Sci Technol, 2011. 45(23): p. 9917-23.
(387)Castillo-Garit, J.A., et al., Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support. Eur J Med Chem, 2011. 46(8): p. 3324-30.
(388)Alvarez-Ginarte, Y.M., et al., Anabolic and androgenic activities of 19-nor-testosterone steroids: QSAR study using quantum and physicochemical molecular descriptors. J Steroid Biochem Mol Biol, 2011. 126(1-2): p. 35-45.
(389)Al-Solaiman, Y., E. Estrada, and M. Allon, The spectrum of infections in catheter-dependent hemodialysis patients. Clin J Am Soc Nephrol, 2011. 6(9): p. 2247-52.
(390)Yang, Y., et al., Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem, 2010. 112(1): p. 134-49.
(391)Savitskaya, Y.A., et al., Circulating Natural IgM Antibodies Against Angiogenin in the Peripheral Blood Sera of Patients with Osteosarcoma as Candidate Biomarkers and Reporters of Tumorigenesis. Biomark Cancer, 2010. 2: p. 65-78.
(392)Sanders, M.R., et al., Flexing to aging: a children's hospital responds to a maturing workforce. J Pediatr, 2010. 157(2): p. 177-178 e1.
(393)Rodriguez-Soca, Y., et al., Trypano-PPI: a web server for prediction of unique targets in trypanosome proteome by using electrostatic parameters of protein-protein interactions. J Proteome Res, 2010. 9(2): p. 1182-90.
(394)Prado-Prado, F.J., et al., Unified QSAR & network-based computational chemistry approach to antimicrobials. II. Multiple distance and triadic census analysis of antiparasitic drugs complex networks. J Comput Chem, 2010. 31(1): p. 164-73.
(395)Prado-Prado, F.J., X. Garcia-Mera, and H. Gonzalez-Diaz, Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg Med Chem, 2010. 18(6): p. 2225-2231.
(396)Palomares-Alonso, F., et al., Two novel ternary albendazole-cyclodextrin-polymer systems: dissolution, bioavailability and efficacy against Taenia crassiceps cysts. Acta Trop, 2010. 113(1): p. 56-60.
(397)Ortega-Broche, S.E., et al., TOMOCOMD-CAMPS and protein bilinear indices--novel bio-macromolecular descriptors for protein research: I. Predicting protein stability effects of a complete set of alanine substitutions in the Arc repressor. FEBS J, 2010. 277(15): p. 3118-46.
(398)Ortega-Broche, S.E., et al., TOMOCOMD-CAMPS and protein bilinear indices--novel bio-macromolecular descriptors for protein research: I. Predicting protein stability effects of a complete set of alanine substitutions in the Arc repressor. FEBS J, 2010. 277(15): p. 3118-46.
(399)Muriel, C., et al., Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. Clin Transl Oncol, 2010. 12(8): p. 562-7.
(400)Marrero-Ponce, Y., et al., Bond-based linear indices of the non-stochastic and stochastic edge-adjacency matrix. 1. Theory and modeling of ChemPhys properties of organic molecules. Mol Divers, 2010. 14(4): p. 731-53.
(401)Marrero-Ponce, Y., et al., Ligand-based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMD-CARDD method to the elucidation of new compounds. Curr Pharm Des, 2010. 16(24): p. 2601-24.
(402)Gonzalez-Diaz, H., et al., Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues. Curr Pharm Des, 2010. 16(24): p. 2737-64.
(403)Gonzalez-Diaz, H., et al., Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr Drug Metab, 2010. 11(4): p. 379-406.
(404)Gonzalez-Diaz, H., et al., QSAR for RNases and theoretic-experimental study of molecular diversity on peptide mass fingerprints of a new Leishmania infantum protein. Mol Divers, 2010. 14(2): p. 349-69.
(405)Gonzalez-Diaz, H., Network topological indices, drug metabolism, and distribution. Curr Drug Metab, 2010. 11(4): p. 283-4.
(406)Gonzalez-Diaz, H., QSAR and complex networks in pharmaceutical design, microbiology, parasitology, toxicology, cancer, and neurosciences. Curr Pharm Des, 2010. 16(24): p. 2598-600.
(407)Estrada, E., et al., Structural contributions of substrates to their binding to P-Glycoprotein. A TOPS-MODE approach. Curr Pharm Des, 2010. 16(24): p. 2676-709.
(408)Estrada, E., Generalized walks-based centrality measures for complex biological networks. J Theor Biol, 2010. 263(4): p. 556-65.
(409)Estrada, E., Universality in protein residue networks. Biophys J, 2010. 98(5): p. 890-900.
(410)Estrada, E., Randic index, irregularity and complex biomolecular networks. Acta Chim Slov, 2010. 57(3): p. 597-603.
(411)Estrada, E., Quantifying network heterogeneity. Phys Rev E Stat Nonlin Soft Matter Phys, 2010. 82(6 Pt 2): p. 066102.
(412)Concu, R., et al., Review of QSAR models for enzyme classes of drug targets: Theoretical background and applications in parasites, hosts, and other organisms. Curr Pharm Des, 2010. 16(24): p. 2710-23.
(413)Castillo-Garit, J.A., et al., Computational discovery of novel trypanosomicidal drug-like chemicals by using bond-based non-stochastic and stochastic quadratic maps and linear discriminant analysis. Eur J Pharm Sci, 2010. 39(1-3): p. 30-6.
(414)Castillo-Garit, J.A., et al., Computational discovery of novel trypanosomicidal drug-like chemicals by using bond-based non-stochastic and stochastic quadratic maps and linear discriminant analysis. Eur J Pharm Sci, 2010. 39(1-3): p. 30-6.
(415)Casanola-Martin, G.M., et al., Bond-based 2D quadratic fingerprints in QSAR studies: virtual and in vitro tyrosinase inhibitory activity elucidation. Chem Biol Drug Des, 2010. 76(6): p. 538-45.
(416)Anadon, A.M., et al., Diagnosing human anisakiasis: recombinant Ani s 1 and Ani s 7 allergens versus the UniCAP 100 fluorescence enzyme immunoassay. Clin Vaccine Immunol, 2010. 17(4): p. 496-502.
(417)Vina, D., et al., Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. Mol Pharm, 2009. 6(3): p. 825-35.
(418)Vilar, S., et al., A network-QSAR model for prediction of genetic-component biomarkers in human colorectal cancer. J Theor Biol, 2009. 261(3): p. 449-58.
(419)Taheri, S., et al., Spatiotemporal correlations between blood-brain barrier permeability and apparent diffusion coefficient in a rat model of ischemic stroke. PLoS One, 2009. 4(8): p. e6597.
(420)Sood, R., et al., Increased apparent diffusion coefficients on MRI linked with matrix metalloproteinases and edema in white matter after bilateral carotid artery occlusion in rats. J Cereb Blood Flow Metab, 2009. 29(2): p. 308-16.
(421)Prado-Prado, F.J., et al., Multi-target spectral moments for QSAR and Complex Networks study of antibacterial drugs. Eur J Med Chem, 2009. 44(11): p. 4516-21.
(422)Prado-Prado, F.J., et al., Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg Med Chem, 2009. 17(2): p. 569-75.
(423)Prado-Prado, F.J., et al., Multi-target spectral moment: QSAR for antiviral drugs vs. different viral species. Anal Chim Acta, 2009. 651(2): p. 159-64.
(424)Prado-Prado, F.J., et al., Multi-target spectral moment: QSAR for antifungal drugs vs. different fungi species. Eur J Med Chem, 2009. 44(10): p. 4051-6.
(425)Peterson, W.J., et al., Treatment of dialysis catheter-related Enterococcus bacteremia with an antibiotic lock: a quality improvement report. Am J Kidney Dis, 2009. 53(1): p. 107-11.
(426)Perez-Montoto, L.G., L. Santana, and H. Gonzalez-Diaz, Scoring function for DNA-drug docking of anticancer and antiparasitic compounds based on spectral moments of 2D lattice graphs for molecular dynamics trajectories. Eur J Med Chem, 2009. 44(11): p. 4461-9.
(427)Perez-Bello, A., et al., Alignment-free prediction of mycobacterial DNA promoters based on pseudo-folding lattice network or star-graph topological indices. J Theor Biol, 2009. 256(3): p. 458-66.
(428)Munteanu, C.R., et al., Complex network spectral moments for ATCUN motif DNA cleavage: first predictive study on proteins of human pathogen parasites. J Proteome Res, 2009. 8(11): p. 5219-28.
(429)Munteanu, C.R., et al., Multi-target QPDR classification model for human breast and colon cancer-related proteins using star graph topological indices. J Theor Biol, 2009. 257(2): p. 303-11.
(430)Marrero-Ponce, Y., et al., Nucleotide's bilinear indices: novel bio-macromolecular descriptors for bioinformatics studies of nucleic acids. I. Prediction of paromomycin's affinity constant with HIV-1 Psi-RNA packaging region. J Theor Biol, 2009. 259(2): p. 229-41.
(431)Marrero-Ponce, Y., et al., Nucleotide's bilinear indices: novel bio-macromolecular descriptors for bioinformatics studies of nucleic acids. I. Prediction of paromomycin's affinity constant with HIV-1 Psi-RNA packaging region. J Theor Biol, 2009. 259(2): p. 229-41.
(432)Gonzalez-Diaz, H., et al., Generalized lattice graphs for 2D-visualization of biological information. J Theor Biol, 2009. 261(1): p. 136-47.
(433)Garcia, I., et al., QSAR and complex network study of the chiral HMGR inhibitor structural diversity. Bioorg Med Chem, 2009. 17(1): p. 165-75.
(434)Estrada, E., Information mobility in complex networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2009. 80(2 Pt 2): p. 026104.
(435)Concu, R., et al., Computational chemistry study of 3D-structure-function relationships for enzymes based on Markov models for protein electrostatic, HINT, and van der Waals potentials. J Comput Chem, 2009. 30(9): p. 1510-20.
(436)Concu, R., et al., 3D entropy and moments prediction of enzyme classes and experimental-theoretic study of peptide fingerprints in Leishmania parasites. Biochim Biophys Acta, 2009. 1794(12): p. 1784-94.
(437)Concu, R., et al., Prediction of enzyme classes from 3D structure: a general model and examples of experimental-theoretic scoring of peptide mass fingerprints of Leishmania proteins. J Proteome Res, 2009. 8(9): p. 4372-82.
(438)Castillo-Gonzalez, D., et al., Prediction of telomerase inhibitory activity for acridinic derivatives based on chemical structure. Eur J Med Chem, 2009. 44(12): p. 4826-40.
(439)Aguero-Chapin, G., et al., Alignment-free prediction of polygalacturonases with pseudofolding topological indices: experimental isolation from Coffea arabica and prediction of a new sequence. J Proteome Res, 2009. 8(4): p. 2122-8.
(440)Vilar, S., et al., QSAR model for alignment-free prediction of human breast cancer biomarkers based on electrostatic potentials of protein pseudofolding HP-lattice networks. J Comput Chem, 2008. 29(16): p. 2613-22.
(441)Sood, R.R., et al., Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab, 2008. 28(2): p. 431-8.
(442)Santana, L., et al., Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem, 2008. 51(21): p. 6740-51.
(443)Roldos, V., et al., Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies. Eur J Med Chem, 2008. 43(9): p. 1797-807.
(444)Alvares-Ginarte, Y., M.; Crespo, R.; Montero-Cabrera, L., A.; Ruiz-Garcia, J., A.; MarreroPonce, Y.; Santana, R.; Pardillo-Fontdevilla, E.; Alonso-Becerra, E. A Novel in-silico Approach for QSAR Studies of Anabolic and Androgenic Activities in the 17β-hydroxy-5-androstane Steroid Family. QSAR Comb. Sci. 2005, 24, 218-226. (Currently known as: Molecular Informatics) DOI: 10.1002/qsar.200430889, ISSN: 1868-1751 and IF: 2.013. 
(445)Marrero-Ponce, Y.; Cabrera, M. A.; Romero-Zaldivar, V.; Bermejo, M.; Siverio, D.; Torrens, F. Prediction of Intestinal Epithelial Transport of Drug in (Caco-2) Cell Culture from Molecular Structure using ‘in silico’ Approaches During Early Drug Discovery. Internet Electronic J. Mol. Des. 2005, 4, 124-150. ISSN: 1538–6414. 
(446)Marrero-Ponce, Y.; Medina-Marrero, R.; Castillo-Garit, J.A.; Romero-Zaldivar, V.; Torrens, F.; Castro, E. A. Protein Linear Indices of the “Macromolecular Pseudograph’s -Carbon Atom Adjacency Matrix” in Bioinformatics. Part 1. Prediction of Protein Stability Effects of a Complete Set of Alanine Substitutions in Arc Repressor. Bioorg. Med. Chem. 2005, 13, 3003- 3015. DOI: 10.1016/j.bmc.2005.01.062, ISSN: 0968-0896 and IF: 3.205.  
(447)Marrero-Ponce, Y.; Medina-Marrero, R.; Torrens, F.; Martinez, Y.; Romero-Zaldivar, V.; Castro, E. A. Atom, Atom-type, and Total Non-Stochastic and Stochastic Quadratic Fingerprints: A promising approach for modeling of antibacterial activity. Bioorg. Med. Chem. 2005, 13, 2881- 2899. DOI: 10.1016/j.bmc.2005.02.015, ISSN: 0968-0896 and IF: 3.205. 
(448)Marrero-Ponce, Y.; Castillo-Garit, J.A.; Nodarse, D. Linear Indices of the “Macromolecular Graph’s Nucleotides Adjacency Matrix” as a Promising Approach for Bioinformatics Studies. 1. Prediction of Paromomycin’s Affinity Constant with HIV-1 -RNA Packaging Region. Bioorg. Med. Chem. 2005, 13, 3397-3404. DOI: 10.1016/j.bmc.2005.03.010, ISSN: 0968-0896 and IF: 3.205. 
(449)Marrero-Ponce, Y.; Castillo-Garit, J. A. 3D-Chiral Atom, Atom-type, and Total Non Stochastic and Stochastic Molecular Linear Indices and their Application to Central Chirality Codification. J. Comput. Aided.-Mol. Des. 2005, 19, 369–383. DOI: 10.1007/s10822-005-7575-8, ISSN: 0920-654X and IF: 2.782. 11 
(450)Marrero-Ponce, Y.; Iyarreta, M.; Montero, A.; Romero, C.; Brandt, C. A.; Ávila, P. E.; Kirchgatter, K. A.; Machado, Y. Ligand-Based Virtual Screening and in silico Design of New Antimalarial Compounds Using Non-Stochastic and Stochastic Total and Atom-type Quadratic Maps. J. Chem. Inf. Comput. Sci. 2005, 45, 1082-1100. DOI: 10.1021/ci050085t, ISSN: 1549- 9596 and IF: 4.068. Most-Cited Articles: 2005. J. Chem. Inf. Comput. Sci. For more information please see… http://acsinfo.acs.org/journals/jcisd8/promo/most/most_cited/2005.html 
(451)Meneses-Marcel, A.; Marrero-Ponce, Y.; Machado-Tugores, Y.; Montero-Torres, A.; Montero Pereira, D.; Escario, J. A.; Nogal-Ruiz, J. J.; Ochoa, C.; Arán, V. J.; Martínez-Fernández, A. R., García Sánchez, R. N. A Linear Discrimination Analysis Based Virtual Screening of Trichomonacidal Lead-Like Compounds. Outcomes of in silico Studies Supported by Experimental Results. Bioorg. Med. Chem Lett. 2005, 17, 3838-3843. DOI: 10.1016/j.bmcl.2005.05.124, ISSN: 0960-894X and IF: 2.331. 
(452)Montero-Torres, A.; Celeste Vega, A.; Marrero-Ponce, Y.; Rolón, M.; Gómez-Barrio, A.; Escario, J. A.; Arán, V. J.; Martínez-Fernández, A. R.; Meneses-Marcel, A. A Novel NonStochastic Quadratic Fingerprints-based Approach for the “in silico” Discovery of New Antitrypanosomal Compounds. Bioorg. Med. Chem. 2005, 13, 6264-6275. DOI: 10.1016/j.bmc.2005.06.049, ISSN: 0968-0896 and IF: 3.205.
(453)Marrero-Ponce, Y.; Meneses-Marcel, A.; Machado-Tugores, Y.; Montero Pereira, D.; Escario, J. A.; Nogal-Ruiz, J. J.; Ochoa, C.; Arán, V. J.; Martínez-Fernández, A. R., García Sánchez, R. N.; Montero-Torres, A.; Francisco Torrens. A Computer-Based Approach to the Rational Discovery of New Antitrichomonas Drugs by Atom-Type Linear Indices. Current Drug Discovery Technologies. 2005, 2, 245-265. DOI: 10.2174/157016305775202955, ISSN: 1570- 1638 and IF: 2.52.
(454)Casañola-Martin, G. M.; Khan, M. T. H.; Marrero-Ponce, Y.; Ather, A.; Sultankhodzhaev, M. N.; Torrens, F. New Tyrosinase Inhibitors Selected by Atomic Linear Indices-Based Classification Models. Bioorg. Med. Chem. Letter. 2006, 16, 324-330. DOI: 10.1016/j.bmcl.2005.09.085, ISSN: 0960-894X and IF: 2.331.
(455)Marrero-Ponce, Y.; Medina-Marrero, R.; Martinez, Y.; Torrens, F.; Romero-Zaldivar, V.; Castro, E. A. Non-Stochastic and Stochastic Linear Indices of the Molecular Pseudograph’s Atom Adjacency Matrix: A Novel Approach for Computational –in silico- Screening and “Rational” Selection of New Lead Antibacterial Agents. J. Mol. Mod. 2006, 12, 255–271. DOI: 10.1007/s00894-005-0024-8, ISSN: 1610-2940 and IF: 2.018. 
(456)Castillo-Garit, J. A.; Marrero-Ponce, Y.; Torrens, F. Atom-based 3D-Chiral Quadratic Indices: 2. Prediction of the Corticosteroid-Binding Globulin Binding Affinity of the Thirty-one Benchmark Steroids data set. Bioorg. Med. Chem. 2006, 14, 2398-2408. DOI: 10.1016/j.bmc.2005.11.024, ISSN: 0968-0896 and IF: 3.205. 
(457)Celeste-Vega, M.; Montero-Torres, A.; Marrero-Ponce, Y.; Rolón, M.; Gómez-Barrio, A.; Escario, J. A.; Arán, V. J.; Martínez-Fernández, A. R., Meneses-Marcel, A and Torrens, F. New Ligand-Based Approach for the Discovery of Antitrypanosomal Compounds. Bioorg. Med. Chem. Letter. 2006, 16, 1898–1904. DOI: 10.1016/j.bmcl.2005.12.087, ISSN: 0960-894X and IF: 2.331. 
(458)Montero-Torres, A.; García, R. N.; Marrero-Ponce, Y.; Machado-Tugores, Y.; Nogal, J. J.; Martínez, A. R.; Arán, V. J.; Ochoa, C.; Meneses-Marcel, A.; Torrens, F. Non-stochastic Quadratic Fingerprints and LDA-Based QSAR Models in Hit and Lead Generation Through 12 Virtual Screening: Theoretical and Experimental Assessment of a Promising Method for the Discovery of New Antimalarial Compounds. Eur. J. Med. Chem. 2006, 41, 483-493. DOI: 10.1016/j.ejmech.2005.12.010, ISSN: 0223-5234 and IF: 4.071.
(459)Marrero-Ponce, Y.; Meneses-Marcel, A.; Machado-Tugores, Y.; Escario, J. A.; GómezBarrio, A; Montero Pereira, D.; Nogal-Ruiz, J. J.; Arán, V. J.; Martínez-Fernández, A. R.; Torrens, F.; Rotondo, R. Predicting Antitrichomonal Activity: A Computational Screening Using Atom Based Bilinear Indices and Experimental Proofs. Bioorg. Med. Chem. 2006, 14, 6502–6524. DOI: 10.1016/j.bmc.2006.06.016, ISSN: 0968-0896 and IF: 3.205.
(460)Alvarez-Ginarte, Y.; Crespo-Otero, R.; Marrero-Ponce, Y.; Padrón-García, A.; Montero Cabrera, L. A.; Ruiz-García, J. A.; Torrens, F. Quantitative Structure-Activity Relationship and Diversity Analysis of the 4,5-dihydrotestosterone Steroid Family: Computational Molecular Models To Test The Anabolic/Androgenic Receptor. QSAR Comb. Sci. 2006, 25, 881–894. (Currently known as: Molecular Informatics) DOI: 10.1002/qsar.200510162, ISSN: 1868-1751 and IF: 2.013.
(461)Marrero-Ponce, Y.; Torrens, F.; Alvarado, Y. J: Rotondo, R. Bond-Based Global and Local (Bond, Group and Bond-Type) Quadratic Indices and Their Applications to Computer-Aided Molecular Design. 1. QSPR Studies of Diverse Sets of Organic Chemicals. J. Comput. Aided Mol. Des. 2006, 20, 685-701. DOI: 10.1007/s10822-006-9089-4, ISSN: 0920-654X and IF: 2.782. 
(462)Marrero-Ponce, Y.; Khan, M. T. H.; Casañola-Martin, G. M.; Ather, A.; Sultankhodzhaev, M. N.; Torrens, F. Atom-Based 2D Quadratic Indices in Drug Discovery of Novel Tyrosinase Inhibitors. Results of in silico Studies Supported by Experimental Results. QSAR Comb. Sci. 2007, 27, 469-487. (Currently known as: Molecular Informatics) DOI: 10.1002/qsar.200610156, ISSN: 1868-1751 and IF: 2.013. 
(463)Marrero-Ponce, Y.; Khan, M. T. H.; Casañola-Martin, G. M.; Ather, A.; Sultankhodzhaev, M. N.; Torrens, F.; Rotondo, R. Prediction of Tyrosinase Inhibition Spectra for Chemicals Using Novel Atom-Based Bilinear Indices. ChemMedChem. 2007, 2, 449-478. DOI: 10.1002/cmdc.200600186, ISSN: 1860-7187 and IF: 3.046
(464)Licencia de Registro:  094/12-XCVIII. Tomo XCVIII. Folio 094. Concedida el 26 de enero 2012 por Instituto Nacional de Nutrición e Higiene de los Alimentos (INHA). Ministerio Salud Publica. República de Cuba: Denominación para uso de ingredientes activos para elaboración de Productos Terapéuticos y Cosmecéuticos protectores de entrada de virus, bacterias y hongos desde las mucosas al interior del organismo.
(465)Licencia de Registro:  095/12-XCVIII. Tomo XCVIII. Folio 095. Concedida el 26 de enero 2012 por Instituto Nacional de Nutrición e Higiene de los Alimentos (INHA). Ministerio Salud Publica. República de Cuba:  Denominación para uso de Ingredientes activos para elaboración de Productos Terapéuticos y Cosmecéuticos con acciones antioxidantes y anti-radicales.
(466)Licencia de Registro 096/12-XCVIII.Tomo XCVIII. Folio 096. Concedida el 26 de enero 2012 por Instituto Nacional de Nutrición e Higiene de los Alimentos (INHA). Ministerio Salud Publica. República de Cuba: Denominación para uso de ingredientes activos para elaboración de Productos Terapéuticos y Cosmecéuticos con acciones moduladoras de las cascadas inflamatorias.
(467)Licencia de Registro  Número 097/12-XCVIII. Tomo XCVIII. Folio 097. Concedida el 26 de enero 2012. por Instituto Nacional de Nutrición e Higiene de los Alimentos (INHA). Ministerio Salud Publica. República de Cuba: Denominación para uso de Ingredientes activos para elaboración de Productos Terapéuticos y Cosmecéuticos con acciones moduladoras de la actividad del sistema inmune. 

(468)Marrero-Ponce, Y.; Castillo-Garit, J.A.; Olazabal, E.; Serrano, H. S.; Morales, A.; Castañedo, N.; Ibarra-Velarde, F.; Huesca-Guillen, A.; Jorge, E.; del Valle, A.; Torrens, F.; Castro, E. A. TOMOCOMD-CARDD, a Novel Approach for Computer-Aided “Rational” Drug Design: I. Theoretical and Experimental Assessment of a Promising Method for Computational Screening and in silico Design of New Anthelmintic Compounds. J. Comput. Aided Mol. Des. 2004, 18, 615-634. DOI: 10.1007/s10822-004-5171-y, ISSN: 0920-654X and IF: 2.782.
(469)Marrero-Ponce, Y.; Montero-Torres, A.; Romero-Zaldivar, C.; Iyarreta-Veitía, I.; Mayón Peréz, M.; García Sánchez, R. Non-Stochastic and Stochastic Linear Indices of the “Molecular Pseudograph’s Atom Adjacency Matrix”: Application to “in silico” Studies for the Rational Discovery of New Antimalarial Compounds. Bioorg. Med. Chem. 2005, 13, 1293-1304. DOI: 10.1016/j.bmc.2004.11.008, ISSN: 0968-0896 and IF: 3.205. 
(470)Marrero-Ponce, Y.; Castillo-Garit, J.A.; Olazabal, E.; Serrano, H. S.; Morales, A.; Castañedo, N.; Ibarra-Velarde, F.; Huesca-Guillen, A.; Jorge, E.; Sánchez, A. M.; Torrens, F.; Castro, E. A. Atom, Atom-Type and Total Molecular Linear Indices as a Promising Approach for Bioorganic & Medicinal Chemistry: Theoretical and Experimental Assessment of a Novel Method 10 for Virtual Screening and Rational Design of New Lead Anthelmintic. Bioorg. Med. Chem. 2005, 13, 1005-1020. DOI: 10.1016/j.bmc.2004.11.040, ISSN: 0968-0896 and IF: 3.205. 
(471)Marrero-Ponce, Y.; Huesca-Guillen, A.; Ibarra-Velarde, F. Quadratic Indices of the “Molecular Pseudograph’s Atom Adjacency Matrix” and Their Stochastic Forms: A Novel Approach for Virtual Screening and in silico Discovery of New Lead Paramphistomicide Drugslike Compounds. J. Theor. Chem. (THEOCHEM). 2005, 717, 67-79. (Currently known as Computational and Theoretical Chemistry) DOI: 10.1016/j.theochem.2004.11.027, ISSN: 2210- 

(472)Materia prima: Extracto blando de propóleos (Excipiente para cosméticos). Registro nacional en Cuba en el  Instituto de Nutrición e Higiene de los Alimentos con Licencia Sanitaria No. 094/12-XCVIII. Tomo XCVIII. Folio 094. Concedida el 26 de enero 2012.

(473)Materia prima: Extracto blando de propóleos con extractos de larvas de zângano (efecto antienvejecimiento). Registro nacional en Cuba en el  Instituto de Nutrición e Higiene de los Alimentos con Licencia Sanitaria No. 095/12-XCVIII. Tomo XCVIII. Folio 095. Concedida el 26 de enero 2012.

(474)Materia prima: Extracto blando de propóleos con extracto de pole(efecto antienvejecimiento). Registro nacional en Cuba en el  Instituto de Nutrición e Higiene de los Alimentos con Licencia Sanitaria No. 096/12-XCVIII. Tomo XCVIII. Folio 096. Concedida el 26 de enero 2012.

(475)Materia prima: Extracto blando de propóleos con extracto de Morinda royoc (efecto antioxidante). Registro nacional en Cuba en el  Instituto de Nutrición e Higiene de los Alimentos con Licencia Sanitaria No. 097/12-XCVIII. Tomo XCVIII. Folio 097. Concedida el 26 de enero 2012. 1X and IF: 1.369. 








(476)Cortés,  R ;Prieto,  J. O ; Armas,  L ;Pérez,  J. A. :Caracterizacão de un principio activo de base silícica para uso como medicamento. Revista CNIC. Vol 26 ,  1995. 
(477)Cortés,  R. ;Morales,  A. ; Teresita   Reiner ; Águila,  Adys.: Estudio de hemosiderina, en bazos de diferentes especies como criterio de toxicidad de medicamentos. Revista. Medicentro. Vol 12 (2),  1995. 
(478)Cortés,  R. ;Perez,  J. A; : Some toxicological issues of the ophtalmic oiment  QUERATOFURAL. Journal  pharmacology and therapeutic. Vol.20,1997
(479)Cortés, R, Pérez JA: Estudio de toxicidad aguda do producto antibiótico denominado G-1 administrado por vía oral en ratas de Sprague Dowley. Revista Produção Animal. Vol 10, 1998. 
(480)Cortés,  R ;Prieto,  J. O. Toxicidad aguda do Medicamento Dermasel. Revista Medicentro. Cuba, Vol 1,1999.
(481)Cortés,  R ;Prieto,  J. O; Perez Ja, Gonzalez M. Efectos provocados sobre la piel por el Medicamento Dermasel.  Revista Medicentro. Cuba, Vol 1,1999.
(482)Cortes R, Monteagudo G, Pérez JA Estudio  preliminar de los efectos irritantes, fototóxicos y fotoprotectores do propóleos sobre la piel.  Revista Cubana de Farmacia. Vol 34, 2000.
(483)Cortés R, Monteagudo G, Pérez JA. Irritabilidad oftálmica primaria de cosméticos elaborados a partir de propóleos. Medicentro. Vol 16, 2002
(484)Cortés R; Pérez JA; Marero O: Estudio preliminar de los efectos fotoprotectores e irritabilidad dérmica y oftálmica de los propóleos sobre la piel.  Revista  Cubana Farmacología.  34: 132-134. 2000
(485)Capote A, Pérez-Alonso N, Pérez A, Barbon R, Salas E, Jiménez E (2008) Perfil metabólico de extractos obtenidos de cultivos in vitro de Morinda royoc L., Psidium guajava L. varg EEA18-40h y Morus alba L. vargCriolla�h. Biotecnologia Vegetal 8 (3):131-135
(486)Cortés R; Pérez J, Olazabal E. ¿Biofuncionalales versus envejecimiento de la piel. ¿son correctas las estrategias actuales? .  Revista Cubana de Farmacia.  Editorial CEDIMED  ISSN 0034-7515. Volumen 42 No.3), 2008.
(487)Meneses A, Olazábal E, Serrano H, González O, Salinas JA. Frecuencia de giardiasis en algunas especies de animales domésticos de la provincia Villa Clara.  Vet Méx 1994;25(4):337-340.
(488)Olazábal E, Morales A, Serrano H, Brito A. Obtencão de metacercarias de Fasciola hepatica en Lymnaea cubensis y relacão parásito-hospedero en ratas Wistar y ratones Balb/c. Vet Méx 1999;30:109-115. 
(489)Olazábal E , Quiroz H, Ibarra F, Castillo R. Efectividad de productos sintéticos sobre  formas inmaduras de Fasciola hepatica en ratones CD-1 infestados artificialmente. Medicentro 1999;3(3) http://capiro.sld.cu/medicentro/v3n399/fasciola.htm.
(490)Olazábal E, Serrano H, Jorge E, Saucedo Y. Reporte de actividad fasciolicida in vitro de algunos extractos de plantas medicinales. SANINET octubre 2001. http://www.iicasaninet.net/pub/gen/pdf/fasciola-extractos.pdf
(491)GuNogueiras C, Olazábal E, Serrano H, Becerra WM. Aislamiento y caracterizacão de saponinas esteroidales con actividad fasciolicida. Revista Cubana de Química 2001;23:425. 
(492)Romero M, Olazábal E, Martínez Y, Serrano H, Monteagudo A. Actividad fasciolicida in vitro de Portulaca oleracea L. Acta Farm. Bonaerense 2002;21:297-300.
(493)Olazábal E, González R, Flores S, Alcina L.  Efectividad de diferentes combinaciones de tratamientos con antibióticos en la mortalidad por Clostridium perfringens en una empresa avícolahttp://www.veterinaria.org/revistas/redvet/ervelio . REDVET. No. 2 Febrero  2005.    
(494)Duenas A, Cortés R, Marrero O, Donato J, Olazábal E. 2013.Toxicidad aguda do extracto hidroalcohólico de  la planta Chuquiraga jusieui, administrado por vía oral en ratas. La Técnica. 2013; (10): 12-17. 
Efecto antioxidante de la Chuquiraga jussieui J.F. Gmell en el ensayo de hemólisis. Duenas AA, Alcívar UE, Olazábal EE, Cortés R. Medicent Electrón 2014:18(2).  



6.2.  Publicaciones Científicas y Contribuciones.
1.Marrero-Ponce, Y.; González-Díaz, H.; Romero-Zaldivar, V.; Torrens, F.; Castro, E. A. 3DChiral Quadratic Indices of the “Molecular Pseudograph’s Atom Adjacency Matrix” and their Application to Central Chirality Codification: Classification of ACE Inhibitors and Prediction of Receptor Antagonist Activities. Bioorg. Med. Chem. 2004, 12, 5331-5342. DOI: 10.1016/j.bmc.2004.07.051, ISSN: 0968-0896, IF: 3.205: This paper has recently been recognised in the "Top-50 most cited articles" as published in Bioorganic & Medicinal Chemistry 2003-2006, & all Tetrahedron Journals as well as Medical Magazine.
2.Marrero-Ponce, Y. Total and Local (Atom and Atom-Type) Molecular Quadratic Indices: Significance-Interpretation, Comparison to Other Molecular Descriptors and QSPR/QSAR Applications. Bioorg. Med. Chem. 2004, 12, 6351-6369. DOI: 10.1016/j.bmc.2004.09.034, ISSN: 0968-0896 and IF: 3.205. This paper has recently been recognised in the "Top-50 most cited articles" as published in Bioorganic & Medicinal Chemistry 2003-2006, & all Tetrahedron Journals as well as Medical Magazine.
3.Marrero-Ponce, Y.; Montero-Torres, A.; Romero-Zaldivar, C.; Iyarreta-Veitía, I.; Mayón Peréz, M.; García Sánchez, R. Non-Stochastic and Stochastic Linear Indices of the “Molecular Pseudograph’s Atom Adjacency Matrix”: Application to “in silico” Studies for the Rational Discovery of New active Compounds. Bioorg. Med. Chem. 2005, 13, 1293-1304. DOI: 10.1016/j.bmc.2004.11.008, ISSN: 0968-0896 and IF: 3.205.This paper has recently been recognised in the "Top-50 most cited articles" as published in Bioorganic & Medicinal Chemistry 2003-2006, & all Tetrahedron Journals as well as Medical Magazine.
4.Marrero-Ponce, Y.; Castillo-Garit, J.A.; Olazabal, E.; Serrano, H. S.; Morales, A.; Castañedo, N.; Ibarra-Velarde, F.; Huesca-Guillen, A.; Jorge, E.; Sánchez, A. M.; Torrens, F.; Castro, E. A. Atom, Atom-Type and Total Molecular Linear Indices as a Promising Approach for Bioorganic & Medicinal Chemistry: heoretical and Experimental Assessment of a Novel Method 10 for Virtual Screening and Rational Design of New Lead active. Bioorg. Med. Chem. 2005, 13, 1005-1020. DOI: 10.1016/j.bmc.2004.11.040, ISSN: 0968-0896 and IF: 3.205. **This paper has recently been recognised in the "Top-50 most cited articles" as published in Bioorganic & Medicinal Chemistry 2004-2007, & all Tetrahedron Journals as well as Medical Magazine.
5.Marrero-Ponce, Y.; Medina-Marrero, R.; Castillo-Garit, J.A.; Romero-Zaldivar, V.; Torrens, F.; Castro, E. A. Protein Linear Indices of the “Macromolecular Pseudograph’s -Carbon Atom Adjacency Matrix” in Bioinformatics. Part 1. Prediction of Protein Stability Effects of a Complete Set of Alanine Substitutions in Arc Repressor. Bioorg. Med. Chem. 2005, 13, 3003- 3015. DOI: 10.1016/j.bmc.2005.01.062, ISSN: 0968-0896 and IF: 3.205. **This paper has recently been recognised in the "Top-50 most cited articles" as published in Bioorganic & Medicinal Chemistry 2005-2008, & all Tetrahedron Journals as well as Medical Magazine.
6.Marrero-Ponce, Y.; Medina-Marrero, R.; Torrens, F.; Martinez, Y.; Romero-Zaldivar, V.; Castro, E. A. Atom, Atom-type, and Total Non-Stochastic and Stochastic Quadratic Fingerprints: A promising approach for modeling of antibacterial activity. Bioorg. Med. Chem. 2005, 13, 2881- 2899. DOI: 10.1016/j.bmc.2005.02.015, ISSN: 0968-0896 and IF: 3.205. *World’s 7th most requested article in 3rd quarter of 2005 according to the American Chemical Society (http://www.cas.org/spotlight/rlist3q05j/rlist3q05j.html).
7.Marrero-Ponce, Y.; Iyarreta, M.; Montero, A.; Romero, C.; Brandt, C. A.; Ávila, P. E.; Kirchgatter, K. A.; Machado, Y. Ligand-Based Virtual Screening and in silico Design of New active Compounds Using Non-Stochastic and Stochastic Total and Atom-type Quadratic Maps. J. Chem. Inf. Comput. Sci. 2005, 45, 1082-1100. DOI: 10.1021/ci050085t, ISSN: 1549- 9596 and IF: 4.068. Most-Cited Articles: 2005. J. Chem. Inf. Comput. Sci. For more information please see …  http://acsinfo.acs.org/journals/jcisd8/promo/most/most_cited/2005.html
8.Casañola-Martin, G. M.; Khan, M. T. H.; Marrero-Ponce, Y.; Ather, A.; Sultankhodzhaev, M. N.; Torrens, F. New Tyrosinase Inhibitors Selected by Atomic Linear Indices-Based Classification Models. Bioorg. Med. Chem. Letter. 2006, 16, 324-330. DOI: 10.1016/j.bmcl.2005.09.085, ISSN: 0960-894X and IF: 2.331.
9.Castillo-Garit, J. A.; Marrero-Ponce, Y.; Torrens, F. Atom-based 3D-Chiral Quadratic Indices: 2. Prediction of the Corticosteroid-Binding Globulin Binding Affinity of the Thirty-one Benchmark Steroids data set. Bioorg. Med. Chem. 2006, 14, 2398-2408. DOI: 10.1016/j.bmc.2005.11.024, ISSN: 0968-0896 and IF: 3.205.
10.Marrero-Ponce, Y.; Meneses-Marcel, A.; Machado-Tugores, Y.; Escario, J. A.; GómezBarrio, A; Montero Pereira, D.; Nogal-Ruiz, J. J.; Arán, V. J.; Martínez-Fernández, A. R.; Torrens, F.; Rotondo, R. Predicting Antitrichomonal Activity: A Computational Screening Using AtomBased Bilinear Indices and Experimental Proofs. Bioorg. Med. Chem. 2006, 14, 6502–6524. DOI: 10.1016/j.bmc.2006.06.016, ISSN: 0968-0896 and IF: 3.205.
11.Marrero-Ponce, Y.; Torrens, F.; Alvarado, Y. J: Rotondo, R. Bond-Based Global and Local (Bond, Group and Bond-Type) Quadratic Indices and Their Applications to Computer-Aided Molecular Design. 1. QSPR Studies of Diverse Sets of Organic Chemicals. J. Comput. Aided Mol. Des. 2006, 20, 685-701. DOI: 10.1007/s10822-006-9089-4, ISSN: 0920-654X and IF: 2.782.
12.Marrero-Ponce, Y.; Huesca-Guillén, A.; Torrens, F.; Ibarra-Velarde, F. Novel Ligand-Based Approach to Screening of Large Databases for Paramphistomicide Lead Generation. NEREIS 2011, 3, 9-15. ISSN: 1888-8550. 
13.Rivera Borroto; O. M.; Hernández Díaz, Y.; García de la Vega, J. M.; Grau Ábalo, R. G; Marrero-Ponce, Y. Novel similarity measures for the effective and efficient retrieval of pharmacological datasets. Afinidad. 2011, LXVIII 551, 50-56. ISSN: 0001-9704 and IF: 0.23.
14.Barigye, S. J.; Marrero-Ponce, Y.; Pérez-Giménez, F.; Bonchev, D. Trends in Information Theory-based Chemical Structure Codification. Mol. Divers. 2014, 18, 673–686. DOI: 10.1007/s11030-014-9517-7, ISSN: 1381-1991 and IF: 2.544.
15.Barigye, S. J. and Marrero-Ponce, Y. Digital Communication and Chemical Structure Codification. In Encyclopedia of Complexity and Systems Science. 2016, R.A. Meyers (ed.), (Section: Complexity in Computational Chemistry, Chapter 10). Springer Science+Business Media New York. DOI: 10.1007/978-3-642-27737-5_625-2, ISBN: 978-3-642-27737-5.
16.Casañola-Martin, G. M.; Le-Thi-Thu, H.; Marrero-Ponce, Y.; Torrens, F.; Rescigno, A.; Abad, C.; Hassan Khan, M. QSAR-based CMs and TOMOCOMD-CARD Approach for the Discovery of New Tyrosinase Inhibitor Chemicals. In Recent Trends on QSAR in the Pharmaeutical Perceptions. Editor: Mahmud T. Hassan Khan. Bethan Books (http://ebooks.benthamscience.com/book/9781608053797/chapter/100538/). 2012, (Chapter 10), 296-337. DOI: 10.2174/97816080537971120101, and ISSN: 978-1-60805-433-6.
17.Cortes R,  Pérez Donato JA, Marrero O, Olazabal E, Rodríguez R. Evaluacion físico químico de  un extracto de polen  para uso alimentario y cosmético con perspectivas antienvejecimiento. Revista Cubana de Ciencia Apícola. 2012;14(2):72-78. 
18.Duenas A, Cortés R, Marrero O, Donato J, Olazábal E. 2013.Toxicidad aguda do extracto hidroalcohólico de  la planta Chuquiraga jusieui, administrado por vía oral en ratas. La Técnica. 2013; (10): 12-17. 
19.René Dionisio Cupull-Santana, Remigio Cortés-Rodríguez, Ervelio Eliseo Olazábal-Manso, Carlos Alberto Hernández Medina Actividad antifúngica de propóleos obtenidos en tres provincias de Cuba sobre hongos contaminantes en cultivo de tejidos vegetales. Acta Universitaria 2013;23(6):3-9.
20.Casañola-Martín, G. M.; Tareq Hassan Khan, M.; Le-Thi-Thu, H.; Marrero-Ponce, Y.; García-Domenech, R.; Torrens, F.; Rescigno, A.; Abad, C. Retrained Classification of Tyrosinase Inhibitors and “In silico” Potency Estimation by Using Atom-Type Linear Indices: A Powerful Tool for Speed up the Discovery of Leads. In Methodologies and Applications for Chemoinformatics and Chemical Engineering. Editor: Haghi, A. K. IGI Global, USA (http://www.igi-global.com/). 2013, (Chapter 21), 322-427. ISSN: 978-1-4666-4010-8.
21.Barigye, S. J. and Marrero-Ponce, Y. Digital Communication and Chemical Structure Codification. In Encyclopedia of Complexity and Systems Science. 2016, R.A. Meyers (ed.), (Section: Complexity in Computational Chemistry, Chapter 10). Springer Science+Business Media New York. DOI: 10.1007/978-3-642-27737-5_625-2, ISBN: 978-3-642-27737-5
22.Quevedo-Tumailli, V.F., B. Ortega-Tenezaca, and H. Gonzalez-Diaz, Chromosome Gene Orientation Inversion Networks (GOINs) of Plasmodium Proteome. J Proteome Res, 2018. 17(3): p. 1258-1268.
23.Pham-The, H., et al., Learning from Multiple Classifier Systems: Perspectives for Improving Decision Making of QSAR Models in Medicinal Chemistry. Curr Top Med Chem, 2018. 17(30): p. 3269-3288.
24.Nieto-Gonzalez, J.C., et al., Salivary gland ultrasound is linked to the autoimmunity profile in patients with primary Sjogren's syndrome. J Int Med Res, 2018: p. 300060518767031.
25.Nieto-Gonzalez, J.C., et al., Switch from intravenous to subcutaneous abatacept: Our experience. Reumatol Clin, 2018.
26.Mirza, N., et al., Expert Exchange Workgroup on Children Aged 5 and Younger with Severe Obesity: A Narrative Review of Medical and Genetic Risk Factors. Child Obes, 2018.
27.Miranda, C., et al., Biowaiver or Bioequivalence: Ambiguity in Sildenafil Citrate BCS Classification. AAPS PharmSciTech, 2018. 19(4): p. 1693-1698.
28.Gasior, P., et al., Novel ultrahigh molecular weight amorphous PLLA bioresorbable coronary scaffold upsized up to 0.8 mm beyond nominal diameter: An OCT and histopathology study in porcine coronary artery model. Catheter Cardiovasc Interv, 2018. 91(3): p. 378-386. Garcia-Jacas, C.R., et al., GOWAWA Aggregation Operator-based Global Molecular Characterizations: Weighting Atom/bond Contributions (LOVIs/LOEIs) According to their Influence in the Molecular Encoding. Mol Inform, 2018.
29.Fiandaca, M.S., R. Gonzalez-Dominguez, and H. Gonzalez-Diaz, New Experimental and Computational Tools for Drug Discovery: From Chemistry to Biology. Metabolomics, Pharmacokinetics, and Medicinal Chemistry. Part - IV. Curr Top Med Chem, 2018. 18(11): p. 881-882.
30.Ferreira da Costa, J., et al., Perturbation Theory/Machine Learning Model of ChEMBL Data for Dopamine Targets: Docking, Synthesis, and Assay of New l-Prolyl-l-leucyl-glycinamide Peptidomimetics. ACS Chem Neurosci, 2018.
31.Estrada, E. and G.J. Ross, Centralities in simplicial complexes. Applications to protein interaction networks. J Theor Biol, 2018. 438: p. 46-60.
32.Corrales-Urena, Y.R., et al., Biogenic silica-based microparticles obtained as a sub-product of the nanocellulose extraction process from pineapple peels. Sci Rep, 2018. 8(1): p. 10417.
33.Cabrera-Perez, M.A. and H. Pham-The, Computational modeling of human oral bioavailability: what will be next? Expert Opin Drug Discov, 2018. 13(6): p. 509-521.
34.Blay, V., T. Yokoi, and H. Gonzalez-Diaz, Perturbation Theory-Machine Learning Study of Zeolite Materials Desilication. J Chem Inf Model, 2018.
35.Betarelli, R.P., et al., The achievement of boar sperm in vitro capacitation is related to an increase of disrupted disulphide bonds and intracellular reactive oxygen species levels. Andrology, 2018.
36.Marrero-Ponce, Y., et al., Bond-based linear indices of the non-stochastic and stochastic edge-adjacency matrix. 1. Theory and modeling of ChemPhys properties of organic molecules. Mol Divers, 2010. 14(4): p. 731-53.
37.Marrero-Ponce, Y., et al., Ligand-based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMD-CARDD method to the elucidation of new compounds. Curr Pharm Des, 2010. 16(24): p. 2601-24.
38.	Marrero-Ponce, Y., et al., Nucleotide's bilinear indices: novel bio-macromolecular descriptors for bioinformatics studies of nucleic acids. I. Prediction of paromomycin's affinity constant with HIV-1 Psi-RNA packaging region. J Theor Biol, 2009. 259(2): p. 229-41.
39.            Marrero-Ponce, Y., et al., Nucleotide's bilinear indices: novel bio-macromolecular descriptors for bioinformatics studies of nucleic acids. I. Prediction of paromomycin's affinity constant with HIV-1 Psi-RNA packaging region. J Theor Biol, 2009. 259(2): p. 229-41.
40.	Marrero-Ponce, Y., et al., Bond-based linear indices in QSAR: computational discovery of novel anti-trichomonal compounds. J Comput Aided Mol Des, 2008. 22(8): p. 523-40.
41.	Marrero-Ponce, Y., et al., Bond-based 2D TOMOCOMD-CARDD approach for drug discovery: aiding decision-making in 'in silico' selection of new lead tyrosinase inhibitors. J Comput Aided Mol Des, 2007. 21(4): p. 167-88.
42.            Marrero-Ponce, Y., et al., Prediction of tyrosinase inhibition activity using atom-based bilinear indices. ChemMedChem, 2007. 2(4): p. 449-78.
43.Marrero-Ponce, Y., et al., Bond-based global and local (bond, group and bond-type) quadratic indices and their applications to computer-aided molecular design. 1. QSPR studies of diverse sets of organic chemicals. J Comput Aided Mol Des, 2006. 20(10-11): p. 685-701.
44.Marrero-Ponce, Y., et al., Predicting antitrichomonal activity: a computational screening using atom-based bilinear indices and experimental proofs. Bioorg Med Chem, 2006. 14(19): p. 6502-24.
45.Marrero-Ponce, Y., et al., Predicting antitrichomonal activity: a computational screening using atom-based bilinear indices and experimental proofs. Bioorg Med Chem, 2006. 14(19): p. 6502-24.
46.Marrero-Ponce, Y., et al., Non-stochastic and stochastic linear indices of the molecular, Automatic extraction of structural alerts for predicting chromosome aberrations of organic compounds. J Mol Graph Model, 2006. 25(3): p. 275-88.
47.Marrero-Ponce, Y., et al., Non-stochastic and stochastic linear indices of the 'molecular pseudograph's atom adjacency matrix': application to 'in silico' studies for the rational discovery of new antimalarial compounds. Bioorg Med Chem, 2005. 13(4): p. 1293-304.
48.Marrero-Ponce, Y., et al., Atom, atom-type, and total nonstochastic and stochastic quadratic fingerprints: a promising approach for modeling of antibacterial activity. Bioorg Med Chem, 2005. 13(8): p. 2881-99.
49.Marrero-Ponce, Y., et al., Protein linear indices of the 'macromolecular pseudograph alpha-carbon atom adjacency matrix' in bioinformatics. Part 1: prediction of protein stability effects of a complete set of alanine substitutions in Arc repressor. Bioorg Med Chem, 2005. 13(8): p. 3003-15.
50.Marrero-Ponce, Y., et al., A computer-based approach to the rational discovery of new trichomonacidal drugs by atom-type linear indices. Curr Drug Discov Technol, 2005. 2(4): p. 245-65. 
51.Marrero-Ponce, Y., et al., Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps. J Chem Inf Model, 2005. 45(4): p. 1082-100.
52.Marrero-Ponce, Y., et al., Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps. J Chem Inf Model, 2005. 45(4): p. 1082-100.
53.Marrero-Ponce, Y., et al., Atom, atom-type and total molecular linear indices as a promising approach for bioorganic and medicinal chemistry: theoretical and experimental assessment of a novel method for virtual screening and rational design of new lead anthelmintic. Bioorg Med Chem, 2005. 13(4): p. 1005-20.
54.Marrero-Ponce, Y. and J.A. Castillo-Garit, 3D-chiral atom, atom-type, and total non-stochastic and stochastic molecular linear indices and their applications to central chirality codification. J Comput Aided Mol Des, 2005. 19(6): p. 369-83.
55.Marrero Ponce, Y., J.A. Castillo Garit, and D. Nodarse, Linear indices of the 'macromolecular graph's nucleotides adjacency matrix' as a promising approach for bioinformatics studies. Part 1: prediction of paromomycin's affinity constant with HIV-1 psi-RNA packaging region. Bioorg Med Chem, 2005. 13(10): p. 3397-404.
56.Marrero-Ponce, Y., Linear indices of the "molecular pseudograph's atom adjacency matrix": definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. J Chem Inf Comput Sci, 2004. 44(6): p. 2010-26.
57.Marrero Ponce, Y., et al., A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci, 2004. 7(2): p. 186-99.
58.Marrero Ponce, Y., et al., A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci, 2004. 7(2): p. 186-99.
59.Marrero Ponce, Y., et al., A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci, 2004. 7(2): p. 186-99.
60.http://compumat.uci.cu/?q=node/2559
61. http://www.sld.cu/sitios/revfarmacia/temas.php?idv=30516
62.http://digital.csic.es/bitstream/10261/86341/4/Art%C3%ADculo.pdf
63. http://ojs.uo.edu.cu/index.php/cq/article/viewFile/2090/1637 
64.http://www.socepa.es/congresos/xii_congreso_iberico_parasitologia.pdf
65. http://www.usc.es/congresos/ecsoc/9/CC/g014/ 
66.https://www.usc.es/congresos/ecsoc/10/BOCNP/c005/c005.pdf
67. https://www.usc.es/congresos/ecsoc/12/hall_g_CC/g0003/g0003.pdf 
68.http://sciforum.net/conference/ecsoc-12/paper/1280
69. http://sciforum.net/conference/ecsoc-12/paper/1282 
70.http://www.informatica2013.sld.cu/index.php/informaticasalud/2013/schedConf/program 
71.http://bvs.sld.cu/revistas/far/vol42_sup2_08/vol42_sup2_08.pdf 
72.http://bvs.sld.cu/revistas/far/vol42_sup1_08/supl1_far48_08.pdf
73. http://www.chemistrycuba.com/Programacientifico.pdf
74. http://hta2014.uclv.edu.cu/wp-content/uploads/2014/07/P452_E8.pdf

Other publications are from contributors and developers of PPG NUTRITIONAL.

1.Simon-Vidal, L., et al., Perturbation-Theory and Machine Learning (PTML) Model for High-Throughput Screening of Parham Reactions: Experimental and Theoretical Studies. J Chem Inf Model, 2018. 58(7): p. 1384-1396.
2.Quevedo-Tumailli, V.F., B. Ortega-Tenezaca, and H. Gonzalez-Diaz, Chromosome Gene Orientation Inversion Networks (GOINs) of Plasmodium Proteome. J Proteome Res, 2018. 17(3): p. 1258-1268.
6.	Pham-The, H., et al., Learning from Multiple Classifier Systems: Perspectives for Improving Decision Making of QSAR Models in Medicinal Chemistry. Curr Top Med Chem, 2018. 17(30): p. 3269-3288.
7.	Nieto-Gonzalez, J.C., et al., Salivary gland ultrasound is linked to the autoimmunity profile in patients with primary Sjogren's syndrome. J Int Med Res, 2018: p. 300060518767031.
8.	Nieto-Gonzalez, J.C., et al., Switch from intravenous to subcutaneous abatacept: Our experience. Reumatol Clin, 2018.
9.	Mirza, N., et al., Expert Exchange Workgroup on Children Aged 5 and Younger with Severe Obesity: A Narrative Review of Medical and Genetic Risk Factors. Child Obes, 2018.
10.	Miranda, C., et al., Biowaiver or Bioequivalence: Ambiguity in Sildenafil Citrate BCS Classification. AAPS PharmSciTech, 2018. 19(4): p. 1693-1698.
11.	Meneses-Marcel, A., et al., Drug repositioning for novel antitrichomonas from known antiprotozoan drugs using hierarchical screening. Future Med Chem, 2018. 10(8): p. 863-878.
12.	Gasior, P., et al., Novel ultrahigh molecular weight amorphous PLLA bioresorbable coronary scaffold upsized up to 0.8 mm beyond nominal diameter: An OCT and histopathology study in porcine coronary artery model. Catheter Cardiovasc Interv, 2018. 91(3): p. 378-386.
13.	Garcia-Jacas, C.R., et al., GOWAWA Aggregation Operator-based Global Molecular Characterizations: Weighting Atom/bond Contributions (LOVIs/LOEIs) According to their Influence in the Molecular Encoding. Mol Inform, 2018.
14.	Fiandaca, M.S., R. Gonzalez-Dominguez, and H. Gonzalez-Diaz, New Experimental and Computational Tools for Drug Discovery: From Chemistry to Biology. Metabolomics, Pharmacokinetics, and Medicinal Chemistry. Part - IV. Curr Top Med Chem, 2018. 18(11): p. 881-882.
15.	Ferreira da Costa, J., et al., Perturbation Theory/Machine Learning Model of ChEMBL Data for Dopamine Targets: Docking, Synthesis, and Assay of New l-Prolyl-l-leucyl-glycinamide Peptidomimetics. ACS Chem Neurosci, 2018.
16.	Estrada, E. and G.J. Ross, Centralities in simplicial complexes. Applications to protein interaction networks. J Theor Biol, 2018. 438: p. 46-60.
17.	Corrales-Urena, Y.R., et al., Biogenic silica-based microparticles obtained as a sub-product of the nanocellulose extraction process from pineapple peels. Sci Rep, 2018. 8(1): p. 10417.
18.	Cabrera-Perez, M.A. and H. Pham-The, Computational modeling of human oral bioavailability: what will be next? Expert Opin Drug Discov, 2018. 13(6): p. 509-521.
19.	Blay, V., T. Yokoi, and H. Gonzalez-Diaz, Perturbation Theory-Machine Learning Study of Zeolite Materials Desilication. J Chem Inf Model, 2018.
20.	Betarelli, R.P., et al., The achievement of boar sperm in vitro capacitation is related to an increase of disrupted disulphide bonds and intracellular reactive oxygen species levels. Andrology, 2018.
21.	Barreiro, E., et al., Net-Net Auto Machine Learning (AutoML) Prediction of Complex Ecosystems. Sci Rep, 2018. 8(1): p. 12340.
22.	Arias, J.H., et al., Epidemics on plants: Modeling long-range dispersal on spatially embedded networks. J Theor Biol, 2018. 453: p. 1-13.
23.	Vazquez-Prieto, S., et al., A study of the Immune Epitope Database for some fungi species using network topological indices. Mol Divers, 2017. 21(3): p. 713-718.
24.	Valdes-Martini, J.R., et al., QuBiLS-MAS, open source multi-platform software for atom- and bond-based topological (2D) and chiral (2.5D) algebraic molecular descriptors computations. J Cheminform, 2017. 9(1): p. 35.
25.	Valdes-Martini, J.R., et al., QuBiLS-MAS, open source multi-platform software for atom- and bond-based topological (2D) and chiral (2.5D) algebraic molecular descriptors computations. J Cheminform, 2017. 9(1): p. 35.
26.	Sylla-Iyarreta Veitia, M., F. Dumas, and H. Gonzalez-Diaz, Editorial: New Experimental and Computational Tools for Drug Discovery: From Chemistry to Biology. Part-II. Curr Top Med Chem, 2017. 17(26): p. 2901-2902.
27.	Shameer, K., et al., Editorial: Improving Neuropharmacology using Big Data, Machine Learning and Computational Algorithms. Curr Neuropharmacol, 2017. 15(8): p. 1058-1061.
28.	Ruiz-Blanco, Y.B., et al., Novel "extended sequons" of human N-glycosylation sites improve the precision of qualitative predictions: an alignment-free study of pattern recognition using ProtDCal protein features. Amino Acids, 2017. 49(2): p. 317-325.
29.	Ruiz-Blanco, Y.B., et al., Novel "extended sequons" of human N-glycosylation sites improve the precision of qualitative predictions: an alignment-free study of pattern recognition using ProtDCal protein features. Amino Acids, 2017. 49(2): p. 317-325.
30.	Ramirez, A.S., E. Estrada, and A. Ruiz, Mapping the Health Information Landscape in a Rural, Culturally Diverse Region: Implications for Interventions to Reduce Information Inequality. J Prim Prev, 2017. 38(4): p. 345-362.
31.	Ramirez, A.S., et al., Bringing Produce to the People: Implementing a Social Marketing Food Access Intervention in Rural Food Deserts. J Nutr Educ Behav, 2017. 49(2): p. 166-174 e1.
32.	Paez, D., et al., Current status of nuclear cardiology practice in Latin America and the Caribbean. J Nucl Cardiol, 2017. 24(1): p. 308-316.
33.	Olvera-Castro, J.O., et al., Bobble-head doll syndrome in an 80-year-old man, associated with a giant arachnoid cyst of the lamina quadrigemina, treated with endoscopic ventriculocystocisternotomy and cystoperitoneal shunt. Acta Neurochir (Wien), 2017. 159(8): p. 1445-1450.
34.	Montejo Carrasco, P., et al., Subjective Memory Complaints in healthy older adults: Fewer complaints associated with depression and perceived health, more complaints also associated with lower memory performance. Arch Gerontol Geriatr, 2017. 70: p. 28-37.
35.	Martinez-Santiago, O., et al., Exploring the QSAR's predictive truthfulness of the novel N-tuple discrete derivative indices on benchmark datasets. SAR QSAR Environ Res, 2017. 28(5): p. 367-389.
36.	Martinez-Santiago, O., et al., Exploring the QSAR's predictive truthfulness of the novel N-tuple discrete derivative indices on benchmark datasets. SAR QSAR Environ Res, 2017. 28(5): p. 367-389.
37.	Martinez-Lopez, Y., et al., State of the Art Review and Report of New Tool for Drug Discovery. Curr Top Med Chem, 2017. 17(26): p. 2957-2976.
38.	Martinez-Lopez, Y., et al., Prediction of aquatic toxicity of benzene derivatives using molecular descriptor from atomic weighted vectors. Environ Toxicol Pharmacol, 2017. 56: p. 314-321.
39.	Martinez-Arzate, S.G., et al., PTML Model for Proteome Mining of B-Cell Epitopes and Theoretical-Experimental Study of Bm86 Protein Sequences from Colima, Mexico. J Proteome Res, 2017. 16(11): p. 4093-4103.
40.	Liu, Y., et al., Experimental Study and ANN Dual-Time Scale Perturbation Model of Electrokinetic Properties of Microbiota. Front Microbiol, 2017. 8: p. 1216.
41.	Hernandez-Caravaca, I., et al., Serum acute phase response induced by different vaccination protocols against circovirus type 2 and Mycoplasma hyopneumoniae in piglets. Res Vet Sci, 2017. 114: p. 69-73.
42.	Hempel, S., et al., A systematic review of modifiable risk factors in the progression of multiple sclerosis. Mult Scler, 2017. 23(4): p. 525-533.
43.	Hempel, S., et al., A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis. Mult Scler, 2017. 23(4): p. 513-524.
44.	Gonzalez-Durruthy, M., et al., Decrypting Strong and Weak Single-Walled Carbon Nanotubes Interactions with Mitochondrial Voltage-Dependent Anion Channels Using Molecular Docking and Perturbation Theory. Sci Rep, 2017. 7(1): p. 13271.
45.	Gonzalez-Durruthy, M., et al., Carbon Nanotubes' Effect on Mitochondrial Oxygen Flux Dynamics: Polarography Experimental Study and Machine Learning Models using Star Graph Trace Invariants of Raman Spectra. Nanomaterials (Basel), 2017. 7(11).
46.	Gonzalez-Durruthy, M., et al., Experimental-Computational Study of Carbon Nanotube Effects on Mitochondrial Respiration: In Silico Nano-QSPR Machine Learning Models Based on New Raman Spectra Transform with Markov-Shannon Entropy Invariants. J Chem Inf Model, 2017. 57(5): p. 1029-1044.
47.	Garcia-Jacas, C.R., et al., Conformation-dependent QSAR approach for the prediction of inhibitory activity of bromodomain modulators. SAR QSAR Environ Res, 2017. 28(1): p. 41-58.
48.	Garcia-Jacas, C.R., et al., Tensor algebra-based geometric methodology to codify central chirality on organic molecules. SAR QSAR Environ Res, 2017. 28(6): p. 541-556.
49.	Estrada, E.S., et al., Multi-tool assessment of trace metals in mangroves combining sediment and clam sampling, DGT passive samplers and caged mussels. Sci Total Environ, 2017. 574: p. 847-857.
50.	Estrada, E., et al., Effects of reduced glutathione on acrosin activity in frozen-thawed boar spermatozoa. Reprod Fertil Dev, 2017. 29(2): p. 283-293.
51.	Estrada, E., et al., The addition of reduced glutathione to cryopreservation media induces changes in the structure of motile subpopulations of frozen-thawed boar sperm. Cryobiology, 2017. 78: p. 56-64.
52.	Estrada, E., A.A. Alhomaidhi, and F. Al-Thukair, Exploring the "Middle Earth" of network spectra via a Gaussian matrix function. Chaos, 2017. 27(2): p. 023109.
53.	Estrada, E., Quasirandom geometric networks from low-discrepancy sequences. Phys Rev E, 2017. 96(2-1): p. 022314.
54.	Cheng, Y., et al., Comparative Biomechanical Behavior and Healing Profile of a Novel Thinned Wall Ultrahigh Molecular Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold. Circ Cardiovasc Interv, 2017. 10(7).
55.	Camacho, D., et al., Descriptions of depression and depression treatment in older Hispanic immigrants in a geriatric collaborative care program. Aging Ment Health, 2017: p. 1-7.
56.	Alexanderson-Rosas, E., et al., [(18)F]-Sodium fluoride uptake in Takayasu arteritis. J Nucl Cardiol, 2017. 24(5): p. 1674-1679.
57.	Aguilera-Pesantes, D., et al., Discovering key residues of dengue virus NS2b-NS3-protease: New binding sites for antiviral inhibitors design. Biochem Biophys Res Commun, 2017. 492(4): p. 631-642.
58.	Abeijon, P., et al., Multi-Target Mining of Alzheimer Disease Proteome with Hansch's QSBR-Perturbation Theory and Experimental-Theoretic Study of New Thiophene Isosters of Rasagiline. Curr Drug Targets, 2017. 18(5): p. 511-521.
59.	Yeste, M., et al., Specific LED-based red light photo-stimulation procedures improve overall sperm function and reproductive performance of boar ejaculates. Sci Rep, 2016. 6: p. 22569.
60.	Yang, F., E.F. Estrada, and M.C. Sanchez, Vibration training improves disability status in multiple sclerosis: A pretest-posttest pilot study. J Neurol Sci, 2016. 369: p. 96-101.
61.	Valdez, Z., et al., Community Perspectives on Access to and Availability of Healthy Food in Rural, Low-Resource, Latino Communities. Prev Chronic Dis, 2016. 13: p. E170.
62.	Vahl, T.P., et al., Four-year polymer biocompatibility and vascular healing profile of a novel ultrahigh molecular weight amorphous PLLA bioresorbable vascular scaffold: an OCT study in healthy porcine coronary arteries. EuroIntervention, 2016. 12(12): p. 1510-1518.
63.	Todeschini, R., et al., Data Analysis in Chemistry and Bio-Medical Sciences. Int J Mol Sci, 2016. 17(12).
64.	Tenorio-Borroto, E., et al., Experimental-Theoretic Approach to Drug-Lymphocyte Interactome Networks with Flow Cytometry and Spectral Moments Perturbation Theory. Curr Pharm Des, 2016. 22(33): p. 5114-5119.
65.	Romero-Duran, F.J., et al., Brain-inspired cheminformatics of drug-target brain interactome, synthesis, and assay of TVP1022 derivatives. Neuropharmacology, 2016. 103: p. 270-8.
66.	Rivera-Borroto, O.M., et al., Relational Agreement Measures for Similarity Searching of Cheminformatic Data Sets. IEEE/ACM Trans Comput Biol Bioinform, 2016. 13(1): p. 158-67.
67.	Rivera-Borroto, O.M., et al., Relational Agreement Measures for Similarity Searching of Cheminformatic Data Sets. IEEE/ACM Trans Comput Biol Bioinform, 2016. 13(1): p. 158-67.
68.	Rivera Fernandez, N., et al., A new type of quinoxalinone derivatives affects viability, invasion, and intracellular growth of Toxoplasma gondii tachyzoites in vitro. Parasitol Res, 2016. 115(5): p. 2081-96.
69.	Ran, T., et al., Gastrointestinal Spatiotemporal mRNA Expression of Ghrelin vs Growth Hormone Receptor and New Growth Yield Machine Learning Model Based on Perturbation Theory. Sci Rep, 2016. 6: p. 30174.
70.	Pham-The, H., et al., Exploring different strategies for imbalanced ADME data problem: case study on Caco-2 permeability modeling. Mol Divers, 2016. 20(1): p. 93-109.
71.	Messina, P.V., et al., Computational Modeling and Experimental Facts of Mixed Self- Assembly Systems. Curr Pharm Des, 2016. 22(34): p. 5249-5256.
72.	Martinez-Santiago, O., et al., Physico-Chemical and Structural Interpretation of Discrete Derivative Indices on N-Tuples Atoms. Int J Mol Sci, 2016. 17(6).
73.	Martinez-Santiago, O., et al., Physico-Chemical and Structural Interpretation of Discrete Derivative Indices on N-Tuples Atoms. Int J Mol Sci, 2016. 17(6).
74.	Martinez-Santiago, O., et al., Generalized Molecular Descriptors Derived From Event-Based Discrete Derivative. Curr Pharm Des, 2016. 22(33): p. 5095-5113.
75.	Gonzalez-Diaz, H., ADMET-Multi-Output Cheminformatics Models for Drug Delivery, Interactomics, and Nanotoxicology. Curr Drug Deliv, 2016.
76.	Garcia-Jacas, C.R., et al., N-tuple topological/geometric cutoffs for 3D N-linear algebraic molecular codifications: variability, linear independence and QSAR analysis. SAR QSAR Environ Res, 2016. 27(12): p. 949-975.
77.	Garcia-Jacas, C.R., et al., N-tuple topological/geometric cutoffs for 3D N-linear algebraic molecular codifications: variability, linear independence and QSAR analysis. SAR QSAR Environ Res, 2016. 27(12): p. 949-975.
78.	Garcia-Jacas, C.R., et al., Examining the predictive accuracy of the novel 3D N-linear algebraic molecular codifications on benchmark datasets. J Cheminform, 2016. 8: p. 10.
79.	Garcia-Jacas, C.R., et al., Examining the predictive accuracy of the novel 3D N-linear algebraic molecular codifications on benchmark datasets. J Cheminform, 2016. 8: p. 10.
80.	Garcia, Y., et al., Orthotropic Piezoelectricity in 2D Nanocellulose. Sci Rep, 2016. 6: p. 34616.
81.	Estrada, E., et al., Epidemic spreading in random rectangular networks. Phys Rev E, 2016. 94(5-1): p. 052316.
82.	Estrada, E., et al., Nicotine dependence and psychosis in Bipolar disorder and Schizoaffective disorder, Bipolar type. Am J Med Genet B Neuropsychiatr Genet, 2016. 171(4): p. 521-4.
83.	Cheng, Y., et al., Comparative Characterization of Biomechanical Behavior and Healing Profile of a Novel Ultra-High-Molecular-Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold. Circ Cardiovasc Interv, 2016. 9(10).
84.	Casanola-Martin, G.M., et al., Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pathway (UPP) Proteins. Curr Protein Pept Sci, 2016. 17(3): p. 220-7.
85.	Casanola-Martin, G.M., et al., Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pathway (UPP) Proteins. Curr Protein Pept Sci, 2016. 17(3): p. 220-7.
86.	Casanola-Martin, G.M., et al., Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pathway (UPP) Proteins. Curr Protein Pept Sci, 2016. 17(3): p. 220-7.
87.	Bayen, S., et al., Pharmaceutically active compounds and endocrine disrupting chemicals in water, sediments and mollusks in mangrove ecosystems from Singapore. Mar Pollut Bull, 2016. 109(2): p. 716-22.
88.	Basak, S.C., et al., Editorial (Thematic Issue: Chemoinformatics Models for Pharmaceutical Design, Part 1). Curr Pharm Des, 2016. 22(33): p. 5041-5042.
89.	Basak, S.C., et al., Editorial (Thematic Issue: Chemoinformatics Models for Pharmaceutical Design, Part 2). Curr Pharm Des, 2016. 22(34): p. 5177-5178.
90.	Aranzamendi, E., et al., Chiral Bronsted Acid-Catalyzed Enantioselective alpha-Amidoalkylation Reactions: A Joint Experimental and Predictive Study. ChemistryOpen, 2016. 5(6): p. 540-549.
91.	Yeste, M., et al., Intracellular calcium movements of boar spermatozoa during 'in vitro' capacitation and subsequent acrosome exocytosis follow a multiple-storage place, extracellular calcium-dependent model. Andrology, 2015. 3(4): p. 729-47.
92.	Yeste, M., et al., Cryotolerance of stallion spermatozoa is related to ROS production and mitochondrial membrane potential rather than to the integrity of sperm nucleus. Andrology, 2015. 3(2): p. 395-407.
93.	Yang, Y., et al., Attenuation of acute stroke injury in rat brain by minocycline promotes blood-brain barrier remodeling and alternative microglia/macrophage activation during recovery. J Neuroinflammation, 2015. 12: p. 26.
94.	Urias, R.W., et al., IMMAN: free software for information theory-based chemometric analysis. Mol Divers, 2015. 19(2): p. 305-19.
95.	Urias, R.W., et al., IMMAN: free software for information theory-based chemometric analysis. Mol Divers, 2015. 19(2): p. 305-19.
96.	Sifontes-Rodriguez, S., et al., The efficacy of 2-nitrovinylfuran derivatives against Leishmania in vitro and in vivo. Mem Inst Oswaldo Cruz, 2015. 110(2): p. 166-73.
97.	Santos-Fita, D., et al., Symbolism and ritual practices related to hunting in Maya communities from central Quintana Roo, Mexico. J Ethnobiol Ethnomed, 2015. 11: p. 71.
98.	Ruiz-Blanco, Y.B., et al., ProtDCal: A program to compute general-purpose-numerical descriptors for sequences and 3D-structures of proteins. BMC Bioinformatics, 2015. 16: p. 162.
99.	Ruiz-Blanco, Y.B., et al., ProtDCal: A program to compute general-purpose-numerical descriptors for sequences and 3D-structures of proteins. BMC Bioinformatics, 2015. 16: p. 162.
100.	Ruiz-Blanco, Y.B., et al., A Hookes law-based approach to protein folding rate. J Theor Biol, 2015. 364: p. 407-17.
101.	Ruiz-Blanco, Y.B., et al., A Hookes law-based approach to protein folding rate. J Theor Biol, 2015. 364: p. 407-17.
102.	Munteanu, C.R., et al., Bio-AIMS Collection of Chemoinformatics Web Tools based on Molecular Graph Information and Artificial Intelligence Models. Comb Chem High Throughput Screen, 2015. 18(8): p. 735-50.
103.	Messina, P.V., et al., Self-Assembled Binary Nanoscale Systems: Multioutput Model with LFER-Covariance Perturbation Theory and an Experimental-Computational Study of NaGDC-DDAB Micelles. Langmuir, 2015. 31(44): p. 12009-18.
104.	Medina Marrero, R., et al., QuBiLs-MAS method in early drug discovery and rational drug identification of antifungal agents. SAR QSAR Environ Res, 2015. 26(11): p. 943-58.
105.	Marrero-Ponce, Y., et al., Novel 3D bio-macromolecular bilinear descriptors for protein science: Predicting protein structural classes. J Theor Biol, 2015. 374: p. 125-37.
106.	Maldonado-Rojas, W., J. Olivero-Verbel, and Y. Marrero-Ponce, Computational fishing of new DNA methyltransferase inhibitors from natural products. J Mol Graph Model, 2015. 60: p. 43-54.
107.	Liu, Y., et al., Experimental and computational studies of fatty acid distribution networks. Mol Biosyst, 2015. 11(11): p. 2964-77.
108.	Jasik, C.B., et al., Characteristics of Youth Presenting for Weight Management: Retrospective National Data from the POWER Study Group. Child Obes, 2015. 11(5): p. 630-7.
109.	Herrera-Ibata, D.M., et al., Mapping chemical structure-activity information of HAART-drug cocktails over complex networks of AIDS epidemiology and socioeconomic data of U.S. counties. Biosystems, 2015. 132-133: p. 20-34.
110.	Hempel, S., et al., in Modifiable Risk Factors in the Progression of Multiple Sclerosis: A Systematic Review of the Epidemiology and Treatment. 2015: Washington (DC).
111.	Gongora, C.A., et al., Vessel Caging Versus Vascular Restoration in the Same Artery: Long-Term Vascular Remodeling and Healing in Response to Overlapping Metal Stent and Bioresorbable Polymer Scaffold. JACC Cardiovasc Interv, 2015. 8(4): p. 631-2.
112.	Giaretta, E., et al., Combining reduced glutathione and ascorbic acid has supplementary beneficial effects on boar sperm cryotolerance. Theriogenology, 2015. 83(3): p. 399-407.
113.	Garcia-Jacas, C.R., et al., Multi-Server Approach for High-Throughput Molecular Descriptors Calculation based on Multi-Linear Algebraic Maps. Mol Inform, 2015. 34(1): p. 60-9.
114.	Estrada, E., E. Vargas-Estrada, and H. Ando, Communicability angles reveal critical edges for network consensus dynamics. Phys Rev E Stat Nonlin Soft Matter Phys, 2015. 92(5): p. 052809.
115.	Estrada, E. and M. Sheerin, Random rectangular graphs. Phys Rev E Stat Nonlin Soft Matter Phys, 2015. 91(4): p. 042805.
116.	Estrada, E. and G. Chen, Synchronizability of random rectangular graphs. Chaos, 2015. 25(8): p. 083107.
117.	Conesa-Zamora, P., et al., Methylome profiling reveals functions and genes which are differentially methylated in serrated compared to conventional colorectal carcinoma. Clin Epigenetics, 2015. 7: p. 101.
118.	Castillo-Gonzalez, D., et al., Harmonization of QSAR Best Practices and Molecular Docking Provides an Efficient Virtual Screening Tool for Discovering New G-Quadruplex Ligands. J Chem Inf Model, 2015. 55(10): p. 2094-110.
119.	Castillo-Garit, J.A., et al., Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening. Eur J Med Chem, 2015. 96: p. 238-44.
120.	Casanola-Martin, G.M., et al., Multi-output model with Box-Jenkins operators of linear indices to predict multi-target inhibitors of ubiquitin-proteasome pathway. Mol Divers, 2015. 19(2): p. 347-56.
121.	Casanola-Martin, G.M., et al., Multi-output model with Box-Jenkins operators of linear indices to predict multi-target inhibitors of ubiquitin-proteasome pathway. Mol Divers, 2015. 19(2): p. 347-56.
122.	Brito-Sanchez, Y., et al., Towards Better BBB Passage Prediction Using an Extensive and Curated Data Set. Mol Inform, 2015. 34(5): p. 308-30.
123.	Bayen, S., et al., Direct injection of tissue extracts in liquid chromatography/tandem mass spectrometry for the determination of pharmaceuticals and other contaminants of emerging concern in mollusks. Anal Bioanal Chem, 2015. 407(19): p. 5553-8.
124.	Aguilera-Mendoza, L., et al., Overlap and diversity in antimicrobial peptide databases: compiling a non-redundant set of sequences. Bioinformatics, 2015. 31(15): p. 2553-9.
125.	Yeste, M., et al., The increase in phosphorylation levels of serine residues of protein HSP70 during holding time at 17 degrees C is concomitant with a higher cryotolerance of boar spermatozoa. PLoS One, 2014. 9(3): p. e90887.
126.	Yeste, M., et al., The improving effect of reduced glutathione on boar sperm cryotolerance is related with the intrinsic ejaculate freezability. Cryobiology, 2014. 68(2): p. 251-61.
127.	Vergara-Galicia, J., F.J. Prado-Prado, and H. Gonzalez-Diaz, Galvez-Markov network transferability indices: review of classic theory and new model for perturbations in metabolic reactions. Curr Drug Metab, 2014. 15(5): p. 557-64.
128.	Vazquez-Prieto, S., et al., A QSPR-like model for multilocus genotype networks of Fasciola hepatica in Northwest Spain. J Theor Biol, 2014. 343: p. 16-24.
129.	Tenorio-Borroto, E., et al., QSPR and flow cytometry analysis (QSPR-FCA): review and new findings on parallel study of multiple interactions of chemical compounds with immune cellular and molecular targets. Curr Drug Metab, 2014. 15(4): p. 414-28.
130.	Tenorio-Borroto, E., et al., Model for high-throughput screening of drug immunotoxicity--study of the anti-microbial G1 over peritoneal macrophages using flow cytometry. Eur J Med Chem, 2014. 72: p. 206-20.
131.	Romero Duran, F.J., et al., Prediction of multi-target networks of neuroprotective compounds with entropy indices and synthesis, assay, and theoretical study of new asymmetric 1,2-rasagiline carbamates. Int J Mol Sci, 2014. 15(9): p. 17035-64.
132.	Ramirez-Garzon, Y.T., et al., Measurement of radiation exposure in relatives of thyroid cancer patients treated with (131)I. Health Phys, 2014. 107(5): p. 410-6.
133.	Ramio-Lluch, L., et al., Oligomycin A-induced inhibition of mitochondrial ATP-synthase activity suppresses boar sperm motility and in vitro capacitation achievement without modifying overall sperm energy levels. Reprod Fertil Dev, 2014. 26(6): p. 883-97.
134.	Perez-Castillo, Y., et al., Toward the computer-aided discovery of FabH inhibitors. Do predictive QSAR models ensure high quality virtual screening performance? Mol Divers, 2014. 18(3): p. 637-54.
135.	Najem, C., et al., An unusual case of hematuria. Arthritis Care Res (Hoboken), 2014. 66(7): p. 1119-26.
136.	Munteanu, C.R., et al., LECTINPred: web Server that Uses Complex Networks of Protein Structure for Prediction of Lectins with Potential Use as Cancer Biomarkers or in Parasite Vaccine Design. Mol Inform, 2014. 33(4): p. 276-85.
137.	Martins Alho, M.A., et al., Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones. Bioorg Med Chem, 2014. 22(5): p. 1568-85.
138.	Martinez-Santiago, O., et al., Discrete Derivatives for Atom-Pairs as a Novel Graph-Theoretical Invariant for Generating New Molecular Descriptors: Orthogonality, Interpretation and QSARs/QSPRs on Benchmark Databases. Mol Inform, 2014. 33(5): p. 343-68.
139.	Martinez-Santiago, O., et al., Discrete Derivatives for Atom-Pairs as a Novel Graph-Theoretical Invariant for Generating New Molecular Descriptors: Orthogonality, Interpretation and QSARs/QSPRs on Benchmark Databases. Mol Inform, 2014. 33(5): p. 343-68.
140.	Luan, F., et al., Computer-aided nanotoxicology: assessing cytotoxicity of nanoparticles under diverse experimental conditions by using a novel QSTR-perturbation approach. Nanoscale, 2014. 6(18): p. 10623-30.
141.	Le-Thi-Thu, H., et al., A rational workflow for sequential virtual screening of chemical libraries on searching for new tyrosinase inhibitors. Curr Top Med Chem, 2014. 14(12): p. 1473-85.
142.	Kleandrova, V.V., et al., Computational tool for risk assessment of nanomaterials: novel QSTR-perturbation model for simultaneous prediction of ecotoxicity and cytotoxicity of uncoated and coated nanoparticles under multiple experimental conditions. Environ Sci Technol, 2014. 48(24): p. 14686-94.
143.	Kleandrova, V.V., et al., Computational ecotoxicology: simultaneous prediction of ecotoxic effects of nanoparticles under different experimental conditions. Environ Int, 2014. 73: p. 288-94.
144.	Ibanez-Escribano, A., et al., A sequential procedure for rapid and accurate identification of putative trichomonacidal agents. J Microbiol Methods, 2014. 105: p. 162-7.
145.	Haemer, M.A., et al., Addressing prediabetes in childhood obesity treatment programs: support from research and current practice. Child Obes, 2014. 10(4): p. 292-303.
146.	Gonzalez-Diaz, H., A. Speck-Planche, and M.N. Cordeiro, Editorial: Chemoinformatics in metabolomics, modeling chemical reactivity and ADMET processes part 1. Curr Drug Metab, 2014. 15(4): p. 345.
147.	Gonzalez-Diaz, H., A. Speck-Planche, and M.N. Cordeiro, Chemoinformatics in metabolomics, from molecular mechanics, dynamics, and docking to complex metabolic networks, part 2. Curr Drug Metab, 2014. 15(5): p. 489.
148.	Gonzalez-Diaz, H., L.G. Perez-Montoto, and F.M. Ubeira, Model for vaccine design by prediction of B-epitopes of IEDB given perturbations in peptide sequence, in vivo process, experimental techniques, and source or host organisms. J Immunol Res, 2014. 2014: p. 768515.
149.	Gonzalez-Diaz, H., et al., ANN multiscale model of anti-HIV drugs activity vs AIDS prevalence in the US at county level based on information indices of molecular graphs and social networks. J Chem Inf Model, 2014. 54(3): p. 744-55.
150.	Gonzalez-Diaz, H., et al., Matrix trace operators: from spectral moments of molecular graphs and complex networks to perturbations in synthetic reactions, micelle nanoparticles, and drug ADME processes. Curr Drug Metab, 2014. 15(4): p. 470-88.
151.	Garcia-Jacas, C.R., et al., N-linear algebraic maps for chemical structure codification: a suitable generalization for atom-pair approaches? Curr Drug Metab, 2014. 15(4): p. 441-69.
152.	Garcia-Jacas, C.R., et al., QuBiLS-MIDAS: a parallel free-software for molecular descriptors computation based on multilinear algebraic maps. J Comput Chem, 2014. 35(18): p. 1395-409.
153.	Garcia-Fuentes, M., H. Gonzalez-Diaz, and N. Csaba, Nanocarriers & drug delivery: rational design and applications. Curr Top Med Chem, 2014. 14(9): p. 1095-6.
154.	Fernandez-Lozano, C., et al., Markov mean properties for cell death-related protein classification. J Theor Biol, 2014. 349: p. 12-21.
155.	Estrada Espinosa, J.C., S.A. Martinez Ovalle, and C.K. Pereira Benavides, Dosimetric algorithm to reproduce isodose curves obtained from a LINAC. Comput Math Methods Med, 2014. 2014: p. 849505.
156.	Estrada, E., et al., Supplementing cryopreservation media with reduced glutathione increases fertility and prolificacy of sows inseminated with frozen-thawed boar semen. Andrology, 2014. 2(1): p. 88-99.
157.	Estrada, E. and J. Gomez-Gardenes, Communicability reveals a transition to coordinated behavior in multiplex networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2014. 89(4): p. 042819.
158.	Estrada, E., et al., Children's Hospital Association consensus statements for comorbidities of childhood obesity. Child Obes, 2014. 10(4): p. 304-17.
159.	Estrada, E. and M. Benzi, Walk-based measure of balance in signed networks: detecting lack of balance in social networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2014. 90(4): p. 042802.
160.	Duardo-Sanchez, A., et al., Modeling complex metabolic reactions, ecological systems, and financial and legal networks with MIANN models based on Markov-Wiener node descriptors. J Chem Inf Model, 2014. 54(1): p. 16-29.
161.	Casanola-Martin, G.M., et al., Tyrosinase enzyme: 1. An overview on a pharmacological target. Curr Top Med Chem, 2014. 14(12): p. 1494-501.
162.	Barigye, S.J., et al., Trends in information theory-based chemical structure codification. Mol Divers, 2014. 18(3): p. 673-86.
163.	Yeste, M., et al., Reduced glutathione and procaine hydrochloride protect the nucleoprotein structure of boar spermatozoa during freeze-thawing by stabilising disulfide bonds. Reprod Fertil Dev, 2013. 25(7): p. 1036-50.
164.	Yeste, M., et al., Good and bad freezability boar ejaculates differ in the integrity of nucleoprotein structure after freeze-thawing but not in ROS levels. Theriogenology, 2013. 79(6): p. 929-39.
165.	Yang, Y., et al., Early inhibition of MMP activity in ischemic rat brain promotes expression of tight junction proteins and angiogenesis during recovery. J Cereb Blood Flow Metab, 2013. 33(7): p. 1104-14.
166.	Tenorio-Borroto, E., et al., Entropy model for multiplex drug-target interaction endpoints of drug immunotoxicity. Curr Top Med Chem, 2013. 13(14): p. 1636-49.
167.	Sobarzo-Sanchez, E., et al., Synthetic oxoisoaporphine alkaloids: in vitro, in vivo and in silico assessment of antileishmanial activities. PLoS One, 2013. 8(10): p. e77560.
168.	Ruiz-Blanco, Y.B., et al., Global stability of protein folding from an empirical free energy function. J Theor Biol, 2013. 321: p. 44-53.
169.	Ruiz-Blanco, Y.B., et al., Global stability of protein folding from an empirical free energy function. J Theor Biol, 2013. 321: p. 44-53.
170.	Rivera, N., et al., In vivo genotoxicity and cytotoxicity assessment of a novel quinoxalinone with trichomonacide activity. J Appl Toxicol, 2013. 33(12): p. 1493-9.
171.	Prado-Prado, F., et al., Patents of bio-active compounds based on computer-aided drug discovery techniques. Front Biosci (Elite Ed), 2013. 5: p. 399-407.
172.	Pham-The, H., et al., The Use of Rule-Based and QSPR Approaches in ADME Profiling: A Case Study on Caco-2 Permeability. Mol Inform, 2013. 32(5-6): p. 459-79.
173.	Pham-The, H., et al., Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number. Mol Pharm, 2013. 10(6): p. 2445-61.
174.	Luan, F., et al., TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases. Bioorg Med Chem, 2013. 21(7): p. 1870-9.
175.	Han, P., et al., Reduction of nutrient contaminants into shallow eutrophic waters through vegetated treatment beds. Water Sci Technol, 2013. 68(6): p. 1280-7.
176.	Gonzalez-Diaz, H., et al., The Rucker-Markov invariants of complex Bio-Systems: applications in Parasitology and Neuroinformatics. Biosystems, 2013. 111(3): p. 199-207.
177.	Gonzalez-Diaz, H., et al., MIANN models in medicinal, physical and organic chemistry. Curr Top Med Chem, 2013. 13(5): p. 619-41.
178.	Gonzalez-Diaz, H., et al., General theory for multiple input-output perturbations in complex molecular systems. 1. Linear QSPR electronegativity models in physical, organic, and medicinal chemistry. Curr Top Med Chem, 2013. 13(14): p. 1713-41.
179.	Gonzalez-Diaz, H., Computational prediction of drug-target interactions in medicinal chemistry. Curr Top Med Chem, 2013. 13(14): p. 1619-21.
180.	Estrada, E. and E. Vargas-Estrada, How peer pressure shapes consensus, leadership, and innovations in social groups. Sci Rep, 2013. 3: p. 2905.
181.	Estrada, E., Communicability in temporal networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2013. 88(4): p. 042811.
182.	Duardo-Sanchez, A. and H. Gonzalez-Diaz, Legal issues for chem-bioinformatics models. Front Biosci (Elite Ed), 2013. 5: p. 361-74.
183.	Castillo-Gonzalez, D., et al., FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA. Curr Pharm Des, 2013. 19(12): p. 2164-73.
184.	Brito-Sanchez, Y., et al., Comparative study to predict toxic modes of action of phenols from molecular structures. SAR QSAR Environ Res, 2013. 24(3): p. 235-51.
185.	Barigye, S.J., et al., Shannon's, mutual, conditional and joint entropy information indices: generalization of global indices defined from local vertex invariants. Curr Comput Aided Drug Des, 2013. 9(2): p. 164-83.
186.	Barigye, S.J., et al., Shannon's, mutual, conditional and joint entropy information indices: generalization of global indices defined from local vertex invariants. Curr Comput Aided Drug Des, 2013. 9(2): p. 164-83.
187.	Barigye, S.J., et al., Relations frequency hypermatrices in mutual, conditional and joint entropy-based information indices. J Comput Chem, 2013. 34(4): p. 259-74.
188.	Barigye, S.J., et al., Event-based criteria in GT-STAF information indices: theory, exploratory diversity analysis and QSPR applications. SAR QSAR Environ Res, 2013. 24(1): p. 3-34.
189.	Barigye, S.J., et al., Event-based criteria in GT-STAF information indices: theory, exploratory diversity analysis and QSPR applications. SAR QSAR Environ Res, 2013. 24(1): p. 3-34.
190.	Alvarez-Ginarte, Y.M., et al., Integration of ligand and structure-based virtual screening for identification of leading anabolic steroids. J Steroid Biochem Mol Biol, 2013. 138: p. 348-58.
191.	Alonso, N., et al., Model for high-throughput screening of multitarget drugs in chemical neurosciences: synthesis, assay, and theoretic study of rasagiline carbamates. ACS Chem Neurosci, 2013. 4(10): p. 1393-403.
192.	Vega, M.C., et al., Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug. Eur J Med Chem, 2012. 58: p. 214-27.
193.	Tenorio-Borroto, E., et al., Immunotoxicity, flow cytometry, and chemoinformatics: review, bibliometric analysis, and new QSAR model of drug effects over macrophages. Curr Top Med Chem, 2012. 12(16): p. 1815-33.
194.	Tenorio-Borroto, E., et al., ANN multiplexing model of drugs effect on macrophages; theoretical and flow cytometry study on the cytotoxicity of the anti-microbial drug G1 in spleen. Bioorg Med Chem, 2012. 20(20): p. 6181-94.
195.	Rivera-Borroto, O.M., et al., Dunn's index for cluster tendency assessment of pharmacological data sets. Can J Physiol Pharmacol, 2012. 90(4): p. 425-33.
196.	Riera-Fernandez, P., et al., New Markov-Shannon Entropy models to assess connectivity quality in complex networks: from molecular to cellular pathway, Parasite-Host, Neural, Industry, and Legal-Social networks. J Theor Biol, 2012. 293: p. 174-88.
197.	Riera-Fernandez, P., et al., From QSAR models of drugs to complex networks: state-of-art review and introduction of new Markov-spectral moments indices. Curr Top Med Chem, 2012. 12(8): p. 927-60.
198.	Prado-Prado, F., et al., 3D MI-DRAGON: new model for the reconstruction of US FDA drug- target network and theoretical-experimental studies of inhibitors of rasagiline derivatives for AChE. Curr Top Med Chem, 2012. 12(16): p. 1843-65.
199.	Perez-Castillo, Y., et al., GA(M)E-QSAR: a novel, fully automatic genetic-algorithm-(meta)-ensembles approach for binary classification in ligand-based drug design. J Chem Inf Model, 2012. 52(9): p. 2366-86.
200.	Morera, C., et al., Contralateral hearing aid use in cochlear implanted patients: multicenter study of bimodal benefit. Acta Otolaryngol, 2012. 132(10): p. 1084-94.
201.	Marrero-Ponce, Y., et al., Derivatives in discrete mathematics: a novel graph-theoretical invariant for generating new 2/3D molecular descriptors. I. Theory and QSPR application. J Comput Aided Mol Des, 2012. 26(11): p. 1229-46.
202.	Jacob, J.C., et al., Coronary artery dissection in Prader-Willi syndrome: case report and literature review. Can J Cardiol, 2012. 28(6): p. 759 e9-759 e11.
203.	Gonzalez-Diaz, H. and P. Riera-Fernandez, New Markov-autocorrelation indices for re-evaluation of links in chemical and biological complex networks used in metabolomics, parasitology, neurosciences, and epidemiology. J Chem Inf Model, 2012. 52(12): p. 3331-40.
204.	Gonzalez-Diaz, H., et al., LIBP-Pred: web server for lipid binding proteins using structural network parameters; PDB mining of human cancer biomarkers and drug targets in parasites and bacteria. Mol Biosyst, 2012. 8(3): p. 851-62.
205.	Gonzalez-Diaz, H., Editorial: QSAR/QSPR models as enabling technologies for drug & targets discovery in: medicinal chemistry, microbiology-parasitology, neurosciences, bioinformatics, proteomics and other biomedical sciences. Curr Top Med Chem, 2012. 12(8): p. 799-801.
206.	Estrada, E., Complex networks in the Euclidean space of communicability distances. Phys Rev E Stat Nonlin Soft Matter Phys, 2012. 85(6 Pt 2): p. 066122.
207.	Estrada, E., Complex biomolecular networks: challenges and opportunities. Brief Funct Genomics, 2012. 11(6): p. 417-9.
208.	Diaz-Molina, J.P., et al., Functional and oncological results of non-surgical vs surgical treatment in squamous cell carcinomas of the oropharynx. Acta Otorrinolaringol Esp, 2012. 63(5): p. 348-54.
209.	Castillo-Gonzalez, D., et al., Computational tools in the discovery of new G-quadruplex ligands with potential anticancer activity. Curr Top Med Chem, 2012. 12(24): p. 2843-56.
210.	Castillo-Garit, J.A., et al., Identification in silico and in vitro of novel trypanosomicidal drug-like compounds. Chem Biol Drug Des, 2012. 80(1): p. 38-45.
211.	Castillo-Garit, J.A., et al., A review of QSAR studies to discover new drug-like compounds actives against leishmaniasis and trypanosomiasis. Curr Top Med Chem, 2012. 12(8): p. 852-65.
212.	Cabrera-Perez, M.A., et al., QSPR in oral bioavailability: specificity or integrality? Mini Rev Med Chem, 2012. 12(6): p. 534-50.
213.	Aguiar-Pulido, V., et al., Naive Bayes QSDR classification based on spiral-graph Shannon entropies for protein biomarkers in human colon cancer. Mol Biosyst, 2012. 8(6): p. 1716-22.
214.	Saiz-Urra, L., et al., Combining molecular docking and QSAR studies for modelling the antigyrase activity of cyclothialidine derivatives. Eur J Med Chem, 2011. 46(7): p. 2736-47.
215.	Rivera-Borroto, O.M., et al., Comparison of combinatorial clustering methods on pharmacological data sets represented by machine learning-selected real molecular descriptors. J Chem Inf Model, 2011. 51(12): p. 3036-49.
216.	Rivera-Borroto, O.M., et al., Comparison of combinatorial clustering methods on pharmacological data sets represented by machine learning-selected real molecular descriptors. J Chem Inf Model, 2011. 51(12): p. 3036-49.
217.	Riera-Fernandez, P., et al., From chemical graphs in computer-aided drug design to general Markov-Galvez indices of drug-target, proteome, drug-parasitic disease, technological, and social-legal networks. Curr Comput Aided Drug Des, 2011. 7(4): p. 315-37.
218.	Rescigno, A., et al., Vanilloid derivatives as tyrosinase inhibitors driven by virtual screening-based QSAR models. Drug Test Anal, 2011. 3(3): p. 176-81.
219.	Prado-Prado, F., et al., 2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins. Eur J Med Chem, 2011. 46(12): p. 5838-51.
220.	Prado-Prado, F., et al., Using entropy of drug and protein graphs to predict FDA drug-target network: theoretic-experimental study of MAO inhibitors and hemoglobin peptides from Fasciola hepatica. Eur J Med Chem, 2011. 46(4): p. 1074-94.
221.	Phulwani, P., et al., Hereditary hypophosphatemic rickets with hypercalciuria and nephrolithiasis-identification of a novel SLC34A3/NaPi-IIc mutation. Am J Med Genet A, 2011. 155A(3): p. 626-33.
222.	Pham The, H., et al., In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Mol Inform, 2011. 30(4): p. 376-85.
223.	Perez-Castillo, Y., et al., Molecular dynamics and docking simulations as a proof of high flexibility in E. coli FabH and its relevance for accurate inhibitor modeling. J Comput Aided Mol Des, 2011. 25(4): p. 371-93.
224.	Moran, V.P., et al., Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba. MEDICC Rev, 2011. 13(1): p. 35-40.
225.	Marzaro, G., et al., Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. Eur J Med Chem, 2011. 46(6): p. 2185-92.
226.	Marrero-Ponce, Y., et al., Discovery of novel anti-inflammatory drug-like compounds by aligning in silico and in vivo screening: the nitroindazolinone chemotype. Eur J Med Chem, 2011. 46(12): p. 5736-53.
227.	Le-Thi-Thu, H., et al., A Comparative Study of Nonlinear Machine Learning for the "In Silico" Depiction of Tyrosinase Inhibitory Activity from Molecular Structure. Mol Inform, 2011. 30(6-7): p. 527-37.
228.	Le-Thi-Thu, H., et al., Novel coumarin-based tyrosinase inhibitors discovered by OECD principles-validated QSAR approach from an enlarged, balanced database. Mol Divers, 2011. 15(2): p. 507-20.
229.	Grindrod, P., et al., Communicability across evolving networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2011. 83(4 Pt 2): p. 046120.
230.	Gonzalez-Diaz, H., et al., NL MIND-BEST: a web server for ligands and proteins discovery--theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum. J Theor Biol, 2011. 276(1): p. 229-49.
231.	Gonzalez-Diaz, H., et al., MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae. J Proteome Res, 2011. 10(4): p. 1698-718.
232.	Gonzalez-Diaz, H., et al., MISS-Prot: web server for self/non-self discrimination of protein residue networks in parasites; theory and experiments in Fasciola peptides and Anisakis allergens. Mol Biosyst, 2011. 7(6): p. 1938-55.
233.	Gonzalez-Diaz, H., QSPR models for computer-aided drug design in microbiology, parasitology, and pharmacology. Curr Comput Aided Drug Des, 2011. 7(4): p. 228-30.
234.	Gonzalez, E.E., et al., Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. Invest New Drugs, 2011. 29(6): p. 1459-64.
235.	Garcia, I., et al., First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines. Mol Divers, 2011. 15(2): p. 561-7.
236.	Estrada, E., F. Kalala-Mutombo, and A. Valverde-Colmeiro, Epidemic spreading in networks with nonrandom long-range interactions. Phys Rev E Stat Nonlin Soft Matter Phys, 2011. 84(3 Pt 2): p. 036110.
237.	Estrada, E., Community detection based on network communicability. Chaos, 2011. 21(1): p. 016103.
238.	Estrada, E., Combinatorial study of degree assortativity in networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2011. 84(4 Pt 2): p. 047101.
239.	Concu, R., et al., Review of computer-aided models for predicting collagen stability. Curr Comput Aided Drug Des, 2011. 7(4): p. 287-303.
240.	Cetina, L., et al., F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma. Rev Invest Clin, 2011. 63(3): p. 227-35.
241.	Caumette, G., et al., Arsenic speciation in plankton organisms from contaminated lakes: transformations at the base of the freshwater food chain. Environ Sci Technol, 2011. 45(23): p. 9917-23.
242.	Castillo-Garit, J.A., et al., Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support. Eur J Med Chem, 2011. 46(8): p. 3324-30.
243.	Alvarez-Ginarte, Y.M., et al., Anabolic and androgenic activities of 19-nor-testosterone steroids: QSAR study using quantum and physicochemical molecular descriptors. J Steroid Biochem Mol Biol, 2011. 126(1-2): p. 35-45.
244.	Al-Solaiman, Y., E. Estrada, and M. Allon, The spectrum of infections in catheter-dependent hemodialysis patients. Clin J Am Soc Nephrol, 2011. 6(9): p. 2247-52.
245.	Yang, Y., et al., Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem, 2010. 112(1): p. 134-49.
246.	Savitskaya, Y.A., et al., Circulating Natural IgM Antibodies Against Angiogenin in the Peripheral Blood Sera of Patients with Osteosarcoma as Candidate Biomarkers and Reporters of Tumorigenesis. Biomark Cancer, 2010. 2: p. 65-78.
247.	Sanders, M.R., et al., Flexing to aging: a children's hospital responds to a maturing workforce. J Pediatr, 2010. 157(2): p. 177-178 e1.
248.	Rodriguez-Soca, Y., et al., Trypano-PPI: a web server for prediction of unique targets in trypanosome proteome by using electrostatic parameters of protein-protein interactions. J Proteome Res, 2010. 9(2): p. 1182-90.
249.	Prado-Prado, F.J., et al., Unified QSAR & network-based computational chemistry approach to antimicrobials. II. Multiple distance and triadic census analysis of antiparasitic drugs complex networks. J Comput Chem, 2010. 31(1): p. 164-73.
250.	Prado-Prado, F.J., X. Garcia-Mera, and H. Gonzalez-Diaz, Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg Med Chem, 2010. 18(6): p. 2225-2231.
251.	Palomares-Alonso, F., et al., Two novel ternary albendazole-cyclodextrin-polymer systems: dissolution, bioavailability and efficacy against Taenia crassiceps cysts. Acta Trop, 2010. 113(1): p. 56-60.
252.	Ortega-Broche, S.E., et al., TOMOCOMD-CAMPS and protein bilinear indices--novel bio-macromolecular descriptors for protein research: I. Predicting protein stability effects of a complete set of alanine substitutions in the Arc repressor. FEBS J, 2010. 277(15): p. 3118-46.
253.	Ortega-Broche, S.E., et al., TOMOCOMD-CAMPS and protein bilinear indices--novel bio-macromolecular descriptors for protein research: I. Predicting protein stability effects of a complete set of alanine substitutions in the Arc repressor. FEBS J, 2010. 277(15): p. 3118-46.
254.	Muriel, C., et al., Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. Clin Transl Oncol, 2010. 12(8): p. 562-7.
255.	Marrero-Ponce, Y., et al., Bond-based linear indices of the non-stochastic and stochastic edge-adjacency matrix. 1. Theory and modeling of ChemPhys properties of organic molecules. Mol Divers, 2010. 14(4): p. 731-53.
256.	Marrero-Ponce, Y., et al., Ligand-based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMD-CARDD method to the elucidation of new compounds. Curr Pharm Des, 2010. 16(24): p. 2601-24.
257.	Gonzalez-Diaz, H., et al., Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues. Curr Pharm Des, 2010. 16(24): p. 2737-64.
258.	Gonzalez-Diaz, H., et al., Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr Drug Metab, 2010. 11(4): p. 379-406.
259.	Gonzalez-Diaz, H., et al., QSAR for RNases and theoretic-experimental study of molecular diversity on peptide mass fingerprints of a new Leishmania infantum protein. Mol Divers, 2010. 14(2): p. 349-69.
260.	Gonzalez-Diaz, H., Network topological indices, drug metabolism, and distribution. Curr Drug Metab, 2010. 11(4): p. 283-4.
261.	Gonzalez-Diaz, H., QSAR and complex networks in pharmaceutical design, microbiology, parasitology, toxicology, cancer, and neurosciences. Curr Pharm Des, 2010. 16(24): p. 2598-600.
262.	Estrada, E., et al., Structural contributions of substrates to their binding to P-Glycoprotein. A TOPS-MODE approach. Curr Pharm Des, 2010. 16(24): p. 2676-709.
263.	Estrada, E., Generalized walks-based centrality measures for complex biological networks. J Theor Biol, 2010. 263(4): p. 556-65.
264.	Estrada, E., Universality in protein residue networks. Biophys J, 2010. 98(5): p. 890-900.
265.	Estrada, E., Randic index, irregularity and complex biomolecular networks. Acta Chim Slov, 2010. 57(3): p. 597-603.
266.	Estrada, E., Quantifying network heterogeneity. Phys Rev E Stat Nonlin Soft Matter Phys, 2010. 82(6 Pt 2): p. 066102.
267.	Concu, R., et al., Review of QSAR models for enzyme classes of drug targets: Theoretical background and applications in parasites, hosts, and other organisms. Curr Pharm Des, 2010. 16(24): p. 2710-23.
268.	Castillo-Garit, J.A., et al., Computational discovery of novel trypanosomicidal drug-like chemicals by using bond-based non-stochastic and stochastic quadratic maps and linear discriminant analysis. Eur J Pharm Sci, 2010. 39(1-3): p. 30-6.
269.	Castillo-Garit, J.A., et al., Computational discovery of novel trypanosomicidal drug-like chemicals by using bond-based non-stochastic and stochastic quadratic maps and linear discriminant analysis. Eur J Pharm Sci, 2010. 39(1-3): p. 30-6.
270.	Casanola-Martin, G.M., et al., Bond-based 2D quadratic fingerprints in QSAR studies: virtual and in vitro tyrosinase inhibitory activity elucidation. Chem Biol Drug Des, 2010. 76(6): p. 538-45.
271.	Anadon, A.M., et al., Diagnosing human anisakiasis: recombinant Ani s 1 and Ani s 7 allergens versus the UniCAP 100 fluorescence enzyme immunoassay. Clin Vaccine Immunol, 2010. 17(4): p. 496-502.
272.	Vina, D., et al., Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. Mol Pharm, 2009. 6(3): p. 825-35.
273.	Vilar, S., et al., A network-QSAR model for prediction of genetic-component biomarkers in human colorectal cancer. J Theor Biol, 2009. 261(3): p. 449-58.
274.	Taheri, S., et al., Spatiotemporal correlations between blood-brain barrier permeability and apparent diffusion coefficient in a rat model of ischemic stroke. PLoS One, 2009. 4(8): p. e6597.
275.	Sood, R., et al., Increased apparent diffusion coefficients on MRI linked with matrix metalloproteinases and edema in white matter after bilateral carotid artery occlusion in rats. J Cereb Blood Flow Metab, 2009. 29(2): p. 308-16.
276.	Prado-Prado, F.J., et al., Multi-target spectral moments for QSAR and Complex Networks study of antibacterial drugs. Eur J Med Chem, 2009. 44(11): p. 4516-21.
277.	Prado-Prado, F.J., et al., Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg Med Chem, 2009. 17(2): p. 569-75.
278.	Prado-Prado, F.J., et al., Multi-target spectral moment: QSAR for antiviral drugs vs. different viral species. Anal Chim Acta, 2009. 651(2): p. 159-64.
279.	Prado-Prado, F.J., et al., Multi-target spectral moment: QSAR for antifungal drugs vs. different fungi species. Eur J Med Chem, 2009. 44(10): p. 4051-6.
280.	Peterson, W.J., et al., Treatment of dialysis catheter-related Enterococcus bacteremia with an antibiotic lock: a quality improvement report. Am J Kidney Dis, 2009. 53(1): p. 107-11.
281.	Perez-Montoto, L.G., L. Santana, and H. Gonzalez-Diaz, Scoring function for DNA-drug docking of anticancer and antiparasitic compounds based on spectral moments of 2D lattice graphs for molecular dynamics trajectories. Eur J Med Chem, 2009. 44(11): p. 4461-9.
282.	Perez-Bello, A., et al., Alignment-free prediction of mycobacterial DNA promoters based on pseudo-folding lattice network or star-graph topological indices. J Theor Biol, 2009. 256(3): p. 458-66.
283.	Munteanu, C.R., et al., Complex network spectral moments for ATCUN motif DNA cleavage: first predictive study on proteins of human pathogen parasites. J Proteome Res, 2009. 8(11): p. 5219-28.
284.	Munteanu, C.R., et al., Multi-target QPDR classification model for human breast and colon cancer-related proteins using star graph topological indices. J Theor Biol, 2009. 257(2): p. 303-11.
285.	Marrero-Ponce, Y., et al., Nucleotide's bilinear indices: novel bio-macromolecular descriptors for bioinformatics studies of nucleic acids. I. Prediction of paromomycin's affinity constant with HIV-1 Psi-RNA packaging region. J Theor Biol, 2009. 259(2): p. 229-41.
286.	Marrero-Ponce, Y., et al., Nucleotide's bilinear indices: novel bio-macromolecular descriptors for bioinformatics studies of nucleic acids. I. Prediction of paromomycin's affinity constant with HIV-1 Psi-RNA packaging region. J Theor Biol, 2009. 259(2): p. 229-41.
287.	Gonzalez-Diaz, H., et al., Generalized lattice graphs for 2D-visualization of biological information. J Theor Biol, 2009. 261(1): p. 136-47.
288.	Garcia, I., et al., QSAR and complex network study of the chiral HMGR inhibitor structural diversity. Bioorg Med Chem, 2009. 17(1): p. 165-75.
289.	Estrada, E., Information mobility in complex networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2009. 80(2 Pt 2): p. 026104.
290.	Concu, R., et al., Computational chemistry study of 3D-structure-function relationships for enzymes based on Markov models for protein electrostatic, HINT, and van der Waals potentials. J Comput Chem, 2009. 30(9): p. 1510-20.
291.	Concu, R., et al., 3D entropy and moments prediction of enzyme classes and experimental-theoretic study of peptide fingerprints in Leishmania parasites. Biochim Biophys Acta, 2009. 1794(12): p. 1784-94.
292.	Concu, R., et al., Prediction of enzyme classes from 3D structure: a general model and examples of experimental-theoretic scoring of peptide mass fingerprints of Leishmania proteins. J Proteome Res, 2009. 8(9): p. 4372-82.
293.	Castillo-Gonzalez, D., et al., Prediction of telomerase inhibitory activity for acridinic derivatives based on chemical structure. Eur J Med Chem, 2009. 44(12): p. 4826-40.
294.	Aguero-Chapin, G., et al., Alignment-free prediction of polygalacturonases with pseudofolding topological indices: experimental isolation from Coffea arabica and prediction of a new sequence. J Proteome Res, 2009. 8(4): p. 2122-8.
295.	Vilar, S., et al., QSAR model for alignment-free prediction of human breast cancer biomarkers based on electrostatic potentials of protein pseudofolding HP-lattice networks. J Comput Chem, 2008. 29(16): p. 2613-22.
296.	Sood, R.R., et al., Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab, 2008. 28(2): p. 431-8.
297.	Santana, L., et al., Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem, 2008. 51(21): p. 6740-51.
298.	Roldos, V., et al., Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies. Eur J Med Chem, 2008. 43(9): p. 1797-807.
299.	Prado-Prado, F.J., et al., Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorg Med Chem, 2008. 16(11): p. 5871-80.
300.	Munteanu, C.R., H. Gonzalez-Diaz, and A.L. Magalhaes, Enzymes/non-enzymes classification model complexity based on composition, sequence, 3D and topological indices. J Theor Biol, 2008. 254(2): p. 476-82.
301.	Munteanu, C.R., et al., Natural/random protein classification models based on star network topological indices. J Theor Biol, 2008. 254(4): p. 775-83.
302.	Morales Helguera, A., et al., Quantitative structure-carcinogenicity relationship for detecting structural alerts in nitroso compounds: species, rat; sex, female; route of administration, gavage. Chem Res Toxicol, 2008. 21(3): p. 633-42.
303.	Meneses-Marcel, A., et al., New antitrichomonal drug-like chemicals selected by bond (edge)-based TOMOCOMD-CARDD descriptors. J Biomol Screen, 2008. 13(8): p. 785-94.
304.	Marrero-Ponce, Y., et al., Bond-based linear indices in QSAR: computational discovery of novel anti-trichomonal compounds. J Comput Aided Mol Des, 2008. 22(8): p. 523-40.
305.	Ibarra-Velarde, F., et al., In silico fasciolicide activity of three experimental compounds in sheep. Ann N Y Acad Sci, 2008. 1149: p. 183-5.
306.	Gonzalez-Diaz, H. and F.J. Prado-Prado, Unified QSAR and network-based computational chemistry approach to antimicrobials, part 1: multispecies activity models for antifungals. J Comput Chem, 2008. 29(4): p. 656-67.
307.	Gonzalez-Diaz, H., F. Prado-Prado, and F.M. Ubeira, Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr Top Med Chem, 2008. 8(18): p. 1676-90.
308.	Gonzalez-Diaz, H., et al., Proteomics, networks and connectivity indices. Proteomics, 2008. 8(4): p. 750-78.
309.	Gonzalez-Diaz, H., Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr Top Med Chem, 2008. 8(18): p. 1554.
310.	Ferino, G., et al., Using spectral moments of spiral networks based on PSA/mass spectra outcomes to derive quantitative proteome-disease relationships (QPDRs) and predicting prostate cancer. Biochem Biophys Res Commun, 2008. 372(2): p. 320-5.
311.	Estrada, E.J., et al., Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant, 2008. 17(12): p. 1295-304.
312.	Estrada, E., D.J. Higham, and N. Hatano, Communicability and multipartite structures in complex networks at negative absolute temperatures. Phys Rev E Stat Nonlin Soft Matter Phys, 2008. 78(2 Pt 2): p. 026102.
313.	Estrada, E. and N. Hatano, Communicability in complex networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2008. 77(3 Pt 2): p. 036111.
314.	Estrada, E. and O. Bodin, Using network centrality measures to manage landscape connectivity. Ecol Appl, 2008. 18(7): p. 1810-25.
315.	Estrada, E., How the parts organize in the whole? A top-down view of molecular descriptors and properties for QSAR and drug design. Mini Rev Med Chem, 2008. 8(3): p. 213-21.
316.	Estrada, E., Quantum-chemical foundations of the topological substructural molecular design. J Phys Chem A, 2008. 112(23): p. 5208-17.
317.	Esteban, E., et al., Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study. Invest New Drugs, 2008. 26(1): p. 67-74.
318.	Ebrahimi, F., et al., Automatic sleep stage classification based on EEG signals by using neural networks and wavelet packet coefficients. Conf Proc IEEE Eng Med Biol Soc, 2008. 2008: p. 1151-4.
319.	Dea-Ayuela, M.A., et al., HP-Lattice QSAR for dynein proteins: experimental proteomics (2D-electrophoresis, mass spectrometry) and theoretic study of a Leishmania infantum sequence. Bioorg Med Chem, 2008. 16(16): p. 7770-6.
320.	Cruz-Monteagudo, M., et al., Quantitative Proteome-Property Relationships (QPPRs). Part 1: finding biomarkers of organic drugs with mean Markov connectivity indices of spiral networks of blood mass spectra. Bioorg Med Chem, 2008. 16(22): p. 9684-93.
321.	Cruz-Monteagudo, M., et al., 3D-MEDNEs: an alternative "in silico" technique for chemical research in toxicology. 2. quantitative proteome-toxicity relationships (QPTR) based on mass spectrum spiral entropy. Chem Res Toxicol, 2008. 21(3): p. 619-32.
322.	Castillo-Garit, J.A., et al., Bond-based 3D-chiral linear indices: theory and QSAR applications to central chirality codification. J Comput Chem, 2008. 29(15): p. 2500-12.
323.	Castillo-Garit, J.A., et al., Estimation of ADME properties in drug discovery: predicting Caco-2 cell permeability using atom-based stochastic and non-stochastic linear indices. J Pharm Sci, 2008. 97(5): p. 1946-76.
324.	Castillo-Garit, J.A., et al., A novel approach to predict aquatic toxicity from molecular structure. Chemosphere, 2008. 73(3): p. 415-27.
325.	Casanola-Martin, G.M., et al., Atom- and bond-based 2D TOMOCOMD-CARDD approach and ligand-based virtual screening for the drug discovery of new tyrosinase inhibitors. J Biomol Screen, 2008. 13(10): p. 1014-24.
326.	Alvarez-Ginarte, Y.M., et al., Applying pattern recognition methods plus quantum and physico-chemical molecular descriptors to analyze the anabolic activity of structurally diverse steroids. J Comput Chem, 2008. 29(3): p. 317-33.
327.	Alvarez-Ginarte, Y.M., et al., Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues. Bioorg Med Chem, 2008. 16(12): p. 6448-59.
328.	Aguero-Chapin, G., et al., MMM-QSAR recognition of ribonucleases without alignment: comparison with an HMM model and isolation from Schizosaccharomyces pombe, prediction, and experimental assay of a new sequence. J Chem Inf Model, 2008. 48(2): p. 434-48.
329.	Aguero-Chapin, G., et al., Comparative study of topological indices of macro/supramolecular RNA complex networks. J Chem Inf Model, 2008. 48(11): p. 2265-77.
330.	Yang, Y., et al., Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab, 2007. 27(4): p. 697-709.
331.	Sood, R., et al., Quantitative evaluation of the effect of propylene glycol on BBB permeability. J Magn Reson Imaging, 2007. 25(1): p. 39-47.
332.	Ruiz-Marcial, C., et al., Antiproliferative, cytotoxic and antitumour activity of coumarins isolated from Calophyllum brasiliense. J Pharm Pharmacol, 2007. 59(5): p. 719-25.
333.	Rosenberg, G.A., E.Y. Estrada, and S. Mobashery, Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: Differences in response based on strains and solvents. Brain Res, 2007. 1133(1): p. 186-92.
334.	Prado-Prado, F.J., et al., Unified QSAR approach to antimicrobials. Part 2: predicting activity against more than 90 different species in order to halt antibacterial resistance. Bioorg Med Chem, 2007. 15(2): p. 897-902.
335.	Maya, I.D., et al., Treatment of dialysis catheter-related Staphylococcus aureus bacteremia with an antibiotic lock: a quality improvement report. Am J Kidney Dis, 2007. 50(2): p. 289-95.
336.	Marrero-Ponce, Y., et al., Bond-based 2D TOMOCOMD-CARDD approach for drug discovery: aiding decision-making in 'in silico' selection of new lead tyrosinase inhibitors. J Comput Aided Mol Des, 2007. 21(4): p. 167-88.
337.	Marrero-Ponce, Y., et al., Prediction of tyrosinase inhibition activity using atom-based bilinear indices. ChemMedChem, 2007. 2(4): p. 449-78.
338.	Gonzalez-Diaz, H., et al., Medicinal chemistry and bioinformatics--current trends in drugs discovery with networks topological indices. Curr Top Med Chem, 2007. 7(10): p. 1015-29.
339.	Gonzalez-Diaz, H., et al., On the applicability of QSAR for recognition of miRNA bioorganic structures at early stages of organism and cell development: embryo and stem cells. Bioorg Med Chem, 2007. 15(7): p. 2544-50.
340.	Gonzalez-Diaz, H., et al., A model for the recognition of protein kinases based on the entropy of 3D van der Waals interactions. J Proteome Res, 2007. 6(2): p. 904-8.
341.	Gonzalez-Diaz, H., et al., Computational chemistry approach to protein kinase recognition using 3D stochastic van der Waals spectral moments. J Comput Chem, 2007. 28(6): p. 1042-8.
342.	Gonzalez-Diaz, H., et al., Computational chemistry comparison of stable/nonstable protein mutants classification models based on 3D and topological indices. J Comput Chem, 2007. 28(12): p. 1990-5.
343.	Gonzalez-Diaz, H., et al., QSAR study of anticoccidial activity for diverse chemical compounds: prediction and experimental assay of trans-2-(2-nitrovinyl)furan. Bioorg Med Chem, 2007. 15(2): p. 962-8.
344.	Gonzalez-Diaz, H., et al., ANN-QSAR model for selection of anticancer leads from structurally heterogeneous series of compounds. Eur J Med Chem, 2007. 42(5): p. 580-5.
345.	Gonzalez-Diaz, H., et al., 2D-RNA-coupling numbers: a new computational chemistry approach to link secondary structure topology with biological function. J Comput Chem, 2007. 28(6): p. 1049-56.
346.	Estrada, E., et al., Ethnobotany in the Cumbres de Monterrey National Park, Nuevo Leon, Mexico. J Ethnobiol Ethnomed, 2007. 3: p. 8.
347.	Estrada, E. and A.R. Matamala, Generalized topological indices. Modeling gas-phase rate coefficients of atmospheric relevance. J Chem Inf Model, 2007. 47(3): p. 794-804.
348.	Estrada, E., Food webs robustness to biodiversity loss: the roles of connectance, expansibility and degree distribution. J Theor Biol, 2007. 244(2): p. 296-307.
349.	Estrada, E., Point scattering: a new geometric invariant with applications from (nano)clusters to biomolecules. J Comput Chem, 2007. 28(4): p. 767-77.
350.	Estrada, E., Topological structural classes of complex networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2007. 75(1 Pt 2): p. 016103.
351.	Estrada, E., Tight-binding "dihedral orbitals" approach to the degree of folding of macromolecular chains. J Phys Chem B, 2007. 111(48): p. 13611-8.
352.	Esteban, E., et al., Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study. Lung Cancer, 2007. 55(2): p. 173-80.
353.	Ebrahimi, F., et al., Assessment of Itakura Distance as a valuable feature for computer-aided classification of sleep stages. Conf Proc IEEE Eng Med Biol Soc, 2007. 2007: p. 3300-3.
354.	Cruz-Monteagudo, M., et al., Computational chemistry development of a unified free energy Markov model for the distribution of 1300 chemicals to 38 different environmental or biological systems. J Comput Chem, 2007. 28(11): p. 1909-23.
355.	Castillo-Garit, J.A., et al., Atom-based stochastic and non-stochastic 3D-chiral bilinear indices and their applications to central chirality codification. J Mol Graph Model, 2007. 26(1): p. 32-47.
356.	Casanola-Martin, G.M., et al., TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-based linear indices. Bioorg Med Chem, 2007. 15(3): p. 1483-503.
357.	Casanola-Martin, G.M., et al., Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays. Eur J Med Chem, 2007. 42(11-12): p. 1370-81.
358.	Candelario-Jalil, E., et al., Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther, 2007. 323(2): p. 488-98.
359.	Vega, M.C., et al., New ligand-based approach for the discovery of antitrypanosomal compounds. Bioorg Med Chem Lett, 2006. 16(7): p. 1898-904.
360.	Santana, L., et al., A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem, 2006. 49(3): p. 1149-56.
361.	Pisco, L., et al., Synthesis of compounds with antiproliferative activity as analogues of prenylated natural products existing in Brazilian propolis. Eur J Med Chem, 2006. 41(3): p. 401-7.
362.	Morales, A.H., M.A. Cabrera Perez, and M.P. Gonzalez, A radial-distribution-function approach for predicting rodent carcinogenicity. J Mol Model, 2006. 12(6): p. 769-80.
363.	Montero-Torres, A., et al., Non-stochastic quadratic fingerprints and LDA-based QSAR models in hit and lead generation through virtual screening: theoretical and experimental assessment of a promising method for the discovery of new antimalarial compounds. Eur J Med Chem, 2006. 41(4): p. 483-93.
364.	Marrero-Ponce, Y., et al., Bond-based global and local (bond, group and bond-type) quadratic indices and their applications to computer-aided molecular design. 1. QSPR studies of diverse sets of organic chemicals. J Comput Aided Mol Des, 2006. 20(10-11): p. 685-701.
365.	Marrero-Ponce, Y., et al., Predicting antitrichomonal activity: a computational screening using atom-based bilinear indices and experimental proofs. Bioorg Med Chem, 2006. 14(19): p. 6502-24.
366.	Marrero-Ponce, Y., et al., Predicting antitrichomonal activity: a computational screening using atom-based bilinear indices and experimental proofs. Bioorg Med Chem, 2006. 14(19): p. 6502-24.
367.	Marrero-Ponce, Y., et al., Non-stochastic and stochastic linear indices of the molecular pseudograph's atom-adjacency matrix: a novel approach for computational in silico screening and "rational" selection of new lead antibacterial agents. J Mol Model, 2006. 12(3): p. 255-71.
368.	Gurney, K.J., E.Y. Estrada, and G.A. Rosenberg, Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis, 2006. 23(1): p. 87-96.
369.	Gonzalez-Diaz, H., et al., Stochastic entropy QSAR for the in silico discovery of anticancer compounds: prediction, synthesis, and in vitro assay of new purine carbanucleosides. Bioorg Med Chem, 2006. 14(4): p. 1095-107.
370.	Gonzalez-Diaz, H., A. Sanchez-Gonzalez, and Y. Gonzalez-Diaz, 3D-QSAR study for DNA cleavage proteins with a potential anti-tumor ATCUN-like motif. J Inorg Biochem, 2006. 100(7): p. 1290-7.
371.	Gonzalez-Diaz, H., et al., Unify QSAR approach to antimicrobials. Part 1: predicting antifungal activity against different species. Bioorg Med Chem, 2006. 14(17): p. 5973-80.
372.	Gonzalez-Diaz, H., et al., QSAR study for mycobacterial promoters with low sequence homology. Bioorg Med Chem Lett, 2006. 16(3): p. 547-53.
373.	Estrada, E., E. Uriarte, and S. Vilar, Effect of protein backbone folding on the stability of protein-ligand complexes. J Proteome Res, 2006. 5(1): p. 105-11.
374.	Estrada, E., et al., An integrated in silico analysis of drug-binding to human serum albumin. J Chem Inf Model, 2006. 46(6): p. 2709-24.
375.	Estrada, E. and Y. Simon-Manso, Rational design and first principles studies toward the discovery of a small and versatile proton sponge. Angew Chem Int Ed Engl, 2006. 45(11): p. 1719-21.
376.	Estrada, E., et al., EOG and EMG: two important switches in automatic sleep stage classification. Conf Proc IEEE Eng Med Biol Soc, 2006. 1: p. 2458-61.
377.	Estrada, E. and E. Molina, Automatic extraction of structural alerts for predicting chromosome aberrations of organic compounds. J Mol Graph Model, 2006. 25(3): p. 275-88.
378.	Estrada, E., G.A. Diaz, and E.J. Delgado, Predicting infinite dilution activity coefficients of organic compounds in water by quantum-connectivity descriptors. J Comput Aided Mol Des, 2006. 20(9): p. 539-48.
379.	Estrada, E., Virtual identification of essential proteins within the protein interaction network of yeast. Proteomics, 2006. 6(1): p. 35-40.
380.	Estrada, E., Protein bipartivity and essentiality in the yeast protein-protein interaction network. J Proteome Res, 2006. 5(9): p. 2177-84.
381.	Esteban, E., et al., Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study. Invest New Drugs, 2006. 24(3): p. 241-8.
382.	Cruz-Monteagudo, M., H. Gonzalez-Diaz, and E. Uriarte, Simple stochastic fingerprints towards mathematical modeling in biology and medicine 2. Unifying Markov model for drugs side effects. Bull Math Biol, 2006. 68(7): p. 1527-54.
383.	Cruz-Monteagudo, M., et al., Simple stochastic fingerprints towards mathematical modeling in biology and medicine. 3. Ocular irritability classification model. Bull Math Biol, 2006. 68(7): p. 1555-72.
384.	Castillo-Garit, J.A., Y. Marrero-Ponce, and F. Torrens, Atom-based 3D-chiral quadratic indices. Part 2: prediction of the corticosteroid-binding globulinbinding affinity of the 31 benchmark steroids data set. Bioorg Med Chem, 2006. 14(7): p. 2398-408.
385.	Casanola-Martin, G.M., et al., New tyrosinase inhibitors selected by atomic linear indices-based classification models. Bioorg Med Chem Lett, 2006. 16(2): p. 324-30.
386.	Caceres, D.C., et al., [Burden of rotavirus-related disease among children under five, Colombia, 2004]. Rev Panam Salud Publica, 2006. 20(1): p. 9-21.
387.	Aguero-Chapin, G., et al., Novel 2D maps and coupling numbers for protein sequences. The first QSAR study of polygalacturonases; isolation and prediction of a novel sequence from Psidium guajava L. FEBS Lett, 2006. 580(3): p. 723-30.
388.	Vilar, S., et al., In silico studies toward the discovery of new anti-HIV nucleoside compounds through the use of TOPS-MODE and 2D/3D connectivity indices. 2. Purine derivatives. J Chem Inf Model, 2005. 45(2): p. 502-14.
389.	Saiz-Urra, L., H. Gonzalez-Diaz, and E. Uriarte, Proteins Markovian 3D-QSAR with spherically-truncated average electrostatic potentials. Bioorg Med Chem, 2005. 13(11): p. 3641-7.
390.	Runge, V.M., et al., Subchronic toxicity of the gadolinium chelates. Acad Radiol, 2005. 12 Suppl 1: p. S6-9.
391.	Randic, M. and E. Estrada, Order from chaos: observing hormesis at the proteome level. J Proteome Res, 2005. 4(6): p. 2133-6.
392.	Morera, C., et al., Advantages of binaural hearing provided through bimodal stimulation via a cochlear implant and a conventional hearing aid: a 6-month comparative study. Acta Otolaryngol, 2005. 125(6): p. 596-606.
393.	Montero-Torres, A., et al., A novel non-stochastic quadratic fingerprints-based approach for the 'in silico' discovery of new antitrypanosomal compounds. Bioorg Med Chem, 2005. 13(22): p. 6264-75.
394.	Meneses-Marcel, A., et al., A linear discrimination analysis based virtual screening of trichomonacidal lead-like compounds: outcomes of in silico studies supported by experimental results. Bioorg Med Chem Lett, 2005. 15(17): p. 3838-43.
395.	Matamala, A.R. and E. Estrada, Simplex optimization of generalized topological index (GTI-simplex): a unified approach to optimize QSPR models. J Phys Chem A, 2005. 109(43): p. 9890-5.
396.	Marrero-Ponce, Y., et al., Non-stochastic and stochastic linear indices of the 'molecular pseudograph's atom adjacency matrix': application to 'in silico' studies for the rational discovery of new antimalarial compounds. Bioorg Med Chem, 2005. 13(4): p. 1293-304.
397.	Marrero-Ponce, Y., et al., Atom, atom-type, and total nonstochastic and stochastic quadratic fingerprints: a promising approach for modeling of antibacterial activity. Bioorg Med Chem, 2005. 13(8): p. 2881-99.
398.	Marrero-Ponce, Y., et al., Protein linear indices of the 'macromolecular pseudograph alpha-carbon atom adjacency matrix' in bioinformatics. Part 1: prediction of protein stability effects of a complete set of alanine substitutions in Arc repressor. Bioorg Med Chem, 2005. 13(8): p. 3003-15.
399.	Marrero-Ponce, Y., et al., A computer-based approach to the rational discovery of new trichomonacidal drugs by atom-type linear indices. Curr Drug Discov Technol, 2005. 2(4): p. 245-65.
400.	Marrero-Ponce, Y., et al., Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps. J Chem Inf Model, 2005. 45(4): p. 1082-100.
401.	Marrero-Ponce, Y., et al., Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps. J Chem Inf Model, 2005. 45(4): p. 1082-100.
402.	Marrero-Ponce, Y., et al., Atom, atom-type and total molecular linear indices as a promising approach for bioorganic and medicinal chemistry: theoretical and experimental assessment of a novel method for virtual screening and rational design of new lead anthelmintic. Bioorg Med Chem, 2005. 13(4): p. 1005-20.
403.	Marrero-Ponce, Y. and J.A. Castillo-Garit, 3D-chiral atom, atom-type, and total non-stochastic and stochastic molecular linear indices and their applications to central chirality codification. J Comput Aided Mol Des, 2005. 19(6): p. 369-83.
404.	Marrero Ponce, Y., J.A. Castillo Garit, and D. Nodarse, Linear indices of the 'macromolecular graph's nucleotides adjacency matrix' as a promising approach for bioinformatics studies. Part 1: prediction of paromomycin's affinity constant with HIV-1 psi-RNA packaging region. Bioorg Med Chem, 2005. 13(10): p. 3397-404.
405.	Manrique, M., et al., Speech perception with the ACE and the SPEAK speech coding strategies for children implanted with the Nucleus cochlear implant. Int J Pediatr Otorhinolaryngol, 2005. 69(12): p. 1667-74.
406.	Helguera, A.M., et al., A topological substructural approach applied to the computational prediction of rodent carcinogenicity. Bioorg Med Chem, 2005. 13(7): p. 2477-88.
407.	Helguera, A.M., et al., A topological substructural approach applied to the computational prediction of rodent carcinogenicity. Bioorg Med Chem, 2005. 13(7): p. 2477-88.
408.	Gonzalez-Diaz, H., E. Uriarte, and R. Ramos de Armas, Predicting stability of Arc repressor mutants with protein stochastic moments. Bioorg Med Chem, 2005. 13(2): p. 323-31.
409.	Gonzalez-Diaz, H. and E. Uriarte, Biopolymer stochastic moments. I. Modeling human rhinovirus cellular recognition with protein surface electrostatic moments. Biopolymers, 2005. 77(5): p. 296-303.
410.	Gonzalez-Diaz, H. and E. Uriarte, Proteins QSAR with Markov average electrostatic potentials. Bioorg Med Chem Lett, 2005. 15(22): p. 5088-94.
411.	Gonzalez-Diaz, H., et al., Markovian chemicals "in silico" design (MARCH-INSIDE), a promising approach for computer-aided molecular design III: 2.5D indices for the discovery of antibacterials. J Mol Model, 2005. 11(2): p. 116-23.
412.	Gonzalez-Diaz, H., et al., 3D QSAR Markov model for drug-induced eosinophilia--theoretical prediction and preliminary experimental assay of the antimicrobial drug G1. Bioorg Med Chem, 2005. 13(5): p. 1523-30.
413.	Gonzalez-Diaz, H., R. Molina, and E. Uriarte, Recognition of stable protein mutants with 3D stochastic average electrostatic potentials. FEBS Lett, 2005. 579(20): p. 4297-301.
414.	Gonzalez-Diaz, H., et al., QSAR for anti-RNA-virus activity, synthesis, and assay of anti-RSV carbonucleosides given a unified representation of spectral moments, quadratic, and topologic indices. Bioorg Med Chem Lett, 2005. 15(6): p. 1651-7.
415.	Gonzalez-Diaz, H., et al., Predicting multiple drugs side effects with a general drug-target interaction thermodynamic Markov model. Bioorg Med Chem, 2005. 13(4): p. 1119-29.
416.	Gonzalez-Diaz, H., et al., 2D RNA-QSAR: assigning ACC oxidase family membership with stochastic molecular descriptors; isolation and prediction of a sequence from Psidium guajava L. Bioorg Med Chem Lett, 2005. 15(11): p. 2932-7.
417.	Gonzalez-Diaz, H., et al., Unified Markov thermodynamics based on stochastic forms to classify drugs considering molecular structure, partition system, and biological species: distribution of the antimicrobial G1 on rat tissues. Bioorg Med Chem Lett, 2005. 15(3): p. 551-7.
418.	Gia, O., et al., Design, synthesis and photobiological properties of 3,4-cyclopentenepsoralens. Bioorg Med Chem, 2005. 13(3): p. 809-17.
419.	Estrada, E. and E. Uriarte, Folding degrees of azurins and pseudoazurins. Implications for structure and function. Comput Biol Chem, 2005. 29(5): p. 345-53.
420.	Estrada, E. and J.A. Rodriguez-Velazquez, Subgraph centrality in complex networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2005. 71(5 Pt 2): p. 056103.
421.	Estrada, E. and J.A. Rodriguez-Velazquez, Spectral measures of bipartivity in complex networks. Phys Rev E Stat Nonlin Soft Matter Phys, 2005. 72(4 Pt 2): p. 046105.
422.	Estrada, E., et al., Itakura Distance: A Useful Similarity Measure between EEG and EOG Signals in Computer-aided Classification of Sleep Stages. Conf Proc IEEE Eng Med Biol Soc, 2005. 2: p. 1189-92.
423.	Cruz-Monteagudo, M. and H. Gonzalez-Diaz, Unified drug-target interaction thermodynamic Markov model using stochastic entropies to predict multiple drugs side effects. Eur J Med Chem, 2005. 40(10): p. 1030-41.
424.	Caceres, D.C., et al., [Acute diarrheal disease: a public health challenge in Colombia]. Rev Panam Salud Publica, 2005. 17(1): p. 6-14.
425.	Yigit, S., et al., Diabetic ketoacidosis secondary to growth hormone treatment in a boy with Prader-Willi syndrome and steatohepatitis. J Pediatr Endocrinol Metab, 2004. 17(3): p. 361-4.
426.	Whelan, M.J., E. Estrada, and R. van Egmond, A modelling assessment of the atmospheric fate of volatile methyl siloxanes and their reaction products. Chemosphere, 2004. 57(10): p. 1427-37.
427.	Sosted, H., et al., Ranking of hair dye substances according to predicted sensitization potency: quantitative structure-activity relationships. Contact Dermatitis, 2004. 51(5-6): p. 241-54.
428.	Ramos de Armas, R., et al., Markovian Backbone Negentropies: Molecular descriptors for protein research. I. Predicting protein stability in Arc repressor mutants. Proteins, 2004. 56(4): p. 715-23.
429.	Ramos de Armas, R., et al., Stochastic-based descriptors studying peptides biological properties: modeling the bitter tasting threshold of dipeptides. Bioorg Med Chem, 2004. 12(18): p. 4815-22.
430.	Moxley, G., et al., Premenopausal sexual dimorphism in lipopolysaccharide-stimulated production and secretion of tumor necrosis factor. J Rheumatol, 2004. 31(4): p. 686-94.
431.	Marrero-Ponce, Y., et al., TOMOCOMD-CARDD, a novel approach for computer-aided 'rational' drug design: I. Theoretical and experimental assessment of a promising method for computational screening and in silico design of new anthelmintic compounds. J Comput Aided Mol Des, 2004. 18(10): p. 615-34.
432.	Marrero-Ponce, Y., et al., TOMOCOMD-CARDD, a novel approach for computer-aided 'rational' drug design: I. Theoretical and experimental assessment of a promising method for computational screening and in silico design of new anthelmintic compounds. J Comput Aided Mol Des, 2004. 18(10): p. 615-34.
433.	Marrero-Ponce, Y., Linear indices of the "molecular pseudograph's atom adjacency matrix": definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. J Chem Inf Comput Sci, 2004. 44(6): p. 2010-26.
434.	Marrero Ponce, Y., et al., A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci, 2004. 7(2): p. 186-99.
435.	Marrero Ponce, Y., et al., A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci, 2004. 7(2): p. 186-99.
436.	Marrero Ponce, Y., et al., A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci, 2004. 7(2): p. 186-99.
437.	Gonzalez-Diaz, H., R. Molina, and E. Uriarte, Markov entropy backbone electrostatic descriptors for predicting proteins biological activity. Bioorg Med Chem Lett, 2004. 14(18): p. 4691-5.
438.	Estrada, E., J.A. Quincoces, and G. Patlewicz, Creating molecular diversity from antioxidants in Brazilian propolis. Combination of TOPS-MODE QSAR and virtual structure generation. Mol Divers, 2004. 8(1): p. 21-33.
439.	Estrada, E., G. Patlewicz, and Y. Gutierrez, From knowledge generation to knowledge archive. A general strategy using TOPS-MODE with DEREK to formulate new alerts for skin sensitization. J Chem Inf Comput Sci, 2004. 44(2): p. 688-98.
440.	Estrada, E., et al., EEG feature extraction for classification of sleep stages. Conf Proc IEEE Eng Med Biol Soc, 2004. 1: p. 196-9.
441.	Estrada, E., et al., Quantum-connectivity descriptors in modeling solubility of environmentally important organic compounds. J Comput Chem, 2004. 25(14): p. 1787-96.
442.	Estrada, E., Characterization of the amino acid contribution to the folding degree of proteins. Proteins, 2004. 54(4): p. 727-37.
443.	Estrada, E., A protein folding degree measure and its dependence on crystal packing, protein size, secondary structure, and domain structural class. J Chem Inf Comput Sci, 2004. 44(4): p. 1238-50.
444.	Chatlapalli, S., et al., Accurate derivation of heart rate variability signal for detection of sleep disordered breathing in children. Conf Proc IEEE Eng Med Biol Soc, 2004. 1: p. 538-41.
445.	Cabrera Perez, M.A. and M.B. Sanz, In silico prediction of central nervous system activity of compounds. Identification of potential pharmacophores by the TOPS-MODE approach. Bioorg Med Chem, 2004. 12(22): p. 5833-43.
446.	Sanchez, R., et al., Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes. Invest New Drugs, 2003. 21(4): p. 459-63.
447.	Ruiz-Arguelles, G.J., et al., Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience. Hematology, 2003. 8(3): p. 151-4.
448.	Perez Gonzalez, M., et al., TOPS-MODE based QSARs derived from heterogeneous series of compounds. Applications to the design of new herbicides. J Chem Inf Comput Sci, 2003. 43(4): p. 1192-9.
449.	Lee, J.H., et al., Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab, 2003. 88(10): p. 4848-56.
450.	Estrada, E., et al., Quantitative structure-toxicity relationships using TOPS-MODE. 3. Structural factors influencing the permeability of commercial solvents through living human skin. SAR QSAR Environ Res, 2003. 14(2): p. 145-63.
451.	Estrada, E., et al., Computer-aided knowledge generation for understanding skin sensitization mechanisms: the TOPS-MODE approach. Chem Res Toxicol, 2003. 16(10): p. 1226-35.
452.	Estrada, E. and H. Gonzalez, What are the limits of applicability for graph theoretic descriptors in QSPR/QSAR? Modeling dipole moments of aromatic compounds with TOPS-MODE descriptors. J Chem Inf Comput Sci, 2003. 43(1): p. 75-84.
453.	Estrada, E. and D. Avnir, Continuous symmetry numbers and entropy. J Am Chem Soc, 2003. 125(14): p. 4368-75.
454.	Estrada, E., Application of a novel graph-theoretic folding degree index to the study of steroid-DB3 antibody binding affinity. Comput Biol Chem, 2003. 27(3): p. 305-13.
455.	Esteban, E., et al., Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study. Breast Cancer Res Treat, 2003. 80(3): p. 257-65.
456.	Esteban, E., et al., Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol, 2003. 14(11): p. 1640-7.
457.	Cabrera Perez, M.A., et al., A topological-substructural molecular design (TOPS-MODE) approach to determining pharmacokinetics and pharmacological properties of 6-fluoroquinolone derivatives. Eur J Pharm Biopharm, 2003. 56(2): p. 197-206.
458.	Yigit, S. and E. Estrada, Recurrent necrobiosis lipoidica diabeticorum associated with venous insufficiency in an adolescent with poorly controlled type 2 diabetes mellitus. J Pediatr, 2002. 141(2): p. 280-2.
459.	Wallace, J.A., et al., Tissue inhibitor of metalloproteinase-3 is associated with neuronal death in reperfusion injury. J Cereb Blood Flow Metab, 2002. 22(11): p. 1303-10.
460.	Perdomo-Lopez, I., et al., Effect of cyclodextrins on the solubility and antimycotic activity of sertaconazole: experimental and computational studies. J Pharm Sci, 2002. 91(11): p. 2408-15.
461.	Moxley, G., et al., Sexual dimorphism in innate immunity. Arthritis Rheum, 2002. 46(1): p. 250-8.
462.	Gonzalez Diaz, H., et al., Markovian chemicals "in silico" design (MARCH-INSIDE), a promising approach for computer aided molecular design II: experimental and theoretical assessment of a novel method for virtual screening of fasciolicides. J Mol Model, 2002. 8(8): p. 237-45.
463.	Gomez-Almaguer, D., et al., Role of bone marrow examination in staging Hodgkin's disease: experience in Mexico. Clin Lab Haematol, 2002. 24(4): p. 221-3.
464.	Estrada, E.G., et al., Dedifferentiated chondrosarcoma with a noncartilaginous component mimicking a conventional giant cell tumor of bone. Ann Diagn Pathol, 2002. 6(3): p. 159-63.
465.	Estrada, E., et al., In silico studies toward the discovery of new anti-HIV nucleoside compounds with the use of TOPS-MODE and 2D/3D connectivity indices. 1. Pyrimidyl derivatives. J Chem Inf Comput Sci, 2002. 42(5): p. 1194-203.
466.	Estrada, E., Characterization of the folding degree of proteins. Bioinformatics, 2002. 18(5): p. 697-704.
467.	Esteban, E., et al., Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer. Invest New Drugs, 2002. 20(3): p. 317-26.
468.	Esteban, E., et al., Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Invest New Drugs, 2002. 20(1): p. 73-82.
469.	Echezarreta-Lopez, M.M., et al., Utility of nuclear magnetic resonance spectroscopy to characterize the structure of dexamethasone sodium phosphate inclusion complexes with cyclodextrins in solution and to analyze potential competitive effects. J Pharm Sci, 2002. 91(6): p. 1536-47.
470.	Cabrera Perez, M.A., et al., A novel approach to determining physicochemical and absorption properties of 6-fluoroquinolone derivatives: experimental assessment. Eur J Pharm Biopharm, 2002. 53(3): p. 317-25.
471.	Cabrera Perez, M.A., et al., A novel approach to determining physicochemical and absorption properties of 6-fluoroquinolone derivatives: experimental assessment. Eur J Pharm Biopharm, 2002. 53(3): p. 317-25.
472.	Ruiz-Arguelles, G.J., et al., Are there "Attenuated" Forms of Evans Syndrome? Hematology, 2001. 6(6): p. 429-32.
473.	Rosenberg, G.A., et al., Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res, 2001. 893(1-2): p. 104-12.
474.	Pose-Vilarnovo, B., et al., Improvement of water solubility of sulfamethizole through its complexation with beta- and hydroxypropyl-beta-cyclodextrin. Characterization of the interaction in solution and in solid state. Eur J Pharm Sci, 2001. 13(3): p. 325-31.
475.	Gasparovic, C., et al., Magnetic resonance lipid signals in rat brain after experimental stroke correlate with neutral lipid accumulation. Neurosci Lett, 2001. 301(2): p. 87-90.
476.	Estrada, E. and E. Uriarte, Recent advances on the role of topological indices in drug discovery research. Curr Med Chem, 2001. 8(13): p. 1573-88.
477.	Estrada, E. and E. Uriarte, Quantitative structure--toxicity relationships using TOPS-MODE. 1. Nitrobenzene toxicity to Tetrahymena pyriformis. SAR QSAR Environ Res, 2001. 12(3): p. 309-24.
478.	Estrada, E., I. Perdomo-Lopez, and J.J. Torres-Labandeira, Combination of 2D-, 3D-connectivity and quantum chemical descriptors in QSPR. Complexation of alpha- and beta-cyclodextrin with benzene derivatives. J Chem Inf Comput Sci, 2001. 41(6): p. 1561-8.
479.	Estrada, E., E. Molina, and E. Uriarte, Quantitative structure-toxicity relationships using TOPS-MODE. 2. Neurotoxicity of a non-congeneric series of solvents. SAR QSAR Environ Res, 2001. 12(5): p. 445-59.
480.	Estrada, E., E. Molina, and I. Perdomo-Lopez, Can 3D structural parameters be predicted from 2D (topological) molecular descriptors? J Chem Inf Comput Sci, 2001. 41(4): p. 1015-21.
481.	Estrada, E. and E. Molina, 3D connectivity indices in QSPR/QSAR studies. J Chem Inf Comput Sci, 2001. 41(3): p. 791-7.
482.	Estrada, E. and E. Molina, Novel local (fragment-based) topological molecular descriptors for QSpr/QSAR and molecular design. J Mol Graph Model, 2001. 20(1): p. 54-64.
483.	Estrada, E., et al., A novel approach for the virtual screening and rational design of anticancer compounds. J Med Chem, 2000. 43(10): p. 1975-85.
484.	Estrada, E., I. Perdomo-Lopez, and J.J. Torres-Labandeira, Molecular modeling (MM2 and PM3) and experimental (NMR and thermal analysis) studies on the inclusion complex of salbutamol and beta-cyclodextrin. J Org Chem, 2000. 65(25): p. 8510-7.
485.	Estrada, E. and A. Pena, In silico studies for the rational discovery of anticonvulsant compounds. Bioorg Med Chem, 2000. 8(12): p. 2755-70.
486.	Estrada, E., Y. Gutierrez, and H. Gonzalez, Modeling diamagnetic and magnetooptic properties of organic compounds with the TOSS-MODE approach. J Chem Inf Comput Sci, 2000. 40(6): p. 1386-99.
487.	Estrada, E., A computer-based approach to describe the 13C NMR chemical shifts of alkanes by the generalized spectral moments of iterated line graphs. Comput Chem, 2000. 24(2): p. 193-201.
488.	Estrada, E., On the topological sub-structural molecular design (TOSS-MODE) in QSPR/QSAR and drug design research. SAR QSAR Environ Res, 2000. 11(1): p. 55-73.
489.	Estrada, E. and Y. Gutierrez, Modeling chromatographic parameters by a novel graph theoretical sub-structural approach. J Chromatogr A, 1999. 858(2): p. 187-99.
490.	Estaban, E., et al., Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Breast Cancer Res Treat, 1999. 58(2): p. 141-50.
491.	Corona, M., E. Estrada, and M. Zurita, Differential expression of mitochondrial genes between queens and workers during caste determination in the honeybee Apis mellifera. J Exp Biol, 1999. 202(Pt 8): p. 929-38.
492.	Rosenberg, G.A., E.Y. Estrada, and J.E. Dencoff, Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke, 1998. 29(10): p. 2189-95.
493.	Estrada, E., A. Pena, and R. Garcia-Domenech, Designing sedative/hypnotic compounds from a novel substructural graph-theoretical approach. J Comput Aided Mol Des, 1998. 12(6): p. 583-95.
494.	Estrada, E., Structure-mutagenicity relationships in 2-furylethylene derivatives. A molecular orbital study of the role of nitro groups. Mutat Res, 1998. 420(1-3): p. 67-75.
495.	Armao, D., et al., Neutral proteases and disruption of the blood-brain barrier in rat. Brain Res, 1997. 767(2): p. 259-64.
496.	Estrada, E., et al., Phosphorylation of yeast plasma membrane H+-ATPase by casein kinase I. J Biol Chem, 1996. 271(50): p. 32064-72.
497.	Rosenberg, G.A., et al., Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res, 1995. 703(1-2): p. 151-5.
498.	Rosenberg, G.A. and E.Y. Estrada, Atrial natriuretic peptide blocks hemorrhagic brain edema after 4-hour delay in rats. Stroke, 1995. 26(5): p. 874-7.
499.	Pelaez, I., et al., Phase II study of mitomycin C plus 5-fluorouracil in patients with refractory ovarian cancer. Eur J Cancer, 1994. 30A(8): p. 1206-7.
500.	Rosenberg, G.A., et al., Bacterial collagenase disrupts extracellular matrix and opens blood-brain barrier in rat. Neurosci Lett, 1993. 160(1): p. 117-9.
501.	Meier, P.P., et al., Breastfeeding support services in the neonatal intensive-care unit. J Obstet Gynecol Neonatal Nurs, 1993. 22(4): p. 338-47.
502.	Esteban, E., et al., Phase II study of oral ftorafur and uracil in patients with advanced renal cell carcinoma. Eur J Cancer, 1993. 29A(9): p. 1354.
503.	Rosenberg, G.A., et al., Arginine vasopressin V1-antagonist and atrial natriuretic peptide reduce hemorrhagic brain edema in rats. Stroke, 1992. 23(12): p. 1767-73; discussion 1773-4.
504.	Rosenberg, G.A., et al., TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res, 1992. 576(2): p. 203-7.
505.	Pang, S., et al., Normal and elevated 3 alpha-androstanediol glucuronide concentrations in women with various causes of hirsutism and its correlation with degree of hirsutism and androgen levels. J Clin Endocrinol Metab, 1992. 75(1): p. 243-8.
506.	Palacio, I., et al., Negative phase II study with carboplatin and 5-fluorouracil in advanced breast cancer. Eur J Cancer, 1992. 28(1): p. 242.






REFERENCES.
1.Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. The American journal of medicine. Feb 2006;119(2):133-141.
2.Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. Dec 14 2002;360(9349):1903-1913.
3.Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. Dec 2003;42(6):1206-1252.
4.Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. Journal of clinical hypertension (Greenwich, Conn.). Jan 2014;16(1):14-26.
5.Sprint Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine. Nov 9 2015;0(0):null.
6.Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Archives of internal medicine. Mar 13 2000;160(5):685-693.
7.Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney international. Mar 1997;51(3):793-797.
8.Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, . . . Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2017.
9.Egan BM, Stevens-Fabry S. Prehypertension--prevalence, health risks, and management strategies. Nature reviews cardiology. May 2015;12(5):289-300.
10.Garofalo C, Borrelli S, Pacilio M, et al. Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. American journal of kidney diseases: the official journal of the National Kidney Foundation. Oct 13 2015.
11.Stocchetti N, Chieregato A, De Marchi M, Croci M, Benti R, Grimoldi N. High cerebral perfusion pressure improves low values of local brain tissue O2 tension (PtiO2) in focal lesions. Acta neurochirurgica. Supplement. 1998;71:162-165.
12.The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine. 2010;362(17):1575-1585.
13.Barzilay JI, Howard AG, Evans GW, et al. Intensive Blood Pressure Treatment Does Not Improve Cardiovascular Outcomes in Centrally Obese Hypertensive Individuals With Diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes care. July 1, 2012 2012;35(7):1401-1405.
14.Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (Clinical research ed.). 2016-02-25 00:06:06 2016;352.
15.Odden MC, Shlipak MG, Whitson HE, et al. Risk factors for cardiovascular disease across the spectrum of older age: the Cardiovascular Health Study. Atherosclerosis. Nov 2014;237(1):336-342.
16.Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. The New England journal of medicine. May 1 2008;358(18):1887-1898.
17.Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. Journal of the American Geriatrics Society. Mar 2007;55(3):383-388.
18.James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA : the journal of the American Medical Association. Feb 5 2014;311(5):507-520.
19.Krakoff LR. Blood Pressure Out of the Office: Its Time Has Finally Come. American journal of hypertension. Nov 6 2015.
20.Fuchs SC, Ferreira-da-Silva AL, Moreira LB, et al. Efficacy of isolated home blood pressure monitoring for blood pressure control: randomized controlled trial with ambulatory blood pressure monitoring - MONITOR study. Journal of hypertension. Jan 2012;30(1):75-80.
21.Breaux-Shropshire TL, Judd E, Vucovich LA, Shropshire TS, Singh S. Does home blood pressure monitoring improve patient outcomes? A systematic review comparing home and ambulatory blood pressure monitoring on blood pressure control and patient outcomes. Integrated blood pressure control. 2015;8:43-49.
22.Agena F, Prado Edos S, Souza PS, et al. Home blood pressure (BP) monitoring in kidney transplant recipients is more adequate to monitor BP than office BP. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. Nov 2011;26(11):3745-3749.
23.Imai Y, Obara T, Asamaya K, Ohkubo T. The reason why home blood pressure measurements are preferred over clinic or ambulatory blood pressure in Japan. Hypertension research : official journal of the Japanese Society of Hypertension. Aug 2013;36(8):661-672.
24.Fuchs SC, Mello RG, Fuchs FC. Home blood pressure monitoring is better predictor of cardiovascular disease and target organ damage than office blood pressure: a systematic review and meta-analysis. Current cardiology reports. Nov 2013;15(11):413.
25.Sacks FM, Appel LJ, Moore TJ, et al. A dietary approach to prevent hypertension: a review of the Dietary Approaches to Stop Hypertension (DASH) Study. Clinical cardiology. Jul 1999;22(7 Suppl):Iii6-10.
26.Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Archives of internal medicine. Feb 8 1999;159(3):285-293.
27.Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. The New England journal of medicine. Apr 17 1997;336(16):1117-1124.
28.Streppel MT, Arends LR, van 't Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Archives of internal medicine. Jan 24 2005;165(2):150-156.
29.Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. The New England journal of medicine. Jan 4 2001;344(1):3-10.
30.Hinderliter AL, Sherwood A, Craighead LW, et al. The long-term effects of lifestyle change on blood pressure: One-year follow-up of the ENCORE study. American journal of hypertension. May 2014;27(5):734-741.
31.Sikand G. Mediterranean, DASH & TLC Dietary Patterns: Mechanisms for CVD Reduction. Paper presented at: 2014 Clinical Lipid Update; March 16th 2014, 2014; Maui.
32.Tognon G, Lissner L, Saebye D, Walker KZ, Heitmann BL. The Mediterranean diet in relation to mortality and CVD: a Danish cohort study. The British journal of nutrition. Jan 14 2014;111(1):151-159.
33.Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean diet, cognitive function, and dementia: a systematic review. Epidemiology (Cambridge, Mass.). Jul 2013;24(4):479-489.
34.Perez-Lopez FR, Chedraui P, Haya J, Cuadros JL. Effects of the Mediterranean diet on longevity and age-related morbid conditions. Maturitas. Oct 20 2009;64(2):67-79.
35.Martinez-Gonzalez MA, Salas-Salvado J, Estruch R, Corella D, Fito M, Ros E. Benefits of the Mediterranean Diet: Insights From the PREDIMED Study. Progress in cardiovascular diseases. Jul-Aug 2015;58(1):50-60.
36.Palkowska E, Bartnikowska E, Owsiak D. [The use of low-caloric diet with modified fatty acids pool in the therapy of the metabolic syndrome]. Roczniki Panstwowego Zakladu Higieny. 2012;63(2):163-169.
37.Trubitsyn AG. The Lag of the Proliferative Aging Clock Underlies the Lifespan-Extending Effect of Calorie Restriction. Current aging science. 2015;8(3):220-226.
38.Stein PK, Soare A, Meyer TE, Cangemi R, Holloszy JO, Fontana L. Caloric restriction may reverse age-related autonomic decline in humans. Aging Cell. Aug 2012;11(4):644-650.
39.McCarty MF. AMPK activation--protean potential for boosting healthspan. Age (Dordrecht, Netherlands). Apr 2014;36(2):641-663.
40.Kishi T, Hirooka Y, Ogawa K, Konno S, Sunagawa K. Calorie restriction inhibits sympathetic nerve activity via anti-oxidant effect in the rostral ventrolateral medulla of obesity-induced hypertensive rats. Clinical and experimental hypertension (New York, N.Y. : 1993). 2011;33(4):240-245.
41.Finckenberg P, Eriksson O, Baumann M, et al. Caloric restriction ameliorates angiotensin II-induced mitochondrial remodeling and cardiac hypertrophy. Hypertension. Jan 2012;59(1):76-84.
42.de Cavanagh EM, Inserra F, Ferder L. Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition. American journal of physiology. Heart and circulatory physiology. Jul 1 2015;309(1):H15-44.
43.Liu Y, Chen H, Liu D. Mechanistic perspectives of calorie restriction on vascular homeostasis. Science China. Life sciences. Aug 2014;57(8):742-754.
44.Jefferson ME, Nicklas BJ, Chmelo EA, et al. Effects of Resistance Training With and Without Caloric Restriction on Arterial Stiffness in Overweight and Obese Older Adults. American journal of hypertension. Aug 20 2015.
45.Walford RL, Mock D, Verdery R, MacCallum T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. The journals of gerontology. Series A, Biological sciences and medical sciences. Jun 2002;57(6):B211-224.
46.Ravussin E, Redman LM, Rochon J, et al. A 2-Year Randomized Controlled Trial of Human Caloric Restriction: Feasibility and Effects on Predictors of Health Span and Longevity. The journals of gerontology. Series A, Biological sciences and medical sciences. Sep 2015;70(9):1097-1104.
47.Riegel G, Moreira LB, Fuchs SC, et al. Long-term effectiveness of non-drug recommendations to treat hypertension in a clinical setting. American journal of hypertension. Nov 2012;25(11):1202-1208.
48.Elsevier. First Consult: Hypertension.
49.Perez V, Chang ET. Sodium-to-potassium ratio and blood pressure, hypertension, and related factors. Advances in nutrition (Bethesda, Md.). Nov 2014;5(6):712-741.
50.Penton D, Czogalla J, Loffing J. Dietary potassium and the renal control of salt balance and blood pressure. Pflugers Arch. Mar 2015;467(3):513-530.
51.Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. Jan 2 2001;134(1):1-11.
52.Kan AW, Hussain T, Carson KA, et al. The Contribution of Age and Weight to Blood Pressure Levels Among Blacks and Whites Receiving Care in Community-Based Primary Care Practices. Preventing chronic disease. 2015;12:E161.
53.Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. Apr 2 2002;136(7):493-503.
54.Cornelissen VA, Fagard RH. Effect of resistance training on resting blood pressure: a meta-analysis of randomized controlled trials. Journal of hypertension. Feb 2005;23(2):251-259.
55.Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure : A meta-analysis of randomized controlled trials. Hypertension. Mar 2000;35(3):838-843.
56.Larsen RN, Kingwell BA, Sethi P, Cerin E, Owen N, Dunstan DW. Breaking up prolonged sitting reduces resting blood pressure in overweight/obese adults. Nutrition, metabolism, and cardiovascular diseases : NMCD. Sep 2014;24(9):976-982.
57.Bazzano LA, Green T, Harrison TN, Reynolds K. Dietary approaches to prevent hypertension. Current hypertension reports. Dec 2013;15(6):694-702.
58.Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. Nov 2001;38(5):1112-1117.
59.Aljadhey H, Tu W, Hansen RA, Blalock SJ, Brater DC, Murray MD. Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC cardiovascular disorders. 2012;12:93.
60.Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. Sep 2015;66(3):524-533.
61.Medicine AAoS. Rising prevalence of sleep apnea in U.S. threatens public health. 2014.
62.Mayo Clinic. Diseases and Conditions. Sleep Apnea. http://www.mayoclinic.org/diseases-conditions/sleep-apnea/basics/complications/con-20020286. 8/25/2015. Accessed 11/19/2015.
63.Liu L, Cao Q, Guo Z, Dai Q. Continuous Positive Airway Pressure in Patients With Obstructive Sleep Apnea and Resistant Hypertension: A Meta-Analysis of Randomized Controlled Trials. Journal of clinical hypertension (Greenwich, Conn.). Aug 17 2015.
64.Hughes JW, Fresco DM, Myerscough R, van Dulmen MH, Carlson LE, Josephson R. Randomized controlled trial of mindfulness-based stress reduction for prehypertension. Psychosomatic medicine. Oct 2013;75(8):721-728.
65.Gasperin D, Netuveli G, Dias-da-Costa JS, Pattussi MP. Effect of psychological stress on blood pressure increase: a meta-analysis of cohort studies. Cadernos de saude publica. Apr 2009;25(4):715-726.
66.Larson AJ, Symons JD, Jalili T. Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Advances in nutrition (Bethesda, Md.). Jan 2012;3(1):39-46.
67.Laskar MAC, M. D. In silico screening of some plant based natural products as angiotensin receptor blockers against cardiovascular diseases. World Journal of Pharmacy and Pharmaceutical Science. 2015;4(1):1248-1257.
68.Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. The British journal of nutrition. Oct 2009;102(7):1065-1074.
69.Pfeuffer M, Auinger A, Bley U, et al. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutrition, metabolism, and cardiovascular diseases : NMCD. May 2013;23(5):403-409.
70.Brull V, Burak C, Stoffel-Wagner B, et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial. The British journal of nutrition. Oct 2015;114(8):1263-1277.
71.Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T. Quercetin reduces blood pressure in hypertensive subjects. The Journal of nutrition. Nov 2007;137(11):2405-2411.
72.Zahedi M, Ghiasvand R, Feizi A, Asgari G, Darvish L. Does Quercetin Improve Cardiovascular Risk factors and Inflammatory Biomarkers in Women with Type 2 Diabetes: A Double-blind Randomized Controlled Clinical Trial. International journal of preventive medicine. Jul 2013;4(7):777-785.
73.Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annual review of nutrition. 2002;22:19-34.
74.Basli A, Soulet S, Chaher N, et al. Wine polyphenols: potential agents in neuroprotection. Oxidative medicine and cellular longevity. 2012;2012:805762.
75.Godse S, Mohan M, Kasture V, Kasture S. Effect of myricetin on blood pressure and metabolic alterations in fructose hypertensive rats. Pharmaceutical biology. May 2010;48(5):494-498.
76.Borde P, Mohan M, Kasture S. Effect of myricetin on deoxycorticosterone acetate (DOCA)-salt-hypertensive rats. Natural product research. Sep 2011;25(16):1549-1559.
77.Hobbs CA, Swartz C, Maronpot R, et al. Genotoxicity evaluation of the flavonoid, myricitrin, and its aglycone, myricetin. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. Sep 2015;83:283-292.
78.Wang SJ, Tong Y, Lu S, et al. Anti-inflammatory activity of myricetin isolated from Myrica rubra Sieb. et Zucc. leaves. Planta medica. Oct 2010;76(14):1492-1496.
79.Domitrovic R, Rashed K, Cvijanovic O, Vladimir-Knezevic S, Skoda M, Visnic A. Myricitrin exhibits antioxidant, anti-inflammatory and antifibrotic activity in carbon tetrachloride-intoxicated mice. Chemico-biological interactions. Mar 25 2015;230:21-29.
80.Fernandez SP, Nguyen M, Yow TT, et al. The flavonoid glycosides, myricitrin, gossypin and naringin exert anxiolytic action in mice. Neurochemical research. Oct 2009;34(10):1867-1875.
81.Sales DS, Carmona F, de Azevedo BC, et al. Eugenia punicifolia (Kunth) DC. as an adjuvant treatment for type-2 diabetes mellitus: a non-controlled, pilot study. Phytotherapy research : PTR. Dec 2014;28(12):1816-1821.
82.Soejarto DD, Kinghorn AD, Farnsworth NR. Potential Sweetening Agents of Plant Origin. III. Organoleptic Evaluation of Stevia Leaf Herbarium Samples For Sweetness. Journal of natural products. 1982/09/01 1982;45(5):590-599.
83.Gardana C, Simonetti P, Canzi E, Zanchi R, Pietta P. Metabolism of stevioside and rebaudioside A from Stevia rebaudiana extracts by human microflora. Journal of agricultural and food chemistry. Oct 22 2003;51(22):6618-6622.
84.Liu JC, Kao PK, Chan P, et al. Mechanism of the antihypertensive effect of stevioside in anesthetized dogs. Pharmacology. Jan 2003;67(1):14-20.
85.Melis MS. Influence of calcium on the blood pressure and renal effects of stevioside. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.]. 1992;25(9):943-949.
86.Melis MS. Stevioside effect on renal function of normal and hypertensive rats. Journal of ethnopharmacology. Jun 1992;36(3):213-217.
87.Onakpoya IJ, Heneghan CJ. Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: A systematic review and meta-analysis of randomised clinical trials. European journal of preventive cardiology. Dec 2015;22(12):1575-1587.
88.Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. International journal of clinical practice. May 2007;61(5):835-845.
89.Pechanova O, Paulis L, Simko F. Peripheral and Central Effects of Melatonin on Blood Pressure Regulation. International journal of molecular sciences. 10/08 07/03/received 09/17/revised 09/17/accepted 2014;15(10):17920-17937.
90.Rodella LF, Favero G, Foglio E, et al. Vascular endothelial cells and dysfunctions: role of melatonin. Frontiers in bioscience (Elite edition). 2013;5:119-129.
91.Li Y, Wang JG. Isolated nocturnal hypertension: a disease masked in the dark. Hypertension. Feb 2013;61(2):278-283.
92.Kimura G. [Nocturnal hypertension and cardio-renal association]. Nihon rinsho. Japanese journal of clinical medicine. Aug 2014;72(8):1404-1409.
93.Li F, Huang H, Song L, Hao H, Ying M. Effects of Obstructive Sleep Apnea Hypopnea Syndrome on Blood Pressure and C-Reactive Protein in Male Hypertension Patients. J Clin Med Res. Mar 2016;8(3):220-224.
94.Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011;7:577-584.
95.Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. Journal of hypertension. Aug 2002;20(8):1493-1499.
96.Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. American journal of hypertension. Jul 2014;27(7):885-896.
97.Endo J, Arita M. Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. Journal of cardiology. Sep 7 2015.
98.Jain AP, Aggarwal KK, Zhang PY. Omega-3 fatty acids and cardiovascular disease. European review for medical and pharmacological sciences. 2015;19(3):441-445.
99.Li D. Omega-3 polyunsaturated fatty acids and non-communicable diseases: meta-analysis based systematic review. Asia Pacific journal of clinical nutrition. 2015;24(1):10-15.
100.Nestel P, Clifton P, Colquhoun D, et al. Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease. Heart, lung & circulation. Aug 2015;24(8):769-779.
101.Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. The Cochrane database of systematic reviews. 2009(4):Cd007435.
102.Wyman M, Leonard M, Morledge T. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia? Cleveland Clinic journal of medicine. Jul 2010;77(7):435-442.
103.Mortensen SA, Rosenfeldt F, Kumar A, et al. The Effect of Coenzyme Q on Morbidity and Mortality in Chronic Heart Failure: Results From Q-SYMBIO: A Randomized Double-Blind Trial. JACC. Heart failure. Sep 25 2014.
104.Gao L, Mao Q, Cao J, Wang Y, Zhou X, Fan L. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. Apr 2012;221(2):311-316.
105.Hamilton SJ, Chew GT, Watts GF. Coenzyme Q10 Improves Endothelial Dysfunction in Statin-Treated Type 2 Diabetic Patients. Diabetes care. May 1, 2009 2009;32(5):810-812.
106.Kedziora-Kornatowska K, Czuczejko J, Motyl J, et al. Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study. Archives of medical science : AMS. Aug 30 2010;6(4):513-518.
107.Alehagen U, Johansson P, Björnstedt M, Rosén A, Dahlström U. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. International journal of cardiology. 9/1/ 2013;167(5):1860-1866.
108.Jee SH, Miller ER, 3rd, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. American journal of hypertension. Aug 2002;15(8):691-696.
109.Shechter M, Shechter A. The Role of Magnesium in the Cardiovascular System. In: Watson RR, Preedy VR, Zibadi S, eds. Magnesium in Human Health and Disease: Humana Press; 2013:191-204.
110.Houston M. Magnesium and Hypertension. In: Watson RR, Preedy VR, Zibadi S, eds. Magnesium in Human Health and Disease: Humana Press; 2013:183-189.
111.Rosanoff A. Magnesium supplements may enhance the effect of antihypertensive medications in stage 1 hypertensive subjects. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. Mar 2010;23(1):27-40.
112.Qu X, Jin F, Hao Y, et al. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PloS one. 2013;8(3):e57720.
113.Grober U, Schmidt J, Kisters K. Magnesium in Prevention and Therapy. Nutrients. 2015;7(9):8199-8226.
114.Rosanoff A, Plesset MR. Oral magnesium supplements decrease high blood pressure (SBP>155 mmHg) in hypertensive subjects on anti-hypertensive medications: a targeted meta-analysis. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. Jul-Sep 2013;26(3):93-99.
115.Tin A, Grams ME, Maruthur NM, et al. Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney international. 04//print 2015;87(4):820-827.
116.Witkowski M, Hubert J, Mazur A. Methods of assessment of magnesium status in humans: a systematic review. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. Dec 2011;24(4):163-180.
117.Fekete AA, Givens DI, Lovegrove JA. Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. Nutrients. Jan 2015;7(1):659-681.
118.Gold Standard. Drug Monograph. Lisinopril. www.clinicalkey.com. Copyright 2015 by Elsevier, Inc. Last updated 8/5/2014. Accessed 11/19/2015.
119.Gold Standard. Drug Monograph. Candesartan. www.clinicalkey.com. Copyright 2015 by Elsevier, Inc. Last updated 6/15/2012. Accessed 11/19/2015.
120.Pal S, Ellis V. The chronic effects of whey proteins on blood pressure, vascular function, and inflammatory markers in overweight individuals. Obesity (Silver Spring, Md.). Jul 2010;18(7):1354-1359.
121.Pal S, Ellis V. Acute effects of whey protein isolate on blood pressure, vascular function and inflammatory markers in overweight postmenopausal women. The British journal of nutrition. May 2011;105(10):1512-1519.
122.FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. The Journal of nutrition. Apr 2004;134(4):980s-988s.
123.Cicero AFG, Aubin F, Azais-Braesco V, Borghi C. Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials. American journal of hypertension. 2013;26(3):442-449.
124.Pins JJ, Keenan JM. Effects of whey peptides on cardiovascular disease risk factors. Journal of clinical hypertension (Greenwich, Conn.). Nov 2006;8(11):775-782.
125.Houston M. The role of nutrition and nutraceutical supplements in the treatment of hypertension. World journal of cardiology. 2014;6(2):38-66.
126.Maes W, Van Camp J, Vermeirssen V, et al. Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells. Regulatory peptides. Apr 15 2004;118(1-2):105-109.
127.Li SH, Tian HB, Zhao HJ, Chen LH, Cui LQ. The acute effects of grape polyphenols supplementation on endothelial function in adults: meta-analyses of controlled trials. PloS one. 2013;8(7):e69818.
128.Li SH, Zhao P, Tian HB, Chen LH, Cui LQ. Effect of Grape Polyphenols on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials. PloS one. 2015;10(9):e0137665.
129.Edirisinghe I, Burton-Freeman B, Tissa Kappagoda C. Mechanism of the endothelium-dependent relaxation evoked by a grape seed extract. Clinical science (London, England : 1979). Feb 2008;114(4):331-337.
130.Park E, Edirisinghe I, Choy YY, Waterhouse A, Burton-Freeman B. Effects of grape seed extract beverage on blood pressure and metabolic indices in individuals with pre-hypertension: a randomised, double-blinded, two-arm, parallel, placebo-controlled trial. The British journal of nutrition. Nov 16 2015:1-13.
131.Asgary S, Keshvari M, Sahebkar A, Hashemi M, Rafieian-Kopaei M. Clinical investigation of the acute effects of pomegranate juice on blood pressure and endothelial function in hypertensive individuals. ARYA atherosclerosis. Nov 2013;9(6):326-331.
132.Asgary S, Sahebkar A, Afshani MR, Keshvari M, Haghjooyjavanmard S, Rafieian-Kopaei M. Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti-inflammatory effects of pomegranate juice in hypertensive subjects. Phytotherapy research : PTR. Feb 2014;28(2):193-199.
133.Tsang C, Smail NF, Almoosawi S, Davidson I, Al-Dujaili EA. Intake of polyphenol-rich pomegranate pure juice influences urinary glucocorticoids, blood pressure and homeostasis model assessment of insulin resistance in human volunteers. Journal of nutritional science. 2012;1:e9.
134.Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis. Sep 2001;158(1):195-198.
135.Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clinical nutrition (Edinburgh, Scotland). Jun 2004;23(3):423-433.
136.de Nigris F, Balestrieri ML, Williams-Ignarro S, et al. The influence of pomegranate fruit extract in comparison to regular pomegranate juice and seed oil on nitric oxide and arterial function in obese Zucker rats. Nitric Oxide. Aug 2007;17(1):50-54.
137.Mohan M, Waghulde H, Kasture S. Effect of pomegranate juice on Angiotensin II-induced hypertension in diabetic Wistar rats. Phytotherapy research : PTR. Jun 2010;24 Suppl 2:S196-203.
138.Susalit E, Agus N, Effendi I, et al. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril. Phytomedicine : international journal of phytotherapy and phytopharmacology. Feb 15 2011;18(4):251-258.
139.Cherif S, Rahal N, Haouala M, et al. [A clinical trial of a titrated Olea extract in the treatment of essential arterial hypertension]. J Pharm Belg. Mar-Apr 1996;51(2):69-71.
140.Perrinjaquet-Moccetti T, Busjahn A, Schmidlin C, Schmidt A, Bradl B, Aydogan C. Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins. Phytotherapy research : PTR. Sep 2008;22(9):1239-1242.
141.de Bock M, Derraik JG, Brennan CM, et al. Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trial. PloS one. 2013;8(3):e57622.
142.Scheffler A, Rauwald HW, Kampa B, Mann U, Mohr FW, Dhein S. Olea europaea leaf extract exerts L-type Ca(2+) channel antagonistic effects. Journal of ethnopharmacology. Nov 20 2008;120(2):233-240.
143.Gilani AH, Khan AU, Shah AJ, Connor J, Jabeen Q. Blood pressure lowering effect of olive is mediated through calcium channel blockade. International journal of food sciences and nutrition. Dec 2005;56(8):613-620.
144.Hansen K, Adsersen A, Christensen SB, Jensen SR, Nyman U, Smitt UW. Isolation of an angiotensin converting enzyme (ACE) inhibitor from Olea europaea and Olea lancea. Phytomedicine : international journal of phytotherapy and phytopharmacology. Mar 1996;2(4):319-325.
145.Parzonko A, Czerwinska ME, Kiss AK, Naruszewicz M. Oleuropein and oleacein may restore biological functions of endothelial progenitor cells impaired by angiotensin II via activation of Nrf2/heme oxygenase-1 pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology. Sep 15 2013;20(12):1088-1094.
146.Madhavi D, Kagan D, Rao V. A Pilot Study to Evaluate the Antihypertensive Effect of a Celery Extract in Mild to Moderate Hypertensive Patients. Age. 2013;57:10.13.
147.Moghadam MH, Imenshahidi M, Mohajeri SA. Antihypertensive effect of celery seed on rat blood pressure in chronic administration. Journal of medicinal food. Jun 2013;16(6):558-563.
148.Ko FN, Huang TF, Teng CM. Vasodilatory action mechanisms of apigenin isolated from Apium graveolens in rat thoracic aorta. Biochimica et biophysica acta. Nov 14 1991;1115(1):69-74.
149.Jorge VG, Angel JR, Adrian TS, et al. Vasorelaxant activity of extracts obtained from Apium graveolens: possible source for vasorelaxant molecules isolation with potential antihypertensive effect. Asian Pac J Trop Biomed. Oct 2013;3(10):776-779.
150.Hamet P. The evaluation of the scientific evidence for a relationship between calcium and hypertension. The Journal of nutrition. Feb 1995;125(2 Suppl):311s-400s.
151.van Mierlo LA, Arends LR, Streppel MT, et al. Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials. Journal of human hypertension. Aug 2006;20(8):571-580.
152.Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. The Journal of nutrition. Nov 2004;134(11):3100-3105.
153.Chow CK. Dietary intake of menaquinones and risk of cancer incidence and mortality. The American journal of clinical nutrition. December 1, 2010 2010;92(6):1533-1534.
154.Shea MK, O'Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. The American journal of clinical nutrition. Jun 2009;89(6):1799-1807.
155.DiNicolantonio JJ, Bhutani J, O'Keefe JH. The health benefits of vitamin K. Open Heart. 10/06 06/01/received 08/27/revised 09/18/accepted 2015;2(1):e000300.
156.Shea MK, Holden RM. Vitamin K status and vascular calcification: evidence from observational and clinical studies. Advances in nutrition (Bethesda, Md.). Mar 2012;3(2):158-165.
157.Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. American heart journal. Dec 2011;162(6):959-965.
158.Kozuma K, Tsuchiya S, Kohori J, Hase T, Tokimitsu I. Antihypertensive effect of green coffee bean extract on mildly hypertensive subjects. Hypertension research : official journal of the Japanese Society of Hypertension. Sep 2005;28(9):711-718.
159.Yamaguchi T, Chikama A, Mori K, et al. Hydroxyhydroquinone-free coffee: a double-blind, randomized controlled dose-response study of blood pressure. Nutrition, metabolism, and cardiovascular diseases : NMCD. Jul 2008;18(6):408-414.
160.Wang J, Xiong X, Feng B. Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evidence-based complementary and alternative medicine : eCAM. 2013;2013:149363.
161.Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clinical nutrition (Edinburgh, Scotland). Feb 2015;34(1):27-34.
162.Izzo JL, Jr., Weir MR. Angiotensin-converting enzyme inhibitors. Journal of clinical hypertension (Greenwich, Conn.). Sep 2011;13(9):667-675.
163.Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy, and safety. Journal of clinical hypertension (Greenwich, Conn.). Sep 2011;13(9):677-686.
164.Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. The Cochrane database of systematic reviews. 2014;8:Cd009096.
165.Akhrass PR, McFarlane SI. Telmisartan and cardioprotection. Vascular Health and Risk Management. 11/15 2011;7:677-683.
166.Lacourciere Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood pressure monitoring. Aug 2004;9(4):203-210.
167.Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. The Canadian journal of cardiology. Sep 2000;16(9):1123-1132.
168.Lacourciere Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood pressure monitoring. Oct 1998;3(5):295-302.
169.Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. May 2004;43(5):993-1002.
170.Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. May 4 2004;109(17):2054-2057.
171.Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Molecular endocrinology (Baltimore, Md.). Apr 2003;17(4):662-676.
172.Takeuchi K, Yamamoto K, Ohishi M, et al. Telmisartan modulates mitochondrial function in vascular smooth muscle cells. Hypertension research : official journal of the Japanese Society of Hypertension. May 2013;36(5):433-439.
173.He H, Yang D, Ma L, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. Hypertension. Apr 2010;55(4):869-879.
174.Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Tager M, Bode-Boger SM. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension. Mar 2008;51(3):696-703.
175.Feng X, Luo Z, Ma L, et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta/AMPK pathway. Journal of cellular and molecular medicine. Jul 2011;15(7):1572-1581.
176.Sanchis-Gomar F, Lippi G. Telmisartan as metabolic modulator: a new perspective in sports doping? Journal of strength and conditioning research / National Strength & Conditioning Association. Mar 2012;26(3):608-610.
177.Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension. May 2006;47(5):1003-1009.
178.Goyal SN, Bharti S, Bhatia J, Nag TC, Ray R, Arya DS. Telmisartan, a dual ARB/partial PPAR-gamma agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes, obesity & metabolism. Jun 2011;13(6):533-541.
179.Iwai M, Inaba S, Tomono Y, et al. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertension research : official journal of the Japanese Society of Hypertension. Jan 2008;31(1):161-168.
180.Iwanami J, Mogi M, Tsukuda K, et al. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. Journal of hypertension. Aug 2010;28(8):1730-1737.
181.Yuen CY, Wong WT, Tian XY, et al. Telmisartan inhibits vasoconstriction via PPARgamma-dependent expression and activation of endothelial nitric oxide synthase. Cardiovascular research. Apr 1 2011;90(1):122-129.
182.Myojo M, Nagata D, Fujita D, et al. Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells. PloS one. 2014;9(5):e96948.
183.de Araujo Junior RF, Leitao Oliveira AL, de Melo Silveira RF, de Oliveira Rocha HA, de Franca Cavalcanti P, de Araujo AA. Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells. Experimental biology and medicine (Maywood, N.J.). Jan 2015;240(1):34-44.
184.Koyama N, Nishida Y, Ishii T, Yoshida T, Furukawa Y, Narahara H. Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PloS one. 2014;9(3):e93050.
185.Lee LD, Mafura B, Lauscher JC, Seeliger H, Kreis ME, Grone J. Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells. Oncology letters. Dec 2014;8(6):2681-2686.
186.Pu Z, Zhu M, Kong F. Telmisartan prevents proliferation and promotes apoptosis of human ovarian cancer cells through upregulating PPARgamma and downregulating MMP9 expression. Molecular medicine reports. Nov 6 2015.
187.Ferri FF. Ferri's Clinical Advisor. Disease Overview: Hypertension. Copyright 2016 by Elsevier, Inc. www.clinicalkey.com. 11/19/2015.
188.Moser M, Feig PU. FIfty years of thiazide diuretic therapy for hypertension. Archives of internal medicine. 2009;169(20):1851-1856.
189.ePocrates. Drugs. hydrochlorothiazide. Adverse Reactions. https://online.epocrates.com/drugs/22205/hydrochlorothiazide/Adverse-Reactions. Accessed 11/19/2015.
190.Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis.
191.Spindler SR, Mote PL, Li R, et al. beta1-Adrenergic receptor blockade extends the life span of Drosophila and long-lived mice. Age (Dordrecht, Netherlands). Dec 2013;35(6):2099-2109.
192.Gomez A, Sanchez-Roman I, Gomez J, et al. Lifelong treatment with atenolol decreases membrane fatty acid unsaturation and oxidative stress in heart and skeletal muscle mitochondria and improves immunity and behavior, without changing mice longevity. Aging Cell. Jun 2014;13(3):551-560.
193.NPS MEDICINEWISE. Medical tests. ACE and ARB - reductions in GFR. http://www.nps.org.au/medical-tests/tests-by-conditions/for-individuals/kidney-problems-and-disorders-tests/for-health-professionals/medicines-to-be-aware-of/ace-arb-reductions-in-gfr#References. 6/30/2012. Accessed 11/20/2015.
194.Schoolwerth A. Cautions with Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) Therapy. CKD Update: Attacking Chronic Kidney Disease. Vol. 1; Issue 3. Copyright 2004 by The National Kidney Foundation. http://www.imakenews.com/ckdupdate/e_article000327587.cfm?x=b11,0,w. Accessed 11/20/2015.
195.Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. Journal of hypertension. Jan 2014;32(1):3-15.
196.Hermida RC, Ayala DE, Mojon A, Fernandez JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. Journal of the American Society of Nephrology : JASN. Dec 2011;22(12):2313-2321.
197.Hermida RC, Ayala DE. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension. Jul 2009;54(1):40-46.
198.Hermida RC, Ayala DE, Fontao MJ, Mojon A, Fernandez JR. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Chronobiology international. Jul 2010;27(6):1287-1303.
199.Hermida RC, Ayala DE, Mojon A, Fernandez JR. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. American journal of hypertension. Aug 2008;21(8):948-954.
200.Hermida RC, Ayala DE, Mojon A, Fontao MJ, Fernandez JR. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiology international. Aug 2011;28(7):601-610.
201.Zeng J, Jia M, Ran H, et al. Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study. Hypertension research : official journal of the Japanese Society of Hypertension. Jun 2011;34(6):767-772.
202.Cruickshank JM. The role of coronary perfusion pressure. European heart journal. Sep 1992;13 Suppl D:39-43.
203.Owens P, O'Brien E. Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events? Heart (British Cardiac Society). Oct 1999;82(4):477-481.
204.Voudris V, Avramides D, Gatzov P, Malakos J, Skoularigis J, Manolis A, . . . Cokkinos DV. The effect of rapid decreases of blood pressure by different mechanisms on coronary flow and flow reserve in normal coronary arteries. American journal of hypertension. Dec 2003;16(12):1000-1005.
205.Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. European heart journal. Dec 2010;31(23):2897-2908.
206.Lanza CM. CITRUS FRUITS | Processed and Derived Products of Oranges. In: Caballero B, ed. Encyclopedia of Food Sciences and Nutrition (Second Edition). Oxford: Academic Press; 2003:1346-1354.
207.Benavente-Garcia O, Castillo J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem. Aug 13 2008;56(15):6185-6205.
RHEUMATOID ARTHRITIS
Summary
Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by an autoimmune response that causes pain and disfigurement in peripheral joints. A dangerously underappreciated fact about RA is that it also significantly increases the risk of cardiovascular disease. Too often, conventional treatment strategies produce only marginal relief, failing to mitigate the intrinsic systemic risks that decrease the longevity of RA patients. Treatments should be focused on the application of intensive protocols for cardiovascular risk reduction, which should be as high a priority as relieving joint pain. Strategies must be conveniently focused through the use of adjuvants that improve therapeutic actions, reduce toxicity and contribute to retraining the immune system to prevent joints, as well as reduce the risk for the development of cardiovascular diseases and even malignant diseases such as cancer. 
Conventional treatments.
Disease-modifying antirheumatic drugs (DMARDs) (eg, methotrexate and sulfasalazine); Glucocorticoids (eg, prednisone); non-steroidal anti-inflammatory drugs (NSAIDs); Statins to prevent cardiovascular disease; Modified-release prednisone to improve on the action of conventional prednisone; Stem cell treatment; Bioidentical hormone replacement therapy
Strategy for use of adjuvants.
To improve the pharmacological actions of the drugs used in the prevention, control and treatment of Rheumatoid arthritis and at the same time counteract the side effects and adverse reactions caused by the use of these drugs in the medium and long term that usually contribute to the development of alterations , syndromes and deadly diseases, such as cancer, and can also reduce the quality life expectancy of people under treatment; the scientists and doctors of "PPG NUTRICIONAL" together with family doctors and specialists from clinics and hospitals, assisted by the "MIS", defined a personalized therapeutic strategy to develop specific adjuvants that improve the actions of the drugs used in each of the stages treatment of Rheumatoid arthritis and at the same time reduce the risk of contracting disorders, syndromes or fatal diseases with decreased quality of life. These adjuvants are, in themselves, unique compositions or combinations of labeled drugs, natural active ingredients, enzyme cofactors, vitamins, trace elements, protein hydrolysates, peptides, probiotics and other products authorized for use in humans by the FDA.
Attach adjuvants photos (Group 6).
REFERENCE.
1.[Anonymous] Monograph. Plant sterols and sterolins. Altern Med Rev. 2001 Apr;6(2):203-6.
2.Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet, 2011. 50(6):349-69.
3.Ahmed S. Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. Arthritis Res Ther, 2010. 12(2):208.
4.Ahn KS, Aggarwal BB. Transcription Factor NF-{kappa}B: A sensor for smoke and stress signals. Ann N Y Acad Sci. 2005 Nov;1056:218-33.
5.Aletaha D, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum, 2010. 62(9):2569-81.
6.American College of Rheumatology Subcommittee on Rheumatic Arthritis Guidelines (2002), Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum, 2002. 46(2):328-46.
7.Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med, 2006. 72(12):1100-16.
8.Balbir-Gurman A, et al. Consumption of pomegranate decreases serum oxidative stress and reduces disease activity in patients with active rheumatoid arthritis: a pilot study. Isr Med Assoc J, 2011. 13(8):474-9.
9.Banji D, et al. Synergistic activity of curcumin with methotrexate in ameliorating Freund's Complete Adjuvant induced arthritis with reduced hepatotoxicity in experimental animals. Eur J Pharmacol, 2011. 668(1-2):293-8.
10.Bao Z, Guan S, Cheng C, et al. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappaB pathway. Am J Respir Crit Care Med. 2009 Apr 15;179(8):657-65.
11.Boers M, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis, 2003. 62(9):842-5.
12.Bouic P, et al. The effects of B-sitosterol (BSS) and B-sitosterol glucoside (BSSG) mixture on selected immune parameters of marathon runners: inhibition of post marathon immune suppression and inflammation. Int J Sports Med. 1999 May;20(4):258-62.
13.Brzeski M, Madhok R, Capell HA. Evening primrose oil in patients with rheumatoid arthritis and side-effects of non-steroidal anti-inflammatory drugs. Br J Rheumatol, 1991. 30(5):370-2.
14.Buhrmann C, et al. Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther, 2010. 12(4):R127.
15.Buttgereit F, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010 Jul;69(7):1275-80. Epub 2010 Jun 11.
16.Buttgereit F. How should impaired morning function in rheumatoid arthritis be treated? Scand J Rheumatol Suppl. 2011;125:28-39.
17.Cai Y, Yuan Q, Xu K, et al. Assessment of the Therapeutic Effect of Total Glucosides of Peony for Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. Evidence-based complementary and alternative medicine: eCAM.2016;2016:8292486.
18.Cairns AP and McVeigh JG. A systematic review of the effects of dynamic exercise in rheumatoid arthritis. Rheumatol Int, 2009. 30(2):147-58.
19.Cameron M, et al. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part 2: Rheumatoid arthritis. Phytother Res, 2009. 23(12):1647-62.
20.Cameron M, Gagnier JJ, Chrubasik S. Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev, 2011(2):CD002948.
21.Caughey GE, et al. Fish oil supplementation increases the cyclooxygenase inhibitory activity of paracetamol in rheumatoid arthritis patients. Complement Ther Med, 2010. 18(3-4):171-4.
22.Chandran B and Goel A. A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis. Published online 9 MAR 2012.
23.Chao WW, Kuo YH, Hsieh SL, Lin BF. Inhibitory effects of ethyl acetate extract of Andrographis paniculata on NF-{kappa}B trans-activation activity and LPS-induced acute inflammation in mice. Evid Based Complement Alternat Med. 2009 Sep 10.
24.Chen T, Guo ZP, Wang L, et al. Paeoniflorin suppresses vascular damage and the expression of E-selectin and ICAM-1 in a mouse model of cutaneous Arthus reaction. Experimental dermatology. Jul 2013;22(7):453-457.
25.Chen Z, Li XP, Li ZJ, Xu L, Li XM. Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. International immunopharmacology.Mar 2013;15(3):474-477.
26.Chiang EP, et al. Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med, 2003. 114(4):283-7.
27.Chiou WF, Chen CF, Lin JJ. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br J Pharmacol. 2000 Apr;129(8):1553-60.
28.Coblyn JS and Brigham and Women's Hospital. Brigham and Women's experts' approach to rheumatology2011, Sudbury, Mass.: Jones and Bartlett. xi, 236.
29.Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev, 2011. 11: CD008872.
30.Cooney JK, et al. Benefits of exercise in rheumatoid arthritis. J Aging Res, 2011. 2011: Article ID 681640. doi: 10.4061/2011/681640.
31.Cush JJ and Kavanaugh A. Rheumatoid arthritis: early diagnosis and treatment. 1st ed. 2005, West Islip, NY: Professional Communications. p.320.
32.Cutolo M, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006 Nov;1089:538-47.
33.Cutolo M, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus. 2004;13(9):635-8.
34.Cutolo M. Androgens in rheumatoid arthritis: when are they effectors? Arthritis Res Ther. 2009;11(5):126. Epub 2009 Sep 22.
35.Cutolo M. Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol. 2011 Aug 2;7(9):500-2. doi: 10.1038/nrrheum.2011.115.
36.Dawczynski C, et al. Incorporation of n-3 PUFA and gamma-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial. Lipids in health and disease, 2011. 10:130.
37.Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res, 1980. 71:632-4.
38.Du JH, Dong BD. [Comparative study on clinical efficacy of using methotrexate singly or combined with total glucosides of Paeony in treating rheumatoid arthritis]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban.Jun 2005;25(6):540-542.
39.Dudics V, et al. Chondrogenic potential of mesenchymal stem cells from patients with rheumatoid arthritis and osteoarthritis: measurements in a microculture system. Cells Tissues Organs, 2009. 189(5):307-16.
40.Duijnisveld BJ, et al. Regenerative potential of human muscle stem cells in chronic inflammation. Arthritis Res Ther, 2011. 13(6):R207.
41.Ebina K, Shi K, Hirao M, et al. Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis. Mod Rheumatol. 2013;23(5):1001-7.
42.Edwards JC, et al. Efficacy of β-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med, 2004. 350(25):2572-81.
43.Endres S, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med, 1989. 320(5):265-71.
44.Faloon W. "ARTHRITIS UPDATE: Drugs That Inhibit COX-2 May Cause Tissue Damage" Life Extension magazine, 1/2001.
45.Feng Z, Xu J, He G, Cao M, Duan L, Chen L, Wu Z. The Efficacy and Safety of the Combination of Total Glucosides of Peony and Leflunomide for the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis. Evidence-based complementary and alternative medicine: eCAM. 2016;2016:9852793.
46.Feng Z-T, Xu J, He G-C, Cai S-J, Li J, Mei Z-G. A systemic review and meta-analysis of the clinical efficacy and safety of total glucosides of peony combined with methotrexate in rheumatoid arthritis. Clinical rheumatology. 2018;37(1):35-42. doi:10.1007/s10067-017-3770-y
47.FDA Import Refusal Report. Available at http://www.accessdata.fda.gov/scripts/importrefusals/ir_detail.cfm?EntryId=UPS-2301487-7&DocId=1&LineId=1&SfxId= Accessed 2/8/2012.
48.Flint-Wagner HG, et al. Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients. J Clin Rheumatol, 2009. 15(4):165-71.
49.Fouda AM and Berika MY. Evaluation of the effect of hydroalcoholic extract of Zingiber officinale rhizomes in rat collagen-induced arthritis. Basic Clin Pharmacol Toxicol, 2009. 104(3):262-71.
50.Funk JL, et al. Comparative effects of two gingerol-containing Zingiber officinale extracts on experimental rheumatoid arthritis. J Nat Prod, 2009. 72(3):403-7.
51.Gheita TA and Kenawy SA. Effectiveness of Nigella sativa Oil in the Management of Rheumatoid Arthritis Patients: A Placebo Controlled Study. Phytother Res, 2011.
52.Gold Standard. Drug Monograph. Methotrexate. www.clinicalkey.com. Last updated 2016. Accessed 10/7/2016.
53.Goldberg RJ and Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain, 2007. 129(1-2):210-23.
54.Gopinath K and Danda D. Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial. Int J Rheum Dis, 2011. 14(4):332-9.
55.Grober U, Reichrath J, Holick M, et al. Vitamin K: an old vitamin in a new perspective. Dermatoendocrinol. 2014;6(1):e968490.
56.Grzanna R, Lindmark L, Frondoza CG. Ginger--an herbal medicinal product with broad anti-inflammatory actions. J Med Food, 2005. 8(2):125-32.
57.Haqqi TM, et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci U S A, 1999. 96(8):4524-9.
58.He DY, Dai SM. Anti-inflammatory and immunomodulatory effects of paeonia lactiflora pall., a traditional chinese herbal medicine. Frontiers in pharmacology.2011;2:10.
59.Henrotin Y, et al. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage, 2010. 18(2):141-9.
60.Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002. 166(5):608-15.
61.Hua J, et al. Evaluation of the suppressive actions of glucosamine on the interleukin-1beta-mediated activation of synoviocytes. Inflamm Res, 2007. 56(10):432-8.
62.Huang SC, et al. Vitamin B(6) supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis. Eur J Clin Nutr, 2010. 64(9):1007-13.
63.Ierna M, et al. Supplementation of diet with krill oil protects against experimental rheumatoid arthritis. BMC musculoskeletal disorders, 2010. 11:136.
64.Jackson JK, et al. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res, 2006. 55(4):168-75.
65.James M, Proudman S, Cleland L. Fish oil and rheumatoid arthritis: past, present and future. Proc Nutr Soc, 2010. 69(3):316-23.
66.James MJ and Cleland LG, Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Semin Arthritis Rheum, 1997. 27(2):85-97.
67.Jia XY, Chang Y, Sun XJ, et al. Total glucosides of paeony inhibit the proliferation of fibroblast-like synoviocytes through the regulation of G proteins in rats with collagen-induced arthritis. International immunopharmacology.Jan 2014;18(1):1-6.
68.Juanola-Falgarona M, Salas-Salvado J, Estruch R, et al. Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk. Cardiovasc Diabetol. 2013;12(7).
69.Ju YH, et al. beta-Sitosterol, beta-Sitosterol Glucoside, and a Mixture of beta-Sitosterol and beta-Sitosterol Glucoside Modulate the Growth of Estrogen-Responsive Breast Cancer Cells In Vitro and in Ovariectomized Athymic Mice. J Nutr. 2004 May;134(5):1145-51.
70.Jurgens MS, Jacobs JW, and Bijlsma JW. The use of conventional disease-modifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol, 2011. 25(4):523-33.
71.Kahlenberg JM and Fox DA. Advances in the medical treatment of rheumatoid arthritis. Hand Clin, 2011. 27(1):11-20.
72.Karlson EW, et al. A prospective study of androgen levels, hormone-related genes and risk of rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R97. Epub 2009 Jun 25.
73.Keystone E, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis, 2009. 68(2):216-21.
74.Khan F, et al. The role of endothelial function and its assessment in rheumatoid arthritis. Nat Rev Rheumatol. 2010 May;6(5):253-61. Epub 2010 Mar 30.
75.Kim HR, et al. Green tea protects rats against autoimmune arthritis by modulating disease-related immune events. J Nutr, 2008. 138(11):2111-6.
76.Klippel, JH. The pocket primer on the rheumatic diseases. 2nd ed2010, Atlanta, GA: Arthritis Foundation. p.242.
77.Kremer JM, et al. Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet, 1985. 1(8422):184-7.
78.Lee JH and Kim GH. Evaluation of antioxidant and inhibitory activities for different subclasses flavonoids on enzymes for rheumatoid arthritis. J Food Sci, 2010. 75(7):H212-7.
79.Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med, 1993. 119(9):867-73.
80.Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with blackcurrant seed oil. Br J Rheumatol, 1994. 33(9):847-52.
81.Life Extension. Available at: http://www.lifeextension.com/HealthWellness/ClinicalResearch/StudyDetails.aspx?study=CL025 Accessed 2/10/2012.
82.Lin J, Xiao L, Ouyang G, et al. Total glucosides of paeony inhibits Th1/Th17 cells via decreasing dendritic cells activation in rheumatoid arthritis. Cell Immunol.Dec 2012;280(2):156-163.
83.Lindler BN, Long KE, Taylor NA, Lei W. Use of Herbal Medications for Treatment of Osteoarthritis and Rheumatoid Arthritis. Medicines (Basel, Switzerland). Oct 28 2020;7(11)doi:10.3390/medicines7110067
84.Liu B, Meng X, Ma Y, et al. Clinical safety of total glucosides of paeony adjuvant therapy for rheumatoid arthritis treatment: a systematic review and meta-analysis. BMC Complement Med Ther. Mar 26 2021;21(1):102. doi:10.1186/s12906-021-03252-y
85.Liu GL, Li YC, Shen YJ. [Inhibitory effect of total glucosides of paeonia on the NF-kappaB/p65 protein expression in paws of RA rats]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.Nov 2010;26(11):1082-1084.
86.Liu J, Wang ZT, Ge BX. Andrograpanin, isolated from Andrographis paniculata, exhibits anti-inflammatory property in lipopolysaccharide-induced macrophage cells through down-regulating the p38 MAPKs signaling pathways. Int Immunopharmacol. 2008 Jul;8(7):951-8.
87.Liu J, Wang ZT, Ji LL, Ge BX. Inhibitory effects of neoandrographolide on nitric oxide and prostaglandin E2 production in LPS-stimulated murine macrophage. Mol Cell Biochem. 2007 Apr;298(1-2):49-57.
88.Liu J, Wang ZT, Ji LL. In vivo and in vitro anti-inflammatory activities of neoandrographolide. Am J Chin Med. 2007;35(2):317-28.
89.Louw I, et al. A pilot study of the clinical effects of a mixture of beta-sitosterol and beta-sitosterol glucoside in active rheumatoid arthritis (RA). Am J Clin Nutr 2002 75: 2 339S-439S [abstract 40].
90.Ma MH, Kingsley GH, and Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford), 2010. 49(1):91-8.
91.Macfarlane GJ, et al. Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review. Rheumatology (Oxford), 2011. 50(9):1672-83.
92.Manganelli P and Rioda WT. [Weekly low-dose methotrexate in rheumatoid arthritis. Review of the literature]. Minerva medica, 1993. 84(10):541-52.
93.Martinez-Calatrava MJ, Largo R, Herrero-Beaumont G. Improvement of experimental accelerated atherosclerosis by chondroitin sulphate. Osteoarthritis Cartilage, 2010. 18 Suppl 1:S12-6.
94.Masi AT, et al. Sex hormones and risks of rheumatoid arthritis and developmental or environmental influences. Ann N Y Acad Sci. 2006 Jun;1069:223-35.
95.McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs, 2011. 71(18): 2457-89.
96.Mikuls TR, et al. The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol, 2007. 34(7):1480-4.
97.Moreland LW and O'Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum, 2002. 46(10):2553-63.
98.Naik SR, Hule A. Evaluation of immunomodulatory activity of an extract of andrographolides from Andographis paniculata. Planta Med. 2009 Jun;75(8):785-91.
99.Nakamura H, et al. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int, 2007. 27(3):213-8.
100.Natarajan V, et al. Formulation and evaluation of quercetin polycaprolactone microspheres for the treatment of rheumatoid arthritis. J Pharm Sci, 2011. 100(1):195-205.
101.Nell VP, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford), 2004. 43(7):906-14.
102.Nesher G, Osborn TG, Moore TL. In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol, 1996. 14(4):395-9.
103.NIAMS. Rheumatoid Arthritis. 2009 December 9, 2011]; Available from: http://www.niams.nih.gov/Health_Info/Rheumatic_Disease/default.asp.
104.Nievergelt A, et al. Ginger phenylpropanoids inhibit IL-1beta and prostanoid secretion and disrupt arachidonate-phospholipid remodeling by targeting phospholipases A2. J Immunol, 2011. 187(8):4140-50.
105.Ohsaki Y, Shirakawa H, Hiwatashi K, et al.Vitamin K Suppresses Lipopolysaccharide-Induced Inflammation in the Rat. Bioscience, Biotechnology, and Biochemistry. 2006;70(4):926-932.
106.Okamoto H, Shidara K, Hoshi D, et al. Anti-arthritis effects of vitamin K(2) (menaquinone-4)--a new potential therapeutic strategy for rheumatoid arthritis. The FEBS J. 2007;274(17):4588-94.
107.Olendzki BC, et al. Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. Evid Based Complement Alternat Med, 2011. 2011: Article ID 827286. doi: 10.1155/2011/827286.
108.Park YB, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol, 1999. 26(8):1701-4.
109.Pearson TA, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation, 2002. 106(3):388-91.
110.Peters MJ, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum, 2009. 61(11): 1571-9.
111.Pietschmann P. Principles of osteoimmunology: molecular mechanisms and clinical applications 2011, New York: Springer.
112.Plasqui G. The role of physical activity in rheumatoid arthritis. Physiol Behav, 2008. 94(2):270-5.
113.Radovits BJ, et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken), 2010. 62(3):362-70.
114.Ramadan G, Al-Kahtani MA, El-Sayed WM. Anti-inflammatory and anti-oxidant properties of Curcuma longa (turmeric) versus Zingiber officinale (ginger) rhizomes in rat adjuvant-induced arthritis. Inflammation, 2011. 34(4):291-301.
115.Rheaume-Bleue K. Choosing the Right Vitamin K2: Menaquinone-4 vs Menaquinone-7: Clinical considerations of different forms of vitamin K2. Natural Medicine Journal. 2015;7(10).
116.Ridker PM and Solomon DH. Should patients with rheumatoid arthritis receive statin therapy? Arthritis Rheum, 2009. 60(5):1205-9.
117.Ruffing V and Bingham III CO. Rheumatoid Arthritis Clinical Presentation. Accessed 3/20/12. Available from: http://www.hopkins-arthritis.org/arthritis-info/rheumatoid-arthritis/rheum_clin_pres.html.
118.Rutjes AW, et al. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst Rev, 2009(4):CD007321.
119.Sengupta K, et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem, 2011. 354(1-2):189-97.
120.Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative efficacy and tolerability of 5-Loxin and Aflapin Against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. 2010;7(6):366–377
121.Shabanova SS, et al. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2008 May-Jun;26(3):436-41.
122.Sheng X, et al. Effectiveness of Statins on Total Cholesterol and Cardiovascular Disease and All-cause Mortality in Osteoarthritis and Rheumatoid Arthritis. J Rheumatol, 2011.
123.Shukla M, et al. Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. Nutrition, 2008. 24(7-8):733-43.
124.Simopoulos AP. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol Neurobiol. 2011 Oct;44(2):203-15. Epub 2011 Jan 29.
125.Soeken KL, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract, 2002. 51(5):425-30.
126.Spector TD, et al. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ, 1993. 306(6877):558.
127.St. Clair EW, Pisetsky DS, and Haynes BJ. Rheumatoid arthritis 2004, Philadelphia: Lippincott Williams & Wilkins. xiv, p.555.
128.Stoll D, et al. High prevalence of hypovitaminosis D in a Swiss rheumatology outpatient population. Swiss Med Wkly. 2011 May 27;141:w13196. doi: 10.4414/smw.2011.13196.
129.Straub RH, et al. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007 Feb;56(2):399-408.
130.Tak PP and Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther, 2011. 13 Suppl 1:S5.
131.Talbott SM and Hughes K. The health professional's guide to dietary supplements2007, Philadelphia: Lippincott Williams & Wilkins. xx, p.444.
132.Tanasescu C, et al. Endothelial dysfunction in inflammatory rheumatic diseases. Rom J Intern Med. 2009;47(2):103-8.
133.Tekeoglu I, et al. Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models. Phytother Res. 2007 Sep;21(9):895-7.
134.Trelle S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ, 2011. 342:c7086.
135.Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Program, 2011. 2011:280-4.
136.Valensa. FlexPro MD Clinical Trial Overview and Results. (Data on File.) 2011
137.van Aken J, et al. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis, 2004. 63(3):274-9.
138.Van den Ende CH, et al. Dynamic exercise therapy in rheumatoid arthritis: a systematic review. Br J Rheumatol, 1998. 37(6):677-87.
139.van Gestel AM, et al. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br J Rheumatol, 1995. 34(4):347-51.
140.van Halm VP, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis, 2007. 66(2): 184-8.
141.Wang Y, Xing HY. [Clinical observation on effect of total glucosides of paeony combined with methotrexate on rheumatoid arthritis]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban.Sep 2007;27(9):839-840.
142.Wang YN, Zhang Y, Wang Y, Zhu DX, Xu LQ, Fang H, Wu W. The beneficial effect of total glucosides of paeony on psoriatic arthritis links to circulating Tregs and Th1 cell function. Phytotherapy research: PTR.Mar 2014;28(3):372-381.
143.Wei CC, You FT, Mei LY, Jian S, Qiang CY. Total glucosides of paeony prevents juxta-articular bone loss in experimental arthritis. BMC complementary and alternative medicine. 2013;13:186.
144.Weiss EP, et al. droepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011 May;3(5):533-42.
145.Weitoft T, et al. Serum levels of sex steroid hormones and matrix metalloproteinases after intra-articular glucocorticoid treatment in female patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Mar;67(3):422-4. Epub 2007 Sep 18.
146.Whittle SL and Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford), 2004. 43(3):267-71.
147.Youssef PP, et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum, 1997. 40(8):1400-8.


</p>

</div>
<script>
        
    </script>
</body>
</html>